<SEC-DOCUMENT>0000950123-20-002595.txt : 20200306
<SEC-HEADER>0000950123-20-002595.hdr.sgml : 20200306
<ACCEPTANCE-DATETIME>20200214171840
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-20-002595
CONFORMED SUBMISSION TYPE:	DRS/A
PUBLIC DOCUMENT COUNT:		17
FILED AS OF DATE:		20200214
<PUBLIC-REL-DATE>20200306
DATE AS OF CHANGE:		20200214

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lyra Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001327273
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-02901
		FILM NUMBER:		20621970

	BUSINESS ADDRESS:	
		STREET 1:		480 ARSENAL STREET
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		617-373-4600

	MAIL ADDRESS:	
		STREET 1:		480 ARSENAL STREET
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	480 Biomedical, Inc.
		DATE OF NAME CHANGE:	20120927

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Arsenal Vascular, Inc.
		DATE OF NAME CHANGE:	20110826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Arsenal Medical, Inc.
		DATE OF NAME CHANGE:	20090414
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS/A
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRS/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">As confidentially submitted to the Securities and Exchange Commission on
<B></B><B></B><B></B>February 14, 2020 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">as Amendment No. 2 to the Draft Registration Statement </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>
</B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:13.5pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13.5pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>W<SMALL>ASHINGTON</SMALL>, D.C. 20549 </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>UNDER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>THE SECURITIES ACT
OF 1933 </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Lyra Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(Exact name of registrant as specified in its charter) </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="29%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>3841</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>84-1700838</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(State or other jurisdiction of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">incorporation or organization)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(Primary Standard Industrial</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Classification Code Number)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(I.R.S. Employer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Identification No.)</P></TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>480 Arsenal Way </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Watertown, MA 02472 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(617) <FONT
STYLE="white-space:nowrap">393-4600</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(Address, including zip code, and telephone number, including area code, of registrant&#146;s
principal executive offices) </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Maria Palasis, Ph.D. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>President and Chief Executive Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Lyra Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>480 Arsenal Way </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Watertown,
MA 02472 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(617) <FONT STYLE="white-space:nowrap">393-4600</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(Name, address, including zip code, and telephone number, including area code, of agent for service) </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><I>Copies to: </I></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Peter N. Handrinos</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Wesley C. Holmes</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Latham&nbsp;&amp; Watkins LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>200 Clarendon Street</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Boston, MA 02116</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(617) <FONT
STYLE="white-space:nowrap">948-6000</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Ilir Mujalovic</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Shearman&nbsp;&amp; Sterling LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>599 Lexington Avenue</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>New
York, NY 10022</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(212) <FONT STYLE="white-space:nowrap">848-4000</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Approximate date of commencement of proposed sale to the public: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As soon as practicable after the effective date of this Registration Statement. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:8%; font-size:8pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, check the following box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:8%; font-size:8pt; font-family:Times New Roman">If this Form is filed to register additional securities for an offering
pursuant to Rule 462(b)&nbsp;under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:8%; font-size:8pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(c)&nbsp;under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration&nbsp;statement&nbsp;for&nbsp;the&nbsp;same&nbsp;offering.&nbsp;&nbsp;&#9744;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:8%; font-size:8pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(d)&nbsp;under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:8%; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
<FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company, or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting
company,&#148; and &#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><B>Large accelerated filer</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B></B>&#9744;<B></B><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Accelerated filer</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B></B>&#9744;<B></B><B></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><B><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B></B>&#9746;<B></B><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Smaller reporting company</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B></B>&#9746;<B></B><B></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Emerging growth company</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B></B>&#9746;<B></B><B></B></TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:8%; font-size:8pt; font-family:Times New Roman"><B>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;</B>&#9744;<B></B><B> </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Title of Each Class&nbsp;of Securities To Be Registered</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Proposed Maximum<BR>Aggregate Offering</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Price<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount&nbsp;of&nbsp;Registration<BR>Fee<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Common Stock, $0.001 par value per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(1)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><B></B>Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the
Securities Act of 1933, as amended. Includes the aggregate offering price of additional shares that the underwriters have the option to purchase. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(2)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><B></B>Calculated pursuant to Rule 457(o) based on an estimate of the proposed maximum aggregate offering price.
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:8%; font-size:8pt; font-family:Times New Roman"><B>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the
Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until the Registration Statement shall
become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#c21128">The information in this prospectus is not complete and may be changed. We may not sell
these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where
the offer or sale is not permitted. </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#c21128">Subject to Completion </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#c21128">Preliminary Prospectus dated
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 </FONT></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>PROSPECTUS
</U></B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g805799g27k30.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This is Lyra
Therapeutics, Inc.&#146;s initial public offering. We are selling &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect the public offering price to be between $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. Currently, no public market exists for the shares. After pricing of the offering, we expect that the shares will trade on the Nasdaq Global Market under the symbol
&#147;LYRA.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are an emerging growth company under the federal securities laws and are subject to reduced public company
disclosure standards. See &#147;Prospectus Summary&#151;Implications of Being an Emerging Growth Company.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:12pt; font-family:Times New Roman"><B>Investing in the
common stock involves risks that are described in the &#147;<A HREF="#toc805799_2">Risk&nbsp;Factors</A>&#148; section beginning on page&nbsp;11 of this prospectus. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Per&nbsp;Share</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discount<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We refer you to &#147;Underwriting&#148; beginning on page&nbsp;172 of this prospectus for additional
information regarding underwriting compensation. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The underwriters may also exercise their option to purchase up to
an additional &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares from us, at the public offering price, less the underwriting discount, for 30 days after the date of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The shares will be ready
for delivery on or about &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Joint
Book-Running Managers </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:18pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:18pt">
<TD VALIGN="bottom"><B>BofA Securities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Jefferies</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>William Blair</B></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I><FONT STYLE="white-space:nowrap">Co-Manager</FONT> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>BTIG </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The date of this
prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Page</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc805799_1">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc805799_2">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc805799_3">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc805799_4">MARKET AND INDUSTRY DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc805799_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc805799_6">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc805799_7">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc805799_8">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc805799_9">SELECTED CONSOLIDATED FINANCIAL DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc805799_10">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
 OF OPERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc805799_11">BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc805799_12">MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc805799_13">EXECUTIVE AND DIRECTOR COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc805799_14">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc805799_15">PRINCIPAL STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc805799_16">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc805799_17">SHARES ELIGIBLE FOR FUTURE SALE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc805799_18">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc805799_19">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc805799_20">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc805799_21">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc805799_22">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc805799_23">INDEX TO FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Neither we nor the underwriters have authorized anyone to provide any information or to make any representations other than those contained in
this prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you.
This prospectus is an offer to sell only the shares of common stock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing
prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have proprietary rights to trademarks, trade names and service marks appearing in this prospectus that are important to our business.
Solely for convenience, the trademarks, trade names and service marks may appear in this prospectus without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and <SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> symbols, but
any such references are not intended to indicate, in any way, that we forgo or will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, trade names and service marks. All
trademarks, trade names and service marks appearing in this prospectus are the property of their respective owners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For investors outside
the United States: Neither we nor the underwriters have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States.
Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside the
United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc805799_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights, and is qualified in its entirety by, the more detailed information and financial statements included elsewhere in
this prospectus. This summary does not contain all of the information that may be important to you in making your investment decision. You should read this entire prospectus carefully, especially the &#147;Risk Factors&#148; section beginning on
page&nbsp;11 and our consolidated financial statements and the related notes appearing at the end of this prospectus, before deciding to invest in our common stock. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>As used in this prospectus, unless the context otherwise requires, references to &#147;we,&#148; &#147;us,&#148; &#147;our&#148; and
&#147;Lyra&#148; refer to the consolidated operations of Lyra Therapeutics, Inc. and its subsidiary. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions
for the localized treatment of patients with ear, nose and throat, or ENT, diseases. Our proprietary technology platform, XTreo, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a
single administration. Our initial product candidates, <FONT STYLE="white-space:nowrap">LYR-210</FONT> and <FONT STYLE="white-space:nowrap">LYR-220,</FONT> are bioresorbable polymeric matrices designed to be administered in a brief, <FONT
STYLE="white-space:nowrap">non-invasive,</FONT> <FONT STYLE="white-space:nowrap">in-office</FONT> procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or
CRS. The therapeutic embedded within <FONT STYLE="white-space:nowrap">LYR-210</FONT> and <FONT STYLE="white-space:nowrap">LYR-220</FONT> is mometasone furoate, or MF, which is the active ingredient in various U.S. Food and Drug Administration, or
FDA, approved drugs and has a well-established efficacy and safety profile. CRS is an inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities and affects approximately 14&nbsp;million people in
the United States. We are advancing <FONT STYLE="white-space:nowrap">LYR-210</FONT> as a potential preferred alternative to surgery in an ongoing Phase 2 clinical trial, which we refer to as our LANTERN clinical trial, for CRS patients who have
failed medical management, and we expect to report topline data in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. In our Phase 1 clinical trial, <FONT STYLE="white-space:nowrap">LYR-210</FONT> met
its primary safety endpoint, and we observed that patients generally experienced significant and rapid, clinically meaningful and durable improvement in <FONT STYLE="white-space:nowrap">SNOT-22</FONT> scores, an established patient symptom severity
scale, through week 25, which was the end of the trial. We are also developing <FONT STYLE="white-space:nowrap">LYR-220</FONT> for use in CRS patients who have an enlarged nasal cavity due to sinus surgery but continue to require treatment to manage
CRS symptoms, and we intend to initiate a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> clinical trial for <FONT STYLE="white-space:nowrap">LYR-220</FONT> in
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Beyond CRS, we believe our XTreo platform has potential applications in other disease areas, which we are actively exploring to further broaden its therapeutic potential. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Chronic Rhinosinusitis: A Prevalent Disease with High Unmet Medical Needs </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">CRS has been described in the literature as an &#147;unrecognized epidemic&#148; due to its high prevalence, its substantial impact on patient
quality of life and the significant limitations of currently available treatment options. We estimate that sinusitis, which includes both CRS and acute rhinosinusitis, impacts approximately 12% of the adult population in the United States, or
approximately 30&nbsp;million people, making it the fifth most common condition in people under the age of 65 and more prevalent than diabetes or heart disease. Of this population, we estimate that approximately 14 million people are affected with
CRS. Moreover, we estimate that approximately 8&nbsp;million people are treated for CRS by physicians annually, of which approximately 4&nbsp;million fail medical management every year. In the United States, over $60&nbsp;billion is spent annually
in direct treatment costs for sinusitis, including approximately $5&nbsp;billion on sinus surgeries. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Current Treatments and Their Limitations
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Current treatments are directed towards managing the symptoms of CRS through a combination of medical management and surgical
intervention techniques. The first line of therapy is medical management involving nasal saline irrigation, intranasal corticosteroidal sprays, oral steroids and antibiotics for patients with an active sinus infection. However, these treatments have
significant limitations. Topical steroid sprays have </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
poor efficacy due to their limited ability to reach the site of the disease, fast clearance of drug from the site of delivery and poor patient compliance. Prolonged use of oral steroids may lead
to systemic complications which limit their use to short courses. Based on published medical literature, we estimate at least 50% of CRS patients who are seen by ENT physicians and receive medical management remain symptomatic. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Patients whose symptoms persist despite medical management are generally recommended to undergo functional endoscopic sinus surgery (or FESS)
or balloon sinus dilation (or BSD), or both. FESS is a highly invasive surgery performed in the operating room, under full anesthesia, to open the blocked sinus pathways by removing inflamed tissue and bone using surgical tools. BSD is a less severe
form of endoscopic sinus surgery, often used in combination with FESS, in which small balloon catheters are inserted and inflated to drain the large nasal sinuses. Although FESS and BSD can improve symptoms and quality of life, limitations remain.
Neither correct the underlying cause of the inflammation, and patients who undergo either or both procedures often experience significant pain and require continued post-operative medical therapy to maintain improvements, with a high incidence of
repeat surgeries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">CRS has two phenotypes: CRS with nasal polyps and CRS without nasal polyps, with the
<FONT STYLE="white-space:nowrap">non-polyp</FONT> form representing approximately <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">70%-to-90%</FONT></FONT> of all CRS patients. For patients with nasal polyps who remain symptomatic
following surgery, who we refer to as refractory patients, there are non-surgical options, such as a steroid-eluting stent and a monoclonal antibody. However, the steroid-eluting stent has only a three month elution profile and has been approved
only as an addition to intranasal steroid sprays. In addition, the antibody treatment is reserved for only the most refractory patients, has an unknown long-term systemic safety profile and is priced at a significant premium even when compared to
surgical options. Currently, there are no <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drug therapies for CRS for <FONT STYLE="white-space:nowrap">non-polyp</FONT> patients, although some drugs approved for nasal polyps are used <FONT
STYLE="white-space:nowrap">off-label</FONT> in this population. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our XTreo Platform </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">XTreo, our innovative and proprietary drug delivery platform, is designed to locally and continuously deliver small molecule drugs to the
affected tissue over a sustained period of time from a single administration. The platform is comprised of three interrelated technology components: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a biocompatible mesh scaffold, which is designed to maximize surface area for drug release while maintaining
underlying tissue function; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an engineered elastomeric matrix, which means a polymeric matrix composed of polymers having elastic
characteristics, which has advanced physical properties resulting in implants with &#147;shape memory&#148; that dynamically adapt to nasal anatomy; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a versatile polymer-drug complex, which can be customized for the treatment of various chronic diseases treatable
with ENT delivery to achieve the desired drug dose and drug elution rate. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Solution for CRS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">LYR-210</FONT> is an anti-inflammatory implantable drug matrix based on our XTreo platform that is designed
to consistently and locally elute MF to the inflamed mucosal tissue for up to six months in <FONT STYLE="white-space:nowrap">surgically-na&iuml;ve</FONT> CRS patients who fail medical management. MF, the active ingredient in various <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> drugs, has a well-established efficacy and safety profile, which we believe will support the development process for <FONT STYLE="white-space:nowrap">LYR-210.</FONT>
<FONT STYLE="white-space:nowrap">LYR-210</FONT> is designed to enable sustained drug delivery at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-access</FONT></FONT> nasal inflammation sites without the need for
patient compliance, while avoiding systemic side effects associated with oral steroids. <FONT STYLE="white-space:nowrap">LYR-210</FONT> is designed to be administered in a brief, <FONT STYLE="white-space:nowrap">non-invasive,</FONT> <FONT
STYLE="white-space:nowrap">in-office</FONT> procedure by an ENT physician under endoscopic visualization via a <FONT STYLE="white-space:nowrap">single-use</FONT> applicator. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">LYR-210</FONT> is currently being studied in our Phase
2 randomized, sham procedure-controlled, patient-blinded LANTERN clinical trial, evaluating the safety and efficacy in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT STYLE="white-space:nowrap">surgically-na&iuml;ve</FONT> CRS patients who
have failed previous medical management. The trial was initiated in May 2019 and is currently ongoing at sites in Australia, Austria, Czech Republic, New Zealand and Poland. In January 2020, the FDA cleared our investigational new drug application,
and we expect to open new sites in the United States. We expect to report topline data from the Phase 2 LANTERN clinical trial in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.
<FONT STYLE="white-space:nowrap">LYR-210</FONT> was previously studied in an open-label, Phase 1 clinical trial with 20 patients in New Zealand and Australia and achieved its primary endpoint of safety at week 4. In the Phase 1 trial, we observed
that patients generally experienced significant and rapid, clinically meaningful and durable improvement in <FONT STYLE="white-space:nowrap">SNOT-22</FONT> scores. Significant reduction in <FONT STYLE="white-space:nowrap">SNOT-22</FONT> scores was
observed at week 1, and this reduction persisted through week 25, which was the end of the trial. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are developing our second
pipeline product candidate, <FONT STYLE="white-space:nowrap">LYR-220,</FONT> for use in CRS patients who continue to require treatment to manage CRS symptoms despite having had sinus surgery. <FONT STYLE="white-space:nowrap">LYR-220</FONT> is also
designed to utilize MF, but will employ an oversized matrix designed for patients whose nasal cavity is enlarged due to sinus surgery. <FONT STYLE="white-space:nowrap">LYR-220</FONT> is designed as a potential preferred alternative to revision sinus
surgery and post-surgical medical management. We expect to initiate a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> clinical trial for <FONT STYLE="white-space:nowrap">LYR-220</FONT> in
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe that the key potential benefits of our current
investigational product portfolio, <FONT STYLE="white-space:nowrap">LYR-210</FONT> and <FONT STYLE="white-space:nowrap">LYR-220,</FONT> include <B><I>clinical activity, patient compliance, patient experience, physician experience, localized
delivery, patient applicability and pharmacoeconomic impact</I></B><I>. </I>We believe <FONT STYLE="white-space:nowrap">LYR-210</FONT> and <FONT STYLE="white-space:nowrap">LYR-220,</FONT> if approved, would be the only products able to deliver up to
six months of continuous topical treatment in a single administration to treat the entire spectrum of CRS patients who fail medical management, including <FONT STYLE="white-space:nowrap">pre-</FONT> and post-surgery patients and those with and
without nasal polyps<I>.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Pipeline </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The current status of our product candidates is summarized below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g805799g99l17.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our mission is to transform the ENT treatment paradigm by utilizing our proprietary drug delivery platform, XTreo, to develop safe and
effective therapies for the treatment of debilitating diseases treatable with ENT delivery. We intend to achieve this through the following strategies: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Complete the development and secure FDA approval of <FONT STYLE="white-space:nowrap">LYR-210</FONT> for the
treatment of CRS. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Advance our second product candidate, <FONT STYLE="white-space:nowrap">LYR-220,</FONT> into the clinic to provide
a comprehensive solution for CRS patients who have failed medical management and surgery. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Build a commercialization infrastructure in the U.S. market for <FONT STYLE="white-space:nowrap">LYR-210</FONT>
and <FONT STYLE="white-space:nowrap">LYR-220.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Maximize the value of our XTreo platform and expand our product pipeline. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Seek strategic collaborative relationships. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property and Barriers to Entry </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We own all the material intellectual property rights related to our platform and product candidate portfolio. As of December 31, 2019, our
product and product candidate portfolio is protected by 21&nbsp;issued and 27 pending patents worldwide with claims directed to composition of matter, drug delivery and method of use, which, exclusive of possible patent term adjustments or
extensions or other forms of exclusivity, are projected to expire between 2030 and 2037. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Management Team and Investors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our management team has extensive drug development, manufacturing and commercialization experience across a broad spectrum of disease areas,
for both drug and drug-device combination products, with a successful track record in large pharmaceutical, medical device and biotech companies. Additionally, our management team has been involved in the development of successfully approved and
commercialized products such as Taxus (drug-eluting stent), AvoneX, Arikayce and Panhematin. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Further, we are supported by a leading group
of biotech investors including, among others, ArrowMark Partners, Intersouth Partners, North Bridge Venture Partners, Perceptive Advisors, Polaris Venture Partners, RA Capital and Soleus Capital. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risk Factors </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our business is subject to
a number of risks of which you should be aware before making an investment decision. You should carefully consider all of the information set forth in this prospectus and, in particular, should evaluate the specific factors set forth under
&#147;Risk Factors&#148; in deciding whether to invest in our common stock. These risks include the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have a limited operating history and a history of escalating operating losses, which may make it difficult to
evaluate the prospects for our future viability; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have incurred significant losses since inception and expect to incur significant additional losses for the
foreseeable future, and we may never achieve profitability; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">even if this offering is successful, we will need significant additional funding in order to complete development
of and obtain regulatory approval for our product candidates and commercialize our products, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our business is highly dependent on the success of our most advanced product candidate, <FONT
STYLE="white-space:nowrap">LYR-210,</FONT> which will require significant additional clinical testing before we can seek regulatory approval and potentially launch commercial sales, and if <FONT STYLE="white-space:nowrap">LYR-210</FONT> does not
receive regulatory approval or is not successfully commercialized, or is significantly delayed in doing so, our business will be harmed; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trials required for our product candidates are expensive and time-consuming, their outcome is uncertain,
and if our clinical trials do not meet safety or efficacy endpoints in these evaluations, or if we experience significant delays in these trials, our ability to commercialize our product candidates and our financial position will be impaired;
</P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments by competitors may render our products or technologies obsolete or
<FONT STYLE="white-space:nowrap">non-competitive</FONT> or may reduce the size of our markets; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the successful commercialization of our product candidates will depend in part on the extent to which
governmental authorities and health insurers establish coverage, adequate reimbursement levels and pricing policies, and the failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our
ability to market those products and decrease our ability to generate revenue; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">even if either LYR-210 or LYR-220 receives marketing approval, it may fail to achieve market acceptance by
physicians, patients, third-party payors or others in the medical community necessary for commercial success; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we will rely on third parties for the manufacture of materials for our research programs, <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials and we do not have long-term contracts with any of these parties, which increases the risk that we will not have sufficient quantities of such materials, product candidates,
or any therapies that we may develop and commercialize, or that such supply will not be available to us at an acceptable cost, which could delay, prevent, or impair our development or commercialization efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we rely on third parties to conduct our pre-clinical studies and clinical trials, and any failure by a third
party to conduct the clinical trials according to GCPs and in a timely manner may delay or prevent our ability to seek or obtain regulatory approval for or commercialize our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we are unable to obtain, maintain or adequately protect our intellectual property rights, we may not be able
to compete effectively in our markets; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we lose key management or scientific personnel, cannot recruit qualified employees, directors, officers or
other significant personnel or experience increases in our compensation costs, our business may materially suffer. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of
Being an Emerging Growth Company </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a company with less than $1.07&nbsp;billion in revenue during our last fiscal year, we qualify as
an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012, as amended, or JOBS Act. An &#147;emerging growth company&#148; may take advantage of reduced reporting requirements that are otherwise applicable
to public companies. These provisions include, but are not limited to: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the option to present only two years of audited financial statements and only two years of related
&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; in this prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley
Act of 2002, as amended; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight
Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements; </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and
registration statements; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder
approval of any golden parachute payments not previously approved. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may take advantage of these provisions until the
last day of our fiscal year following the fifth anniversary of the completion of this offering. However, if prior to the end of such five-year period, (i)&nbsp;our annual gross revenue exceeds $1.07&nbsp;billion, (ii)&nbsp;we issue more than
$1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt in any three-year period or (iii)&nbsp;we become a &#147;large accelerated filer&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the
Securities Exchange Act of 1934, as amended, or the Exchange Act), then we will cease to be an emerging growth company prior to the end of such five-year period. We will be deemed to be a &#147;large accelerated filer&#148; at such time that we
(a)&nbsp;have an aggregate worldwide market value of common equity securities held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> of $700.0&nbsp;million or more as of the last business day of our most recently completed second fiscal
quarter, (b)&nbsp;have been required to file annual and quarterly reports under the Exchange Act, for a period of at least 12 months and (c)&nbsp;have filed at least one annual report pursuant to the Exchange Act. Even after we no longer qualify as
an emerging growth company, we may still qualify as a &#147;smaller reporting company,&#148; which would allow us to take advantage of many of the same exemptions from disclosure requirements, including reduced disclosure obligations regarding
executive compensation in this prospectus and our periodic reports and proxy statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have elected to take advantage of certain of
the reduced disclosure obligations in the registration statement of which this prospectus is a part and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information that we provide to our
stockholders may be different than you might receive from other public reporting companies in which you hold equity interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In
addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We were
incorporated under the laws of the state of Delaware in November 2005 under the name WMR Biomedical, Inc. In July 2018, we changed our name to Lyra Therapeutics, Inc. Our principal executive offices are located at 480 Arsenal Way, Watertown, MA
02472 and our telephone number is (617) <FONT STYLE="white-space:nowrap">393-4600.</FONT> Our website address is <I>www.lyratherapeutics.com</I>. The information contained in, or accessible through, our website does not constitute a part of this
prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Offering </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock offered by us </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding after this offering </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares (or &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares if the underwriters exercise their option to purchase additional shares in full).
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Option to purchase additional shares </P></TD>
<TD>The underwriters have a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of our common stock at the public offering price less
estimated underwriting discounts and commissions. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We estimate that the net proceeds from this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million (or approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million if the underwriters exercise in full their option to purchase additional shares of common stock), at an assumed public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (the midpoint of the price range set forth on the cover page of this prospectus), after deducting the estimated underwriting discounts and commissions and the
estimated offering expenses payable by us. We anticipate that we will use the net proceeds of this offering, together with our existing cash and cash equivalents, to fund the clinical development and pre-commercialization expenses for LYR-210
through &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;; to fund the development of LYR-220 through &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;; and the remainder, if any, for platform
development and other research and development expenses for our pipeline, and for working capital and general corporate purposes. See &#147;Use of Proceeds&#148; beginning on page&nbsp;76 for additional information. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>You should carefully read the &#147;Risk Factors&#148; beginning on page&nbsp;11 and the other information included in this prospectus for a discussion of factors you should consider carefully before deciding to invest in our common stock.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Proposed Nasdaq Global Market symbol </P></TD>
<TD>&#147;LYRA&#148; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering is based on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock outstanding as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, and
excludes: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock issuable upon
exercise of stock options outstanding under our 2016 Equity Incentive Plan, or our 2016 Plan, as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, at a weighted-average
exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock issuable upon
exercise of stock options outstanding under our 2005 Equity Incentive Plan, or our 2005 Plan, as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, at a weighted-average
exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock issuable upon
the exercise of stock options granted after &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 pursuant to our 2016 Plan; </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock reserved for
future issuance under our 2020 Incentive Award Plan, or our 2020 Plan, which will become effective in connection with this offering, as well as any automatic increases in the number of shares of our common stock reserved for future issuance under
our 2020 Plan; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock that will
become available for future issuance under our 2020 Employee Stock Purchase Plan, or our 2020 ESPP, which will become effective in connection with this offering, and shares of our common stock that become available pursuant to provisions in the 2020
ESPP that automatically increase the share reserve under our 2020 ESPP. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, this prospectus
reflects and assumes the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a &nbsp;&nbsp;&nbsp;&nbsp; <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">-for-</FONT></FONT>
&nbsp;&nbsp;&nbsp;&nbsp; reverse stock split of our common stock, which will become effective prior to the effectiveness of the registration statement of which this prospectus forms a part; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the automatic cashless exercise of outstanding warrants to purchase shares of common stock, which, based on an
assumed initial public offering price of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range set forth on the cover of this prospectus, would result in the issuance of shares of our common stock upon the
closing of this offering (a $1.00 increase in the assumed initial public offering price of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share would increase the number of additional shares of our common stock
issuable in connection with such automatic exercise by an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares; a $1.00 decrease in the assumed initial public offering price of $
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share would decrease the number of additional shares of our common stock issuable in connection with such exercise by an aggregate of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares); </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the conversion of all outstanding shares of our preferred stock into an aggregate of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock upon the closing of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise of outstanding options after
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020; </P></TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise by the underwriters of their option to purchase additional shares of our common stock; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the filing of our restated certificate of incorporation, which will occur upon the closing of this offering.
</P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Summary Consolidated Financial Data </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following tables set forth our summary consolidated financial data as of, and for the periods ended on, the dates indicated. We have
derived the consolidated statements of operations data for the years ended December&nbsp;31, 2019 and 2018 and the consolidated balance sheet data as of December&nbsp;31, 2019 from our audited consolidated financial statements included elsewhere in
this prospectus. Our historical results are not necessarily indicative of the results that should be expected for any future period. You should read the following summary consolidated financial data together with the more detailed information
contained in &#147;Selected Consolidated Financial Data,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our consolidated financial statements and the related notes included elsewhere
in this prospectus. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands, except share and<BR>per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statement of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,519</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,259</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of tranche liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,029</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders&#151;basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.07</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares outstanding&#151;basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,998,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,728,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share attributable to common stockholders&#151;basic and diluted
(unaudited)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.08</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted-average common shares outstanding&#151;basic and diluted (unaudited)<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">216,118,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See Note 2 to our to audited consolidated financial statements included elsewhere in this prospectus for an
explanation of the method used to calculate the historical and pro forma basic and diluted net loss per common share and the weighted average number of shares used in the computation of the per share amounts. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>As of December&nbsp;31,
2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Pro&nbsp;Forma<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Pro&nbsp;Forma&nbsp;As<BR>Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(2)(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(127,757</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(123,338</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The pro forma consolidated balance sheet data gives effect to (1) the issuance and sale of 78,306,611 shares of
our Series C preferred stock, at a price of $0.38811 per share, and warrants to purchase 23,491,979 shares of our common stock, in each case, in January 2020, (2) the automatic conversion of all outstanding shares of our preferred stock into an
aggregate of 287,426,285 shares of common stock and (3) the automatic cashless exercise of outstanding warrants to purchase shares of common stock, which, based on an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover of this prospectus, would result in the issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of our common stock upon the closing of this offering (a $1.00 increase in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share would increase the number of
additional shares of our common stock issuable in connection with such automatic exercise by an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares; a $1.00 decrease in the assumed initial public offering
price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share would decrease the number of additional shares of our common stock issuable in connection with such exercise by an aggregate of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares), which will occur upon the closing of this offering. </P></TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects the pro forma adjustments described in footnote (1)&nbsp;and the issuance and sale of shares of common
stock in this offering at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after
deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash
and cash equivalents, working capital, total assets, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital and total stockholders&#146; equity by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million,
assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each
increase (decrease) of 1.0&nbsp;million shares in the number of shares offered by us at the assumed initial public offering price would increase (decrease) each of cash and cash equivalents, working capital, total assets, additional <FONT
STYLE="white-space:nowrap">paid-in</FONT> capital and total stockholders&#146; equity by $<B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B></B><B> </B>million. The pro forma information discussed above
is illustrative only and will be adjusted based on the actual initial public offering price and other terms of our initial public offering determined at pricing. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We define working capital as current assets less current liabilities. See our consolidated financial statements
for further details regarding our current assets and current liabilities. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc805799_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>You should carefully consider the risks and uncertainties described below and the other information in this prospectus before making an
investment in our common stock. Our business, financial condition, results of operations, or prospects could be materially and adversely affected if any of these risks occurs, and as a result, the market price of our common stock could decline and
you could lose all or part of your investment. This prospectus also contains <FONT STYLE="white-space:nowrap">forward-looking</FONT> statements that involve risks and uncertainties. See &#147;Special Note Regarding
<FONT STYLE="white-space:nowrap">Forward-Looking</FONT> Statements.&#148; Our actual results could differ materially and adversely from those anticipated in these <FONT STYLE="white-space:nowrap">forward-looking</FONT> statements as a result of
certain factors, including those set forth below. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Financial Position and Need for Additional Capital </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have a limited operating history and a history of escalating operating losses, which may make it difficult to evaluate the prospects for our future
viability. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage therapeutics company established in November 2005. Our operations to date have been limited to
financing and staffing our company, developing our technology and identifying and developing our product candidates. Our prospects must be considered in light of the uncertainties, risks, expenses, and difficulties frequently encountered by
companies in their early stages of operations. We have not yet demonstrated an ability to obtain marketing approval, manufacture a commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing
activities necessary for successful product commercialization. Consequently, predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing,
obtaining marketing approval for and commercializing CRS treatments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, we may encounter unforeseen expenses, difficulties,
complications, delays and other known and unknown obstacles. We will eventually need to transition from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a
transition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As we continue to build our business, we expect our financial condition and operating results may fluctuate significantly
from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any particular quarterly or annual period as indications of future operating
performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred significant losses since inception and expect to incur significant additional losses for the foreseeable future. We
may never achieve or maintain profitability. </I></B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have incurred significant operating losses since our inception, including
operating losses of approximately $16.3&nbsp;million and $6.0 million for the fiscal years ended December&nbsp;31, 2019 and December&nbsp;31, 2018, respectively. In addition, we have not commercialized any products and have never generated any
revenue from product sales. We have devoted almost all of our financial resources to research and development, including our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> development activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, we expect to continue to incur significant additional operating losses for the foreseeable future as we seek to advance product
candidates through <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical development, expand our research and development activities, develop new product candidates, complete <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies
and clinical trials, seek regulatory approval and, if we receive FDA approval, commercialize our products. In order to obtain FDA approval of any product candidate, we must submit to the FDA an NDA demonstrating that the product candidate is safe
for humans and effective for its intended use. This demonstration requires significant research and animal tests, which are referred to as <FONT STYLE="white-space:nowrap">non-clinical</FONT> or <FONT STYLE="white-space:nowrap">pre-clinical</FONT>
studies, as well as human tests, which are referred to as clinical trials. Furthermore, the costs of advancing product candidates into each succeeding clinical phase tend to increase substantially over time. The total costs to advance any of our
product candidates to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
marketing approval in even a single jurisdiction would be substantial. Because of the numerous risks and uncertainties associated with ENT disease treatment product development, we are unable to
accurately predict the timing or amount of increased expenses or when, or if, we will be able to begin generating revenue from the commercialization of products or achieve or maintain profitability. Our expenses will also increase substantially if
and as we: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue additional clinical trials of our most advanced product candidate, LYR-210, including the Phase&nbsp;2
LANTERN trial, which commenced in May 2019 and one or more planned pivotal Phase&nbsp;3 clinical trials of LYR-210; </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advance the development of LYR-220; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue to discover and develop additional product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish manufacturing and supply chain capacity sufficient to provide commercial quantities of any product
candidates for which we may obtain marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek regulatory and marketing approvals for product candidates that successfully complete clinical trials, if
any; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish a sales, marketing and distribution infrastructure to commercialize any products for which we may
obtain regulatory approval in geographies in which we plan to commercialize our products ourselves; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain, expand and protect our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hire additional staff, including clinical, scientific, technical, regulatory, operational, financial, commercial
and support personnel, to execute our business plan; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add clinical, scientific operational, financial and management information systems and personnel to support our
product development and potential future commercialization efforts, and as to enable us to operate as a public reporting company; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">utilize external vendors for support with respect to research, development, commercialization, regulatory,
pharmacovigilance and other functions; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other commercial products, product candidates and
technologies; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expand internationally; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make royalty, milestone or other payments under current and any future
<FONT STYLE="white-space:nowrap">in-license</FONT> agreements; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">implement additional internal systems and infrastructure; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">operate as a public company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Furthermore, our ability to successfully develop, commercialize and license our products and generate product revenue is subject to
substantial additional risks and uncertainties. Each of our product candidates will require additional <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and/or clinical development, potential regulatory approval in multiple jurisdictions, the
securing of manufacturing supply, capacity and expertise, the use of external vendors, the building of a commercial organization, substantial investment and significant marketing efforts before we generate any revenue from product sales. As a
result, we expect to continue to incur net losses and negative cash flows for the foreseeable future. These net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#146; equity and working
capital. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The amount of future losses and when, if ever, we will achieve profitability are uncertain.
We have no products that have generated any commercial revenue, do not expect to generate revenues from the commercial sale of products in the foreseeable future, and might never generate revenues from the sale of products. Our ability to generate
revenue and achieve profitability will depend on, among other things, successful completion of the clinical development of our product candidates; obtaining necessary regulatory approvals from the FDA and international regulatory agencies;
establishing manufacturing, sales, market acceptance of our products and marketing infrastructure to commercialize our product candidates for which we obtain approval; and raising sufficient funds to finance our activities. We might not succeed at
any of these undertakings. If we are unsuccessful at some or all of these undertakings, our business, prospects, and results of operations may be materially adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if this offering is successful, we will need significant additional funding in order to complete development of and obtain regulatory approval for
our product candidates and commercialize our products, if approved. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Even after the consummation of this offering, we will continue to need additional capital beyond the proceeds of this offering, which we may
raise through equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or other sources. Additional sources of financing might not be available on favorable
terms, if at all. If we do not succeed in raising additional funds on acceptable terms, we might be unable to complete planned clinical trials or obtain approval of any of our product candidates from the FDA, or any foreign regulatory authorities,
and could be forced to discontinue product development. In addition, attempting to secure additional financing may divert the time and attention of our management from
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities and harm our product candidate development efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We will require substantial funds to further develop, obtain approval for and commercialize our product candidates, including <FONT
STYLE="white-space:nowrap">LYR-210,</FONT> which is currently in Phase 2 clinical development. We will also require substantial funds to further develop, obtain approval for and commercialize our other product candidate, <FONT
STYLE="white-space:nowrap">LYR-220,</FONT> which is in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Based on our
current operating plan, we believe that the anticipated net proceeds from this offering and our current cash and cash equivalents will be sufficient to enable us to fund our operating expenses and capital expenditure requirements until
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. This estimate is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect.
Changing circumstances could cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more than currently expected because of circumstances beyond our control. Because the length of time and activities
associated with successful development of <FONT STYLE="white-space:nowrap">LYR-210</FONT> and <FONT STYLE="white-space:nowrap">LYR-220</FONT> is highly uncertain, we are unable to estimate the actual funds we will require for development, approval
and any approved marketing and commercialization activities. Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope and results of our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of, and the costs involved in, obtaining regulatory approvals for
<FONT STYLE="white-space:nowrap">LYR-210</FONT> and <FONT STYLE="white-space:nowrap">LYR-220;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of changes in the regulatory environment and enforcement rules; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing in changes in pharmaceutical pricing and reimbursement infrastructure;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs involved in preparing, filing, prosecuting, maintaining and enforcing patent claims and other
patent-related costs, including any litigation costs and the results of such litigation; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of competing technological and market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire other products and
technologies; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of establishing sales, marketing and distribution capabilities for our product candidates in regions
where we choose to commercialize our products; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, progress, timing and results of our commercialization of
<FONT STYLE="white-space:nowrap">LYR-210</FONT> and <FONT STYLE="white-space:nowrap">LYR-220,</FONT> if approved for commercial sale. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Depending on our business performance, the economic climate and market conditions, we may be unable to raise additional funds through any
sources. If we are unable to obtain adequate funding on a timely basis, we may be required to curtail or discontinue one or more of our development programs for <FONT STYLE="white-space:nowrap">LYR-210</FONT> or
<FONT STYLE="white-space:nowrap">LYR-220,</FONT> or to reduce our operations. If we raise additional funds by issuing equity securities, our then-existing stockholders will experience dilution and the terms of any new equity securities may have
preference over those of our existing common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause dilution to our stockholders, including purchasers of
common stock in this offering, restrict our operations or require us to relinquish rights to our technologies or product candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as we can generate substantial revenue, we may finance our cash needs through a combination of equity offerings,
debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we
believe that we have sufficient funds for our current or future operating plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To the extent that we raise additional capital through
the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and
preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our operations, our ability to take specific actions, such as incurring additional debt, making capital expenditures, declaring
dividends, redeeming our stock, making certain investments and engaging in certain merger, consolidation or asset sale transactions, among other restrictions. If we raise additional funds through collaborations, strategic alliances or marketing,
distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are
unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product
candidates that we would otherwise prefer to develop and market ourselves. </P>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have no approved products. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To date, we have no approved product on the market and have generated no product revenues. Unless we receive approval from the FDA or other
regulatory authorities for our product candidates, we will not have product revenues. Therefore, for the foreseeable future, we will have to fund all of our operations and capital expenditures from the net proceeds of this offering, cash on hand,
and licensing fees and grants, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates are in various stages of development. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are a therapeutics company focused on the development and commercialization of novel integrated drug and drug delivery solutions for the
localized treatment of patients with ENT diseases. Our product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
candidates are at stages of pre-clinical or clinical development, and favorable results in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> or early stage clinical trials may not be
predictive of success in later clinical trials and may not lead to commercially viable products for any of several reasons. For example, our product candidates may fail to be safe and effective in current or future clinical trials or <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> studies, or we may have inadequate financial or other resources to pursue discovery and development efforts for new product candidates. Our product candidates will require significant additional
development, clinical trials, regulatory clearances and additional investment by us before they can be commercialized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business is highly
dependent on the success of our most advanced product candidate, <FONT STYLE="white-space:nowrap">LYR-210,</FONT> which will require significant additional clinical testing before we can seek regulatory approval and potentially launch commercial
sales. If <FONT STYLE="white-space:nowrap">LYR-210</FONT> does not receive regulatory approval or is not successfully commercialized, or is significantly delayed in doing so, our business will be harmed. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A substantial portion of our business and future success depends on our ability to develop, obtain regulatory approval for and successfully
commercialize our most advanced product candidate, <FONT STYLE="white-space:nowrap">LYR-210.</FONT> We currently have no products that are approved for commercial sale and have not completed the development of any product candidates, and may never
be able to develop marketable products. We expect that a substantial portion of our efforts and expenditures over the next few years will be devoted to <FONT STYLE="white-space:nowrap">LYR-210,</FONT> which will require additional clinical
development and potential additional <FONT STYLE="white-space:nowrap">pre-clinical</FONT> development, management of clinical, medical affairs and manufacturing activities, regulatory approval in multiple jurisdictions, the securing of manufacturing
supply, the building of a commercial organization, substantial investment and significant marketing efforts before we can generate any revenues from any commercial sales. We cannot be certain that <FONT STYLE="white-space:nowrap">LYR-210</FONT> will
be successful in ongoing or future clinical trials, receive regulatory approval or be successfully commercialized even if we receive regulatory approval. Even if we receive approval to market <FONT STYLE="white-space:nowrap">LYR-210</FONT> from the
FDA or other regulatory bodies, we cannot be certain that our product candidates will be successfully commercialized, widely accepted in the marketplace or more effective than other commercially available alternatives. Nor can we be certain that, if
and when approved, the safety and efficacy profile of <FONT STYLE="white-space:nowrap">LYR-210</FONT> or our other product candidates will be consistent with the profiles observed in clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If the required regulatory approvals for <FONT STYLE="white-space:nowrap">LYR-210</FONT> are not obtained or are significantly delayed, or any
approved products are not commercially successful, our business, financial condition and results of operations may be materially harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">LYR-210</FONT> is our most advanced product candidate, and if we experience regulatory or developmental issues with respect to <FONT STYLE="white-space:nowrap">LYR-210,</FONT> our development plans and business could be
significantly harmed. Moreover, if we experience similar regulatory or developmental issues with our other pipeline product candidates, our development plans and business could be significantly harmed. Further, our competitors may be developing
products with similar mechanisms of action and may experience problems with their products that could identify problems that would potentially harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in our efforts to identify and successfully commercialize additional product candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Part of our strategy involves identifying novel product candidates. The process by which we identify product candidates may fail to yield
product candidates for clinical development for a number of reasons, including those discussed in these risk factors and also: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be able to assemble sufficient resources to acquire or discover additional product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competitors may develop alternatives that render our potential product candidates obsolete or less attractive;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential product candidates we develop may nevertheless be covered by third parties&#146; patents or other
exclusive rights; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential product candidates may, on further study, be shown to have harmful side effects, toxicities or other
characteristics that indicate that they are unlikely to be products that will receive marketing approval or achieve market acceptance; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential product candidates may not be effective in treating their targeted diseases or symptoms;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the market for a potential product candidate may change so that the continued development of that product
candidate is no longer reasonable; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a potential product candidate may not be capable of being produced in commercial quantities at an acceptable
cost, or at all; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the regulatory pathway for a potential product candidate is highly complex and difficult to navigate successfully
or economically. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, we may choose to focus our efforts and resources on a potential product candidate that
ultimately proves to be unsuccessful, or to license or purchase a marketed product that does not meet our financial expectations. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to
forego or delay pursuit of opportunities with other product candidates or other diseases that may later prove to have greater commercial potential, or relinquish valuable rights to such product candidates through collaboration, licensing or other
royalty arrangements in cases in which it would have been advantageous for us to retain sole development and commercialization rights. If we are unable to identify and successfully commercialize additional suitable product candidates, this would
adversely impact our business strategy and our financial position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may expend our limited resources to pursue a particular product candidate or
indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific
indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to timely
capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we
do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it
would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to
Discovery, Development, Clinical Testing, Manufacturing and Regulatory Approval </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical trials required for our product candidates are
expensive and time-consuming, their outcome is uncertain, and if our clinical trials do not meet safety or efficacy endpoints in these evaluations, or if we experience significant delays in these trials, our ability to commercialize our product
candidates and our financial position will be impaired. </I></B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We began dosing patients in our Phase 2 LANTERN clinical trial of our
most advanced product, <FONT STYLE="white-space:nowrap">LYR-210,</FONT> in May 2019. Our other product candidate, <FONT STYLE="white-space:nowrap">LYR-220,</FONT> is in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> development. It is
impossible to predict when or if </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
either of our product candidates will prove effective and safe in humans or if we will receive regulatory approval for any of our product candidates, and the risk of failure through the
development process is high. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete <FONT STYLE="white-space:nowrap">pre-clinical</FONT> development and then conduct extensive clinical
trials to demonstrate the safety and efficacy of our product candidates in humans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Clinical development is a long, expensive and
uncertain process that is subject to significant delays. Due to known or unknown circumstances beyond our control, it may take us several years to complete our testing, and failure can occur at any stage of testing. The outcome of <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> testing and early clinical trials may not be predictive of the results of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. We cannot assure you
that any clinical trial that we are conducting, or may conduct in the future, will demonstrate consistent or adequate efficacy and safety to obtain regulatory approval to market our product candidates. Moreover,
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical data are often susceptible to varying interpretations and analysis, and many companies that have believed their product candidates performed satisfactorily in <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials have nonetheless failed to obtain marketing approval of their products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Delays associated with products for which we are directly conducting <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical
trials may cause us to incur additional operating expenses. The commencement and rate of completion of <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trials may be delayed by, or terminated because of, many factors,
including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to obtain regulatory approval to commence a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to reach, or delays in reaching, an agreement on acceptable terms with prospective contract research
organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">slower than expected rates of recruitment of patients or failure to recruit a sufficient number of patients;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">modification of <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trial protocols;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in regulatory requirements for <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of unusual placebo effects; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of effectiveness during <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the emergence of unforeseen safety issues or undesirable side effects; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to obtain institutional review board, or the IRB, approval at each site; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays, suspension, or termination of clinical trials by the IRB responsible for overseeing the trial at a
particular trial site; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure of patients in completing a trial or returning for post-treatment
<FONT STYLE="white-space:nowrap">follow-up;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical sites deviating from trial protocol, dropping out of a trial or failing to comply with regulatory
requirements; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to address patient safety concerns that arise during the course of a trial; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to manufacture sufficient quantities of product candidate for use in clinical trials; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">government, IRB or other regulatory delays or &#147;clinical holds&#148; requiring suspension or termination of
the trials. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or
prevent our ability to receive marketing approval or commercialize our product candidates or significantly increase the cost of such trials, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may receive feedback from regulatory authorities that requires us to modify the design of our clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or
regulators may require us, to conduct additional clinical trials or abandon development programs; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of patients required for clinical trials of our product candidates may be larger than we anticipate,
enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials or fail to return for post-treatment <FONT STYLE="white-space:nowrap">follow-up</FONT> at a higher rate than we anticipate;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to enroll a sufficient number of patients in our clinical trials to ensure adequate statistical
power to detect any statistically significant treatment effects; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations
to us in a timely manner, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulators, IRBs or independent ethics committees, or IECs, may not authorize us or our investigators to commence
a clinical trial or conduct a clinical trial at a prospective trial site or may require that we or our investigators suspend or terminate clinical trials of our product candidates for various reasons, including
<FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory requirements, a finding that our product candidates have undesirable side effects or other unexpected characteristics, or a finding that the participants are being exposed to
unacceptable health risks; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may experience delays in reaching or fail to reach agreement on acceptable
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> study or clinical trial contracts or <FONT STYLE="white-space:nowrap">pre-clinical</FONT> study or clinical trial protocols with prospective trial sites; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trials of our product
candidates may be greater than we anticipate and we may not have funds to cover the costs; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the supply or quality of our product candidates or other materials necessary to conduct <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trials of our product candidates may be insufficient or inadequate; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulators may revise the requirements for approving our product candidates, or such requirements may not be as
we anticipate; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any current or future collaborators that conduct <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or
clinical trials may face any of the above issues, and may conduct <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trials in ways they view as advantageous to them but that are suboptimal for us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we are required to extend the duration of current <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trials or to
conduct additional <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trials or other testing of our product candidates beyond those that we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
currently contemplate, if we are unable to successfully complete <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trials of our product candidates or other testing, if the
results of these trials, studies or tests are not positive or are only modestly positive, if there are safety concerns or if we determine that the observed safety or efficacy profile would not be competitive in the marketplace, we may: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incur unplanned costs; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be delayed in obtaining marketing approval for our product candidates or not obtain marketing approval at all;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain marketing approval in some countries and not in others; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain marketing approval for indications or patient populations that are not as broad as intended or desired;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain marketing approval with labeling that includes significant use or distribution restrictions or safety
warnings, including boxed warnings; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be subject to additional post-marketing testing requirements; or </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">have the product removed from the market after obtaining marketing approval. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We could encounter delays if a clinical trial is materially modified, suspended or terminated by us, by the IRBs of the institutions in which
such trials are being conducted, by the Data Safety Monitoring Board, or DSMB, for such trial or by the FDA or other regulatory authorities. Such authorities may impose such a material modification, suspension or termination due to a number of
factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the
imposition of a clinical hold, unforeseen safety issues or adverse side effects for our product candidates, or other products or product candidates in the same drug class, failure to demonstrate a benefit from using a drug, changes in governmental
regulations or administrative actions or lack of adequate funding to continue the clinical trial. Furthermore, we may rely on CROs and clinical trial sites to ensure the proper and timely conduct of clinical trials and while we would have agreements
governing their committed activities, we would have limited influence over their actual performance, as described in &#147;&#151;Risks Related to Our Dependence on Third Parties.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our most advanced product candidate, <FONT STYLE="white-space:nowrap">LYR-210,</FONT> is in clinical development and will require the
completion of clinical testing before we are prepared to submit an NDA for regulatory approval. We cannot predict if or when we might complete the development of <FONT STYLE="white-space:nowrap">LYR-210</FONT> and submit an NDA or whether any such
NDA will be approved by the FDA. We may also seek feedback from the FDA or other regulatory authorities on our clinical development programs, and the FDA or such regulatory authorities may not provide such feedback on a timely basis, or such
feedback may not be favorable, which could further delay our development programs. If the results of ongoing and future clinical trials for <FONT STYLE="white-space:nowrap">LYR-210</FONT> are positive, we plan to submit an NDA in the United States.
However, no assurance can be given that we will be successful in the near term, obtain regulatory approval or have any commercial sales of <FONT STYLE="white-space:nowrap">LYR-210.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any clinical test may fail to produce results satisfactory to the FDA or foreign regulatory authorities.
<FONT STYLE="white-space:nowrap">Pre-clinical</FONT> and clinical data can be interpreted in different ways by different reviewers and regulators, which could delay, limit or prevent regulatory approval. Drug-related adverse events during a <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> study or clinical trial could cause us to repeat a trial or study, perform an additional trial or study, expand the size and/or duration of a trial or study, terminate a trial or study or even cancel a <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> or clinical program. The failure of <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trials to demonstrate safety and effectiveness for the desired indications could harm the
development of that product candidate and other product candidates. This failure could cause us to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
abandon a product candidate and could delay development of other product candidates. Any delay in, or termination of, our clinical trials would delay the filing of our NDAs with the FDA and,
ultimately, our ability to commercialize our product candidates and generate product revenues. A number of companies in the biotechnology and pharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of
efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Even if our future and ongoing <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials are completed as planned, we cannot be certain
that their results will support the safety and effectiveness of <FONT STYLE="white-space:nowrap">LYR-210,</FONT> <FONT STYLE="white-space:nowrap">LYR-220</FONT> and/or any future product candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we experience delays in the commencement or completion of, or have to extend or expand, our
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trials, or if we terminate a <FONT STYLE="white-space:nowrap">pre-clinical</FONT> study or clinical trial prior to completion, the commercial prospects of <FONT
STYLE="white-space:nowrap">LYR-210,</FONT> <FONT STYLE="white-space:nowrap">LYR-220</FONT> or any future product candidate could be harmed, and our ability to generate revenues from <FONT STYLE="white-space:nowrap">LYR-210,</FONT> <FONT
STYLE="white-space:nowrap">LYR-220</FONT> or any future product candidate may be delayed. In addition, any delays in our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trials could increase our costs, slow down the
development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may harm our business, financial condition and results of operations. In addition, many of the factors that cause,
or lead to, a delay in the commencement or completion of <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials may fail to demonstrate adequately the safety and efficacy of any
of our product candidates and the development of our product candidates may be delayed or unsuccessful, which could prevent or delay regulatory approval and commercialization. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Both of our current product candidates are in clinical or <FONT STYLE="white-space:nowrap">pre-clinical</FONT> development stages.
Notwithstanding the data obtained to date with respect to <FONT STYLE="white-space:nowrap">LYR-210</FONT> and <FONT STYLE="white-space:nowrap">LYR-220</FONT> in CRS, <FONT STYLE="white-space:nowrap">LYR-210</FONT> and
<FONT STYLE="white-space:nowrap">LYR-220</FONT> will require additional clinical and <FONT STYLE="white-space:nowrap">non-clinical</FONT> development, regulatory review and approval in multiple jurisdictions, substantial investment, access to
sufficient commercial manufacturing capacity and significant marketing efforts before we can generate any revenue from our product sales. In addition, if we encounter safety or efficacy problems, developmental delays or regulatory issues or other
problems, our developmental plans and business could be significantly harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If the development of
<FONT STYLE="white-space:nowrap">LYR-210,</FONT> <FONT STYLE="white-space:nowrap">LYR-220</FONT> or any other future product candidate is unsuccessful, our ability to generate revenues will be adversely affected. Our development of current and
future product candidates is subject to the risks of failure and delay inherent in the development of new products and product candidates, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in product development, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> or clinical testing or
manufacturing; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unplanned expenditures in product development, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> or clinical
testing or manufacturing; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to receive regulatory approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to secure rights from third parties for new technology; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to achieve market acceptance; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">emergence of superior or equivalent products. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, product candidates in later stages of clinical trials may fail to show the desired safety profiles and efficacy results despite
having progressed through <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of
efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Based upon negative or inconclusive results, we may decide, or regulators may require us, to conduct additional clinical
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
trials or <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies. In addition, data obtained from trials and studies are susceptible to varying interpretations, and regulators may not
interpret our data as favorably as we do, which may delay, limit or prevent regulatory approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Additionally, we have not conducted, nor
do we believe we are required to conduct, any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> trials comparing <FONT STYLE="white-space:nowrap">LYR-210</FONT> to other approved or experimental treatments
for CRS. Any such <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> trial, if conducted, may show that <FONT STYLE="white-space:nowrap">LYR-210</FONT> is not more effective than any of such other drugs.
Material adverse differences in the relative efficacy of <FONT STYLE="white-space:nowrap">LYR-210</FONT> could significantly harm the adoption of <FONT STYLE="white-space:nowrap">LYR-210</FONT> and our business prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Because of these risks, our research and development efforts may not result in any commercially viable products. If a significant portion of
these development efforts are not successfully completed, required regulatory approvals are not obtained, or any approved products are not commercially successful, our business, financial condition and results of operations may be materially harmed.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Success in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> or earlier clinical trials may not be indicative of results in future clinical
trials. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Success in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and early clinical trials does not ensure that
later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate. <FONT STYLE="white-space:nowrap">Pre-clinical</FONT> studies and Phase 1 and Phase 2 clinical
trials are primarily designed to test safety, to study pharmacokinetics and pharmacodynamics and to understand the side effects of product candidates at various doses and schedules. Success in <FONT STYLE="white-space:nowrap">pre-clinical</FONT>
studies and early clinical trials does not ensure that later, large-scale efficacy trials will be successful nor does it predict final results. Our product candidates may fail to show the desired safety and efficacy in clinical development despite
positive results in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or having successfully advanced through initial clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, the design of a clinical trial can determine whether its results will support approval of a product, and flaws in the design of a
clinical trial may not become apparent until the clinical trial is well advanced. As an organization, we have limited experience designing clinical trials and may be unable to design and execute a clinical trial to support regulatory approval. Many
companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and earlier-stage
clinical trials. Data obtained from <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval. In addition, we may experience regulatory
delays or rejections as a result of many factors, including changes in regulatory policy during the period of our product candidate development. Any such delays could negatively impact our business, financial condition, results of operations and
prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the FDA does not conclude that certain of our product candidates satisfy the requirements for the Section&nbsp;505(b)(2) regulatory
approval pathway, or if the requirements for such product candidates under Section&nbsp;505(b)(2) are not as we expect, the approval pathway for those product candidates may likely take significantly longer, cost significantly more and entail
significantly greater complications and risks than anticipated, and in either case may not be successful. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We intend to seek FDA
approval for our current product candidates, <FONT STYLE="white-space:nowrap">LYR-210</FONT> and <FONT STYLE="white-space:nowrap">LYR-220,</FONT> and we may seek FDA approval for future product candidates, through the Section&nbsp;505(b)(2)
regulatory pathway. The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Amendments, added Section&nbsp;505(b)(2) to the Federal Food, Drug and Cosmetic Act, or FDCA. Section&nbsp;505(b)(2) permits the
filing of an NDA where at least some of the information required for approval comes from trials that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference. Section&nbsp;505(b)(2), if applicable
to us under the FDCA, would allow an NDA we submit to the FDA to rely in part on data in the public domain or the FDA&#146;s prior conclusions regarding the safety and effectiveness of approved drugs, which could expedite the development program for
our product candidates by potentially decreasing the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amount of clinical data that we would need to generate in order to obtain FDA approval. If the FDA does not allow us to pursue the Section&nbsp;505(b)(2) regulatory pathway as we anticipate, we
may need to conduct additional clinical trials, provide additional data and information and meet additional standards for regulatory approval. If this were to occur, the time and financial resources required to obtain FDA approval for our product
candidates, and complications and risks associated with the development of our product candidates, would likely substantially increase. Moreover, inability to pursue the Section&nbsp;505(b)(2) regulatory pathway could result in competitive products
reaching the market before our product candidates, which could impact our competitive position and prospects. Even if we are allowed to pursue the Section&nbsp;505(b)(2) regulatory pathway, we cannot assure you that our product candidates will
receive the requisite approvals for commercialization, or that a competitor would not obtain approval first along with subsequent market exclusivity from the FDA, thereby delaying potential approval of our product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, the pharmaceutical industry is highly competitive, and Section&nbsp;505(b)(2) NDAs are subject to special requirements designed
to protect the patent rights of sponsors of previously approved drugs that are referenced in a Section&nbsp;505(b)(2) NDA. These requirements may give rise to patent litigation and mandatory delays in approval of our NDAs for up to 30 months or
longer depending on the outcome of any litigation. It is not uncommon for a manufacturer of an approved product to file a citizen petition with the FDA seeking to delay approval of, or impose additional approval requirements for, pending competing
products. If successful, such petitions can significantly delay, or even prevent, the approval of the new product. However, even if the FDA ultimately denies such a petition, the FDA may substantially delay approval while it considers and responds
to the petition. In addition, even if we are able to utilize the Section&nbsp;505(b)(2) regulatory pathway, there is no guarantee this would ultimately lead to accelerated product development or earlier approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Moreover, even if our product candidates are approved under Section&nbsp;505(b)(2), the approval may be subject to limitations on the
indicated uses for which the products may be marketed or to other conditions of approval, or may contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have conducted, are conducting and in the future, we may conduct clinical trials for our product candidates in sites outside the United States, and
the FDA may not accept data from trials conducted in foreign locations. </I></B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have conducted and are conducting clinical trials
for LYR-210 outside the United States, specifically in Australia, Austria, Czech Republic, New Zealand and Poland, and we may in the future choose to conduct other clinical trials outside the United States for LYR-210, LYR-220 or any of our other
future product candidates. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to certain conditions imposed by the FDA. For example, the clinical trial must be well designed
and conducted and performed by qualified investigators in accordance with good clinical practice, or GCP, including review and approval by an IEC and receipt of informed consent from subjects. In general, the patient population for any clinical
trials conducted outside of the United States must be representative of the population for which we intend to seek approval for the product in the United States. In addition, while these clinical trials are subject to the applicable local laws, FDA
acceptance of the data will be dependent upon its determination that the trials also complied with all applicable U.S. laws and regulations. There can be no assurance the FDA will accept data from trials conducted outside of the United States. If
the FDA does not accept the data from our clinical trials of our product candidates, it would likely result in the need for additional trials, which would be costly and time-consuming and delay or permanently halt our development of our product
candidates. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, there are risks inherent in conducting clinical trials in multiple jurisdictions, inside and outside of the
United States, such as: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory and administrative requirements of the jurisdiction where the trial is conducted that could burden or
limit our ability to conduct our clinical trials; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign exchange fluctuations; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing, customs, shipment and storage requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cultural differences in medical practice and clinical research; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that the patient populations in such trials are not considered representative as compared to the patient
population in the target markets where approval is being sought. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interim and preliminary data from our clinical trials that we
announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">From time to time, we may publish interim or preliminary data from our clinical trials. Interim data from clinical trials that we may complete
are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Interim or preliminary data also remain subject to audit and verification procedures that
may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Differences between interim or
preliminary data and final data could significantly harm our business prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">LYR-210</FONT> and <FONT
STYLE="white-space:nowrap">LYR-220</FONT> are drug-device combinations, which may result in additional regulatory and other risks. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">LYR-210</FONT> and <FONT STYLE="white-space:nowrap">LYR-220</FONT> are drug-device combination products. We
may experience delays in obtaining regulatory approval of these product candidates given the increased complexity of the review process when approval of a drug and a delivery device is sought under a single marketing application. Both <FONT
STYLE="white-space:nowrap">LYR-210</FONT> and <FONT STYLE="white-space:nowrap">LYR-220</FONT> will be regulated as drug-device combination products, which require coordination within the FDA and similar foreign regulatory agencies for review of the
product candidates&#146; device and drug components. The determination whether a combination product requires a single marketing application or two separate marketing applications for each component is made by the FDA on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis. Although we believe a single marketing application for the approval of a combination product would be successful, there can be no assurance that the FDA
will not determine that separate marketing applications are necessary. This determination could significantly increase the resources and time required to bring a particular combination product to market. Although the FDA and similar foreign
regulatory agencies have systems in place for the review and approval of combination products such as ours, we may experience delays in the development and commercialization of our product candidates due to regulatory timing constraints and
uncertainties in the product development and approval process, as well as coordination between two different centers within FDA responsible for review of the different components of the combination product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Failure to successfully develop or supply the device component, delays in or failure of the studies conducted by us, our collaborators, or
third-party providers, or failure of our Company, our collaborators, or third-party providers to obtain or maintain regulatory approval or clearance of the device component of <FONT STYLE="white-space:nowrap">LYR-210</FONT> or <FONT
STYLE="white-space:nowrap">LYR-220,</FONT> as appropriate, could result in increased development costs, delays in or failure to obtain regulatory approval, and associated delays in these product candidates reaching the market. Further, failure to
successfully develop or supply the device, or to gain or maintain its approval, could adversely affect sales of <FONT STYLE="white-space:nowrap">LYR-210</FONT> and <FONT STYLE="white-space:nowrap">LYR-220.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to obtain the necessary U.S. regulatory approvals to commercialize any product candidate, we will not be able to generate revenue in the U.S.
market. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We cannot assure you that we will receive the approvals necessary to commercialize our product candidates, or any product
candidate we acquire or develop in the future. We will need FDA approval to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercialize our product candidates in the United States and approvals from equivalent regulatory authorities in foreign jurisdictions to commercialize our product candidates in those
jurisdictions. Satisfaction of the FDA&#146;s regulatory requirements typically takes many years, depends upon the type, complexity and novelty of the product candidate and requires substantial resources for research, development and testing. We
cannot predict whether our research and clinical efforts will result in drugs that the FDA will determine are safe for humans and effective for their intended uses. The FDA has substantial discretion in the drug approval process and may require us
to conduct additional <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical testing, perform post-marketing studies, address manufacturing concerns, or otherwise limit or impose conditions on any approval we obtain. The approval process
may also be delayed by changes in government regulation, future legislation or administrative action or changes in FDA policy that occur prior to or during our regulatory review. Delays in obtaining regulatory approvals may: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delay commercialization of, and our ability to derive product revenues from, our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">impose costly procedures on us; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diminish any competitive advantages that we may otherwise enjoy. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Even if we receive approval of an NDA or comparable foreign regulatory filing for our product candidates, the FDA or the applicable foreign
regulatory body may approve our product candidates for a more limited indication than we originally requested, and the FDA may not approve the labeling that we believe is necessary or desirable for the successful commercialization of our product
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Even if we comply with all FDA requests, the FDA may ultimately reject one or more of our NDAs. We cannot be sure that we
will ever obtain regulatory clearance for our product candidates. Failure to obtain FDA approval of our product candidates will severely undermine our business by leaving us without a commercially available product, and therefore without any source
of revenues, until another product candidate can be developed or obtained and ultimately approved. There is no guarantee that we will ever be able to develop or acquire another product candidate or that we will be able to obtain FDA approval to
commercialize such product candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we obtain FDA approval for our product candidates in the United States, we may never obtain approval
for or commercialize them in any other jurisdiction, which would limit our ability to realize its full market potential. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We
intend either on our own or through collaborations or partnerships, to market our products in international markets. In order to market any products in the European Union and many other foreign jurisdictions, we must establish and comply with
numerous and varying regulatory requirements on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis regarding safety and efficacy. Approval by the FDA in the United States does not ensure
approval by regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. In addition, clinical trials conducted in one country
may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Approval processes vary among countries and can involve additional product testing and validation and additional administrative review
periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trials which could be costly and time consuming.
Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including in international
markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any
product we develop will be unrealized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, costly,
time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed. We cannot predict when or if, and in which territories, we, or any of
our potential future collaborators, will obtain marketing approval to commercialize a product candidate. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The time required to
obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory
authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#146;s clinical development and may vary among jurisdictions. We have
not obtained regulatory approval for any product candidate and it is possible that neither <FONT STYLE="white-space:nowrap">LYR-210,</FONT> <FONT STYLE="white-space:nowrap">LYR-220</FONT> nor any future product candidates we may seek to develop in
the future will ever obtain regulatory approval. Neither we nor any future collaborator is permitted to market any of our product candidates in the United States until we receive regulatory approval of an NDA from the FDA. It is possible that the
FDA may refuse to accept for substantive review any NDAs that we submit for our product candidates or may conclude after review of our data that our application is insufficient to obtain marketing approval of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we or our collaborators must demonstrate with
substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or foreign regulatory agencies, that such product candidates are safe and effective for their intended uses in patients. Results from <FONT
STYLE="white-space:nowrap">non-clinical</FONT> studies and clinical trials can be interpreted in different ways. Even if we believe the <FONT STYLE="white-space:nowrap">non-clinical</FONT> or clinical data for our product candidates are promising,
such data may not be sufficient to support approval by the FDA and other regulatory authorities. The FDA may also require us to conduct additional <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trials for our product
candidates either prior to or post-approval, or it may object to elements of our clinical development program. Depending on the extent of these or any other <FONT STYLE="white-space:nowrap">FDA-required</FONT> studies, approval of any NDA or other
application that we submit may be delayed by several years, or may require us to expend significantly more resources than we have available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Of the large number of potential products in development, only a small percentage successfully complete the FDA or foreign regulatory approval
processes and are commercialized. The lengthy and costly approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would
significantly harm our business, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Moreover, principal investigators for our clinical trials may serve
as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign
regulatory authorities. The FDA or comparable foreign regulatory authorities may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The
FDA or comparable foreign regulatory authorities may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in
approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authorities, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we encounter delays or difficulties enrolling patients in our clinical trials, our clinical
development activities and receipt of regulatory approvals could be delayed or otherwise adversely affected. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The timely
completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion. Trials may be subject to delays as a result of
patient enrollment taking longer than anticipated or patient withdrawal. We may encounter delays in enrolling, or be unable to enroll, a sufficient number of patients to complete any of our clinical trials, and even once enrolled we may be unable to
retain a sufficient number of patients to complete any of our trials. We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate
in these trials as required by the FDA or similar regulatory authorities outside the United States. We cannot predict how successful we will be at enrolling subjects in future clinical trials. The enrollment of patients depends on many factors,
including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patient eligibility criteria defined in the protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size of the patient population required for analysis of the trial&#146;s primary endpoints;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proximity of patients to trial sites; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the design of the trial; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinicians&#146; and patients&#146; perceptions as to the potential advantages of the product candidate being
studied in relation to other available therapies, including any new products that may be approved for the indications we are investigating; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the perceived risks and benefits of the product candidate in the trial; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of alternative therapies; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain patient consents; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that patients enrolled in clinical trials will drop out of the trials before completion.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same
therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted
by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients
who are available for our clinical trials in such clinical trial site. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Delays or failures in planned patient enrollment or retention may
result in increased costs, program delays or both, which could have a harmful effect on our ability to develop <FONT STYLE="white-space:nowrap">LYR-210,</FONT> <FONT STYLE="white-space:nowrap">LYR-220</FONT> and/or any other future product
candidates, or could render further development impossible. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates may cause serious adverse events or undesirable side effects including injury
and death or have other properties which may delay or prevent their regulatory approval, limit the commercial profile of an approved label, or, result in significant negative consequences following marketing approval, if any. If any of our product
candidates receives marketing approval and we, or others, later discover that the drug is less effective than previously believed or causes undesirable side effects that were not previously identified, our ability, or that of any potential future
collaborators, to market the drug could be compromised. </I></B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Before obtaining regulatory approvals for the commercial sale of our
product candidates, we must demonstrate through lengthy, complex and expensive <FONT STYLE="white-space:nowrap">pre-clinical</FONT> testing and clinical trials that our product candidates are both safe and effective for use in each target
indication, and failures can occur at any stage of testing. Clinical trials often fail to demonstrate safety and efficacy of the product candidate studied for the target indication. Serious adverse events, or SAEs, or undesirable side effects caused
by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign
authorities. Results of our clinical trials or <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies could reveal a high and unacceptable severity and prevalence of side effects, toxicities or unexpected characteristics, including death. For
example, in our Phase 1 clinical trial for our most advanced product candidate, <FONT STYLE="white-space:nowrap">LYR-210,</FONT> there has been one SAE in the active group (acute myocardial infarction), which was considered not related to <FONT
STYLE="white-space:nowrap">LYR-210.</FONT> For more information, see <FONT STYLE="white-space:nowrap">&#147;Business&#151;LYR-210</FONT> for the Treatment of CRS&#151;Overview of Our Clinical Development.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, subjects treated with <FONT STYLE="white-space:nowrap">LYR-210</FONT> have experienced adverse events, including facial pain,
nasopharyngitis, sinusitis, upper respiratory tract infection, procedural headache, nasal discomfort and nasal odor, among others. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If
unacceptable side effects arise in the development of our product candidates, we, the FDA, the IRBs at the institutions in which our studies are conducted or DSMB, could materially modify, suspend or terminate our clinical trials or the FDA or
comparable foreign regulatory authorities could order us to cease <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trials, require us to conduct additional animal or human studies regarding the safety and efficacy of our
product candidates which we have not planned or anticipated, or deny approval of our product candidates for any or all targeted indications. Many product candidates that initially showed promise in early stage testing have later been found to cause
side effects that prevented further development of the product candidate. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims.
In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We currently train and expect to have to train medical personnel using our product candidates to understand the side effect profiles for
our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these
occurrences may harm our business, financial condition and prospects significantly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If any of our product candidates receives marketing
approval, and we or others later identify undesirable side effects caused by any such product, including during any long-term <FONT STYLE="white-space:nowrap">follow-up</FONT> observation period recommended or required for patients who receive
treatment using our products, a number of potentially significant negative consequences could result, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may withdraw approvals of such product; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to recall a product or change the way such product is administered to patients;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes
for the product; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require additional warnings on the label, such as a &#147;black box&#148; warning or
contraindication; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require long-term patient registries for the product; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a medication guide
outlining the risks of such side effects for distribution to patients; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the product could become less competitive; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we could be sued and held liable for harm caused to patients; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reputation may suffer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There can be no assurance that we will resolve any issues related to any product-related adverse events to the satisfaction of the FDA or any
regulatory agency in a timely manner or at all. Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations
and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As product candidates proceed through <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies to late-stage clinical trials towards
potential approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize processes and results. Such changes carry the
risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered
materials. Such changes may also require additional testing, FDA notification or FDA approval. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase
clinical trial costs, delay approval of our product candidates and jeopardize our ability to commence sales and generate revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our insurance
policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We do not carry insurance for all categories of risk that our business may encounter. Some of the policies we currently maintain include
general liability, employment practices liability, property, auto, workers&#146; compensation, umbrella, and directors&#146; and officers&#146; insurance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any additional product liability insurance coverage we acquire in the future, may not be sufficient to reimburse us for any expenses or losses
we may suffer. Moreover, insurance coverage is becoming increasingly expensive and in the future we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If we
obtain marketing approval for <FONT STYLE="white-space:nowrap">LYR-210</FONT> and/or <FONT STYLE="white-space:nowrap">LYR-220,</FONT> we intend to acquire insurance coverage to include the sale of commercial products; however, we may be unable to
obtain product liability insurance on commercially reasonable terms or in adequate amounts. A successful product liability claim or series of claims brought against us could cause our share price to decline and, if judgments exceed our insurance
coverage, could adversely affect our results of operations and business, including preventing or limiting the development and commercialization of any product candidates we develop. We do not carry specific biological or hazardous waste insurance
coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or
injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We also expect that operating as a public company will make it more difficult and more expensive for us to obtain director and officer
liability insurance, and we may be required to accept reduced policy limits and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified people to serve on our board of
directors, our board committees or as executive officers. We do not know, however, if we will be able to maintain existing insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts,
which would adversely affect our cash position and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees and independent contractors, including principal
investigators, CROs, consultants, vendors, and any third parties we may engage in connection with research, development, regulatory, manufacturing, quality assurance and other pharmaceutical functions and commercialization may engage in misconduct
or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Misconduct by our employees and independent contractors, including principal investigators, CROs, consultants, vendors, and any third parties
we may engage in connection with research, development, regulatory, manufacturing, quality assurance and other pharmaceutical functions and commercialization, could include intentional, reckless or negligent conduct or unauthorized activities that
violate: (i)&nbsp;the laws and regulations of the FDA, the European Medicines Agency, or the EMA, and other similar regulatory authorities, including those laws that require the reporting of true, complete and accurate information to such
authorities; (ii)&nbsp;manufacturing standards; (iii)&nbsp;data privacy, security, fraud and abuse and other healthcare laws and regulations; or (iv)&nbsp;laws that require the reporting of true, complete and accurate financial information and data.
Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations
may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws could also involve the improper use or
misrepresentation of information obtained in the course of <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trials, creation of fraudulent data in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical
trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the
precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with
such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending
ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements,
possible exclusion from participation in Medicare, Medicaid, other U.S. federal healthcare programs or healthcare programs in other jurisdictions, integrity oversight and reporting obligations to resolve allegations of
<FONT STYLE="white-space:nowrap">non-compliance,</FONT> individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business and operations would suffer in the event of system failures. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our computer systems, as well as those of our CROs and other contractors, vendors, suppliers and consultants, are vulnerable to damage from
computer viruses, unauthorized access, natural disasters (including hurricanes), terrorism, war and telecommunication and electrical failures. If such an event were to occur and cause interruptions in our operations, it could result in a material
disruption of our product candidate development programs and our business. For example, the loss of <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trial data from completed, ongoing or planned trials could result in delays
in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate
disclosure of personal, confidential or proprietary information, we could incur liability and the further development of <FONT STYLE="white-space:nowrap">LYR-210,</FONT> LYR-220 or any other product candidate could be delayed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the ordinary course of our business, we directly or indirectly collect and store sensitive data, including intellectual property,
confidential information, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trial data, proprietary business </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
information, personal data and personally identifiable health information of our clinical trial subjects and employees, in our data centers and on our networks, or on those of third parties. The
secure processing, maintenance and transmission of this information is critical to our operations. Despite our security measures, our information technology and infrastructure has been and, from time to time, may be vulnerable to attacks by hackers
or internal bad actors, or breached due to employee error, a technical vulnerability, malfeasance or other disruptions. Although, to our knowledge, we have not experienced any material security breach to date, any such breach could compromise our
networks and the information stored there could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of
personal information, significant regulatory penalties, and such an event could disrupt our operations, damage our reputation, and cause a loss of confidence in us and our ability to conduct clinical trials, which could adversely affect our business
reputation and delay our clinical development of our product candidates. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Healthcare Laws and Other Legal Compliance Matters
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will be subject to extensive and costly government regulation. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Product candidates employing our technology will be subject to extensive and rigorous domestic government regulation including regulation by
the FDA, the Centers for Medicare and Medicaid Services, or CMS, other divisions of the United States Department of Health and Human Services, the United States Department of Justice, state and local governments, and their respective equivalents
outside of the United States. The FDA regulates the research, development, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical testing, manufacture, safety, effectiveness, record-keeping, reporting, labeling, packaging, storage,
approval, advertising, promotion, sale, distribution, import, and export of pharmaceutical products. If products employing our technologies are marketed abroad, they will also be subject to extensive regulation by foreign governments, whether or not
they have obtained FDA approval for a given product and its uses. Such foreign regulation may be equally or more demanding than corresponding United States regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Government regulation substantially increases the cost and risk of researching, developing, manufacturing, and selling our products. The
regulatory review and approval process, which includes <FONT STYLE="white-space:nowrap">pre-clinical</FONT> testing and clinical trials of each product candidate, is lengthy, expensive, and uncertain. We or our collaborators must obtain and maintain
regulatory authorization to conduct <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials. We or our collaborators must obtain regulatory approval for each product we intend to market, and the manufacturing facilities used
for the products must be inspected and meet legal requirements. Securing regulatory approval requires the submission of extensive <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical data and other supporting information for each
proposed therapeutic indication in order to establish the product&#146;s safety and efficacy, potency and purity, for each intended use. The development and approval process takes many years, requires substantial resources, and may never lead to the
approval of a product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Even if we are able to obtain regulatory approval for a particular product, the approval may limit the indicated
medical uses for the product, may otherwise limit our ability to promote, sell, and distribute the product, may require that we conduct costly post-marketing surveillance, and/or may require that we conduct ongoing post-marketing studies. Material
changes to an approved product, such as, for example, manufacturing changes or revised labeling, may require further regulatory review and approval. Once obtained, any approvals may be withdrawn, including, for example, if there is a later discovery
of previously unknown problems with the product, such as a previously unknown safety issue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we, our collaborators, consultants,
contract manufacturers, CROs or other vendors, fail to comply with applicable regulatory requirements at any stage during the regulatory process, such noncompliance could result in, among other things, delays in the approval of applications or
supplements to approved applications; refusal of a regulatory authority, including the FDA, to review pending market approval applications or supplements to approved applications; warning letters; fines; import and/or export restrictions; product
recalls or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
seizures; injunctions; total or partial suspension of production; civil penalties; withdrawals of previously approved marketing applications or licenses; recommendations by the FDA or other
regulatory authorities against governmental contracts; and/or criminal prosecutions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Enacted and future healthcare legislation may increase the
difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and could adversely affect our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the United States, the EU and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and
regulatory changes and proposed changes to the healthcare system that could prevent or delay marketing approval of our products in development, restrict or regulate post-approval activities involving any product candidates for which we obtain
marketing approval, impact pricing and reimbursement and impact our ability to sell any such products profitably. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce
healthcare costs and improve the quality of healthcare. In addition, new regulations and interpretations of existing healthcare statutes and regulations are frequently adopted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively
the ACA, was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers. Among the provisions of the ACA, those of greatest importance to the pharmaceutical and biotechnology industries include the
following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an annual, <FONT STYLE="white-space:nowrap">non-deductible</FONT> fee payable by any entity that manufactures or
imports certain branded prescription drugs and biologic agents (other than those designated as orphan drugs), which is apportioned among these entities according to their market share in certain government healthcare programs; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#146;s
outpatient drugs to be covered under Medicare Part D; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">new requirements to report certain financial arrangements with physicians and teaching hospitals, including
reporting &#147;transfers of value&#148; made or distributed to prescribers and other healthcare providers and reporting investment interests held by physicians and their immediate family members; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to
23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated
for drugs that are inhaled, infused, instilled, implanted or injected; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">extension of a manufacturer&#146;s Medicaid rebate liability to covered drugs dispensed to individuals who are
enrolled in Medicaid managed care organizations; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid
coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#146;s Medicaid rebate liability; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative
clinical effectiveness research, along with funding for such research; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishment of a Center for Medicare Innovation at CMS to test innovative payment and service delivery models
to lower Medicare and Medicaid spending, potentially including prescription drug spending. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Since its enactment, there
have been judicial and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, the creation of the Independent Payment Advisory Board, which had
been included as part of the provisions of the ACA, was repealed in February 2018. The current presidential administration and Congress will likely continue to seek to modify, repeal, or otherwise invalidate all, or certain provisions of, the ACA.
It is uncertain the extent to which any such changes may impact our business or financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, other legislative
changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011 resulted in aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect in
April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2029 unless additional action is taken by Congress. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among
other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers
from three to five years. These new laws or any other similar laws introduced in the future may result in additional reductions in Medicare and other healthcare funding, which could negatively affect our customers and accordingly, our financial
operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example,
CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted
in several U.S. Congressional inquiries and proposed and enacted federal legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, and review the relationship between
pricing and manufacturer patient programs. The Trump administration&#146;s budget proposal for fiscal year 2020 contains further drug price control measures that could be enacted during the 2020 budget process or in other future legislation,
including, for example, measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for <FONT
STYLE="white-space:nowrap">low-income</FONT> patients. Further, the Trump administration released a &#147;Blueprint&#148;, or plan, to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase drug
manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out of pocket costs of drug products paid by consumers. The
Department of Health and Human Services has already started the process of soliciting feedback on some of these measures and, at the same, is immediately implementing others under its existing authority. While any proposed measures will require
authorization through additional legislation to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. We expect that additional
U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product
candidates or additional pricing pressures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Individual states in the United States have also increasingly passed legislation and
implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency
measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally-mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations,
financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates or put pressure on our
product pricing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the EU, similar political, economic and regulatory developments may affect our ability to profitably commercialize
our product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or member state level may result in significant additional requirements or obstacles that may
increase our operating costs. The delivery of healthcare in the EU, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and
policy. National governments and health service providers have different priorities and approaches to the delivery of healthcare and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints
in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market
products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize our product candidates, if approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In markets outside of the United States and the EU, reimbursement and healthcare payment systems vary significantly by country, and many
countries have instituted price ceilings on specific products and therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, legislative and regulatory proposals have been
made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA&#146;s regulations, guidance or
interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#146;s approval process may significantly delay
or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in
the United States, the EU or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not
able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we receive regulatory approval of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review,
which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling,
packaging, distribution, adverse event reporting, storage, recordkeeping, export, import, advertising and promotional activities for such product, among other things, will be subject to extensive and ongoing requirements of and review by the FDA,
the EMA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, establishment registration and drug listing requirements, continued compliance with current good
manufacturing practice, or cGMP, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping
and GCP requirements for any clinical trials that we conduct post-approval. In addition, the sponsor of an approved NDA is subject to periodic inspections and other FDA monitoring and reporting obligations, including obligations to monitor and
report adverse events and other information such as the failure of a product to meet the specifications in the NDA. NDA sponsors must submit new or supplemental applications </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and obtain FDA approval for certain changes to the approved product, product labeling, or manufacturing process. Application holders must also submit advertising and other promotional material to
the FDA and report on ongoing clinical trials. The FDA may require changes in the labeling of already approved drug products and require that sponsors conduct post-marketing studies. Accordingly, we and others with whom we work must continue to
expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Even if
marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, including the requirement to implement a REMS, which could
include requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk mitigation tools. If any of our product candidates
receives marketing approval, the accompanying label may limit the approved use of our product, which could limit sales of the product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy
of our approved products. In addition, advertising and promotional materials must comply with FDA rules in addition to other potentially applicable federal and state laws. The FDA closely regulates the post-approval marketing and promotion of drugs
to ensure they are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#146; communications regarding
<FONT STYLE="white-space:nowrap">off-label</FONT> use, and if we market our products outside of their approved indications, we may be subject to enforcement action for <FONT STYLE="white-space:nowrap">off-label</FONT> marketing. Violations of the
FDA&#146;s restrictions relating to the promotion of prescription products may also lead to investigations alleging violations of federal and state health care fraud and abuse laws, as well as state consumer protection laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The distribution of product samples to physicians must comply with the requirements of the FDCA. NDA sponsors must obtain FDA approval for
product, manufacturing, and labeling changes, depending on the nature of the change. Depending on the circumstances, failure to meet these post-approval requirements can result in criminal prosecution, fines, injunctions, consent decrees of
permanent injunction, recall or seizure of products, total or partial suspension of production, denial or withdrawal of <FONT STYLE="white-space:nowrap">pre-marketing</FONT> product approvals, or refusal to allow us to enter into supply contracts,
including government contracts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, later discovery of previously unknown adverse events or other problems with our products,
manufacturers or manufacturing processes, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various
results, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on manufacturing such products; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the labeling or marketing of a product; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on product distribution or use; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requirements to conduct post-marketing studies or clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">warning letters or holds on clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of the products from the market; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal to approve pending applications or supplements to approved applications that we submit;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recall of products; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, restitution or disgorgement of profits or revenues; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspension or withdrawal of marketing approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal to permit the import or export of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention; or </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any government investigation of alleged violations of law could require us to expend significant time and resources in response, and could
generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenues. If regulatory sanctions are applied or if regulatory approval is
withheld or withdrawn, the value of our company and our operating results will be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA&#146;s policies may change
and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of <FONT STYLE="white-space:nowrap">LYR-210,</FONT> <FONT STYLE="white-space:nowrap">LYR-220</FONT> and/or any other future product
candidate. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained
which would adversely affect our business, prospects and ability to achieve or sustain profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We also cannot predict the
likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the Trump administration may impact our
business and industry. Namely, the Trump administration has taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#146;s ability to
engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict how these requirements will be implemented,
and the extent to which they will impact the FDA&#146;s ability to exercise its regulatory authority. If these executive actions impose constraints on FDA&#146;s ability to engage in oversight and implementation activities in the normal course, our
business may be negatively impacted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in funding for the&nbsp;FDA&nbsp;and other government agencies could hinder their ability to hire and
retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The ability of the&nbsp;FDA&nbsp;to review and approve new products can be affected by a variety of factors, including government budget and
funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government
funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Disruptions at the&nbsp;FDA&nbsp;and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary
government agencies, which would adversely affect our business.&nbsp;For example, over the last several years, including for 35 days beginning on December&nbsp;22, 2018, the U.S. government has shut down several times and certain regulatory
agencies, such as the&nbsp;FDA, have had to furlough critical&nbsp;employees and stop critical activities. If a prolonged&nbsp;government&nbsp;shutdown&nbsp;occurs, it could significantly impact the ability of the FDA to timely review and process
our regulatory submissions, which could have a material adverse effect on our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business operations and current and future relationships with investigators, healthcare
professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors,
patient organizations and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our
operations, including how we research, market, sell and distribute our product candidates, if approved. Such laws include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly
and willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the
referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and
Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. federal civil and criminal false claims laws, including the civil False Claims Act, which, among other
things, impose criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or
approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation
to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes
of the False Claims Act; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal civil monetary penalties laws, which impose civil fines for, among other things, the offering or
transfer of remuneration to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary&#146;s selection of a particular provider, practitioner, or supplier of services reimbursable
by Medicare or a state healthcare program, unless an exception applies; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal
and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making
any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services; similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute
or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 and its
implementing regulations, which also imposes certain obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information without appropriate
authorization by covered entities subject to the rule, such as health plans, healthcare clearinghouses and healthcare providers as well as their business associates that perform certain services involving the use or disclosure of individually
identifiable health information; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical
devices; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. Physician Payments Sunshine Act and its implementing regulations, which requires certain manufacturers
of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#146;s Health Insurance Program to report annually to the government information related to certain payments and other transfers of
value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and
activities that potentially harm consumers; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may apply
to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that
require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to
healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of
value provided to healthcare professionals and entities; state and local laws that require the registration of pharmaceutical sales representatives; and state laws governing the privacy and security of health information in certain circumstances,
many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">similar healthcare laws and regulations in the EU and other jurisdictions, including reporting requirements
detailing interactions with and payments to healthcare providers and laws governing the privacy and security of certain protected information, such as the General Data Protection Regulation, or the GDPR, which imposes obligations and restrictions on
the collection and use of personal data relating to individuals located in the EU (including health data). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Ensuring
that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business
practices, including our relationships with physicians and other healthcare providers, some of whom are compensated in the form of stock options for consulting services provided, may not comply with current or future statutes, regulations, agency
guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to
us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or
jurisdictions, integrity oversight and reporting obligations to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance,</FONT> disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the
curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or
administrative sanctions, including exclusions from government funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly, time-consuming and may
require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to governmental regulation and other legal obligations, particularly related to
privacy, data protection and information security, and we are subject to consumer protection laws that regulate our marketing practices and prohibit unfair or deceptive acts or practices. Our actual or perceived failure to comply with such
obligations could harm our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are subject to diverse laws and regulations relating to data privacy and security,
including, in the United States, HIPAA and, in the EU and the European Economic Area, or EEA, Regulation 2016/679, known as the GDPR. New privacy rules are being enacted in the United States and globally, and existing ones are being updated and
strengthened. For example, on June&nbsp;28, 2018, California enacted the California Consumer Privacy Act, or CCPA, which takes effect on January&nbsp;1, 2020. The CCPA creates individual privacy rights for California consumers and increases the
privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation.
Complying with these numerous, complex and often changing regulations is expensive and difficult, and failure to comply with any privacy laws or data security laws or any security incident or breach involving the misappropriation, loss or other
unauthorized use or disclosure of sensitive or confidential patient or consumer information, whether by us, one of our business associates or another third-party, could adversely affect our business, financial condition and results of operations,
including but not limited to: investigation costs, material fines and penalties; compensatory, special, punitive and statutory damages; litigation; consent orders regarding our privacy and security practices; requirements that we provide notices,
credit monitoring services and/or credit restoration services or other relevant services to impacted individuals; adverse actions against our licenses to do business; and injunctive relief. Furthermore, these rules are constantly changing; for
example, the GDPR came into force in May 2018 changing the European regime. Before that, the <FONT STYLE="white-space:nowrap">US-EU</FONT> Safe Harbor framework was declared invalid in 2015 and replaced with the
<FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Privacy Shield framework which, along with other methods which permit transfer under European privacy law, are under ongoing review and subject to challenge. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The privacy laws in the EU have been significantly reformed. On May&nbsp;25, 2018, the GDPR entered into force and became directly applicable
in all EU member states. The GDPR implements more stringent operational requirements than its predecessor legislation. For example, the GDPR requires us to make more detailed disclosures to data subjects, requires disclosure of the legal basis on
which we can process personal data, makes it harder for us to obtain valid consent for processing, will require the appointment of data protection officers when sensitive personal data, such as health data, is processed on a large scale, provides
more robust rights for data subjects, introduces mandatory data breach notification through the EU, imposes additional obligations on us when contracting with service providers and requires us to adopt appropriate privacy governance including
policies, procedures, training and data audit. If we do not comply with our obligations under the GDPR, we could be exposed to fines of up to the greater of &#128;20&nbsp;million or up to 4% of our total global annual revenue in the event of a
significant breach. In addition, we may be the subject of litigation and/or adverse publicity, which could adversely affect our business, results of operations and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We cannot assure you that our third-party service providers with access to our or our customers&#146;, suppliers&#146;, trial patients&#146;
and employees&#146; personally identifiable and other sensitive or confidential information in relation to which we are responsible will not breach contractual obligations imposed by us, or that they will not experience data security breaches or
attempts thereof, which could have a corresponding effect on our business, including putting us in breach of our obligations under privacy laws and regulations and/or which could in turn adversely affect our business, results of operations and
financial condition. We cannot assure you that our contractual measures and our own privacy and security-related safeguards will protect us from the risks associated with the third-party processing, storage and transmission of such information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face potential liability related to the privacy of health information we obtain from clinical trials sponsored by us. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Most healthcare providers, including research institutions from which we obtain patient health information, are subject to privacy and
security regulations promulgated under HIPAA, as amended by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
HITECH. We are not currently classified as a covered entity or business associate under HIPAA and thus are not subject to its requirements or penalties. However, any person may be prosecuted
under HIPAA&#146;s criminal provisions either directly or under <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">aiding-and-abetting</FONT></FONT> or conspiracy principles. Consequently, depending on the facts and circumstances, we
could face substantial criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA&#146;s requirements for disclosure of
individually identifiable health information. In addition, we may maintain sensitive personally identifiable information, including health information, that we receive throughout the clinical trial process, in the course of our research
collaborations, and directly from individuals (or their healthcare providers) who enroll in our patient assistance programs. As such, we may be subject to state laws requiring notification of affected individuals and state regulators in the event of
a breach of personal information, which is a broader class of information than the health information protected by HIPAA. Our clinical trial programs outside the United States may implicate international data protection laws, including the EU Data
Protection Directive and legislation of the EU member states implementing it. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our activities outside the United States impose additional
compliance requirements and generate additional risks of enforcement for noncompliance. Failure by our CROs and other third-party contractors to comply with the strict rules on the transfer of personal data outside of the European Union into the
United States may result in the imposition of criminal and administrative sanctions on such collaborators, which could adversely affect our business. Furthermore, certain health privacy laws, data breach notification laws, consumer protection laws
and genetic testing laws may apply directly to our operations and/or those of our collaborators and may impose restrictions on our collection, use and dissemination of individuals&#146; health information. Moreover, patients about whom we or our
collaborators obtain health information, as well as the providers who share this information with us, may have statutory or contractual rights that limit our ability to use and disclose the information. We may be required to expend significant
capital and other resources to ensure ongoing compliance with applicable privacy and data security laws. Claims that we have violated individuals&#146; privacy rights or breached our contractual obligations, even if we are not found liable, could be
expensive and time-consuming to defend and could result in adverse publicity that could harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we or third-party CMOs,
CROs or other contractors or consultants fail to comply with applicable federal, state or local regulatory requirements, we could be subject to a range of regulatory actions that could affect our or our contractors&#146; ability to develop and
commercialize our product candidates and could harm or prevent sales of any affected products that we are able to commercialize, or could substantially increase the costs and expenses of developing, commercializing and marketing our products. Any
threatened or actual government enforcement action could also generate adverse publicity and require that we devote substantial resources that could otherwise be used in other aspects of our business. Increasing use of social media could give rise
to liability, breaches of data security or reputational damage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to environmental, health and safety laws and regulations, and we may
become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our
operations, including our development, testing and manufacturing activities, are subject to numerous environmental, health and safety laws and regulations. These laws and regulations govern, among other things, the controlled use, handling, release
and disposal of and the maintenance of a registry for, hazardous materials and biological materials, such as chemical solvents, human cells, carcinogenic compounds, mutagenic compounds and compounds that have a toxic effect on reproduction,
laboratory procedures and exposure to blood-borne pathogens. If we fail to comply with such laws and regulations, we could be subject to fines or other sanctions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As with other companies engaged in activities similar to ours, we face a risk of environmental liability inherent in our current and
historical activities, including liability relating to releases of or exposure to hazardous or biological materials. Environmental, health and safety laws and regulations are becoming more stringent. We may be required to incur substantial expenses
in connection with future environmental compliance or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
remediation activities, in which case, the production efforts of our third-party manufacturers or our development efforts may be interrupted or delayed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We and our employees are increasingly utilizing social media tools as a means of communication both internally and externally. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Despite our efforts to monitor evolving social media communication guidelines and comply with applicable rules, there is risk that the use of
social media by us or our employees to communicate about our product candidates or business may cause us to be found in violation of applicable requirements. In addition, our employees may knowingly or inadvertently make use of social media in ways
that may not comply with our policies and other legal or contractual requirements, which may give rise to liability, lead to the loss of trade secrets or other intellectual property or result in public exposure of personal information of our
employees, clinical trial patients, customers and others. Furthermore, negative posts or comments about us or our product candidates in social media could seriously damage our reputation, brand image and goodwill. Any of these events could have a
material adverse effect on our business, prospects, operating results and financial condition and could adversely affect the price of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Commercialization </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Developments
by competitors may render our products or technologies obsolete or <FONT STYLE="white-space:nowrap">non-competitive</FONT> or may reduce the size of our markets. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our industry has been characterized by extensive research and development efforts, rapid developments in technologies, intense competition and
a strong emphasis on proprietary products. We face potential competition from many different sources, including pharmaceutical, biotechnology and specialty pharmaceutical companies either marketing or developing therapeutics to treat CRS. Academic
research institutions, governmental agencies, as well as public and private institutions are also potential sources of competitive products and technologies. Our competitors may have or may develop superior technologies or approaches, which may
provide them with competitive advantages. Our potential products may not compete successfully. If these competitors access the marketplace before we do with better or less expensive therapeutics, our product candidates, if approved for
commercialization, may not be profitable to sell or worthwhile to continue to develop. Technology in the pharmaceutical industry has undergone rapid and significant change, and we expect that it will continue to do so. Any compounds, products or
processes that we develop may become obsolete or uneconomical before we recover any expenses incurred in connection with their development. The success of our product candidates will depend upon factors such as product efficacy, safety, reliability,
availability, timing, scope of regulatory approval, acceptance and price, among other things. Other important factors to our success include speed in developing product candidates, completing clinical development and laboratory testing, obtaining
regulatory approvals and manufacturing and selling commercial quantities of potential products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our product candidates are intended to
compete directly or indirectly with existing products and treatments. Even if approved and commercialized, our product candidates may fail to achieve market acceptance with hospitals, physicians or patients. Hospitals, physicians or patients may
conclude that our potential products are less safe or effective or otherwise less attractive than these existing drugs. If our product candidates do not receive market acceptance for any reason, our revenue potential would be diminished, which would
materially adversely affect our ability to become profitable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Significant competition exists in the treatment of CRS. We will need to
compete with all currently available or future therapies within the indications where our development is focused. <FONT STYLE="white-space:nowrap">LYR-210,</FONT> if approved and commercialized, will face significant competition. The main classes of
marketed products that are available for the treatment of CRS include nasal saline irrigation, intranasal corticosteroidal sprays and antibiotics, as well as surgical intervention. In addition, one company is currently marketing, and several
companies are also currently developing, biologic monoclonal antibodies, or mAbs, for the treatment of nasal polyps. If these biologic mAbs </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
are successfully developed and approved for marketing, they could represent competition for <FONT STYLE="white-space:nowrap">LYR-220</FONT> for the segment of patients that have polyps. Finally,
one company is developing an oral <FONT STYLE="white-space:nowrap">DP-2</FONT> antagonist currently in Phase 2 clinical trials for CRS patients that could represent competition across the spectrum of CRS patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There are a number of companies developing or marketing therapies for the treatment and management of CRS that may compete with our current
product candidates, including many major pharmaceutical and biotechnology companies. These companies include, among others: Hoffman-La Roche, GlaxoSmithKline, Gossamer Bio, AnaptysBio, Regeneron, OptiNose and Intersect ENT. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Most of our competitors, including many of those listed above, have substantially greater capital resources, robust product candidate
pipelines, established presence in the market and expertise in research and development, manufacturing, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical testing, obtaining regulatory approvals and reimbursement and marketing
approved products than we do. As a result, our competitors may achieve product commercialization or patent protection earlier than we can. Smaller or early-stage companies may also prove to be significant competitors, particularly through
collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified clinical, regulatory, scientific, sales, marketing and management personnel and establishing clinical trial
sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize
products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop or that would render any products that we may develop obsolete or noncompetitive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The successful commercialization of our product candidates will depend in part on the extent to which governmental authorities and health insurers
establish coverage, adequate reimbursement levels and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our
ability to generate revenue. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The availability of coverage and adequacy of reimbursement by governmental healthcare programs such
as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford medical services and pharmaceutical products such as our product candidates, assuming FDA approval. Our ability to
achieve acceptable levels of coverage and reimbursement for our products or procedures using our products by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize
our product candidates. Obtaining coverage and adequate reimbursement for our products may be particularly difficult because of the higher prices often associated with drugs administered under the supervision of a physician. Separate reimbursement
for the product itself or the treatment or procedure in which our product is used may not be available. A decision by a third-party payor not to cover or separately reimburse for our products or procedures using our products, could reduce physician
utilization of our products once approved. Assuming there is coverage for our product candidates or procedures using our product candidates by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require <FONT
STYLE="white-space:nowrap">co-payments</FONT> that patients find unacceptably high. Patients are unlikely to use our product candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our
product candidates. Similarly, our product candidates are physician-administered treatments and as such, separate reimbursement for the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed
only for providing the treatment or procedure in which our product is used. To the extent separate coverage and reimbursement should become available for <FONT STYLE="white-space:nowrap">LYR-210,</FONT> we anticipate that it will be sold to
physicians on a &#147;buy and bill&#148; basis. Buy and bill products must be purchased by healthcare providers before they can be administered to patients. Healthcare providers subsequently must seek reimbursement for the product from the
applicable third-party payor, such as Medicare or a health insurance company. Healthcare providers may be reluctant to administer our product candidates, if approved, because they would have to fund the purchase of the product and then seek
reimbursement, which may be lower than their purchase price, or because they do not want the additional administrative burden required to obtain reimbursement for the product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Further, the status of reimbursement codes for any of our product candidates, if approved,
could also affect reimbursement. <FONT STYLE="white-space:nowrap">J-Codes</FONT> and <FONT STYLE="white-space:nowrap">Q-Codes</FONT> are reimbursement codes maintained by the Centers for Medicare and Medicaid Services, or CMS, that are a component
of the Healthcare Common Procedure Coding System and are typically used to report injectable drugs that ordinarily cannot be self-administered. We currently do not have a specific <FONT STYLE="white-space:nowrap">J-Code</FONT> or <FONT
STYLE="white-space:nowrap">Q-Code</FONT> for any of our product candidates. If our product candidates are approved, we may apply for one but cannot guarantee that a <FONT STYLE="white-space:nowrap">J-Code</FONT> or
<FONT STYLE="white-space:nowrap">Q-Code</FONT> will be granted. To the extent separate coverage or reimbursement is available for any product candidate, if approved, and a specific <FONT STYLE="white-space:nowrap">J-Code</FONT> or <FONT
STYLE="white-space:nowrap">Q-Code</FONT> is not available, physicians would need to use a <FONT STYLE="white-space:nowrap">non-specific</FONT> miscellaneous <FONT STYLE="white-space:nowrap">J-Code</FONT> to bill third-party payors for these
physician-administered drugs. Because miscellaneous <FONT STYLE="white-space:nowrap">J-Codes</FONT> may be used for a wide variety of products, health plans may have more difficulty determining the actual product used and billed for the patient.
These claims must often be submitted with additional information and manually processed, which can delay claims processing times as well as increase the likelihood for claim denials and claim errors. We cannot be sure that coverage and reimbursement
in the United States, the EU or elsewhere will be available for our product candidates or any product that we may develop, and any reimbursement that may become available may not be adequate or may be decreased or eliminated in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may
refuse to provide coverage and reimbursement for particular drugs and biologics when an equivalent generic drug, biosimilar or a less expensive therapy is available. It is possible that a third-party payor may consider our product candidates as
substitutable and only offer to reimburse patients for the less expensive product. Even if we show improved efficacy or improved convenience of administration with our product candidates, pricing of existing third-party therapeutics may limit the
amount we will be able to charge for our product candidates. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an
appropriate return on our investment in our product candidates. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates, and may not be able to obtain a
satisfactory financial return on our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There is significant uncertainty related to the insurance coverage and
reimbursement of newly-approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and
biologics will be covered. The Medicare and Medicaid programs increasingly are used as models in the United States for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some
third-party payors may require <FONT STYLE="white-space:nowrap">pre-approval</FONT> of coverage for new or innovative drug therapies before they will reimburse healthcare providers who use such therapies. We cannot predict at this time what
third-party payors will decide with respect to the coverage and reimbursement for our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">No uniform policy for coverage
and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a
time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently
or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases on short notice, and we believe that changes in these rules and regulations are likely. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Outside the United States, international operations are generally subject to extensive governmental price controls and other market
regulations, and we believe the increasing emphasis on cost-containment initiatives in the EU and other jurisdictions have and will continue to put pressure on the pricing and usage of our product candidates. In many countries, the prices of medical
products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products, but monitor and control company profits. Additional foreign price controls or
other changes in pricing regulation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our product candidates may be reduced
compared with the United States and may be insufficient to generate commercially-reasonable revenue and profits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Moreover, increasing
efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they
may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of our product candidates due to the trend toward managed healthcare, the increasing influence of health
maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense. As a result,
increasingly high barriers are being erected to the entry of new products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our clinical studies were designed to demonstrate the safety and
efficacy of <FONT STYLE="white-space:nowrap">LYR-210</FONT> based on FDA requirements and may not be seen as compelling to physicians or patients. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our success depends on the medical community&#146;s acceptance of <FONT STYLE="white-space:nowrap">LYR-210,</FONT> if approved, as a treatment
for CRS patients. <FONT STYLE="white-space:nowrap">LYR-210</FONT> was previously studied in an open-label, Phase 1 clinical trial with 20 patients in New Zealand and Australia, which achieved its primary endpoint of safety at week 4. In the Phase 1
trial, we also observed that patients generally experienced significant and rapid, clinically meaningful and durable improvement in SNOT-22 scores. Significant reduction in <FONT STYLE="white-space:nowrap">SNOT-22</FONT> scores was observed at week
1, and this reduction persisted through week 25, which was the end of the trial. While the results of this early clinical trial suggest a favorable safety and efficacy profile, the study design and results, and the design and results of future
clinical trials we conduct, may not be viewed as compelling to our physician customers or patients. If physicians do not find our data compelling, even if <FONT STYLE="white-space:nowrap">LYR-210</FONT> receives marketing approval they may choose
not to use our products or limit their use. We cannot assure you that any data that we or others generate will be consistent with that observed in the Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">LYR-210,</FONT> nor that results will
be maintained beyond the time points studied. We also cannot assure you that any data that may be collected will be compelling to the medical community because the data may not be clinically meaningful and may not demonstrate that <FONT
STYLE="white-space:nowrap">LYR-210</FONT> is an attractive procedure when compared against data from alternative treatments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if either LYR-210
or LYR-220 receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If either LYR-210 or LYR-220 receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians,
patients, third-party payors and others in the medical community. If it does not achieve an adequate level of acceptance, we may not generate significant product revenues or become profitable. The degree of market acceptance of <FONT
STYLE="white-space:nowrap">LYR-210</FONT> or LYR-220, if approved for commercial sale, will depend on a number of factors, including but not limited to: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">perceptions by members of the healthcare community, including physicians, about the safety and effectiveness of
our platform; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the perception by members of the healthcare community, including physicians, or patients that the process of
administering <FONT STYLE="white-space:nowrap">LYR-210</FONT> or LYR-220, is not unduly cumbersome; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efficacy and potential advantages compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effectiveness of sales and marketing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of treatment in relation to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to offer our products for sale at competitive prices; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the convenience and ease of administration compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these
therapies; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the strength of marketing and distribution support; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of market introduction of competitive products; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of third-party coverage and adequate reimbursement; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product labeling or product insert requirements of the FDA, the EMA or other regulatory authorities, including
any limitations or warnings contained in a product&#146;s approved labeling; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prevalence and severity of any side effects; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any restrictions on the use of our product together with other medications. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If our product candidates are approved, but do not achieve an adequate level of acceptance by physicians, healthcare payors, and patients, we
may not generate sufficient revenue from these products, and we may not be able to achieve or sustain profitability. Our efforts to educate the medical community and third-party payors on the benefits of our product candidates may require
significant resources and may never be successful. In addition, our ability to successfully commercialize our product candidates will depend on our ability to manufacture our products through third-party manufacturers, differentiate our products
from competing products and defend the intellectual property of our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Because we expect sales of
<FONT STYLE="white-space:nowrap">LYR-210,</FONT> if approved, to generate substantially all of our product revenues for a substantial period, the failure of this product to find market acceptance would harm our business and could require us to seek
additional financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If physicians or patients are not willing to change current practices and adopt our office-based administration procedure for
<FONT STYLE="white-space:nowrap">LYR-210</FONT> and <FONT STYLE="white-space:nowrap">LYR-220,</FONT> our products may fail to gain market acceptance, and our business will be harmed. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our initial product candidates, <FONT STYLE="white-space:nowrap">LYR-210</FONT> and <FONT STYLE="white-space:nowrap">LYR-220,</FONT> are
bioresorbable polymeric matrices designed to be administered in a brief, <FONT STYLE="white-space:nowrap">non-invasive,</FONT> <FONT STYLE="white-space:nowrap">in-office</FONT> procedure by an ENT physician under endoscopic visualization via a <FONT
STYLE="white-space:nowrap">single-use</FONT> applicator. While we believe ENT physicians will be able to administer our product candidates, if successfully developed and approved, in conjunction with an endoscopy procedure, thereby making the
placement aligned with the existing care continuum for CRS patients and eliminating the need for ENT physicians to schedule separate surgical time, ENT physicians may not adopt our <FONT STYLE="white-space:nowrap">in-office</FONT> procedure for a
number of reasons, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lack of significant experience with the placement procedure via a
<FONT STYLE="white-space:nowrap">single-use</FONT> applicator; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lack of availability of adequate insurance coverage or reimbursement for the placement procedure;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">perceived inadequacy of evidence supporting clinical benefits or cost-effectiveness of the placement procedure
and/or our products in general over existing alternatives; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a perception that patients may be unable to tolerate the placement procedure in the physician office setting; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">liability risks generally associated with the use of new products and procedures. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If ENT physicians do not adopt the placement procedure for any reason, including those
listed above, our ability to grow our business would be impaired, even if <FONT STYLE="white-space:nowrap">LYR-210</FONT> and <FONT STYLE="white-space:nowrap">LYR-220</FONT> receive marketing approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe recommendations and support of our products by notable ENT physicians could influence market acceptance and adoption. If we do not
receive support from influential ENT physicians, our ability to achieve broad market acceptance for our products may be impaired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In
addition, if patient receptivity toward treatment in an ENT physician office setting becomes less favorable in the future, this shift could negatively impact market acceptance of our products. Any negative change due to patient receptivity could
also be compounded by patients reporting to physicians or other patients through <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">word-of-mouth</FONT></FONT> or social media. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Additionally, while it is currently more cost-effective to the healthcare system for providers to perform the placement procedure in an ENT
physician&#146;s office than a FESS procedure in an operating room, healthcare economics are subject to change. If the use of our products were to cease being more cost-effective than FESS due to changes in reimbursement economics, our products may
fail to gain market acceptance, our future growth would be limited and our business may be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to establish sales,
marketing and distribution capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing <FONT STYLE="white-space:nowrap">LYR-210</FONT> or LYR-220, if approved, and we may not be able to generate
any revenue. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We do not have any infrastructure for the sales, marketing or distribution of our products, and the cost of
establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect to build our own focused
sales, distribution and marketing infrastructure to market <FONT STYLE="white-space:nowrap">LYR-210</FONT> and LYR-220 in the United States, if approved. There are significant expenses and risks involved with establishing our own sales, marketing
and distribution capabilities, including our ability to hire, retain and appropriately incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel, and effectively manage a
geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities could delay any product launch, which would adversely impact the commercialization of <FONT
STYLE="white-space:nowrap">LYR-210.</FONT> Additionally, if the commercial launch of <FONT STYLE="white-space:nowrap">LYR-210</FONT> or LYR-220 for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for
any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Factors that may inhibit our efforts to commercialize our product candidates on our own include: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to recruit and retain adequate numbers of effective sales and marketing personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to
prescribe any future products; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to equip medical and sales personnel with effective materials, including medical and sales
literature to help them educate physicians and other healthcare providers regarding applicable diseases and our future products; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of complementary products to be offered by sales personnel, which may put us at a competitive
disadvantage relative to companies with more extensive product lines; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to develop or obtain sufficient operational functions to support our commercial activities; and
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unforeseen costs and expenses associated with creating an independent sales and marketing organization.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We do not anticipate having the resources in the foreseeable future to allocate to the sales and marketing of <FONT
STYLE="white-space:nowrap">LYR-210,</FONT> LYR-220 or any future product candidates in markets outside of the United States. Therefore, our future sales in these markets will largely depend on our ability to enter into and maintain collaborative
relationships for such capabilities, the collaborator&#146;s strategic interest in the product and such collaborator&#146;s ability to successfully market and sell the product. We intend to selectively pursue collaborative arrangements regarding the
sale and marketing of <FONT STYLE="white-space:nowrap">LYR-210,</FONT> if approved, for certain markets outside of the United States; however, we cannot assure that we will be able to establish or maintain such collaborative arrangements, or if able
to do so, that they will have effective sales forces. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we are unable to build our own sales force or negotiate a collaborative
relationship for the commercialization of <FONT STYLE="white-space:nowrap">LYR-210</FONT> or LYR-220, we may be forced to delay the potential commercialization of <FONT STYLE="white-space:nowrap">LYR-210</FONT> or LYR-220 or reduce the scope of our
sales or marketing activities for <FONT STYLE="white-space:nowrap">LYR-210</FONT> or LYR-220. If we elect to increase our expenditures to fund commercialization activities ourselves, we will need to obtain additional capital, which may not be
available to us on acceptable terms, or at all. We could enter into arrangements with collaborative partners at an earlier stage than otherwise would be ideal and we may be required to relinquish rights to
<FONT STYLE="white-space:nowrap">LYR-210</FONT> or LYR-220 or otherwise agree to terms unfavorable to us, any of which may have an adverse effect on our business, operating results and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we are unable to establish adequate sales, marketing and distribution capabilities, either on our own or in collaboration with third
parties, we will not be successful in commercializing <FONT STYLE="white-space:nowrap">LYR-210</FONT> or LYR-220 and may not become profitable and may incur significant additional losses. We will be competing with many companies that currently have
extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future growth may depend, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other
risks and uncertainties. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our future profitability may depend, in part, on our ability to commercialize our product candidates in
foreign markets for which we may rely on collaboration with third parties. We are evaluating the opportunities for the development and commercialization of our product candidates in foreign markets. We are not permitted to market or promote any of
our product candidates before we receive regulatory approval from the applicable regulatory authority in that foreign market, and we may never receive such regulatory approval for any of our product candidates. To obtain separate regulatory
approvals in other countries we may be required to comply with numerous and varying regulatory requirements of such countries regarding the safety and efficacy of our product candidates and governing, among other things, clinical trials and
commercial sales, pricing and distribution of our product candidates, and we cannot predict success in these jurisdictions. If we obtain approval of our product candidates and ultimately commercialize our product candidates in foreign markets, we
would be subject to additional risks and uncertainties, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our customers&#146; ability to obtain reimbursement for our product candidates in foreign markets;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to directly control commercial activities if we are relying on third parties;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">different medical practices and customs in foreign countries affecting acceptance in the marketplace;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">import or export licensing requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">longer accounts receivable collection times; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">longer lead times for shipping; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">language barriers for technical training and the need for language translations; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced protection of intellectual property rights in some foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the existence of additional potentially relevant third-party intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign currency exchange rate fluctuations; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Foreign sales of our product candidates could also be adversely affected by the imposition of governmental controls,
political and economic instability, trade restrictions and changes in tariffs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In some countries, particularly the countries in Europe,
the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a drug. To obtain
reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. If reimbursement of our products is unavailable or
limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed, possibly materially. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The sizes of the
patient populations that our product candidates are intended to treat have not been established with precision. If the market opportunities for our product candidates are smaller than we estimate, or if any approval that we obtain is based on a
narrower definition of the patient population than we anticipate, our revenue and ability to achieve profitability may be materially adversely affected. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The precise incidence and prevalence of the conditions we aim to address with our programs is unknown and cannot be precisely determined. Our
projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on beliefs and estimates. These estimates
have been derived from a variety of sources, including the scientific literature, surveys of clinics, patient foundations or market research, and may prove to be incorrect. Further, new information may change the estimated incidence or prevalence of
these diseases, and the incidence or prevalence of these diseases is subject to change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The total addressable market across all of our
product candidates will ultimately depend upon, among other things, the indications and conditions of use for which the product candidates are approved and may be marketed, acceptance by the medical community and patient access, drug pricing and
reimbursement. The sizes of the patient populations that our product candidates are intended to treat in the United States and other major markets and elsewhere may turn out to be smaller than expected, patients may not be otherwise amenable to
treatment with our product candidates or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business. Further, even if we obtain significant market
share for our product candidates, we may never achieve profitability despite obtaining such significant market share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we cannot compete for market share against other drug companies, we may not achieve sufficient
product revenues and our business will suffer. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If our product candidates receive FDA approval, they will compete with a number of
existing and future drugs and therapies developed, manufactured and marketed by other companies. Existing or future competing products may provide greater therapeutic convenience or clinical or other benefits for a specific indication than our
products, or may offer comparable performance at a lower cost. If our products fail to capture and maintain market share, we may not achieve sufficient product revenues and our business will suffer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We will compete against fully integrated pharmaceutical companies and smaller companies that are collaborating with larger pharmaceutical
companies, academic institutions, government agencies and other public and private research organizations. Many of these competitors may have compounds already approved or in development in the therapeutic categories that we are targeting with our
current and future product candidates. In addition, many of these competitors, either alone or together with their collaborative partners, may operate larger research and development programs or have substantially greater financial resources than we
do, as well as greater experience in: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">undertaking <FONT STYLE="white-space:nowrap">pre-clinical</FONT> testing and clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining NDA approval by the FDA and comparable foreign regulatory approvals of product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">formulating and manufacturing products; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">launching, marketing and selling products. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we obtain approval to commercialize any products outside of the United States, a variety of risks associated with international operations could
materially adversely affect our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If either LYR-210 or LYR-220 is approved for commercialization, we intend to
selectively partner with third parties to market it in certain jurisdictions outside the United States. We expect that we will be subject to additional risks related to international pharmaceutical operations, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">different regulatory requirements for drug approvals and rules governing drug commercialization in foreign
countries; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced protection for intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign reimbursement, pricing and insurance regimes; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential noncompliance with the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act 2010 and similar
anti-bribery and anticorruption laws in other jurisdictions; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities
abroad. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have no prior experience in these areas. In addition, there are complex regulatory, tax, labor and other
legal requirements imposed by both the European Union and many of the individual countries in Europe with which we will need to comply. Many U.S.-based biotechnology companies have found the process of marketing their own products in Europe to be
very challenging. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Certain legal and political risks are also inherent in foreign operations. For example, it
may be more difficult for us to enforce our agreements or collect receivables through foreign legal systems. There is a risk that foreign governments may nationalize private enterprises in certain countries where we may operate. In certain countries
or regions, terrorist activities and the response to such activities may threaten our operations more than in the United States. Social and cultural norms in certain countries may not support compliance with our corporate policies including those
that require compliance with substantive laws and regulations. Also, changes in general economic and political conditions in countries where we may operate are a risk to our financial performance and future growth. Additionally, the need to identify
financially and commercially strong partners for commercialization outside the United States who will comply with the high manufacturing and legal and regulatory compliance standards we require is a risk to our financial performance. As we operate
our business globally, our success will depend, in part, on our ability to anticipate and effectively manage these and other related risks. There can be no assurance that the consequences of these and other factors relating to our international
operations will not have an adverse effect on our business, financial condition or results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Potential product liability lawsuits
against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
use of our product candidates, including <FONT STYLE="white-space:nowrap">LYR-210</FONT> and LYR-220, in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. For
example, complications arising from the placement procedure for <FONT STYLE="white-space:nowrap">LYR-210</FONT> or <FONT STYLE="white-space:nowrap">LYR-220,</FONT> or from the degradation or dislodgment of the
<FONT STYLE="white-space:nowrap">LYR-210</FONT> or <FONT STYLE="white-space:nowrap">LYR-220</FONT> polymeric matrix within the sinuses after placement, or from foreign growth occurring in the sinus after placement, could give rise to product
liability claims against us. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. On occasion, large judgments have
been awarded in class action lawsuits based on products that had unanticipated adverse effects. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs, which may not be covered by insurance.
In addition, regardless of merit or eventual outcome, product liability claims may result in: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">impairment of our business reputation and significant negative media attention; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of participants from our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant costs to defend the related litigation and related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">distraction of management&#146;s attention from our primary business; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial monetary awards to patients or other claimants; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to commercialize <FONT STYLE="white-space:nowrap">LYR-210</FONT> or LYR-220 or any other product
candidate; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product recalls, withdrawals or labeling, marketing or promotional restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased demand for <FONT STYLE="white-space:nowrap">LYR-210</FONT> or LYR-220 or any other product candidate,
if approved for commercial sale; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of revenue. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Dependence on Third Parties </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will rely on third parties for the manufacture of materials for our research programs, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies
and clinical trials and we do not have long-term contracts with any of these parties. This reliance on third parties increases the risk that we will not have sufficient quantities of such materials, product candidates, or any therapies that we may
develop and commercialize, or that such supply will not be available to us at an acceptable cost, which could delay, prevent, or impair our development or commercialization efforts. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Although we currently conduct certain manufacturing operations internally, we currently have no plans to build our own clinical or commercial
scale manufacturing capabilities. Instead, we expect to rely on third parties for the manufacture of our product candidates and related raw materials for future <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical development, as well
as for commercial manufacture if any of our product candidates receive marketing approval. We do not have a long-term agreement with any of the third-party manufacturers we currently use to provide
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical drug supply, and purchase any required materials on a purchase order basis. Certain of these manufacturers are critical to our production and the loss of these manufacturers to one of
our competitors or otherwise, or an inability to obtain quantities at an acceptable cost or quality, could delay, prevent or impair our ability to timely conduct <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trials, and
would materially and adversely affect our development and commercialization efforts. The facilities used by third-party manufacturers to manufacture our product candidates must be approved by the FDA pursuant to inspections that will be conducted
after we submit an NDA to the FDA. We do not control the manufacturing process of, and are completely dependent on, third-party manufacturers for compliance with cGMP requirements for manufacture of drug products and other laws and regulations. If
these third-party manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, they will not be able to secure and/or maintain regulatory approval for their
manufacturing facilities. Some of our contract manufacturers may not have produced a commercially-approved product and therefore may not have obtained the requisite FDA approvals to do so. In addition, we have no control over the ability of
third-party manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if
it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on
us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could
significantly and adversely affect supplies of our products. In addition, we may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks,
including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure of third-party manufacturers to comply with regulatory requirements and maintain quality assurance;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">breach of the manufacturing agreement by the third party; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to manufacture our product according to our specifications; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to manufacture our product according to our schedule or at all; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">misappropriation of our proprietary information, including our trade secrets and
<FONT STYLE="white-space:nowrap">know-how;</FONT> and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our product candidates and any products that we may develop may compete with other product candidates and products for
access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. Any performance failure on the part of our existing or future manufacturers could
delay clinical development or marketing approval, and any related remedial measures may be costly or time-consuming to implement. We do not currently have arrangements in place for redundant supply or a second source for all required raw materials
used in the manufacture of our product candidates. If our current third-party manufacturers cannot perform as agreed, we may be required to replace such manufacturers and we may be unable to replace them on a timely basis or at all. Our current and
anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and
competitive basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on third parties to conduct our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials. Any
failure by a third party to conduct the clinical trials according to GCPs and in a timely manner may delay or prevent our ability to seek or obtain regulatory approval for or commercialize our product candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are dependent on third parties to conduct our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials, including
our ongoing clinical trials for <FONT STYLE="white-space:nowrap">LYR-210,</FONT> and we expect to rely on third parties to conduct any future clinical trials and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies for our product
candidates, including <FONT STYLE="white-space:nowrap">LYR-220.</FONT> Specifically, we have used and relied on, and intend to continue to use and rely on, medical institutions, clinical investigators, CROs and consultants to conduct our clinical
trials in accordance with our clinical protocols and regulatory requirements. These CROs, investigators and other third parties play a significant role in the conduct and timing of these trials and subsequent collection and analysis of data. While
we have agreements governing the activities of our third-party contractors, we have limited influence over their actual performance. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the
applicable protocol and legal, regulatory and scientific standards, and our reliance on the CROs and other third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with GCP requirements, which are
regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors,
principal investigators and trial sites. If we or any of our CROs or trial sites fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory
authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our
clinical trials complies with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay
the regulatory approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There is no guarantee that any such CROs, investigators or other third parties will devote adequate time
and resources to such trials or perform as contractually required. If any of these third parties fail to meet expected deadlines, adhere to our clinical protocols or meet regulatory requirements, or otherwise performs in a substandard manner, our
clinical trials may be extended, delayed or terminated. In addition, many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical
trials or other drug development activities that could harm our competitive position. In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity
compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected the interpretation of the
trial, the integrity of the data generated at the applicable clinical trial site may be questioned, and the utility of the clinical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
trial itself may be jeopardized, which could result in the delay or rejection of any NDA we submit to the FDA. Any such delay or rejection could prevent us from commercializing our product
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If any of our relationships with these third-parties terminate, we may not be able to enter into arrangements with
alternative third parties or do so on commercially reasonable terms. Switching or adding additional CROs, investigators and other third parties involves additional cost and requires management time and focus. In addition, there is a natural
transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our CROs, investigators and
other third parties, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may collaborate with third parties for the development and commercialization of <FONT STYLE="white-space:nowrap">LYR-210,</FONT> LYR-220 and any of
our future product candidates. We may not succeed in establishing and maintaining collaborative relationships, which may significantly limit our ability to develop and commercialize <FONT STYLE="white-space:nowrap">LYR-210,</FONT> LYR-220 or our
future product candidates successfully, if at all. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may seek collaborative relationships for the development and
commercialization of <FONT STYLE="white-space:nowrap">LYR-210,</FONT> <FONT STYLE="white-space:nowrap">LYR-220</FONT> or any future product candidates. Failure to obtain a collaborative relationship for
<FONT STYLE="white-space:nowrap">LYR-210,</FONT> LYR-220 or any future product candidates may significantly impair the potential for these product candidates. We also may need to enter into collaborative relationships to provide funding to support
our other research and development programs. The process of establishing and maintaining collaborative relationships is difficult, time-consuming and involves significant uncertainty, such as: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaboration partner may shift its priorities and resources away from our product candidates due to a change
in business strategies, or a merger, acquisition, sale or downsizing; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaboration partner may seek to renegotiate or terminate their relationships with us due to unsatisfactory
clinical results, manufacturing issues, a change in business strategy, a change of control or other reasons; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaboration partner may cease development in therapeutic areas which are the subject of our strategic
collaboration; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaboration partner may not devote sufficient capital or resources towards our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaboration partner may change the success criteria for a product candidate, thereby delaying or ceasing
development of such candidate; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a significant delay in initiation of certain development activities by a collaboration partner will also delay
payment of milestones tied to such activities, thereby impacting our ability to fund our own activities; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaboration partner could develop a product that competes, either directly or indirectly, with our product
candidate; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaboration partner with commercialization obligations may not commit sufficient financial or human resources
to the marketing, distribution or sale of a product; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaboration partner with manufacturing responsibilities may encounter regulatory, resource or quality issues
and be unable to meet demand requirements; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaboration partner may terminate a strategic alliance; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a dispute may arise between us and a partner concerning the research, development or commercialization of a
product candidate resulting in a delay in milestones, royalty payments or termination of an alliance and possibly resulting in costly litigation or arbitration which may divert management attention and resources; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a partner may use our products or technology in such a way as to invite litigation from a third party.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If any collaborator fails to fulfill its responsibilities in a timely manner, or at all, our research, clinical
development, manufacturing or commercialization efforts related to that collaboration could be delayed or terminated, or it may be necessary for us to assume responsibility for expenses or activities that would otherwise have been the responsibility
of our collaborator. If we are unable to establish and maintain collaborative relationships on acceptable terms or to successfully transition terminated collaborative agreements, we may have to delay or discontinue further development of one or more
of our product candidates, undertake development and commercialization activities at our own expense or find alternative sources of capital. Moreover, any collaborative partners we enter into agreements with in the future may shift their priorities
and resources away from our product candidates or seek to renegotiate or terminate their relationships with us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we seek, but are not able to
establish, collaborations, we may have to alter our development and commercialization plans. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our product development programs and
the potential commercialization of our product candidates will require substantial additional capital. We may decide to collaborate with pharmaceutical and biotechnology companies for the development and potential commercialization of our product
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a
collaboration will depend, among other things, upon our assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#146;s evaluation of a number of factors.
Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or comparable regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and
complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership
without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether
such a collaboration could be more attractive than the one with us for our product candidate. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations
among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may not be able to
negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of such product candidate, reduce or delay its development program or one or more of our other development
programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our
expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further
develop our product candidates or bring them to market and generate revenue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Data provided by collaborators and others upon which we rely that has not been independently verified
could turn out to be false, misleading, or incomplete. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We rely on third-party vendors, such as CROs, scientists and collaborators
to provide us with significant data and other information related to our projects, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trials and our business. If such third parties provide inaccurate, misleading or incomplete
data, our business, prospects and results of operations could be materially adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We do not have multiple sources of supply for some
of the components used in <FONT STYLE="white-space:nowrap">LYR-210</FONT> or LYR-220, nor long-term supply contracts, and certain of our suppliers are critical to our production. If we were to lose a supplier, it could have a material adverse effect
on our ability to complete the development of <FONT STYLE="white-space:nowrap">LYR-210</FONT> or LYR-220. If we obtain regulatory approval for <FONT STYLE="white-space:nowrap">LYR-210</FONT> or LYR-220, we would need to expand the supply of their
components in order to commercialize them. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We do not have multiple sources of supply for the components used in the manufacturing
of <FONT STYLE="white-space:nowrap">LYR-210</FONT> or LYR-220. We also do not have long-term supply agreements with any of our component suppliers. We may not be able to establish additional sources of supply for our product candidates, or may be
unable to do so on acceptable terms. Manufacturing suppliers are subject to cGMP quality and regulatory requirements, covering manufacturing, testing, quality control and record keeping relating to our product candidates and subject to ongoing
inspections by the regulatory agencies. Failure by any of our suppliers to comply with applicable regulations may result in long delays and interruptions in supply. Manufacturing suppliers are also subject to local, state and federal regulations and
licensing requirements. Failure by any of our suppliers to comply with all applicable regulations and requirements may result in long delays and interruptions in supply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The number of suppliers of the raw material components of our product candidates is limited. In the event it is necessary or desirable to
acquire supplies from alternative suppliers, we might not be able to obtain them on commercially reasonable terms, if at all. It could also require significant time and expense to redesign our manufacturing processes to work with another company.
Additionally, certain of our suppliers are critical to our production and the loss of these suppliers to one of our competitors or otherwise would materially and adversely affect our development and commercialization efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As part of any marketing approval, regulatory authorities conduct inspections that must be successful prior to the approval of the product.
Failure of manufacturing suppliers to successfully complete these regulatory inspections will result in delays. If supply from the approved supplier is interrupted, there could be a significant disruption in commercial supply. An alternative vendor
would need to be qualified through an NDA amendment or supplement which could result in further delay. The FDA or other regulatory agencies outside of the United States may also require additional studies if a new supplier is relied upon for
commercial production. Switching vendors may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we are unable to obtain the supplies we need at a reasonable price or on a timely basis, it could have a material adverse effect on our
ability to complete the development of <FONT STYLE="white-space:nowrap">LYR-210</FONT> or LYR-220 or, if we obtain regulatory approval for <FONT STYLE="white-space:nowrap">LYR-210</FONT> or LYR-220, to commercialize them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may enter into collaborations, <FONT STYLE="white-space:nowrap">in-licensing</FONT> arrangements, joint ventures, strategic alliances or partnerships
with third-parties that may not result in the development of commercially viable products or the generation of significant future revenues. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the ordinary course of our business, we may enter into collaborations, <FONT STYLE="white-space:nowrap">in-licensing</FONT> arrangements,
joint ventures, strategic alliances, partnerships or other arrangements to develop new products and to pursue new markets. Proposing, negotiating and implementing collaborations, <FONT STYLE="white-space:nowrap">in-licensing</FONT> arrangements,
joint ventures, strategic alliances or partnerships may be a lengthy and complex process. Other companies, including those with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
substantially greater financial, marketing, sales, technology or other business resources, may compete with us for these opportunities or arrangements. We may not identify, secure, or complete
any such transactions or arrangements in a timely manner, on a cost-effective basis, on acceptable terms or at all. We have limited institutional knowledge and experience with respect to these business development activities, and we may also not
realize the anticipated benefits of any such transaction or arrangement. In particular, these collaborations may not result in the development of products that achieve commercial success or result in significant revenues and could be terminated
prior to developing any products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Additionally, we may not be in a position to exercise sole decision making authority regarding the
transaction or arrangement, which could create the potential risk of creating impasses on decisions, and our future collaborators may have economic or business interests or goals that are, or that may become, inconsistent with our business interests
or goals. It is possible that conflicts may arise with our collaborators, such as conflicts concerning the achievement of performance milestones, or the interpretation of significant terms under any agreement, such as those related to financial
obligations or the ownership or control of intellectual property developed during the collaboration. If any conflicts arise with any current or future collaborators, they may act in their self-interest, which may be adverse to our best interest, and
they may breach their obligations to us. In addition, we may have limited control over the amount and timing of resources that any current or future collaborators devote to our or their future products. Disputes between us and our collaborators may
result in litigation or arbitration which would increase our expenses and divert the attention of our management. Further, these transactions and arrangements will be contractual in nature and will generally be terminable under the terms of the
applicable agreements and, in such event, we may not continue to have rights to the products relating to such transaction or arrangement or may need to purchase such rights at a premium. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we enter into <FONT STYLE="white-space:nowrap">in-bound</FONT> intellectual property license agreements, we may not be able to fully
protect the licensed intellectual property rights or maintain those licenses. Future licensors could retain the right to prosecute and defend the intellectual property rights licensed to us, in which case we would depend on the ability of our
licensors to obtain, maintain and enforce such licensed intellectual property. These licensors may determine not to pursue litigation against other companies or may pursue such litigation less aggressively than we would. If our licensors do not
adequately protect such licensed intellectual property, competitors may be able to use such intellectual property and erode or negate any competitive advantage we may have, which could materially harm our business, negatively affect our position in
the marketplace, limit our ability to commercialize our products and product candidates and delay or render impossible our achievement of profitability. Further, entering into such license agreements could impose various diligence,
commercialization, royalty or other obligations on us. Future licensors may allege that we have breached our license agreement with them, and accordingly seek to terminate our license, which could adversely affect our competitive business position
and harm our business prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Intellectual Property </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to obtain, maintain or adequately protect our intellectual property rights, we may not be able to compete effectively in our markets.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect our intellectual
property and prevent others from duplicating <FONT STYLE="white-space:nowrap">LYR-210,</FONT> <FONT STYLE="white-space:nowrap">LYR-220</FONT> and any future product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The strength of patents in the biotechnology and pharmaceutical field involves complex legal, factual and scientific questions and can be
uncertain. It is possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. The patent applications that we own may fail to result in issued patents with claims
that cover our product candidates in the United States or in other foreign countries. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent
or prevent a patent from issuing from a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pending patent application. Even if patents do successfully issue and even if such patents cover our product candidates, third parties may challenge the inventorship, ownership, validity,
enforceability or scope of such patents, which may result in such patents being narrowed or invalidated, or being held unenforceable. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our
intellectual property, provide exclusivity for our product candidates or prevent others from designing around our claims. In addition, no assurances can be given that third parties will not create new products or methods that achieve similar results
without infringing upon our patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If the patent applications we hold with respect to our programs or product candidates fail to issue, if their breadth or strength of
protection is threatened, or if they fail to provide meaningful exclusivity for our product candidates, it could dissuade companies from collaborating with us to develop product candidates, and threaten our ability to commercialize future products.
Several patent applications covering our product candidates have been filed recently. We cannot offer any assurances about which, if any, patents will issue, the breadth of any such patents or whether any issued patents will be found invalid or
unenforceable or will be threatened by third parties. Any successful opposition to these patents or any other patents owned by us could deprive us of rights necessary for the successful commercialization of any product candidates that we may
develop. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate
under patent protection could be reduced. Since patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we were the first to
file any patent application related to a product candidate. Furthermore, if third parties have filed such patent applications before enactment of the Leahy-Smith Act on March&nbsp;16, 2013, an interference proceeding in the United States can be
initiated by a third party to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. In addition, patents have a limited lifespan. In the United States, the expiration of a patent is
generally 20 years after it is filed. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for
the patent covering a product, we may be open to competition from generic competing products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The issuance of a patent is not conclusive
as to its inventorship, ownership, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. In addition, the issuance of a patent does not give us the right to practice the
patented invention. Third parties may have blocking patents that could prevent us from marketing our product candidate, if approved, or practicing our own patented technology. As a result, the issuance, scope, validity, enforceability and commercial
value of our patent rights are highly uncertain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition to the protection afforded by patents, we rely on trade secret protection
and confidentiality agreements to protect proprietary <FONT STYLE="white-space:nowrap">know-how</FONT> that is either not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our
product candidate discovery and development processes that involve proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> information or technology that is not covered by patents. However, trade secrets can be difficult to protect. We seek to
protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of our data and
trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may
be breached, and we may not have adequate remedies for any breach. Once disclosed, we are likely to lose trade secret protection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Although we require all of our employees and consultants to assign their inventions to us, to the extent that employees or consultants use
intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting <FONT STYLE="white-space:nowrap">know-how</FONT> and inventions. Further, although we require that all of our
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employees, consultants, collaborators, advisors and any third parties who have access to our proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> information or technology enter into
confidentiality agreements, we cannot provide any assurances that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently
discover our trade secrets or develop substantially equivalent information and techniques. Any of these parties may breach these agreements and we may not have adequate remedies for any specific breach. Misappropriation or unauthorized disclosure of
our trade secrets or other confidential proprietary information could impair our competitive position and may have a material adverse effect on our business. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is
difficult, expensive and time-consuming, and the outcome is unpredictable. Additionally, if the steps taken to maintain our trade secrets or other confidential proprietary information are deemed inadequate, we may have insufficient recourse against
third parties for misappropriating the trade secret or other confidential proprietary information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we are unable to prevent material
disclosure of the <FONT STYLE="white-space:nowrap">non-patented</FONT> intellectual property related to our technologies to third parties, and there is no guarantee that we will have any such enforceable trade secret protection, we may not be able
to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results of operations and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our commercial success depends in part on our avoiding infringement, or allegations of infringement, of the patents and other proprietary
rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent
infringement lawsuits, interferences, oppositions, reexamination, and inter partes review proceedings before the United States Patent and Trademark Office, or USPTO, and corresponding foreign patent offices. Numerous U.S. and foreign issued patents
and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. Many companies in intellectual property-dependent industries, including the biotechnology and pharmaceutical
industries, have employed intellectual property litigation as a means to gain an advantage over their competitors. As the biotechnology and pharmaceutical industries expand and more patents are issued, and as we gain greater visibility and market
exposure as a public company, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. Some claimants may have substantially greater resources than we do and may be able to
sustain the costs of complex intellectual property litigation to a greater degree and for longer periods of time than we could. In addition, patent holding companies that focus solely on extracting royalties and settlements by enforcing patent
rights may target us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Third parties may assert that we are employing their proprietary technology without authorization. There may be
third-party patents or patent applications with claims to composition of matter, drug delivery, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. We cannot guarantee that our technologies,
products, compositions and their uses do not or will not infringe third party patent or other intellectual property rights. Because patent applications can take many years to issue, there may be currently pending patent applications which may later
result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Pending patent applications that have been published
can, subject to certain limitations, be later amended in a manner that could cover our product candidates or the use of our product candidates. After issuance, the scope of patent claims remains subject to construction as determined by an
interpretation of the law, the written disclosure in a patent and the patent&#146;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability
to market our product candidates. If any third-party patents were held by a court of competent jurisdiction to cover the composition of matter of any of our product candidates, the manufacturing process of any of our product candidates, the method
of use for any of our product candidates, the holders of any such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, which may not be available or may not be available on
commercially reasonable terms, or until such patents expire. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Parties making claims against us may obtain injunctive or other equitable
relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates and/or harm our reputation and financial results. Defense of these claims, regardless of their merit, could involve
substantial litigation expense and could be a substantial diversion of management and employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble
damages and attorneys&#146; fees for willful infringement, pay royalties, redesign our infringing products, in the case of claims concerning registered trademarks, rename our product candidates, or obtain one or more licenses from third parties,
which may require substantial time and monetary expenditure, and which might be impossible or technically infeasible. Furthermore, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to
obtain a license, it could be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same technologies licensed to us; alternatively or additionally it could include terms that impede or destroy our
ability to compete successfully in the commercial marketplace. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be involved in lawsuits to protect or enforce our patents or other
intellectual property, which could be expensive, time-consuming and unsuccessful. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Competitors may infringe our patents,
trademarks, copyrights or other intellectual property. It may be difficult to detect infringers who do not advertise the components that are used in their products. Moreover, it may be difficult or impossible to obtain evidence of infringement in a
competitor&#146;s or potential competitor&#146;s product. To counter infringement or unauthorized use, we may be required to file infringement claims on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, which can be expensive and time-consuming and divert the time and attention of our management and scientific personnel. There can be no
assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Any claims we assert against perceived infringers could also provoke these
parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid, is unenforceable and/or is not infringed,
or may construe the patent&#146;s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense
proceedings could put one or more of our patents at risk of being invalidated, interpreted narrowly or held unenforceable, could put our patent applications at risk of not issuing, and could limit our ability to assert those patents against those
parties or other competitors and curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have
asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks, which could
materially harm our business and negatively affect our position in the marketplace. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Even if we establish infringement, the court may
decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with
intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other
interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent patent reform legislation has increased the uncertainties and costs surrounding the prosecution
of our patent applications and the enforcement or defense of our issued patents, and may diminish the value of patents in general. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As is the case with other biopharmaceutical companies, our commercial success is heavily dependent on intellectual property, particularly
patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Recent wide-ranging patent reform legislation in the United
States, including the Leahy-Smith America Invents Act, or the Leahy-Smith Act, could increase those uncertainties and costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
Leahy-Smith Act includes a number of significant changes to U.S. patent law, including provisions that affect the way patent applications are prosecuted and may also affect patent litigation. Under The Leahy-Smith Act, the United States transitioned
from a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-invent&#148;</FONT></FONT> to a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> system for deciding
which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. This will require us to be cognizant going forward of the time from invention to filing of a patent application
and be diligent in filing patent applications, but circumstances could prevent us from promptly filing patent applications on our inventions. The Leahy-Smith Act also enlarged the scope of disclosures that qualify as prior art, and it expanded the
scope of procedures that a third party may use to challenge a U.S. patent, including post grant review and inter partes review procedures. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S.
federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the
claim if first presented in a district court action. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents,
all of which could have a material adverse effect on our business and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, recent court rulings in cases
such as <I>Association for Molecular Pathology v. Myriad Genetics,</I><I></I><I>&nbsp;Inc., BRCA1-</I>&nbsp;&amp;<I> BRCA2-Based Hereditary Cancer Test Patent Litigation,</I> and <I>Promega Corp.</I><I></I><I>&nbsp;v. Life Technologies Corp.</I>
have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this
combination of events has created uncertainty with respect to the value of patents once obtained. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant <FONT STYLE="white-space:nowrap">law-making</FONT> bodies
in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of
third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may
employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and independent
contractors do not use the proprietary information or <FONT STYLE="white-space:nowrap">know-how</FONT> of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or
otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of our employee&#146;s former employers or other third parties. Litigation may be necessary to defend against these claims. If we
fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, or our ability to hire personnel, which, in any case of the foregoing, could adversely impact our business.
Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural,
document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The USPTO, European and other patent agencies require compliance with a number of procedural, documentary, fee payment and other
similar provisions during the patent application process. Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent
agencies outside of the United States in several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these fees
due to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> patent agencies. The USPTO and various <FONT STYLE="white-space:nowrap">non-U.S.</FONT> governmental patent agencies require compliance with a number of procedural, documentary, fee payment and
other similar provisions during the patent application process. We employ law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the
applicable rules. However, there are situations in which <FONT STYLE="white-space:nowrap">non-compliance</FONT> can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the
relevant jurisdiction. In such an event, our competitors might be able to enter the market, which could have a material adverse effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we initiated legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could
counterclaim that the patent covering our product candidate is invalid and/or unenforceable. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or <FONT
STYLE="white-space:nowrap">non-enablement.</FONT> Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement,
during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Such mechanisms include <FONT STYLE="white-space:nowrap">re-examination,</FONT> post grant review, and equivalent proceedings in foreign
jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for
example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at
least part, and perhaps all, of the patent protection on one or more of our product candidates. Such a loss of patent protection could have a material adverse impact on our business. A defendant could also challenge our ownership of patents assigned
to us. We cannot be certain that a third party would not challenge our rights to these patents and patent applications. Any legal proceeding or enforcement action can also be expensive and time-consuming. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The term of any individual patent depends on applicable law in the country where the patent is granted. In the United States, provided all
maintenance fees are timely paid, a patent generally has a term of 20 years from its application filing date or earliest claimed <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. Extensions may be available under certain
circumstances, but the life of a patent and, correspondingly, the protection it affords is limited. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates
might expire before or shortly after such candidates are commercialized. For patents that are eligible for extension of patent term, we expect to seek extensions of patent terms in the United States </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and, if available, in other countries. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the
normal expiration of the patent, which is limited to the approved indication (or any additional indications approved during the period of extension). We might not be granted an extension because of, for example, failure to apply within applicable
periods, failure to apply prior to the expiration of relevant patents or otherwise failure to satisfy any of the numerous applicable requirements. Moreover, the applicable authorities, including the FDA and the USPTO in the United States, and any
equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs,
our competitors may be able to obtain approval of competing products following our patent expiration by referencing our clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> data and launch their product earlier than might otherwise be
the case. If this were to occur, it could have a material adverse effect on our ability to generate revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to protect our
intellectual property rights throughout the world. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Filing, prosecuting and defending our intellectual property in all countries
throughout the world could be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. Therefore, we may choose not to pursue or maintain
protection for certain intellectual property in certain jurisdictions. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we
may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may
use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong
as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent such competitors from competing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The
legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make
it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and
divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims
against us. We may not prevail in any lawsuit that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be
inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. In addition, many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third
parties (for example, the patent owner has failed to &#147;work&#148; the invention in that country, or the third party has patented improvements) or limit the enforceability of patents against government agencies or government contractors. In these
countries, the patent owner may have limited remedies, which could materially diminish the value of the patent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our trademarks and trade names
are not adequately protected, then we may not be able to build name recognition in our trademarks of interest and our business may be adversely affected. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">While we seek to protect the trademarks we use in the United States and in other countries, we may be unsuccessful in obtaining registrations
and/or otherwise protecting these trademarks. If that were to happen, we may be prevented from using our names, brands and trademarks unless we enter into appropriate royalty, license or coexistence agreements, which may not be available or may not
be available on commercially reasonable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
terms. Over the long term, if we are unable to establish name recognition based on our trademarks, trade names, service marks and domain names, then we may not be able to compete effectively,
resulting in a material adverse effect on our business. Our registered or unregistered trademarks or trade names may be challenged, infringed, diluted or declared generic, or determined to be infringing on other marks. We rely on both registration
and common law protection for our trademarks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need to build name recognition among potential partners or customers in
our markets of interest. At times, competitors may adopt trademarks and trade names similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trademark
infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks. Over the long term, if we are unable to establish name recognition based on our trademarks,
then we may not be able to compete effectively and our business may be adversely affected. During trademark registration proceedings, we may receive rejections. Although we would be given an opportunity to respond to those rejections, we may be
unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks.
Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. Effective trademark protection may not be available or may not be sought in every country in which our products are made
available. Any name we propose to use for our products in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product
names, including an evaluation of potential for confusion with other product names. If the FDA objects to any of our proposed product names, we may be required to expend significant additional resources in an effort to identify a usable substitute
name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to
compete effectively and our business may be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our proprietary rights may not adequately protect our technologies and product
candidates, and do not necessarily address all potential threats to our competitive advantage. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The degree of future protection
afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are
illustrative: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may be able to make products that are the same as or similar to our product candidates but that are not
covered by the claims of the patents that we own; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others, including inventors or developers of our patented technologies who may become involved with competitors,
may independently develop similar technologies that function as alternatives or replacements for any of our technologies without infringing our intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we might not have been the first to conceive and reduce to practice the inventions covered by our patents or
patent applications; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we might not have been the first to file patent applications covering certain of our patents or patent
applications; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that our pending patent applications will not result in issued patents; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that there are prior public disclosures that could invalidate our patents; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our issued patents may not provide us with any commercially viable products or competitive advantage, or may be
held invalid or unenforceable, as a result of legal challenges by our competitors; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Supreme Court of the United States, other U.S. federal courts, Congress, the USPTO or similar foreign
authorities may change the standards of patentability and any such changes could narrow or invalidate, or change the scope of, our or our collaboration partners&#146; patents; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patent terms may be inadequate to protect our competitive position on our product candidates for an adequate
amount of time; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors might conduct research and development activities in countries where we do not have patent
rights, or in countries where research and development safe harbor laws exist, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ownership, validity or enforceability of our patents or patent applications may be challenged by third parties;
and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patents of third parties or pending or future applications of third parties, if issued, may have an adverse
effect on our business. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Employee Matters and Managing Growth </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations. </I></B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of
product candidate development, regulatory affairs and sales, marketing and distribution. As of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, we had
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; full-time employees. To manage our growth activities, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and
continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the
expansion of our operations or recruit and train additional qualified personnel. As we expand our organization, we may have difficulty identifying, hiring and integrating new personnel. Future growth would impose significant additional
responsibilities on our management, including the need to identify, recruit, maintain, motivate and integrate additional employees, consultants and contractors. Also, our management may need to divert a disproportionate amount of its attention away
from our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our
operations, which may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could require significant
capital expenditures and may divert financial resources from other projects, such as the development of product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to
generate and/or grow revenues could be reduced, and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize our product candidates and compete effectively will depend, in part, on our
ability to effectively manage any future growth. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Many of the biotechnology and pharmaceutical companies that we compete against for
qualified personnel and consultants have greater financial and other resources, different risk profiles and a longer history in the industry than we do. If we are unable to continue to attract and retain high-quality personnel and consultants, the
rate and success at which we can discover and develop product candidates and operate our business will be limited. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we lose key management or scientific personnel, cannot recruit qualified employees, directors,
officers or other significant personnel or experience increases in our compensation costs, our business may materially suffer. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We
are highly dependent on our management and directors, including our chief executive officer, Maria Palasis, Ph.D., and our chief scientific officer, Dana Washburn, M.D., among others. Due to the specialized knowledge each of our officers and key
employees possesses with respect to our product candidates and our operations, the loss of service of any of our officers or directors could delay or prevent the successful enrollment and completion of our clinical trials. We do not carry key person
life insurance on our officers or directors. Although we have formal employment agreements with our executive officers, these agreements do not prevent them from terminating their employment with us at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, our future success and growth will depend in part on the continued service of our directors, employees and management personnel
and our ability to identify, hire, and retain additional personnel. If we lose one or more of our executive officers or key employees, our ability to implement our business strategy successfully could be seriously harmed. Furthermore, replacing
executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain regulatory approval of and
commercialize product candidates successfully. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these additional key personnel on acceptable terms given the competition among numerous
pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors,
including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be engaged by entities other than us and may have commitments under consulting or
advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to develop and commercialize product candidates will be limited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Many of our employees have become or will soon become vested in a substantial amount of our common stock or a number of common stock options.
Our employees may be more likely to leave us if the shares they own have significantly appreciated in value relative to the original purchase prices of the shares, or if the exercise prices of the options that they hold are significantly below the
market price of our common stock, particularly after the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described herein. Our future success also depends on our ability to continue to attract and retain additional
executive officers and other key employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may engage in acquisitions or strategic partnerships that could disrupt our business, cause dilution
to our stockholders, reduce our financial resources, cause or to incur debt or assume contingent liabilities, and subject us to other risks. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the future, we may enter into transactions to acquire other businesses, products or technologies or enter into strategic partnerships,
including licensing. If we do identify suitable acquisition or partnership candidates, we may not be able to make such acquisitions or partnerships on favorable terms, or at all. Any acquisitions or partnerships we make may not strengthen our
competitive position, and these transactions may be viewed negatively by customers or investors. We may decide to incur debt in connection with an acquisition or issue our common stock or other equity securities to the stockholders of the acquired
company, which would reduce the percentage ownership of our existing stockholders. We could incur losses resulting from undiscovered liabilities of the acquired business or partnership that are not covered by the indemnification we may obtain from
the seller or our partner. In addition, we may not be able to successfully integrate any acquired personnel, technologies and operations into our existing business in an effective, timely and <FONT STYLE="white-space:nowrap">non-disruptive</FONT>
manner. Acquisitions or partnerships may also divert management attention from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> responsibilities, lead to a loss of key personnel, increase our expenses and
reduce our cash available for operations and other uses. We cannot predict the number, timing or size of future acquisitions or partnerships or the effect that any such transactions might have on our operating results. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We or the third parties upon whom we depend may be adversely affected by natural disasters and our
business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Natural disasters could
severely disrupt our operations and have a material adverse effect on our business, results of operations, financial condition and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a
significant portion of our headquarters, that damaged critical infrastructure, such as the manufacturing facilities on which we rely, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our
business for a substantial period of time. The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited
nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business. For example, following Hurricane Maria, shortages in production and delays in a number of medical supplies produced in Puerto
Rico resulted, and any similar interruption due to a natural disaster affecting us or any of our third-party manufacturers could materially delay our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Litigation against us could be costly and time-consuming to defend and could result in additional liabilities. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may from time to time be subject to legal proceedings and claims that arise in the ordinary course of business or otherwise, such as claims
brought by our customers in connection with commercial disputes and employment claims made by our current or former employees. Claims may also be asserted by or on behalf of a variety of other parties, including government agencies, patients or
vendors of our customers, or stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any litigation involving us may result in substantial costs, operationally restrict our
business, and may divert management&#146;s attention and resources, which may seriously harm our business, overall financial condition, and results of operations. Insurance may not cover existing or future claims, be sufficient to fully compensate
us for one or more of such claims, or continue to be available on terms acceptable to us. A claim brought against us that is uninsured or underinsured could result in unanticipated costs, thereby adversely impacting our results of operations and
resulting in a reduction in the trading price of our stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Common Stock and this Offering </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>An active trading market for our common stock may not develop. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no public market for our common stock. The initial public offering price for our common stock will be
determined through negotiations with the underwriters. Although we have applied to have our common stock listed on The Nasdaq Global Market, an active trading market for our shares may never develop or be sustained following this offering. If an
active market for our common stock does not develop, it may be difficult for you to sell shares you purchase in this offering without depressing the market price for the shares, or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The market price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common
stock in this offering. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our stock price is likely to be volatile. The stock market in general and the market for smaller
biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your common stock at or
above the initial public offering price. The market price for our common stock may be influenced by many factors, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of competitive products or technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or expected changes in our growth rate relative to our competitors; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">results of clinical trials of our product candidates or those of our competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments related to our existing or any future collaborations; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory actions with respect to our product candidates or our competitors&#146; products and product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory or legal developments in the United States and other countries; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">development of new product candidates that may address our markets and make our product candidates less
attractive; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in physician, hospital or healthcare provider practices that may make our product candidates less useful;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements by us, our partners or our competitors of significant acquisitions, strategic partnerships, joint
ventures, collaborations or capital commitments; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments or disputes concerning patent applications, issued patents or other proprietary rights;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the level of expenses related to any of our product candidates or clinical development programs;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to meet or exceed financial estimates and projections of the investment community or that we provide to
the public; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of our efforts to discover, develop, acquire or <FONT STYLE="white-space:nowrap">in-license</FONT>
additional product candidates or products; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or expected changes in estimates as to financial results, development timelines or recommendations by
securities analysts; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">variations in our financial results or those of companies that are perceived to be similar to us;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the structure of healthcare payment systems; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market conditions in the pharmaceutical and biotechnology sectors; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic, industry and market conditions; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the other factors described in this &#147;Risk Factors&#148; section and elsewhere in this prospectus.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>After this offering, our executive officers, directors and principal stockholders, if they choose to act together, will continue
to have the ability to control or significantly influence all matters submitted to stockholders for approval. </I></B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon the
closing of this offering, based on the number of shares of common stock outstanding as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, our executive officers,
directors and stockholders who owned more than 5% of our outstanding common stock before this offering and their respective affiliates will, in the aggregate, hold shares representing approximately&nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding voting
stock. As a result, if these stockholders choose to act together, they would be able to control or significantly influence all matters submitted to our stockholders for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control or significantly influence the election of directors, the composition of
our management and approval of any merger, consolidation or sale of all or substantially all of our assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If you purchase shares of common stock
in this offering, you will suffer immediate dilution of your investment. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The initial public offering price of our common stock
will be substantially higher than the net tangible book value per share of our common stock. Therefore, if you purchase shares of our common stock in this offering, you will pay a price per share that substantially exceeds our net tangible book
value per share after this offering. To the extent shares subsequently are issued under outstanding options or warrants, you will incur further dilution. Based on an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (the midpoint of the price range set forth on the cover page of this prospectus), you will experience immediate dilution of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share as of December&nbsp;31, 2019, representing the difference between our pro forma as adjusted net tangible book value per share, after giving
effect to this offering, and the assumed initial public offering price. In addition, purchasers of common stock in this offering will have contributed approximately&nbsp;&nbsp;&nbsp;&nbsp;% of the aggregate price paid by all purchasers of our stock
but will own only approximately&nbsp;&nbsp;&nbsp;&nbsp;% of our common stock outstanding after this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have broad discretion in the use
of the net proceeds from this offering and may not use them effectively. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion in the
application of the net proceeds from this offering and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our common stock. We expect that we will use the net proceeds of this offering, together
with our existing cash and cash equivalents, to fund the clinical development of LYR-210 and LYR-220, for future product candidate and platform development and the remainder, if any, for working capital and other general corporate purposes as set
forth under &#147;Use of Proceeds.&#148; However, our use of these proceeds may differ substantially from our current plans. The failure by our management to apply these funds effectively could result in financial losses that could have a material
adverse effect on our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that
loses value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A significant portion of our total outstanding shares are eligible to be sold into the market in the near future, which could cause
the market price of our common stock to drop significantly, even if our business is doing well. </I></B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Sales of a substantial number
of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. After this offering, we will have outstanding
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock based on the number of shares outstanding as of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020. This includes the shares that we are selling in this offering, which may be resold in the public market immediately
without restriction, unless purchased by our affiliates or existing stockholders. The remaining shares are currently restricted as a result of securities laws or <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements (which may be waived, with
or without notice, by BofA Securities, Inc. and Jefferies LLC) but will become eligible to be sold at various times beginning 180 days after this offering, unless held by one of our affiliates, in which case the resale of those securities will be
subject to volume limitations under Rule 144 of the Securities Act of 1933, as amended, or Rule 144. Moreover, after this offering, holders of an aggregate of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock will have rights, subject to specified conditions, to require us to file registration statements covering their shares or to
include their shares in registration statements that we may file for ourselves or other stockholders, until such shares can otherwise be sold without restriction under Rule 144 or until the rights terminate pursuant to the terms of the
stockholders&#146; agreement between us and such holders. We also intend to register all shares of common stock that we may issue under our equity compensation plans. Once we register these shares, they can be freely sold in the public market upon
issuance, subject to volume limitations applicable to affiliates and the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described in the &#147;Underwriting&#148; section of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an &#147;emerging growth company,&#148; and the reduced disclosure requirements applicable to
emerging growth companies may make our common stock less attractive to investors. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company,&#148;
as defined in the JOBS Act, and may remain an emerging growth company until the last day of the fiscal year following the fifth anniversary of the closing of this offering. However, if certain events occur prior to the end of such five-year period,
including if we become a &#147;large accelerated filer,&#148; our annual gross revenues exceed $1.07&nbsp;billion or we issue more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt in any three-year period, we
will cease to be an emerging growth company prior to the end of such five-year period. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to
other public companies that are not emerging growth companies. These exemptions include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">being permitted to provide only two years of audited financial statements, in addition to any required unaudited
interim financial statements, with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure in this prospectus; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with the auditor attestation requirements in the assessment of our internal control
over financial reporting; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight
Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure obligations regarding executive compensation; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder
approval of any golden parachute payments not previously approved. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have taken advantage of reduced reporting burdens
in this prospectus. In particular, in this prospectus, we have provided only two years of audited financial statements and have not included all of the executive compensation related information that would be required if we were not an emerging
growth company. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our
common stock and our stock price may be reduced or more volatile. In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This
allows an emerging growth company to delay the adoption of these accounting standards until they would otherwise apply to private companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We
will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a public company, and particularly after we are no longer an emerging growth company, we will incur significant legal, accounting and other
expenses that we did not incur as a private company. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The Nasdaq Global Market and other applicable securities rules and
regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a
substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that these
rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified members of our board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are evaluating these rules and regulations, and cannot predict or estimate the amount of
additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time
as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or Section&nbsp;404, we will be required to furnish a report by our management
on our internal control over financial reporting. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public
accounting firm. To achieve compliance with Section&nbsp;404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard,
we will need to continue to dedicate internal resources, potentially engage outside consultants, adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes
as appropriate, validate through testing whether such controls are functioning as documented, and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we
will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section&nbsp;404. We may discover significant deficiencies or material weaknesses, which we may
not successfully remediate on a timely basis or at all. Any failure to remediate any significant deficiencies or material weaknesses identified by us or to implement required new or improved controls, or difficulties encountered in their
implementation, could cause us to fail to meet our reporting obligations or result in material misstatements in our financial statements. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets
due to a loss of confidence in the reliability of our financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts do not publish research or reports
about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline, even if our business is doing well. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us
or our business. We do not currently have, and may never obtain, research coverage by securities and industry analysts. If no or few securities or industry analysts commence coverage of us, the trading price for our stock would be negatively
impacted. In the event we obtain securities or industry analyst coverage, if any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our
target <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trials and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts ceases coverage of us or
fails to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are a &#147;smaller reporting company&#148; and the reduced disclosure requirements applicable to smaller reporting companies may make our common
stock less attractive to investors. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are considered a &#147;smaller reporting company.&#148; We are therefore entitled to rely
on certain reduced disclosure requirements, such as an exemption from providing selected financial data and executive compensation information. We are also exempt from the requirement to obtain an external audit on the effectiveness of internal
control over financial reporting provided in Section&nbsp;404(b) of the Sarbanes-Oxley Act. These exemptions and reduced disclosures in our SEC filings due to our status as a smaller reporting company mean our auditors do not review our internal
control over financial reporting and may make it harder for investors to analyze our results of operations and financial prospects. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If
some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock prices may be more volatile. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provisions in our restated certificate of incorporation and restated bylaws and under Delaware law
could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Provisions in our restated certificate of incorporation and our restated bylaws, which will become effective upon the closing of this offering
may discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions could
also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members
of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other
things, these provisions include those establishing: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to
change the membership of a majority of our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect
director candidates; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of
the board of directors or the resignation, death or removal of a director, which prevents stockholders from filling vacancies on our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the
terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of our board of directors to alter our bylaws without obtaining stockholder approval;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the required approval of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the shares
entitled to vote at an election of directors to adopt, amend or repeal our bylaws or repeal the provisions of our restated certificate of incorporation regarding the election and removal of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual
or special meeting of our stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the requirement that a special meeting of stockholders may be called only by the chairman of the board of
directors, the chief executive officer, the president or the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of
directors or to propose matters to be acted upon at a stockholders&#146; meeting, which may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#146;s own slate of directors or otherwise
attempting to obtain control of us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Moreover, because we are incorporated in Delaware, we are governed by the
provisions of Section&nbsp;203 of the General Corporation Law of the State of Delaware, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date
of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our restated certificate of incorporation will designate specific courts as the exclusive forum for
certain litigation that may be initiated by our stockholders, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our restated certificate of incorporation, which will become effective upon the closing of this offering, specifies that, unless we consent in
writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for most legal actions involving claims brought against us by stockholders; provided that, the exclusive forum
provision will not apply to suits brought to enforce any liability or duty created by the Securities Act, the Exchange Act, the rules and regulations thereunder or any other claim for which the federal courts have exclusive jurisdiction; and
provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware.
Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our restated certificate of incorporation described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe this provision benefits us by providing increased consistency in the application of Delaware law by chancellors particularly
experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. However, the provision may have the effect of
discouraging lawsuits against our directors, officers, employees and agents as it may limit any stockholder&#146;s ability to bring a claim in a judicial forum that such stockholder finds favorable for disputes with us or our directors, officers,
employees or agents. The enforceability of similar choice of forum provisions in other companies&#146; certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought
against us, a court could find the choice of forum provisions contained in our restated certificate of incorporation to be inapplicable or unenforceable in such action. If a court were to find the choice of forum provision contained in our restated
certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business, financial condition or results of
operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because we do not anticipate paying any cash dividends on our common shares in the foreseeable future, capital appreciation, if any,
would be your sole source of gain. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividends on our common shares. We currently
anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. As a result, capital appreciation, if any, of our
common shares would be your sole source of gain on an investment in our common shares for the foreseeable future. See the &#147;Dividend Policy&#148; section of this prospectus for additional information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We could be subject to securities class action litigation. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its
securities. This risk is especially relevant for us because biopharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of
management&#146;s attention and resources, which could harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to use our net operating losses and research and development
credits to offset future taxable income may be subject to certain limitations. </I></B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019, we had net
operating loss carryforwards, or NOLs, of $114.3&nbsp;million for federal income tax purposes and $95.6&nbsp;million for state income tax purposes, which may be available to offset our future taxable income, if any, and begin to expire at various
dates through 2037. As of December&nbsp;31, 2019, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
we also had federal and state research and development credit carryforwards of $5.0&nbsp;million, which begin to expire at various dates through 2034. In general, under Sections 382 and 383 of
the Internal Revenue Code of 1986, as amended, or the Code, a corporation that undergoes an &#147;ownership change,&#148; generally defined as a greater than 50% change by value in its equity ownership over a three-year period, is subject to
limitations on its ability to utilize its <FONT STYLE="white-space:nowrap">pre-change</FONT> NOLs and its research and development credit carryforwards to offset future taxable income. Our existing NOLs and research and development credit
carryforwards may be subject to limitations arising from previous ownership changes, and if we undergo an ownership change in connection with or after this offering, our ability to utilize NOLs and research and development credit carryforwards could
be further limited by Sections 382 and 383 of the Code. Future changes in our stock ownership, some of which might be beyond our control, could result in an ownership change under Section&nbsp;382 of the Code. For these reasons, in the event we
experience a change of control, we may not be able to utilize a material portion of the NOLs or research and development credit carryforwards even if we attain profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The impact of the Tax Cuts and Jobs Act on our financial results is not entirely clear and could differ materially from the financial statements
provided herein. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On December&nbsp;22, 2017, the United States enacted the Tax Cuts and Jobs Act, or TCJA, that significantly
reformed the Code. The TCJA, among other things, contained significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%; limitation of the tax deduction for interest
expense; limitation of the deduction for NOLs and elimination of NOL carrybacks, in each case, for losses arising in taxable years beginning after December&nbsp;31, 2017 (though any such tax losses may be carried forward indefinitely); and modifying
or repealing many business deductions and credits. The financial statements contained herein reflect the effects of the TCJA based on current guidance. However, there remain uncertainties and ambiguities in the application of certain provisions of
the TCJA, and, as a result, we made certain judgments and assumptions in the interpretation thereof. The U.S. Treasury Department and the Internal Revenue Service may issue further guidance on how the provisions of the TCJA will be applied or
otherwise administered that differs from our current interpretation. In addition, the TCJA could be subject to potential amendments and technical corrections, any of which could materially lessen or increase certain adverse impacts of the
legislation on us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc805799_3"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus contains forward-looking statements. All statements other than statements of historical facts contained in this prospectus are
forward-looking statements, including but not limited to statements regarding: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans to develop and commercialize our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of our ongoing or planned clinical trials for <FONT STYLE="white-space:nowrap">LYR-210,</FONT> <FONT
STYLE="white-space:nowrap">LYR-220</FONT> and any future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of and our ability to obtain and maintain regulatory approvals for
<FONT STYLE="white-space:nowrap">LYR-210,</FONT> <FONT STYLE="white-space:nowrap">LYR-220</FONT> and any future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the clinical utility of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our commercialization, marketing and manufacturing capabilities and strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations about the willingness of healthcare professionals to use
<FONT STYLE="white-space:nowrap">LYR-210,</FONT> <FONT STYLE="white-space:nowrap">LYR-220</FONT> and any future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our intellectual property position; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expected use of proceeds from this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitive position and the development or and projections relating to our competitors or our industry;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify, recruit and retain key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of laws and regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the time during which we will be an emerging growth company under the JOBS Act;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans to identify additional product candidates with significant commercial potential that are consistent
with our commercial objectives; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">research and development cost; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates and statements regarding our future revenue, future results of operations and financial position;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our business strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our research and development costs; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans and objectives of management for future operations; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the plans and objectives of management. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or
achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In some cases, you can identify forward-looking statements by terms such as &#147;may,&#148;
&#147;will,&#148; &#147;should,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;could,&#148; &#147;intend,&#148; &#147;target,&#148; &#147;project,&#148; &#147;contemplate,&#148; &#147;believe,&#148; &#147;estimate,&#148;
&#147;predict,&#148; &#147;potential,&#148; &#147;would&#148; or &#147;continue&#148; or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. The forward-looking statements in
this prospectus are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These
forward-looking statements speak only as of the date of this prospectus and are subject to a number of known and unknown risks, uncertainties and assumptions, including those described under the sections in this prospectus entitled &#147;Risk
Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and elsewhere in this prospectus. Because forward-looking statements are inherently subject to risks and uncertainties, some of
which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may
not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is
not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information,
future events, changed circumstances or otherwise. The forward-looking statements contained in this prospectus are excluded from the safe harbor protection provided by the Private Securities Litigation Reform Act of 1995 and Section&nbsp;27A of the
Securities Act of 1933, as amended. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc805799_4"></A>MARKET AND INDUSTRY DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We obtained the industry, market and competitive position data in this prospectus from our own internal estimates and research as well as from
industry and general publications and research, surveys and studies conducted by third parties. Industry publications, studies and surveys generally state that they have been obtained from sources believed to be reliable, although they do not
guarantee the accuracy or completeness of such information. While we believe that each of these studies and publications is reliable, we have not independently verified market and industry data from third-party sources. Management&#146;s estimates
are derived from publicly available information, their knowledge of our industry and their assumptions based on such information and knowledge, which we believe to be reasonable. While we believe our internal company research as to such matters is
reliable and the market definitions are appropriate, neither such research nor these definitions have been verified by any independent source. This data involves a number of assumptions and limitations which are necessarily subject to a high degree
of uncertainty and risk due to a variety of factors, including those described in &#147;Risk Factors.&#148; These and other factors could cause our future performance to differ materially from our assumptions and estimates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc805799_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds to us from our issuance and sale of shares of our common stock in this offering will be approximately
$<B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B> </B>million, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <B></B>per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting the estimated
underwriting discounts and commissions and estimated offering expenses payable by us. If the underwriters&#146; option to purchase additional shares from us is exercised in full, we estimate that our net proceeds will be approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each $1.00 increase (decrease)
in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share would increase (decrease) the net proceeds to us from this offering by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the
estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each increase (decrease) of 1.0&nbsp;million in the number of shares we are offering would increase (decrease) the net proceeds to us from this offering,
after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming the assumed
initial public offering price stays the same. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We anticipate that we will use the net proceeds of this offering, together with our
existing cash and cash equivalents, for the following purposes: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to $
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to fund the clinical development and pre-commercialization expenses for LYR-210 through &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to $
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to fund the development of LYR-220 through &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the remainder, if any, for platform development and other research and development expenses for our pipeline, and
for working capital and other general corporate purposes. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This expected use of the net proceeds from this offering
represents our intentions based upon our current plans and business conditions, which could change in the future as our plans and business conditions evolve. We may also use a portion of the net proceeds to
<FONT STYLE="white-space:nowrap">in-license,</FONT> acquire, or invest in additional businesses, technologies, products or assets, although currently we have no specific agreements, commitments or understandings in this regard. As of the date of
this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the closing of this offering or the amounts that we will actually spend on the uses set forth above. Predicting the cost necessary
to develop product candidates can be difficult and we anticipate that we will need additional funds to complete the development of any product candidates we identify. The amounts and timing of our actual expenditures and the extent of clinical
development may vary significantly depending on numerous factors, including the progress of our development efforts, the status of and results from <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and any ongoing clinical trials or
clinical trials we may commence in the future, as well as any collaborations that we may enter into with third parties for our product candidates and any unforeseen cash needs. As a result, our management will retain broad discretion over the
allocation of the net proceeds from this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Based on our planned use of the net proceeds of this offering and our current cash and
cash equivalents, we estimate that such funds will be sufficient to enable us to fund our operating expenses and capital expenditure requirements through
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have based this estimate on assumptions that may prove to be incorrect, and we could use our available capital resources sooner than we currently
expect. We may satisfy our future cash needs through the sale of equity securities, debt financings, working capital lines of credit, corporate collaborations or license agreements, grant funding, interest income earned on invested cash balances or
a combination of one or more of these sources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pending our use of the net proceeds from this offering, we intend to invest the net
proceeds in a variety of capital preservation investments, including short-term and intermediate-term, investment-grade, interest-bearing instruments and U.S. government securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc805799_6"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and future earnings,
if any, for the operation and expansion of our business and do not anticipate declaring or paying any dividends in the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of our board of
directors after considering our financial condition, results of operations, capital requirements, contractual requirements, business prospects and other factors the board of directors deems relevant, and subject to the restrictions contained in any
future financing instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc805799_7"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash and cash equivalents and capitalization as of December&nbsp;31, 2019, as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma basis to reflect (1) the issuance and sale of 78,306,611 shares of our Series C preferred stock,
at a price of $0.38811 per share, and warrants to purchase 23,491,979 shares of our common stock, in each case, in January 2020, (2) the automatic conversion of all outstanding shares of our preferred stock into 287,426,285 shares of common stock
upon the closing of this offering, (3) the automatic cashless exercise of outstanding warrants to purchase shares of common stock, which, based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
share, the midpoint of the price range set forth on the cover of this prospectus, would result in the issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock upon the closing of this offering
and (4) the filing and effectiveness of our restated certificate of incorporation which will occur upon the closing of this offering; and </P></TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma as adjusted basis to give further effect to our issuance and sale of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in this offering at an assumed initial public offering price of
$<B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B> </B>per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting
the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our capitalization
following the closing of this offering will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. You should read this information in conjunction with our consolidated financial
statements and the related notes appearing at the end of this prospectus and the &#147;Use of Proceeds,&#148; &#147;Selected Consolidated Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations&#148; sections and other financial information contained in this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As&nbsp;of&nbsp;December 31, 2019</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(in&nbsp;
thousands,&nbsp;except&nbsp;share&nbsp;data)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Actual&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Pro&nbsp;Forma </B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Pro&nbsp;Forma&nbsp;As<BR>Adjusted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock (Series A-1/A, Series A-1/B, Series A-1/C, Series <FONT
STYLE="white-space:nowrap">A-2,</FONT> <FONT STYLE="white-space:nowrap">Series&nbsp;A-3,</FONT> <FONT STYLE="white-space:nowrap">Series&nbsp;A-4,</FONT> Series B and Series C), par value $0.001 per share; 210,786,340 shares authorized, 209,119,674
shares issued and outstanding, actual; no shares authorized, issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">130,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.001 par value; no shares authorized, issued or outstanding, actual; no shares
authorized and no shares issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, par value $0.001 per share; 275,000,000 shares authorized, 7,962,008 shares issued
and outstanding, actual;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, pro forma;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares issued and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(127,757</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(123,338</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted
amount of each of cash and cash equivalents, additional paid in capital, total stockholders&#146; equity and total capitalization by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming
that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase
(decrease) of 1.0&nbsp;million shares in the number of shares offered by us at the assumed initial public offering price per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease)
the pro forma as adjusted amount of each of cash and cash equivalents, additional paid in capital, total stockholders&#146; equity and total capitalization by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The number of
shares in the table above does not include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">19,759,224 shares of common stock issuable upon the exercise of stock options outstanding, pursuant to our 2016
Plan, as of December&nbsp;31, 2019, at a weighted-average exercise price of $0.08 per share; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">7,568,326 shares of common stock issuable upon the exercise of stock options outstanding, pursuant to our 2005
Plan, as of December&nbsp;31, 2019, at a weighted-average exercise price of $0.48 per share; </P></TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common
stock issuable upon the exercise of stock options granted after December&nbsp;31, 2019 pursuant to our 2016 Plan; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our
common stock reserved for future issuance under our 2020 Plan, which will become effective in connection with this offering, as well as any automatic increases in the number of shares of our common stock reserved for future issuance under our 2020
Plan; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our
common stock that will become available for future issuance under our 2020 ESPP, which will become effective in connection with this offering, and shares of our common stock that become available pursuant to provisions in our 2020 ESPP that
automatically increase the share reserve under our 2020 ESPP. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc805799_8"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference
between the initial public offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019, we had a historical net tangible book value (deficit) of $(127.6) million, or $(16.03) per share of common
stock. Our historical net tangible book value (deficit) per share represents total tangible assets less total liabilities, divided by the number of shares of our common stock outstanding as of December&nbsp;31, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our pro forma net tangible book value as of December&nbsp;31, 2019 was $
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. Pro forma net tangible book value
represents the amount of our total tangible assets less total liabilities, after giving effect to (1) the issuance and sale of 78,306,611 shares of our Series C preferred stock, at a price of $0.38811 per share, and warrants to purchase 23,491,979
shares of our common stock, in each case, in January 2020, (2) the automatic conversion of all shares of our preferred stock into an aggregate of 287,426,285 shares of our common stock in connection with this offering and (3) the automatic cashless
exercise of outstanding warrants to purchase shares of common stock, which, based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover
of this prospectus, would result in the issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock upon the closing of this offering. Pro forma net tangible book value per share represents our pro
forma net tangible book value divided by the total number of shares outstanding as of December&nbsp;31, 2019, after giving effect to the pro forma adjustment described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">After giving further effect to receipt of the net proceeds from our issuance and the sale of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in this offering at an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting the estimated underwriting
discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of December&nbsp;31, 2019 would have been approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. This amount
represents an immediate increase in pro forma net tangible book value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share to our existing stockholders and an immediate dilution of
approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share to new investors participating in this offering. We determine dilution by subtracting the pro forma as adjusted net tangible
book value per share after this offering from the amount of cash that a new investor paid for a share of common stock. The following table illustrates this dilution: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value (deficit) per share as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16.03</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase (decrease) per share attributable to the issuance and sale of shares of our Series C
preferred stock and warrants to purchase shares of our common stock, in each case, in January 2020 and the conversion of our preferred stock and the automatic cashless exercise of outstanding warrants to purchase shares of our common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net tangible book value per share as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase per share attributable to this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted
net tangible book value per share after this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, and dilution in pro forma net tangible book value per share to new investors by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming that the number of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses
payable by us. Each increase (decrease) of 1.0&nbsp;million shares in the number of shares offered by us would increase (decrease) our pro forma as adjusted net tangible book value per share after this offering by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share and decrease (increase) the dilution to new investors by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, assuming that the assumed initial public offering price remains the same, and after deducting the estimated underwriting discounts and
commissions and the estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If the underwriters exercise their option to purchase additional shares of
our common stock in full, the pro forma as adjusted net tangible book value after this offering would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the increase in pro forma net
tangible book value per share would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and the dilution per share to new investors would be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, in each case assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting the estimated underwriting
discounts and commissions and the estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table summarizes on the pro forma as adjusted
basis described above, as of December&nbsp;31, 2019, the differences between the number of shares purchased from us, the total consideration paid to us in cash and the average price per share that existing stockholders and new investors paid. The
calculation below is based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover
page of this prospectus, before deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Shares&nbsp;Purchased</B></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Total&nbsp;Consideration</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Average&nbsp;Price</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Per&nbsp;Share</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Percent</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;Amount&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Percent</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A $1.00 increase or decrease in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease the total consideration
paid by new investors by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million and, in the case of an increase, would increase the percentage of total consideration paid by new investors by
&nbsp;&nbsp;&nbsp;&nbsp; percentage points and, in the case of a decrease, would decrease the percentage of total consideration paid by new investors by &nbsp;&nbsp;&nbsp;&nbsp; percentage points, assuming that the number of shares offered by us, as
set forth on the cover page of this prospectus, remains the same. An increase or decrease of 1.0&nbsp;million shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase or decrease the total
consideration paid by new investors by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million and, in the case of an increase, would increase the percentage of total consideration paid by new
investors by &nbsp;&nbsp;&nbsp;&nbsp;% and, in the case of a decrease, would decrease the percentage of total consideration paid by new investors by &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
percentage points, assuming no change in the assumed initial public offering price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The foregoing tables and calculations are based on
the number of shares of our common stock outstanding as of December&nbsp;31, 2019, after giving effect to the automatic conversion of all outstanding shares of our preferred stock into common stock in connection with this offering, and exclude: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">19,759,224 shares of common stock issuable upon exercise of stock options outstanding under our 2016 Plan as of
December&nbsp;31, 2019, at a weighted-average exercise price of $0.08 per share; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">7,568,326 shares of common stock issuable upon exercise of stock options outstanding under our 2005 Plan as of
December&nbsp;31, 2019, at a weighted-average exercise price of $0.48 per share; </P></TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common
stock issuable upon the exercise of stock options granted after December&nbsp;31, 2019 pursuant to our 2016 Plan; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our
common stock reserved for future issuance under our 2020 Plan, which will become effective in connection with this offering, as well as any automatic increases in the number of shares of our common stock reserved for future issuance under our 2020
Plan; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our
common stock that will become available for future issuance under our 2020 ESPP, which will become effective in connection with this offering, and shares of our common stock that become available pursuant to provisions in our 2020 ESPP that
automatically increase the share reserve under our 2020 ESPP. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To the extent any of these outstanding options is
exercised, there will be further dilution to new investors. If all of such outstanding options had been exercised as of December&nbsp;31, 2019, the pro forma as adjusted net tangible book value per share after this offering would be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and total dilution per share to new investors would be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If the underwriters exercise their
option to purchase additional shares of our common stock in full: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the percentage of shares of common stock held by existing stockholders will decrease to approximately
&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of our common stock outstanding after this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares held by new investors will increase to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, or approximately &nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of our common stock outstanding after this offering. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc805799_9"></A>SELECTED CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">You should read the following selected consolidated financial data together with our consolidated financial statements and the related notes
appearing at the end of this prospectus and the &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; section of this prospectus. We have derived the consolidated statement of operations data for the
years ended December&nbsp;31, 2019 and 2018 and the consolidated balance sheet data as of December&nbsp;31, 2019 and 2018 from our audited consolidated financial statements included elsewhere in this prospectus. Our historical results are not
necessarily indicative of results that may be expected in any future period. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;share<BR>and&nbsp;per&nbsp;share&nbsp;data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statement of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,519</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,259</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of tranche liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,029</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders&#151;basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.07</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares outstanding&#151;basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,998,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,728,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share attributable to common stockholders&#151;basic and diluted
(unaudited)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.08</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted-average common shares outstanding&#151;basic and diluted (unaudited)<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">216,118,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See Note 2 to our consolidated financial statements included elsewhere in this prospectus for an explanation of
the method used to calculate the historical and pro forma basic and diluted net loss per common share and the weighted average number of shares used in the computation of the per share amounts. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As&nbsp;of&nbsp;December&nbsp;
31,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(123,338</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(107,074</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We define working capital as current assets less current liabilities. See our consolidated financial statements
for further details regarding our current assets and current liabilities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc805799_10"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion and analysis of our financial condition and results
of operations together with the &#147;Selected Consolidated Financial Data&#148; section of this prospectus and our consolidated financial statements and the related notes included elsewhere in this prospectus. Some of the information contained in
this discussion and analysis or set forth elsewhere in this prospectus, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As
a result of many factors, including those factors set forth in the &#147;Risk Factors&#148; section of this prospectus, our actual results could differ materially from the results described in or implied by the forward-looking statements contained
in the following discussion and analysis. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions
for the localized treatment of patients with ear, nose and throat diseases. Our proprietary technology platform, XTreo, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single
administration. Our initial product candidates, <FONT STYLE="white-space:nowrap">LYR-210</FONT> and <FONT STYLE="white-space:nowrap">LYR-220,</FONT> are bioresorbable polymeric matrices designed to be administered in a brief, <FONT
STYLE="white-space:nowrap">non-invasive,</FONT> <FONT STYLE="white-space:nowrap">in-office</FONT> procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or
CRS. The therapeutic embedded within <FONT STYLE="white-space:nowrap">LYR-210</FONT> and <FONT STYLE="white-space:nowrap">LYR-220</FONT> is mometasone furoate, which is the active ingredient in various U.S. Food and Drug Administration, or FDA,
approved drugs and has a well-established efficacy and safety profile. CRS is an inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities and affects approximately 14&nbsp;million people in the
United States. We are advancing <FONT STYLE="white-space:nowrap">LYR-210</FONT> as a preferred alternative to surgery in an ongoing Phase 2 LANTERN clinical trial for CRS patients who have failed medical management. In our Phase 1 clinical trial, <FONT
STYLE="white-space:nowrap">LYR-210</FONT> met its primary safety endpoint, and we observed that patients generally experienced significant and rapid, clinically meaningful and durable improvement in <FONT STYLE="white-space:nowrap">SNOT-22</FONT>
scores, an established patient symptom severity scale, through week 25, which was the end of the trial. We are also developing <FONT STYLE="white-space:nowrap">LYR-220</FONT> for use in CRS patients who have an enlarged nasal cavity due to sinus
surgery but continue to require treatment to manage CRS symptoms. Beyond CRS, we believe our XTreo platform has potential applications in other disease areas, which we are actively exploring to further broaden its therapeutic potential. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We were incorporated as a Delaware corporation on November&nbsp;21, 2005, and our headquarters is located in Watertown, Massachusetts. On
July&nbsp;16, 2018, we formally changed our name to Lyra Therapeutics, Inc. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, developing our technology, building our intellectual
property portfolio and conducting research and development activities for our product candidates. We do not have any products approved for sale and have not generated any revenue from product sales. To date, we have funded our operations primarily
through private placements of redeemable convertible preferred stock and funding from government contracts. From inception through December&nbsp;31, 2019, we have raised an aggregate of $148.9 million to fund our operations, of which $131.8 million
were gross proceeds from sales of our redeemable convertible preferred stock, $0.3 million were gross proceeds from the issuance of common stock and $16.8 million were gross proceeds from government contracts. In January 2020, we raised $30.4
million of gross proceeds from the sale of our Series C redeemable convertible preferred stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have incurred significant net operating losses in every year since our inception and
expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. Our net losses may fluctuate significantly from quarter to quarter and year to year and could be substantial. Our net losses were $16.3
million and $6.0 million for the years ended December&nbsp;31, 2019 and 2018, respectively. As of December&nbsp;31, 2019, we had an accumulated deficit of $127.8 million. We anticipate that our expenses will increase significantly as we: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conduct additional clinical trials of our most advanced product candidate,
<FONT STYLE="white-space:nowrap">LYR-210,</FONT> including the Phase 2 LANTERN trial which commenced in May 2019 and one or more planned pivotal Phase 3 clinical trials of <FONT STYLE="white-space:nowrap">LYR-210;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advance the development of <FONT STYLE="white-space:nowrap">LYR-220;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue to discover and develop additional product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish manufacturing and supply chain capacity sufficient to provide commercial quantities of any product
candidates for which we may obtain marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek regulatory and marketing approvals for product candidates that successfully complete clinical trials, if
any; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish a sales, marketing and distribution infrastructure to commercialize any products for which we may
obtain regulatory approval in geographies in which we plan to commercialize our products ourselves; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain, expand and protect our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hire additional staff, including clinical, scientific, technical, regulatory, operational, financial commercial
and support personnel, to execute our business plan; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add clinical, scientific, operational, financial and management information systems and personnel to support our
product development and potential future commercialization efforts, and to enable us to operate as a public company. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We
do not expect to generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for a product candidate. Additionally, we currently use contract research organizations, or CROs, to
carry out our clinical development activities. We do not yet have a sales organization. If we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales,
marketing, manufacturing and distribution. Furthermore, commencing upon the closing of this offering, we will incur additional costs associated with operating as a public company. As a result, we will need substantial additional funding to support
our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to fund our operations through public or private equity or debt financings or other sources,
including strategic collaborations. We may, however, be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such other arrangements as and when
needed would have a negative impact on our financial condition and our ability to develop our current product candidates, or any additional product candidates, if developed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and uncertainties associated with therapeutics product development, we are unable to accurately predict the
timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenue from product sales, we may not become profitable. If we fail to become profitable or are unable to
sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019, we had cash and cash equivalents totaling $9.8 million. We
believe that the net proceeds from this offering, together with our existing cash and cash equivalents and the funds we raised in January 2020, will enable us to fund our operating expenses and capital expenditure requirements
into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have based these estimates on assumptions that may prove to be imprecise or incorrect, and we may use our available capital resources sooner
than we currently expect. See &#147;&#151;Liquidity and Capital Resources.&#148; Because of the numerous risks and uncertainties associated with the development of our product candidates and any future product candidates, our platform and technology
and because the extent to which we may enter into collaborations with third parties for development of any of our product candidates is unknown, we are unable to estimate the amounts of increased capital outlays and operating expenses associated
with completing the research and development of our product candidates. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we raise additional funds through collaborations,
strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to
us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our product development programs or any future commercialization efforts or grant rights to
develop and market product candidates that we would otherwise prefer to develop and market ourselves. </P>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Operations Overview </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To date, we have not
generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval and
successful commercialization efforts, we may generate revenue in the future from product sales. We cannot predict if, when, or to what extent we will generate revenue from the commercialization and sale of our product candidates. We may never
succeed in obtaining regulatory approval for any of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To date, all of our revenue has been derived from government
awards. In July 2016, we were awarded a grant from the National Institutes of Health, or NIH, titled &#147;Novel Bioabsorbable, Flexible Polymeric Stent for Pulmonary Artery Stenosis,&#148; which we refer to as
<FONT STYLE="white-space:nowrap">PED-PA.</FONT> The amount awarded of approximately $1.0&nbsp;million related to the award period of August 2016 through July 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In September 2016, we received a <FONT STYLE="white-space:nowrap">fixed-fee</FONT> award of approximately $0.4&nbsp;million from NIH for the
development leading to the commercialization of bioresorbable stents, or BRS, for the treatment of coarctation of the aorta in neonates, which we refer to as <FONT STYLE="white-space:nowrap">PED-CA.</FONT> In November 2017, we were awarded an
amendment to this contract which increased the amount by approximately $3.0&nbsp;million. We recognized revenue under the government awards as we incurred qualifying expenses. During the years ended December&nbsp;31, 2019 and 2018, we recognized $0
and approximately $1.2&nbsp;million, respectively, of revenue under the NIH awards. In 2019, we focused our efforts on the development of <FONT STYLE="white-space:nowrap">LYR-210</FONT> and our other product development efforts and are no longer
conducting research under the NIH awards and as a result do not expect any future revenue from government awards. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Expenses
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our operating expenses since inception have consisted solely of research and development costs and general and administrative
costs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Research and development expenses consist primarily of costs incurred for our research activities, including the development of and pursuit of
regulatory approval of our most advanced product candidate, <FONT STYLE="white-space:nowrap">LYR-210,</FONT> for the treatment of CRS, which include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">employee-related expenses, including salaries, benefits and stock-based compensation expense for personnel
engaged in research and development functions; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses incurred in connection with the preclinical and clinical development of our product candidates,
including under agreements with CROs, investigative sites and consultants; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs of manufacturing our product candidates for use in our preclinical studies and clinical trials as well as
manufacturers that provide components of our product candidates for use in our preclinical and potential future clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">consulting and professional fees related to research and development activities; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to compliance with clinical regulatory requirements; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">facility costs and other allocated expenses, which include expenses for rent and maintenance of our facility,
utilities, depreciation and other supplies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expense research and development costs as incurred. We recognize costs
for certain development activities, such as clinical trials, based on an evaluation of the progress to completion of specific tasks using data such as clinical site activations, patient enrollment, or information provided to us by our vendors and
our clinical investigative sites. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and may be reflected in our consolidated financial statements as prepaid or
accrued research and development expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our external research and development expenses consist primarily of costs such as fees paid to
consultants, contractors and CROs in connection with our preclinical and clinical development activities. We typically use our employee and infrastructure resources across our development programs and we do not allocate personnel costs and other
internal costs to specific product candidates or development programs with the exception of the costs to manufacture our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally
have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will continue to increase for
the foreseeable future as we initiate additional clinical trials, including one or more clinical trials for <FONT STYLE="white-space:nowrap">LYR-210</FONT> and LYR-220, scale our manufacturing processes, continue to discover and develop additional
product candidates and hire additional clinical and scientific personnel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The successful development of
<FONT STYLE="white-space:nowrap">LYR-210,</FONT> LYR-220 and other potential future product candidates is highly uncertain. Accordingly, at this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be
necessary to complete the development of these product candidates. We are also unable to predict when, if ever, we will generate revenue and material net cash inflows from the commercialization and sale of any of our product candidates for which we
may obtain marketing approval. We may never succeed in achieving regulatory approval for any of our product candidates. The duration, costs and timing of preclinical studies, clinical trials and development of our product candidates will depend on a
variety of factors, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful completion of clinical trials with safety, tolerability and efficacy profiles for <FONT
STYLE="white-space:nowrap">LYR-210,</FONT> LYR-220 and any potential future product candidates that are satisfactory to the FDA or any comparable foreign regulatory authority; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval of an IND for LYR-220 and any potential future product candidate to commence planned or future clinical
trials in the United States or foreign countries; </P></TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant and changing government regulation and regulatory guidance; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">timing and receipt of marketing approvals from applicable regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing arrangements with contract manufacturing organizations, or CMOs, for third-party clinical and
commercial manufacturing to obtain sufficient supply of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and maintaining patent and other intellectual property protection and regulatory exclusivity for our
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">commercializing the product candidates, if and when approved, whether alone or in collaboration with others;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acceptance of the product, if and when approved, by patients, the medical community and third-party payors;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competition with other therapies; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintenance of a continued acceptable safety profile of the products following approval. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A change in the outcome of any of these variables with respect to the development, manufacture or commercialization enabling activities of any
of our product candidates would significantly change the costs, timing and viability associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials
beyond those that we anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in our clinical trials due to patient enrollment or other reasons, we would be required to
expend significant additional financial resources and time on the completion of clinical development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>General and Administrative
Expenses </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of salaries and other related costs, including stock-based
compensation, for personnel in executive, finance and administrative functions. General and administrative expenses also include direct and allocated facility-related costs as well as professional fees for legal, patent, consulting, investor and
public relations, accounting, auditing, tax services and insurance costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect that our general and administrative expenses will
increase in the future to support continued research and development activities and potential commercialization of our product candidates. These increases will likely include increased costs related to the hiring of additional personnel and fees to
outside consultants, attorneys and accountants, among other expenses. Additionally, we expect to incur increased expenses associated with being a public company, including costs of additional personnel, accounting, audit, legal, regulatory and <FONT
STYLE="white-space:nowrap">tax-related</FONT> services associated with maintaining compliance with exchange listing and Securities and Exchange Commission, or SEC, requirements, director and officer insurance costs, and investor and public relations
costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Income (Expense), Net </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Interest income (expense), net, primarily consists of <FONT STYLE="white-space:nowrap">non-cash</FONT> interest expense incurred on our
convertible notes, <FONT STYLE="white-space:nowrap">non-cash</FONT> accretion of the fair value of the conversion feature related to our convertible notes, and interest income earned on our cash and cash equivalents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Change in Fair Value of Tranche Liability </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Change in fair value of tranche liability consists of <FONT STYLE="white-space:nowrap">non-cash</FONT> changes in the fair value of the
tranche rights associated with our Series B redeemable convertible preferred stock which provided investors with the right to participate in a subsequent offering of Series B redeemable convertible preferred stock in the event specified development
milestone was achieved. We classified the tranche rights as a derivative liability on our consolidated balance sheet that was initially recorded at fair value and that we remeasured to fair value at each reporting date, and we recognized changes in
the fair value of the derivative associated with the tranche rights as a component of other income in our consolidated statement of operations and comprehensive loss. The tranche liability was valued using the Black-Scholes option pricing model,
which considered as inputs (a)&nbsp;the expected stock price volatility of the underlying common stock, (b)&nbsp;the expected term of the tranche right, (c)&nbsp;the risk-free interest rate and (d)&nbsp;expected dividends. The tranche rights were
settled in 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Use of Estimates </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our management&#146;s discussion and analysis of financial condition and results of operations is based on our consolidated financial
statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported
amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements during the reporting periods. These items are monitored and analyzed by us for changes in facts and
circumstances, and material changes in these estimates could occur in the future. We base our estimates on historical experience, known trends and events, and on various other factors that we believe are reasonable under the circumstances, the
results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become
known. Actual results may differ materially from these estimates under different assumptions or conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">While our significant
accounting policies are described in more detail in the notes to our consolidated financial statements appearing elsewhere in this prospectus, we believe the following accounting policies used in the preparation of our consolidated financial
statements require the most significant judgments and estimates. </P>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Research and Development Expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development
expenses. This process involves reviewing purchase orders and open contracts, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred
for the services when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed, on a <FONT STYLE="white-space:nowrap">pre-determined</FONT>
schedule or when contractual milestones are met; however, some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to us at
that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. The significant estimates in our accrued research and development expenses include the following costs incurred for
services in connection with research and development activities for which we have not yet been invoiced: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">vendors in connection with the preclinical development activities; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">vendors in connection with the testing of preclinical and clinical trial materials; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">CROs in connection with preclinical and clinical studies; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">investigative sites in connection with clinical trials. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We contract with CROs to conduct clinical and other research and development services on our
behalf. We base our expenses related to CROs on our estimates of the services received and efforts expended pursuant to quotes and contracts with them. The financial terms of these agreements are subject to negotiation, vary from contract to
contract and may result in uneven payment flows. There may be instances in which payments made to our CROs will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, we
estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or
amount of prepaid expense accordingly. <FONT STYLE="white-space:nowrap">Non-refundable</FONT> advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed
or when the goods have been received rather than when the payment is made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Although we do not expect our estimates to be materially
different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in
any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We
apply the fair value recognition provisions of ASC 718, <I>Compensation&#151;Stock Compensation</I>, or ASC 718, for stock-based awards granted to employees and directors for their services on the board of directors. Determining the amount of
stock-based compensation to be recorded requires us to develop estimates of the fair value of stock options as of their grant date. We estimate the fair value of each stock option grant using the Black-Scholes option-pricing model. Calculating the
fair value of stock-based awards requires that we make subjective assumptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to ASC 718, we measure stock-based awards granted
to employees and members of the board of directors at fair value on the date of grant and recognize the corresponding stock-based compensation expense of those awards on a straight-line basis over the requisite service period, which is generally the
vesting period of the respective award. We have historically granted stock options with exercise prices equivalent to the fair value of our common stock as of the date of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We account for stock-based awards to <FONT STYLE="white-space:nowrap">non-employees</FONT> in accordance with ASU <FONT
STYLE="white-space:nowrap">No.&nbsp;2018-07,</FONT> <I>Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment</I> <I>Accounting</I>, or ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-07,</FONT> which permits
the valuation of stock-based awards granted to <FONT STYLE="white-space:nowrap">non-employees</FONT> to be measured at fair value at the grant date rather than on an accelerated attribution basis over the vesting period and recognizes <FONT
STYLE="white-space:nowrap">non-employee</FONT> stock-based compensation expense over the related service period of the <FONT STYLE="white-space:nowrap">non-employee</FONT> award. Prior to January&nbsp;1, 2019, we accounted for stock-based payments
to <FONT STYLE="white-space:nowrap">non-employees</FONT> in accordance with ASC <FONT STYLE="white-space:nowrap">505-50,</FONT> <I>Equity-Based Payments to <FONT STYLE="white-space:nowrap">Non-Employees</FONT></I>, or ASC <FONT
STYLE="white-space:nowrap">505-50.</FONT> Pursuant to ASC <FONT STYLE="white-space:nowrap">505-50,</FONT> we measured stock-based awards granted to <FONT STYLE="white-space:nowrap">non-employees</FONT> at fair value as the awards vest and recognize
the resulting value as expense during the period the related services are rendered, which is typically the vesting period. At the end of each financial reporting period prior to completion of the service, we
<FONT STYLE="white-space:nowrap">re-measured</FONT> the unvested portion of these awards using the then-current fair value of our common stock and updated assumption inputs in the Black-Scholes option-pricing model. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Black-Scholes option-pricing model uses the following inputs: the fair value of our common stock, the expected volatility of our common
stock, the expected term of our stock options, the risk-free interest rate for a period that approximates the expected term of our stock options and our expected dividend yield. Due to the lack of a public market for our common stock and a lack of
company-specific historical and implied volatility data, we have based our computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to us, including stage of product
development, life science industry </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
focus, length of trading history and similar vesting provisions. The historical volatility data is calculated based on a period of time commensurate with the expected term assumption. We will
continue to apply this process until a sufficient amount of historical information regarding the volatility of our own stock price becomes available or until circumstances change, such that the identified entities are no longer representative
companies. In the latter case, more suitable, similar entities whose share prices are publicly available would be utilized in the calculation. We use the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&nbsp;107,
<I>Share-Based Payment</I>, to calculate the expected term for options granted to employees as we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. Under this approach, the
weighted-average expected option term is presumed to be the average of the contractual term (ten years) and the vesting term (generally four years) of our stock options. We utilize this method due to lack of historical exercise data and the
&#147;plain-vanilla&#148; nature of our stock-based awards. The expected term is applied to the stock option grant group as a whole, as we do not expect substantially different exercise or post-vesting termination behavior among our employee
population. For options granted to <FONT STYLE="white-space:nowrap">non-employees,</FONT> we utilize the contractual term of the arrangement as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument
whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as we have never paid cash dividends and have no current plans to pay any cash dividends on our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The fair value of stock options granted to employees, directors and non-employees was estimated on the date of grant using the Black-Scholes
option-pricing model, with the following range of assumptions for the years ended December&nbsp;31, 2019 and 2018: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="55.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">These assumptions represented our best estimates, but the estimates involve inherent uncertainties and
the application of our judgment. As a result, if factors change and we use significantly different assumptions or estimates, our stock-based compensation expense could be materially different. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table presents the grant dates, number of underlying shares of common stock and the per share exercise prices of stock options
granted between January&nbsp;1, 2018 and the date of this prospectus, along with the fair value per share utilized to calculate stock-based compensation expense: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Grant Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Type of<BR>Award</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number
of<BR>Common<BR>Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exercise<BR>Price
of<BR>Award&nbsp;per<BR>Share<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Fair&nbsp;Value&nbsp;of<BR>Common<BR>Stock per<BR>Share on<BR>Grant
Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Per
Share<BR>Estimated<BR>Fair&nbsp;Value&nbsp;of<BR>Award<SUP STYLE="font-size:85%; vertical-align:top">(2)(3)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November&nbsp;5, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Option</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,980,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March&nbsp;6, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Option</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,315,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June&nbsp;20, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Option</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,170,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September&nbsp;24, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Option</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,225,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February 6, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Option</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,767,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Exercise Price of Award per Share represents the fair value of our common stock on the date of grant, as
determined by our board of directors, after taking into account our most recently available contemporaneous valuations of our common stock as well as additional factors that may have changed since the date of such contemporaneous valuations through
the date of grant. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Per Share Estimated Fair Value of Award reflects the fair value of options as estimated at the date of
grant using the Black-Scholes option-pricing model. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purposes of recording stock-based compensation for stock options granted to <FONT
STYLE="white-space:nowrap">non-employees,</FONT> upon adoption of ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-07</FONT> on January&nbsp;1, 2019, we measure the fair value of the award at the grant date rather than on an accelerated
attribution basis over the vesting period and recognize <FONT STYLE="white-space:nowrap">non-employee</FONT> stock-based compensation expense over the related service period of the <FONT STYLE="white-space:nowrap">non-employee</FONT> award. Prior to
adoption of ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-07,</FONT> we measured the fair value of the award on the service completion date (vesting date). At the end of each reporting period prior to completion of the services, we <FONT
STYLE="white-space:nowrap">re-measured</FONT> the value of any unvested portion of the award based on the then-current fair value of the award and adjusted expense accordingly. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We undertook a retrospective valuation of the fair value of our common stock as of September 19, 2019 and this
value represents our estimated fair value per common share in accordance with such retrospective valuation, as no contemporaneous valuation was performed at the time of such grants. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Determination of Fair Value of Common Stock </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a private company with no active public market for our common stock, our board of directors has historically determined the fair value of
our common stock on each date of grant, with input from management. Our board of directors periodically determined the estimated per share fair value of our common stock at various dates using contemporaneous valuations performed by third parties.
Once a public trading market for our common stock has been established in connection with the completion of this offering, it will no longer be necessary for us to estimate the fair value of our common stock in connection with our accounting for
stock options. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We performed contemporaneous valuations, with the assistance of a third-party specialist, as of September&nbsp;30,
2018, May&nbsp;31, 2019 and January 23, 2020, which resulted in valuations of our common stock of $0.08, $0.13 and $0.25 per share, respectively. As no contemporaneous valuation was performed at the time of such grants, we performed a retrospective
valuation as of September 19, 2019, which resulted in a valuation of our common stock of $0.25 per share. In conducting the valuations, we considered all objective and subjective factors that we believed to be relevant for each valuation conducted,
including our best estimate of our business condition, prospects and operating performance at each valuation date. Within the valuations performed, a range of factors, assumptions and methodologies were used. The significant factors included: </P>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of an active public market for our common stock and redeemable convertible preferred stock;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prices at which we sold shares of our redeemable convertible preferred stock in arm&#146;s length
transactions and the superior rights, preferences and privileges of the convertible preferred stock relative to our common stock, including the liquidation preferences of our preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our results of operations and financial condition, including cash on hand; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the material risks related to our business; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our stage of development and business strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the composition of, and changes to, our management team and board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the market performance of publicly traded companies in the life sciences and biotechnology sectors, as well as
recently completed initial public offerings, or IPOs, of companies in the life sciences and biotechnology sectors; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the likelihood of achieving a liquidity event such as an IPO given prevailing market conditions.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Historically, the dates of our valuations have not coincided with the dates of our
stock-based compensation grants. In determining the exercise prices of the stock options granted, our board of directors considered, among other things, the most recent valuations of our common stock and our assessment of additional objective and
subjective factors we believed were relevant as of the grant date. The additional factors considered when determining any changes in fair value of our common stock between the most recent valuation and the grant dates included the status of our
stage of research and development, our operating and financial performance and current business conditions. The fair value of 3,225,761 options granted on September 24, 2019 was determined retrospectively as no contemporaneous valuation was
performed at the time of such grants. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There are significant judgments and estimates inherent in the determination of the fair value
of our common stock. These judgments and estimates are management&#146;s best estimates and include assumptions regarding our future operating performance, the time to completing an initial public offering or other liquidity event, the related
company valuations associated with such events and the determinations of the appropriate valuation methods. If we had made different assumptions, our stock-based compensation expense, net loss and net loss per common share could have been different.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Common Stock Valuation Methodologies </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our common stock valuations were prepared in accordance with the guidelines in the American Institute of Certified Public Accountants Practice
Aid, V<I>aluation of Privately-Held Company Equity Securities Issued as Compensation</I>, which prescribes several valuation approaches for determining the value of an enterprise, such as the cost, market and income approaches, and various
methodologies for allocating the value of an enterprise to its capital structure and specifically the common stock. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our common stock
valuation as of September&nbsp;30, 2018 was prepared using an option pricing method, or OPM, framework and utilized a recent transactions market approach for inferring the equity value implied by our recently completed sales of Series B redeemable
convertible preferred stock. The OPM treats common stock and preferred stock as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a
company&#146;s securities changes. Under this method, the common stock has value only if the funds available for distribution to stockholders exceeded the value of the preferred stock liquidation preference at the time of the liquidity event, such
as a strategic sale or a merger. A discount to reflect a lack of marketability of 40% was then applied to arrive at a $0.08 per share valuation of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our common stock valuation as of May&nbsp;31, 2019 was prepared using a hybrid method of two potential liquidity outcomes: a merger and
acquisition scenario utilizing the Guideline Transaction approach and an IPO scenario utilizing the Direct Waterfall approach. The hybrid method is a probability-weighed expected return method, or PWERM, where the equity value in one or more
scenarios is calculated using the OPM. The PWERM is a scenario-based methodology that estimates the fair value of common stock based upon an analysis of future values for the company, assuming various outcomes. The common stock value is based on the
probability-weighted present value of expected future investment returns considering each of the possible outcomes available as well as the rights of each class of stock. The future value of the common stock under each outcome is discounted back to
the valuation date at an appropriate risk-adjusted discount rate and probability weighted to arrive at an indication of value for the common stock. For the May&nbsp;31, 2019 valuation, we (i)&nbsp;assigned a 90% probability of occurrence to the
merger and acquisition scenario, with a 30% weighted average cost of capital within this scenario, then reflected a calculated discount for lack of marketability of 34.5%; and (ii)&nbsp;we assigned a 10% probability of occurrence to the IPO
scenario, with a 30% weighted average cost of capital and a <FONT STYLE="white-space:nowrap">0.75-year</FONT> estimated term to an IPO event, then reflected a calculated discount for lack of marketability of 15%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our common stock valuation as of September 19, 2019 was prepared using a hybrid method of two potential liquidity outcomes: a merger and
acquisition scenario utilizing the Guideline Transaction approach and an IPO scenario utilizing the Direct Waterfall approach. For the retrospective September 19, 2019 valuation, we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(i)&nbsp;assigned a 60% probability of occurrence to the merger and acquisition scenario, with a 25% weighted average cost of capital within this scenario, then reflected a calculated discount
for lack of marketability of 30%; and (ii)&nbsp;we assigned a 40% probability of occurrence to the IPO scenario, with a 25% weighted average cost of capital and a 0.53-year estimated term to an IPO event, then reflected a calculated discount for
lack of marketability of 10%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our common stock valuation as of January 23, 2020 was prepared using a recent transactions market approach
for inferring the equity value implied by our recent sales of Series C redeemable convertible preferred stock and a hybrid of the OPM and Direct Waterfall, including a future IPO scenario utilizing the Direct Waterfall approach, to allocate the
total equity value. For the January 23, 2020 valuation, we (i)&nbsp;assigned a 45% probability of occurrence to the merger and acquisition scenario and applied a discount for lack of marketability of 30%; and (ii)&nbsp;we assigned a 55% probability
of occurrence to the IPO scenario, with a 25% weighted average cost of capital and a 0.19-year estimated term to an IPO event, then reflected a calculated discount for lack of marketability of 5%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Tranche Rights </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our sale
of Series B redeemable convertible preferred stock provided our investors with the right to participate in a subsequent offering of Series B redeemable convertible preferred stock in the event specified development milestone was achieved. We
classified the tranche rights as a derivative liability on our consolidated balance sheet because it met the definition of a freestanding financial instrument that could have required the Company to transfer assets upon exercise. We remeasured the
derivative liability associated with the tranche right to fair value at each reporting date, and recognized changes in the fair value of the derivative liability as a component of other income (expense) in our consolidated statements of operations
and comprehensive loss. The fair value of the derivative liability was determined using the Black-Scholes option pricing model, which considered as inputs (a)&nbsp;the expected stock price volatility of the underlying common stock, (b)&nbsp;the
expected term of the tranche right, (c)&nbsp;the risk-free interest rate and (d)&nbsp;expected dividends. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Years Ended December&nbsp;31, 2019 and 2018 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations for the years ended December&nbsp;31, 2019 and 2018 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Dollar<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,244</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,057</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(959</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,016</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,519</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,259</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,260</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of tranche liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,184</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,017</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,029</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,277</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Revenue </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Grant revenue decreased from $1.2&nbsp;million for the year ended December&nbsp;31, 2018 to $0 for the year ended December&nbsp;31, 2019. The
decrease was a result of the conclusion of our activities related to the NIH awards. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Research and development expense increased by $7.0 million to $12.0 million for the year ended December&nbsp;31, 2019 from
$5.0&nbsp;million for the year ended December&nbsp;31, 2018. </P>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The increase in research and development expense was primarily
attributable to an increase in clinical development external costs of $3.5 million for the year ended December 31, 2019, primarily as a result of Phase&nbsp;2 LANTERN clinical trial costs associated with
<FONT STYLE="white-space:nowrap">LYR-210;</FONT> an increase in chemistry, manufacturing and controls costs of $0.7&nbsp;million for the year ended December 31, 2019, primarily as a result of increased spending on
<FONT STYLE="white-space:nowrap">LYR-210</FONT> as it began the Phase 2 LANTERN clinical trial; an increase in employee compensation and benefits of $1.1 million for the year ended December 31, 2019, primarily as result of an increase in headcount
and a decrease in charges to Arsenal Medical, Inc., or Arsenal, a company which shared certain common owners with us, for employee compensation and benefit costs related to our employees working on Arsenal-sponsored projects in accordance with the
terms of the Transition Services Agreement between the two companies. Additionally, research and development expense increased by $1.4 million for the year ended December 31, 2019, as a result of a decrease in non-employee related charges to Arsenal
and a resulting increase in facilities and allocated expenses. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">General and administrative expense increased by $1.0 million from $3.5&nbsp;million for the year ended December&nbsp;31, 2018 to $4.5 million
for the year ended December&nbsp;31, 2019. </P>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The increase in general and administrative expenses was primarily attributable to an
increase in employee compensation and benefits of $0.3 million for the year ended December&nbsp;31, 2019, primarily due to an increase in headcount and related expenses; an increase in consulting and professional services of $0.5 million for the
year ended December&nbsp;31, 2019, primarily as a result of increased consulting and professional fees resulting from the growth in our general business operations; and the write-off the $0.2 million receivable from the NIH as a result of the
conclusion of our activities related to the NIH awards. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Interest Income (Expense), net </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Interest income (expense), net consists of interest income earned on our cash and cash equivalents and
<FONT STYLE="white-space:nowrap">non-cash</FONT> interest expense incurred on our convertible notes payable. Interest income increased $0.2 million from $36,000 for the year ended December&nbsp;31, 2018 to $0.2 million for the year ended
December&nbsp;31, 2019. The increase was attributable to the interest earned on higher average cash and cash equivalents balances during the year ended December&nbsp;31, 2019 after the closing of the second tranche of our Series B redeemable
convertible preferred stock financing in October 2018. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Change in Fair Value of Tranche Liability </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Change in fair value of tranche liability consists of the change in fair value of the tranche rights related to the sale of our Series B
redeemable convertible preferred stock. It decreased from $1.2&nbsp;million for the year ended December&nbsp;31, 2018 to none for the year ended December&nbsp;31, 2019. The decrease was attributable to the change in fair value of the tranche rights
which were settled in October 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sources of Liquidity </I></B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have
funded our operations from inception through December&nbsp;31, 2019 primarily through gross proceeds of $131.8 million from sales of our redeemable convertible preferred stock and $16.8 million from government contracts. The following table provides
information regarding our total cash and cash equivalents at December&nbsp;31, 2019 and 2018 (in thousands): </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="55.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>As
of<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;December&nbsp;31,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table provides information regarding our cash flows for the years ended December&nbsp;31, 2019 and 2018 (in thousands): </P>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,754</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,640</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(211</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(115</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (decrease) increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,080</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Net Cash Used in Operating Activities </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The cash used in operating activities resulted primarily from our net losses adjusted for <FONT STYLE="white-space:nowrap">non-cash</FONT>
charges and changes in components of working capital. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities was $13.8 million for the year ended
December&nbsp;31, 2019 compared to $6.6&nbsp;million for the year ended December&nbsp;31, 2018. The increase in cash used in operating activities of $7.2&nbsp;million was attributable to: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$10.3 million increase in net loss; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$1.1 million increase in <FONT STYLE="white-space:nowrap">non-cash</FONT> charges for the year ended
December&nbsp;31, 2019 primarily because there was no non-cash income in the year ended December 31, 2019, which differed from the prior year which had $1.2&nbsp;million of <FONT STYLE="white-space:nowrap">non-cash</FONT> income from the change in
fair value of the tranche liability; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$2.0 million increase in changes in the components of working capital. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Net Cash Used in Investing Activities </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities was $0.2 million for the year ended December&nbsp;31, 2019 compared to $37,000 for the year ended
December&nbsp;31, 2018. The increase in cash used for investing activities of $0.2&nbsp;million was attributable to an increase in purchases of property and equipment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Net Cash Provided by Financing Activities </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities was $0.1 million for the year ended December&nbsp;31, 2019 compared to $29.2&nbsp;million for the
year ended December&nbsp;31, 2018. The decrease in cash provided by financing activities of $29.1 million was attributable to: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">net proceeds of $28.7&nbsp;million from the sale of our Series B redeemable convertible preferred stock and the
$0.5&nbsp;million of proceeds from the sale of our convertible notes payable during the year ended December&nbsp;31, 2018; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$0.1 million increase in proceeds from the exercise of common stock options in the year ended December&nbsp;31,
2019 compared to the year ended December&nbsp;31, 2018; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$0.2 million in payments for deferred financing costs in the year ended December&nbsp;31, 2019.
</P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Funding Requirements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development for,
initiate later stage clinical trials for, and seek marketing approval for, our product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to
product sales, marketing, manufacturing and distribution. Furthermore, upon the closing of this offering, we expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional
funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect that the net proceeds from this offering, together with our existing cash and cash equivalents and the funds we raised in
January 2020 will enable us to fund our operating expenses and capital expenditure requirements into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have based this estimate on assumptions that may
prove to be wrong, and we may use our available capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of conducting future clinical trials of <FONT STYLE="white-space:nowrap">LYR-210;</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of manufacturing additional material for one or more pivotal Phase 3 clinical trials of <FONT
STYLE="white-space:nowrap">LYR-210</FONT> and potential future clinical studies we might conduct for our other product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of scaling up our manufacturing process and supply chain capacity to provide sufficient quantities of <FONT
STYLE="white-space:nowrap">LYR-210</FONT> for the potential commercialization of <FONT STYLE="white-space:nowrap">LYR-210</FONT> if our clinical development program is successful and we obtain marketing approval; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the advancement of <FONT STYLE="white-space:nowrap">LYR-220;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, results and costs of discovery, preclinical development, laboratory testing and clinical
trials for other potential product candidates we may develop, if any; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs, timing and outcome of regulatory review of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish and maintain collaborations on favorable terms, if at all; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the achievement of milestones or occurrence of other developments that trigger payments under any collaboration
agreements we might have at such time; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of future commercialization activities, including product sales, marketing, manufacturing
and distribution, for any of our product candidates for which we receive marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount of revenue, if any, received from commercial sales of our product candidates, should any of our
product candidates receive marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of preparing, filing and prosecuting patent applications, obtaining, maintaining and enforcing our
intellectual property rights and defending intellectual property-related claims; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our headcount growth and associated costs as we expand our business operations and our research and development
activities; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of operating as a public company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain
process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our
commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business
objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as we can
generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. We do not have any committed external source of
funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interests may be diluted, and the terms of these securities may include liquidation or other preferences that could
adversely affect your rights as a common stockholder. Any debt financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital
expenditures or declaring dividends, that could adversely impact our ability to conduct our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we raise funds through
collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may
not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to
develop and market product candidates that we would otherwise prefer to develop and market ourselves. </P>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table summarizes our significant contractual obligations as of payment due date by period at December&nbsp;31, 2019 (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;Less&nbsp;than&nbsp;1&nbsp;&nbsp;<BR>&nbsp;year&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;1&nbsp;to&nbsp;3&nbsp;years&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;3&nbsp;to&nbsp;5&nbsp;years&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>More&nbsp;than<BR>5
years</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease obligation<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents future minimum lease payments under our <FONT STYLE="white-space:nowrap">non-cancelable</FONT>
operating lease which expires April 2023. The minimum lease payments above do not include any related common area maintenance charges, operating expenses or real estate taxes. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We enter into agreements in the normal course of business with CROs for clinical trials,
third party manufacturers for clinical supply manufacturing, professional consultants for expert advice and other vendors for other services for operating purposes. We have not included these payments in the table of contractual obligations above
since the contracts do not contain any minimum purchase commitments and are cancelable at any time by us, generally upon 30 days prior written notice and therefore we believe that our <FONT STYLE="white-space:nowrap">non-cancelable</FONT>
obligations under these agreements are not material. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We did not have during the periods presented, and we do not currently have, any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet
arrangements, as defined under applicable SEC rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosures About Market Risk </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are exposed to market risk related to changes in interest rates. As of December&nbsp;31, 2019 and 2018, our cash equivalents consisted of
interest-bearing checking accounts. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Due to the short-term nature and the low risk profile of our
interest-bearing accounts, an immediate 10% change in interest rates would not have a material effect on the fair market value of our cash and cash equivalents or on our financial position or results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are not currently exposed to significant market risk related to changes in foreign currency exchange rates; however, we have contracted
with and may continue to contract with foreign vendors located in Europe, Australia and New Zealand. Our operations may be subject to fluctuations in foreign currency exchange rates in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Inflation generally affects us by increasing our clinical trial costs. We do not believe that inflation had a material effect on our business,
financial condition or results of operations during the years ended December&nbsp;31, 2019 and 2018. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Emerging Growth Company Status </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Jumpstart Our Business Startups Act of 2012, or the JOBS Act, permits an &#147;emerging growth company&#148; such as us to take advantage
of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are in the process of evaluating the benefits of relying on other exemptions and reduced reporting requirements under the JOBS Act. Subject
to certain conditions, as an emerging growth company, or EGC, we intend to rely on certain of these exemptions, including exemptions from the requirement to provide an auditor&#146;s attestation report on our system of internal controls over
financial reporting pursuant to Section&nbsp;404(b) of the Sarbanes-Oxley Act and from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s
report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc805799_11"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage
therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases. Our proprietary technology platform, XTreo, is
designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. Our initial product candidates, <FONT STYLE="white-space:nowrap">LYR-210</FONT> and <FONT
STYLE="white-space:nowrap">LYR-220,</FONT> are bioresorbable polymeric matrices designed to be administered in a brief, <FONT STYLE="white-space:nowrap">non-invasive,</FONT> <FONT STYLE="white-space:nowrap">in-office</FONT> procedure and intended to
deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS. The therapeutic embedded within <FONT STYLE="white-space:nowrap">LYR-210</FONT> and
<FONT STYLE="white-space:nowrap">LYR-220</FONT> is mometasone furoate, or MF, which is the active ingredient in various U.S. Food and Drug Administration, or FDA, approved drugs and has a well-established efficacy and safety profile. CRS is an
inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities and affects approximately 14&nbsp;million people in the United States. We are advancing <FONT STYLE="white-space:nowrap">LYR-210</FONT> as
a potential preferred alternative to surgery in an ongoing Phase 2 clinical trial, which we refer to as our LANTERN clinical trial, for CRS patients who have failed medical management, and we expect to report topline data in
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. In our Phase 1 clinical trial, <FONT STYLE="white-space:nowrap">LYR-210</FONT> met its primary safety endpoint, and we observed that patients generally
experienced significant and rapid, clinically meaningful and durable improvement on a patient symptom severity scale through week 25, which was the end of the trial. We are also developing <FONT STYLE="white-space:nowrap">LYR-220</FONT> for use in
CRS patients who have an enlarged nasal cavity due to sinus surgery but continue to require treatment to manage CRS symptoms, and we intend to initiate a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> clinical trial for <FONT STYLE="white-space:nowrap">LYR-220</FONT> in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Beyond
CRS, we believe our XTreo platform has potential applications in other disease areas, which we are actively exploring to further broaden its therapeutic potential. </P>
<P STYLE="margin-top:11pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">CRS has been described in the literature as an &#147;unrecognized epidemic&#148; due to its high prevalence, its substantial impact on patient
quality of life and the significant limitations of currently available treatment options. We estimate that sinusitis, which includes both CRS and acute rhinosinusitis, impacts approximately 12% of the adult population in the United States, or
approximately 30&nbsp;million people, making it the fifth most common condition in people under the age of 65 and more prevalent than diabetes or heart disease. Of this population, we estimate that approximately 14 million people are affected with
CRS. Moreover, we estimate that approximately 8 million people are treated for CRS by physicians annually, of which approximately 4 million fail medical management each year. In the United States, over $60&nbsp;billion is spent annually in direct
treatment costs for sinusitis, including approximately $5&nbsp;billion on sinus surgeries. </P> <P STYLE="margin-top:11pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe
<FONT STYLE="white-space:nowrap">LYR-210</FONT> and <FONT STYLE="white-space:nowrap">LYR-220,</FONT> if successfully developed and approved, will be able to treat the entire spectrum of CRS patients, including
<FONT STYLE="white-space:nowrap">pre-</FONT> and post-surgical patients and those with and without nasal polyps, with up to six months of treatment in a single administration. Our most advanced product candidate,
<FONT STYLE="white-space:nowrap">LYR-210,</FONT> is being evaluated in CRS patients who have failed medical management but have not undergone endoscopic sinus surgery, who we refer to as <FONT STYLE="white-space:nowrap">surgically-na&iuml;ve</FONT>
CRS patients, in our ongoing randomized, sham procedure-controlled, patient-blinded, Phase 2 LANTERN clinical trial. We initiated this trial in May 2019 and expect to report topline data in
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. In an open-label, multi-center Phase 1 clinical trial, we placed 40 <FONT STYLE="white-space:nowrap">LYR-210</FONT> matrices bilaterally in 20 patients
at sites in New Zealand and Australia. <FONT STYLE="white-space:nowrap">LYR-210</FONT> met its primary safety endpoint in the Phase 1 trial, and we observed significant and rapid, clinically meaningful and durable improvement through week 25 in
SinoNasal Outcome Test scores, or <FONT STYLE="white-space:nowrap">SNOT-22</FONT> scores, an established patient symptom severity scale. At week 24, improvement versus baseline was observed in 90% of patients, with similar activity observed across
both polyp and <FONT STYLE="white-space:nowrap">non-polyp</FONT> patients. Additionally, we intend to initiate a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> clinical trial for <FONT
STYLE="white-space:nowrap">LYR-220</FONT> in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and to submit a supplemental new drug application, or sNDA, to the FDA for a potentially faster path to approval of LYR-220 if a
new drug application, or NDA, for <FONT STYLE="white-space:nowrap">LYR-210</FONT> is approved by the FDA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our XTreo Platform </B></P>
<P STYLE="margin-top:11pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">XTreo, our innovative and proprietary drug delivery platform, is designed to locally and continuously deliver small molecule drugs to the
affected tissue over a sustained period of time from a single administration. The platform is comprised of three interrelated technology components: </P> <P STYLE="font-size:11pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a biocompatible mesh scaffold, which is designed to maximize surface area for drug release while maintaining
underlying tissue function; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an engineered elastomeric matrix, which means a polymeric matrix composed of polymers having elastic
characteristics, which has advanced physical properties resulting in implants with &#147;shape memory&#148; that dynamically adapt to nasal anatomy; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a versatile polymer-drug complex, which can be customized for the treatment of various chronic diseases treatable
with ENT delivery to achieve the desired drug dose and drug elution rate. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Chronic Rhinosinusitis: A Prevalent Disease with High
Unmet Medical Needs </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">CRS is an inflammatory disease of the paranasal sinuses causing the soft, moist layer of mucus-producing tissue,
or mucosa, that lines the sinuses to become swollen and inflamed, leading to significant patient morbidities. The inflammation may be caused by infections, allergies or environmental factors, as well as structural issues such as blockages of an
ostium. Patients with CRS on average experience a lower quality of life index than people suffering from congestive heart failure, angina, chronic obstructive pulmonary disease or back pain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">CRS has two phenotypes: CRS with nasal polyps, which are teardrop-shaped benign masses arising from the mucosa lining, and CRS without nasal
polyps. The <FONT STYLE="white-space:nowrap">non-polyp</FONT> form of CRS represents approximately <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">70%-to-90%</FONT></FONT> of CRS patients. We estimate that approximately
8&nbsp;million people are treated for CRS by physicians annually, of which approximately 4&nbsp;million fail medical management every year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Current
Treatments and Their Limitations </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The goals of therapy for CRS are to reduce mucosal swelling resulting from underlying inflammation,
promote sinus drainage, and eradicate infections that may be present. The treatment of CRS is progressive in nature and typically begins with medical management, primarily with topical intranasal steroids and oral steroids. If this treatment is
unsuccessful, an ENT physician may perform a sinus surgery. </P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g805799g20m10.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>Figure 1. Current Primary Treatment Paradigm for CRS. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Currently, there are no <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drug therapies
for CRS for <FONT STYLE="white-space:nowrap">non-polyp</FONT> patients, although some drugs approved for nasal polyps are used <FONT STYLE="white-space:nowrap">off-label</FONT> in this population. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Solution for CRS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">LYR-210</FONT> is an anti-inflammatory implantable drug matrix based on our XTreo platform that is designed to consistently and locally elute MF to the inflamed mucosal tissue for up to six months in <FONT
STYLE="white-space:nowrap">surgically-na&iuml;ve</FONT> CRS patients who fail medical management. MF, the active ingredient in various <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drugs, has a well-established efficacy and safety profile,
which we believe will support the development process for <FONT STYLE="white-space:nowrap">LYR-210.</FONT> <FONT STYLE="white-space:nowrap">LYR-210</FONT> is designed to enable sustained drug delivery at <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">difficult-to-access</FONT></FONT> nasal inflammation sites without the need for patient compliance, while avoiding the systemic side effects associated with oral steroids. <FONT STYLE="white-space:nowrap">LYR-210</FONT> is
designed to be administered in a brief, <FONT STYLE="white-space:nowrap">non-invasive,</FONT> <FONT STYLE="white-space:nowrap">in-office</FONT> procedure by an ENT physician under endoscopic visualization via a
<FONT STYLE="white-space:nowrap">single-use</FONT> applicator. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">LYR-210</FONT> is currently being
studied in a Phase 2 randomized, sham procedure-controlled, patient-blinded clinical trial, which we refer to as LANTERN, evaluating the safety and efficacy in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT
STYLE="white-space:nowrap">surgically-na&iuml;ve</FONT> CRS patients who have failed previous medical management. The trial was initiated in May 2019 and is currently ongoing at sites in Australia, Austria, Czech Republic, New Zealand and Poland. In
January 2020, the FDA cleared our investigational new drug application, or IND, and we expect to open new sites in the United States. We expect to report topline data from the Phase 2 LANTERN clinical trial in
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">LYR-210</FONT> was
previously studied in an open-label, Phase 1 clinical trial with 20 patients in New Zealand and Australia, and achieved its primary endpoint of safety at week 4. In the Phase 1 trial, we also observed that patients generally experienced significant
and rapid, clinically meaningful and durable improvement in SNOT-22 scores. Significant reduction in <FONT STYLE="white-space:nowrap">SNOT-22</FONT> was observed at week 1, and this reduction persisted through week 25, which was the end of the
trial. The changes from baseline, or CFBL, in <FONT STYLE="white-space:nowrap">SNOT-22</FONT> score were statistically significant (P &lt; 0.01) at all measured intervals. The average change from baseline in
<FONT STYLE="white-space:nowrap">SNOT-22</FONT> score at week 1 was <FONT STYLE="white-space:nowrap">-13.0</FONT> points (P=0.008 to <FONT STYLE="white-space:nowrap">pre-treatment),</FONT> achieving the minimal clinically significant difference of <FONT
STYLE="white-space:nowrap">-8.9</FONT> points. Further, symptom relief as measured by <FONT STYLE="white-space:nowrap">SNOT-22</FONT> score was observed through the entire duration of the trial, achieving an average change from baseline of <FONT
STYLE="white-space:nowrap">-20.5</FONT> points at week 24, the end of the treatment period (P=0.00005 to <FONT STYLE="white-space:nowrap">pre-treatment),</FONT> and -20.0 points (p &lt; 0.0001) at week 25, one week after the removal of LYR-210. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are developing our second pipeline product candidate, <FONT STYLE="white-space:nowrap">LYR-220,</FONT> for use in CRS patients who continue
to require medical management despite having had sinus surgery. <FONT STYLE="white-space:nowrap">LYR-220</FONT> is also designed to utilize MF, but will employ an oversized matrix designed for patients whose nasal cavity is enlarged due to sinus
surgery. <FONT STYLE="white-space:nowrap">LYR-220</FONT> is designed as a potential preferred alternative to revision sinus surgery and post-surgical medical management. We expect to initiate a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> clinical trial for <FONT STYLE="white-space:nowrap">LYR-220</FONT> in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe that the key potential benefits of our current investigational product portfolio, <FONT STYLE="white-space:nowrap">LYR-210</FONT>
and <FONT STYLE="white-space:nowrap">LYR-220,</FONT> include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Clinical Activity</B>: We believe <FONT STYLE="white-space:nowrap">LYR-210</FONT> and <FONT
STYLE="white-space:nowrap">LYR-220</FONT> have the potential to significantly improve symptoms by maintaining a steady, high dose of MF at the site of inflammation for up to six months with a single administration, without any dependence on patient
compliance. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Patient Compliance</B>: Because drug delivery for <FONT STYLE="white-space:nowrap">LYR-210</FONT> and <FONT
STYLE="white-space:nowrap">LYR-220</FONT> is designed to be sustained for up to six months with a single administration, the efficacy of <FONT STYLE="white-space:nowrap">LYR-210</FONT> and <FONT STYLE="white-space:nowrap">LYR-220</FONT> will not
depend on patient compliance within the treatment period, unlike other CRS treatment options that require repeated daily administrations, such as topical intranasal steroids and oral steroids. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Patient Experience</B>: <FONT STYLE="white-space:nowrap">LYR-210</FONT> and
<FONT STYLE="white-space:nowrap">LYR-220</FONT> are designed to be administered via a simple, <FONT STYLE="white-space:nowrap">in-office</FONT> procedure every six months, which is intended to enhance convenience for patients, unlike
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
the repeated daily medical management and/or time-consuming and painful surgery required by certain other CRS treatment options. Moreover, we believe patients may also benefit from the
biocompatible, flexible structure of <FONT STYLE="white-space:nowrap">LYR-210</FONT> and <FONT STYLE="white-space:nowrap">LYR-220</FONT> that is designed to maximize comfort over the therapy period. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Physician Experience</B>: <FONT STYLE="white-space:nowrap">LYR-210</FONT> and
<FONT STYLE="white-space:nowrap">LYR-220</FONT> are designed to enable physicians to perform the placement of <FONT STYLE="white-space:nowrap">LYR-210</FONT> and <FONT STYLE="white-space:nowrap">LYR-220</FONT>
<FONT STYLE="white-space:nowrap">in-office</FONT> in conjunction with an endoscopy procedure, thereby making the placement aligned with the existing care continuum for CRS patients and eliminating the need for physicians to schedule separate
surgical time. Moreover, the elastomeric matrix encapsulates the underlying mesh fibers to facilitate removal. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Localized Delivery</B>: <FONT STYLE="white-space:nowrap">LYR-210</FONT> and
<FONT STYLE="white-space:nowrap">LYR-220</FONT> are designed to benefit from our XTreo platform, which is intended to provide localized delivery to avoid systemic side effects that are common with certain other CRS treatment options, such as oral
steroids. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Patient Applicability</B>: <FONT STYLE="white-space:nowrap">LYR-210</FONT> and
<FONT STYLE="white-space:nowrap">LYR-220</FONT> are designed to treat the entire spectrum of CRS patients who have failed medical management, including <FONT STYLE="white-space:nowrap">pre-</FONT> and post-surgical patients and those with and
without polyps. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Pharmacoeconomic Impact</B>: <FONT STYLE="white-space:nowrap">LYR-210</FONT> and <FONT
STYLE="white-space:nowrap">LYR-220</FONT> are designed as an alternative to surgery (initial or revision), and as such have the potential to provide significant savings to the healthcare industry by reducing the number and frequency of expensive
surgical treatment options. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe <FONT STYLE="white-space:nowrap">LYR-210</FONT> and <FONT
STYLE="white-space:nowrap">LYR-220,</FONT> if approved, would be the only products able to deliver up to six months of continuous topical treatment in a single administration to treat the entire spectrum of CRS patients who fail medical management,
including <FONT STYLE="white-space:nowrap">pre-</FONT> and post-surgery patients and those with and without nasal polyps. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property and
Barriers to Entry </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We own all the material intellectual property rights related to our platform and product candidate portfolio.
As of December 31, 2019, our product candidate portfolio is protected by 21 issued and 27 pending patents worldwide with claims directed to composition of matter, drug delivery and method of use, which, exclusive of possible patent term adjustments
or extensions or other forms of exclusivity, are projected to expire between 2030 and 2037. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We also rely upon <FONT
STYLE="white-space:nowrap">know-how,</FONT> continuing technological innovation, and technical barriers to entry, including manufacturing and drug delivery complexities, to develop and maintain our competitive intellectual property position. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Management Team and Investors </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our
management team has extensive drug development, manufacturing and commercialization experience across a broad spectrum of disease areas, for both drug and drug-device combination products, with a successful track record in large pharmaceutical,
medical device and biotech companies. Additionally, our management team has been involved in the development of successfully approved and commercialized products such as Taxus (drug-eluting stent), AvoneX, Arikayce and Panhematin. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Further, we are supported by a leading group of biotech investors including, among others, ArrowMark Partners, Intersouth Partners, North
Bridge Venture Partners, Perceptive Advisors, Polaris Venture Partners, RA Capital and Soleus Capital. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Pipeline </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The current status of our product candidates is summarized below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g805799g99l17.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our mission is to transform the ENT treatment paradigm by utilizing our proprietary drug delivery platform, XTreo, to develop safe and
effective therapies for the treatment of debilitating diseases treatable with ENT delivery. We intend to achieve this through the following strategies: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Complete the development and secure FDA approval of <FONT STYLE="white-space:nowrap">LYR-210</FONT> for the
treatment of CRS.</B> We believe <FONT STYLE="white-space:nowrap">LYR-210,</FONT> if approved, is well positioned in the CRS treatment paradigm to provide a preferred alternative to surgery. <FONT STYLE="white-space:nowrap">LYR-210,</FONT> which is
currently in an ongoing randomized, sham procedure-controlled, patient-blinded Phase 2 LANTERN clinical trial, utilizes MF, the active ingredient in various <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drugs. We expect to report topline data
from the Phase 2 LANTERN trial of <FONT STYLE="white-space:nowrap">LYR-210</FONT> in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Our goal is to advance <FONT STYLE="white-space:nowrap">LYR-210</FONT> through Phase 2 and
into one or more pivotal Phase 3 clinical trials, followed by potential marketing approval through a 505(b)(2) NDA submitted to the FDA. </P></TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Advance our second product candidate, <FONT STYLE="white-space:nowrap">LYR-220,</FONT> into the clinic to
provide a comprehensive solution for CRS patients who have failed medical management and surgery. </B>We are developing a larger version of <FONT STYLE="white-space:nowrap">LYR-210</FONT> designed for use in the enlarged nasal cavity of CRS patients
who have had sinus surgery. We believe <FONT STYLE="white-space:nowrap">LYR-220,</FONT> if successfully developed and approved, is well positioned to provide a preferred alternative to revision surgery and post-surgical medical management. <FONT
STYLE="white-space:nowrap">LYR-220</FONT> is currently in product feasibility studies. We plan to advance <FONT STYLE="white-space:nowrap">LYR-220</FONT> into a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> clinical trial in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and intend to seek approval through the sNDA pathway if an NDA
for <FONT STYLE="white-space:nowrap">LYR-210</FONT> is approved by the FDA. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Build a commercialization infrastructure in the U.S. market for
<FONT STYLE="white-space:nowrap">LYR-210</FONT> and <FONT STYLE="white-space:nowrap">LYR-220.</FONT> </B>If any of our product candidates are approved, we plan to launch an efficient,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">go-to-market</FONT></FONT> commercialization model focused on targeted outreach to our key physician, payer and patient audiences. We plan to build an
<FONT STYLE="white-space:nowrap">in-house</FONT> sales force that will target ENT physicians whose <FONT STYLE="white-space:nowrap">sub-specialty</FONT> is general otolaryngology or rhinology, which together represent roughly 60% of the 12,000 ENT
physicians in the United States. Ensuring physician and patient market access to our products will be critical to our success, and we plan to execute a holistic reimbursement strategy that will integrate payer coverage and physician practice
management initiatives. In addition, we also plan to selectively use cost-effective, patient-directed marketing strategies to further increase awareness among the CRS patient community of our products with the goal of increasing ENT physician
visits. Finally, we plan to leverage our commercial infrastructure in the subsequent launch of <FONT STYLE="white-space:nowrap">LYR-220</FONT> and any future product candidates. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Maximize the value of our XTreo platform and expand our product pipeline. </B>Our XTreo platform provides a
versatile drug development engine that enables us to focus on other indications where long-term delivery of existing treatments may provide improved local bioavailability and enhanced efficacy or safety. We plan to utilize our platform to identify
additional product candidates, with an initial focus on conditions treatable with nasal delivery, potentially including allergic rhinitis, rare disorders where nasal disease contributes to the disease pathology and central nervous system disorders.
In addition, we believe we can adapt our platform to target conditions treatable with delivery to other tissues beyond the nasal cavities, such as the ear. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Seek strategic collaborative relationships. </B>We intend to develop our product candidates on our own in the
U.S. and retain all U.S. rights, but seek strategic collaborations <FONT STYLE="white-space:nowrap">ex-U.S.</FONT> to facilitate the capital-efficient development of our product candidates. We may also enter into collaborative relationships within
the U.S. for our future pipeline candidates. We believe these collaborations could potentially provide <FONT STYLE="white-space:nowrap">non-dilutive</FONT> funding to advance our pipeline candidates while allowing us to benefit from the development
expertise of our collaborators. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Technology Platform </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">XTreo, our innovative and proprietary drug delivery platform is designed to locally and continuously deliver small molecule drugs to the
affected tissue over a sustained period of time from a single administration. Our technology platform, developed over the past decade, was first patented in 2009 by members of our team who have extensive experience in drug formulation and delivery,
material science and biotechnology. This expertise has allowed us to significantly improve upon polymer drug delivery technology and add shape-memory properties to bioresorbable polymeric implants, one of our key innovations. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g805799g25m49.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>Figure 2. XTreo Proprietary Platform.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">XTreo, our drug-eluting bioresorbable technology platform is comprised of three polymeric components, which are designed to work together to
enable highly efficient, localized drug delivery (see Figure 2, above). This proprietary technology platform is designed to enable sustained delivery of medications for many </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
months of therapy, targeting tissues deep in the ENT passages and potentially other diseased tissues that are not accessible with conventional therapeutic approaches. The components of our
platform include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Biocompatible Mesh Scaffold</B>&#151;variants of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">poly(L-lactide-co-glycolide),</FONT></FONT></FONT> or PLGA, braided to form an implantable mesh with a high surface area. Our biocompatible mesh scaffold is intended to provide the
foundation for efficient drug delivery. We have designed the mesh scaffold to optimize surface area for drug release while maintaining underlying tissue function through an open-cell design. The mesh scaffold is comprised of bioresorbable polymers
and is pliable to maximize patient comfort. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Engineered Elastomeric Matrix</B>&#151;overlying elastomer of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">poly(L-lactide-co-</FONT></FONT></FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#101;</FONT>-caprolactone), or PLCL, coating that constrains the intersection points of the braid. Over the last
decade we have developed a highly sophisticated and proprietary engineered elastomeric matrix which has advanced physical properties to dynamically conform to nasal anatomy. Its adaptive elastic tension, which gives it shape-memory to resist
deformation, is key to ensuring persistent positioning in the target location. The matrix works in conjunction with the underlying mesh to exert outward retention force, keeping it in place as tissue remodels. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Versatile Polymer-Drug Complex</B>&#151;active therapeutic embedded in a polymer designed to control its
release. We have extensive drug-delivery <FONT STYLE="white-space:nowrap">know-how</FONT> which has enabled us to design a versatile polymer-drug complex that can accommodate most small molecule drugs and achieve tunable elution profiles. We believe
our versatile polymer-drug complex is potentially amenable to continuous, prolonged drug release across a wide range of drugs for different therapeutic applications. With proprietary bioresorbable polymer-drug formulations, we believe our platform
can be used to customize controlled-release drugs for various chronic diseases treatable with ENT delivery and improve the efficacy of therapeutic properties of existing active pharmaceutical ingredients, or APIs, through more prolonged delivery.
</P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The three integrated components are fundamental to the successful function and versatility of the XTreo
technology. For application to a targeted tissue, the implant is compressed into a narrow applicator, which allows <FONT STYLE="white-space:nowrap">non-invasive</FONT> placement deep within cavities of the ear, nose, and throat. The shape-memory
properties ensure the implant self-expands as it is administered through the applicator to conformably fit within and adapt to the target anatomy. The implant is designed to be oversized for the target anatomy and therefore will push outwards to
stay fixed at the target location. Over time, as inflammation recedes due to the local drug therapy, the shape-memory properties are intended to allow the implant to actively adapt to the anatomy and continue to stay in place to elute drug locally
for a prolonged period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In engineering the implant, we use polymers that are biocompatible and bioresorbable which, if left in place,
would gradually dissolve over time. The polymers used in our formulations have established safety profiles as they have previously been used in <FONT STYLE="white-space:nowrap">FDA-approved</FONT> therapeutics. The mesh scaffold and elastomeric
matrix are composed of PLGA and PLCL elastomer, both of which are well-established biodegradable polymers commonly used in medical applications. The customizable polymer drug complex consists of the active therapeutic embedded in the inactive
ingredients containing PLCL and <FONT STYLE="white-space:nowrap">poly(L-lactide),</FONT> or PLA, to control the drug elution rate. The polymer composition and drug formulation are tailored to achieve the desired drug dose and dissolution rate. Our
expertise allows us to balance polymer resorption with drug elution to achieve a sustained rate of drug release over months in addition to varying the dosing and release rates to provide chronic local treatment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Chronic Rhinosinusitis and the Treatment Landscape </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Sinuses are <FONT STYLE="white-space:nowrap">air-filled</FONT> pockets within the bones of the face and skull. The four types of sinuses are
frontal, ethmoid, sphenoid and maxillary (see Figure 3, below). One of each type of sinus lies on either side of the face. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g805799g88b20.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>Figure 3. Illustration of Nasal Sinuses. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The sinuses are lined with a soft, moist layer of mucus-producing tissue, or mucosa. Mucus moistens the nasal lining and protects the body
from inhaled impurities such as dust, pollutants and bacteria. Each of the maxillary, sphenoid and frontal sinuses has a corresponding ostium, or opening, through which mucus drains. The ethmoid sinuses are a series of cells with multiple, often
interconnected openings and drainage pathways. The surface tissues of the sinuses are covered with millions of cilia, which are small, hair-like structures that act in coordination to sweep the mucus through the ostium of each sinus cavity to the
back of the throat. The drainage of mucus is a normal process that keeps the sinuses healthy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">CRS is an inflammatory disease of the
paranasal sinus causing the mucosa lining to become swollen and inflamed, leading to significant patient morbidities. The inflammation may be caused by infections, allergies or environmental factors, as well as structural issues such as blockages of
an ostium. If one or more sinus drainage pathways becomes blocked, normal mucus drainage is prevented and damage to ciliary function may occur. There are two categories of sinusitis: acute and chronic. Acute sinusitis is transient in nature and
lasts less than four weeks. Chronic sinusitis is more severe and lasts 12 weeks or longer. The term &#147;chronic sinusitis&#148; is generally used interchangeably with &#147;CRS&#148; in the medical community, and we refer to the condition as CRS
in this prospectus. The four cardinal symptoms of CRS are nasal obstruction and congestion, facial pain and pressure, nasal discharge and olfactory loss (loss of sense of smell). Other symptoms include chronic headaches, bodily pain, fatigue, sleep
deprivation, depression and recurrent infections. CRS may be diagnosed when two of the four cardinal symptoms persist for 12 weeks or longer and when inflammation is confirmed via endoscopy or CT scan. Patients with CRS experience a lower quality of
life index than people suffering from congestive heart failure, angina, chronic obstructive pulmonary disease or back pain. In addition, CRS symptoms are estimated to cause patients to miss over 11&nbsp;million workdays per year in the United States
alone, resulting over $1&nbsp;billion in indirect economic costs. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We estimate that sinusitis impacts approximately 12% of the adult
population in the United States, or approximately 30&nbsp;million people, making it the fifth most common condition in people under the age of 65, and more prevalent than diabetes or heart disease. Beyond the United States, sinusitis has a similarly
high prevalence in Europe, with approximately 27&nbsp;million cases in the EU5 (France, Germany, Italy, Spain and the United Kingdom), and in Asia, with approximately 104&nbsp;million cases in China alone. Of the approximately 30&nbsp;million people
impacted by sinusitis in the United States, we estimate approximately 14&nbsp;million are affected with CRS. Of these, we estimate that approximately 8&nbsp;million people are treated for CRS by physicians annually, of which approximately
4&nbsp;million fail medical management every year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">CRS has two phenotypes: CRS with nasal polyps, which are teardrop-shaped benign masses
arising from the mucosa, and CRS without nasal polyps, with the <FONT STYLE="white-space:nowrap">non-polyp</FONT> form representing approximately <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">70%-to-90%</FONT></FONT> of CRS
patients. Patients with polyps develop <FONT STYLE="white-space:nowrap">non-cancerous</FONT> polyps on the chronically inflamed surfaces, but both subgroups typically share the same symptoms. Currently, the majority of our competitors target CRS
patients with polyps, and there are no approved treatments for CRS without polyps, creating a vast untapped market opportunity for a more effective treatment solution. Given no approved treatments for CRS without polyps exist, there is only <FONT
STYLE="white-space:nowrap">off-label</FONT> drug usage for this segment of the patient population. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Current treatments are directed
towards managing the symptoms of CRS through a combination of medical management and surgical intervention techniques. The first line of therapy is medical management involving nasal saline irrigation, intranasal corticosteroidal sprays, oral
steroids and antibiotics for patients with an active sinus infection. CRS is the most common reason for adult outpatient antibiotic use in the United States. It has been estimated that antibiotic use to treat infections relating to CRS may cost more
than $150 million per year in the aggregate. Patients whose symptoms persist despite medical management are generally recommended to undergo functional endoscopic sinus surgery (or FESS) or balloon sinus dilation (or BSD), or both. FESS is a highly
invasive surgery performed in the operating room, under full anesthesia, to open the blocked sinus pathways by removing inflamed tissue and bone using surgical tools. BSD is a less severe form of endoscopic sinus surgery, often used in combination
with FESS, in which small balloon catheters are inserted and inflated to drain the large nasal sinuses. Although FESS and BSD can improve symptoms and quality of life, limitations remain. Neither correct the underlying cause of the inflammation and
patients who undergo either or both procedures often experience significant pain and require continued post-operative medical therapy to maintain improvements, with a high incidence of repeat surgeries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Medical Management </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
first-line of treatment for CRS is medical therapy, which typically includes nasal saline irrigation, corticosteroids, and antibiotics for patients with an active infection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Steroids represent the current first-line standard of care for CRS patients, given they are generally pharmacologically effective at treating
inflammation. Intranasal steroid sprays and aerosols, commonly indicated for rhinitis, or inflammation of the nasal passage, are routinely prescribed and used
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> for the treatment of CRS symptoms. Physicians may also prescribe oral steroids on an episodic basis to patients who have not received sufficient
symptomatic relief. They are generally prescribed for short-term use by patients with severe symptoms or exacerbations of CRS who are already on maintenance therapy, such as nasal irrigation or intranasal corticosteroid sprays. Finally, physicians
may prescribe antibiotics for patients with an active infection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Intranasal steroid sprays, oral steroids and antibiotics each have
significant limitations: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">While intranasal steroid sprays avoid systemic exposure and thus lack such serious side effects, penetration of
the spray beyond the nasal cavities into the paranasal sinuses&#151;the site of inflammation&#151;is limited, particularly in <FONT STYLE="white-space:nowrap">pre-operative</FONT> patients, despite requiring multiple, inconvenient administrations
per day. In a published study, a large fraction of the spray is deposited in the anterior nasal cavity without any significant penetration into the paranasal sinuses. Additionally, intranasal spray efficacy is also limited due to fast clearance
rates, as it has been demonstrated that mucocilliary action removes approximately 50% of the spray from the nasal cavity within 10 to 15 minutes of dosing. Poor patient compliance further limits the effectiveness of intranasal steroid sprays. While
a recently launched intranasal exhalation delivery product has been developed to enhance the delivery of steroid to areas of inflammation within the sinus, the product is still subject to the limitations resulting from fast clearance and poor
patient compliance. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oral steroid therapy is effective at reaching the sinus lining, but it does so by means of systemic exposure and
therefore carries the risk of serious side effects associated with prolonged use, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
including glaucoma, bone loss, weight gain, psychosis and difficulty in controlling blood glucose levels in patients with diabetes. Additionally, studies have shown that long-term benefits from
their use are limited. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Although antibiotics are generally prescribed for patients with an active infection, their role for treatment of
CRS is unclear, and there is limited evidence that supports their use for the treatment of CRS. In addition, their prolonged use can lead to antibiotic resistance, and CRS is identified as a major target in national efforts to reduce unnecessary
antibiotic intervention. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Medical management is used as a first-line of medical therapy for <FONT
STYLE="white-space:nowrap">pre-operative</FONT> patients and as maintenance therapy for post-operative patients. Therefore, patients in both stages of the condition are managed medically and hence are subject to the limitations described above.
Based on published medical literature, we estimate that at least 50% of CRS patients who are seen by ENT physicians and receive medical management remain symptomatic. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sinus Surgery </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The primary
alternative after medical management is FESS, an invasive surgery during which a physician enlarges the inflamed and obstructed sinus pathways by removing inflamed tissue and bone in order to facilitate normal sinus drainage and aeration as well as
provide greater access for delivery of steroids. First introduced in the United States in the 1980s, FESS is considered the standard of care for surgical intervention to treat CRS. However, while approximately 400,000 FESS procedures are performed
each year, many surgical candidates opt not to have surgery given that it does not correct the underlying inflammation or obviate the need for medical management. Approximately, 65% of patients have recurrent symptoms post-FESS and up to 20% require
a revision surgery. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">FESS is a highly invasive procedure, requiring general anesthesia and involving significant post-operative
discomfort. During this procedure, a physician inserts an endoscope into the nasal cavity to provide visualization of the patient&#146;s anatomy, the turbinate is identified with help of the endoscope and the uncinated process is removed exposing
the ethmoid bulla. Surgical instruments, powered cutting tools and balloon dilation devices are used to remove or dilate the obstructive tissue and bone. Given the essential role of the ethmoid bulla in sinus function, the ethmoid sinuses are then
opened in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">75%-to-85%</FONT></FONT> of FESS procedures. The dependent sinuses each drain into the ethmoid sinuses through ostia, which may be enlarged by either surgically removing
tissue or via balloon dilation. Following the surgical intervention, physicians often pack the newly opened ethmoid sinuses with gauze or other obstructive sinus packing materials to hold the sinus cavities open. A
<FONT STYLE="white-space:nowrap">follow-up</FONT> office visit is required several days after the procedure to remove the sinus packing materials and depending on the circumstances a patient may have to visit the surgeon two to three times a week
for a period of time using nasal irrigation or will be allowed to carry out simple nasal douching several times a day. A typical FESS procedure costs approximately $14,000 on average. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Since the introduction of FESS, several new technologies, such as image-guided surgical navigation systems, powered surgical instruments and
BSD devices have expanded the addressable patient population who can benefit from FESS. For instance, BSD devices were developed to be used in combination with traditional surgical instruments during FESS to treat the dependent sinuses and have now
allowed for treatment of some patients in the physician office setting as a standalone procedure. The cost of a BSD procedure can range from $3,000 to $7,000 per treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On an annual basis, approximately 4&nbsp;million CRS patients fail medical management, but ultimately only approximately 400,000 patients
choose to undergo an endoscopic sinus surgery each year. Physicians report that many patients, when presented with sinus surgery as a treatment option, opt to forego the procedure. Some patients regard the often temporary benefits provided by
surgery as not worth the expense, recovery time or use of general anesthesia. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">While sinus surgery is the standard of care for treating CRS after the failure of medical
management, it has several significant limitations: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Invasive surgery with significant post-operative pain and nasal care.</I></B> FESS is an invasive surgery
that results in irreversible changes to the anatomy and significant post-operative pain, discomfort and recovery time. As with any invasive surgery, a FESS entails the potential for bleeding, infection and scar tissue. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Requirement for post-operative maintenance.</I></B> As the underlying inflammation of CRS is still
unaddressed by sinus surgery, patients are required to post-operatively maintain their treatment with medical management. Additionally, reports have shown nasal polyp regrowth following surgery in many cases and post-nasal discharge often times
remains a challenge. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Additional FESS procedures may be needed.</I></B> Approximately 65% of patients have recurring symptoms
post-FESS, and approximately 20% of patients will require a revision of sinus surgery within five years, 43% of whom will be within the first post-operative year. This is because sinus surgery does not cure the underlying cause of the inflammation
of the sinus pathways, which can cause repeat flare ups. We believe the risk of potential revision surgery is a significant deterrent to some patients that would otherwise undergo sinus surgery. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Potential for severe complications.</I></B> As a result of the use of surgical tools in close proximity to
the brain, eyes and other critical anatomy, the potential for significant complications is a concern of physicians and patients alike. The risks of FESS, particularly in the frontal sinuses, cause some ENT physicians to avoid performing surgery in
the frontal sinus drainage pathway. Major complications, such as cerebral spinal fluid leaks, swelling of the eye or blindness, occur in approximately 0.3% of FESS procedures. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Drug Eluting Stents and Monoclonal Antibodies </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For patients with nasal polyps who remain symptomatic following surgery, who we refer to as refractory patients, certain non-surgical options
are available. A steroid-eluting implant that continuously delivers three months of MF was approved to treat CRS in adults with nasal polyps. In addition, a subcutaneously-administered biweekly <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-IL-4/IL-13</FONT></FONT></FONT> monoclonal antibody, or mAb, was recently approved also to treat CRS in adults with nasal polyps. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">However, each of these treatments have limitations. The drug-eluting stent has only a three month elution profile and has been approved as an
addition to intranasal steroid sprays, presenting a more burdensome treatment regimen and requiring patient compliance. Meanwhile, the mAb is generally reserved for the most refractory patients, given that its long-term systemic safety is unknown
and that it is priced at a significant premium even when compared to surgical options. In addition, both of these treatment options are only approved for the treatment of nasal polyps, leaving <FONT STYLE="white-space:nowrap">non-polyp</FONT>
patients (who represent approximately <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">70%-to-90%</FONT></FONT> of all CRS patients) who are refractory with no approved treatment options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">LYR-210</FONT> for the Treatment of CRS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe <FONT STYLE="white-space:nowrap">LYR-210,</FONT> if successfully developed and approved, has the potential to become a preferred
alternative to surgery for the treatment of CRS. It is the only product candidate that we are aware of that is designed to provide up to six months of local delivery of anti-inflammatory medication with a single administration. The brief, <FONT
STYLE="white-space:nowrap">non-invasive,</FONT> <FONT STYLE="white-space:nowrap">in-office</FONT> procedure allows for its implantation without the need for surgery. Further, we believe our studies have shown that
<FONT STYLE="white-space:nowrap">LYR-210</FONT> has the potential to be an effective treatment for both patients with and without polyps. We believe LYR-210 has the potential to be a safe, effective and broadly applicable CRS treatment, designed to
enhance patient comfort and physician experience and eliminate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patient compliance issues associated with other CRS treatments, such as intranasal steroid sprays, while achieving reduced costs compared to other CRS treatments, such as sinus surgery. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g805799g19c30.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>Figure 4. Illustration of Placement of <FONT STYLE="white-space:nowrap">LYR-210</FONT> in Middle Meatus. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">LYR-210</FONT> is an investigational miniaturized local drug delivery system designed to fit within, and
conform to, the confined space of a <FONT STYLE="white-space:nowrap">surgically-na&iuml;ve</FONT> patient&#146;s middle meatus, an <FONT STYLE="white-space:nowrap">air-containing</FONT> space that plays a fundamental role in drainage of the
paranasal sinuses (see Figure 4, above). <FONT STYLE="white-space:nowrap">LYR-210</FONT> consists of MF, the active ingredient in various <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drugs, embedded in biocompatible polymers to aid in the
controlled and sustained delivery of MF to the sinonasal mucosal tissue from a single drug administration. <FONT STYLE="white-space:nowrap">LYR-210</FONT> has a tubular braid configuration with a uniform diamond pattern throughout and is 13 mm in
diameter and 10 mm in length in the unconstrained state. It has elastic properties to promote patient comfort and is designed to be self-retaining against the mucosal tissue to allow effective drug transfer. The matrix is comprised of a base
structure and a drug formulation. The base structure is composed of PLGA and PLCL elastomer to provide a <FONT STYLE="white-space:nowrap">3-dimensional</FONT> structure and elasticity. The drug formulation matrix consists of the active ingredient,
MF, embedded in the inactive ingredients containing PLCL and PLA to control the release rate of MF. The composition and mass of the drug formulation matrix is specified to achieve the drug dose over time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">LYR-210</FONT> is intended to be administered bilaterally into the
<FONT STYLE="white-space:nowrap">non-operated</FONT> middle meatus by an ENT physician under endoscopic visualization via a provided, single use applicator. It is designed for office-based administration performed with topical anesthesia. Once
administered, <FONT STYLE="white-space:nowrap">LYR-210</FONT> is designed to gradually release MF to the inflamed mucosal tissue for up to six months from a single administration. <FONT STYLE="white-space:nowrap">LYR-210</FONT> can be removed at six
months or earlier at the physician&#146;s discretion using standard instruments and, if needed, replaced with a new LYR-210. <FONT STYLE="white-space:nowrap">LYR-210</FONT> is made with bioresorbable polymers that, if left in place, would gradually
dissolve over time. Moreover, the elastomeric matrix encapsulates the underlying mesh fibers to facilitate removal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview of Our Clinical Development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The table below summarizes our completed and ongoing clinical trials for LYR-210 for CRS in patients who have failed medical management and
have not undergone endoscopic sinus surgery. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Trial </B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Status</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Trial Design</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Trial Objectives</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Trial Results</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Phase&nbsp;1 </B></P> <P STYLE="font-size:60pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Completed; Results presented in October 2018</P> <P STYLE="font-size:60pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:8pt; font-family:Times New Roman">&#149;&#8195;&#8202;Prospective, multi-center, non-randomized, single-arm, open-label clinical
trial</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:8pt; font-family:Times New Roman">&#149;&#8195;&#8202;25 week trial,
including 24 week treatment period, plus one week post-removal</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:8pt; font-family:Times New Roman">&#149;&#8195;&#8202;Bilateral 2,500 <FONT STYLE="FONT-FAMILY:SYMBOL">&#109;</FONT>g dose</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:8pt; font-family:Times New Roman">&#149;&#8195;&#8202;20&nbsp;patients</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:8pt; font-family:Times New Roman">&#149;&#8195;&#8202;5 study sites</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:8pt; font-family:Times New Roman">&#149;&#8195;&#8202;Study objective: Evaluate the safety and feasibility over 24 weeks of continuous
anti-inflammatory treatment with a single administration of <FONT STYLE="white-space:nowrap">LYR-210</FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:8pt; font-family:Times New Roman">&#149;&#8195;&#8202;Primary endpoint: Product-related serious adverse events from baseline to 4 weeks
post-procedure</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:8pt; font-family:Times New Roman">&#149;&#8195;&#8202;Additional
data collected: Morning serum cortisol, change in intraocular pressure, plasma pharmacokinetics, quality of life by SNOT-22 (secondary endpoint), endoscopy and MRI</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:8pt; font-family:Times New Roman">&#149;&#8195;&#8202;Primary safety endpoint achieved / 2,500
<FONT STYLE="FONT-FAMILY:SYMBOL">&#109;</FONT>g was well tolerated during entire duration of treatment</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:8pt; font-family:Times New Roman">&#149;&#8195;&#8202;Significant and rapid, clinically meaningful and durable improvement in SNOT-22 scores was observed
from week 1 through week 25</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.50em; text-indent:-1.50em; font-size:8pt; font-family:Times New Roman">&#149;&#8195;&#8202;Average change in baseline SNOT-22 score at week 1 was -13.0 points (P= 0.008 to pre-treatment)</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.50em; text-indent:-1.50em; font-size:8pt; font-family:Times New Roman">&#149;&#8195;&#8202;Symptom relief, as measured by
<FONT STYLE="white-space:nowrap">SNOT-22</FONT> score, was observed through the entire duration of study, achieving an average change from baseline of -20.5 points at week 24 (P=0.00005 to pre-treatment), which was the end of the treatment period,
and <FONT STYLE="white-space:nowrap">-20.0</FONT> (p &lt; 0.0001) at week 25, which was the end of the study</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Phase&nbsp;2 (LANTERN) </B></P> <P STYLE="font-size:42pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Initiated May 2019</P> <P STYLE="font-size:42pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:8pt; font-family:Times New Roman">&#149;&#8195;&#8202;Randomized, blinded, sham-controlled, dose-ranging, parallel-group clinical
trial</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:8pt; font-family:Times New Roman">&#149;&#8195;&#8202;24 week treatment
period, plus 24 week safety follow up post-removal</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:8pt; font-family:Times New Roman">&#149;&#8195;&#8202;Bilateral 2,500 <FONT STYLE="FONT-FAMILY:SYMBOL">&#109;</FONT>g or 7,500&nbsp;<FONT
STYLE="FONT-FAMILY:SYMBOL">&#109;</FONT>g dose</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:8pt; font-family:Times New Roman">&#149;&#8195;&#8202;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; patients</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:8pt; font-family:Times New Roman">&#149;&#8195;&#8202;Up to 50 study sites
globally</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:8pt; font-family:Times New Roman">&#149;&#8195;&#8202;Primary endpoint: Change in composite score of 7-day average of 4 cardinal
symptoms from baseline at week&nbsp;4</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:8pt; font-family:Times New Roman">&#149;&#8195;&#8202;Secondary objectives: Symptom improvement at week 24, sinus imaging to assess reduction in
inflammation, SNOT-22, time to treatment failure, reduction in inflammation, frequency of exacerbations, pharmacokinetics/pharmacodynamics</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:8pt; font-family:Times New Roman">&#149;&#8195;&#8202;Expect to complete enrollment, data base lock and report topline data
in</P></TD></TR>
</TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Phase 2 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our Phase 2 LANTERN clinical trial for <FONT STYLE="white-space:nowrap">LYR-210</FONT> was initiated in May 2019. The clinical trial is
designed as a multi-center, randomized, sham procedure-controlled, patient blinded trial. The study will evaluate &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; patients across up to 50 sites in the United States,
Australia, Austria, Czech Republic, New Zealand and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Poland. The goal of the trial is to evaluate the efficacy of <FONT STYLE="white-space:nowrap">LYR-210</FONT> in treating adult <FONT STYLE="white-space:nowrap">surgically-na&iuml;ve</FONT> CRS
patients who have failed medical management. We expect to report topline data in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g805799g24g58.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#687f7f"><I>EOT = End of Treatment; EOS = End of Study. </I></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>Figure 5. Design of Phase 2 LANTERN Clinical Trial for <FONT STYLE="white-space:nowrap">LYR-210.</FONT> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The trial consists of three arms: (1)&nbsp;an experimental arm with bilateral placement of 2,500 &micro;g of
<FONT STYLE="white-space:nowrap">LYR-210</FONT> consisting of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; subjects; (2)&nbsp;an experimental arm with bilateral placement of 7,500 &micro;g of <FONT
STYLE="white-space:nowrap">LYR-210</FONT> consisting of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; subjects; and (3)&nbsp;a control arm with a bilateral sham procedure only consisting of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; subjects (see Figure 5, above). In addition, subjects will be supplied with saline for nasal irrigation treatment during the course of the treatment period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The primary endpoint of the trial is a change from baseline in the <FONT STYLE="white-space:nowrap">7-day</FONT> average scores of the <FONT
STYLE="white-space:nowrap">4-Cardinal</FONT> Symptoms Score, or 4CSS, at week 4. The FDA prefers a composite score of the cardinal symptoms of CRS for patients with CRS, and we will utilize the 4CSS for the trial. The 4CSS is comprised of four
domains that are scored <FONT STYLE="white-space:nowrap">0-3</FONT> with a total score of 12. The four domains are: (1)&nbsp;obstruction and congestion; (2)&nbsp;facial pain and pressure; (3)&nbsp;nasal discharge; and (4)&nbsp;olfactory loss (loss
of sense of smell). </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The key secondary endpoints for the trial are the change from baseline in
<FONT STYLE="white-space:nowrap">7-day</FONT> average 4CSS at week 24, time to treatment failure, and change from baseline in Zinreich score (a measure of inflammation) for the posterior ethmoid, frontal or spheoid sinuses at week 24. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Phase 1 </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our Phase 1 clinical trial for <FONT STYLE="white-space:nowrap">LYR-210</FONT> was a prospective, multi-center,
<FONT STYLE="white-space:nowrap">non-randomized,</FONT> <FONT STYLE="white-space:nowrap">single-arm,</FONT> open-label clinical trial with adult <FONT STYLE="white-space:nowrap">surgically-na&iuml;ve</FONT> CRS patients who have failed medical
management. The objective of the trial was to evaluate safety and feasibility over 24 weeks of continuous anti-inflammatory treatment with a single administration of <FONT STYLE="white-space:nowrap">LYR-210</FONT> with an additional measurement
taken one week post-removal. The trial was conducted across five sites in New Zealand and Australia. Forty <FONT STYLE="white-space:nowrap">LYR-210</FONT> matrices were placed bilaterally in 20 patients with and without nasal polyps. Each matrix
contained 2,500 &micro;g of MF. <FONT STYLE="white-space:nowrap">LYR-210</FONT> met its primary safety endpoint, and significant and rapid, clinically meaningful and durable improvement on a patient symptom severity scale was observed through 25
weeks. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Study Design</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Prospective, multi-center, non-randomized, single-arm, open-label clinical trial</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Study Objectives</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Safety and feasibility over 24 weeks of continuous anti-inflammatory treatment with a single administration of LYR-210 with an additional measurement taken one week post-removal</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patient Population</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Adult CRS patients who have failed medical management and have not had surgery</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of Subjects</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">20 patients with CRS (40 LYR-210 matrices placed)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of Sites</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">5 study sites (New Zealand and Australia)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dose</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">2,500 mcg bilaterally</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Primary Endpoint</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Product-related serious adverse events from baseline to week 4</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional Data Collected</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Morning serum cortisol</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Intraocular pressure</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Plasma pharmacokinetics</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Quality of life by SNOT-22</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Endoscopy and MRI</P></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>Figure 6. Description of Phase 1 Clinical Trial for <FONT STYLE="white-space:nowrap">LYR-210.</FONT> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Twenty patients were enrolled, 12 of whom exhibited no bilateral nasal polyps and eight of whom exhibited bilateral nasal polyps. All 20
patients received bilateral administration of <FONT STYLE="white-space:nowrap">LYR-210</FONT> at 2,500 &micro;g in an office setting. The study population was predominantly male with a mean age of 39.9 (range:
<FONT STYLE="white-space:nowrap">24-67)</FONT> years old. All patients reported <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> CRS symptoms with a mean
<FONT STYLE="white-space:nowrap">SNOT-22</FONT> score of 50.9, of which nine patients reported severe symptoms <FONT STYLE="white-space:nowrap">(SNOT-22</FONT> score &gt; 50). All patients complained of nasal obstruction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Phase 1 trial achieved its primary safety endpoint at week 4. <FONT
STYLE="white-space:nowrap">LYR-210</FONT> at 2,500 &micro;g was well tolerated by patients during the entire duration of treatment and also gave insight into the successful office-based placement of the matrix and clinical outcomes in <FONT
STYLE="white-space:nowrap">non-polyp</FONT> and polyp patients. There were no reports of unexpected adverse events, or AEs, or local nasal AEs, including epistaxis, nasal burning, nasal dryness, nasal irritation and nasal septal perforation during
the <FONT STYLE="white-space:nowrap">24-week</FONT> MF local dosing treatment duration. Additionally, no change in morning serum cortisol levels or intraocular pressures were noted. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g805799g50p93.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">AEs coded using the MedDRA dictionary, version 21.0. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">N=20 total patients. Patients experiencing the same AEs are counted only once. An additional 5 AEs occurred
during the screening period, prior to treatment and are not included in this table. 25-week period includes one week post-removal. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>Figure 7. Adverse Event Profile for Phase 1 Clinical Trial for <FONT STYLE="white-space:nowrap">LYR-210.</FONT> </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The most common reported AEs were nasopharyngitis, upper respiratory tract infection,
sinusitis, nasal odor, procedural headache, nasal discomfort, and facial pain. There was one serious adverse event, an acute myocardial infarction, which was deemed to be unrelated to <FONT STYLE="white-space:nowrap">LYR-210.</FONT> <FONT
STYLE="white-space:nowrap">LYR-210</FONT> was removed due to AEs before the end of the <FONT STYLE="white-space:nowrap">24-week</FONT> treatment period from two patients who dropped out of the trial prior to completion. One patient requested removal
after 20 weeks of treatment due to complaints of memory loss, which was deemed to be unrelated to <FONT STYLE="white-space:nowrap">LYR-210.</FONT> The other patient requested removal after 17 weeks of treatment due to a recurrence of a sinus
infection that was <FONT STYLE="white-space:nowrap">non-serious</FONT> and moderate in severity and the patient reported relief of AE symptoms within four days following removal and medical treatment. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g805799g30r61.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>Figure 8. Plasma Drug Concentration for the 50% of Patients with Levels Above LLQ. Note: at day 1, week 1, week 4 and
week 12, there were 11, 10, 16 and 10 patients, respectively, whose plasma drug concentration was below the lower limit of quantification, or LLQ. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The trial results indicated low levels of systemically circulated steroid from <FONT STYLE="white-space:nowrap">LYR-210.</FONT> MF plasma
concentrations were unquantifiable in about 50% of patients and near the lower limit of quantification of 20 pg/ML in the other 50% of patients (see Figure 8, above). There were no AEs associated with systemic levels of MF. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">All of the matrices were successfully bilaterally placed in the sinonasal passages, in both <FONT STYLE="white-space:nowrap">non-polyp</FONT>
and polyp patients. In 7 out of the 40 matrices placed, the investigator felt that the initial placement was not ideal, and therefore the matrix was removed and a new matrix was placed. Patients did not report feeling the matrices
post-administration. Further, <FONT STYLE="white-space:nowrap">LYR-210</FONT> had high levels of intranasal retention out to 24 weeks, with a retention rate of more than 80%. There were no AEs associated with the matrices that were dislodged. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Sino-Nasal Outcome Test, or <FONT STYLE="white-space:nowrap">SNOT-22,</FONT> is a
disease-specific questionnaire for sinus disease. A validated patient-reported outcome measure, the <FONT STYLE="white-space:nowrap">SNOT-22</FONT> is used widely by ENTs to assess disease status and treatment outcomes in CRS patients with and
without polyps. It is comprised of 20 questions which address <FONT STYLE="white-space:nowrap">CRS-related</FONT> symptoms and quality of life that can be grouped into 5 domains including rhinologic, extranasal rhinologic, ear/facial, psychological
and sleep. Each question is scored on a scale from 0 to 5 for a total score ranging from 0 to 110 points. Mild disease is defined on the <FONT STYLE="white-space:nowrap">SNOT-22</FONT> as a score of 8 to 20, moderate as a score of 21 to 50 and
severe as greater than 50. If a patient has a <FONT STYLE="white-space:nowrap">SNOT-22</FONT> score of 7 or lower they are considered &#147;normal&#148; or absent of sino-nasal disease. The <FONT STYLE="white-space:nowrap">SNOT-22</FONT> minimal
clinically important difference, or MCID, which is the smallest change in <FONT STYLE="white-space:nowrap">SNOT-22</FONT> score that can be detected by a patient, has been established as a change of 8.9 points. </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g805799g14i04.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><FONT COLOR="#687f7f"><I>* P&lt;0.05, **P&lt;0.01, *** P&lt;0.001, **** P&lt;0.0001 to baseline by paired two tailed <FONT
STYLE="white-space:nowrap">t-test</FONT></I></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>Figure 9. Total Symptom Improvement by <FONT STYLE="white-space:nowrap">SNOT-22</FONT> Score in Phase 1 Clinical Trial for <FONT
STYLE="white-space:nowrap">LYR-210.</FONT> </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g805799g66u56.jpg" ALT="LOGO">
 </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><FONT COLOR="#687f7f"><I>** P&lt;0.01, ***P&lt;0.001, **** P&lt;0.0001 to baseline by paired two tailed
<FONT STYLE="white-space:nowrap">t-test</FONT></I></FONT></P></TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>Figure 10. Symptom Improvement by Retrospective Analysis of the Scores Corresponding to the Composite 4CSS
Extracted from the Corresponding Individual SNOT-22 Scores. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Patients generally experienced significant and rapid, clinically
meaningful and durable improvements in CRS symptoms in the Phase 1 trial, as measured by <FONT STYLE="white-space:nowrap">SNOT-22</FONT> score (see Figure 9, above). Significant reduction in <FONT STYLE="white-space:nowrap">SNOT-22</FONT> scores was
observed at week 1 and this reduction persisted through week 25, at the end of the trial (see Figure 9, above). Changes from baseline, or CFBL, in <FONT STYLE="white-space:nowrap">SNOT-22</FONT> score were statistically significant (P &lt; 0.01) at
all measured intervals. The average change from baseline in <FONT STYLE="white-space:nowrap">SNOT-22</FONT> score at week 1 was <FONT STYLE="white-space:nowrap">-13.0</FONT> points (P=&nbsp;0.008 to
<FONT STYLE="white-space:nowrap">pre-treatment),</FONT> achieving the MCID of <FONT STYLE="white-space:nowrap">-8.9</FONT> points. Further, symptom relief was observed through the entire duration of study, and achieved
<FONT STYLE="white-space:nowrap">-20.5</FONT> points at week 24 (P=0.00005 to <FONT STYLE="white-space:nowrap">pre-treatment),</FONT> at the time <FONT STYLE="white-space:nowrap">LYR-210</FONT> was removed. Significant symptom improvement was
achieved in all of the <FONT STYLE="white-space:nowrap">SNOT-22</FONT> subdomains at week 24. We conducted a retrospective analysis of symptom improvement as measured by CFBL in the individual domain scores extracted from the individual SNOT-22
scores that correspond to the cardinal symptoms comprising the 4CSS (see Figure 10, above), which is the primary endpoint of our Phase 2 LANTERN clinical trial. This retrospective analysis showed that the CFBL in the individual domain scores were
generally consistent with the CFBL in the SNOT-22 scores. This composite score produced as a result of the retrospective analysis was not a primary endpoint of our Phase 1 clinical trial and was done for illustrative purposes only. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g805799g25x88.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>Figure 11. Percent of Patients with Symptom Improvement by <FONT STYLE="white-space:nowrap">SNOT-22</FONT> Score,
Showing Improvement with MCID and without MCID, in Phase 1 Clinical Trial for <FONT STYLE="white-space:nowrap">LYR-210.</FONT> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At
week 24, 90% of patients improved versus the baseline score, with clinically meaningful improvement observed in 70% of patients (see Figure 11, above). </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g805799g23k01.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#687f7f"><I>* P&lt;0.05, **P&lt;0.01, ***P&lt;0.001, **** P&lt;0.0001 to baseline by paired two tailed <FONT STYLE="white-space:nowrap">t-test</FONT></I></FONT></TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>Figure 12. Symptom Improvement in Polyp and <FONT STYLE="white-space:nowrap">Non-Polyp</FONT> Patients by Change from
Baseline in <FONT STYLE="white-space:nowrap">SNOT-22</FONT> Score in Phase 1 Clinical Trial for <FONT STYLE="white-space:nowrap">LYR-210.</FONT> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Similar efficacy was observed in both polyp and <FONT STYLE="white-space:nowrap">non-polyp</FONT> patients (see Figure&nbsp;12, above).
Further, even though each of the clinical trial patients were surgery candidates at the trial entry and no topical intranasal spray was utilized in conjunction with <FONT STYLE="white-space:nowrap">LYR-210</FONT> during the <FONT
STYLE="white-space:nowrap">25-week</FONT> trial, none of the patients underwent sinus surgery during the treatment period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g805799g11t78.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>Figure 13. Endoscopy Images Before and After Treatment with <FONT STYLE="white-space:nowrap">LYR-210</FONT> in Phase 1
Clinical Trial. For illustrative purposes only. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Figure 13, above, shows via nasal endoscopy images from our Phase 1 clinical trial
the impact of <FONT STYLE="white-space:nowrap">LYR-210</FONT> observed in a patient without nasal polyps and a patient with nasal polyps at three time points: before <FONT STYLE="white-space:nowrap">LYR-210</FONT> placement, after <FONT
STYLE="white-space:nowrap">LYR-210</FONT> placement and at week 25, one week after <FONT STYLE="white-space:nowrap">LYR-210</FONT> was removed. The middle image for each patient shows the deployment of <FONT STYLE="white-space:nowrap">LYR-210</FONT>
in the middle meatus of a <FONT STYLE="white-space:nowrap">non-polyp</FONT> and a polyp patient, and how LYR-210 conformed to the walls of the obstructed nasal anatomy to maximize tissue contact. In the third image for each patient, the erythema and
inflammation present before treatment was observed to be resolved and less evident after 24 weeks of treatment and one week post-removal. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT
STYLE="white-space:nowrap">LYR-220</FONT> for the Treatment of CRS </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">LYR-220</FONT> is a new
investigative therapy for CRS patients with and without nasal polyps that have failed medical management and have had a prior endoscopic sinus surgery. In the treatment paradigm, <FONT STYLE="white-space:nowrap">LYR-220,</FONT> if approved, is
positioned for use for patients post-surgical intervention who continue to have recurrent CRS symptoms or relapse, as a potential preferred alternative to revision surgery. <FONT STYLE="white-space:nowrap">LYR-220</FONT> utilizes the same API as <FONT
STYLE="white-space:nowrap">LYR-210,</FONT> but with a larger matrix to treat larger nasal cavities consistent with those in post-surgical CRS patients. We estimate that 40% of patients that present to an ENT physician with CRS have had a prior
surgery. These patients represent the addressable market for <FONT STYLE="white-space:nowrap">LYR-220.</FONT> </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">No product is
currently approved by the FDA to treat post-surgery CRS patients that do not have polyps, representing the vast majority of such CRS patients, and only a three-month steroid-eluting sinus implant and a mAb have been approved by the FDA for the
treatment of post-surgery CRS patients that have polyps. We believe <FONT STYLE="white-space:nowrap">LYR-220</FONT> is meaningfully differentiated from currently approved products because, if successfully developed and approved, it would be the only
product able to deliver up to six months of topical treatment in a single administration to treat both polyp and <FONT STYLE="white-space:nowrap">non-polyp</FONT> post-surgery CRS patients who fail medical management. Further, with respect to the
mAb, <FONT STYLE="white-space:nowrap">LYR-220</FONT> is differentiated because it would provide localized delivery so as to avoid systemic side effects with the added benefit of being a significantly more economical treatment alternative. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect to initiate a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> clinical trial for <FONT
STYLE="white-space:nowrap">LYR-220</FONT> in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and, if <FONT STYLE="white-space:nowrap">LYR-210</FONT> is approved by the FDA, to submit an sNDA for a potentially faster path to
approval for LYR-220. We believe the clinical development of LYR-220 may require only a single Phase 3 study for registration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Future Product Candidates </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our XTreo platform provides a versatile drug development engine that enables us to focus on other indications where long-term delivery of
existing treatments may provide improved local bioavailability and enhanced efficacy or safety. Other conditions we may pursue with nasal delivery include allergic rhinitis, rare disorders where nasal disease contributes to the disease pathology and
central nervous system disorders. Additionally, we believe our platform can be adapted to locally address conditions of the ear. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Post-Approval
Commercialization Strategy </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If <FONT STYLE="white-space:nowrap">LYR-210</FONT> and <FONT STYLE="white-space:nowrap">LYR-220</FONT>
are successfully developed and approved, we intend to engage in targeted outreach to our key physician, payer and patient audiences. ENT physicians are the primary treaters of CRS patients who have failed medical management and thus represent our
target physician base. Given the requirement for endoscopic placement of our products, we plan to build an <FONT STYLE="white-space:nowrap">in-house</FONT> sales force, consisting of approximately 75-100 employees, that will target ENT physicians
whose <FONT STYLE="white-space:nowrap">sub-specialty</FONT> is general otolaryngology or rhinology, which together represent approximately 60% of the approximately 12,000 ENT physicians in the United States. Given that
<FONT STYLE="white-space:nowrap">LYR-210</FONT> and <FONT STYLE="white-space:nowrap">LYR-220</FONT> can be administered in a brief, simple procedure requiring no additional equipment, we anticipate that our sales representatives&#146; time will
primarily be directed at educating the ENT physicians around product attributes and patient selection. We plan to supplement our direct physician outreach with appropriate medical education and marketing efforts to further penetrate our physician
base and drive adoption of our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Ensuring physician and patient market access to our products will be critical to our success,
and we plan to execute a holistic reimbursement strategy, consisting of a reimbursement support hub and approximately <FONT STYLE="white-space:nowrap">15-20</FONT> field-based reimbursement experts, that will integrate payer coverage and physician
practice management initiatives. We believe that the primary decision makers from a payer perspective are private payers, which represent approximately 80% of the payer mix for our products. We intend to deploy a market access team to educate payers
on the clinical and pharmacoeconomic attributes of our products and to seek to secure favorable coverage policies and to maximize the covered lives that have reimbursement for our products. The team will also secure the necessary codes to facilitate
physician and patient payment including a <FONT STYLE="white-space:nowrap">J-code,</FONT> which is required for physician-administered products. In addition, we expect to be able to use existing current procedural terminology codes for procedures
involving the placement and removal of our product candidates, if approved. To maximize access to <FONT STYLE="white-space:nowrap">LYR-210</FONT> and <FONT STYLE="white-space:nowrap">LYR-220,</FONT> we plan to develop a reimbursement support model
which aims to reduce physician financial risk associated with physician-administered products. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Subsequent to our initial ENT
physician and payer efforts, we also plan to selectively use cost-effective, patient-directed marketing strategies to further increase awareness among the CRS patient community of our products with the goal of increasing ENT physician visits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, we may also consider entering into collaborative relationships with established entities outside the U.S. for a potentially
faster path to bringing our products to market. We may also enter into collaborative relationships within the U.S. for future pipeline product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our industry is highly
competitive and subject to rapid and significant technological change as research provides a deeper understanding of the pathology of diseases and new technologies and treatments are developed. We believe our scientific knowledge, technology, and
development capabilities provide us with substantial competitive advantages, but we face potential competition from multiple sources, including large pharmaceutical, biotechnology, specialty pharmaceutical and, to a lesser degree, medical device
companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our competitors may have significantly greater financial resources, robust drug pipelines, established presence in the market
and expertise in research and development, <FONT STYLE="white-space:nowrap">manufacturing,&nbsp;pre-clinical&nbsp;and</FONT> clinical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
testing, obtaining regulatory approvals and reimbursement and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified clinical,
regulatory, scientific, sales, marketing and management personnel, in establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or
early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">LYR-210</FONT> and <FONT STYLE="white-space:nowrap">LYR-220</FONT> are positioned following the failure of
medical management and therefore are not anticipated to compete directly with branded, generic or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter,</FONT></FONT> inhaled corticosteroids. <FONT
STYLE="white-space:nowrap">LYR-210</FONT> is positioned for use in <FONT STYLE="white-space:nowrap">surgically-na&iuml;ve</FONT> CRS patients where the primary competitive treatment is surgical procedures, including FESS with and without BSD and BSD
as a standalone procedure. In this space, <FONT STYLE="white-space:nowrap">LYR-210</FONT> would be the only product we are aware of that may deliver six months of local treatment with a single administration for both patients with and without polyps
as a preferred alternative to surgical interventions. <FONT STYLE="white-space:nowrap">LYR-220</FONT> is positioned for use in patients that have had a prior FESS. Currently there are no competitive treatments for post-surgical patients without
polyps. For patients with polyps, <FONT STYLE="white-space:nowrap">LYR-220</FONT> would compete against steroid-releasing sinus implants and mAbs. We believe <FONT STYLE="white-space:nowrap">LYR-220</FONT> has competitive advantages over these
interventions, including a longer elution profile than the existing sinus implant and no systemic exposure relative to the mAb. Key competitive factors affecting the commercial success of both <FONT STYLE="white-space:nowrap">LYR-210</FONT> and <FONT
STYLE="white-space:nowrap">LYR-220</FONT> and any other product candidates we may develop are likely to be efficacy, safety and tolerability profile, reliability, convenience of administration, price and reimbursement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Several companies are also currently developing treatments for CRS patients with nasal polyps, including Hoffmann-La Roche, GlaxoSmithKline,
Gossamer Bio, AnaptysBio, Regeneron, OptiNose and Intersect ENT. If these treatments are approved by the FDA, they could represent competition across the spectrum of CRS patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing and Supply </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We currently
manufacture our drug delivery products at our facility in Watertown, Massachusetts with components supplied by external suppliers. We perform inspections of these components before use in our manufacturing operations. Using these components, we
manufacture, assemble, inspect, and package our implants, and send them to a third-party sterilization vendor. After sterilization, we inspect the product and test via third-party laboratories to determine compliance with our specifications. Upon
release of the lot to inventory, the product is labeled and distributed via a third-party vendor to clinical sites. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The API and a
number of the components used in our implants are currently supplied to us from single source suppliers. We source our supplies from manufacturers with a track record of Good Manufacturing Procedures (GMP). We rely on single source suppliers for
some of our polymer materials, some extrusions and molded components, and for finished goods testing, labeling and distribution. Our ability to supply our products and to develop our product candidates depends, in part, on our ability to obtain
successfully the API and polymer materials used in these products in accordance with regulatory requirements and in sufficient quantities. We plan to enter into manufacturing, supply and quality agreements with our single source suppliers. We
generally acquire our single source components pursuant to purchase orders placed in the ordinary course of business. We currently maintain sufficient supplies of the API and components from our single source suppliers to support our ongoing Phase 2
LANTERN clinical trial and ongoing development activities. In the future, we intend to maintain sufficient supplies such that our ability to supply the clinic or commercial market will not be compromised and so as to allow for sufficient time
necessary to obtain another source of API or components. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are currently improving our manufacturing capabilities and increasing
capacity to better support further clinical studies and commercialization. We plan to use an outsourcing model and choose a contract manufacturer with the appropriate infrastructure, technical experience, quality systems and a track record of FDA
compliance. We plan to continue to use an outsourcing model for our operations until we reach a sufficient scale to justify investment in internal manufacturing capacity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We actively seek to protect the intellectual property and proprietary technology platform that we believe is important to our business, which
includes seeking and maintaining patents covering our technology platform and products, and any other inventions that are commercially or strategically important to the development of our business. We also rely upon trademarks to build and maintain
the integrity of our brand, and we seek to protect the confidentiality of trade secrets that may be important to the development of our business. For more information, please see &#147;Risk Factors&#151;Risks Related to Our Intellectual
Property&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Patents and Patent Applications </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of December 31, 2019, we own 18 issued U.S. patents, nine foreign issued patents, seven U.S. pending applications, and 21 foreign pending
applications, out of which 12 issued U.S. patents, nine foreign issued patents, six U.S. pending applications, and 21 foreign pending applications are directed to our XTreo platform, <FONT STYLE="white-space:nowrap">LYR-210,</FONT> and <FONT
STYLE="white-space:nowrap">LYR-220.</FONT> </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">All technology material to our business has been developed
<FONT STYLE="white-space:nowrap">in-house</FONT> and is protected with patents and patent applications in two major lineages, along with the beginning of a third, more recent lineage of patent applications. The first lineage dates from 2009 and
provides protection potentially until 2030, exclusive of possible patent term adjustments or extensions or other forms of exclusivity. This first lineage includes issued patents in the U.S., Europe, Japan, Canada and Great Britain, that are not
limited to any particular drug, site of delivery or patient condition, but specify features of the implant, system, method and polymers. The second lineage dates from 2015 and provides protection potentially until 2036, exclusive of possible patent
term adjustments or extensions or other forms of exclusivity. This second lineage includes issued U.S. patents with <FONT STYLE="white-space:nowrap">ENT-specific</FONT> method claims directed to the specific drug, site of delivery (i.e. middle
meatus) and patient condition, along with numerous pending applications in the U.S., Europe, Japan, Canada, China and the Great Britain. The third, more recent lineage dates from 2017 with the prospect of patent protection potentially until 2037,
exclusive of possible patent term adjustments or extensions or other forms of exclusivity. This third lineage attempts to capture the drug release features and patient results from the recent clinical trial. It includes pending applications in the
U.S. and Great Britain, along with a patent application filed under the Patent Cooperation Treaty that entered the National Phase in October of 2019 in the following countries: the U.S., Canada, Australia, Europe, Korea, Singapore, China and Japan.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Trademarks and Trade Secrets </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of December 31, 2019, our trademark portfolio contained one U.S. trademark registration and eight foreign trademark registrations. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We also rely upon trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> and continuing technologies innovation, and may pursue
licensing opportunities in the future, to develop and maintain our competitive position. We seek to protect our proprietary rights through a variety of methods, including confidentiality agreements, invention assignment agreements, <FONT
STYLE="white-space:nowrap">non-solicitation</FONT> and <FONT STYLE="white-space:nowrap">non-compete</FONT> agreements with suppliers, employees, consultants and others who may have access to proprietary information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation and Product Approval </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Government authorities in the United States, at the federal, state and local level, and in other countries extensively regulate, among other
things, the research, development, testing, manufacturing, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, import, and export of pharmaceutical products such as those we are developing. We will be
required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval of our product candidates. The processes for
obtaining regulatory approvals in the United States and other countries, as appropriate, along with subsequent compliance with appropriate federal, state, local and foreign statutes and regulations, require the expenditure of substantial time and
resources. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Government Regulation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the United States, we are subject to extensive regulation by the FDA, which regulates drugs under the Federal Food, Drug, and Cosmetic Act,
or the FDCA, and its implementing regulations, and other federal, state, and local regulatory authorities. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and
regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an
applicant to a variety of administrative or judicial sanctions, such as the FDA&#146;s refusal to approve pending NDAs, withdrawal of an approval, imposition of a clinical hold, issuance of warning or untitled letters, product recalls, product
seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The process required by the FDA before a drug may be marketed in the United States generally involves the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the
FDA&#146;s Good Laboratory Practice regulations; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an IND which must become effective before human clinical trials may begin;
</P></TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval by an independent institutional review board, or IRB at each clinical site before each trial may be
initiated; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performance of adequate and well-controlled human clinical trials in accordance with good clinical practice (GCP)
requirements to establish the safety and efficacy of the proposed drug product for each indication; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an NDA; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA advisory committee review, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is
produced to assess compliance with current good manufacturing practice, or cGMP, requirements and to assure that the facilities, methods and controls are adequate to preserve the drug&#146;s identity, strength, quality and purity;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA inspection of selected clinical sites to assure compliance with GCPs and the
integrity of the clinical data; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payment of user fees; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA review and approval of the NDA. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are developing our product candidates using an innovative drug delivery platform comprised of a mesh scaffold, an elastomeric matrix and a
polymer-drug complex delivered through a narrow applicator. In the United States, products composed of components that would normally be regulated by different centers at the FDA are known as combination products. Typically, the FDA&#146;s Office of
Combination Products assigns a combination product to a specific Agency Center as the lead reviewer. The FDA determines which Center will lead a product&#146;s review based upon the product&#146;s primary mode of action. Depending on the type of
combination product, its approval, clearance or licensure may usually be obtained through the submission of a single </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
marketing application. We anticipate that <FONT STYLE="white-space:nowrap">LYR-210</FONT> and <FONT STYLE="white-space:nowrap">LYR-220</FONT> will be regulated as drugs, and for each product
candidate, the FDA will permit a single regulatory submission seeking approval. However, the FDA sometimes will require separate marketing applications for individual constituent parts of the combination product which may require additional time,
effort, and information. Even when a single marketing application is required for a combination product, such as an NDA for a combination pharmaceutical and device product, both the FDA&#146;s Center for Drug Evaluation and Research and the
FDA&#146;s Center for Devices and Radiological Health may participate in the review. An applicant will also need to discuss with the Agency how to apply certain premarket requirements and post-marketing regulatory requirements, including conduct of
clinical trials, adverse event reporting and good manufacturing practices, to their combination product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preclinical Studies </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Preclinical studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as animal studies to assess
potential safety and efficacy. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data and any available clinical data or literature, among other things, to the FDA as part of an IND.
Some preclinical testing may continue even after the IND is submitted. An IND automatically becomes effective and a clinical trial proposed in the IND may begin 30 days after the FDA receives the IND, unless before that time the FDA raises concerns
or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result,
submission of an IND may not result in the FDA allowing clinical trials to commence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Trials </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators
in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among
other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part
of the IND. An IRB at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must continue to oversee the clinical trial while it is being
conducted. Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health, or NIH, for public dissemination on their www.clinicaltrials.gov website. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Human clinical trials are typically conducted in three or four sequential phases, which may overlap or be combined: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 1: The drug is initially introduced into healthy human subjects or patients with the target disease or
condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 2: The drug is administered to a limited patient population to identify possible adverse effects and safety
risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 3: The drug is administered to an expanded patient population, generally at geographically dispersed
clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate
information for the labeling of the product. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 4: In some cases, the FDA may conditionally approve an NDA for a product candidate on the sponsor&#146;s
agreement to conduct additional clinical trials after NDA approval. In other cases, a </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
sponsor may voluntarily conduct additional clinical trials post approval to gain more information about the drug. Such post approval trials are typically referred to as Phase 4 clinical trials.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA, and more
frequently if serious adverse events occur. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any
time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being
conducted in accordance with the IRB&#146;s requirements or if the drug has been associated with unexpected serious harm to patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the
chemistry and physical characteristics of the product and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality
batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested and
stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Marketing Approval </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Assuming
successful completion of the required clinical testing, the results of the preclinical and clinical studies, together with detailed information relating to the product&#146;s chemistry, manufacture, controls and proposed labeling, among other
things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. In most cases, the submission of an NDA is subject to a substantial application user fee. Under the Prescription Drug User Fee
Act (PDUFA) guidelines that are currently in effect, the FDA has a goal of 10 months to review and act on a standard NDA and 6 months to review and act on a priority NDA, measured from the &#147;filing&#148; date for an NDA for a new molecular
entity (NME) or from the receipt date for an NDA for a <FONT STYLE="white-space:nowrap">non-NME</FONT> product. Measuring from the &#147;filing&#148; date typically adds approximately two months to the timeline for review and decision, because the
FDA has sixty days from receipt to make a &#147;filing&#148; decision, as described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, under the Pediatric Research
Equity Act of 2003 as amended and reauthorized, certain NDAs or supplements to an NDA must contain data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations, and to
support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until
after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA also may
require submission of a risk evaluation and mitigation strategy, or REMS, plan to ensure that the benefits of the drug outweigh its risks. The REMS plan could include medication guides, physician communication plans, assessment plans, and/or
elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA
conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information
rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for
filing, the FDA begins an <FONT STYLE="white-space:nowrap">in-depth</FONT> substantive review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facility in which it is manufactured,
processed, packaged or held meets standards designed to assure the product&#146;s continued safety, quality and purity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA may refer an application for a novel drug to an advisory committee. An advisory
committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by
the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Before approving an
NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements
and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA generally accepts data from foreign clinical trials in support of an NDA if the trials were conducted under an IND. If a foreign
clinical trial is not conducted under an IND, the FDA nevertheless may accept the data in support of an NDA if the study was conducted in accordance with GCP requirements and the FDA is able to validate the data through an <FONT
STYLE="white-space:nowrap">on-site</FONT> inspection, if deemed necessary. Although the FDA generally requests that marketing applications be supported by some data from domestic clinical studies, the FDA may accept foreign data as the sole basis
for marketing approval if (1)&nbsp;the foreign data are applicable to the U.S. population and U.S. medical practice, (2)&nbsp;the studies were performed by clinical investigators with recognized competence, and (3)&nbsp;the data may be considered
valid without the need for an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection or, if the FDA considers the inspection to be necessary, the FDA is able to validate the data through an <FONT STYLE="white-space:nowrap">on-site</FONT>
inspection or other appropriate means. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The testing and approval process for an NDA requires substantial time, effort and financial
resources, and each may take several years to complete. Data obtained from preclinical and clinical testing are not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The FDA
may not grant approval on a timely basis, or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">After evaluating the NDA and all related information, including the advisory
committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter generally
contains a statement of specific conditions that must be met to secure final approval of the NDA and may require additional clinical testing, preclinical testing, manufacturing or formulation modifications or other changes in order for the FDA to
reconsider the application. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#146;s
satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings or
precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug&#146;s safety after approval, require testing and surveillance programs to monitor the
product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may
prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and
additional labeling claims, are subject to further testing requirements and FDA review and approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Hatch-Waxman Amendments </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our current regulatory strategy is to pursue development of <FONT STYLE="white-space:nowrap">LYR-210</FONT> as a Section&nbsp;505(b)(2) NDA.
As an alternative path to FDA approval for modifications to formulations or uses of drugs previously approved by the FDA, an applicant may submit an NDA under Section&nbsp;505(b)(2) of the FDCA. Section&nbsp;505(b)(2) was enacted as part of the
Hatch-Waxman Amendments. A Section&nbsp;505(b)(2) NDA is an application that contains full reports of investigations of safety and effectiveness, but where at least some of the information required for approval comes from studies not conducted by,
or for, the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted. This type of application permits reliance for such approvals on literature or on an FDA
finding of safety, effectiveness or both for an approved drug product. As such, under Section&nbsp;505(b)(2), the FDA may rely, for approval of an NDA, on data not developed by the applicant. Therefore, if we can satisfy the conditions required for
a Section&nbsp;505(b)(2) NDA submission, it may eliminate the need for us to conduct some of the preclinical studies or clinical trials for the new product candidate that might otherwise have been required, although the review time is not shortened.
The FDA may then approve the new product candidate for the new indication sought by the 505(b)(2) applicant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Orange Book Listing </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In seeking approval for a drug through an NDA, applicants are required to list with the FDA certain patents whose claims cover the
applicant&#146;s product. Upon approval of an NDA, each of the patents listed in the application for the drug is then published in the FDA&#146;s Approved Drug Products with Therapeutic Equivalence Evaluations, known as the Orange Book. Any
applicant who files an Abbreviated New Drug Application (ANDA) seeking approval of a generic equivalent version of a drug listed in the Orange Book or a 505(b)(2) NDA referencing a drug listed in the Orange Book must certify, for each patent listed
in the Orange Book for the referenced drug, to the FDA that (1)&nbsp;no patent information on the drug product that is the subject of the application has been submitted to the FDA, (2)&nbsp;such patent has expired, (3)&nbsp;the date on which such
patent expires or (4)&nbsp;such patent is invalid or will not be infringed upon by the manufacture, use or sale of the drug product for which the application is submitted. The fourth certification described above is known as a paragraph IV
certification. A notice of the paragraph IV certification must be provided to each owner of the patent that is the subject of the certification and to the holder of the approved NDA to which the ANDA refers. The applicant may also elect to submit a
&#147;section viii&#148; statement certifying that its proposed label does not contain (or carves out) any language regarding the patented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">method-of-use</FONT></FONT> rather than
certify to a listed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">method-of-use</FONT></FONT> patent. This section viii statement does not require notice to the patent holder or NDA owner. There might also be no relevant patent
certification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If the reference NDA holder and patent owners assert a patent challenge directed to one of the Orange Book listed patents
within 45 days of the receipt of the paragraph IV certification notice, the FDA is prohibited from approving the application until the earlier of 30 months from the receipt of the paragraph IV certification expiration of the patent, settlement of
the lawsuit, or a decision in the infringement case that is favorable to the applicant. Even if the 45 days expire, a patent infringement lawsuit can be brought and could delay market entry, but it would not extend the
<FONT STYLE="white-space:nowrap">FDA-related</FONT> <FONT STYLE="white-space:nowrap">30-month</FONT> stay of approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The ANDA or
505(b)(2) application also will not be approved until any applicable <FONT STYLE="white-space:nowrap">non-patent</FONT> exclusivity listed in the Orange Book for the branded reference drug has expired. Specifically, the holder of the NDA for the
listed drug may be entitled to a period of <FONT STYLE="white-space:nowrap">non-patent</FONT> exclusivity, during which the FDA cannot approve an ANDA or 505(b)(2) application that relies on the listed drug. For example, a pharmaceutical
manufacturer may obtain five years of <FONT STYLE="white-space:nowrap">non-patent</FONT> exclusivity upon NDA approval of an NCE, which is a drug that contains an active moiety that has not been approved by FDA in any other NDA. An &#147;active
moiety&#148; is defined as the molecule or ion responsible for the drug substance&#146;s physiological or pharmacologic action. During the five-year exclusivity period, the FDA cannot accept for filing any ANDA seeking approval of a generic version
of that drug or any 505(b)(2) NDA for the same active moiety and that relies on the FDA&#146;s findings regarding that drug, except that FDA may accept an application for filing after four years if the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">follow-on</FONT> applicant makes a paragraph IV certification. This exclusivity period may be extended by an additional six months if certain requirements are met
to qualify the product for pediatric exclusivity, including the receipt of a written request from the FDA that the NDA holder conduct certain pediatric studies, the submission of study reports from such studies to the FDA after receipt of the
written request and satisfaction of the conditions specified in the written request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expedited Review and Approval Programs </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA has various programs, including Fast Track Designation, accelerated approval, priority review, and breakthrough therapy designation,
which are intended to expedite or simplify the process for the development and FDA review of drugs that are intended for the treatment of serious or life threatening diseases or conditions and demonstrate the potential to address unmet medical
needs. The purpose of these programs is to provide important new drugs to patients earlier than under standard FDA review procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To
be eligible for a Fast Track Designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical
need. The FDA will determine that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. The FDA may
review sections of the NDA for a fast track product on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and
determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA may give a priority review designation to drugs that offer major advances in treatment, or provide a treatment where no adequate
therapy exists. A priority review means that the goal for the FDA to review an application is six months, rather than the standard review of ten months under current PDUFA guidelines. Under the new PDUFA agreement, these six and ten month review
periods are measured from the &#147;filing&#148; date rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two months to the timeline for review and decision from the date of submission. Most products
that are eligible for Fast Track Designation are also likely to be considered appropriate to receive a priority review. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition,
products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may be eligible for accelerated approval and may be approved on the basis
of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible
morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of
alternative treatments. As a condition of approval, the FDA may require a sponsor of a drug receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other
clinical endpoint, and the drug may be subject to accelerated withdrawal procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Moreover, under the provisions of the Food and Drug
Administration Safety and Innovation Act, a sponsor can request designation of a product candidate as a &#147;breakthrough therapy.&#148; A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other
drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as
substantial treatment effects observed early in clinical development. Drugs designated as breakthrough therapies are also eligible for accelerated approval. The FDA must take certain actions, such as holding timely meetings and providing advice,
intended to expedite the development and review of an application for approval of a breakthrough therapy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Even if a product qualifies for one or more of these programs, the FDA may later decide that
the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. We may explore some of these opportunities for our product candidates as appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Post Approval Requirements </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Drugs
manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA and other government authorities, including, among other things, requirements relating to recordkeeping, periodic reporting, product
sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications, manufacturing changes or other labeling claims, are
subject to prior FDA review and approval. There also are continuing annual program fee requirements for any marketed products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA
may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#146;s
safety and effectiveness after commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, drug manufacturers and other entities involved in the manufacture and
distribution of approved drugs are required to register their establishments with the FDA and state authorities, and are subject to periodic unannounced inspections by the FDA and these state authorities for compliance with cGMP requirements.
Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and
documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain
cGMP compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards
is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure
to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other
restrictions under a REMS program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Other potential consequences include, among other things: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market
or product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning letters or holds on post-approval clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of
product license approvals; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention, or refusal to permit the import or export of products; or </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted
only for the approved indications and in accordance with the provisions of the approved label, although physicians, in the practice of medicine, may prescribe approved drugs for unapproved indications. The FDA and other authorities actively enforce
the laws and regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses, and a company that is found to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses may be subject to
significant liability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, the distribution of prescription pharmaceutical products is subject to the
Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state
laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other
Healthcare Laws </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pharmaceutical and medical device manufacturers are subject to additional healthcare regulation and enforcement
by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation, U.S. federal anti-kickback, fraud and abuse, false claims, consumer fraud, pricing
reporting, data privacy and security, and transparency laws and regulations as well as similar foreign laws in the jurisdictions outside the U.S. Similar state and local laws and regulations may also restrict business practices in the pharmaceutical
industry, such as state anti-kickback and false claims laws, which may apply to business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed
by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers, or by patients themselves; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary
compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require
drug manufacturers to file reports relating to pricing and marketing information or which require tracking gifts and other remuneration and items of value provided to physicians, other healthcare providers and entities; state and local laws that
require the registration of pharmaceutical sales representatives; and state and local laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not
preempted by HIPAA, thus complicating compliance efforts. Violation of any of such laws or any other governmental regulations that apply may result in penalties, including, without limitation, civil and criminal penalties, damages, fines, additional
reporting obligation, the curtailment or restructuring of operations, exclusion from participation in governmental healthcare programs and individual imprisonment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Coverage and Reimbursement </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Sales
of any pharmaceutical product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state and foreign government healthcare programs, commercial insurance and managed healthcare organizations,
and the level of reimbursement for such product by third-party payors. Significant uncertainty exists as to the coverage and reimbursement status of any newly approved product. Decisions regarding the extent of coverage and amount of reimbursement
to be provided are made on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">plan-by-plan</FONT></FONT> basis. One third-party payor&#146;s decision to cover a particular product does not ensure that other payors will also provide
coverage for the product. As a result, the coverage determination process can require manufactures to provide scientific and clinical support for the use of a product to each payor separately and can be a time-consuming process, with no assurance
that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult
because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, third-party payors are increasingly reducing reimbursements for pharmaceutical products and services. The U.S. government and
state legislatures have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Third-party payors are more and more challenging
the prices charged, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical products, in addition to questioning their safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more
restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price
ceilings on specific products and therapies. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control
the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product
on the market. Pharmaceutical products may face competition from lower-priced products in foreign countries that have placed price controls on pharmaceutical products and may also compete with imported foreign products. Furthermore, there is no
assurance that a product will be considered medically reasonable and necessary for a specific indication, will be considered cost-effective by third-party payors, that an adequate level of reimbursement will be established even if coverage is
available or that the third-party payors&#146; reimbursement policies will not adversely affect the ability for manufacturers to sell products profitably. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare Reform </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the United
States and certain foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system. In March 2010, the Patient Protection and Affordable Care Act, as amended by
the Health Care and Education Reconciliation Act, or collectively the ACA, was signed into law, which substantially changed the way healthcare is financed by both governmental and private insurers in the United States. By way of example, the ACA
increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1%; required collection of rebates for drugs paid by Medicaid managed care organizations; imposed a
<FONT STYLE="white-space:nowrap">non-deductible</FONT> annual fee on pharmaceutical manufacturers or importers who sell certain &#147;branded prescription drugs&#148; to specified federal government programs, implemented a new methodology by which
rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; expanded eligibility criteria for Medicaid programs; creates a new Patient-Centered Outcomes
Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare Innovation at CMS to test innovative payment and service
delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Since its enactment, there
have been judicial and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, in 2017, Congress enacted the Tax Cuts and Jobs Act, which
eliminated the <FONT STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the
&#147;individual mandate.&#148; On December&nbsp;14, 2018, a U.S. District Court Judge in the Northern District of Texas, or the Texas District Court Judge, ruled that the individual mandate is a critical and inseverable feature of the ACA, and
therefore, because it was repealed as part of the Tax Cuts and Jobs Act, the remaining provisions of the ACA are invalid as well. While the Texas U.S. District Court Judge, as well as the Trump administration and CMS, have stated that the ruling
will have no immediate effect, and on December&nbsp;30, 2018 the Texas District Court Judge issued an order staying the judgment pending appeal, it is unclear how this decision, subsequent appeals, and other efforts to repeal and replace the ACA
will impact the ACA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Other legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions
of Medicare payments to providers of 2% per fiscal year and reduced payments to several types of Medicare providers, which will remain in effect through 2027 absent additional congressional action. Moreover, there has recently been heightened
governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted legislation designed, among other things, to bring more transparency
to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for pharmaceutical products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Individual states in the United States have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing, including price or patient
reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures and, in some cases, mechanisms to encourage importation from other countries and bulk purchasing. Furthermore, there
has been increased interest by third party payors and governmental authorities in reference pricing systems and publication of discounts and list prices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, we had &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; full-time
employees, including &nbsp;&nbsp;&nbsp;&nbsp; employees with M.D. or&nbsp;Ph.D. degrees. Of these full-time employees, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; employees are engaged in research
and development activities. None of our employees is represented by a labor union or covered by a collective bargaining agreement. We consider our relationship with our employees to be good. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our principal office is
located at 480 Arsenal Way, Watertown, Massachusetts, where we lease approximately 22,343 square feet of office and laboratory space. We lease this space under a lease agreement, as amended, that terminates on April&nbsp;30, 2023. We believe that
our facilities are sufficient to meet our current needs and that suitable additional space will be available as and when needed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We were incorporated under the laws of the state of Delaware in November 2005 under the name WMR Biomedical, Inc. In July 2018, we
changed our name to Lyra Therapeutics, Inc. Our principal executive offices are located at 480 Arsenal Way, Watertown, MA 02472 and our telephone number is (617) <FONT STYLE="white-space:nowrap">393-4600.</FONT> Our website address is
<I>www.lyratherapeutics.com</I>. The information contained in, or accessible through, our website does not constitute a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are not subject to
any material legal proceedings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc805799_12"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers and Directors </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
following table sets forth the name, age and position of each of our executive officers and directors as of the date of this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="63%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Age</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Position</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><I>Executive Officers</I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Maria Palasis, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Executive Officer and Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R. Don Elsey</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer, Treasurer and Secretary</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dana Washburn, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Medical Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laura Edgerly-Pflug</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President of Technical Operation</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corinne Noyes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President of Commercial Strategy and Market Development</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><I>Directors</I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Altman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Edward Anderson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert S. Langer, D.Sc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">C. Ann Merrifield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Konstantin Poukalov</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">W. Bradford Smith</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">George Whitesides, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the audit committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the compensation committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the nominating and corporate governance committee. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Maria Palasis,
Ph.D.</I> has served as our President and Chief Executive Officer and a member of our board of directors since January 2015. Prior to her role with us as President and Chief Executive Officer, Dr.&nbsp;Palasis held positions of increasing
responsibility, the most recent of which was Executive Vice President and Chief Technology Officer from 2011 to 2015. Before that, in 2008, Dr.&nbsp;Palasis joined Arsenal Medical, Inc., a biotechnology company, as Executive Vice President and
subsequently served as President and Chief Executive Officer and a member of the board of directors of Arsenal Medical from January 2015 to June 2018. Before that, from November 1995 to January 2008, Dr.&nbsp;Palasis served as Director at Boston
Scientific Corporation, a medical device company, where she managed a portfolio of external biotech and medical device investments and led the development of several combination therapies. Dr. Palasis holds a B.S. and Ph.D. in Chemical Engineering
from the University of Cincinnati, and she held a postdoctoral fellowship in molecular biology at the University of Cincinnati School of Medicine. We believe that Dr. Palasis&#146; experience in the industry and knowledge of our company qualifies
her to serve on our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>R. Don Elsey </I>has served as our Chief Financial Officer since August 2019 and as our
Treasurer and Secretary since October 2019. Prior to joining our company, from February 2015 to February 2019, Mr.&nbsp;Elsey served as Chief Financial Officer at Senseonics, Inc., a medical device company. From May 2014 until February 2015,
Mr.&nbsp;Elsey served as Chief Financial Officer of Regado Biosciences, Inc., a biopharmaceutical company. From December 2012 to February 2014, Mr.&nbsp;Elsey served as Chief Financial Officer of LifeCell Corporation, a privately held regenerative
medicine company. Mr.&nbsp;Elsey holds a B.A. in economics and an M.B.A. in finance from Michigan State University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Dana Washburn</I>,
<I>M.D.</I> has served as our Chief Medical Officer since October 2019. Prior to joining our company, from November 2012 to October 2019, Dr.&nbsp;Washburn served in positions of increasing responsibility
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
at Parexel International, a global contract research organization, most recently as Corporate Vice President, Head, Global Medical Services from 2015 to 2019, where he oversaw clinical research
activities in support of client development programs. Before that, from April 2010 to November 2012, Dr.&nbsp;Washburn served in positions of increasing responsibility at Lantheus Medical Imaging, Inc., a medical imaging agent manufacturer, most
recently serving as Chief Medical Officer from September 2011 to November 2012. Dr.&nbsp;Washburn holds a B.A. in biology from Dartmouth College and an M.D. from the University of Massachusetts Medical School. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Laura Edgerly-Pflug</I> has served as our Senior Vice President of Technical Operations since July 2019. Prior to joining our company, from
October 2016 to June 2019, Ms.&nbsp;Edgerly-Pflug served as Vice President of Manufacturing Operations and Quality Control at Adgero Biopharmaceuticals Holdings, Inc., a biopharmaceutical company, where she led the manufacturing, formulation,
analytical, and quality control and assurance activities for the development of a therapeutic. Before that, from January 2014 to September 2016, Ms.&nbsp;Edgerly-Pflug was the Owner at Pflug BioPharm Solutions, a biopharmaceutical consulting firm,
where she provided strategic direction and implementation to clients in the areas of manufacturing, quality assurance, new technologies, new products and life cycle initiatives. Before that, from June 2012 to December 2013, Ms.&nbsp;Edgerly-Pflug
served as Vice President of Technical Operations and Chemistry, Manufacturing and Controls at Insmed Incorporated, formerly Transave Inc., a pharmaceutical company, where she was responsible for product development and manufacturing of sterile
liposomal products from preclinical development through commercialization. From July 2006 to June 2012, she served as Executive Director of Technical Operations and Chemistry, Manufacturing and Controls at Insmed. Ms.&nbsp;Edgerly-Pflug earned a
B.S. in Chemistry from Kean College of New Jersey. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Corinne Noyes</I> has served as our Senior Vice President of Commercial Strategy
and Market Development since September 2018. Prior to joining our company, from January 2018 to August 2018, Ms.&nbsp;Noyes served as an independent contractor to our Company, providing biopharmaceutical consulting services. Before that, from
January 2005 to August 2018, Ms.&nbsp;Noyes worked as a strategic advisor and independent biopharmaceutical consultant providing commercial leadership to emerging life sciences companies, including, among others, AMAG Pharmaceuticals, Inc., Avila
Therapeutics, Inc. (Celgene Corporation), Adnexus Therapeutics Inc. (Bristol-Myers Squibb Company), Constellation Pharmaceuticals, Inc., and Editas Medicine, Inc. Before that, from 1997 to 2004, Ms.&nbsp;Noyes held various commercial leadership
positions at Biogen Inc., a biotechnology company. Prior to joining Biogen Inc., from 1992 to 1996, Ms.&nbsp;Noyes worked as a health care strategy consultant at Deloitte&nbsp;&amp; Touche LLP. Ms.&nbsp;Noyes holds a B.A. in Humanities and a B.B.A.
in Business from St. Mary&#146;s College of Notre Dame and an M.B.A. in finance from University of Chicago Graduate School of Business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Directors </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Michael Altman</I> has served as a member of our board of directors since
June 2018. Since 2007, Mr. Altman has been employed on the investment team at Perceptive Advisors, a life sciences focused investment firm, where he currently serves as Managing Director and focuses on medical devices, diagnostics, digital health
and specialty pharmaceuticals investments. Since October 2018, Mr. Altman has also served as Chief Financial Officer and member of the board of directors of ARYA Sciences Acquisition Corp., a special purpose acquisition company. From October 2005 to
October 2007, Mr. Altman served as a healthcare trader and analyst at First New York Securities. Mr. Altman has served on the board of directors of Vitruvius Therapeutics, Inc., a pharmaceutical company, since December 2017, and served on the board
of directors of Vensun Pharmaceuticals, Inc., a pharmaceutical company, from November 2016 to January 2019. Mr. Altman holds a B.S. in Business Administration from the University of Vermont. We believe that Mr. Altman&#146;s broad operational and
transactional experience qualifies him to serve on our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Edward Anderson.</I> has served as a member of our board of
directors since February 2019. Since June 1994, Mr.&nbsp;Anderson has served as the Founder and a Managing Partner at North Bridge Venture Partners&nbsp;&amp; Growth Equity, a venture capital firm. Mr.&nbsp;Anderson holds a B.F.A. from the
University of Denver and an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
M.B.A. from Columbia University Graduate School of Business. We believe that Mr.&nbsp;Anderson&#146;s extensive experience in venture capital investments qualifies him to serve on our board of
directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Robert S. Langer, D.Sc.</I> has served as a member of our board of directors since March 2006. Since 2005, Dr.&nbsp;Langer
has served as a David H. Koch Institute Professor at the Massachusetts Institute of Technology. Dr.&nbsp;Langer has served on the board of directors of Abpro Corporation, a biotechnology company, since December 2016 and since September 2016 on the
board of directors of Frequency Therapeutics, Inc., a biotechnology company. Dr.&nbsp;Langer has also served on the board of directors of Rubius Therapeutics, Inc., a biopharmaceutical company, since December 2014 and since December 2010 on the
board of directors of Moderna, Inc., a biopharmaceutical company. Dr.&nbsp;Langer has also served on the board of directors of Puretech Health plc, a biotechnology company, and previously served on the boards of directors of Momenta Pharmaceuticals,
Inc., a biotechnology company, Wyeth Pharmaceuticals, a biopharmaceutical company, Kala Pharmaceuticals, Inc., a biopharmaceutical company, Fibrocell Science, Inc., a biotechnology company, and Millipore Corp., a life-sciences device manufacturer.
Dr.&nbsp;Langer holds a D.Sc. in Chemical Engineering from the Massachusetts Institute of Technology and a B.S. in Chemical Engineering from Cornell University. We believe Dr.&nbsp;Langer&#146;s pioneering academic work, extensive medical and
scientific knowledge, and experience serving on public company boards of directors qualify him to serve on our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>C.
Ann Merrifield</I> has served as a member of our board of directors since September 2019. Ms.&nbsp;Merrifield has also served as a member of the boards of directors for a portfolio of public and private companies in the life sciences sector which
include Flexion Therapeutics, Inc., since June 2014, InVivo Therapeutics Holdings Corp., since November 2014 and Veritas Genetics Inc., since December 2016. From July 2015 to August 2018, she served as a director of Juniper Pharmaceuticals, Inc.,
until it was acquired by Catalent, Inc. Ms.&nbsp;Merrifield also serves as a Trustee for MassMutual Premier, Select and MML Series Investment Funds, Partners Continuing Care (the post-acute care services division of Partners HealthCare) and the
Huntington Theatre Company. From November 2012 to July 2014, Ms. Merrifield served as President, Chief Executive Officer and director of PathoGenetix Inc., a genomics company, which voluntarily filed for Chapter 7 bankruptcy in July 2014. Before
that, Ms. Merrifield spent 18 years at Genzyme Corporation, serving in several leadership roles, including President of Genzyme Biosurgery, President of Genzyme Genetics and Senior Vice President, Business Excellence. Ms.&nbsp;Merrifield holds a
B.A. in Zoology and a Master of Education from the University of Maine and an M.B.A. from the Tuck School of Business at Dartmouth College. We believe that Ms. Merrifield&#146;s extensive industry experience qualifies her to serve on our board of
directors. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Konstantin Poukalov</I> has served as a member of our board of directors since January 2020. Since March 2019, Mr.
Poukalov has served as Managing Director at Perceptive Advisors, a life sciences focused investment firm. Since August 2019, Mr. Poukalov has also served on the board of directors of Landos Biopharma, Inc., a biopharmaceutical company. From July
2012 to October 2018, Mr. Poukalov served in roles of increasing responsibility at Kadmon Holdings, Inc., a biopharmaceutical company, most recently serving as Executive Vice President and Chief Financial Officer from July 2014 to October 2018. Mr.
Poukalov holds a B.S. in Electrical Engineering from Stony Brook University. We believe that Mr. Poukalov&#146;s extensive financial and industry experience qualify him to serve on our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>W. Bradford Smith</I> has served a member of our board of directors since November 2019. Mr. Smith has served as Chief Financial Officer
and Treasurer of Homology Medicines, Inc., a genetic medicines company, since April 2017 and as Secretary since July 2017. From March 2014 to April 2017, Mr. Smith was Chief Financial Officer of Ocular Therapeutix, Inc., a biopharmaceutical company.
Prior to joining Ocular Therapeutix, Mr. Smith served as Chief Financial Officer of OmniGuide, Inc., a medical device company, from July 2008 to March 2014. Mr. Smith holds a B.S. in Biology from Tufts University and an M.B.A. from the Whittemore
School of Business and Economics at the University of New Hampshire. We believe that Mr. Smith&#146;s extensive financial and industry experience qualify him to serve on our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>George Whitesides, Ph.D.</I><SUP STYLE="font-size:85%; vertical-align:top"> </SUP>has served as a member of our board of directors since
March 2006. Since 2004, he has served as the Woodford L. and Ann A. Flowers University Professor at Harvard University. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Dr.&nbsp;Whitesides joined Harvard&#146;s department of chemistry in 1982 and served as department chairman from 1986 to 1989. From 1963 to 1982, he was a faculty member at the Massachusetts
Institute of Technology. Dr.&nbsp;Whitesides held advisory positions on the National Research Council, National Science Foundation and the Department of Defense&#146;s Defense Advanced Research Projects Agency (DARPA), and is a member of the
American Academy of Arts and Sciences, National Academy of Sciences, National Academy of Engineering and the American Philosophical Society, among other organizations. Dr.&nbsp;Whitesides has served on the board of directors of Theravance Biopharma,
Inc., a biopharmaceutical company, since October 2013. Dr.&nbsp;Whitesides is also a <FONT STYLE="white-space:nowrap">co-founder</FONT> of a number of companies, including Genzyme Corporation, GelTex Pharmaceuticals Inc., Theravance Biopharma, Inc.,
Soft Robotics Inc. and Arsenal Medical, Inc. Dr.&nbsp;Whitesides holds an A.B. from Harvard University and a Ph.D. in chemistry from the California Institute of Technology. We believe that Dr.&nbsp;Whitesides&#146; extensive scientific and industry
experience qualifies him to serve on our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Composition and Election of Directors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Director Independence </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our board
of directors currently consists of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; members. Our board of directors has determined that, of our
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; directors, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; do not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that
each of these directors is &#147;independent&#148; as that term is defined under the rules of The Nasdaq Stock Market LLC, or Nasdaq. There are no family relationships among any of our directors or executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Classified Board of Directors </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In
accordance with our restated certificate of incorporation that will go into effect upon the closing of this offering, our board of directors will be divided into three classes with staggered, three-year terms.&nbsp;At each annual meeting of
stockholders, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual meeting following election. Effective upon the closing of this offering, our directors will
be divided among the three classes as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;I directors will be
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their terms will expire at our first annual
meeting of stockholders following this offering; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;II directors will be
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their terms will expire at our second annual meeting of stockholders following this offering; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;III directors will
be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their terms will expire at the third annual meeting of stockholders following this offering. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our restated certificate of incorporation that will go into effect upon the closing of this offering will provide that the authorized number
of directors may be changed only by resolution of the board of directors. Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will
consist of <FONT STYLE="white-space:nowrap">one-third</FONT> of the directors. The division of our board of directors into three classes with staggered three-year terms may delay or prevent a change of our management or a change in control of our
company. Our directors may be removed only for cause by the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of our outstanding voting stock entitled to vote in the election of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our directors were elected to and currently serve on the board pursuant to a voting agreement among us and several of our largest
stockholders. See &#147;Certain Relationships and Related Party Transactions&#151;Voting Agreement.&#148; This agreement will terminate upon the closing of this offering, after which there will be no further contractual obligations regarding the
election of our directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Leadership Structure </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our board of directors is currently chaired by &nbsp;&nbsp;&nbsp;&nbsp;. Our corporate governance guidelines provide that, if the chairman of
the board is a member of management or does not otherwise qualify as independent, the independent directors of the board may elect a lead director. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
currently serves as our lead director. The lead director&#146;s responsibilities include, but are not limited to: presiding over all meetings of the board of directors at which the chairman is not present, including any executive sessions of the
independent directors; approving board meeting schedules and agendas; and acting as the liaison between the independent directors and the chief executive officer and chairman of the board. Our corporate governance guidelines further provide the
flexibility for our board of directors to modify our leadership structure in the future as it deems appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Role of the Board in Risk Oversight
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">One of the key functions of our board of directors is informed oversight of our risk management process. Our board of directors does
not have a standing risk management committee, but rather administers this oversight function directly through our board of directors as a whole, as well as through various standing committees of our board of directors that address risks inherent in
their respective areas of oversight. In particular, our board of directors is responsible for monitoring and assessing strategic risk exposure and our audit committee has the responsibility to consider and discuss our major financial risk exposures
and the steps our management has taken to monitor and control these exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. Our audit committee also monitors compliance with legal and
regulatory requirements. Our nominating and corporate governance committee monitors the effectiveness of our corporate governance practices, including whether they are successful in preventing illegal or improper liability-creating conduct. Our
compensation committee assesses and monitors whether any of our compensation policies and programs has the potential to encourage excessive risk-taking. While each committee is responsible for evaluating certain risks and overseeing the management
of such risks, our entire board of directors is regularly informed through committee reports about such risks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Committees </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our board of directors has an audit committee, a compensation committee and a nominating and corporate governance committee, each of which has
the composition and the responsibilities described below. In addition, from time to time, special committees may be established under the direction of our board of directors when necessary to address specific issues. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each of the three standing committees&#151;audit, compensation and nominating and corporate governance&#151;operate under a charter that has
been approved by our board of directors. Upon our listing on The Nasdaq Global Market, each committee&#146;s charter will be available under the Corporate Governance section of our website at <I>www.lyratherapeutics.com</I>. The reference to our
website address does not constitute incorporation by reference of the information contained at or available through our website, and you should not consider it to be a part of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The audit
committee&#146;s responsibilities include, among other things: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appointing, approving the compensation of, and assessing the independence of our registered public accounting
firm; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing the work of our registered public accounting firm, including through the receipt and consideration of
reports from such firm; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and discussing with management and the registered public accounting firm our annual and quarterly
financial statements and related disclosures; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">coordinating our board of directors&#146; oversight of our internal control over financial reporting, disclosure
controls and procedures and code of business conduct and ethics; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">discussing our risk management policies; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">meeting independently with our internal auditing staff, if any, registered public accounting firm and management;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving or ratifying any related person transactions; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparing the audit committee report required by Securities Exchange Commission, or SEC, rules.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The members of our audit committee
are&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serves as the chairperson of the committee. All
members of our audit committee meet the requirements for financial literacy under the applicable listing rules of Nasdaq, or the Nasdaq rules. Our board of directors has determined that each of these individuals meets the independence requirements
of Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act and the applicable Nasdaq rules. Each member of our audit committee can read and understand fundamental financial statements in accordance with the Nasdaq audit committee
requirements. In arriving at this determination, the board has examined each audit committee member&#146;s scope of experience and the nature of their prior and/or current employment. Our board of directors has determined that
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; is an &#147;audit committee financial expert&#148; as defined by applicable SEC rules and has the requisite financial sophistication as defined under
the applicable Nasdaq rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe that the composition and functioning of our audit committee complies with all applicable
requirements of the Sarbanes-Oxley Act, and all applicable SEC and Nasdaq rules and regulations. We intend to comply with future requirements to the extent they become applicable to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
compensation committee&#146;s responsibilities include, among other things: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving, or recommending for approval by the board of directors, the compensation of our CEO and
our other executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing and administering our cash and equity incentive plans; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and making recommendations to our board of directors with respect to director compensation;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and discussing annually with management our &#147;Compensation Discussion and Analysis,&#148; to the
extent required; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparing the annual compensation committee report required by SEC rules, to the extent required.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The members of our compensation committee are
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;serves as the chairperson of the committee. Our board
of directors has determined that each of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; is independent under the applicable Nasdaq rules, including the Nasdaq rules specific to membership on the compensation committee,
and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; is a <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> director&#148; as defined in Rule <FONT STYLE="white-space:nowrap">16b-3</FONT>
promulgated under the Exchange Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe that the composition and functioning of our compensation committee complies with
all applicable requirements of the Sarbanes-Oxley Act, and all applicable SEC and Nasdaq rules and regulations. We intend to comply with future requirements to the extent they become applicable to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Corporate Governance Committee </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The nominating and corporate governance committee&#146;s responsibilities include, among other things: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying individuals qualified to become board members; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recommending to our board of directors the persons to be nominated for election as directors and to each board
committee; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing and recommending to our board of directors corporate governance guidelines, and reviewing and
recommending to our board of directors proposed changes to our corporate governance guidelines from time to time; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing a periodic evaluation of our board of directors. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The members of our nominating and corporate governance committee are
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serves as the chairperson of the committee. Our board
of directors has determined that &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are independent under the applicable Nasdaq rules and the SEC rules and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee Interlocks and Insider Participation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">No member of our compensation committee is or has been our current or former officer or employee. None of our executive officers currently
serves, or in the past year has served, as a director or a member of a compensation committee (or other committee serving an equivalent function) of any other entity, one of whose executive officers served as a director or member of our compensation
committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Ethics and Code of Conduct </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal
executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. Upon our listing on The Nasdaq Global Market, our code of business conduct and ethics will be available under the
Corporate Governance section of our website at <I>www.lyratherapeutics.com</I>. In addition, we intend to post on our website all disclosures that are required by law or the Nasdaq rules concerning any amendments to, or waivers from, any provision
of the code. The reference to our website address does not constitute incorporation by reference of the information contained at or available through our website, and you should not consider it to be a part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc805799_13"></A>EXECUTIVE AND DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This section discusses the material components of the executive compensation program for our executive officers who are named in the
&#147;2019 Summary Compensation Table&#148; below. In 2019, our &#147;named executive officers&#148; and their positions were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Maria Palasis, Ph.D., President and Chief Executive Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">R. Don Elsey, Chief Financial Officer; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Laura Edgerly-Pflug, Senior Vice President of Technical Operations. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This discussion may contain forward-looking statements that are based on our current plans, considerations, expectations and determinations
regarding future compensation programs. Actual compensation programs that we adopt following the completion of this offering may differ materially from the currently planned programs summarized in this discussion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2019 Summary Compensation Table </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
following table sets forth information concerning the compensation of our named executive officers for the year ended December&nbsp;31, 2019. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Year</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Salary<BR>($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Bonus<BR>($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Option<BR>Awards<BR>($)<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive
Plan<BR>Compensation<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>All
Other<BR>Compensation<BR>($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Total ($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Maria Palasis, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">388,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">318,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">842,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>President and Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R. Don Elsey</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130,625</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">501,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,934</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">728,477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laura Edgerly-Pflug</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,923</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,658</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,158</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">316,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Senior Vice President of Technical Operations</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts represent the full grant date fair value of stock options granted during 2019 computed in accordance
with ASC Topic 718, rather than the amounts paid to or realized by the named individual. We provide information regarding the assumptions used to calculate the value of all option awards made to named executive officers in Note&nbsp;8 to the
consolidated financial statements included in this prospectus. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts represent discretionary performance-based annual cash bonuses made by our board for the named executive
officers for fiscal year 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Elsey commenced employment with us in July 2019, and Ms.&nbsp;Edgerly-Pflug commenced employment with
us in a part-time capacity in June 2019 and in a full-time capacity in July 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amount represents use of a corporate apartment, commuting expenses and related tax gross-ups.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amount represents a signing bonus. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amount represents reimbursement of commuting expenses and related tax gross-up. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Narrative to Summary Compensation Table </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2019 Salaries </I></B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The named
executive officers receive a base salary to provide a fixed component of compensation reflecting the executive&#146;s skill set, experience, role and responsibilities. For 2019, our board of directors established an annual base salary of $388,025
for Dr.&nbsp;Palasis, effective January&nbsp;1, 2019. Mr.&nbsp;Elsey&#146;s and Ms.&nbsp;Edgerly-Pflug&#146;s 2019 annual base salaries were $325,000 and $280,000, respectively, and were established by our board of directors in connection with their
commencing employment with us. During the period in which Ms.&nbsp;Edgerly-Pflug was employed with us in a part-time capacity, her annual base salary was $140,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2019 Bonuses </I></B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We offer our
named executive officers the opportunity to earn annual cash bonuses to compensate them for attaining short-term company goals as approved by our board of directors. For 2019, bonuses were based entirely on (i) completing steps towards a Phase 2
LANTERN trial for LYR-210 and attaining other value-driving milestones, (ii) attaining corporate goals relating to overall business development and fundraising and (iii) building an executive team and board of directors, with these categories
weighted at 30%, 50% and 20%, respectively. The 2019 target bonuses for each of Dr.&nbsp;Palasis, Mr.&nbsp;Elsey and Ms.&nbsp;Edgerly-Pflug were 35%, 30% and 25%, respectively, of his or her annual base salary. The target cash bonuses for Mr. Elsey
and Ms. Edgerly-Pflug were prorated from their respective dates of hire. The actual annual cash bonuses awarded to each named executive officer for 2019 performance are set forth above in the 2019 Summary Compensation Table in the column titled
&#147;Non-Equity Incentive Plan Compensation&#148;. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity Compensation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We offer stock options to our employees, including our named executive officers, as the long-term incentive component of our compensation
program. Our stock options generally allow employees to purchase shares of our common stock at a price equal to the fair market value of our common stock on the date of grant, as determined by the board of directors. With respect to grants made in
connection with the commencement of employment, our stock options typically vest as to 25% of the underlying shares on the first anniversary of the vesting commencement date and in equal monthly installments over the following three years, subject
to the holder&#146;s continued employment with us. From time to time, our board of directors may also construct alternate vesting schedules as it determines are appropriate to motivate particular employees. Historically, our stock options have been
intended to qualify as &#147;incentive stock options&#148; to the extent permitted under the Internal Revenue Code. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following
table sets forth the stock options granted to our named executive officers in during 2019. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="38%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Named Executive Officer</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2019&nbsp;Stock<BR>Options<BR>Granted</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Maria Palasis, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,877,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R. Don Elsey</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,578,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laura Edgerly-Pflug</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">These options were granted under our 2016 Equity Incentive Plan, which we refer to as the 2016 Plan,
with exercise prices equal to the fair market value of our common stock on the date of grant, as determined by the board of directors, and with respect to Dr.&nbsp;Palasis, vest in equal monthly installments over four years following the vesting
commencement date and with respect to Mr.&nbsp;Elsey and Ms.&nbsp;Edgerly-Pflug, subject to our standard vesting schedule for grants made in connection with the commencement of employment described above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with this offering, we intend to adopt a 2020 Incentive Award Plan, referred
to below as the 2020 Plan, in order to facilitate the grant of cash and equity incentives to directors, employees (including our named executive officers) and consultants of our company and to enable our company to obtain and retain services of
these individuals. Following the effective date of the 2020 Plan, we will not make any further grants under the 2016 Plan. However, the 2016 Plan will continue to govern the terms and conditions of the outstanding awards granted under it. For
additional information about the 2020 Plan, please see the section titled &#147;Incentive Compensation Plans&#148; below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Elements of
Compensation </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Retirement Plan </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We maintain a 401(k) retirement savings plan for our employees, including our named executive officers, who satisfy certain eligibility
requirements. Our named executive officers are eligible to participate in the 401(k) plan on the same terms as other full-time employees. We believe that providing a vehicle for <FONT STYLE="white-space:nowrap">tax-deferred</FONT> retirement savings
though our 401(k) plan adds to the overall desirability of our executive compensation package and further incentivizes our employees, including our named executive officers, in accordance with our compensation policies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Employee Benefits and Perquisites </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">All of our full-time employees, including our named executive officers, are eligible to participate in our employee benefit plans and
programs, including medical, dental, and vision benefits, health spending accounts, and short- and long-term disability, accidental death and dismemberment, and life insurance, to the same extent as our other full-time employees, subject to the
terms and eligibility requirements of those plans. For 2019, we did not provide an employer matching contribution under our 401(k) plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding
Equity Awards at 2019 Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table summarizes the number of shares of
common stock underlying outstanding equity incentive plan awards for each named executive officer as of December&nbsp;31, 2019. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="17" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Option Awards</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Vesting<BR>Commencement<BR>Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number
of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Exercisable</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number
of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Unexercisable</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Equity<BR>Incentive<BR>Plan<BR>Awards:<BR>Number
of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Unearned<BR>Options (#)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Option<BR>Exercise<BR>Price<BR>($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Option<BR>Expiration<BR>Date</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Maria Palasis, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">11/16/2011</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">786,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">11/16/2021</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2/26/2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">840,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6/26/2023</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1/1/2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,251,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9/23/2025</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6/13/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,083,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,083,775</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6/13/2027</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3/6/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,102,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,775,763</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3/6/2029</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R. Don Elsey</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">7/29/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,578,761</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9/24/2029</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laura Edgerly-Pflug</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6/3/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6/20/2029</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Options vest and become exercisable in equal monthly installments over four years following the vesting
commencement date, subject to Dr. Palasis&#146; continued employment with us on each applicable vesting date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Options vest and become exercisable at the end of any given three-month period occurring prior to six years
from the vesting commencement date in which we recognize revenue from the commercial sale of an FDA-</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
approved product each month and in amounts, with respect to the second and third months of such period that increase from the revenue recognized from such product sales in the immediately
preceding month, subject to Dr. Palasis&#146; continued employment with us on each applicable vesting date. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Options vest and become exercisable as to 25% of the underlying shares on the first anniversary of the vesting
commencement date and in 36 equal monthly installments over the following three years, subject to the named executive officer&#146;s continued employment with us on each applicable vesting date. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Compensation Arrangements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with this offering, we intend to enter into employment agreements with each named executive officer that will supersede their
current compensation arrangements and become effective on the effectiveness of the registration statement of which this prospectus is a part. The terms of those arrangements are not currently known. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Compensation </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2019 Director Compensation
Table </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Fees<BR>Earned<BR>or&nbsp;Paid&nbsp;in<BR>Cash ($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Option<BR>Awards<BR>($)<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Total ($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Langer D.Sc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">George Whitesides Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Altman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">C. Ann Merrifield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Edward Anderson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">W. Bradford Smith</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Konstantin Poukalov</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts reflect the full grant-date fair value of stock awards and stock options granted during 2019 computed
in accordance with ASC Topic 718, rather than the amounts paid to or realized by the named individual. We provide information regarding the assumptions used to calculate the value of all stock awards and option awards made to our directors in Note 8
to the consolidated financial statements included in this prospectus. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The table below shows the aggregate numbers
of option awards (exercisable and unexercisable) held as of December&nbsp;31, 2019 by each <FONT STYLE="white-space:nowrap">non-employee</FONT> director who was serving as of December&nbsp;31, 2019. None of our non-employee directors held unvested
stock awards as of December&nbsp;31, 2019. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Options<BR>Outstanding<BR>at
Fiscal<BR>Year End</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Langer D.Sc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,692,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">George Whitesides Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,192,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Altman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">C. Ann Merrifield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Edward Anderson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">W. Bradford Smith</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Konstantin Poukalov</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We intend to approve and implement a compensation program for our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors that consists of annual retainer fees and long-term equity awards. The terms of this program are not currently known. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Incentive Compensation Plans </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following summarizes the material terms of 2020 Plan and the 2020 Employee Stock Purchase Plan, which will be the long-term incentive
compensation plans in which our directors and named executive officers are eligible to participate following the consummation of this offering, and the 2016 Plan, under which we have previously made periodic grants of equity and equity-based awards
to our directors and named executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2020 Incentive Award Plan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Effective the day prior to the first public trading date of our common stock, we intend to adopt and ask our stockholders to approve the 2020
Plan, under which we may grant cash and equity-based incentive awards to eligible service providers in order to attract, retain and motivate the persons who make important contributions to our company. The material terms of the 2020 Plan are
summarized below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Eligibility and Administration </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our employees, consultants and directors, and employees and consultants of our subsidiaries, will be eligible to receive awards under the 2020
Plan. The 2020 Plan will be administered by our board of directors, which may delegate its duties and responsibilities to one or more committees of our directors and/or officers (referred to collectively as the plan administrator below), subject to
the limitations imposed under the 2020 Plan, Section&nbsp;16 of the Exchange Act, stock exchange rules and other applicable laws. The plan administrator will have the authority to take all actions and make all determinations under the 2020 Plan, to
interpret the 2020 Plan and award agreements and to adopt, amend and repeal rules for the administration of the 2020 Plan as it deems advisable. The plan administrator will also have the authority to grant awards, determine which eligible service
providers receive awards and set the terms and conditions of all awards under the 2020 Plan, including any vesting and vesting acceleration provisions, subject to the conditions and limitations in the 2020 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Shares Available for Awards </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">An
aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock will initially be available for issuance under the 2020 Plan. The number of shares initially available for issuance will be increased by
an annual increase on January&nbsp;1 of each calendar year beginning in 2021 and ending in and including 2030, equal to the lesser of (A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the shares of common stock outstanding on the final day of the immediately
preceding calendar year and (B)&nbsp;a smaller number of shares determined by our board of directors. No more than &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock may be issued under the 2020 Plan upon
the exercise of incentive stock options. Shares issued under the 2020 Plan may be authorized but unissued shares, shares purchased on the open market or treasury shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If an award under the 2020 Plan or the 2016 Plan, expires, lapses or is terminated, exchanged for cash, surrendered, repurchased, canceled
without having been fully exercised or forfeited, any unused shares subject to the award will, as applicable, become or again be available for new grants under the 2020 Plan. Awards granted under the 2020 Plan in substitution for any options or
other stock or stock-based awards granted by an entity before the entity&#146;s merger or consolidation with us or our acquisition of the entity&#146;s property or stock will not reduce the shares available for grant under the 2020 Plan, but may
count against the maximum number of shares that may be issued upon the exercise of incentive stock options, or ISOs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Awards </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The 2020 Plan provides for the grant of stock options, including ISOs, and nonqualified stock options, or NSOs, stock appreciation rights, or
SARs, restricted stock, dividend equivalents, restricted stock units, or RSUs, and other stock or cash based awards. Certain awards under the 2020 Plan may constitute or provide for payment of &#147;nonqualified deferred compensation&#148; under
Section&nbsp;409A of the Code. All awards under the 2020 Plan will be set </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
forth in award agreements, which will detail the terms and conditions of awards, including any applicable vesting and payment terms and post-termination exercise limitations. A brief description
of each award type follows. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Stock Options and SARs. Stock options provide for the purchase of shares of our common stock in the future at an
exercise price set on the grant date. ISOs, by contrast to NSOs, may provide tax deferral beyond exercise and favorable capital gains tax treatment to their holders if certain holding period and other requirements of the Code are satisfied. SARs
entitle their holder, upon exercise, to receive from us an amount equal to the appreciation of the shares subject to the award between the grant date and the exercise date. The plan administrator will determine the number of shares covered by each
option and SAR, the exercise price of each option and SAR and the conditions and limitations applicable to the exercise of each option and SAR. The exercise price of a stock option or SAR will not be less than 100% of the fair market value of the
underlying share on the grant date (or 110% in the case of ISOs granted to certain significant stockholders), except with respect to certain substitute awards granted in connection with a corporate transaction. The term of a stock option or SAR may
not be longer than ten years (or five years in the case of ISOs granted to certain significant stockholders). </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Restricted Stock and RSUs. Restricted stock is an award of nontransferable shares of our common stock that remain
forfeitable unless and until specified conditions are met and which may be subject to a purchase price. RSUs are contractual promises to deliver shares of our common stock in the future, which may also remain forfeitable unless and until specified
conditions are met and may be accompanied by the right to receive the equivalent value of dividends paid on shares of our common stock prior to the delivery of the underlying shares. The plan administrator may provide that the delivery of the shares
underlying RSUs will be deferred on a mandatory basis or at the election of the participant. The terms and conditions applicable to restricted stock and RSUs will be determined by the plan administrator, subject to the conditions and limitations
contained in the 2020 Plan. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Other Stock or Cash Based Awards. Other stock or cash based awards are awards of cash, fully vested shares of our
common stock and other awards valued wholly or partially by referring to, or otherwise based on, shares of our common stock or other property. Other stock or cash based awards may be granted to participants and may also be available as a payment
form in the settlement of other awards, as standalone payments and as payment in lieu of compensation to which a participant is otherwise entitled. The plan administrator will determine the terms and conditions of other stock or cash based awards,
which may include any purchase price, performance goal, transfer restrictions and vesting conditions. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Performance Criteria
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The plan administrator may select performance criteria for an award to establish performance goals for a performance period.
Performance criteria under the 2020 Plan may include, but are not limited to, the following: net earnings or losses (either before or after one or more of interest, taxes, depreciation, amortization, and
<FONT STYLE="white-space:nowrap">non-cash</FONT> equity-based compensation expense); gross or net sales or revenue or sales or revenue growth; net income (either before or after taxes) or adjusted net income; profits (including but not limited to
gross profits, net profits, profit growth, net operation profit or economic profit), profit return ratios or operating margin; budget or operating earnings (either before or after taxes or before or after allocation of corporate overhead and bonus);
cash flow (including operating cash flow and free cash flow or cash flow return on capital); return on assets; return on capital or invested capital; cost of capital; return on stockholders&#146; equity; total stockholder return; return on sales;
costs, reductions in costs and cost control measures; expenses; working capital; earnings or loss per share; adjusted earnings or loss per share; price per share or dividends per share (or appreciation in or maintenance of such price or dividends);
regulatory achievements or compliance; implementation, completion or attainment of objectives relating to research, development, regulatory, commercial, or strategic milestones or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
developments; market share; economic value or economic value added models; division, group or corporate financial goals; customer satisfaction/growth; customer service; employee satisfaction;
recruitment and maintenance of personnel; human resources management; supervision of litigation and other legal matters; strategic partnerships and transactions; financial ratios (including those measuring liquidity, activity, profitability or
leverage); debt levels or reductions; sales-related goals; financing and other capital raising transactions; cash on hand; acquisition activity; investment sourcing activity; and marketing initiatives, any of which may be measured in absolute terms
or as compared to any incremental increase or decrease. Such performance goals also may be based solely by reference to the company&#146;s performance or the performance of a subsidiary, division, business segment or business unit of the company or
a subsidiary, or based upon performance relative to performance of other companies or upon comparisons of any of the indicators of performance relative to performance of other companies. When determining performance goals, the plan administrator may
provide for exclusion of the impact of an event or occurrence which the plan administrator determines should appropriately be excluded, including, without limitation, <FONT STYLE="white-space:nowrap">non-recurring</FONT> charges or events,
acquisitions or divestitures, changes in the corporate or capital structure, events unrelated to the business or outside of the control of management, foreign exchange considerations, and legal, regulatory, tax or accounting changes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certain Transactions </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In
connection with certain corporate transactions and events affecting our common stock, including a change in control, or change in any applicable laws or accounting principles, the plan administrator has broad discretion to take action under the 2020
Plan to prevent the dilution or enlargement of intended benefits, facilitate the transaction or event or give effect to the change in applicable laws or accounting principles. This includes canceling awards for cash or property, accelerating the
vesting of awards, providing for the assumption or substitution of awards by a successor entity, adjusting the number and type of shares subject to outstanding awards and/or with respect to which awards may be granted under the 2020 Plan and
replacing or terminating awards under the 2020 Plan. In addition, in the event of certain <FONT STYLE="white-space:nowrap">non-reciprocal</FONT> transactions with our stockholders, the plan administrator will make equitable adjustments to awards
outstanding under the 2020 Plan as it deems appropriate to reflect the transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provisions of the 2020 Plan Relating to Director Compensation.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The 2020 Plan provides that the plan administrator may establish compensation for
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors from time to time subject to the 2020 Plan&#146;s limitations. Prior to commencing this offering, we intend to approve and implement a compensation program for our <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors, which is described above under the heading &#147;Director Compensation.&#148; Our board of directors or its authorized committee may modify the
<FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation program from time to time in the exercise of its business judgment, taking into account such factors, circumstances and considerations as it shall deem relevant from time to
time, provided that the sum of any cash compensation or other compensation and the grant date fair value of any equity awards granted under the 2020 Plan as compensation for services as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director
during any fiscal year may not exceed $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in the fiscal year of the <FONT STYLE="white-space:nowrap">non-employee</FONT> director&#146;s initial service and
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in any other fiscal year. The plan administrator may make exceptions to this limit for individual <FONT STYLE="white-space:nowrap">non-employee</FONT> directors in
extraordinary circumstances, as the plan administrator may determine in its discretion, subject to the limitations in the 2020 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Plan Amendment
and Termination </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our board of directors may amend or terminate the 2020 Plan at any time; however, no amendment, other than an
amendment that increases the number of shares available under the 2020 Plan, may materially and adversely affect an award outstanding under the 2020 Plan without the consent of the affected participant and stockholder approval will be obtained for
any amendment to the extent necessary to comply with applicable laws. Further, the plan administrator may, without the approval of our stockholders, amend any outstanding stock option or SAR to reduce its price per share, other than in the context
of corporate transactions or equity </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
restructurings, as described above. The 2020 Plan will remain in effect until the tenth anniversary of its effective date, unless earlier terminated by our board of directors. No awards may be
granted under the 2020 Plan after its termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Participants, Claw-Back Provisions, Transferability and Participant Payments
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The plan administrator may modify awards granted to participants who are foreign nationals or employed outside the United States
or establish subplans or procedures to address differences in laws, rules, regulations or customs of such foreign jurisdictions. All awards will be subject to any company claw-back policy as set forth in such claw-back policy or the applicable award
agreement. Except as the plan administrator may determine or provide in an award agreement, awards under the 2020 Plan are generally <FONT STYLE="white-space:nowrap">non-transferrable,</FONT> except by will or the laws of descent and distribution,
or, subject to the plan administrator&#146;s consent, pursuant to a domestic relations order, and are generally exercisable only by the participant. With regard to tax withholding obligations arising in connection with awards under the 2020 Plan and
exercise price obligations arising in connection with the exercise of stock options under the 2020 Plan, the plan administrator may, in its discretion, accept cash, wire transfer or check, shares of our common stock that meet specified conditions, a
promissory note, a &#147;market sell order,&#148; such other consideration as the plan administrator deems suitable or any combination of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2020 Employee Stock Purchase Plan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Effective the day prior to the first public trading date of our common stock, we intend to adopt and ask our stockholders to approve the 2020
Employee Stock Purchase Plan, or the 2020 ESPP, the material terms of which are summarized below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Shares Available for Awards; Administration
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A total of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock will initially be
reserved for issuance under the 2020 ESPP. In addition, the number of shares available for issuance under the 2020 ESPP will be annually increased on January&nbsp;1 of each calendar year beginning in 2021 and ending in and including 2030, by an
amount equal to the lesser of (A) &nbsp;&nbsp;&nbsp;&nbsp;% of the shares outstanding on the final day of the immediately preceding calendar year and (B)&nbsp;such smaller number of shares as is determined by our board of directors, provided that no
more than &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock may be issued under the 2020 ESPP. Our board of directors or a committee of our board of directors will administer and will have
authority to interpret the terms of the 2020 ESPP and determine eligibility of participants. We expect that the compensation committee will be the initial administrator of the 2020 ESPP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Eligibility </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">All of our employees
are eligible to participate in the 2020 ESPP. However, an employee may not be granted rights to purchase stock under our 2020 ESPP if the employee, immediately after the grant, would own (directly or through attribution) stock possessing 5% or more
of the total combined voting power or value of all classes of our stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Grant of Rights </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The 2020 ESPP is intended to qualify under Section&nbsp;423 of the Code and stock will be offered under the 2020 ESPP during offering periods.
The length of the offering periods under the 2020 ESPP will be determined by the plan administrator and may be up to twenty-seven months long. Employee payroll deductions will be used to purchase shares on each purchase date during an offering
period. The purchase dates for each offering period will be the final trading day in the offering period. Offering periods under the 2020 ESPP will commence when determined by the plan administrator. The plan administrator may, in its discretion,
modify the terms of future offering periods. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The 2020 ESPP permits participants to purchase common stock through payroll deductions of up
to a specified percentage of their eligible compensation. The plan administrator will establish a maximum number of shares that may be purchased by a participant during any offering period. In addition, no employee will be permitted to accrue the
right to purchase stock under the 2020 ESPP at a rate in excess of $25,000 worth of shares during any calendar year during which such a purchase right is outstanding (based on the fair market value per share of our common stock as of the first day
of the offering period). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On the first trading day of each offering period, each participant will automatically be granted an option to
purchase shares of our common stock. The option will expire at the end of the applicable offering period, and will be exercised at that time to the extent of the payroll deductions accumulated during the offering period. The purchase price of the
shares, in the absence of a contrary designation, will be 85% of the lower of the fair market value of our common stock on the first trading day of the offering period or on the purchase date. Participants may voluntarily end their participation in
the 2020 ESPP at any time during a specified period prior to the end of the applicable offering period, and will be paid their accrued payroll deductions that have not yet been used to purchase shares of common stock. Participation ends
automatically upon a participant&#146;s termination of employment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A participant may not transfer rights granted under the 2020 ESPP
other than by will or the laws of descent and distribution, and are generally exercisable only by the participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certain Transactions
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the event of certain <FONT STYLE="white-space:nowrap">non-reciprocal</FONT> transactions or events affecting our common stock,
the plan administrator will make equitable adjustments to the 2020 ESPP and outstanding rights. In the event of certain unusual or <FONT STYLE="white-space:nowrap">non-recurring</FONT> events or transactions, including a change in control, the plan
administrator may provide for (1)&nbsp;either the replacement of outstanding rights with other rights or property or termination of outstanding rights in exchange for cash, (2)&nbsp;the assumption or substitution of outstanding rights by the
successor or survivor corporation or parent or subsidiary thereof, if any, (3)&nbsp;the adjustment in the number and type of shares of stock subject to outstanding rights, (4)&nbsp;the use of participants&#146; accumulated payroll deductions to
purchase stock on a new purchase date prior to the next scheduled purchase date and termination of any rights under ongoing offering periods or (5)&nbsp;the termination of all outstanding rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Plan Amendment </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The plan
administrator may amend, suspend or terminate the 2020 ESPP at any time. However, stockholder approval will be obtained for any amendment that increases the aggregate number or changes the type of shares that may be sold pursuant to rights under the
2020 ESPP, changes the corporations or classes of corporations whose employees are eligible to participate in the 2020 ESPP or changes the 2020 ESPP in any manner that would cause the 2020 ESPP to no longer be an employee stock purchase plan within
the meaning of Section&nbsp;423(b) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2016 Plan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our board of directors adopted our 2016 Plan in February 2016, and our stockholders approved our 2016 Plan in June 2016. Following the
effectiveness of the 2020 Plan, we will cease granting additional awards under our 2016 Plan. However, our 2016 Plan will continue to govern the terms and conditions of the outstanding stock option awards previously granted thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Share Reserve</I>. As of December 31, 2019, stock options covering 19,759,224&nbsp;shares with a weighted-average exercise price of $0.08
per share and no shares of restricted stock were outstanding under our 2016 Plan, and 13,249,002 shares of our common stock remained available for the future grant of awards under our 2016 Plan. If an option granted under our 2016 Plan expires,
lapses or is terminated, exchanged for cash, surrendered, repurchased, canceled without having been fully exercised or forfeited, in each case after effectiveness of the 2020 Plan, any unused shares subject to the option will become available for
issuance under our 2020 Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Administration</I>. Our board of directors or a committee delegated by our board of
directors administers our 2016 Plan. Subject to the terms of our 2016 Plan, the administrator has the power to, among other things, determine who will be granted awards, to determine the terms and conditions of each award (including the number of
shares, exercise price, if any, and any vesting conditions), to accelerate the time(s) when an award may vest or be exercised and to construe and interpret the terms of our 2016 Plan and awards granted thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Options and Restricted Stock</I>. Options and restricted stock granted under our 2016 Plan may be granted subject to terms and conditions
generally similar to those described above with respect to options and restricted stock that may be granted under our 2020 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Changes to Capital Structure</I>. In the event of any dividend or other distribution, reorganization, merger, consolidation, combination,
repurchase, recapitalization, liquidation, dissolution, or sale, transfer, exchange or other disposition of assets of the Company, or sale or exchange of our common stock or other securities of the Company, issuance of warrants or other rights to
purchase our common stock or other securities of the Company, or other similar corporate transaction or event affecting our shares, the plan administrator may adjust the number and kind of shares that may be delivered under the 2016 Plan, the
number, kind and price of shares covered by each outstanding award and/or the terms and conditions of any outstanding award (including any performance &#147;targets&#148;) in order to prevent to prevent dilution or enlargement of the benefits or
potential benefits intended by the Company under the 2016 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Additionally, in the event of any of the transactions described above or
any other unusual or nonrecurring transaction or event , affecting the Company or the financial statements or financial condition of the Company, or any change in any applicable laws or accounting principles, the plan administrator is authorized to
take any one or more of the following actions whenever the plan administrator determines that such action is appropriate in order to (x)&nbsp;prevent dilution or enlargement of the benefits or potential benefits intended by the Company to be made
available under the 2016 Plan or with respect to any award granted or issued under the 2016 Plan, (y)&nbsp;to facilitate such transaction or event or (z)&nbsp;give effect to such changes in applicable laws or accounting principles: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">To provide for the cancellation of awards in exchange for either an amount of cash or other property with a value
equal to the amount that could have been obtained upon the exercise or settlement of the vested portion of such award; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">To provide that awards shall vest and be fully exercisable; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">To make adjustments in the number and type of shares subject to outstanding awards, and/or in the terms and
conditions of (including, without limitation, the grant or exercise price), and the criteria included in, outstanding awards; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">To provide that awards be assumed by the successor or survivor corporation, or a parent or subsidiary thereof, or
shall be substituted for by awards covering the stock of the successor or survivor corporation, or a parent or subsidiary thereof; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">To replace awards with other rights or property selected by the plan administrator; and/or </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">To provide that awards will terminate and cannot vest, be exercised or become payable after the applicable event.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Plan Amendment or Termination</I>. Our board of directors may amend, alter, suspend or terminate our 2016 Plan at
any time, subject to stockholder approval to the extent required by applicable law. No amendment to our 2016 Plan may materially and adversely affect any outstanding award outstanding without the consent of the affected award holder. As discussed
above, we will terminate our 2016 Plan prior to the closing of this offering and no new awards will be granted thereunder following such termination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2005 Plan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our board of directors adopted our 2005 Equity Incentive Plan which we refer to as the 2005 Plan, and our stockholders approved our 2005 Plan
in November 2005. No additional awards under our 2005 Plan can be made. However, our 2005 Plan continues to govern the terms and conditions of the outstanding awards previously granted thereunder, which include options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Share Reserve</I>. As of December&nbsp;31, 2019, stock options covering 7,568,326 shares with a weighted-average exercise price of $0.48
per share were outstanding under our 2005 Plan. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Administration</I>. Our board of directors or a committee delegated by our board
of directors administers our 2005 Plan. Subject to the terms of our 2005 Plan, the administrator has the power to, among other things, determine who will be granted awards, to determine the terms and conditions of each awards, to accelerate the
time(s) when an award may vest or be exercised and to construe and interpret the terms of our 2005 Plan and awards granted thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Options. </I>Options granted under our 2005 Plan are subject to terms and conditions generally similar to those described above with
respect to options that may be granted under our 2020 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Changes to Capital Structure</I>. In the event of stock dividend,
extraordinary cash dividend, recapitalization, reorganization, merger, consolidation, <FONT STYLE="white-space:nowrap">split-up,</FONT> <FONT STYLE="white-space:nowrap">spin-off,</FONT> combination, exchange of shares or other transaction affects
the common stock such that an adjustment is required in order to preserve the benefits intended to be provided by the 2005 Plan, the plan administrator shall adjust the number, kind and price of shares covered by each outstanding award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Change in Control</I>. In order to preserve a holder&#146;s rights under an award in the event of a change in control (as defined by the
plan administrator), the plan administrator in its discretion may take one or more of the following actions: (i)&nbsp;provide for the acceleration of any time period relating to the exercise or payment of the award, (ii)&nbsp;provide for payment to
the holder of cash or other property equal to the amount that would have been received upon the exercise or payment of the award had the award been exercised or paid upon the change in control, (iii)&nbsp;adjust the terms of the award in a manner
determined by the plan administrator to reflect the change in control, (iv)&nbsp;cause the award to be assumed, or new rights substituted therefor, by another entity, or (v)&nbsp;make such other provision as the plan administrator may consider
equitable to award holders and in the best interests of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc805799_14"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following includes a summary of transactions since January&nbsp;1, 2017 to which we have been a party in which the amount involved
exceeded or will exceed $120,000, and in which any of our directors, executive officers or, to our knowledge, beneficial owners of more than 5% of our capital stock or any member of the immediate family of any of the foregoing persons had or will
have a direct or indirect material interest, other than equity and other compensation, termination, change in control and other arrangements, which are described under &#147;Executive and Director Compensation.&#148; We also describe below certain
other transactions with our directors, executive officers and stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Promissory Notes </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On March&nbsp;14, 2018, we issued $0.5&nbsp;million in aggregate principal amount of convertible promissory notes to various investors
pursuant to a convertible note purchase agreement. Certain of our officers and/or directors, including Carmichael Roberts, Terrance McGuire, Dennis Dougherty and Guido Neels participated in the convertible notes financing either personally or
through affiliated trusts or funds. Certain holders of 5% or more of our common stock, on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, including entities affiliated with Polaris Venture Partners, entities affiliated with North
Bridge Venture Partners and Intersouth Partners VII, L.P., participated in the convertible notes financing. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock Financings </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Series B Preferred Stock Financing.</I> On June&nbsp;5, 2018, we issued and sold to investors 41,685,292 shares of our Series B preferred
stock at a price per share of $0.30, for aggregate consideration of approximately $12.5&nbsp;million, consisting of approximately $12.0&nbsp;million in cash proceeds plus the conversion of certain convertible notes in an aggregate amount of
approximately $0.5&nbsp;million. On July&nbsp;30, 2018, we issued and sold to investors an additional 16,666,667 shares of our Series B preferred stock for aggregate consideration of approximately $5.0&nbsp;million. On September&nbsp;14, 2018, we
issued and sold to investors an additional 11,666,666 shares of our Series B preferred stock for aggregate consideration of approximately $3.5&nbsp;million. On October&nbsp;12, 2018, we issued and sold to investors an additional 28,333,328 shares of
our Series B preferred stock for aggregate consideration of approximately $8.5&nbsp;million. Certain of our officers and/or directors, including Michael Altman, Carmichael Roberts, Terrance McGuire, Dennis Dougherty and Guido Neels participated in
the Series B preferred stock financing either personally or through affiliated trusts or funds. Certain holders of 5% or more of our common stock, on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, including entities affiliated with
Polaris Venture Partners, entities affiliated with North Bridge Venture Partners, Intersouth Partners VII, L.P., Perceptive Life Sciences Master Fund, Ltd., RA Capital Healthcare Fund, L.P., entities affiliated with ArrowMark Partners and Soleus
Private Equity Fund I, L.P., participated in the Series B preferred stock financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Series C Preferred Stock Financing. </I>At
various closings between January 10, 2020 and January 31, 2020, we issued and sold to investors an aggregate of 78,306,611 shares of our Series C preferred stock at a price per share of $0.38811, for aggregate consideration of approximately $30.4
million. We also issued to such investors warrants to purchase up to an aggregate of 23,491,979 shares of common stock, at an exercise price per share equal to the fair market value of our common stock following January 10, 2020 (as determined by
our board of directors, in good faith, based on the most recent independent third party valuation of our company available following January 10, 2020 performed pursuant to Section 409A of the Internal Revenue Code, and taking into account any
changes to our business between the date of such third party valuation and January 10, 2020). In accordance with such terms, on February 6, 2020, our board of directors determined such fair market value of our common stock to be $0.25 per share.
Certain holders of 5% or more of our common stock, on an as-converted basis, including entities affiliated with Polaris Venture Partners, entities affiliated with North Bridge Venture Partners, Intersouth Partners VII, L.P., entities affiliated with
Perceptive Advisors, LLC, RA Capital Healthcare Fund, L.P., entities affiliated with ArrowMark Partners and Soleus Private Equity Fund I, L.P., participated in the Series C preferred stock financing, including the issuance of the warrants to
purchase common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth the aggregate number of shares of our capital stock
acquired by beneficial owners of more than 5% of our common stock, on an as-converted basis, in the financing transactions described above. Each share of our Series B preferred stock and Series C preferred stock identified in the following table
will convert into one share of common stock immediately prior to the closing of this offering. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Participants</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Series
B<BR>Preferred&nbsp;Stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Series
C<BR>Preferred&nbsp;Stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Warrants&nbsp;to<BR>Purchase<BR>Common&nbsp;Stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5%&nbsp;or&nbsp;Greater&nbsp;Stockholders</B><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Polaris Venture
Partners<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,651,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,061,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">618,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intersouth Partners VII, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,300,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,030,635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">309,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with North Bridge Venture Partners<SUP
STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,651,629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,153,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,545,953</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Perceptive Advisors,
LLC<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,666,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,267,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,580,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RA Capital Healthcare Fund, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,666,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,288,294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">386,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with ArrowMark
Partners<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,666,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,864,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,159,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Soleus Private Equity Fund I, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,666,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,607,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,082,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Additional details regarding these stockholders and their equity holdings are provided in this prospectus under
the caption &#147;Principal Stockholders.&#148; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents securities acquired by (i)&nbsp;Polaris Venture Partners Entrepreneurs&#146; Fund V, L.P., (ii)
Polaris Venture Partners V, L.P., (iii) Polaris Venture Partners Founders&#146; Fund V, L.P. and (iv)&nbsp;Polaris Venture Partners Special Founders&#146; Fund V, L.P. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents securities acquired by (i)&nbsp;North Bridge Venture Partners
<FONT STYLE="white-space:nowrap">V-A,</FONT> L.P., (ii) North Bridge Venture Partners <FONT STYLE="white-space:nowrap">V-B,</FONT> L.P. and (iii)&nbsp;North Bridge Venture Partners VI, L.P. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents securities acquired by (i) Perceptive Life Sciences Master Fund, Ltd. and (ii) Perceptive LS (A),
LLC. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents securities acquired by (i) ArrowMark Fundamental Opportunity Fund, L.P. and (ii) Meridian Small Cap
Growth Fund. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Some of our directors are associated with our principal stockholders as indicated in the table below:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="56%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Director</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Principal&nbsp;Stockholder</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Altman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Entities affiliated with Perceptive Advisors, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Edward Anderson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Entities&nbsp;affiliated&nbsp;with&nbsp;North&nbsp;Bridge&nbsp;Venture&nbsp;Partners</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert S. Langer D.Sc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Entities affiliated with Polaris Venture Partners</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Konstantin Poukalov</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Entities affiliated with Perceptive Advisors, LLC</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Agreements with Arsenal </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In 2011, we entered into a Collaboration Agreement, a Technology License Agreement, a Trademark Coexistence Agreement and a Transition
Services Agreement with Arsenal Medical, Inc., or Arsenal, a company in which certain of our principal stockholders are stockholders. During the year ended December 31, 2017 and 2018, we invoiced Arsenal for an aggregate of approximately
$2.1&nbsp;million and $1.2 million, respectively, for various costs and other obligations under these agreements. In October 2018, we entered an Acknowledgment and Release Agreement with Arsenal with respect to the expiration of the Collaboration
Agreement and certain other intellectual property matters. In November 2019, we entered into an amendment to the Acknowledgement and Release Agreement, which clarifies our and Arsenal&#146;s rights to each of our and Arsenal&#146;s respective
patents and patent applications, including patents and patent applications existing as of the effective date of the Collaboration Agreement, the Technology License Agreement, the Trademark Coexistence Agreement and the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Transition Services Agreement. The amendment to the Acknowledgment and Release Agreement also provides for a mutual release of all claims arising under such patents and patent applications. The
Technology License Agreement is a non-exclusive in-license agreement covering certain intellectual property regarding in situ forming foam and nanofiber, which is unrelated to our current and future expected product candidates. The Technology
License Agreement provides for no future payments by us and remains in effect. In addition, the Trademark Coexistence Agreement relates to certain trademarks around our previous corporate name, which we no longer use. Finally, the Transition
Services Agreement expired in June 2019. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Rights Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We entered into an Eighth Amended and Restated Investor Rights Agreement in January 2020 with the holders of our preferred stock, including
entities with which certain of our directors are related. The agreement provides for certain rights relating to the registration of such holders&#146; common stock, including shares issuable upon conversion of preferred stock, and a right of first
refusal to purchase future securities sold by us. See &#147;Description of Capital Stock&#151;Registration Rights&#148; for additional information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Agreement </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We entered into a
Ninth Amended and Restated Stockholders&#146; Voting Agreement by and among us and certain of our stockholders, pursuant to which the following directors were elected to serve as members on our board of directors and, as of the date of this
prospectus, continue to so serve: Maria Palasis, Ph.D., Michael Altman, Edward Anderson, Robert S. Langer and Konstantin Poukalov. Ms.&nbsp;Palasis was selected to serve on our board of directors in her capacity as our chief executive officer.
Messrs. Altman, Anderson Langer and Poukalov were selected to serve on our board of directors as representatives of holders of our preferred stock. Messrs.&nbsp;Altman and Poukalov were designated by entities affiliated with Perceptive Advisors,
LLC. Messrs.&nbsp;Anderson and Langer were designated by entities affiliated with North Bridge Venture Partners and entities affiliated with Polaris Venture Partners, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The voting agreement will terminate upon the closing of this offering, and members previously elected to our board of directors pursuant to
this agreement will continue to serve as directors until they resign, are removed or their successors are duly elected by the holders of our common stock. The composition of our board of directors after this offering is described in more detail
under &#147;Management&#151;Board Composition and Election of Directors.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Agreements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have entered into employment agreements with our named executive officers. For more information regarding the agreements with our named
executive officers, see &#147;Executive and Director Compensation&#151;Executive Compensation Arrangements.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We intend to enter into indemnification agreements with each of our directors and executive officers. These agreements, among other things,
require us or will require us to indemnify each director (and in certain cases their related venture capital funds) and executive officer to the fullest extent permitted by Delaware law, including indemnification of expenses such as attorneys&#146;
fees, judgments, fines and settlement amounts incurred by the director or executive officer in any action or proceeding, including any action or proceeding by or in right of us, arising out of the person&#146;s services as a director or executive
officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Option Grants to Executive Officers and Directors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have granted stock options to our executive officers and certain of our directors as more fully described in the section entitled
&#147;Executive and Director Compensation.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policies and Procedures for Related Person Transactions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our board of directors has adopted a written related person transaction policy, to be effective upon the closing of this offering, setting
forth the policies and procedures for the review and approval or ratification of related person transactions. This policy will cover, with certain exceptions set forth in Item 404 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the
Securities Act, any transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we were or are to be a participant, where the amount involved exceeds $120,000 in any fiscal year and a
related person had, has or will have a direct or indirect material interest, including without limitation, purchases of goods or services by or from the related person or entities in which the related person has a material interest, indebtedness,
guarantees of indebtedness and employment by us of a related person. In reviewing and approving any such transactions, our audit committee is tasked to consider all relevant facts and circumstances, including, but not limited to, whether the
transaction is on terms comparable to those that could be obtained in an arm&#146;s length transaction and the extent of the related person&#146;s interest in the transaction. All of the transactions described in this section occurred prior to the
adoption of this policy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc805799_15"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth information with respect to the beneficial ownership of our common stock, as of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 by: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person or group of affiliated persons known by us to beneficially own more than 5% of our common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our named executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our executive officers and directors as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The number of shares beneficially owned by each stockholder is determined under rules issued by the Securities and Exchange Commission. Under
these rules, beneficial ownership includes any shares as to which the individual or entity has sole or shared voting power or investment power. Applicable percentage ownership is based on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock outstanding as of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, assuming the conversion of all outstanding shares of preferred stock into common stock. In computing the number of shares
beneficially owned by an individual or entity and the percentage ownership of that person, shares of common stock subject to options, warrants or other rights held by such person that are currently exercisable or will become exercisable within 60
days of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 are considered outstanding, although these shares are not considered outstanding for purposes of computing the
percentage ownership of any other person. Unless noted otherwise, the address of all listed stockholders is 480 Arsenal Way, Watertown, MA 02472. Each of the stockholders listed has sole voting and investment power with respect to the shares
beneficially owned by the stockholder unless noted otherwise, subject to community property laws where applicable. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Shares&nbsp;Beneficially&nbsp;Owned<BR>Prior&nbsp;to&nbsp;Offering</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Shares&nbsp;Beneficially&nbsp;Owned<BR>After&nbsp;Offering</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name&nbsp;of&nbsp;Beneficial&nbsp;Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Percentage</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Percentage</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>5% or Greater Stockholders</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with Polaris Venture
Partners<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intersouth Partners VII, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with North Bridge Venture Partners<SUP
STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with Perceptive Advisors,
LLC<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RA Capital Healthcare Fund, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with ArrowMark
Partners<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Soleus Private Equity Fund I,
L.P.<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Named Executive Officers and Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Maria Palasis, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R. Don Elsey<SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laura Edgerly-Pflug<SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Edward Anderson<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Altman<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert S. Langer D.Sc.<SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">C. Ann Merrifield<SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">George Whitesides, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">W. Bradford Smith<SUP STYLE="font-size:85%; vertical-align:top">(14)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Konstantin Poukalov<SUP STYLE="font-size:85%; vertical-align:top">(15)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All executive officers and directors as a group (12 persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than 1%. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock issuable upon conversion of shares of convertible preferred stock held by Polaris Venture Partners IV, L.P. (&#147;PVP IV&#148;);
(ii) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock issuable upon conversion of shares of convertible preferred stock held by Polaris Venture Partners Entrepreneurs&#146; Fund
IV, L.P. (&#147;PVPEF IV&#148; and, together with PVP IV, the &#147;Polaris IV Funds&#148;); (iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock issuable upon conversion
of shares of convertible preferred stock held by Polaris Venture Partners V, L.P. (&#147;PVP V&#148;); (iv) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock issuable upon
conversion of shares of convertible preferred stock held by Polaris Venture Partners Entrepreneurs&#146; Fund V, L.P. (&#147;PVPEF V&#148;); (v) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares
of common stock issuable upon conversion of shares of convertible preferred stock held by Polaris Venture Partners Founders&#146; Fund V, L.P. (&#147;PVPFF V&#148;); and
(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock issuable upon conversion of shares of convertible preferred stock held by Polaris Venture Partners Special
Founders&#146; Fund V, L.P. (&#147;PVPSFF V,&#148; and together with PVP V, PVPEF V and PVPFF V, the &#147;Polaris V Funds&#148; and the Polaris V Funds, together with the Polaris IV Funds, the &#147;Polaris Funds&#148;). Polaris Venture Management
Co., IV, L.L.C. (&#147;PVM IV&#148;) is the sole general partner of each of the Polaris IV Funds and may be deemed to have sole voting and dispositive power with respect to the shares held by each of the Polaris IV Funds. Polaris Venture Management
Co. V, L.L.C. (&#147;PVM V&#148;) is the sole general partner of each of the Polaris V Funds and may be deemed to have sole voting and dispositive power with respect to the shares held by each of the Polaris V Funds. Jonathan A. Flint and Terrance
G. McGuire are the managing members of each of PVM V and PVM IV. Each of Messrs. Flint and McGuire, as managing members of each of PVM V and PVM IV, may be deemed to have shared voting and dispositive power with respect to the shares held by each of
the Polaris Funds. Each of PVM IV, PVM V and Messrs. Flint and McGuire expressly disclaim beneficial ownership of the shares held by the each of the Polaris Funds, except to the extent of their respective pecuniary interests therein, if any. The
mailing address of the individuals and entities listed above is One Marina Park Drive, 10th Floor, Boston, MA 02210. </P></TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of common stock issuable upon conversion of shares of convertible preferred stock held by Intersouth Partners VII, L.P. (&#147;ISP VII&#148;), which shares are indirectly held by Intersouth Associates VII, LLC (&#147;ISA VII&#148;), as
general partner of ISP VII, and each of the individual managing members of ISA VII. The individual managing members of ISA VI and ISA VII are Mitch Mumma and Dennis Dougherty. Member Managers may share voting and dispositive power over the shares
directly held by such entities. The mailing address of the individuals and entities listed above is 4711 Hope Valley Road, Suite <FONT STYLE="white-space:nowrap">4F-632,</FONT> Durham NC 27707. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of
(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock issuable upon conversion of shares of convertible preferred stock held by North Bridge Venture Partners <FONT
STYLE="white-space:nowrap">V-A,</FONT> L.P. (&#147;NBVP <FONT STYLE="white-space:nowrap">V-A&#148;),</FONT> (ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock
issuable upon conversion of shares of convertible preferred stock held by North Bridge Venture Partners <FONT STYLE="white-space:nowrap">V-B,</FONT> L.P. (&#147;NBVP <FONT STYLE="white-space:nowrap">V-B&#148;)</FONT> and
(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock issuable upon conversion of shares of convertible preferred stock held by North Bridge Venture Partners VI, L.P.
(&#147;NBVP VI&#148;). North Bridge Venture Management V, L.P. (&#147;NBVM V&#148;), is the sole General Partner of NBVP <FONT STYLE="white-space:nowrap">V-A</FONT> and NBVP <FONT STYLE="white-space:nowrap">V-B.</FONT> NBVM GP, LLC, the General
Partner of NBVM V, has ultimate voting and dispositive power over the shares held of record by NBVP VA and NBVP <FONT STYLE="white-space:nowrap">V-B.</FONT> Shared voting and dispositive power of such shares are vested in Edward&nbsp;T. Anderson and
Richard&nbsp;A. D&#146;Amore. Mr.&nbsp;Anderson, a member of our board of directors and a manager of NBVM GP, LLC, disclaims beneficial ownership over such shares, except to the extent of his pecuniary interest therein. North Bridge Venture
Management VI, L.P. (&#147;NBVM VI&#148;), is the sole General Partner of NBVP VI. NBVM GP, LLC, the General Partner of NBVM VI, has ultimate voting and dispositive power over the shares held of record by NBVP VI. Shared voting and dispositive power
of such shares are vested in Edward&nbsp;T. Anderson and Richard&nbsp;A. D&#146;Amore. Mr.&nbsp;Anderson, a member of our board of directors and a manager of NBVM GP, LLC, disclaims beneficial ownership over such shares, except to the extent of his
pecuniary interest therein. The address of all entities affiliated with North Bridge Venture Partners is 60&nbsp;William Street, Suite&nbsp;350, Wellesley, MA 02481. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of common stock issuable upon conversion of shares of convertible preferred stock held by Perceptive Life Sciences Master Fund, Ltd. (&#147;Perceptive Life&#148;) and (ii)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
shares of common stock issuable upon conversion of shares of convertible preferred stock held by Perceptive LS (A), LLC (&#147;Perceptive LS&#148;). Perceptive Advisors, LLC serves as the
investment advisor to Perceptive Life. Perceptive LS GP, LLC is the manager of Perceptive LS. Joseph Edelman is the managing member of Perceptive Advisors, LLC and the sole member of Perceptive LS GP, LLC. Michael Altman and Konstantin Poukalov, two
of our directors, are Managing Directors at Perceptive Advisors, LLC. The address of Perceptive Life and Perceptive LS is c/o Perceptive Advisors, LLC, 51 Astor Place, 10th Floor, New York, New York 10003. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of common stock issuable upon conversion of shares of convertible preferred stock held by RA Capital Healthcare Fund, L.P. (&#147;RA Capital&#148;). RA Capital Management, L.P., is the investment advisor (&#147;Adviser&#148;) of RA Capital
and RA Capital Management GP, LLC (&#147;Adviser GP&#148;) is the general partner of the Adviser. Dr. Kolchinsky and Rajeev Shah are the controlling persons of the Adviser GP. The Adviser, Dr. Kolchinsky, and Mr. Shah may be deemed to beneficially
own the shares held by RA Capital. The address of RA Capital is c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston, Massachusetts 02116. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock
issuable upon conversion of shares of convertible preferred stock held by Meridian Small Cap Growth Fund (&#147;Meridian&#148;) and (ii) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock issuable upon
conversion of shares of convertible preferred stock held by ArrowMark Fundamental Opportunity Fund, L.P. (&#147;ArrowMark&#148; and, together with Meridian, the &#147;ArrowMark Funds&#148;). ArrowMark Partners GP, LLC (&#147;ArrowMark GP&#148;) is
the general partner of ArrowMark and David Corkins is the managing member of ArrowMark GP. ArrowMark Colorado Holdings LLC (ArrowMark Colorado) is investment advisor to ArrowMark Funds. Mr. Corkins is a managing member of ArrowMark Colorado and Tony
Yao is a portfolio manager of ArrowMark Colorado. Mr. Corkins and Mr. Yao may be considered the beneficial owners of the shares held by the ArrowMark Funds and each disclaim beneficial ownership of such shares, except to the extent of any pecuniary
interest therein. The address of the ArrowMark Funds is 100 Fillmore Street, Suite 325, Denver, Colorado 80206. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares held by Soleus
Private Equity Fund I, L.P. (&#147;Soleus PE&#148;). Soleus Private Equity GP I, LLC (&#147;Soleus GP&#148;) is the general partner of Soleus PE. Soleus GP holds voting and dispositive power over the shares held by Soleus PE. The address of Soleus
PE is 104 Field Point Road, Second Floor, Greenwich CT 06830. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares which are exercisable within 60 days of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares which are exercisable within 60 days of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares which are exercisable within 60 days of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares which are exercisable within 60 days of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares which are exercisable within 60 days of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares which are exercisable within 60 days of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares which are exercisable within 60 days of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares which are exercisable within 60 days of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc805799_16"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following description
summarizes some of the terms of our amended and restated certificate of incorporation and amended and restated bylaws that will become effective upon the closing of this offering, of the Seventh Amended and Restated Investor Rights Agreement, or
investor rights agreement, and of the General Corporation Law of the State of Delaware. Because it is only a summary, it does not contain all the information that may be important to you. For a complete description, you should refer to our amended
and restated certificate of incorporation, amended and restated bylaws and investor rights agreement, copies of which have been or will be filed as exhibits to the registration statement of which this prospectus is a part, as well as the relevant
provisions of the General Corporation Law of the State of Delaware. The description of our common stock and preferred stock reflects changes to our capital structure that will occur immediately prior the closing of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Following the closing of this offering, our authorized capital stock will consist of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock, par value $0.001 per share, and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of preferred stock, par value $0.001 per share. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, there were &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock
outstanding and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock issuable upon the automatic conversion of all outstanding shares of our preferred stock in connection with
this offering, held of record by &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Holders of our common
stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. An election of directors by our stockholders shall be determined by a plurality of the votes cast by the
stockholders entitled to vote on the election. Subject to the supermajority votes for some matters, other matters shall be decided by the affirmative vote of our stockholders having a majority in voting power of the votes cast by the stockholders
present or represented and voting on such matter. Our amended and restated certificate of incorporation and amended and restated bylaws also provide that our directors may be removed only for cause and only by the affirmative vote of the holders of
at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> in voting power of the outstanding shares of capital stock entitled to vote thereon. In addition, the affirmative vote of the holders of at least
<FONT STYLE="white-space:nowrap">two-thirds</FONT> in voting power of the outstanding shares of capital stock entitled to vote thereon is required to amend or repeal, or to adopt any provision inconsistent with, several of the provisions of our
amended and restated certificate of incorporation. See below under &#147;&#151;Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws&#151;Amendment of Charter Provisions.&#148; Holders of common stock are entitled to
receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of any series of preferred stock that we may designate and issue in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the event of our liquidation or dissolution, the holders of common stock are entitled to receive proportionately our net assets available
for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Holders of common stock have no preemptive, subscription, redemption or conversion rights. Our
outstanding shares of common stock are, and the shares offered by us in this offering will be, when issued and paid for, validly issued, fully paid and nonassessable. The rights, preferences and privileges of holders of common stock are subject to
and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the terms of our
amended and restated certificate of incorporation that will become effective upon the closing of this offering, our board of directors is authorized to direct us to issue shares of preferred stock in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
one or more series without stockholder approval. Our board of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend
rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The purpose of
authorizing our board of directors to issue preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in
connection with possible acquisitions, future financings and other corporate purposes, could have the effect of making it more difficult for a third party to acquire, or could discourage a third party from seeking to acquire, a majority of our
outstanding voting stock. Upon the closing of this offering, there will be no shares of preferred stock outstanding, and we have no present plans to issue any shares of preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Options </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, options to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock were
outstanding under our 2005 Plan (of which &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares were vested and exercisable as of such date) and options to purchase
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock were outstanding under our 2016 Plan (of which
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares were vested and exercisable as of such date). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrants </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, warrants to purchase an aggregate total of 23,491,979 shares of our common stock were outstanding. Pursuant to the terms
thereof, these warrants were to have an exercise price per share equal to the fair market value of our common stock following January 10, 2020 (as determined by our board of directors, in good faith, based on the most recent independent third party
valuation of our company available following January 10, 2020 performed pursuant to Section 409A of the Internal Revenue Code, and taking into account any changes to our business between the date of such third party valuation and January 10, 2020).
In accordance with such terms, on February 6, 2020, our board of directors determined such fair market value of our common stock to be $0.25 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">These warrants are exercisable immediately and expire on the earlier to occur of January 10, 2030, immediately prior to the closing of an
initial public offering of shares of our common stock and the close of certain other liquidation transactions. Unless earlier exercised, these warrants will be automatically exercised, on a cashless basis, immediately prior to, and contingent upon,
the closing of this offering, so long as the initial public offering price of our common stock exceeds the exercise price of the warrants. In the event the initial public offering price of our common stock would be less than the exercise price of
the warrants, then the warrants will expire immediately prior to the closing of this offering. Based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range set
forth on the cover of this prospectus, the warrants would be exercised, on a cashless basis, for &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock immediately prior to the closing of this offering. A
$1.00 increase or decrease in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range set forth on the cover page of this prospectus, would, in case of an increase,
increase the number of shares of common stock issuable by &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares and, in case of a decrease, decrease the number of shares of common stock issuable by
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares, upon the automatic exercise, on a cashless basis, of the warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Holders of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock are entitled to certain rights with respect to the registration of such shares for public resale under the Securities Act,
pursuant to an amended and restated investor rights agreement by and among us and certain of our stockholders, until the rights otherwise terminate pursuant to the terms of the investor rights agreement. The registration of shares of common stock as
a result of the following rights being exercised would enable holders to trade these shares without restriction under the Securities Act when the applicable registration statement is declared effective. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Form <FONT STYLE="white-space:nowrap">S-1</FONT> Registration Rights </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If at any time after the earlier of (i)&nbsp;January&nbsp;10, 2025 or (ii)&nbsp;the date that is six months after the closing date of this
offering, the holders of at least 30% of the registrable securities then outstanding request in writing that we effect a registration with respect to all or part of such registrable securities then outstanding having an anticipated aggregate
offering price that would exceed $5,000,000, we may be required to register their shares. We are obligated to effect at most two registrations in response to these demand registration rights. If the holders requesting registration intend to
distribute their shares by means of an underwriting, the managing underwriter of such offering will have the right to limit the numbers of shares to be underwritten for reasons related to the marketing of the shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Piggyback Registration Rights </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If
at any time after this offering, we propose to register any shares of our common stock under the Securities Act, subject to certain exceptions, the holders of registrable securities then outstanding will be entitled to notice of the registration and
to include their shares of registrable securities in the registration. If our proposed registration involves an underwriting, the managing underwriter of such offering will have the right to limit the number of shares to be underwritten for reasons
related to the marketing of the shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Form <FONT STYLE="white-space:nowrap">S-3</FONT> Registration Rights </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If, at any time after we become entitled under the Securities Act to register our shares on a registration statement on Form <FONT
STYLE="white-space:nowrap">S-3,</FONT> the holders of the registrable securities then outstanding request in writing that we effect a registration with respect to all or part of such registrable securities having an anticipated aggregate offering
price to the public in the offering of at least $2,000,000, we will be required to effect such registration; provided, however, that we will not be required to effect such a registration if, within any twelve month period, we have already effected
two registrations on Form <FONT STYLE="white-space:nowrap">S-3</FONT> for the holders of registrable securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expenses and Indemnification
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Ordinarily, other than underwriting discounts and commissions, we will be required to pay all expenses incurred by us related to
any registration effected pursuant to the exercise of these registration rights. These expenses may include all registration and filing fees, printing expenses, fees and disbursements of our counsel, reasonable fees and disbursements of a counsel
for the selling securityholders and blue sky fees and expenses. Additionally, we have agreed to indemnify selling stockholders for damages, and any legal or other expenses reasonably incurred, arising from or based upon any untrue statement of a
material fact contained in any registration statement, an omission or alleged omission to state a material fact in any registration statement or necessary to make the statements therein not misleading, or any violation or alleged violation by the
indemnifying party of securities laws, subject to certain exceptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Termination of Registration Rights </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The registration rights terminate upon the earlier of the date that is five years after the closing of this offering, the date on which no
stockholder holds any registrable securities, the closing of a company sale, as defined in the investor rights agreement, or at such time as SEC Rule&nbsp;144 or another similar exemption under the Securities Act is available for the sale of all of
a stockholder&#146;s shares without limitation during a three-month period without registration. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of Delaware Law and Our
Certificate of Incorporation and Bylaws </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Some provisions of Delaware law, our restated certificate of incorporation and our restated
bylaws could make the following transactions more difficult: an acquisition of us by means of a tender offer; an acquisition of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
us by means of a proxy contest or otherwise; or the removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter
transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions which provide for payment of a premium over the market price for our shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">These provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are
also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of the increased protection of our potential ability to negotiate with the proponent of an unfriendly or
unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Undesignated Preferred Stock </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
ability of our board of directors, without action by the stockholders, to issue up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of undesignated preferred stock with voting or other rights
or preferences as designated by our board of directors could impede the success of any attempt to change control of us. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of our
company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stockholder Meetings </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our restated bylaws provide that a special meeting of stockholders may be called only by our chairman of the board, chief executive officer or
president (in the absence of a chief executive officer), or by a resolution adopted by a majority of our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Requirements for
Advance Notification of Stockholder Nominations and Proposals </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our restated bylaws establish advance notice procedures with
respect to stockholder proposals to be brought before a stockholder meeting and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of
directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Elimination of Stockholder Action by Written Consent </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our restated certificate of incorporation eliminates the right of stockholders to act by written consent without a meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Staggered Board </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our board of
directors is divided into three classes. The directors in each class will serve for a three-year term, one class being elected each year by our stockholders. For more information on the classified board, see &#147;Management&#151;Board Composition
and Election of Directors.&#148; This system of electing and removing directors may tend to discourage a third-party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for
stockholders to replace a majority of the directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Removal of Directors </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our restated certificate of incorporation provides that no member of our board of directors may be removed from office by our stockholders
except for cause and, in addition to any other vote required by law, upon the approval of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> in voting power of the outstanding shares of stock entitled to vote in the election
of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stockholders Not Entitled to Cumulative Voting </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our restated certificate of incorporation does not permit stockholders to cumulate their votes in the election of directors. Accordingly, the
holders of a majority of the outstanding shares of our common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they choose, other than any directors that holders of our preferred stock may
be entitled to elect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delaware Anti-Takeover Statute </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are subject to Section&nbsp;203 of the General Corporation Law of the State of Delaware, which prohibits persons deemed to be
&#147;interested stockholders&#148; from engaging in a &#147;business combination&#148; with a publicly held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or
the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#147;interested stockholder&#148; is a person who, together with affiliates and
associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#146;s voting stock. Generally, a &#147;business combination&#148; includes a merger, asset or stock sale, or
other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Choice of Forum </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our restated
certificate of incorporation provides that, unless we consent in writing to the selection of an alternative form, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for: (1)&nbsp;any derivative action or proceeding
brought on our behalf; (2)&nbsp;any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders; (3)&nbsp;any action asserting a claim against us arising
pursuant to any provision of the General Corporation Law of the State of Delaware or our certificate of incorporation or bylaws; (4)&nbsp;any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or
bylaws; or (5)&nbsp;any action asserting a claim governed by the internal affairs doctrine. Under our amended and restated certificate of incorporation, this exclusive forum provision will not apply to claims which are vested in the exclusive
jurisdiction of a court or forum other than the Court of Chancery of the State of Delaware, or for which the Court of Chancery of the State of Delaware does not have subject matter jurisdiction. For instance, the provision would not apply to actions
arising under federal securities laws, including suits brought to enforce any liability or duty created by the Securities Act, Exchange Act, or the rules and regulations thereunder. Our restated certificate of incorporation also provides that any
person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to this choice of forum provision. It is possible that a court of law could rule that the choice of
forum provision contained in our restated certificate of incorporation is inapplicable or unenforceable if it is challenged in a proceeding or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendment of Charter Provisions </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The amendment of any of the above provisions, except for the provision making it possible for our board of directors to issue preferred stock
and the provision prohibiting cumulative voting, would require approval by holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> in voting power of the outstanding shares of stock entitled to vote thereon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The provisions of Delaware law, our restated certificate of incorporation and our restated bylaws could have the effect of discouraging others
from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the
effect of preventing changes in the composition of our board and management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock will be
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Exchange Listing </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have applied to have our common stock listed on The Nasdaq Global Market under the symbol &#147;LYRA.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc805799_17"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Immediately prior to this offering, there was no public market for our common stock. Future sales of substantial amounts of common stock in
the public market, or the perception that such sales may occur, could adversely affect the market price of our common stock. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon the
closing of this offering, we will have outstanding an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock, assuming the issuance of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock offered by us in this offering, the automatic conversion of all outstanding shares of our preferred stock into
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock, the automatic cashless exercise of outstanding warrants to purchase
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock, which, based on an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range set forth on the cover of this prospectus, would result in the issuance of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock upon the closing of this offering and no exercise of options after
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020. Of these shares, all shares sold in this offering will be freely tradable without restriction or further registration under the Securities Act,
except for any shares purchased by our &#147;affiliates,&#148; as that term is defined in Rule 144 under the Securities Act, whose sales would be subject to the Rule 144 resale restrictions described below, other than the holding period requirement.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The remaining &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common
stock will be &#147;restricted securities,&#148; as that term is defined in Rule 144 under the Securities Act. These restricted securities are eligible for public sale only if they are registered under the Securities Act or if they qualify for an
exemption from registration under Rules 144 or 701 under the Securities Act, which are summarized below. We expect that substantially all of these shares will be subject to the <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT
STYLE="white-space:nowrap">lock-up</FONT> period under the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below. Upon expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, we estimate that approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares will be available for sale in the public market, subject in some cases to applicable volume limitations under Rule 144. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, of the &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common
stock that were subject to stock options outstanding as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, options to purchase
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock were vested as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 and,
upon exercise, these shares will be eligible for sale subject to the lock&#150;up agreements described below and Rules 144 and 701 under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We and each of our directors and executive officers and holders of substantially all of our outstanding capital stock, have agreed that,
without the prior written consent of BofA Securities, Inc. and Jefferies LLC, we and they will not, subject to certain exceptions, during the period ending 180 days after the date of this prospectus, offer, pledge, sell, contract to sell, sell any
option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of our common stock or any securities convertible
into or exercisable or exchangeable for common stock; or enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of our common stock, whether any transaction described
above is to be settled by delivery of our common stock or such other securities, in cash or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon the expiration of the
applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> periods, substantially all of the shares subject to such <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions will become eligible for sale, subject to the limitations discussed
above. For a further description of these <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, please see &#147;Underwriting.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 144
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Affiliate Resales of Restricted Securities </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In general, beginning 90 days after the effective date of the registration statement of which this prospectus is a part, a person who is an
affiliate of ours, or who was an affiliate at any time during the 90 days </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
before a sale, who has beneficially owned shares of our common stock for at least six months would be entitled to sell in &#147;broker&#146;s transactions&#148; or certain &#147;riskless
principal transactions&#148; or to market makers, a number of shares within any three-month period that does not exceed the greater of: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1% of the number of shares of our common stock then outstanding, which will equal approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares immediately after this offering; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly trading volume in our common stock on The Nasdaq Global Market during the four calendar weeks
preceding the filing of a notice on Form 144 with respect to such sale. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Affiliate resales under Rule 144 are also
subject to the availability of current public information about us. In addition, if the number of shares being sold under Rule 144 by an affiliate during any three-month period exceeds 5,000 shares or has an aggregate sale price in excess of
$50,000, the seller must file a notice on Form 144 with the Securities and Exchange Commission and Nasdaq concurrently with either the placing of a sale order with the broker or the execution directly with a market maker. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Affiliate</FONT> Resales of Restricted Securities </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In general, beginning 90 days after the effective date of the registration statement of which this prospectus is a part, a person who is not
an affiliate of ours at the time of sale, and has not been an affiliate at any time during the three months preceding a sale, and who has beneficially owned shares of our common stock for at least six months but less than a year, is entitled to sell
such shares subject only to the availability of current public information about us. If such person has held our shares for at least one year, such person can resell under Rule 144(b)(1) without regard to any Rule 144 restrictions, including the <FONT
STYLE="white-space:nowrap">90-day</FONT> public company requirement and the current public information requirement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">Non-affiliate</FONT> resales are not subject to the manner of sale, volume limitation or notice filing provisions of Rule 144. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 701 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In general, under Rule 701,
any of an issuer&#146;s employees, directors, officers, consultants or advisors who purchases shares from the issuer in connection with a compensatory stock or option plan or other written agreement before the effective date of a registration
statement under the Securities Act is entitled to sell such shares 90 days after such effective date in reliance on Rule 144. An affiliate of the issuer can resell shares in reliance on Rule 144 without having to comply with the holding period
requirement, and <FONT STYLE="white-space:nowrap">non-affiliates</FONT> of the issuer can resell shares in reliance on Rule 144 without having to comply with the current public information and holding period requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Securities and Exchange Commission has indicated that Rule 701 will apply to typical stock options granted by an issuer before it becomes
subject to the reporting requirements of the Exchange Act, along with the shares acquired upon exercise of such options, including exercises after an issuer becomes subject to the reporting requirements of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Plans </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We intend to file one or
more registration statements on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Securities Act to register all shares of common stock subject to outstanding stock options and common stock issued or issuable under our stock plans. We
expect to file the registration statement covering shares offered pursuant to our stock plans shortly after the date of this prospectus, permitting the resale of such shares by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> in the public
market without restriction under the Securities Act and the sale by affiliates in the public market, subject to compliance with the resale provisions of Rule 144. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon the closing of this offering, the holders of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock, which includes all of the shares of common stock issuable upon the automatic conversion of our preferred stock upon the closing
of this offering, or their transferees will be entitled to various rights with respect to the registration of these shares under the Securities Act. Registration of these shares under the Securities Act would result in these shares becoming fully
tradable without restriction under the Securities Act immediately upon the effectiveness of the registration, except for shares purchased by affiliates. See &#147;Description of Capital Stock&#151;Registration Rights&#148; for additional
information. Shares covered by a registration statement will be eligible for sale in the public market upon the expiration or release from the terms of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement described above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc805799_18"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following discussion is a summary of the material U.S. federal income tax
consequences to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders (as defined below) of the purchase, ownership and disposition of our common stock issued pursuant to this offering, but does not purport to be a complete analysis of all
potential tax effects. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws are not discussed. This discussion is based on the U.S.
Internal Revenue Code of 1986, as amended, or the Code, Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the U.S. Internal Revenue Service, or the IRS, in each case in effect
as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of our common stock. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary
position to that discussed below regarding the tax consequences of the purchase, ownership and disposition of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This
discussion is limited to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders that hold our common stock as a &#147;capital asset&#148; within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). This
discussion does not address all U.S. federal income tax consequences relevant to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s particular circumstances, including the impact of the Medicare contribution tax on net investment
income. In addition, it does not address consequences relevant to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders subject to special rules, including, without limitation: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. expatriates and certain former citizens or long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons subject to the alternative minimum tax; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding our common stock as part of a hedge, straddle or other risk reduction strategy or as part of a
conversion transaction or other integrated investment; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">banks, insurance companies, and other financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">brokers, dealers or traders in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies,&#148; and corporations
that accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and
investors therein); </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations or governmental organizations;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons deemed to sell our common stock under the constructive sale provisions of the Code;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons for whom our common stock constitutes &#147;qualified small business stock&#148; within the meaning of
Section&nbsp;1202 of the Code; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who hold or receive our common stock pursuant to the exercise of any employee stock option or otherwise
as compensation; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;qualified foreign pension funds&#148; as defined in Section&nbsp;897(l)(2) of the Code and entities all of
the interests of which are held by qualified foreign pension funds. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If an entity or arrangement treated as a partnership for U.S. federal income tax purposes
holds our common stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level. Accordingly, partnerships holding our common
stock and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. INVESTORS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE
APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF
ANY STATE, LOCAL OR <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Definition
of a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, a
<FONT STYLE="white-space:nowrap">&#147;Non-U.S.</FONT> Holder&#148; is any beneficial owner of our common stock that is neither a &#147;U.S. person&#148; nor an entity treated as a partnership for U.S. federal income tax purposes. A U.S. person is
any person that, for U.S. federal income tax purposes, is or is treated as any of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation created or organized under the laws of the United States, any state thereof, or the District of
Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust that (1)&nbsp;is subject to the primary supervision of a U.S. court and the control of one or more
&#147;United States persons&#148; (within the meaning of Section&nbsp;7701(a)(30) of the Code), or (2)&nbsp;has a valid election in effect to be treated as a United States person for U.S. federal income tax purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Distributions </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As described in
the section entitled &#147;Dividend Policy,&#148; we do not anticipate declaring or paying dividends to holders of our common stock in the foreseeable future. However, if we do make distributions of cash or property on our common stock, such
distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S.
federal income tax purposes will constitute a return of capital and first be applied against and reduce a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s adjusted tax basis in its common stock, but not below zero. Any excess will be
treated as capital gain and will be treated as described below under &#147;&#151;Sale or Other Taxable Disposition.&#148; Because we may not know the extent to which a distribution is a dividend for U.S. federal income tax purposes at the time it is
made, for purposes of the withholding rules discussed below we or the applicable withholding agent may treat the entire distribution as a dividend. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Subject to the discussion below on effectively connected income, dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder
of our common stock will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends (or such lower rate specified by an applicable income tax treaty, provided the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Holder furnishes a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or other applicable documentation) certifying qualification for the lower
treaty rate). A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that does not timely furnish the required documentation, but that qualifies for a reduced treaty rate, may obtain a refund of any excess amounts withheld by timely filing an
appropriate claim for refund with the IRS. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding their entitlement to benefits under any applicable income tax treaty. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder are
effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a permanent establishment in the United States to which such dividends are attributable), the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be exempt from the U.S.
federal withholding tax described above. To claim the exemption, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder must furnish to the applicable withholding agent a valid IRS Form <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> certifying
that the dividends are effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any such effectively connected dividends will be subject to U.S. federal income tax on a net income basis at the regular graduated rates. A <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on such effectively connected dividends, as
adjusted for certain items. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding any applicable tax treaties that may provide for different rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sale or Other Taxable Disposition </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will not be subject to U.S. federal income tax on any gain realized upon the sale or
other taxable disposition of our common stock unless: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct
of a trade or business within the United States (and, if required by an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a permanent establishment in the United States to which such gain is
attributable); </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a nonresident alien individual present in the
United States for 183 days or more during the taxable year of the disposition and certain other requirements are met; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our common stock constitutes a U.S. real property interest, or USRPI, by reason of our status as a U.S. real
property holding corporation, or USRPHC, for U.S. federal income tax purposes. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Gain described in the first bullet point
above generally will be subject to U.S. federal income tax on a net income basis at the regular graduated rates. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may be subject to a branch profits tax at a rate of
30% (or such lower rate specified by an applicable income tax treaty) on such effectively connected gain, as adjusted for certain items. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Gain described in the second bullet point above will be subject to U.S. federal income tax at a rate of 30% (or such lower rate specified by
an applicable income tax treaty), which may be offset by U.S. source capital losses of the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder (even though the individual is not considered a resident of the United States), provided the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder has timely filed U.S. federal income tax returns with respect to such losses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">With
respect to the third bullet point above, we believe we currently are not, and do not anticipate becoming, a USRPHC. Because the determination of whether we are a USRPHC depends, however, on the fair market value of our USRPIs relative to the fair
market value of our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> real property interests and our other business assets, there can be no assurance we currently are not a USRPHC or will not become one in the future. Even if we are or were to
become a USRPHC, gain arising from the sale or other taxable disposition by a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of our common stock will not be subject to U.S. federal income tax if our common stock is &#147;regularly
traded,&#148; as defined by applicable Treasury Regulations, on an established securities market, and such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder owned, actually and constructively, 5% or less of our common stock throughout the
shorter of the five-year period ending on the date of the sale or other taxable disposition or the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s holding period. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders are encouraged
to consult their tax advisors regarding the possible consequences to them if we are, or were to become, a USRPHC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding potentially applicable income tax treaties that may provide for different rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Information Reporting and Backup Withholding </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Payments of dividends on our common stock will not be subject to backup withholding, provided the applicable withholding agent does not have
actual knowledge or reason to know the holder is a United States person and the holder either certifies its <FONT STYLE="white-space:nowrap">non-U.S.</FONT> status, such as by furnishing a valid IRS Form
<FONT STYLE="white-space:nowrap">W-8BEN,</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> or otherwise establishes an exemption. However, information
returns are required to be filed with the IRS in connection with any dividends on our common stock paid to the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder, regardless of whether any tax was actually withheld. In addition, proceeds of the
sale or other taxable disposition of our common stock within the United States or conducted through certain U.S.-related brokers generally will not be subject to backup withholding or information reporting, if the applicable withholding agent
receives the certification described above and does not have actual knowledge or reason to know that such holder is a United States person, or the holder otherwise establishes an exemption. Proceeds of a disposition of our common stock conducted
through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> broker generally will not be subject to backup withholding or information reporting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Copies of information returns that are filed with the IRS may also be made available under the provisions of an applicable treaty or agreement
to the tax authorities of the country in which the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder resides or is established. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit
against a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Additional Withholding Tax on Payments Made to Foreign Accounts </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Withholding taxes may be imposed under Sections 1471 to 1474 of the Code (such Sections commonly referred to as the Foreign Account Tax
Compliance Act, or &#147;FATCA&#148;) on certain types of payments made to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> financial institutions and certain other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entities. Specifically, a 30%
withholding tax may be imposed on dividends on, or (subject to the proposed Treasury Regulations discussed below) gross proceeds from the sale or other disposition of, our common stock paid to a &#147;foreign financial institution&#148; or a <FONT
STYLE="white-space:nowrap">&#147;non-financial</FONT> foreign entity&#148; (each as defined in the Code), unless (1)&nbsp;the foreign financial institution undertakes certain diligence and reporting obligations, (2)&nbsp;the <FONT
STYLE="white-space:nowrap">non-financial</FONT> foreign entity either certifies it does not have any &#147;substantial United States owners&#148; (as defined in the Code) or furnishes identifying information regarding each substantial United States
owner, or (3)&nbsp;the foreign financial institution or <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity otherwise qualifies for an exemption from these rules. If the payee is a foreign financial institution and is subject to the
diligence and reporting requirements in (1)&nbsp;above, it must enter into an agreement with the U.S. Department of the Treasury requiring, among other things, that it undertake to identify accounts held by certain &#147;specified United States
persons&#148; or &#147;United States owned foreign entities&#148; (each as defined in the Code), annually report certain information about such accounts, and withhold 30% on certain payments to <FONT STYLE="white-space:nowrap">non-compliant</FONT>
foreign financial institutions and certain other account holders. Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing FATCA may be subject to different rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the applicable Treasury Regulations and administrative guidance, withholding under FATCA generally applies to payments of dividends on
our common stock. While withholding under FATCA would have applied also to payments of gross proceeds from the sale or other disposition of stock on or after January&nbsp;1, 2019, recently proposed Treasury Regulations eliminate FATCA withholding on
payments of gross proceeds entirely. Taxpayers generally may rely on these proposed Treasury Regulations until final Treasury Regulations are issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Because we may not know the extent to which a distribution is a dividend for U.S. federal income tax purposes at the time it is made, for
purposes of these withholding rules we or the applicable withholding agent may treat the entire distribution as a dividend. Prospective investors should consult their tax advisors regarding the potential application of withholding under FATCA to
their investment in our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc805799_19"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">BofA Securities, Inc., Jefferies LLC and William Blair&nbsp;&amp; Company, L.L.C. are acting as representatives of each of the underwriters
named below. Subject to the terms and conditions set forth in an underwriting agreement among us and the underwriters, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to purchase from
us, the number of shares of common stock set forth opposite its name below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:6.44em; font-size:8pt; font-family:Times New Roman"><B><U>Underwriter</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BofA Securities, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William Blair&nbsp;&amp; Company, L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BTIG, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.15em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions set forth in the underwriting agreement, the underwriters have agreed,
severally and not jointly, to purchase all of the shares sold under the underwriting agreement if any of these shares are purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the nondefaulting
underwriters may be increased or the underwriting agreement may be terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the underwriters against
certain liabilities, including liabilities under the Securities Act, or to contribute to payments the underwriters may be required to make in respect of those liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The underwriters are offering the shares, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal
matters by their counsel, including the validity of the shares, and other conditions contained in the underwriting agreement, such as the receipt by the underwriters of officer&#146;s certificates and legal opinions. The underwriters reserve the
right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commissions and Discounts </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The representatives have advised us that the underwriters propose initially to offer the shares to the public at the public offering price set
forth on the cover page of this prospectus and to dealers at that price less a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. After the initial offering, the public offering price, concession or any other
term of the offering may be changed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table shows the public offering price, underwriting discount and proceeds before
expenses to us. The information assumes either no exercise or full exercise by the underwriters of their option to purchase additional shares. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Per&nbsp;Share</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Without&nbsp;Option</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>With&nbsp;Option</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The expenses of the offering, not including the underwriting discount, are estimated at
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and are payable by us. We have also agreed to reimburse the underwriters for their expenses relating to clearance of this offering with the Financial Industry Regulatory Authority in an amount up to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Option to Purchase Additional Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have granted an option to the underwriters, exercisable for 30 days after the date of this prospectus, to purchase up to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares at the public offering price, less the underwriting discount. If the underwriters exercise this option, each will be obligated,
subject to conditions contained in the underwriting agreement, to purchase a number of additional shares proportionate to that underwriter&#146;s initial amount reflected in the above table. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Sales of Similar Securities </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We, our
executive officers and directors and our other existing security holders have agreed not to sell or transfer any common stock or securities convertible into, exchangeable for, exercisable for, or repayable with common stock, for 180 days after the
date of this prospectus without first obtaining the written consent of BofA Securities, Inc. and Jefferies LLC. Specifically, we and these other persons have agreed, with certain limited exceptions, not to directly or indirectly: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">offer, pledge, sell or contract to sell any common stock, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sell any option or contract to purchase any common stock, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchase any option or contract to sell any common stock, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">grant any option, right or warrant for the sale of any common stock, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lend or otherwise dispose of or transfer any common stock, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">request or demand that we file or make a confidential submission of a registration statement related to the
common stock, </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any swap or other agreement that transfers, in whole or in part, the economic consequence of ownership
of any common stock whether any such swap or transaction is to be settled by delivery of shares or other securities, in cash or otherwise, or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publicly disclose the intention to do any of the foregoing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This <FONT STYLE="white-space:nowrap">lock-up</FONT> provision applies to common stock and to securities convertible into or exchangeable or
exercisable for or repayable with common stock. It also applies to common stock owned now or acquired later by the person executing the agreement or for which the person executing the agreement later acquires the power of disposition. BofA
Securities, Inc. and Jefferies LLC, in their sole discretion, may release the common stock and other securities subject to <FONT STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;agreements</FONT> described above in whole or in part at any time with
or without notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Global Market Listing </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect the shares to be approved for listing on the Nasdaq Global Market, subject to notice of issuance, under the symbol &#147;LYRA.&#148;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Before this offering, there has been no public market for our common stock. The initial public offering price will be determined through
negotiations between us and the representatives. In addition to prevailing market conditions, the factors to be considered in determining the initial public offering price are </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the valuation multiples of publicly traded companies that the representatives believe to be comparable to us,
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial information, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the history of, and the prospects for, our company and the industry in which we compete, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an assessment of our management, its past and present operations, and the prospects for, and timing of, our
future revenues, </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the present state of our development, and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the above factors in relation to market values and various valuation measures of other companies engaged in
activities similar to ours. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">An active trading market for the shares may not develop. It is also possible that after the
offering the shares will not trade in the public market at or above the initial public offering price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The underwriters do not expect to
sell more than 5% of the shares in the aggregate to accounts over which they exercise discretionary authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Price Stabilization, Short Positions
and Penalty Bids </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Until the distribution of the shares is completed, SEC rules may limit underwriters and selling group members from
bidding for and purchasing our common stock. However, the representatives may engage in transactions that stabilize the price of the common stock, such as bids or purchases to peg, fix or maintain that price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with the offering, the underwriters may purchase and sell our common stock in the open market. These transactions may include
short sales, purchases on the open market to cover positions created by short sales and stabilizing transactions. Short sales involve the sale by the underwriters of a greater number of shares than they are required to purchase in the offering.
&#147;Covered&#148; short sales are sales made in an amount not greater than the underwriters&#146; option to purchase additional shares described above. The underwriters may close out any covered short position by either exercising their option to
purchase additional shares or purchasing shares in the open market. In determining the source of shares to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the
open market as compared to the price at which they may purchase shares through the option granted to them. &#147;Naked&#148; short sales are sales in excess of such option. The underwriters must close out any naked short position by purchasing
shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of our common stock in the open market after pricing that could adversely affect
investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of shares of common stock made by the underwriters in the open market prior to the completion of the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the
underwriting discount received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Similar to other purchase transactions, the underwriters&#146; purchases to cover the syndicate short sales may have the effect of raising or
maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. The
underwriters may conduct these transactions on the Nasdaq Global Market, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Neither we nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the
transactions described above may have on the price of our common stock. In addition, neither we nor any of the underwriters make any representation that the representatives will engage in these transactions or that these transactions, once
commenced, will not be discontinued without notice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic Distribution </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with the offering, certain of the underwriters or securities dealers may distribute prospectuses by electronic means, such as <FONT
STYLE="white-space:nowrap">e-mail.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Relationships </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Some of the underwriters and their affiliates have engaged in, and may in the future engage in, investment banking and other commercial
dealings in the ordinary course of business with us or our affiliates. They have received, or may in the future receive, customary fees and commissions for these transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, in the ordinary course of their business activities, the underwriters and their affiliates may make or hold a broad array of
investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers. Such investments and securities activities
may involve securities and/or instruments of ours or our affiliates. The underwriters and their affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial
instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>European
Economic Area and the United Kingdom </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In relation to each Member State of the European Economic Area and the United Kingdom (each a
&#147;Relevant State&#148;), no Shares have been offered or will be offered pursuant to the initial offering to the public in that Relevant State prior to the publication of a prospectus in relation to the Shares which has been approved by the
competent authority in that Relevant State or, where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation), except that offers of Shares may
be made to the public in that Relevant State at any time under the following exemptions under the Prospectus Regulation: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any legal entity which is a qualified investor as defined under the Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus
Regulation), subject to obtaining the prior consent of the representative for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided that no such offer of Shares shall require the Issuer or any Manager to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or
supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each person in a Relevant State who initially acquires any
Shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with the Company and the Managers that it is a qualified investor within the meaning of the Prospectus Regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the case of any Shares being offered to a financial intermediary as that term is used in Article 5(1) of the Prospectus Regulation, each
such financial intermediary will be deemed to have represented, acknowledged and agreed that the Shares acquired by it in the offer have not been acquired on a non-discretionary basis on behalf of, nor have they been acquired with a view to their
offer or resale to, persons in circumstances which may give rise to an offer to the public other than their offer or resale in a Relevant State to qualified investors, in circumstances in which the prior consent of the underwriters has been obtained
to each such proposed offer or resale. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company, the underwriters and their affiliates will rely upon the truth and accuracy
of the foregoing representations, acknowledgements and agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an &#147;offer to
the public&#148; in relation to any Shares in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any Shares to be offered so as to enable an investor to decide to purchase
or subscribe for any Shares, and the expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">References to the
Prospectus Regulation includes, in relation to the UK, the Prospectus Regulation as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The above selling restriction is in addition to any other selling restrictions set out below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the United Kingdom </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This document is for distribution only to persons who (i) have professional experience in matters relating to investments and who qualify as
investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the &#147;Financial Promotion Order&#148;), (ii) are persons falling within Article 49(2)(a) to
(d) (&#147;high net worth companies, unincorporated associations etc.&#148;) of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the
meaning of Section 21 of the Financial Services and Markets Act 2000, as amended (&#147;FSMA&#148;)) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons
together being referred to as &#147;relevant persons&#148;). This document is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this
document relates is available only to relevant persons and will be engaged in only with relevant persons. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in
Switzerland </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any
other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure
standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating
to the shares or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Neither this document nor
any other offering or marketing material relating to the offering, the Company, the shares have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of shares
will not be supervised by, the Swiss Financial Market Supervisory Authority, or FINMA, and the offer of shares has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The investor protection
afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective
Investors in the Dubai International Financial Centre </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus relates to an Exempt Offer in accordance with the Offered
Securities Rules of the Dubai Financial Services Authority, or DFSA. This prospectus is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any
other person. The DFSA has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no responsibility
for the prospectus. The shares to which this prospectus relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the shares offered should conduct their own due diligence on the shares. If you do not
understand the contents of this prospectus you should consult an authorized financial advisor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Australia </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian Securities
and Investments Commission, or ASIC, in relation to the offering. This prospectus does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001, or the Corporations Act, and does not
purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any offer in Australia of the shares may only be made to persons, or the Exempt Investors, who are &#147;sophisticated investors&#148; (within
the meaning of section 708(8) of the Corporations Act), &#147;professional investors&#148; (within the meaning of section 708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in section 708 of the Corporations
Act so that it is lawful to offer the shares without disclosure to investors under Chapter 6D of the Corporations Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The shares applied
for by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12 months after the date of allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act
would not be required pursuant to an exemption under section 708 of the Corporations Act or otherwise or where the offer is pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring shares must
observe such Australian <FONT STYLE="white-space:nowrap">on-sale</FONT> restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus contains general information only
and does not take account of the investment objectives, financial situation or particular needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors
need to consider whether the information in this prospectus is appropriate to their needs, objectives and circumstances, and, if necessary, seek expert advice on those matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Hong Kong </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to
&#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or (b)&nbsp;in other circumstances which do not result in the document being a
&#147;prospectus&#148; as defined in the Companies Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation or document relating to the shares has been or
may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if
permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the Securities and
Futures Ordinance and any rules made under that Ordinance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Japan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The shares have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948, as
amended) and, accordingly, will not be offered or sold, directly or indirectly, in Japan, or for the benefit of any Japanese Person or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or
to any Japanese Person, except in compliance with all applicable laws, regulations and ministerial guidelines promulgated by relevant Japanese governmental or regulatory authorities in effect at the relevant time. For the purposes of this paragraph,
&#147;Japanese Person&#148; shall mean any person resident in Japan, including any corporation or other entity organized under the laws of Japan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Singapore </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, the shares were not offered or
sold or caused to be made the subject of an invitation for subscription or purchase and will not be offered or sold or caused to be made the subject of an invitation for subscription or purchase, and this prospectus or any other document or material
in connection with the offer or sale, or invitation for subscription or purchase, of the shares, has not been circulated or distributed, nor will it be circulated or distributed, whether directly or indirectly, to any person in Singapore other than
(i)&nbsp;to an institutional investor (as defined in Section&nbsp;4A of the Securities and Futures Act (Chapter 289) of Singapore, or, as modified or amended from time to time, the SFA, pursuant to Section&nbsp;274 of the SFA, (ii) to a relevant
person (as defined in Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of the SFA, or any person pursuant to Section&nbsp;275(1A) of the SFA, and in accordance with the conditions specified in Section&nbsp;275 of the SFA, or
(iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Where the shares
are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole
business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each
beneficiary of the trust is an individual who is an accredited investor, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">securities or securities-based derivatives contracts (each
term as defined in Section&nbsp;2(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the
shares pursuant to an offer made under Section&nbsp;275 of the SFA except: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to an institutional investor or to a relevant person, or to any person arising from an offer referred to in
Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where no consideration is or will be given for the transfer; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where the transfer is by operation of law; or </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as specified in Section&nbsp;276(7) of the SFA. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Canada </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in
National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> <I>Prospectus Exemptions</I> or subsection 73.3(1) of the <I>Securities Act</I> (Ontario), and are permitted clients, as defined in National Instrument
<FONT STYLE="white-space:nowrap">31-103</FONT> <I>Registration Requirements, Exemptions and Ongoing Registrant Obligations</I>. Any resale of the shares must be made in accordance with an exemption from, or in a transaction not subject to, the
prospectus requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a
purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed
by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or
consult with a legal advisor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 (or, in the case of securities issued or guaranteed by the
government of a <FONT STYLE="white-space:nowrap">non-Canadian</FONT> jurisdiction, section 3A.4) of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> <I>Underwriting Conflicts</I>, or NI
<FONT STYLE="white-space:nowrap">33-105,</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this
offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc805799_20"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The validity of the shares of common stock offered hereby will be passed upon for us by Latham&nbsp;&amp; Watkins LLP. Certain legal matters
will be passed upon for the underwriters by Shearman&nbsp;&amp; Sterling LLP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc805799_21"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements as of December&nbsp;31, 2019 and 2018 and for the years then ended included in this Prospectus have been
so included in reliance on the report of BDO USA, LLP, an independent registered public accounting firm, appearing elsewhere herein and in the Registration Statement, given on the authority of said firm as experts in auditing and accounting. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc805799_22"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have filed with the Securities and Exchange Commission a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under
the Securities Act with respect to the shares of common stock offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits
and schedules filed therewith. For further information about us and the common stock offered hereby, we refer you to the registration statement and the exhibits and schedules filed thereto. Statements contained in this prospectus regarding the
contents of any contract or any other document that is filed as an exhibit to the registration statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract or other
document filed as an exhibit to the registration statement. Upon completion of this offering, we will be required to file periodic reports, proxy statements, and other information with the Securities and Exchange Commission pursuant to the
Securities Exchange Act of 1934. The Securities and Exchange Commission maintains an Internet website that contains such reports, proxy statements and other information about registrants, like us, that file electronically with the Securities and
Exchange Commission. The address of that site is <I>www.sec.gov</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We also maintain a website at <I>www.lyratherapeutics.com</I>.
Information contained in, or accessible through, our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is only as an inactive textual reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc805799_23"></A><A NAME="index"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin805799_1">Report of independent registered public accounting firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin805799_2">Consolidated balance sheet</A>s</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin805799_3">Consolidated statements of operations and comprehensive loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin805799_4">Consolidated statements of redeemable convertible preferred stock and stockholders&#146;
 (deficit</A>) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin805799_5">Consolidated statements of cash flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin805799_6">Notes to consolidated financial statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin805799_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Board of Directors and Stockholders </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lyra Therapeutics, Inc.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Watertown, MA </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Consolidated Financial
Statements </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have audited the accompanying consolidated balance sheets of Lyra Therapeutics, Inc. (the &#147;Company&#148;) and
subsidiary as of December&nbsp;31, 2019 and 2018, the related consolidated statements of operations and comprehensive loss, redeemable convertible preferred stock and stockholders&#146; (deficit) equity, and cash flows for the years then ended, and
the related notes (collectively referred to as the &#147;consolidated financial statements&#148;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at
December&nbsp;31, 2019 and 2018, and the results of its operations and its cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">These consolidated
financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s consolidated financial statements based on our audits. We are a public accounting firm registered with
the Public Company Accounting Oversight Board (United States) (&#147;PCAOB&#148;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the
Securities and Exchange Commission and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We conducted our audit in accordance with the standards of the PCAOB. Those standards
require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged
to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness
of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our audit included
performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis,
evidence regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation
of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/ BDO USA, LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have
served as the Company&#146;s auditor since 2013. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February 14, 2020 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin805799_2"></A>LYRA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED BALANCE SHEETS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In Thousands, Except Share and Per Share Data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Pro
Forma<BR>December&nbsp;31,<BR>2019</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Grants receivable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Operating lease right-of-use asset</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Liabilities, Redeemable Convertible Preferred Stock and Stockholders&#146; (Deficit)
Equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Operating lease liability, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Commitments and contingencies (Note 11)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred stock, $0.001
par value; 34,017,033 shares authorized, issued and outstanding at December&nbsp;31, 2019 and 2018 (aggregate liquidation preference of $14,157 at December&nbsp;31, 2019); no shares authorized, issued or outstanding, pro&nbsp;forma
(unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-2</FONT> redeemable convertible preferred stock, $0.001
par value; 26,680,202 shares authorized, issued and outstanding at December&nbsp;31, 2019 and 2018 (aggregate liquidation preference of $9,063 at December&nbsp;31, 2019); no shares authorized, issued or outstanding, pro&nbsp;forma
(unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-3</FONT> redeemable convertible preferred stock, $0.001
par value; 30,070,487 shares authorized, issued and outstanding at December&nbsp;31, 2019 and 2018 (aggregate liquidation preference of $18,779 at December&nbsp;31, 2019); no shares authorized, issued or outstanding, pro&nbsp;forma
(unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-4</FONT> redeemable convertible preferred stock, $0.001
par value; 19,999,999 shares authorized, issued and outstanding at December&nbsp;31, 2019 and 2018 (aggregate liquidation preference of $6,000 at December&nbsp;31, 2019); no shares authorized, issued or outstanding, pro&nbsp;forma
(unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Series B redeemable convertible preferred stock, $0.001 par value; 100,018,619 shares authorized at
December&nbsp;31, 2019 and 2018; 98,351,953 shares issued and outstanding at December&nbsp;31, 2019 and 2018 (aggregate liquidation preference of $29,506 at December&nbsp;31, 2019); no shares authorized, issued or outstanding, pro&nbsp;forma
(unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stockholders&#146; (deficit) equity:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Common stock, $0.001 par value; 275,000,000 shares authorized at December&nbsp;31, 2019 and 2018;
7,962,008 and 5,868,605&nbsp;shares issued and outstanding at December&nbsp;31, 2019 and 2018, respectively; 217,081,682 shares issued and outstanding, pro forma at December 31, 2019 (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(127,757</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(111,451</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(127,757</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(123,338</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(107,074</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total liabilities, redeemable convertible preferred stock and stockholders&#146; (deficit)
equity</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes to consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin805799_3"></A>LYRA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In Thousands, Except Share and Per Share Data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Year Ended December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,519</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,259</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of tranche liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,029</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,029</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.07</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares outstanding&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,998,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,728,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share attributable to common stockholders&#151;basic and diluted
(unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.08</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted-average common shares outstanding&#151;basic and diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">216,118,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes to consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin805799_4"></A>LYRA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#146; (DEFICIT) EQUITY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In Thousands, Except Share Amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Series <FONT STYLE="white-space:nowrap">A-1</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Redeemable<BR>Convertible<BR>Preferred Stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Series <FONT STYLE="white-space:nowrap">A-2</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Redeemable<BR>Convertible<BR>Preferred Stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Series <FONT STYLE="white-space:nowrap">A-3</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Redeemable<BR>Convertible<BR>Preferred Stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Series <FONT STYLE="white-space:nowrap">A-4</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Redeemable<BR>Convertible<BR>Preferred Stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Series B</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Redeemable<BR>Convertible<BR>Preferred Stock</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Common Stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Additional<BR><FONT
STYLE="white-space:nowrap">Paid-In</FONT><BR>Capital</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Accumulated<BR>Deficit</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Total<BR>Stockholders&#146;<BR>(Deficit)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Equity</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,017,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,680,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,070,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,715,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(105,422</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(101,382</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Issuance of Series B redeemable convertible preferred stock, net of issuance costs of $299</P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,666,656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Issuance of Series B redeemable convertible preferred stock in exchange for convertible
debt</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,685,297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Accretion of convertible preferred stock to redemption value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(81</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(81</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Settlement of tranche liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Exercise of common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">153,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,029</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,029</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,017,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,680,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,070,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,351,953</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,868,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(111,451</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(107,074</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Accretion of convertible preferred stock to redemption value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(313</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(313</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Exercise of common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,093,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>Balance at December 31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,017,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,680,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,070,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,351,953</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,962,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(127,757</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(123,338</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Conversion of preferred stock into common stock (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,017,033</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,742</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,680,202</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,393</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,070,487</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,114</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,999,999</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(98,351,953</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,417</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">209,119,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130,457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>Balance at December 31, 2019</B> <B>pro forma (unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">217,081,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">134,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(127,757</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes to consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin805799_5"></A>LYRA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In Thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,029</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reserve for uncollectible accounts </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of tranche liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,184</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grants receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(291</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease right-of-use asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(205</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(840</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,754</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,640</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(211</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(211</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from the sale of Series B redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of offering costs related to sale of Series B redeemable convertible preferred
stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(299</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from exercise of common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from convertible notes payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments for deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(226</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(115</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (decrease) increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,080</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents and restricted cash, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents and restricted cash, end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of <FONT STYLE="white-space:nowrap">non-cash</FONT> financing and
investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment purchases included in accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of convertible notes payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Allocation of redeemable convertible preferred stock to tranche liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Settlement of tranche liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(899</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of redeemable convertible preferred stock to redemption value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Right-of-use asset obtained in exchange of operating lease obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,046</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs included in accounts payable and accrued expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes to financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin805799_6"></A>LYRA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Organization and Basis of Presentation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Lyra Therapeutics, Inc. (the &#147;Company&#148;) is a clinical-stage therapeutics company focused on the development and commercialization of
novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (&#147;ENT&#148;) diseases. The Company&#146;s proprietary technology platform, XTreo, is designed to precisely and consistently deliver
medicines directly to the affected tissue for sustained periods with a single administration. The Company&#146;s initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief,
non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis (&#147;CRS&#148;). The Company was incorporated as a Delaware corporation on
November&nbsp;21, 2005 and is located in Watertown, Massachusetts. On July&nbsp;16, 2018, the Company formerly changed its name from 480 Biomedical, Inc. to Lyra Therapeutics, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company is subject to risks common to companies in the specialty pharmaceuticals industry, including but not limited to, risks of failure
of preclinical studies and clinical trials, the need to obtain marketing approval for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates,
dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations, reliance on third party manufacturers, ability to transition from pilot-scale
manufacturing to large-scale production of products and the need to obtain adequate additional financing to fund the development of its product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Since inception, the Company has funded its operations with proceeds from sales of redeemable convertible preferred stock and funding from
government contracts. The Company has incurred recurring net losses since inception of approximately $16.3 million and $6.0&nbsp;million for the years ended December&nbsp;31, 2019 and 2018, respectively. In addition, the Company has an accumulated
deficit of approximately $127.8&nbsp;million at December&nbsp;31, 2019. The Company expects to continue to generate operating losses for the foreseeable future. At December&nbsp;31, 2019, the Company had approximately $9.8&nbsp;million of cash and
cash equivalents. In January 2020, the Company issued 78,306,611 shares of Series C redeemable convertible preferred stock for $0.38811 per share, in exchange for gross cash proceeds of approximately $30.4 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company believes that its cash and cash equivalents as of December&nbsp;31, 2019 along with the proceeds from its sale of Series C
redeemable convertible preferred stock in January 2020 will be sufficient to fund the Company&#146;s operating plan for a period of at least one year from the issuance date of the consolidated financial statements. The future viability of the
Company beyond that point is dependent on its ability to raise additional capital to finance its future operations. The Company will seek additional funding through an initial public offering of its common stock or private financings, debt
financing, collaboration agreements or government grants. The inability to obtain funding, including an initial public offering, as and when needed, would have a negative impact on the Company&#146;s financial condition and ability to pursue its
business strategies. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could
adversely affect its business prospects, or the Company may be unable to continue operations. Although management intends to pursue plans to obtain additional funding to finance its operations, there is no assurance that the Company will be
successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all. If the Company is unable to complete a sufficient public offering in a timely manner, it would need to pursue other financing
alternatives, such as private financing of debt or equity or collaboration agreements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LYRA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the
United States of America (&#147;GAAP&#148;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standard Codification
(&#147;ASC&#148;) and Accounting Standards Updates (&#147;ASU&#148;) of the Financial Accounting Standards Board (&#147;FASB&#148;). </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited
Pro Forma Financial Information </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The accompanying unaudited pro forma balance sheet as of December 31, 2019 has been prepared to
give effect to the automatic conversion of all outstanding shares of redeemable convertible preferred stock into 209,119,674 shares of common stock as if the Company&#146;s proposed initial public offering had occurred on December 31, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the accompanying statements of operations and comprehensive loss, the unaudited pro forma net loss attributable to common stockholders used
in the calculation of unaudited basic and diluted pro forma net loss per share attributable to common stockholders does not include the effects of the accretion of issuance costs on redeemable convertible preferred stock because it assumes that the
conversion of convertible preferred stock into common stock occurred on the later of the beginning of the reporting period or the issuance date of the redeemable convertible preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma basic and diluted weighted-average common shares outstanding used in the calculation of unaudited pro forma basic and
diluted net loss per share attributable to common stockholders for the year ended December 31, 2019 give effect to the automatic conversion of all outstanding shares of redeemable convertible preferred stock into shares of common stock as if the
conversion had occurred on the later of January 1, 2019 or the issuance date of the redeemable convertible preferred stock for the year ended December 31, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Principles of Consolidation </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
consolidated financial statements include the accounts of Lyra Therapeutics, Inc. and its wholly owned subsidiary Lyra Therapeutics Security Corporation, which was incorporated in December 2018. All intercompany transactions and balances have been
eliminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements reflect the application of certain significant accounting policies as
described in this note and elsewhere in the accompanying consolidated financial statements and notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The preparation of the Company&#146;s consolidated financial statements in conformity with GAAP requires management to make estimates and
assumptions that affect the reported amounts of assets, liabilities, expenses and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LYRA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reported amounts of expenses during the reporting period. On an ongoing basis, the Company&#146;s management evaluates its estimates, which include but are not limited to management&#146;s
judgments of accrued expenses, fair value of common stock, valuation of share-based awards and deferred income taxes. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company utilizes significant estimates and assumptions in determining the fair value of its common stock. The Company has utilized various
valuation methodologies to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company&#146;s judgment. These estimates and assumptions include a number of objective and
subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company&#146;s common stock at the time of, and the likelihood
of, achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could result in different fair values of common stock at each valuation date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Segment Information </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Operating
segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the
Company&#146;s chief operating decision-maker, the Company&#146;s chief executive officer, views the Company&#146;s operations and manages its business as a single operating segment, which is the business of developing targeted medicines to address
ENT diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive Income (Loss) </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and
circumstances from <FONT STYLE="white-space:nowrap">non-owner</FONT> sources. As the Company did not have any element of other comprehensive income (loss), its comprehensive loss is equal to its net loss for all periods presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash Equivalents </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash held in banks and amounts held in money market funds. Cash equivalents are stated
at cost, which approximates market value. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents consist of cash held in banks at December&nbsp;31, 2019 and 2018.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Cash </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company had restricted cash of approximately $0.3&nbsp;million as of December&nbsp;31, 2019 and 2018, which was held in certificates of
deposit at the Company&#146;s financial institution to secure the Company&#146;s letter of credit for its facility lease. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentrations of
Credit Risk and <FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Risk </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially expose the
Company to concentrations of credit risk consist primarily of cash, cash equivalents and grants receivable. The Company maintains all its cash and cash equivalents at a single accredited financial institution, in amounts that exceed federally
insured limits. The grants receivable as of December&nbsp;31, 2018 are from various government agencies as discussed below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LYRA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has no significant <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet risk
such as foreign exchange contracts, option contracts, or other foreign exchange hedging arrangements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Grants Receivable </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, the Company had grants receivable of $0.2&nbsp;million from the National Institute of Health&#146;s
(&#147;NIH&#148;) National Heart, Lung and Blood Institute (&#147;NHLBI&#148;). During the year ended December 31, 2019, the Company fully reserved the grant receivable as the Company determined it was unlikely to collect it and as a result, at
December 31, 2019, it had grants receivable of $0. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Significant Suppliers </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. In
particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the drug product and associated applicator related to these programs. These programs could be adversely affected
by a significant interruption in the supply of the materials required to manufacture the drug product and associated applicator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of
Financial Instruments </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a
liability between market participants at a measurement date. ASC Topic 820, <I>Fair Value Measurements</I> (&#147;ASC 820&#148;), establishes a three-level valuation hierarchy for instruments measured at fair value that prioritizes the inputs used
to measure fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing
the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#146;s assumptions about the inputs that market participants would use in pricing the asset or
liability and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported or disclosed fair value of the financial instruments and is not
a measure of the investment credit quality. The three levels of the fair value hierarchy established by ASC 820 in order of priority are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Level&nbsp;1&nbsp;-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Level&nbsp;2 -</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Inputs other than quoted prices included within Level&nbsp;1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Level&nbsp;3 -</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar
techniques.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the
market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&nbsp;3. A financial instrument&#146;s level
within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">An entity
may elect to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LYRA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
elected will be reported in net loss. The Company did not elect to measure any financial instruments or other items at fair value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Derivative Liabilities </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In
connection with certain debt and equity financings, the Company may issue financial instruments in which a derivative instrument is &#147;embedded.&#148; Upon issuing the financial instrument, the Company assesses whether the economic
characteristics of the embedded derivative are clearly and closely related to the economic characteristics of the remaining component of the financial instrument (i.e., the host contract) and whether a separate,
<FONT STYLE="white-space:nowrap">non-embedded</FONT> instrument with the same terms as the embedded instrument would meet the definition of a derivative instrument. When it is determined that (1)&nbsp;the embedded derivative possesses economic
characteristics that are not clearly and closely related to the economic characteristics of the host contract, and (2)&nbsp;a separate, stand-alone instrument with the same terms would qualify as a derivative instrument, the embedded derivative is
separated from the host contract and carried at fair value until the derivative is settled. Changes in the fair value of the derivative liabilities are recognized as other income (expense) in the consolidated statement of operations and
comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Classification and Accretion of Redeemable Convertible Preferred Shares </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has classified the redeemable convertible preferred stock outside of stockholders&#146; (deficit) equity in the accompanying
consolidated balance sheets in accordance with authoritative guidance for the classification and measurement of redeemable securities as the redeemable convertible preferred stock is redeemable at a determinable price on a fixed date or upon the
occurrence of a deemed liquidation event. The carrying values of the redeemable convertible preferred shares are accreted to their redemption values from the date of issuance through the earliest date of redemption. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Property
and equipment are stated at cost, less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="55%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Estimated Useful Life</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Laboratory equipment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Computer software and equipment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Office furniture and fixtures</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">7 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Leasehold improvements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Shorter of useful life or remaining term of related lease</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Costs for capital assets not yet placed into service are capitalized as construction in progress and are
depreciated in accordance with the above guidelines once placed into service. Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are
reflected in the consolidated statement of operations and comprehensive loss. Repairs and maintenance that do not improve or extend the lives of the respective assets are expensed as incurred, while costs of major additions and betterments are
capitalized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of Long-Lived Assets </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Long-lived assets consist of property and equipment. The Company continually evaluates long-lived assets for potential impairment when events
or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LYRA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the
book values of the assets exceed their fair value. The Company did not record any impairment losses on long-lived assets during the years ended December&nbsp;31, 2019 and 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">ASU No. 2016-02, Leases
(Topic 842) (&#147;ASU No. 2016-02&#148;), became effective January 1, 2019. As of the effective date of ASU No. 2016-02, the Company determines at the inception of an arrangement whether the arrangement contains a lease. If a lease is identified in
an arrangement, the Company recognizes a right-of-use asset and liability on its balance sheet and determines whether the lease should be classified as a finance or operating lease. The Company does not recognize assets or liabilities for leases
with lease terms of less than 12&nbsp;months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A lease qualifies as a finance lease if any of the following criteria are met at the
inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease
term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, (v) the nature of the leased asset is
specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Finance and operating lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease
payments over the lease term using the discount rate implicit in the lease. If the rate implicit in the lease is not readily determinable, the Company utilizes its incremental borrowing rate at the lease commencement date. Operating lease assets are
further adjusted for prepaid or accrued lease payments. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. Finance lease assets are amortized to depreciation expense using the
straight-line method over the shorter of the useful life of the related asset or the lease term. Finance lease payments are bifurcated into (i) a portion that is recorded as imputed interest expense and (ii) a portion that reduces the finance
liability associated with the lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company separates lease and non-lease components when determining which lease payments to
include in the calculation of its lease assets and liabilities. Variable lease payments are expensed as incurred. If a lease includes an option to extend or terminate the lease, the Company reflects the option in the lease term if it is reasonably
certain it will exercise the option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Operating leases are recorded in &#147;Operating lease right-of use asset,&#148; &#147;Operating
lease liability&#148; and &#147;Operating lease liability, net of current portion&#148; in the Company&#146;s consolidated balance sheets. The Company did not have any finance leases recorded in its consolidated balance sheet as of December 31,
2019. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Costs </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Research and development costs are expensed as incurred. Research and development expenses include salaries and benefits, materials and
supplies, preclinical and clinical trial expenses, manufacturing expenses, stock-based compensation expense, depreciation of equipment, contract services and other outside expenses. Costs of certain development activities, such as clinical trials,
are recognized based on an evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the
consolidated financial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LYRA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
statements as prepaid or accrued research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities
are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
Company has entered into various research and development contracts with companies both inside and outside of the United States. These agreements are generally cancelable, and related payments are recorded as research and development expenses as
incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or trials, including the phase or completion of events, invoices
received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#146;s estimates. The Company&#146;s historical accrual
estimates have not been materially different from the actual costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent Costs </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses
in the accompanying consolidated statements of operations and comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accounting for Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, <I>Compensation&#151;Stock Compensation</I> (&#147;ASC
718&#148;). ASC 718 requires all stock-based payments to employees and directors to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company estimates the fair
value of options granted using the Black-Scholes option pricing model for stock option grants to both employees and <FONT STYLE="white-space:nowrap">non-employees.</FONT> The Company believes the fair value of the stock options granted to <FONT
STYLE="white-space:nowrap">non-employees</FONT> is more reliably determinable than the fair value of the services provided. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (a)&nbsp;the expected stock price volatility, (b)&nbsp;the expected term of the award, (c)&nbsp;the risk-free interest rate and (d)&nbsp;expected
dividends. Due to the lack of a public market for the Company&#146;s common stock and a lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a
representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with the
expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&nbsp;107, <I>Share-Based Payment</I>, to calculate the expected term for options granted to employees as it does not have
sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or
post-vesting termination behavior among its employee population. For options granted to <FONT STYLE="white-space:nowrap">non-employees,</FONT> the Company utilizes the contractual term of the share-based payment as the basis for the expected term
assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid cash dividends and has no
current plans to pay any cash dividends on its common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has elected as a policy to recognize forfeitures as they occur
as described in ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-09,</FONT> <I>Compensation&#151;Stock Compensation</I> (&#147;ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-09&#148;).</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LYRA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company expenses the fair value of its stock-based compensation awards to employees on a
straight-line basis over the requisite service period, which is generally the vesting period. The Company records the expense for stock-based compensation awards subject to performance-based milestone vesting when management determines that
achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions as of the reporting date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company adopted ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-07,</FONT> <I>Compensation-Stock Compensation (Topic 718): Improvements
to Nonemployee Share-Based Payment Accounting</I> (&#147;ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-07&#148;)</FONT> on January&nbsp;1, 2019 which permits the valuation of stock-based awards granted to
<FONT STYLE="white-space:nowrap">non-employees</FONT> to be measured at fair value at the grant date rather than on an accelerated attribution basis over the vesting period and recognizes <FONT STYLE="white-space:nowrap">non-employee</FONT>
stock-based compensation expense over the related service period of the <FONT STYLE="white-space:nowrap">non-employee</FONT> award. Prior to January&nbsp;1, 2019, the Company accounted for stock-based payments to
<FONT STYLE="white-space:nowrap">non-employees</FONT> in accordance with ASC Topic 505, <I>Equity-Based Payments to <FONT STYLE="white-space:nowrap">Non-Employees</FONT></I> (&#147;ASC 505&#148;). ASC 505 requires that the expense related to
stock-based payments to <FONT STYLE="white-space:nowrap">non-employees</FONT> be recognized in the consolidated statement of operations and comprehensive loss based on the awards&#146; vesting date fair values. Under ASC 505, stock-based
compensation awards to <FONT STYLE="white-space:nowrap">non-employees</FONT> were adjusted through stock-based compensation expense at each reporting period end to reflect the current fair value of such awards and were expensed on a straight-line
basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
Company accounts for income taxes using the liability method in accordance with ASC Topic 740, <I>Income Taxes</I> (&#147;ASC 740&#148;). The difference between the financial statement and tax basis of the assets and liabilities is determined
annually. Deferred income tax assets and liabilities are computed using the tax laws and rates that are expected to apply for periods in which such differences reverse. Valuation allowances are established, if necessary, to reduce the deferred tax
asset to the amount that will more likely than not be realized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company recognizes the effect of income tax positions only if those
positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which
the change in judgment occurs. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contingencies </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In accordance with ASC Topic 450, Contingencies, the Company records accruals for contingencies and legal proceedings expected to be incurred
in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If a loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, the nature of the contingent
liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Guarantees </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has identified the guarantees described below as disclosable, in accordance with ASC Topic 460, <I>Guarantees</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while the officer or
director is, or was, serving at the Company&#146;s request in such capacity. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LYRA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors&#146; and officers&#146; insurance coverage that should limit
its exposure and enable it to recover a portion of any future amounts paid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company is a party to a number of agreements entered into
in the ordinary course of business that contain typical provisions that obligate the Company to indemnify the other parties to such agreements upon the occurrence of certain events. Such indemnification obligations are usually in effect from the
date of execution of the applicable agreement for a period equal to the applicable statute of limitations. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company leases office space under a noncancelable operating lease. The Company has standard indemnification arrangements under the lease
that requires it to indemnify the landlord against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation, or nonperformance of any covenant or condition of the lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019 and 2018, the Company had not experienced any losses related to these indemnification obligations, and no
material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related
reserves have been established. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Deferred Offering Costs </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity
financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders&#146; (deficit) equity as a reduction of additional paid-in capital generated as a
result of the offering. Should the planned equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statement of operations and comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Government Contracts and Revenue Recognition </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company generated revenue from government contracts that reimbursed the Company for certain allowable costs for funded projects. For
contracts with government agencies, when the Company has concluded that it is the principal in conducting the research and development activities and where the funding arrangement is considered central to the Company&#146;s ongoing operations, the
Company classifies the recognized funding received as revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In July 2016, the Company was awarded a grant from the NIH titled
&#147;Novel Bioabsorbable, Flexible Polymeric Stent for Pulmonary Artery Stenosis&#148;. The amount awarded of approximately $1.0&nbsp;million related to the period August 2016 through July 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In September 2016, the Company received a <FONT STYLE="white-space:nowrap">fixed-fee</FONT> award of approximately $0.4&nbsp;million from NIH
for the development leading to the commercialization of bioresorbable stents (&#147;BRS&#148;) for the treatment of coarctation of the aorta in neonates. In November 2017, the Company was awarded an amendment to the contract increasing the amount by
approximately $3.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Grants are invoiced and revenue is recognized as expenses are incurred as that is the depiction of the
timing of the transfer of services. Reimbursements are based on actual costs agreed upon in the proposal (salary, fringe benefits, overhead, and direct costs such as materials and subcontractors). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LYRA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company recognized revenue under these best-efforts, cost-reimbursable and cost-plus <FONT
STYLE="white-space:nowrap">fixed-fee</FONT> awards, as the Company performed services as long as an award agreement had been executed and the fees for these services were fixed or determinable, legally billable and reasonably assured of collection.
Recognized amounts reflected the Company&#146;s partial performance under the awards and equal direct and indirect costs incurred plus fixed fees, where applicable. The Company did not recognize revenue under these arrangements for amounts related
to contract periods where funding was not yet committed, as amounts above committed funding thresholds would not be considered fixed or determinable or reasonably assured of collection. Revenues and expenses under these arrangements are presented
gross in the consolidated statements of operations and comprehensive loss, as the Company had determined it was the primary obligor under these arrangements relative to the research and development activities it performed as the lead technical
expert. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Total revenue for the years ended December&nbsp;31, 2019 and 2018 under the grants was $0 and $1.2&nbsp;million, respectively. Of
the amounts recognized during the years ended December&nbsp;31, 2018, approximately $1.1&nbsp;million was received as of <FONT STYLE="white-space:nowrap">year-end.</FONT> The remaining balance of approximately $0.2&nbsp;million as of
December&nbsp;31, 2018 was recorded as grants receivable. During the year ended December 31, 2019, the Company fully reserved the grant receivable as the Company determined it was unlikely to collect it. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss per Share </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company
has reported losses since inception and has computed basic net loss per share attributable to common stockholders by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period,
without consideration for potentially dilutive securities. The Company has computed diluted net loss per common share after giving consideration to all potentially dilutive common shares, including options to purchase common stock and redeemable
convertible preferred stock, outstanding during the period determined using the treasury-stock and <FONT STYLE="white-space:nowrap">if-converted</FONT> methods, except where the effect of including such securities would be antidilutive. Because the
Company has reported net losses since inception, these potential common shares have been anti-dilutive and basic and diluted loss per share have been the same. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share
data): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Year Ended
December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,029</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(313</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(81</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,619</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,110</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,998,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,728,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.07</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LYRA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth the potentially dilutive securities that have been excluded
from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Year Ended
December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred stock</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,017,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,017,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-2</FONT> redeemable convertible preferred stock</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,680,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,680,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-3</FONT> redeemable convertible preferred stock</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,070,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,070,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-4</FONT> redeemable convertible preferred stock</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,351,953</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,351,953</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,327,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,092,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">236,447,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">228,212,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Pro Forma Net Loss per Share </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Unaudited pro forma net loss per share attributable to common stockholders is computed using the weighted-average number of common shares
outstanding after giving effect to the conversion of all the redeemable convertible preferred stock into shares of common stock as if such conversion had occurred at the beginning of the period presented or the date of original issuance, if later.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table summarizes the Company&#146;s unaudited pro forma net loss per share attributable to common stockholders (in
thousands, except share and per share data): </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Year
Ended<BR>December&nbsp;31,&nbsp;2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(313</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,619</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,998,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustment for assumed conversion of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">209,119,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted-average common shares&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">216,118,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share attributable to common stockholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.08</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Adopted Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the
specified effective date. </P>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-02.</FONT> The
standard requires that all lessees recognize the assets and liabilities that arise from leases on the balance sheet and disclose qualitative and quantitative information about its leasing arrangements. In July 2018, the FASB issued ASU <FONT
STYLE="white-space:nowrap">No.&nbsp;2018-11,</FONT> <I>Leases (Topic 842): Targeted Improvements</I> (&#147;ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-11&#148;),</FONT> which offers a transition option to entities adopting ASC Topic 842.
Under ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-11</FONT> entities can elect to apply ASC 842 using a modified-retrospective adoption approach resulting in a cumulative effect adjustment to accumulated deficit at the beginning of the year
in which </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LYRA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the new lease standard is adopted, rather than adjustments to the earliest comparative period presented in their financial statements. Pursuant to the guidance under ASU <FONT
STYLE="white-space:nowrap">No.&nbsp;2016-02,</FONT> the Company elected the optional package of practical expedients, which allow the Company to not reassess: (i)&nbsp;whether expired or existing contracts contain leases; (ii)&nbsp;lease
classification for any expired or existing leases; and (iii)&nbsp;initial direct costs for any existing leases. The standard also allows entities to make certain policy elections, some of which the Company also plans to elect, including: (i)&nbsp;a
policy to not record short-term leases on the balance sheet and (ii)&nbsp;a policy to not separate lease and <FONT STYLE="white-space:nowrap">non-lease</FONT> components for certain classes of underlying assets. The Company adopted ASC No.&nbsp;842
as of January&nbsp;1, 2019 using the modified-retrospective method and recorded a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset of approximately $4.0&nbsp;million and corresponding liability of
approximately $4.2&nbsp;million related to its real estate lease with a term of more than 12 months which is not treated as financing lease under ASC 842, accordingly. These adjustments had no impact on the Company&#146;s consolidated statement of
operations and comprehensive loss and no material impact on the Company&#146;s accumulated deficit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In July 2017, the FASB issued ASU <FONT
STYLE="white-space:nowrap">2017-11,</FONT> <I>Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II.
Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception</I> (&#147;ASU
<FONT STYLE="white-space:nowrap">No.&nbsp;2017-11&#148;).</FONT> Part I of ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2017-11</FONT> addresses the complexity of accounting for certain financial instruments with down round features. Down round
features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for
entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. Part II of ASU
<FONT STYLE="white-space:nowrap">No.&nbsp;2017-11</FONT> addresses the difficulty of navigating Topic 480, <I>Distinguishing Liabilities from Equity</I>, because of the existence of extensive pending content in the FASB Accounting Standards
Codification. This pending content is the result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable noncontrolling interests. The
amendments in Part II of ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2017-11</FONT> do not have an accounting effect. ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2017-11</FONT> is effective for fiscal years, and interim periods within those
years, beginning after December&nbsp;15, 2018. The Company adopted ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2017-11</FONT> as of January&nbsp;1, 2019. The adoption of ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2017-11</FONT> did not have a
material impact on the Company&#146;s consolidated financial position, results of operations or cash flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In June 2018, the FASB issued
ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-07,</FONT> <I>Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting</I> (&#147;ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-07&#148;).</FONT>
The new standard largely aligns the accounting for share-based payment awards issued to employees and <FONT STYLE="white-space:nowrap">non-employees</FONT> by expanding the scope of ASC 718 to apply to
<FONT STYLE="white-space:nowrap">non-employee</FONT> share-based transactions, as long as the transaction is not effectively a form of financing. The Company adopted ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-07</FONT> as of January&nbsp;1,
2019. The adoption of ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-07</FONT> did not have a material impact on the Company&#146;s consolidated financial position, results of operations or cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In August 2018, the SEC adopted the final rule under SEC Release <FONT STYLE="white-space:nowrap">No.&nbsp;33-10532,</FONT> <I>Disclosure
Update and Simplification</I>, amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements on the analysis of stockholders&#146;
equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders&#146; equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a
reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income (loss) is required to be filed. This final rule was effective on November&nbsp;5, 2018. The adoption of SEC Release <FONT
STYLE="white-space:nowrap">No.&nbsp;33-10532</FONT> did not have a material impact on the Company&#146;s its financial position, results of operations or cash flows. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LYRA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Issued Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In August 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-13,</FONT> <I>Fair Value Measurement (Topic 820):
Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</I> (&#147;ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-13&#148;),</FONT> which modifies the disclosure requirements on fair value measurements. The new
guidance will become effective for the Company on January&nbsp;1, 2020. Early adoption is permitted. The Company currently is evaluating the impact the adoption of ASU <FONT STYLE="white-space:nowrap">2018-13</FONT> will have on its consolidated
financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In August 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-15,</FONT>
<I>Intangibles&#151;Goodwill and <FONT STYLE="white-space:nowrap">Other&#151;Internal-Use</FONT> Software (Subtopic <FONT STYLE="white-space:nowrap">350-40):</FONT> Customer&#146;s Accounting for Implementation Costs Incurred in a Cloud Computing
Arrangement That Is a Service Contract</I> (&#147;ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-15&#148;),</FONT> which clarifies the accounting for implementation costs in cloud computing arrangements. The new guidance will become effective
for the Company on January&nbsp;1, 2020. Early adoption is permitted. The Company is currently evaluating the impact the adoption of ASU <FONT STYLE="white-space:nowrap">2018-15</FONT> will have on its consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In December 2019, the FASB issued ASU No. 2019-12, <I>Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</I> (&#147;ASU No.
2019-12&#148;), makes a number of changes meant to add or clarify guidance on accounting for income taxes. The new guidance will become effective for the Company on January 1, 2022. Early adoption is permitted. The Company currently is evaluating
the impact the adoption of ASU 2019-12 will have on its consolidated financial statements. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Fair Value Measurements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company did not have financial assets and liabilities measured at fair value at December&nbsp;31, 2019 and 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There have been no changes to the valuation methods used during the years ended December&nbsp;31, 2019 and 2018. There were no transfers
within the fair value hierarchy during the years ended December&nbsp;31, 2019 and 2018. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The carrying values of the Company&#146;s
grants receivable, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tranche
Rights </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company&#146;s sales of Series B redeemable convertible preferred stock (&#147;Series B Preferred Stock&#148;) (see
Note 6) provided investors with the right to participate in a subsequent offering of Series B Preferred Stock in the event specified development milestone was achieved. The Company classified the tranche rights as a derivative liability on its
consolidated balance sheet because it met the definition of a freestanding financial instrument that could have required the Company to transfer assets upon exercise. The Company remeasured the derivative liability associated with the tranche right
to fair value at each reporting date, and recognized changes in the fair value of the derivative liability as a component of other income (expense) in the consolidated statements of operations and comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The fair value of the derivative liability was determined using the Black-Scholes option pricing model, which considered as inputs
(a)&nbsp;the expected stock price volatility of the underlying common stock, (b)&nbsp;the expected term of the tranche right, (c)&nbsp;the risk-free interest rate and (d)&nbsp;expected dividends. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LYRA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The fair value of the tranche right related to the Company&#146;s Series B Preferred Stock
upon issuance in June 2018 was approximately $2.1&nbsp;million. Upon the issuance of Series B Preferred Stock in October 2018, the tranche right was cancelled, and the fair value of the derivative liability was $0, with the change in fair value
recorded in other income (expense) in the consolidated statements of operations and comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table provides a
roll forward of the fair value of the Company&#146;s tranche right, for which fair value was determined by Level&nbsp;3 inputs (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="55.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Tranche<BR>Right</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value at issuance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,184</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Settlement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(899</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Property and Equipment </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Property and equipment consist of the following at December&nbsp;31, 2019 and 2018 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer software and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Construction in progress</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,829</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,802</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company recognized approximately $0.0 million and $0.1&nbsp;million of depreciation expense for
the years ended December&nbsp;31, 2019 and 2018, respectively. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Accrued Expenses and Other Current Liabilities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities consist of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payroll and employee related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third-party research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional and consulting fees </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LYRA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Redeemable Convertible Preferred Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On June&nbsp;5, 2018, the Company filed an amended and restated certificate of incorporation which authorizes its Board of Directors to issue
up to 210,786,340 shares of preferred stock, par value $0.001 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On August&nbsp;25, 2011, the Company filed an amended and
restated certificate of incorporation to recapitalize its outstanding shares of previously outstanding Series A, Series B and Series C preferred stock into 34,017,033 shares of a new Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable
convertible preferred stock (&#147;Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock&#148;). As the substance of the transaction was a consolidation of the existing stockholders&#146; holdings into a single class of shares without
conferring any substantive additional rights or obligations between the stockholders and the Company, the transaction was recorded at the then existing book value of the previously outstanding Series A, B and C preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During 2011, the Company issued 26,680,202 shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> redeemable convertible preferred stock
(&#147;Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock&#148;) for $0.6894 per share, in exchange for cash proceeds of approximately $13.0&nbsp;million and the conversion of approximately $5.4&nbsp;million of convertible promissory
notes and accrued interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During 2013, the Company issued 16,736,530 shares of Series <FONT STYLE="white-space:nowrap">A-3</FONT>
redeemable convertible preferred stock (&#147;Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Stock&#148;) for $1.2675 per share, in exchange for cash proceeds of approximately $15.0&nbsp;million and the conversion of approximately
$6.2&nbsp;million of convertible promissory notes and accrued interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During 2015, the Company issued 9,205,805 shares of Series <FONT
STYLE="white-space:nowrap">A-3</FONT> Preferred Stock for $1.2675 per share, in exchange for cash proceeds of approximately $3.3&nbsp;million and the conversion of approximately $8.4&nbsp;million of certain convertible promissory notes and accrued
interest. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During 2016, the Company issued 4,128,152 shares of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Stock for
$1.2675 per share and 19,999,999 shares of Series <FONT STYLE="white-space:nowrap">A-4</FONT> redeemable convertible preferred stock (&#147;Series <FONT STYLE="white-space:nowrap">A-4</FONT> Preferred Stock&#148;) for $0.30 per share, in exchange
for total cash proceeds of approximately $11.2&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During 2018, the Company issued 98,351,953&nbsp;shares of Series B Preferred
Stock for $0.30 per share, in exchange for total cash proceeds of approximately $29.0&nbsp;million and the conversion of approximately $0.5&nbsp;million of convertible promissory notes originally issued in March and April 2018 and accrued interest.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The rights, preferences, and privileges of the Series <FONT STYLE="white-space:nowrap">A-1,</FONT>
<FONT STYLE="white-space:nowrap">A-2,</FONT> <FONT STYLE="white-space:nowrap">A-3,</FONT> <FONT STYLE="white-space:nowrap">A-4</FONT> and Series B Preferred Stock (collectively, the &#147;Preferred Stock&#148;) are the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The holders of
Preferred Stock are entitled to receive dividends in any fiscal year, when, as, and if declared by the Board of Directors provided that such dividend payable on the Series B Preferred Stock shall not be lesser than the amount of any dividend to be
paid on any other class or series of capital stock. The Company shall not declare or pay any cash dividends on shares of common stock until each of the holders of the Preferred Stock then outstanding shall have first received, or there shall have
been declared and set aside for payment, a cash dividend on each outstanding share of Preferred Stock. No cash dividends have been declared since the Company&#146;s inception. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LYRA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The holders of Preferred Stock are entitled to vote on all matters with the common stockholders as if they were one class of stock. The
holders of Preferred Stock are entitled to the number of votes equal to the number of shares of common stock into which such holders&#146; share of the Preferred Stock is then convertible. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Conversion </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each share of
Preferred Stock is convertible, at the option of the holder, at any time, into one share of common stock, adjusted for certain dilutive events and per the conversion rates as defined below under &#147;Liquidation.&#148; In addition, all shares of
Preferred Stock will automatically convert into shares of common stock upon the earlier of (i)&nbsp;the closing of a firm commitment underwritten public offering in which the per share price to the public is not less than $2.06 per share, and which
results in at least $35.0&nbsp;million of gross proceeds to the Company or (ii)&nbsp;upon the written notice from the holders of at least 75% of the then-outstanding shares of Preferred Stock, voting together as a separate class on an <FONT
STYLE="white-space:nowrap">as-converted</FONT> basis at the then effective conversion rate. The Preferred Stock will convert at 1:1 ratio into shares of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the event of any
voluntary or involuntary liquidation, dissolution, or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company, including a change of control, as defined in its amended and restated certificate of incorporation, the holders of the Preferred
Stock will be entitled to be paid a preference payment, prior to any payment to holders of common stock or any other capital stock ranking junior on liquidation to the Preferred Stock. In the case of Series
<FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, this preference payment is equal to the greater of (a) $0.4162 per share, subject to certain adjustments, as defined, plus any dividends declared but unpaid on such shares, or (b)&nbsp;the
amount per share which the holders of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock would be entitled to if the shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock had been converted into shares of
common stock immediately prior to such voluntary or involuntary liquidation, dissolution, or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company. In the case of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, this
preference payment is equal to the greater of (a) $0.3397 per share, subject to certain adjustments, as defined, plus any dividends declared but unpaid on such shares, or (b)&nbsp;the amount per share which the holders of Series <FONT
STYLE="white-space:nowrap">A-2</FONT> Preferred Stock would be entitled to if the shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock had been converted into shares of common stock immediately prior to such voluntary or
involuntary liquidation, dissolution, or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company. In the case of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Stock, this preference payment is equal to the greater of (a)
$0.6245 per share, subject to certain adjustments, as defined, plus any dividends declared but unpaid on such shares, or (b)&nbsp;the amount per share which the holders of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Stock would be
entitled to if the shares of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Stock had been converted into shares of common stock immediately prior to such voluntary or involuntary liquidation, dissolution, or <FONT
STYLE="white-space:nowrap">winding-up</FONT> of the Company. In the case of Series <FONT STYLE="white-space:nowrap">A-4</FONT> Preferred Stock, this preference payment is equal to the greater of (a) $0.30 per share, subject to certain adjustments,
as defined, plus any dividends declared but unpaid on such shares, or (b)&nbsp;the amount per share which the holders of Series <FONT STYLE="white-space:nowrap">A-4</FONT> Preferred Stock would be entitled to if the shares of Series <FONT
STYLE="white-space:nowrap">A-4</FONT> Preferred Stock had been converted into shares of common stock immediately prior to such voluntary or involuntary liquidation, dissolution, or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company.
In the case of Series B Preferred Stock, this preference payment is equal to the greater of (a) $0.30 per share, subject to certain adjustments, as defined, plus any dividends declared but unpaid on such shares, or (b)&nbsp;the amount per share
which the holders of Series B Preferred Stock would be entitled to if the shares of Series B Preferred Stock had been converted into shares of common stock immediately prior to such voluntary or involuntary liquidation, dissolution, or <FONT
STYLE="white-space:nowrap">winding-up</FONT> of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">After the payment of all required preferential amounts to the holders of
Preferred Stock, upon the dissolution, liquidation, or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company, any remaining assets and funds of the Company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LYRA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
available for distribution shall be distributed among the holders of the then outstanding common stock, pro rata, according to the number of shares of common stock held by such holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redemption </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Series <FONT
STYLE="white-space:nowrap">A-1,</FONT> <FONT STYLE="white-space:nowrap">A-2</FONT> <FONT STYLE="white-space:nowrap">A-3,</FONT> <FONT STYLE="white-space:nowrap">A-4</FONT> and B Preferred Stock are required to be redeemed by the Company at a price
of $0.4162, $0.3397, $0.6245, $0.30 and $0.30 per share, respectively, subject to certain adjustments, as defined in its amended and restated certificate of incorporation, plus all declared but unpaid dividends in three annual installments
commencing 60 days after receipt by the Company, at any time on or after June&nbsp;5, 2023 (the fifth anniversary of the Series B Preferred Stock original issue date), of written notice requesting redemption of all shares of Preferred Stock from the
holders of at least 75% of the then outstanding shares of Preferred Stock (which must include at least 50% of the then outstanding shares of Series B Preferred Stock). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Common Stock </B></P>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The holders of
common stock are entitled to one vote for each share held. Common stockholders are not entitled to receive dividends, unless declared by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has reserved for future issuances the following shares of common stock as of December&nbsp;31, 2019: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="55.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>December&nbsp;31,&nbsp;2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,017,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,680,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,070,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-4</FONT> Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,351,953</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,576,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">249,696,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Stock-Based Compensation Expense </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company adopted the 2016 Equity Incentive Plan (&#147;2016 Plan&#148;) in February 2016. Upon adoption of the 2016 Plan, no further grants
were made under the 2005 Equity Incentive Plan (&#147;2005 Plan&#148;, together with the 2016 Plan, the &#147;Plans&#148;). The 2016 Plan initially provided for the grant of awards for 4,500,000 shares of common stock. In June 2017, the Company
amended the 2016 Plan to provide for the grant of awards for a total of 14,200,000 shares of common stock. In June 2018, the Company amended the 2016 Plan to provide for the grant of awards for a total of 35,200,000 shares of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">All of the Company&#146;s employees, officers, directors, consultants and advisors are eligible to be granted options, restricted stock,
restricted stock units, and other share-based awards under the terms of the 2016 Plan. As of December&nbsp;31, 2019, 13,249,002&nbsp;shares of common stock were available for future grant under the 2016 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">All stock option grants are <FONT STYLE="white-space:nowrap">non-statutory</FONT> stock options except option grants to employees and officers
intended to qualify as incentive stock options under the Internal Revenue Code of 1986, as amended. Stock options may not be granted at less than the fair market value of the Company&#146;s common stock on the date of grant. Vesting periods of
awards are determined by the Board of Directors. Vesting periods of awards granted to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LYRA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
date range from vesting upon grant to vesting over a four-year period. Vesting conditions are generally based on service provisions, whereby the awards vest over time. Additionally, the Company
has granted certain awards which vest upon the achievement of certain financing and revenue milestones. Stock options granted under the Plans expire no more than 10 years from the date of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense included in the Company&#146;s statements of operations and comprehensive loss is as follows (in thousands):
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="55.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;2019&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;2018&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the year ended December&nbsp;31, 2018, the Company recorded approximately $36,000 of stock-based
compensation for the award related to the achievement of a financial-based milestone. The Company did not record any stock-based compensation associated with milestone-based awards in the year ended December&nbsp;31, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The fair value of each stock option granted to employees, directors and non-employees was estimated on the date of grant using the
Black-Scholes option-pricing model, with the following weighted-average assumptions: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="55.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;2019&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;2018&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A summary of the stock option activity under the Plans for the year ended December&nbsp;31, 2019 is
as follows: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Weighted-<BR>Average<BR>Exercise<BR>Price</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Weighted-<BR>Average<BR>Remaining<BR>Contractual<BR>Life</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>(in years)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aggregate<BR>Intrinsic&nbsp;Value</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>(in&nbsp;thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,092,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,711,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,093,403</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(382,854</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,327,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,123,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and expected to vest at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,327,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The weighted-average fair value of options granted to employees and directors during the years ended
December&nbsp;31, 2019 and 2018 was $0.10 and $0.06, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LYRA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The aggregate intrinsic value of stock options is calculated as the difference between
the exercise price of the stock options and the fair value of the Company&#146;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#146;s common stock. The total intrinsic value of options
exercised during the years ended December&nbsp;31, 2019 and 2018 was approximately $0.1 million and $0, respectively. The Company satisfies stock option exercises with newly issued shares of its common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019, total unrecognized stock-based compensation expense relating to unvested stock options was approximately
$1.0&nbsp;million. This amount is expected to be recognized over a weighted-average period of 3.3&nbsp;years. Additionally, as of December&nbsp;31, 2019, there was approximately $36,000 of unrecognized stock-based compensation related to a stock
option award related to the achievement of a revenue-based milestone. As the Company believes the achievement of the revenue-based milestone is currently not probable, it has not recorded any stock-based compensation related to this award. The
Company will continue to assess the probability of achieving the revenue-based milestone at each reporting period. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Related Parties </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has consulting agreements with two of its founders who are also directors of the Company. Total consulting expense related to
these consulting agreements was approximately $50,000 in each of the years ended December&nbsp;31, 2019 and 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company entered
into a Contribution Agreement, Transition Services Agreement (as amended), Collaboration Agreement, Technology License Agreement and Trademark Coexistence Agreement with Arsenal Medical, Inc. (&#147;Arsenal&#148;), a company which shares certain
common owners with the Company. During the years ended December&nbsp;31, 2019 and 2018, the Company invoiced Arsenal for an aggregate of approximately $0.3&nbsp;million and $1.0&nbsp;million, respectively, primarily for its employee costs and its
share of rent and other overhead costs. Additionally, during the year ended December&nbsp;31, 2018, the Company invoiced Arsenal approximately $0.2&nbsp;million for certain costs incurred in connection with Arsenal&#146;s grants with the government.
The Company has reflected these billed amounts as offsets against operating expenses in the accompanying consolidated statements of operations and comprehensive loss. Of these charges, approximately $0.7&nbsp;million remained unpaid as of
December&nbsp;31, 2018 and are included in prepaid expenses and other current assets in the accompanying consolidated balance sheet. All amounts receivable from Arsenal were collected as of December 31, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Income Taxes </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company records a
provision or benefit for income taxes on <FONT STYLE="white-space:nowrap">pre-tax</FONT> income or loss based on its estimated effective tax rate for the year. During the years ended December&nbsp;31, 2019 and 2018, the Company recorded net losses
of approximately $16.3 million and $6.0&nbsp;million, respectively, and, since it maintains a full valuation allowance on its deferred tax assets, the Company did not record an income tax benefit for the years ended December&nbsp;31, 2019 and 2018.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LYRA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A reconciliation of income tax expense computed at the statutory federal income tax rate to
income taxes reflected in the consolidated financial statements is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax computed at federal statutory tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Permanent differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.2</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State taxes, net of federal benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development and other tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in deferred tax asset valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30.7</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33.3</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.1</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.8</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Net deferred tax assets as of December&nbsp;31, 2019 and 2018 consisted of the following (in
thousands): </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>December&nbsp;31, </B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total gross deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,144</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease right-of-use asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(870</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(870</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019, the Company had U.S. federal net operating loss carryforwards of
approximately $91.4&nbsp;million which may be able to offset future income tax liabilities and expire at various dates through 2037 and approximately $22.9&nbsp;million of federal net operating loss carryforwards that may be carried forward
indefinitely. As of December&nbsp;31, 2019, the Company also had state net operating loss carryforwards of approximately $95.6&nbsp;million which may be available to offset future income tax liabilities and expire at various dates through 2039. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019 and 2018, the Company had federal research and development tax credit carryforwards of approximately $3.2 million
and $2.7&nbsp;million, respectively, available to reduce future tax liabilities which expire at various dates through 2039. As of December&nbsp;31, 2019 and 2018, the Company had state research and development tax credit carryforwards of
approximately $1.8 million and $1.7&nbsp;million, respectively, available to reduce future tax liabilities which expire at various dates through 2034. The Company has generated research credits but has not conducted a study to document the qualified
activity. This study may result in an adjustment to the Company&#146;s research and development credit carryforwards; however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position. A
full valuation allowance has been provided against the Company&#146;s research and development credits and, if an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LYRA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adjustment is required, this adjustment would be offset by an adjustment to the deferred tax asset established for the research and development credit carryforwards and the valuation allowance.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the provisions of the Internal Revenue Code, the net operating loss and tax credit carryforwards are subject to review and possible
adjustment by the Internal Revenue Service and state tax authorities. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant
shareholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized
annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the
limitation in future years. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with
such a study. If the Company has experienced a change of control, as defined by Section&nbsp;382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject
to an annual limitation under Section&nbsp;382, which is determined by first multiplying the value of the Company&#146;s stock at the time of the ownership change by the applicable long-term <FONT STYLE="white-space:nowrap">tax-exempt</FONT> rate,
and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. Further, until a
study is completed by the Company and any limitation is known, no amounts are being presented as an uncertain tax position. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">ASC 740
requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the
evidence, both positive and negative, the Company has recorded a valuation allowance against its deferred tax assets at December&nbsp;31, 2019 and 2018 because the Company&#146;s management has determined that it is more likely than not that the
Company will not recognize the benefits of its federal and state deferred tax assets primarily due to its history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from
product sales since inception and, as a result, a valuation allowance of approximately $35.2 million and $30.1&nbsp;million, respectively, has been established at December&nbsp;31, 2019 and 2018. Management reevaluates the positive and negative
evidence at each reporting period. The valuation allowance increased by approximately $5.1 million and $2.0&nbsp;million, respectively, during the years ended December&nbsp;31, 2019 and 2018 due primarily to the generation of net operating losses.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has recorded adjustments to deferred tax assets for unrecognized tax benefits as of December&nbsp;31, 2019 and 2018. The
Company&#146;s policy is to record interest and penalties related to uncertain tax positions as part of its income tax provision. As of December&nbsp;31, 2019 and 2018, the Company had no accrued interest or penalties related to uncertain tax
positions and no such amounts have been recognized in the Company&#146;s statement of operations and comprehensive loss. In many cases, the Company&#146;s uncertain tax positions are related to years that remain subject to examination by relevant
tax authorities. The statute of limitations for federal and state tax authorities is closed for years prior to December&nbsp;31, 2016. However, since the Company is in a loss carryforward position, the Company is generally subject to examination by
the U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is available. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Leases </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In August 2007, the Company entered into an operating lease, as amended, for approximately 22,343 square feet of office and laboratory space
in Watertown, Massachusetts. In November 2017, the Company amended its lease (&#147;2017 Amendment&#148;) and extended the lease term through April 2023. Initial base rent under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LYRA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the 2017 Amendment was approximately $1.0&nbsp;million per year. The 2017 Amendment includes annual rent escalations over the term of the operating lease. The Company maintains a letter of credit
of approximately $0.3&nbsp;million securing its obligations under the operating lease which is secured by approximately $0.3&nbsp;million of certificate of deposits, which are included as restricted cash in the consolidated balance sheets. At
December&nbsp;31, 2018 rent escalations are included in deferred rent in the consolidated balance sheets. Rent expense is recognized on a straight-line basis over the terms of occupancy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The components of lease cost recorded in the Company&#146;s consolidated financial statements were as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="55.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Year&nbsp;Ended</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>December&nbsp;31,<BR>2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease Cost:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Variable lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sublease income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease cost, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Variable lease payments include the Company&#146;s allocated share of costs incurred and expenditures
made by the landlord in the operation and management of the building. The Company&#146;s sublease income during the year ended December 31, 2019 related to subleases for a portion of the Company&#146;s office and lab space. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The weighted-average remaining lease term and discount rate related to the Company&#146;s operating lease were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2019</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average remaining lease term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="right">3.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="right">5.5%</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Maturity of the Company&#146;s operating lease liability in accordance with ASC 842 as of December
31, 2019 are as follows (in thousands): </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Year ending December 31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total maturities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Amount representing interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(327</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Present value of operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Current portion of operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(899</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating lease liability, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Rent expense for the year ended December&nbsp;31, 2018 was approximately $0.5&nbsp;million. Rent expense
was net of sublease income of approximately $0.5&nbsp;million for the year ended December&nbsp;31, 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LYRA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Retirement Plan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has a defined-contribution plan under Section&nbsp;401(k) of the Internal Revenue Code (&#147;401(k) Plan&#148;). The 401(k) Plan
covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a <FONT STYLE="white-space:nowrap">pre-tax</FONT> basis. As currently established, the Company is
not required to make and to date has not made any contributions to the 401(k) Plan. The Company did not make any matching contributions during the years ended December&nbsp;31, 2019 and 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Subsequent Event </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On January 10,
2020, the Company filed an amended and restated certificate of incorporation which authorizes its Board of Directors to issue up to 299,300,288 shares of preferred stock, par value $0.001 per share, and up to 400,000,000 shares of common stock, par
value $0.001 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In January 2020, the Company issued 78,306,611 shares of Series C redeemable convertible preferred stock
(&#147;Series C Preferred Stock&#148;) for $0.38811 per share, in exchange for gross cash proceeds of approximately $30.4 million. In conjunction with the issuance of the Series C Preferred Stock, the Company issued warrants to purchase 23,491,979
shares of common stock at an exercise price $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. </P>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The rights, preferences,
and privileges of the Preferred Stock and Series C Preferred Stock (collectively, the &#147;2020 Preferred Stock&#148;) are the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The holders of 2020
Preferred Stock are entitled to receive dividends in any fiscal year, when, as, and if declared by the Board of Directors provided that such dividend payable on the Series C Preferred Stock and Series B Preferred Stock shall not be lesser than the
amount of any dividend to be paid on any other class or series of capital stock. The Company shall not declare or pay any cash dividends on shares of common stock until each of the holders of the 2020 Preferred Stock then outstanding shall have
first received, or there shall have been declared and set aside for payment, a cash dividend on each outstanding share of 2020 Preferred Stock. No cash dividends have been declared since the Company&#146;s inception. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The holders of 2020
Preferred Stock are entitled to vote on all matters with the common stockholders as if they were one class of stock. The holders of 2020 Preferred Stock are entitled to the number of votes equal to the number of shares of common stock into which
such holders&#146; share of the 2020 Preferred Stock is then convertible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Conversion </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each share of 2020 Preferred Stock is convertible, at the option of the holder, at any time, into one share of common stock, adjusted for
certain dilutive events and per the conversion rates as defined below under &#147;Liquidation.&#148; In addition, all shares of 2020 Preferred Stock will automatically convert into shares of common stock upon the earlier of (i) the closing of a firm
underwritten public offering which results in at least $40.0 million of net proceeds to the Company or (ii) upon the written notice from the holders of a majority of the then-outstanding shares of 2020 Preferred Stock, voting together as a separate
class on an as-converted basis at the then effective conversion rate. The 2020 Preferred Stock will convert at 1:1 ratio into shares of common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LYRA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the event of any voluntary or involuntary liquidation, dissolution, or winding-up of the Company, including a change of control, as defined
in its amended and restated certificate of incorporation, the holders of the 2020 Preferred Stock will be entitled to be paid a preference payment, prior to any payment to holders of common stock or any other capital stock ranking junior on
liquidation to the 2020 Preferred Stock. In the case of Series A-1 Preferred Stock, (a) for the previously outstanding Series A preferred stock this preference payment is equal to the greater of (i) $0.4058 per share, subject to certain adjustments,
as defined, plus any dividends declared but unpaid on such shares, or (ii)&nbsp;the amount per share which the holders of the previously outstanding Series A preferred stock would be entitled to if the shares of the previously outstanding Series A
had been converted into shares of common stock immediately prior to such voluntary or involuntary liquidation, dissolution, or winding-up of the Company; (b) for the previously outstanding Series B preferred stock this preference payment is equal to
the greater of (i) $0.4503 per share, subject to certain adjustments, as defined, plus any dividends declared but unpaid on such shares, or (ii)&nbsp;the amount per share which the holders of the previously outstanding Series B preferred stock would
be entitled to if the shares of the previously outstanding Series B had been converted into shares of common stock immediately prior to such voluntary or involuntary liquidation, dissolution, or winding-up of the Company; and (c) for the previously
outstanding Series C preferred stock this preference payment is equal to the greater of (i) $0.4002 per share, subject to certain adjustments, as defined, plus any dividends declared but unpaid on such shares, or (ii)&nbsp;the amount per share which
the holders of the previously outstanding Series C preferred stock would be entitled to if the shares of the previously outstanding Series C had been converted into shares of common stock immediately prior to such voluntary or involuntary
liquidation, dissolution, or winding-up of the Company. In the case of Series A-2 Preferred Stock, this preference payment is equal to the greater of (a) $0.3397 per share, subject to certain adjustments, as defined, plus any dividends declared but
unpaid on such shares, or (b)&nbsp;the amount per share which the holders of Series A-2 Preferred Stock would be entitled to if the shares of Series A-2 Preferred Stock had been converted into shares of common stock immediately prior to such
voluntary or involuntary liquidation, dissolution, or winding-up of the Company. In the case of Series A-3 Preferred Stock, this preference payment is equal to the greater of (a) $0.6245 per share, subject to certain adjustments, as defined, plus
any dividends declared but unpaid on such shares, or (b)&nbsp;the amount per share which the holders of Series A-3 Preferred Stock would be entitled to if the shares of Series A-3 Preferred Stock had been converted into shares of common stock
immediately prior to such voluntary or involuntary liquidation, dissolution, or winding-up of the Company. In the case of Series A-4 Preferred Stock, this preference payment is equal to the greater of (a) $0.30 per share, subject to certain
adjustments, as defined, plus any dividends declared but unpaid on such shares, or (b)&nbsp;the amount per share which the holders of Series A-4 Preferred Stock would be entitled to if the shares of Series A-4 Preferred Stock had been converted into
shares of common stock immediately prior to such voluntary or involuntary liquidation, dissolution, or winding-up of the Company. In the case of Series B Preferred Stock, this preference payment is equal to the greater of (a) $0.30 per share,
subject to certain adjustments, as defined, plus any dividends declared but unpaid on such shares, or (b)&nbsp;the amount per share which the holders of Series B Preferred Stock would be entitled to if the shares of Series B Preferred Stock had been
converted into shares of common stock immediately prior to such voluntary or involuntary liquidation, dissolution, or winding-up of the Company. In the case of Series C Preferred Stock, this preference payment is equal to the greater of (a) $0.38811
per share, subject to certain adjustments, as defined, plus any dividends declared but unpaid on such shares, or (b)&nbsp;the amount per share which the holders of Series C Preferred Stock would be entitled to if the shares of Series C Preferred
Stock had been converted into shares of common stock immediately prior to such voluntary or involuntary liquidation, dissolution, or winding-up of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">After the payment of all required preferential amounts to the holders of 2020 Preferred Stock, upon the dissolution, liquidation, or
winding-up of the Company, any remaining assets and funds of the Company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LYRA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
available for distribution shall be distributed among the holders of the then outstanding common stock, pro rata, according to the number of shares of common stock held by such holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redemption </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Series A-1, A-2 A-3,
A-4, B and C Preferred Stock are required to be redeemed by the Company at a price of $0.4162, $0.3397, $0.6245, $0.30, $0.30 and $0.38811 per share, respectively, subject to certain adjustments, as defined in its amended and restated certificate of
incorporation, plus all declared but unpaid dividends in three annual installments commencing 60 days after receipt by the Company, at any time on or after January 10, 2025 (the fifth anniversary of the Series C Preferred Stock original issue date),
of written notice requesting redemption of all shares of 2020 Preferred Stock from the holders of a majority of the then outstanding shares of 2020 Preferred Stock (which must include at least 50% of the then outstanding shares of Series B Preferred
Stock and 50% of the then outstanding shares of Series C Preferred Stock). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Through and including
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, (the 25th day after the date of this prospectus), all dealers effecting transactions in the Common Stock, whether or not participating in this
offering, may be required to deliver a prospectus. This delivery requirement is in addition to a dealer&#146;s obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription. </P>
<P STYLE="margin-top:75pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g805799g27k30.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:75pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
</B></P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center>
<P STYLE="margin-top:75pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>BofA Securities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Jefferies </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>William
Blair </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>BTIG </B></P>
<P STYLE="margin-top:75pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P><center>
<P STYLE="line-height:3.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P></center>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;13. Other Expenses of Issuance and Distribution. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table indicates the expenses to be incurred in connection with the offering described in this registration statement, other than
underwriting discounts and commissions, all of which will be paid by us. All amounts are estimated except the Securities and Exchange Commission registration fee, the Financial Industry Regulatory Authority, Inc., or FINRA, filing fee and the Nasdaq
listing fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Amount</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Securities and Exchange Commission registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accountants&#146; fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Blue Sky fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer Agent&#146;s fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be filed by amendment. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;14. Indemnification of Directors and Officers. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Section&nbsp;102 of the General Corporation Law of the State of Delaware permits a corporation to eliminate the personal liability of
directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional
misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. Our restated certificate of incorporation provides that no
director of the Registrant shall be personally liable to it or its stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except to the extent that the General
Corporation Law of the State of Delaware prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the General Corporation Law of the State of Delaware provides that a corporation has the power to indemnify a director,
officer, employee, or agent of the corporation, or a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in related capacities against expenses (including attorneys&#146;
fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he was or is a party or is threatened to be made a party to any threatened, ending or
completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding,
had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall
have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such
person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our restated certificate of incorporation provides that we will indemnify each person who
was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of us) by reason of the fact that he or she is or was, or has agreed to become, a director
or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (all such
persons being referred to as an &#147;Indemnitee&#148;), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement
actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, and,
with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful. Our restated certificate of incorporation provides that we will indemnify any Indemnitee who was or is a party to an
action or suit by or in the right of us to procure a judgment in our favour by reason of the fact that the Indemnitee is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as a
director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against
all expenses (including attorneys&#146; fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in
good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, except that no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be
liable to us, unless a court determines that, despite such adjudication but in view of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been
successful, on the merits or otherwise, he or she will be indemnified by us against all expenses (including attorneys&#146; fees) actually and reasonably incurred in connection therewith. Expenses must be advanced to an Indemnitee under certain
circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with each of our directors and officers. These indemnification agreements
may require us, among other things, to indemnify our directors and officers for some expenses, including attorneys&#146; fees, judgments, fines and settlement amounts incurred by a director or officer in any action or proceeding arising out of his
or her service as one of our directors or officers, or any of our subsidiaries or any other company or enterprise to which the person provides services at our request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We maintain a general liability insurance policy that covers certain liabilities of directors and officers of our corporation arising out of
claims based on acts or omissions in their capacities as directors or officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In any underwriting agreement we enter into in connection
with the sale of common stock being registered hereby, the underwriters will agree to indemnify, under certain conditions, us, our directors, our officers and persons who control us within the meaning of the Securities Act of 1933, as amended, or
the Securities Act, against certain liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;15. Recent Sales of Unregistered Securities. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Set forth below is information regarding shares of capital stock issued by the registrant within the past two years. Also included is the
consideration received by us for such shares and information relating to the section of the Securities Act, or rule of the Securities and Exchange Commission, under which exemption from registration was claimed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Issuance of Capital Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Since January&nbsp;1, 2017, the registrant issued (i) an aggregate of 98,351,953 shares of Series B preferred stock for an aggregate
consideration of approximately $29.5&nbsp;million to accredited investors, and (ii) an aggregate of 78,306,611 shares of our Series C preferred stock for an aggregate consideration of approximately $30.4&nbsp;million to accredited investors, in each
case, pursuant to Section&nbsp;4(a)(2) of the Securities Act and Rule 506 as a transaction not involving a public offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Equity Grants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Since January&nbsp;1, 2017, the registrant granted stock options to purchase an aggregate of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of its common stock, at a weighted average exercise price per share of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, to employees,
<FONT STYLE="white-space:nowrap">non-employees</FONT> and directors in connection with services provided to the registrant by such parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The issuances of such stock options, the shares of common stock issuable upon the exercise of such options and such restricted shares of
common stock were issued pursuant to written compensatory plans or arrangements with the registrant&#146;s employees, directors and consultants, in reliance on the exemption provided by Rule 701 promulgated under the Securities Act, or pursuant to
Section&nbsp;4(a)(2) under the Securities Act, relative to transactions by an issuer not involving any public offering, to the extent an exemption from such registration was required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Warrants </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Since January 1, 2017, the registrant issued warrants to purchase up to an aggregate of 23,491,979 shares of common stock to accredited
investors pursuant to Section 4(a)(2) of the Securities Act as a transaction not involving a public offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Issuance of Notes </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On March&nbsp;14, 2018, the registrant issued up to $500,000 in aggregate principal amount of convertible promissory notes to accredited
investors pursuant to Section&nbsp;4(a)(2) of the Securities Act as a transaction not involving a public offering. On June&nbsp;5, 2018, upon the closing of the Series B preferred stock financing, these convertible promissory notes, as well as
accrued interest thereon, converted into 1,685,297 shares of Series B preferred stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;16. Exhibits and Financial Statement Schedules. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Exhibits. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Underwriting Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certificate of Incorporation of the Registrant, as amended (currently in effect)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Bylaws of the Registrant (currently in effect)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Restated Certificate of Incorporation of the Registrant (to be effective upon the closing of this offering)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.4*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Restated Bylaws of the Registrant (to be effective upon the closing of this offering)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Eighth Amended and Restated Investor Rights Agreement, dated as of January&nbsp;10, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Stock Certificate evidencing the shares of common stock</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Warrants to Purchase Common Stock, dated various dates, issued by the Registrant to various investors, together with a schedule of warrants and warrantholders</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of Latham&nbsp;&amp; Watkins LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1#**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2005 Equity Incentive Plan, as amended, and form of agreements thereunder</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2#**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2016 Equity Incentive Plan, as amended, and form of agreements thereunder</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2020 Incentive Award Plan and form of agreements thereunder</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Program</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2020 Employee Stock Purchase Plan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Indemnification Agreement for directors and officers of the Registrant</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Lease Agreement between the Registrant and <FONT STYLE="white-space:nowrap">ARE-480</FONT> Arsenal St, LLC, dated August&nbsp;14, 2007, as amended</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Employment Agreement between the Registrant and Maria Palasis, Ph.D.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Offer Letter between the Registrant and R. Don Elsey</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Offer Letter between the Registrant and Laura Edgerly-Pflug</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Subsidiaries of the Registrant</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of BDO USA, LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Latham&nbsp;&amp; Watkins LLP (included in Exhibit 5.1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Power of Attorney (included on signature page)</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be filed by amendment. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Previously Filed </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">#</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indicates management contract or compensatory plan. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Financial Statement Schedules. Schedules not listed above have been omitted because the information required to be set forth therein is
not applicable or is shown in the financial statements or notes thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;17. Undertakings. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes to provide to the underwriter, at the closing specified in the underwriting agreement,
certificates in such denominations and registered in such names as required by the underwriter to permit prompt delivery to each purchaser. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of
the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is,
therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful
defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The undersigned hereby undertakes that: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For purposes of determining any liability under the Securities Act of 1933, the information omitted from the
form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be
part of this registration statement as of the time it was declared effective. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment
that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by
the undersigned, thereunto duly authorized, in the City of Watertown, Commonwealth of Massachusetts, on this &nbsp;&nbsp;&nbsp;&nbsp; day of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">LYRA THERAPEUTICS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Maria Palasis, Ph.D.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">President and Chief
Executive Officer</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES AND POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We, the undersigned officers and directors of Lyra Therapeutics, Inc., hereby severally constitute and appoint Maria Palasis, Ph.D. and R. Don
Elsey, and each of them singly (with full power to each of them to act alone), our true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, with full power of substitution and
resubstitution in each of them for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement (or any other registration
statement for the same offering that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and
Exchange Commission, granting unto said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, and each of them, full power and authority to do and perform each and every act and thing requisite
or necessary to be done in and about the premises, as full to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents or any of them, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the
capacities held on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Maria Palasis, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President, Chief Executive Officer and Director (principal executive officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">R. Don Elsey</P>
<P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer (principal financial officer and principal accounting officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</P>
<P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Michael Altman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director</P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</P>
<P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Edward Anderson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director</P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</P>
<P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Robert S. Langer, D.Sc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director</P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</P>
<P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">C. Ann Merrifield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</P>
<P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:1pt">&nbsp;</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Konstantin Poukalov</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director</P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</P>
<P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">W. Bradford Smith</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director</P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</P>
<P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">George Whitesides, Ph.D.</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-7 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>filename2.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">State of Delaware</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Secretary of State</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Division of
Corporations</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Delivered 12:28 PM 01/10/2020</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FILED 12:28 PM 01/10/2020</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SR
20200201657 - File Number 4064768</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Exhibit 3.1</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LYRA THERAPEUTICS,
INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lyra Therapeutics, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the
&#147;<U>General Corporation Law</U>&#148;), does hereby certify as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The name of the corporation is Lyra Therapeutics, Inc. The
original Certificate of Incorporation of this corporation was filed with the Secretary of State of the State of Delaware on November&nbsp;21, 2005 under the corporate name WMR Biomedical, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. This Amended and Restated Certificate of Incorporation, which amends, restates and integrates the provisions of this corporation&#146;s
Certificate of Incorporation (this &#147;<U>Amended and Restated Certificate of Incorporation</U>&#148;), was duly adopted in accordance with the provisions of Sections 141, 242 and 245 of the General Corporation Law and by the written consent of
its stockholders in accordance Section&nbsp;228 of the General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. This corporation&#146;s Certificate of Incorporation
is hereby amended and restated in its entirety to provide as herein set forth in full. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>FIRST</U>: The name of the corporation is Lyra
Therapeutics, Inc. (the &#147;<U>Corporation</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>SECOND:</U> The address of the Corporation&#146;s registered office in the
State of Delaware is 1209 Orange Street, in the City of Wilmington, County of New Castle, State of Delaware, Zip Code 19801. The name of its registered agent at such address is: The Corporation Trust Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>THIRD:</U> The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the
General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>FOURTH:</U> Effective immediately and automatically upon the filing with the Secretary of State of the State
of Delaware of this Amended and Restated Certificate of Incorporation (the &#147;<U>Effective Time</U>&#148;), (i) each share of Series <FONT STYLE="white-space:nowrap">A-l</FONT> Preferred Stock (as defined below) that was previously reclassified
from <FONT STYLE="white-space:nowrap">Pre-Recapitalization</FONT> Series A Preferred Stock (as defined below) outstanding or issued and held in treasury immediately prior to the Effective Time shall be reclassified into one share of Series <FONT
STYLE="white-space:nowrap">A-l/A</FONT> Preferred Stock (as defined below), (ii) each share of Series <FONT STYLE="white-space:nowrap">A-l</FONT> Preferred Stock that was previously reclassified from
<FONT STYLE="white-space:nowrap">Pre-Recapitalization</FONT> Series B Preferred Stock (as defined below) outstanding or issued and held in treasury immediately prior to the Effective Time shall be reclassified into one share of Series <FONT
STYLE="white-space:nowrap">A-l/B</FONT> Preferred Stock (as defined below), and (iii)&nbsp;each share of Series <FONT STYLE="white-space:nowrap">A-l</FONT> Preferred Stock that was previously reclassified from
<FONT STYLE="white-space:nowrap">Pre-Recapitalization</FONT> Series C Preferred Stock (as defined below) outstanding or issued and held in treasury immediately prior to the Effective Time shall be reclassified into one share of Series <FONT
STYLE="white-space:nowrap">A-l/C</FONT> Preferred Stock (as defined below). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The total number of shares of all classes of stock which the Corporation shall have
authority to issue is Six Hundred Ninety-Nine Million Three Hundred Thousand Two Hundred Eighty-Eight (699,300,288), of which (a)&nbsp;Four Hundred Million (400,000,000) shares shall be Common Stock, $0.001 par value per share (&#147;<U>Common
Stock</U>&#148;), and (b)&nbsp;Two Hundred Ninety-Nine Million Three Hundred Thousand Two Hundred Eighty-Eight (299,300,288) shares shall be Preferred Stock, $0.001 par value per share (&#147;<U>Preferred Stock</U>&#148;), Seven Million Five Hundred
Fifty-Four Thousand Six Hundred Fifty-Four (7,554,654) of which shall be designated Series <FONT STYLE="white-space:nowrap">A-1/A</FONT> Convertible Preferred Stock (&#147;<U>Series <FONT STYLE="white-space:nowrap">A-l/A</FONT> Preferred
Stock</U>&#148;), Ten Million Five Thousand Six Hundred Seventy-Seven (10,005,677) of which shall be designated Series <FONT STYLE="white-space:nowrap">A-l/B</FONT> Convertible Preferred Stock (&#147;<U>Series
<FONT STYLE="white-space:nowrap">A-l/B</FONT> Preferred Stock</U>&#148;), Sixteen Million Four Hundred <FONT STYLE="white-space:nowrap">Fifty-Six</FONT> Thousand Seven Hundred Two (16,456,702) of which shall be designated Series <FONT
STYLE="white-space:nowrap">A-l/C</FONT> Convertible Preferred Stock (&#147;<U>Series <FONT STYLE="white-space:nowrap">A-l/C</FONT> Preferred Stock</U>&#148; and, together with the Series <FONT STYLE="white-space:nowrap">A-l/A</FONT> Preferred Stock
and the Series <FONT STYLE="white-space:nowrap">A-l/B</FONT> Preferred Stock, the &#147;<U>Series <FONT STYLE="white-space:nowrap">A-l</FONT> Preferred Stock</U>&#148;), <FONT STYLE="white-space:nowrap">Twenty-Six</FONT> Million Six Hundred Eighty
Thousand Two Hundred Two (26,680,202) of which shall be designated Series <FONT STYLE="white-space:nowrap">A-2</FONT> Convertible Preferred Stock (&#147;<U>Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock</U>&#148;), Thirty Million
Seventy Thousand Four Hundred Eighty-Seven (30,070,487) of which shall be designated Series <FONT STYLE="white-space:nowrap">A-3</FONT> Convertible Preferred Stock (&#147;<U>Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred
Stock</U>&#148;), Nineteen Million Nine Hundred Ninety-Nine Thousand Nine Hundred Ninety-Nine (19,999,999) of which shall be designated Series <FONT STYLE="white-space:nowrap">A-4</FONT> Convertible Preferred Stock (&#147;<U>Series <FONT
STYLE="white-space:nowrap">A-4</FONT> Preferred Stock</U>&#148;), Ninety-Eight Million Three Hundred <FONT STYLE="white-space:nowrap">Fifty-One</FONT> Thousand Nine Hundred Fifty-Three (98,351,953) of which shall be designated Series B Convertible
Preferred Stock (&#147;<U>Series B Preferred Stock</U>&#148;), and Ninety Million One Hundred Eighty Thousand Six Hundred Fourteen (90,180,614) of which shall be designated Series C Convertible Preferred Stock (&#147;<U>Series C Preferred
Stock</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a statement of the designations and the powers, privileges and rights, and the qualifications,
limitations or restrictions thereof, in respect of each class of capital stock of the Corporation. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>COMMON STOCK</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>General</U>. The voting, dividend and liquidation rights of the holders of Common Stock are subject to and qualified by the rights of the
holders of Preferred Stock of any series as may be designated by the Board of Directors of the Corporation (the &#147;<U>Board of Directors</U>&#148;) upon any issuance of Preferred Stock of any series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Voting</U>. The holders of Common Stock are entitled to one vote for each share held at all meetings of stockholders (and written
actions in lieu of meetings). There shall be no cumulative voting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of authorized shares of Common Stock may be increased or
decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the capital stock of the Corporation entitled to vote, irrespective of the provisions of Section&nbsp;242(b) of the
General Corporation Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Dividends</U>. Dividends may be declared and paid on Common Stock from funds lawfully
available therefor as and when determined by the Board of Directors and subject to any preferential dividend rights of any then outstanding Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Liquidation</U>. Upon the dissolution or liquidation of the Corporation, whether voluntary or involuntary, holders of Common Stock will
be entitled to receive all assets of the Corporation available for distribution to its stockholders, subject to any preferential rights of any then outstanding Preferred Stock. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>PREFERRED STOCK</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Preferred Stock has the following rights, preferences, powers, privileges and restrictions, qualifications and limitations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Dividends</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The
holders of shares of Preferred Stock shall be entitled to receive dividends in any fiscal year, when, as and if declared by the Board of Directors, out of any assets at the time legally available therefor, provided that such dividend payable on the
Series C Preferred Stock and Series B Preferred Stock shall not be lesser than the amount of any dividend to be paid on any other class or series of capital stock of the Corporation. Any dividends may, at the option of the holder of Preferred Stock,
be paid to such holder in such number of shares of Common Stock determined in accordance with the then effective Conversion Price (as defined below), as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Corporation shall not declare or pay any dividends on shares of any other class or series of capital stock of the Corporation (other
than dividends on shares of Common Stock payable in shares of Common Stock) unless each of the holders of the Series C Preferred Stock and Series B Preferred Stock then outstanding shall have first received, or there shall have been declared and set
aside for payment, a cash dividend on each outstanding share of Series C Preferred Stock and Series B Preferred Stock in an amount at least equal to the product of (i)&nbsp;the per share amount, if any, of the dividends to be declared, paid or set
aside for the Common Stock, multiplied by (ii)&nbsp;the number of shares of Common Stock into which such share of Series C Preferred Stock or Series B Preferred Stock, as applicable, is then convertible. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Thereafter, the Corporation shall not declare or pay any cash dividends on shares of Common Stock unless each of the holders of the Series
<FONT STYLE="white-space:nowrap">A-4</FONT> Preferred Stock and Junior Preferred Stock (as defined below) then outstanding shall have first received, or there shall have been declared and set aside for payment, a cash dividend on each outstanding
share of Series <FONT STYLE="white-space:nowrap">A-4</FONT> Preferred Stock and Junior Preferred Stock in an amount equal to the product of (i)&nbsp;the per share amount, if any, of the dividends to be declared, paid or set aside for the Common
Stock, multiplied by (ii)&nbsp;the number of shares of Common Stock into which such share of Series <FONT STYLE="white-space:nowrap">A-4</FONT> Preferred Stock and Junior Preferred Stock is then convertible. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Liquidation, Dissolution or Winding Up; Certain Mergers, Consolidations and Asset Sales</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Liquidation Amount</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Reference is hereby made to the Corporation&#146;s amended and restated certificate of incorporation as it was amended and restated on
August&nbsp;25, 2011, whereby effective immediately and automatically upon the filing by the Corporation with the Secretary of State of the State of Delaware of such amended and restated certificate of incorporation (the &#147;<U>Recapitalization
Effective Time</U>&#148;), (A) each share of the Corporation&#146;s Series A Convertible Preferred Stock, $0.001 par value per share (&#147;<U><FONT STYLE="white-space:nowrap">Pre-Recapitalization</FONT> Series A Preferred Stock</U>&#148;),
outstanding or issued and held in treasury immediately prior to the Recapitalization Effective Time was reclassified into one share of the Corporation&#146;s Series <FONT STYLE="white-space:nowrap">A-l</FONT> Preferred Stock, (B)&nbsp;each share of
the Corporation&#146;s Series B Convertible Preferred Stock, $0.001 par value per share (&#147;<U><FONT STYLE="white-space:nowrap">Pre-Recapitalization</FONT> Series B Preferred Stock</U>&#148;), outstanding or issued and held in treasury
immediately prior to the Recapitalization Effective Time was reclassified into such number of shares of Series <FONT STYLE="white-space:nowrap">A-l</FONT> Preferred Stock equal to the quotient of $1.43 divided by $1.32, and (C)&nbsp;each share of
the Corporation&#146;s Series C Convertible Preferred Stock, $0.001 par value per share (&#147;<U><FONT STYLE="white-space:nowrap">Pre-Recapitalization</FONT> Series C Preferred Stock</U>&#148;), outstanding or issued and held in treasury
immediately prior to the Recapitalization Effective Time was reclassified into one share of Series <FONT STYLE="white-space:nowrap">A-l</FONT> Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of shares of the
Series C Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Corporation available for distribution to its stockholders, before any payment shall be made to the holders of Series
<FONT STYLE="white-space:nowrap">A-l</FONT> Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Stock (together with the Series <FONT
STYLE="white-space:nowrap">A-l</FONT> Preferred Stock and the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, the &#147;<U>Junior Preferred Stock</U>&#148;), Series <FONT STYLE="white-space:nowrap">A-4</FONT> Preferred Stock,
Series B Preferred Stock, the Common Stock or any other class or series of stock ranking on liquidation junior to the Series C Preferred Stock by reason of their ownership thereof, an amount equal to the greater of (A)&nbsp;the Series C Per Share
Liquidation Amount (as defined below) plus any dividends declared but unpaid thereon, and (B)&nbsp;such amount per share as would have been payable had each such share of Series C Preferred Stock (but no other shares of Preferred Stock) converted
into Common Stock pursuant to Section&nbsp;4 immediately prior to such liquidation, dissolution or winding up. If upon any such liquidation, dissolution or winding up of the Corporation the remaining assets of the Corporation available for
distribution to its stockholders shall be insufficient to pay each of the holders of the Series C Preferred Stock the full amount to which such holder shall be entitled, the holders of the Series C Preferred Stock shall share ratably in any
distribution of the remaining assets and funds of the Corporation in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such
shares were paid in full. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation,
following any payments made to the holders of Series C Preferred Stock pursuant to the preceding paragraph, the holders of shares of the Series B Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Corporation
available for distribution to its stockholders, before any payment shall be made to the holders of Junior Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-4</FONT> Preferred Stock, the Common Stock or any other class or series of stock
ranking on liquidation junior to the Series B Preferred Stock by reason of their </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 4 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ownership thereof, an amount equal to the greater of (A)&nbsp;the Series B Per Share Liquidation Amount (as defined below) plus any dividends declared but unpaid thereon, and (B)&nbsp;such amount
per share as would have been payable had each such share of Series B Preferred Stock (but no other shares of Preferred Stock) converted into Common Stock pursuant to Section&nbsp;4 immediately prior to such liquidation, dissolution or winding up. If
upon any such liquidation, dissolution or winding up of the Corporation the remaining assets of the Corporation available for distribution to its stockholders shall, following payment to the holders of the Series C Preferred Stock under
Section&nbsp;2(a)(ii) above, be insufficient to pay each of the holders of the Series B Preferred Stock the full amount to which such holder shall be entitled, the holders of the Series B Preferred Stock and any class or series of stock ranking on
liquidation on a parity with the Series B Preferred Stock shall share ratably in any distribution of the remaining assets and funds of the Corporation in proportion to the respective amounts which would otherwise be payable in respect of the shares
held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) In the event of any
voluntary or involuntary liquidation, dissolution or winding up of the Corporation, following any payments made to the holders of Series C Preferred Stock and Series B Preferred Stock pursuant to the immediately preceding paragraphs, the holders of
shares of the Series <FONT STYLE="white-space:nowrap">A-4</FONT> Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Corporation available for distribution to its stockholders, before any payment shall be made to
the holders of Junior Preferred Stock, the Common Stock or any other class or series of stock ranking on liquidation junior to the Series <FONT STYLE="white-space:nowrap">A-4</FONT> Preferred Stock by reason of their ownership thereof, an amount
equal to the greater of (A)&nbsp;the Series <FONT STYLE="white-space:nowrap">A-4</FONT> Per Share Liquidation Amount (as defined below) plus any dividends declared but unpaid thereon, and (B)&nbsp;such amount per share as would have been payable had
each such share of Series <FONT STYLE="white-space:nowrap">A-4</FONT> Preferred Stock converted into Common Stock pursuant to Section&nbsp;4 immediately prior to such liquidation, dissolution or winding up, subject to the Liquidation Cap (as defined
below). If upon any such liquidation, dissolution or winding up of the Corporation the remaining assets of the Corporation available for distribution to its stockholders shall, following payment to the holders of the Series C Preferred Stock and
Series B Preferred Stock under Sections 2(a)(ii) and (iii)&nbsp;above, be insufficient to pay each of the holders of the Series <FONT STYLE="white-space:nowrap">A-4</FONT> Preferred Stock the full amount to which such holder shall be entitled, the
holders of the Series <FONT STYLE="white-space:nowrap">A-4</FONT> Preferred Stock and any class or series of stock ranking on liquidation on a parity with the Series <FONT STYLE="white-space:nowrap">A-4</FONT> Preferred Stock shall share ratably in
any distribution of the remaining assets and funds of the Corporation in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to
such shares were paid in full. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) In the event of any voluntary or involuntary liquidation, dissolution or winding up of the
Corporation, following any payments made to the holders of Series C Preferred Stock, Series B Preferred Stock and Series <FONT STYLE="white-space:nowrap">A-4</FONT> Preferred Stock pursuant to the preceding paragraphs, the holders of shares of the
Junior Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Corporation available for distribution to its stockholders, before any payment shall be made to the holders of the Common Stock or any other class or
series of stock ranking on liquidation junior to the Junior Preferred Stock by reason of their ownership thereof, an amount equal to (A)&nbsp;in the case of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, the greater of
(I)&nbsp;the applicable Series <FONT STYLE="white-space:nowrap">A-1</FONT> Per Share Liquidation Amount (as defined below) plus any dividends declared but unpaid thereon, or (II)&nbsp;such amount per share as would have
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 5 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
been payable had each such share of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock converted into Common Stock pursuant to Section&nbsp;4 immediately prior to such
liquidation, dissolution or winding up, (B)&nbsp;in the case of the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, the greater of (I)&nbsp;the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Per Share Liquidation Amount (as
defined below) plus any dividends declared but unpaid thereon, or (II)&nbsp;such amount per share as would have been payable had each such share of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock converted into Common Stock
pursuant to Section&nbsp;4 immediately prior to such liquidation, dissolution or winding up, and (C)&nbsp;in the case of the Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Stock, the greater of (I)&nbsp;the Series <FONT
STYLE="white-space:nowrap">A-3</FONT> Per Share Liquidation Amount (as defined below) plus any dividends declared but unpaid thereon, or (II)&nbsp;such amount per share as would have been payable had each such share of Series <FONT
STYLE="white-space:nowrap">A-3</FONT> Preferred Stock converted into Common Stock pursuant to Section&nbsp;4 immediately prior to such liquidation, dissolution or winding up. In calculating whether a particular series of Junior Preferred Stock would
receive upon conversion more than its stated liquidation amount, the conversion of each other series of Junior Preferred Stock is to be assumed if and only if such other series of Junior Preferred Stock would receive upon such conversion more than
its stated liquidation amount. The combined aggregate Series <FONT STYLE="white-space:nowrap">A-4</FONT> Per Share Liquidation Amount and Junior Preferred Liquidation Amount payable pursuant to Section&nbsp;2(a)(iv) and Section&nbsp;2(a)(v) shall
not exceed forty eight million dollars ($48,000,000) (the &#147;Liquidation Cap&#148;). The aggregate Series A-1 Per Share Liquidation Amount payable pursuant to clause (A)&nbsp;of this Section&nbsp;2(a)(v) shall in no event exceed $29,806,552. If
upon any such liquidation, dissolution or winding up of the Corporation the remaining assets of the Corporation available for distribution to its stockholders shall be insufficient to pay each of the holders of the Junior Preferred Stock the full
amount to which such holder shall be entitled, the holders of the Junior Preferred Stock and any class or series of stock ranking on liquidation on a parity with the Junior Preferred Stock shall share ratably in any distribution of the remaining
assets and funds of the Corporation in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) For purposes of this Article FOURTH, the following definitions shall apply: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(A) &#147;<U>Junior Preferred Liquidation Amount</U>&#148; means, collectively, the Series A-1 Per Share Liquidation Amount, Series <FONT
STYLE="white-space:nowrap">A-2</FONT> Per Share Liquidation Amount, and Series <FONT STYLE="white-space:nowrap">A-3</FONT> Per Share Liquidation Amount; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(B) &#147;<U>Series A-1 Per Share Liquidation Amount</U>&#148; means, at a time of determination: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(1) for each share of Series A-1/A Preferred Stock, $0.4058 per share (subject to appropriate adjustment in the event of any stock dividend,
stock split, combination or other similar recapitalization occurring after the date hereof and affecting the number of issued and outstanding shares of Series A-1/A Preferred Stock); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(2) for each share of Series A-1/B Preferred Stock, $0.4503 per share (subject to appropriate adjustment in the event of any stock dividend,
stock split, combination or other similar recapitalization occurring after the date hereof and affecting the number of issued and outstanding shares of Series <FONT STYLE="white-space:nowrap">A-1/B</FONT> Preferred Stock); and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 6 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(3) for each share of Series A-1/C Preferred Stock, $0.4002 per share (subject to
appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization occurring after the date hereof and affecting the number of issued and outstanding shares of Series A-1/C Preferred Stock); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(C) &#147;<U>Series <FONT STYLE="white-space:nowrap">A-2</FONT> Per Share Liquidation Amount</U>&#148; means $0.3397 per share (subject to
appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization occurring after the date hereof and affecting the number of issued and outstanding shares of Series
<FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(D) &#147;<U>Series <FONT STYLE="white-space:nowrap">A-3</FONT> Per Share
Liquidation Amount</U>&#148; means $0.6245 per share (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization occurring after the date hereof and affecting the number of issued
and outstanding shares of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Stock); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(E) &#147;<U>Series <FONT
STYLE="white-space:nowrap">A-4</FONT> Per Share Liquidation Amount</U>&#148; means $0.30 per share (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization occurring after the
date hereof and affecting the number of issued and outstanding shares of Series <FONT STYLE="white-space:nowrap">A-4</FONT> Preferred Stock); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(F) &#147;<U>Series B Per Share Liquidation Amount</U>&#148; means $0.30 per share (subject to appropriate adjustment in the event of any
stock dividend, stock split, combination or other similar recapitalization occurring after the date hereof and affecting the number of issued and outstanding shares of Series B Preferred Stock); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(G) &#147;<U>Series C Per Share Liquidation Amount</U>&#148; means $0.38811 per share (subject to appropriate adjustment in the event of any
stock dividend, stock split, combination or other similar recapitalization occurring after the date hereof and affecting the number of issued and outstanding shares of Series C Preferred Stock). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) Any sale, assignment, transfer or other disposition, whether voluntarily or by operation of law (collectively,
&#147;<U>Transfer</U>&#148;), of any shares of Preferred Stock shall be void and shall transfer no right, title, or interest in or to such shares to the purported transferee (the &#147;<U>Transferee</U>&#148;) unless prior to such Transfer the
purported transferor (the &#147;<U>Transferor</U>&#148;) of such shares delivers to the Secretary of the Corporation written notice of such Transfer (the &#147;<U>Transfer Notice</U>&#148;). The Transfer Notice shall specify: (i)&nbsp;the name and
address of the Transferee and (ii)&nbsp;the number of shares of Preferred Stock subject to the Transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) After the payment of all
preferential amounts required to be paid to the holders of Series C Preferred Stock, Series B Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-4</FONT> Preferred Stock, Junior Preferred Stock and any other class or series of stock of the
Corporation ranking on liquidation on a parity with the Series C Preferred Stock, Series B Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-4</FONT> Preferred Stock, or Junior Preferred Stock, upon the dissolution, liquidation or winding
up of the Corporation, any remaining assets and funds of the Corporation available for distribution to stockholders shall be distributed among the holders of the then outstanding Common Stock, pro rata according to the number of shares of Common
Stock held by such holders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 7 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) A merger or consolidation in which the Corporation is a constituent party (except any
such merger or consolidation involving the Corporation in which the holders of capital stock of the Corporation immediately prior to such merger or consolidation continue to hold immediately following such merger or consolidation a majority by
voting power of the capital stock of (1)&nbsp;the surviving or resulting corporation or (2)&nbsp;if the surviving or resulting corporation is a wholly owned subsidiary of another corporation immediately following such merger or consolidation, the
parent corporation of such resulting or surviving corporation, in each case in substantially the same proportions as such stockholders held the outstanding stock of the Corporation immediately prior thereto), or the sale, conveyance, lease, or other
transfer (including by an irrevocable, exclusive, worldwide license having a duration of not less than the then-remaining life of the patents included in such license) of all or substantially all of the assets of the Corporation (except where such
sale, conveyance, lease or other transfer is to a wholly owned subsidiary of the Corporation) shall be deemed to be a liquidation, dissolution or winding up of the Corporation for purposes of this Section&nbsp;2 unless (A)&nbsp;the holders of a
majority of the then outstanding shares of Preferred Stock voting together as a separate class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, and (B)&nbsp;the holders of a majority of the then outstanding shares of Series C
Preferred Stock voting together as a separate class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, elect otherwise by giving written notice thereof to the Corporation before the effective date of such event. The Corporation shall
promptly provide to the holders of shares of Preferred Stock such information concerning the terms of such merger, consolidation, sale, conveyance, lease or other transfer (including by an irrevocable, exclusive, worldwide license having a duration
of not less than the then-remaining life of the patents included in such license) and the value of the assets of the Corporation in order to assist the holders of shares of Preferred Stock in determining whether to make such an election. The amount
deemed distributed to the holders of Preferred Stock or Common Stock in connection with a transaction referred to in this Section&nbsp;2(c) shall be the cash or the value of the property, rights or other securities distributed to such holders by the
acquiring person, firm or other entity, or in the case of a sale, conveyance, lease or other transfer (including by an irrevocable, exclusive, worldwide license having a duration of not less than the then-remaining life of the patents included in
such license) of assets, shall be the cash or the value of the property, rights or other securities distributed to such holder of capital stock of the Corporation in a dividend relating to such transaction. The value or property, rights or other
securities shall be determined by and in the good faith discretion of the Board of Directors. Payment of preferential amounts required to be paid to the holders of Preferred Stock shall constitute a redemption of such Preferred Stock, and after such
payment such shares of Preferred Stock shall cease to be outstanding for any purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Voting.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each holder of outstanding shares of Preferred Stock shall be entitled to the number of votes equal to the number of whole shares of
Common Stock into which the shares of Preferred Stock held by such holder are then convertible (as adjusted from time to time pursuant to Section&nbsp;4 hereof), at each meeting of stockholders of the Corporation (and written actions of stockholders
in lieu of meetings) with respect to any and all matters presented to the stockholders of the Corporation for their action or consideration. Except as provided by law, or as otherwise set forth in this Amended and Restated Certificate of
Incorporation, holders of Preferred Stock shall vote together with the holders of Common Stock as a single class on any actions to be taken by the stockholders of the Corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 8 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In addition to any other vote required by law or this Amended and Restated Certificate
of Incorporation, without the written consent or affirmative vote of the holders of a majority of the shares of Series <FONT STYLE="white-space:nowrap">A-l</FONT> Preferred Stock then outstanding, the Corporation shall not, either directly or by
amendment, merger, consolidation or otherwise, amend or repeal the rights, preferences or privileges of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock set forth in this Amended and Restated Certificate of Incorporation, in a
manner that adversely affects the holders of the Series <FONT STYLE="white-space:nowrap">A-l</FONT> Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) In addition to
any other vote required by law or this Amended and Restated Certificate of Incorporation, without the written consent or affirmative vote of the holders of at least sixty-five percent (65%) of the shares of Series
<FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock then outstanding, the Corporation shall not, either directly or by amendment, merger, consolidation or otherwise, amend or repeal the rights, preferences or privileges of the Series <FONT
STYLE="white-space:nowrap">A-2</FONT> Preferred Stock set forth in this Amended and Restated Certificate of Incorporation, in a manner that adversely affects the holders of the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) In addition to any other vote required by law or this Amended and Restated Certificate of Incorporation, without the written consent or
affirmative vote of the holders of at least sixty-five percent (65%) of the shares of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Stock then outstanding, the Corporation shall not, either directly or by amendment, merger,
consolidation or otherwise, amend or repeal the rights, preferences or privileges of the Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Stock set forth in this Amended and Restated Certificate of Incorporation, in a manner that
adversely affects the holders of the Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) In addition to any other
vote required by law or this Amended and Restated Certificate of Incorporation, without the written consent or affirmative vote of the holders of at least sixty-five percent (65%) of the shares of Series <FONT STYLE="white-space:nowrap">A-4</FONT>
Preferred Stock then outstanding, the Corporation shall not, either directly or by amendment, merger, consolidation or otherwise, amend or repeal the rights, preferences or privileges of the Series <FONT STYLE="white-space:nowrap">A-4</FONT>
Preferred Stock set forth in this Amended and Restated Certificate of Incorporation, in a manner that adversely affects the holders of the Series <FONT STYLE="white-space:nowrap">A-4</FONT> Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) In addition to any other vote required by law or this Amended and Restated Certificate of Incorporation, without the written consent or
affirmative vote of the holders of a majority of the shares of Series B Preferred Stock then outstanding, the Corporation shall not, either directly or by amendment, merger, consolidation or otherwise, amend or repeal the rights, preferences or
privileges of the Series B Preferred Stock set forth in this Amended and Restated Certificate of Incorporation, in a manner that adversely affects the holders of the Series B Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) In addition to any other vote required by law or this Amended and Restated Certificate of Incorporation, without the written consent or
affirmative vote of the holders of a majority of the shares of Series C Preferred Stock then outstanding, the Corporation shall not, either directly or by amendment, merger, consolidation or otherwise, amend or repeal the rights, preferences or
privileges of the Series C Preferred Stock set forth in this Amended and Restated Certificate of Incorporation, in a manner that adversely affects the holders of the Series C Preferred Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 9 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) The holders of record of the shares of Series
<FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Stock, exclusively and as a separate class, shall be entitled to elect one (1)&nbsp;director of the Corporation (the &#147;<U>Series <FONT STYLE="white-space:nowrap">A-3</FONT>
Director</U>&#148;); the holders of record of the shares of Series <FONT STYLE="white-space:nowrap">A-4</FONT> Preferred Stock, exclusively and as a separate class, shall be entitled to elect one (1)&nbsp;director of the Corporation (the
&#147;<U>Series <FONT STYLE="white-space:nowrap">A-4</FONT> Director</U>&#148;); the holders of record of the shares of Series B Preferred Stock, exclusively and as a separate class, shall be entitled to elect one (1)&nbsp;director of the
Corporation (the &#147;<U>Series B Director</U>,&#148;); and the holders of record of the shares of Series C Preferred Stock, exclusively and as a separate class, shall be entitled to elect one (1)&nbsp;director of the Corporation (the
&#147;<U>Series C Director</U>,&#148; and, together with the Series <FONT STYLE="white-space:nowrap">A-3</FONT> Director, the Series <FONT STYLE="white-space:nowrap">A-4</FONT> Director and the Series B Director, the &#147;<U>Preferred
Directors</U>&#148;). Any director elected as provided in the preceding sentence may be removed with or without cause by, and only by, the affirmative vote of the holders of the shares of the class or series of capital stock entitled to elect such
director or directors, given either at a special meeting of such stockholders duly called for that purpose or pursuant to a written consent of stockholders. If the holders of shares of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred
Stock, Series <FONT STYLE="white-space:nowrap">A-4</FONT> Preferred Stock, Series B Preferred Stock, or Series C Preferred Stock, as the case may be, fail to elect a sufficient number of directors to fill all directorships for which they are
entitled to elect directors, voting exclusively and as a separate class, pursuant to the first sentence of this <U>Subsection 3(h),</U> then any directorship not so filled shall remain vacant until such time as the holders of the Series <FONT
STYLE="white-space:nowrap">A-3</FONT> Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-4</FONT> Preferred Stock, Series B Preferred Stock, or Series C Preferred Stock, as the case may be, elect a person to fill such directorship by vote or
written consent in lieu of a meeting; and no such directorship may be filled by stockholders of the Corporation other than by the stockholders of the Corporation that are entitled to elect a person to fill such directorship, voting exclusively and
as a separate class. The holders of record of the shares of Common Stock and of any other class or series of voting stock (including the Preferred Stock), voting together as a single class, shall be entitled to elect the balance of the total number
of directors of the Corporation. At any meeting held for the purpose of electing a director, the presence in person or by proxy of the holders of a majority of the outstanding shares of the class or series entitled to elect such director shall
constitute a quorum for the purpose of electing such director. Except as otherwise provided in this <U>Subsection 3(h)</U>, a vacancy in any directorship filled by the holders of any class or series shall be filled only by vote or written consent in
lieu of a meeting of the holders of such class or series or by any remaining director or directors elected by the holders of such class or series pursuant to this <U>Subsection 3(h)</U>. The rights of the holders of the Series <FONT
STYLE="white-space:nowrap">A-3</FONT> Preferred Stock under the first sentence of this <U>Subsection 3(h)</U> shall terminate on the first date following the Series C Original Issue Date (as defined below) on which there are issued and outstanding
less than Twenty Two Million Five Hundred <FONT STYLE="white-space:nowrap">Fifty-Two</FONT> Thousand Eight Hundred Sixty-Five (22,552,865) shares of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Stock (subject to appropriate
adjustment in the event of any stock dividend, stock split, combination, or other similar recapitalization with respect to the Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Stock). The rights of the holders of the Series <FONT
STYLE="white-space:nowrap">A-4</FONT> Preferred Stock under the first sentence of this <U>Subsection 3(h)</U> shall terminate on the first date following the Series C Original Issue Date (as defined below) on which there are issued and outstanding
less than Fourteen Million Nine Hundred Ninety-Nine Thousand Nine Hundred Ninety-Nine 14,999,999 shares of Series <FONT STYLE="white-space:nowrap">A-4</FONT> Preferred Stock (subject to appropriate adjustment in the event of any stock dividend,
stock split, combination, or other similar recapitalization with respect to the Series <FONT STYLE="white-space:nowrap">A-4</FONT> Preferred Stock). The rights of the holders of the Series B Preferred Stock under the first sentence of this
<U>Subsection 3(h)</U> shall terminate on the first date following the Series C Original Issue Date (as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 10 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
defined below) on which there are issued and outstanding less than Seven Million (7,000,000) shares of Series B Preferred Stock (subject to appropriate adjustment in the event of any stock
dividend, stock split, combination, or other similar recapitalization with respect to the Series B Preferred Stock). The rights of the holders of the Series C Preferred Stock under the first sentence of this <U>Subsection 3(h)</U> shall terminate on
the first date following the Series C Original Issue Date (as defined below) on which there are issued and outstanding less than Seven Million (7,000,000) shares of Series C Preferred Stock (subject to appropriate adjustment in the event of any
stock dividend, stock split, combination, or other similar recapitalization with respect to the Series C Preferred Stock). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) In
addition to any other rights provided by law, so long as at least Seven Million (7,000,000) shares of Series C Preferred Stock (such number to be proportionately adjusted in the event of any stock splits, stock dividends, recapitalizations or
similar events occurring after the date hereof and affecting the number of issued and outstanding shares of Preferred Stock) are outstanding, the Corporation shall not, without the prior written consent or affirmative vote of the holders of a
majority of the then outstanding shares of Series C Preferred Stock, voting together as a separate class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, take any of the following actions (whether by merger, consolidation or
otherwise): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) effect or obligate itself to effect, any merger, sale, lease, assignment, transfer or other conveyance (including by an
irrevocable, exclusive, worldwide license having a duration of not less than the then-remaining life of the patents included in such license) of all or substantially all of the assets of the Corporation and its subsidiaries, taken as a whole, or any
consolidation, merger or reorganization involving the Corporation or any subsidiary thereof, or any dissolution, liquidation or winding up of the Corporation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) authorize or issue any new or existing class or classes or series of capital stock having any preference or priority as to dividends,
liquidation preferences or redemption rights superior to or on a parity with the Series C Preferred Stock, or authorize or issue shares of stock of the Corporation of any class or any bonds, debentures, notes or other obligations convertible into or
exchangeable for, or having rights to purchase, any shares of stock of the Corporation having any preference or priority as to dividends, liquidation preferences or redemption rights superior to or on a parity with the Series C Preferred Stock; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) amend or delete any provision of, or add any provision to, this Amended and Restated Certificate of Incorporation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) purchase or redeem or pay any dividend on any capital stock prior to the Series C Preferred Stock; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) increase the number of shares of Common Stock available to be granted to employees, directors or consultants of the Corporation pursuant
to any of the Corporation&#146;s equity incentive plans, except as provided in any such plan that has been approved either by the Board of Directors, including a majority of the Preferred Directors; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) enter into any transaction with any affiliate of the Corporation (as defined in Rule 144 under the Securities Act (as defined below))
except for compensation and expense reimbursement arrangements with officers and outside directors in the ordinary course of business; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 11 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) grant any contractual rights to register shares of the Company&#146;s capital stock
under the Securities Act (other than pursuant to the Seventh Amended and Restated Investor Rights Agreement, dated on or about the date this Amended and Restated Certificate of Incorporation is filed with the Secretary of State of the State of
Delaware, by and among the Corporation and the other parties named therein, as such Seventh Amended and Restated Investor Rights Agreement may be amended from time to time in accordance with its terms (the &#147;<U>Investor Rights
Agreement</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(viii) reclassify any shares of capital stock of the Corporation; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ix) change the number of seats on the Board of Directors from eight (8)&nbsp;to any other number. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) In addition to any other rights provided by law, so long as at least Twenty Million (20,000,000) shares of Preferred Stock (such number to
be proportionately adjusted in the event of any stock splits, stock dividends, recapitalizations or similar events occurring after the date hereof and affecting the number of issued and outstanding shares of Preferred Stock) are outstanding, the
Corporation shall not, without the prior written consent or affirmative vote of the holders of a majority of the then outstanding shares of Preferred Stock, voting together as a separate class on an
<FONT STYLE="white-space:nowrap">as-converted</FONT> basis, take any of the following actions (whether by merger, consolidation or otherwise): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) effect or obligate itself to effect, any merger, sale, lease, assignment, transfer or other conveyance (including by an irrevocable,
exclusive, worldwide license having a duration of not less than the then-remaining life of the patents included in such license) of all or substantially all of the assets of the Corporation and its subsidiaries, taken as a whole, or any
consolidation, merger or reorganization involving the Corporation or any subsidiary thereof, or any dissolution, liquidation or winding up of the Corporation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) authorize or issue any new or existing class or classes or series of capital stock having any preference or priority as to dividends,
liquidation preferences or redemption rights superior to or on a parity with the Preferred Stock, or authorize or issue shares of stock of the Corporation of any class or any bonds, debentures, notes or other obligations convertible into or
exchangeable for, or having rights to purchase, any shares of stock of the Corporation having any preference or priority as to dividends, liquidation preferences or redemption rights superior to or on a parity with the Preferred Stock; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) amend or delete any provision of, or add any provision to, this Amended and Restated Certificate of Incorporation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) increase the number of shares of Common Stock available to be granted to employees, directors or consultants of the Corporation pursuant
to any of the Corporation&#146;s equity incentive plans, except as provided in any such plan that has been approved either by the Board of Directors, including a majority of the Preferred Directors; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 12 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) enter into any transaction with any affiliate of the Corporation (as defined in Rule
144 under the Securities Act (as defined below)) except for compensation and expense reimbursement arrangements with officers and outside directors in the ordinary course of business; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) grant any contractual rights to register shares of the Company&#146;s capital stock under the Securities Act (other than pursuant to the
Investor Rights Agreement); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) reclassify any shares of capital stock of the Corporation; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(viii) increase or decrease the size of the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As used in this Amended and Restated Certificate of Incorporation, &#147;<U>Securities Act</U>&#148; means the Securities Act of 1933, as amended, or any
successor federal statute, and the rules and regulations of the Securities and Exchange Commission issued under such Act, as they each may, from time to time, be in effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Optional Conversion</U>. The holders of the Preferred Stock shall have conversion rights as follows (the &#147;<U>Conversion
Rights</U>&#148;): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Right to Convert</U>. Each share of Series <FONT STYLE="white-space:nowrap">A-l</FONT> Preferred Stock shall be
convertible, at the option of the holder thereof, at any time and from time to time, and without the payment of additional consideration by the holder thereof, into such number of fully paid and nonassessable shares of Common Stock as is determined
by dividing $0.4162 (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization occurring after the date hereof and affecting the number of issued and outstanding shares of Series
<FONT STYLE="white-space:nowrap">A-l</FONT> Preferred Stock) by the Series <FONT STYLE="white-space:nowrap">A-l</FONT> Conversion Price (as defined below) in effect at the time of conversion. Each share of Series
<FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock shall be convertible, at the option of the holder thereof, at any time and from time to time, and without the payment of additional consideration by the holder thereof, into such number of
fully paid and nonassessable shares of Common Stock as is determined by dividing $0.3397 (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization occurring after the date
hereof and affecting the number of issued and outstanding shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock) by the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Conversion Price (as defined below) in effect at the
time of conversion. Each share of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Stock shall be convertible, at the option of the holder thereof, at any time and from time to time, and without the payment of additional consideration by
the holder thereof, into such number of fully paid and nonassessable shares of Common Stock as is determined by dividing $0.6245 (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar
recapitalization occurring after the date hereof and affecting the number of issued and outstanding shares of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Stock) by the Series <FONT STYLE="white-space:nowrap">A-3</FONT> Conversion
Price (as defined below) in effect at the time of conversion. Each share of Series <FONT STYLE="white-space:nowrap">A-4</FONT> Preferred Stock shall be convertible, at the option of the holder thereof, at any time and from time to time, and without
the payment of additional consideration by the holder thereof, into such number of fully paid and nonassessable shares of Common Stock as is determined by dividing $0.30 (subject to appropriate adjustment in the event of any stock dividend, stock
split, combination or other similar recapitalization occurring after the date hereof and affecting the number of issued and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 13 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outstanding shares of Series <FONT STYLE="white-space:nowrap">A-4</FONT> Preferred Stock) by the Series <FONT STYLE="white-space:nowrap">A-4</FONT> Conversion Price (as defined below) in effect
at the time of conversion. Each share of Series B Preferred Stock shall be convertible, at the option of the holder thereof, at any time and from time to time, and without the payment of additional consideration by the holder thereof, into such
number of fully paid and nonassessable shares of Common Stock as is determined by dividing $0.30 (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization occurring after the
date hereof and affecting the number of issued and outstanding shares of Series B Preferred Stock) by the Series B Conversion Price (as defined below) in effect at the time of conversion. Each share of Series C Preferred Stock shall be convertible,
at the option of the holder thereof, at any time and from time to time, and without the payment of additional consideration by the holder thereof, into such number of fully paid and nonassessable shares of Common Stock as is determined by dividing
$0.38811 (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization occurring after the date hereof and affecting the number of issued and outstanding shares of Series C
Preferred Stock) by the Series C Conversion Price (as defined below) in effect at the time of conversion. The &#147;<U>Series <FONT STYLE="white-space:nowrap">A-l</FONT> Conversion Price</U>&#148; shall mean $0.4162 at the date hereof, the
&#147;<U>Series <FONT STYLE="white-space:nowrap">A-2</FONT> Conversion Price</U>&#148; shall mean $0.3397 at the date hereof, the &#147;<U>Series <FONT STYLE="white-space:nowrap">A-3</FONT> Conversion Price</U>&#148; shall mean $0.6245 at the date
hereof, the &#147;<U>Series <FONT STYLE="white-space:nowrap">A-4</FONT> Conversion Price</U>&#148; shall mean $0.30 at the date hereof, the &#147;<U>Series B Conversion Price</U>&#148; shall mean $0.30 at the date hereof, and the &#147;<U>Series C
Conversion Price</U>&#148; shall mean $0.38811 at the date hereof. The &#147;<U>Conversion Price</U>&#148; shall mean, collectively, the Series <FONT STYLE="white-space:nowrap">A-l</FONT> Conversion Price, Series
<FONT STYLE="white-space:nowrap">A-2</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-3</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-4</FONT> Conversion Price, Series B Conversion Price, and Series C
Conversion Price, as applicable. Such initial Series <FONT STYLE="white-space:nowrap">A-l</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-3</FONT> Conversion
Price, Series <FONT STYLE="white-space:nowrap">A-4</FONT> Conversion Price, Series B Conversion Price, and Series C Conversion Price, and the rate at which shares of Series <FONT STYLE="white-space:nowrap">A-l</FONT> Preferred Stock, Series <FONT
STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-4</FONT> Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock may
be converted into shares of Common Stock, shall be subject to adjustment as provided below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) In the event of a notice of redemption
of any shares of Preferred Stock pursuant to Section&nbsp;6 hereof, the Conversion Rights of the shares designated for redemption shall terminate at the close of business on the full day preceding the date fixed for redemption, unless the redemption
price is not fully paid when due, in which case the Conversion Rights for such shares shall continue until such price is paid in full. In the event of a liquidation, dissolution or winding up of the Corporation, the Conversion Rights shall terminate
at the close of business on the second full day preceding the date fixed for the payment of any amounts distributable on such event to the holders of Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Fractional Shares</U>. No fractional shares of Common Stock shall be issued upon conversion of Preferred Stock. In lieu of any
fractional shares to which the holder would otherwise be entitled, the Corporation shall pay cash equal to such fraction multiplied by the then effective Series <FONT STYLE="white-space:nowrap">A-l</FONT> Conversion Price, Series <FONT
STYLE="white-space:nowrap">A-2</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-3</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-4</FONT> Conversion Price, Series B Conversion Price or Series C Conversion Price,
as the case may be. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 14 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Mechanics of Conversion</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) In order for a holder of Preferred Stock to voluntarily convert shares of Preferred Stock into shares of Common Stock, such holder shall
surrender the certificate or certificates for such shares of Preferred Stock (or, if such holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to
indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate), at the office of the transfer agent for the Preferred Stock (or at the principal office
of the Corporation if the Corporation serves as its own transfer agent), together with written notice that such holder elects to convert all or any number of the shares of Preferred Stock represented by such certificate or certificates and, if
applicable, any event on which such conversion is contingent. Such notice shall state such holder&#146;s name or the names of the nominees in which such holder wishes the certificate or certificates for shares of Common Stock to be issued. If
required by the Corporation, certificates surrendered for conversion shall be endorsed or accompanied by a written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the registered holder or his or its
attorney duly authorized in writing. The date of receipt of such certificates (or lost certificate affidavit and agreement) and notice by the transfer agent (or by the Corporation if the Corporation serves as its own transfer agent) shall be the
conversion date (&#147;<U>Conversion Date</U>&#148;), and such conversion shall be effective at the close of business on the Conversion Date. The Corporation shall, as soon as practicable after the Conversion Date, issue and deliver to such holder
of Preferred Stock, or to his or its nominees, a certificate or certificates for the number of shares of Common Stock to which such holder shall be entitled, together with cash in lieu of any fraction of a share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) The Corporation shall at all times when any Preferred Stock shall be outstanding, reserve and keep available out of its authorized but
unissued stock, for the purpose of effecting the conversion of the Preferred Stock, such number of its duly authorized shares of Common Stock as shall from time to time be sufficient to effect the conversion of all outstanding Preferred Stock; and
if at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect the conversion of all then outstanding shares of the Preferred Stock, the Corporation shall take such corporate action as may be necessary
to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purposes, including, without limitation, engaging in best efforts to obtain the requisite stockholder approval of any necessary
amendment to this Amended and Restated Certificate of Incorporation. Before taking any action which would cause an adjustment reducing the Series <FONT STYLE="white-space:nowrap">A-l</FONT> Conversion Price, Series
<FONT STYLE="white-space:nowrap">A-2</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-3</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-4</FONT> Conversion Price, Series B Conversion Price, or Series C Conversion
Price below the then par value of the shares of Common Stock issuable upon conversion of the Series <FONT STYLE="white-space:nowrap">A-l</FONT> Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, Series <FONT
STYLE="white-space:nowrap">A-3</FONT> Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-4</FONT> Preferred Stock, Series B Preferred Stock, or Series C Preferred Stock, the Corporation will take any corporate action which may, in the
opinion of its counsel, be necessary in order that the Corporation may validly and legally issue fully paid and nonassessable shares of Common Stock at such adjusted Series <FONT STYLE="white-space:nowrap">A-l</FONT> Conversion Price, Series <FONT
STYLE="white-space:nowrap">A-2</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-3</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-4</FONT> Conversion Price, Series B Conversion Price, or Series C Conversion
Price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 15 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) Upon any such conversion, no adjustment to the Series
<FONT STYLE="white-space:nowrap">A-l</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-3</FONT> Conversion Price, Series
<FONT STYLE="white-space:nowrap">A-4</FONT> Conversion Price, Series B Conversion Price, or Series C Conversion Price shall be made for any declared but unpaid dividends on the Preferred Stock surrendered for conversion or on the Common Stock
delivered upon conversion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) All shares of Preferred Stock which shall have been surrendered for conversion as herein provided shall
no longer be deemed to be outstanding and all rights with respect to such shares, including the rights, if any, to receive notices and to vote, shall immediately cease and terminate at the close of business on the Conversion Date, except only the
right of the holders thereof to receive shares of Common Stock in exchange therefor, to receive payment in lieu of any fraction of a share otherwise issuable upon such conversion as provided above and to receive payment of any dividends declared but
unpaid thereon as of the close of business on the Conversion Date. Any shares of Preferred Stock so converted shall be retired and cancelled and shall not be reissued, and the Corporation (without the need for stockholder action) may from time to
time take such appropriate action as may be necessary to reduce the authorized number of shares of such series of Preferred Stock accordingly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) The Corporation shall pay any and all issue and other taxes that may be payable in respect of any issuance or delivery of shares of
Common Stock upon conversion of shares of Preferred Stock pursuant to this Section&nbsp;4. The Corporation shall not, however, be required to pay any tax which may be payable in respect of any transfer involved in the issuance and delivery of shares
of Common Stock in a name other than that in which the shares of Preferred Stock so converted were registered, and no such issuance or delivery shall be made unless and until the person or entity requesting such issuance has paid to the Corporation
the amount of any such tax or has established, to the satisfaction of the Corporation, that such tax has been paid. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Adjustments to
Conversion Prices for Diluting Issues</U>: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <U>Special Definitions</U>. For purposes of this Article FOURTH, the following definitions
shall apply: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(A) &#147;<U>Option</U>&#148; shall mean rights, options or warrants to subscribe for, purchase or otherwise acquire Common
Stock or Convertible Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(B) &#147;<U>Series C Original Issue Date</U>&#148; shall mean the first date on which a share of
Series C Preferred Stock was issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(C) &#147;<U>Convertible Securities</U>&#148; shall mean any evidences of indebtedness, shares or
other securities directly or indirectly convertible into or exchangeable for Common Stock, but excluding Options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(D)
&#147;<U>Additional Shares of Common Stock</U>&#148; shall mean all shares of Common Stock issued (or, pursuant to Subsection 4(d)(iii) below, deemed to be issued) by the Corporation after the Series C Original Issue Date other than: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(I) shares of Common Stock issued or issuable upon conversion or exchange of any Convertible Securities or exercise of any Options outstanding
on the Series C Original Issue Date; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 16 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(II) shares of Common Stock issued or issuable as a dividend or distribution on Preferred
Stock; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(III) shares of Common Stock issued or issuable by reason of a dividend, stock split,
<FONT STYLE="white-space:nowrap">split-up</FONT> or other distribution on shares of Common Stock that is covered by Subsection 4(e) or 4(f) below; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(IV) shares of Common Stock issued or issuable in a firm underwritten public offering pursuant to an effective registration statement under
the Securities Act of 1933, as amended; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(V) shares of Common Stock (or Options or Convertible Securities with respect thereto)
authorized for issuance as of November&nbsp;9, 2016 under the Corporation&#146;s 2005 Equity Incentive Plan, as amended (the &#147;<U>2005 Plan</U>&#148;), and the Corporation&#146;s 2016 Equity Incentive Plan, as amended (the &#147;<U>2016
Plan</U>&#148;, and together with the 2005 Plan, the &#147;<U>Plans</U>&#148;), that are issued or deemed issued to employees or directors of, or consultants to, the Corporation or any of its subsidiaries pursuant to the Plans, or any additional
shares of Common Stock (or Options or Convertible Securities with respect thereto) authorized for issuance pursuant to any amendment to the Plans, or pursuant to any other plan, agreement or arrangement, that are issued or deemed issued to such
employees, directors or consultants, provided that any such amendment or other plan, agreement or arrangement has been approved by a majority of the Board of Directors (which majority must include a majority of the Preferred Directors); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(VI) shares of Common Stock (or Options or Convertible Securities with respect thereto) issued solely in consideration for the acquisition
(whether by merger or otherwise) by the Corporation or any of its subsidiaries of all or substantially all of the stock or assets of any other entity; provided that such transaction, and the issuance of shares in connection therewith, has been
approved by a majority of the Board of Directors (which majority must include a majority of the Preferred Directors); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(VII) shares of
Common Stock (or Options or Convertible Securities with respect thereto) issued or issuable to financial institutions or lessors in connection with commercial credit agreements, equipment financings or similar transactions; provided that such
transaction, and the issuance of shares in connection therewith, has been approved by a majority of the Board of Directors (which majority must include a majority of the Preferred Directors); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(VIII) shares of Common Stock (or Options or Convertible Securities with respect thereto) issued or issuable in connection with strategic
transactions involving the Company and other entities, including joint ventures, manufacturing, marketing or distribution arrangements and technology transfer or development arrangements; provided that such strategic transactions, and the issuance
of shares in connection therewith, has been approved by a majority of the Board of Directors (which majority must include a majority of the Preferred Directors); or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 17 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(IX) shares of Common Stock (or Options or Convertible Securities with respect thereto)
issued or issuable pursuant to that certain Series C Convertible Preferred Stock and Warrant Purchase Agreement, by and among the Corporation and the investors party thereto, as amended from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) <U>No Adjustment of Conversion Prices</U>. No adjustment in the number of shares of Common Stock into which the Series <FONT
STYLE="white-space:nowrap">A-l</FONT> Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-4</FONT>
Preferred Stock, Series B Preferred Stock, or Series C Preferred Stock, respectively, is convertible shall be made, by adjustment in the Series <FONT STYLE="white-space:nowrap">A-l</FONT> Conversion Price, Series
<FONT STYLE="white-space:nowrap">A-2</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-3</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-4</FONT> Conversion Price, Series B Conversion Price, or Series C Conversion
Price thereof: (a)&nbsp;unless the consideration per share (determined pursuant to Subsection 4(d)(vi)) for an Additional Share of Common Stock issued or deemed to be issued by the Corporation is less than the Series
<FONT STYLE="white-space:nowrap">A-l</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-3</FONT> Conversion Price, Series
<FONT STYLE="white-space:nowrap">A-4</FONT> Conversion Price, Series B Conversion Price, or Series C Conversion Price in effect immediately prior to the issue of such Additional Shares of Common Stock, or (b)&nbsp;if prior to such issuance, the
Corporation receives written notice from the holders of at least a majority of the then outstanding shares of Series <FONT STYLE="white-space:nowrap">A-l</FONT> Preferred Stock, the holders of at least a majority of the then outstanding shares of
Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, the holders of at least a majority of the then outstanding shares of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Stock, the holders of at least a majority of the
then outstanding shares of Series <FONT STYLE="white-space:nowrap">A-4</FONT> Preferred Stock, the holders of at least a majority of the then outstanding shares of Series B Preferred Stock, or the holders of at least a majority of the then
outstanding shares of Series C Preferred Stock, as the case may be, agreeing that no such adjustment shall be made as the result of the issuance or deemed issuance of such Additional Shares of Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) <U>Issue of Securities Deemed Issue of Additional Shares of Common Stock</U>. If the Corporation at any time or from time to time after
the Series C Original Issue Date shall issue any Options (excluding Options covered by Subsection 4(d)(i)(D)(I), (IV), (V), (VI) and (VII)&nbsp;above) or Convertible Securities (excluding Convertible Securities covered by Subsection 4(d)(i)(D)(I),
(V), (VI) and (VII)&nbsp;above) or shall fix a record date for the determination of holders of any class of securities entitled to receive any such Options or Convertible Securities, then the maximum number of shares of Common Stock (as set forth in
the instrument relating thereto without regard to any provision contained therein for a subsequent adjustment of such number) issuable upon the exercise of such Options or, in the case of Convertible Securities and Options therefor, the conversion
or exchange of such Convertible Securities, shall be deemed to be Additional Shares of Common Stock issued as of the time of such issue or, in case such a record date shall have been fixed, as of the close of business on such record date, provided
that in any such case in which Additional Shares of Common Stock are deemed to be issued: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(A) No adjustment or further adjustment in the
Series <FONT STYLE="white-space:nowrap">A-l</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-3</FONT> Conversion Price, Series
<FONT STYLE="white-space:nowrap">A-4</FONT> Conversion Price, Series B Conversion Price, or Series C Conversion Price shall be made upon the subsequent issue of Convertible Securities or shares of Common Stock upon the exercise of such Options or
conversion or exchange of such Convertible Securities; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 18 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(B) If such Options or Convertible Securities by their terms provide, with the passage of
time or otherwise, for any increase or decrease in the consideration payable to the Corporation, upon the exercise, conversion or exchange thereof, the Series <FONT STYLE="white-space:nowrap">A-l</FONT> Conversion Price, Series <FONT
STYLE="white-space:nowrap">A-2</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-3</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-4</FONT> Conversion Price, Series B Conversion Price, or Series C Conversion Price
computed upon the original issue thereof (or upon the occurrence of a record date with respect thereto), and any subsequent adjustments based thereon, shall, upon any such increase or decrease becoming effective, be recomputed to reflect such
increase or decrease insofar as it affects such Options or the rights of conversion or exchange under such Convertible Securities; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(C)
Upon the expiration or termination of any unexercised Option, the affected Series <FONT STYLE="white-space:nowrap">A-l</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Conversion Price, Series <FONT
STYLE="white-space:nowrap">A-3</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-4</FONT> Conversion Price, Series B Conversion Price, or Series C Conversion Price shall be readjusted to the Series
<FONT STYLE="white-space:nowrap">A-l</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-3</FONT> Conversion Price, Series
<FONT STYLE="white-space:nowrap">A-4</FONT> Conversion Price, Series B Conversion Price, or Series C Conversion Price that would be in effect had such Option never been issued, and the Additional Shares of Common Stock deemed issued as the result of
the original issue of such Option shall not be deemed issued for the purposes of any subsequent adjustment of the affected Series <FONT STYLE="white-space:nowrap">A-l</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-2</FONT>
Conversion Price, Series <FONT STYLE="white-space:nowrap">A-3</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-4</FONT> Conversion Price, Series B Conversion Price, or Series C Conversion Price; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(D) In the event of any change in the number of shares of Common Stock issuable upon the exercise, conversion or exchange of any such Option
or Convertible Security, including, but not limited to, a change resulting from the anti-dilution provisions thereof (but excluding any change resulting from any events resulting in changes under Section&nbsp;4(e) or 4(f) below), the Series <FONT
STYLE="white-space:nowrap">A-l</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-3</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-4</FONT>
Conversion Price, Series B Conversion Price, or Series C Conversion Price then in effect shall forthwith be readjusted to such Series <FONT STYLE="white-space:nowrap">A-l</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-2</FONT>
Conversion Price, Series <FONT STYLE="white-space:nowrap">A-3</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-4</FONT> Conversion Price, Series B Conversion Price, or Series C Conversion Price as would have obtained had the
adjustment which was made upon the issuance of such Option or Convertible Security not exercised or converted prior to such change been made upon the basis of such change; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(E) No readjustment pursuant to clause (B), (C) or (D)&nbsp;above shall have the effect of increasing the Series <FONT
STYLE="white-space:nowrap">A-l</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-3</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-4</FONT>
Conversion Price, Series B Conversion Price, or Series C Conversion Price to an amount which exceeds the lower of (i)&nbsp;such Series <FONT STYLE="white-space:nowrap">A-l</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-2</FONT>
Conversion Price, Series <FONT STYLE="white-space:nowrap">A-3</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-4</FONT> Conversion Price, Series B Conversion Price, or Series C Conversion Price on the original adjustment date, or
(ii)&nbsp;the Series <FONT STYLE="white-space:nowrap">A-l</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-3</FONT> Conversion Price, Series <FONT
STYLE="white-space:nowrap">A-4</FONT> Conversion Price, Series B Conversion Price, or Series C Conversion Price that would have resulted from any issuances of Additional Shares of Common Stock between the original adjustment date and such
readjustment date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event the Corporation, after the Series C Original Issue Date, amends the terms of any such Options or
Convertible Securities (whether such Options or Convertible Securities were outstanding as of the Series C Original Issue Date or were issued after the Series C Original Issue Date), then such Options or Convertible Securities, as so amended, shall
be deemed to have been issued after the Series C Original Issue Date and the provisions of this Subsection 4(d)(iii) shall apply. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 19 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) <U>Adjustment of Conversion Price Upon Issuance of Additional Shares of Common
Stock</U>. In the event the Corporation shall at any time after the Series C Original Issue Date issue Additional Shares of Common Stock (including Additional Shares of Common Stock deemed to be issued pursuant to Subsection 4(d)(iii), but excluding
shares issued as a stock split or combination as provided in Subsection 4(e) or upon a dividend or distribution as provided in Subsection 4(f)), without consideration or for a consideration per share less than the Series <FONT
STYLE="white-space:nowrap">A-l</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-3</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-4</FONT>
Conversion Price, Series B Conversion Price, or Series C Conversion Price in effect immediately prior to such issue, then and in such event, such Series <FONT STYLE="white-space:nowrap">A-l</FONT> Conversion Price, Series <FONT
STYLE="white-space:nowrap">A-2</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-3</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-4</FONT> Conversion Price, Series B Conversion Price, or Series C Conversion Price
shall be reduced, concurrently with such issue, to a price (calculated to the nearest cent) determined by multiplying the Series <FONT STYLE="white-space:nowrap">A-l</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-2</FONT>
Conversion Price, Series <FONT STYLE="white-space:nowrap">A-3</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-4</FONT> Conversion Price, Series B Conversion Price, or Series C Conversion Price in effect immediately prior to such
issue of Additional Shares of Common Stock by a fraction, (A)&nbsp;the numerator of which shall be (1)&nbsp;the number of shares of Common Stock outstanding immediately prior to such issue (calculated assuming conversion of all issued and
outstanding shares of Preferred Stock as well as all other issued and outstanding Convertible Securities, and the exercise, exchange or conversion of all then outstanding Options) plus (2)&nbsp;the number of shares of Common Stock which the
aggregate consideration received or to be received by the Corporation for the total number of Additional Shares of Common Stock so issued would purchase at the Series <FONT STYLE="white-space:nowrap">A-l</FONT> Conversion Price, Series <FONT
STYLE="white-space:nowrap">A-2</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-3</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-4</FONT> Conversion Price, Series B Conversion Price, or Series C Conversion Price
in effect immediately prior to such issue of Additional Shares of Common Stock; and (B)&nbsp;the denominator of which shall be the number of shares of Common Stock outstanding immediately prior to such issue (calculated assuming conversion of all
issued and outstanding shares of Preferred Stock as well as all other issued and outstanding Convertible Securities, and the exercise, exchange or conversion of all then outstanding Options) plus the number of such Additional Shares of Common Stock
so issued; provided that, the number of shares of Common Stock deemed issuable upon exercise or conversion of such outstanding Options and Convertible Securities shall not give effect to any adjustments to the conversion price or conversion rate of
such Options or Convertible Securities resulting from the issuance of Additional Shares of Common Stock that is the subject of this calculation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) [Reserved.] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi)
<U>Determination of Consideration</U>. For purposes of this Subsection 4(d), the consideration received by the Corporation for the issue of any Additional Shares of Common Stock shall be computed as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(A) <U>Cash and Property</U>: Such consideration shall: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(I) insofar as it consists of cash, be computed at the aggregate of cash received by the Corporation, excluding amounts paid or payable for
accrued interest; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 20 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(II) insofar as it consists of property other than cash, be computed at the fair market
value thereof at the time of such issue, as determined in good faith by the Board of Directors; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(III) in the event Additional Shares
of Common Stock are issued together with other shares or securities or other assets of the Corporation for consideration which covers both, be the proportion of such consideration so received, computed as provided in clauses (I)&nbsp;and (II) above,
as determined in good faith by the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(B) <U>Options and Convertible Securities</U>. The consideration per share
received by the Corporation for Additional Shares of Common Stock deemed to have been issued pursuant to Subsection 4(d)(iii), relating to Options and Convertible Securities, shall be determined by dividing: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(I) the total amount, if any, received or receivable by the Corporation as consideration for the issue of such Options or Convertible
Securities, plus the minimum aggregate amount of additional consideration (as set forth in the instruments relating thereto, without regard to any provision contained therein for a subsequent adjustment of such consideration) payable to the
Corporation upon the exercise of such Options or the conversion or exchange of such Convertible Securities, or in the case of Options for Convertible Securities, the exercise of such Options for Convertible Securities and the conversion or exchange
of such Convertible Securities, by </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(II) the maximum number of shares of Common Stock (as set forth in the instruments relating thereto,
without regard to any provision contained therein for a subsequent adjustment of such number) issuable upon the exercise of such Options or the conversion or exchange of such Convertible Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) <U>Multiple Closing Dates</U>. In the event the Corporation shall issue on more than one date Additional Shares of Common Stock which
are comprised of shares of the same series or class of Preferred Stock, and such issuance dates occur within a period of no more than one hundred eighty (180)&nbsp;days, then, upon the final such issuance, the Series
<FONT STYLE="white-space:nowrap">A-l</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-3</FONT> Conversion Price, Series
<FONT STYLE="white-space:nowrap">A-4</FONT> Conversion Price, Series B Conversion Price, or Series C Conversion Price shall be adjusted to give effect to all such issuances as if they occurred on the date of the final such issuance (and without
giving effect to any adjustments as a result of such prior issuances within such period). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Adjustment for Stock Splits and
Combinations</U>. If the Corporation shall at any time or from time to time after the Series C Original Issue Date effect a subdivision of the outstanding Common Stock without a comparable subdivision of the Series
<FONT STYLE="white-space:nowrap">A-l</FONT> Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-4</FONT>
Preferred Stock, Series B Preferred Stock, or Series C Preferred Stock, the Series <FONT STYLE="white-space:nowrap">A-l</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Conversion Price, Series <FONT
STYLE="white-space:nowrap">A-3</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-4</FONT> Conversion Price, Series B Conversion Price, or Series C Conversion Price then in effect immediately before that subdivision shall be
proportionately decreased so that the number of shares of Common Stock </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 21 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
issuable on conversion of each share of Series <FONT STYLE="white-space:nowrap">A-l</FONT> Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, Series <FONT
STYLE="white-space:nowrap">A-3</FONT> Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-4</FONT> Preferred Stock, Series B Preferred Stock, or Series C Preferred Stock shall be increased in proportion to such increase in the aggregate
number of shares of Common Stock outstanding. If the Corporation shall at any time or from time to time after the Series C Original Issue Date combine the outstanding shares of Common Stock without a comparable combination of the Series <FONT
STYLE="white-space:nowrap">A-l</FONT> Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-4</FONT>
Preferred Stock, Series B Preferred Stock, or Series C Preferred Stock, the Series <FONT STYLE="white-space:nowrap">A-l</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Conversion Price, Series <FONT
STYLE="white-space:nowrap">A-3</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-4</FONT> Conversion Price, Series B Conversion Price, or Series C Conversion Price then in effect immediately before the combination shall be
proportionately increased so that the number of shares of Common Stock issuable on conversion of each share of such series shall be decreased in proportion to such decrease in the aggregate number of shares of Common Stock outstanding. Any
adjustment under this paragraph shall become effective at the close of business on the date the subdivision or combination becomes effective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Adjustment for Certain Dividends and Distributions</U>. In the event the Corporation at any time, or from time to time after the Series
C Original Issue Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable in additional shares of Common Stock, then and in each such event the
Series <FONT STYLE="white-space:nowrap">A-l</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-3</FONT> Conversion Price, Series
<FONT STYLE="white-space:nowrap">A-4</FONT> Conversion Price, Series B Conversion Price, or Series C Conversion Price then in effect immediately before such event shall be decreased as of the time of such issuance or, in the event such a record date
shall have been fixed, as of the close of business on such record date, by multiplying the Series <FONT STYLE="white-space:nowrap">A-l</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Conversion Price, Series <FONT
STYLE="white-space:nowrap">A-3</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-4</FONT> Conversion Price, Series B Conversion Price, or Series C Conversion Price then in effect by a fraction: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) the numerator of which shall be the total number of shares of Common Stock actually issued and outstanding immediately prior to the time
of such issuance or the close of business on such record date, and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) the denominator of which shall be the total number of shares of
Common Stock actually issued and outstanding immediately prior to the time of such issuance or the close of business on such record date, plus the number of shares of Common Stock issuable in payment of such dividend or distribution to the holders
of Common Stock; <U>provided</U>, <U>however</U>, that if such record date shall have been fixed and such dividend is not fully paid or if such distribution is not fully made on the date fixed therefor, the Series
<FONT STYLE="white-space:nowrap">A-l</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-3</FONT> Conversion Price, Series
<FONT STYLE="white-space:nowrap">A-4</FONT> Conversion Price, Series B Conversion Price, or Series C Conversion Price shall be recomputed accordingly as of the close of business on such record date and thereafter the Series <FONT
STYLE="white-space:nowrap">A-l</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-3</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-4</FONT>
Conversion Price, Series B Conversion Price, or Series C Conversion Price shall be adjusted pursuant to this paragraph as of the time of actual payment of such dividends or distributions; and <U>provided further</U>, <U>however</U>, that no such
adjustment shall be made with respect to the Series <FONT STYLE="white-space:nowrap">A-l</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-3</FONT> Conversion
Price, Series <FONT STYLE="white-space:nowrap">A-4</FONT> Conversion Price, Series B Conversion Price, or Series C Conversion Price if the holders of Series <FONT STYLE="white-space:nowrap">A-l</FONT> Preferred Stock, Series <FONT
STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-4</FONT> Preferred Stock, Series B
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 22 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Preferred Stock, or Series C Preferred Stock, as the case may be, simultaneously receive (i)&nbsp;a dividend or other distribution of shares of Common Stock in a number equal to the number of
shares of Common Stock as they would have received if all outstanding shares of Series <FONT STYLE="white-space:nowrap">A-l</FONT> Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, Series <FONT
STYLE="white-space:nowrap">A-3</FONT> Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-4</FONT> Preferred Stock, Series B Preferred Stock, or Series C Preferred Stock had been converted into Common Stock on the date of such event or
(ii)&nbsp;a dividend or other distribution of shares of Series <FONT STYLE="white-space:nowrap">A-l</FONT> Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-3</FONT>
Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-4</FONT> Preferred Stock, Series B Preferred Stock, or Series C Preferred Stock which are convertible, as of the date of such event, into such number of shares of Common Stock as is equal to
the number of additional shares of Common Stock being issued with respect to each share of Common Stock in such dividend or distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Adjustments for Other Dividends and Distributions</U>. In the event the Corporation at any time or from time to time after the Series C
Original Issue Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable in securities of the Corporation other than shares of Common Stock, then and
in each such event each holder of Preferred Stock shall receive, simultaneously with the distribution to the holders of Common Stock, a dividend or other distribution of such securities in an amount equal to the amount of such securities as such
holder would have received if all shares of Preferred Stock owned by such holder had been converted into Common Stock on the date of such event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <U>Adjustment for Reclassification, Exchange, or Substitution</U>. If the Common Stock issuable upon the conversion of the Preferred Stock
shall be changed into the same or a different number of shares of any class or classes of stock, whether by capital reorganization, reclassification, or otherwise (other than a subdivision or combination of shares or stock dividend provided for
above, or a reorganization, merger, consolidation, or sale of assets provided for below), then and in each such event the holder of each such share of Preferred Stock shall have the right thereafter to convert such share into the kind and amount of
shares of stock and other securities and property receivable, upon such reorganization, reclassification, or other change, by holders of the number of shares of Common Stock into which such shares of Preferred Stock might have been converted
immediately prior to such reorganization, reclassification, or change, all subject to further adjustment as provided herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)
<U>Adjustment for Merger or Reorganization, etc</U>. In case of any consolidation or merger of the Corporation with or into another corporation or the sale of all or substantially all of the assets of the Corporation to another corporation (other
than a consolidation, merger or sale which is covered by Subsection 2(c)), each share of Preferred Stock shall thereafter be convertible (or shall be converted into a security which shall be convertible) into the kind and amount of shares of stock
or other securities or property to which a holder of the number of shares of Common Stock of the Corporation deliverable upon conversion of such Preferred Stock would have been entitled upon such consolidation, merger or sale; and, in such case,
appropriate adjustment (as determined in good faith by the Board of Directors) shall be made in the application of the provisions in this Section&nbsp;4 set forth with respect to the rights and interest thereafter of the holders of Preferred Stock
to the end that the provisions set forth in this Section&nbsp;4 (including provisions with respect to changes in and other adjustments of the Series <FONT STYLE="white-space:nowrap">A-</FONT> 1 Conversion Price, Series
<FONT STYLE="white-space:nowrap">A-2</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-3</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-4</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 23 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Conversion Price, Series B Conversion Price, or Series C Conversion Price) shall thereafter be applicable, as nearly as reasonably may be, in relation to any shares of stock or other property
thereafter deliverable upon the conversion of the Series <FONT STYLE="white-space:nowrap">A-l</FONT> Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred
Stock, Series <FONT STYLE="white-space:nowrap">A-4</FONT> Preferred Stock, Series B Preferred Stock, or Series C Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j)
<U>No Impairment</U>. The Corporation will not, by amendment of this Amended and Restated Certificate of Incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other
voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed under this Section&nbsp;4 by the Corporation, without the written consent of the holders of a majority of the then outstanding
shares of Preferred Stock, consenting together as a separate class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, but will at all times in good faith assist in the carrying out of all the provisions of this Section&nbsp;4 and in
the taking of all such action as may be necessary or appropriate in order to protect the Conversion Rights of the holders of the Preferred Stock against impairment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) <U>Certificate as to Adjustments</U>. Upon the occurrence of each adjustment or readjustment of the Series
<FONT STYLE="white-space:nowrap">A-l</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-3</FONT> Conversion Price, Series
<FONT STYLE="white-space:nowrap">A-4</FONT> Conversion Price, Series B Conversion Price, or Series C Conversion Price pursuant to this Section&nbsp;4, the Corporation at its expense shall promptly compute such adjustment or readjustment in
accordance with the terms hereof and furnish to each holder of Preferred Stock a certificate setting forth such adjustment or readjustment and showing in detail the facts upon which such adjustment or readjustment is based. The Corporation shall,
upon the written request at any time of any holder of Preferred Stock, furnish or cause to be furnished to such holder a similar certificate setting forth (i)&nbsp;such adjustments and readjustments, (ii)&nbsp;the Series <FONT
STYLE="white-space:nowrap">A-l</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-3</FONT> Conversion Price, Series <FONT STYLE="white-space:nowrap">A-4</FONT>
Conversion Price, Series B Conversion Price, or Series C Conversion Price then in effect, and (iii)&nbsp;the number of shares of Common Stock and the amount, if any, of other property which then would be received upon the conversion of Series <FONT
STYLE="white-space:nowrap">A-l</FONT> Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-4</FONT>
Preferred Stock, Series B Preferred Stock, or Series C Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(1) <U>Notice of Record Date</U>. In the event: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) that the Corporation declares a dividend (or any other distribution) on its Common Stock payable in Common Stock or other securities of
the Corporation; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) that the Corporation subdivides or combines its outstanding shares of Common Stock; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) of any reclassification of the Common Stock of the Corporation (other than a subdivision or combination of its outstanding shares of
Common Stock or a stock dividend or stock distribution thereon), or of any consolidation or merger of the Corporation into or with another corporation, or of the sale of all or substantially all of the assets of the Corporation; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 24 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) of the involuntary or voluntary dissolution, liquidation or winding up of the
Corporation; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">then the Corporation shall use reasonable efforts to cause to be filed at its principal office or at the office of the transfer agent of the
Preferred Stock, and shall cause to be mailed to the holders of the Preferred Stock or such transfer agent, at least ten (10)&nbsp;days prior to the date specified in (A)&nbsp;below or twenty (20)&nbsp;days before the date specified in
(B)&nbsp;below, a notice stating </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(A) the record date of such dividend, distribution, subdivision or combination, or, if a record is not
to be taken, the date as of which the holders of Common Stock of record to be entitled to such dividend, distribution, subdivision or combination are to be determined, or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(B) the date on which such reclassification, consolidation, merger, sale, dissolution, liquidation or winding up is expected to become
effective, and the date as of which it is expected that holders of Common Stock of record shall be entitled to exchange their shares of Common Stock for securities or other property deliverable upon such reclassification, consolidation, merger,
sale, dissolution or winding up; <U>provided</U>, <U>however</U>, that the Corporation&#146;s failure to provide any notice required under this Section&nbsp;4(1) after using reasonable efforts shall not be deemed a default, breach or violation of
this Section&nbsp;4(1). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Mandatory Conversion.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Upon the earlier of (i)&nbsp;the closing of the sale of shares of Common Stock in a firm underwritten public offering pursuant to an
effective registration statement under the Securities Act of 1933, as amended, resulting in at least Forty Million Dollars ($40,000,000) (net of any underwriting discount and commissions) to the Corporation or (ii)&nbsp;a date agreed to in writing
by a vote of the holders of a majority of the then outstanding shares of Preferred Stock, voting together as a separate class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis (each a &#147;<U>Mandatory Conversion Event</U>&#148;),
all outstanding shares of Preferred Stock shall automatically be converted into shares of Common Stock, at the then effective conversion rate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) All holders of record of shares of Preferred Stock shall be given written notice of the Mandatory Conversion Event and the place and date
(the &#147;<U>Mandatory Conversion Date</U>&#148;) designated for mandatory conversion of all such shares of Preferred Stock pursuant to this Section&nbsp;5. Such notice need not be given in advance of the occurrence of the Mandatory Conversion
Event. Such notice shall be sent by first class or registered mail, postage prepaid, or given by electronic communication in compliance with the provisions of the General Corporation Law, to each record holder of Preferred Stock. Upon receipt of
such notice, each holder of shares of Preferred Stock shall surrender his or its certificate or certificates for all such shares to the Corporation at the place designated in such notice, and shall thereafter receive certificates for the number of
shares of Common Stock to which such holder is entitled pursuant to this Section&nbsp;5. On the Mandatory Conversion Date, all outstanding shares of Preferred Stock shall be deemed to have been converted into shares of Common Stock, which shall be
deemed to be outstanding of record, and all rights with respect to the Preferred Stock so converted, including the rights, if any, to receive notices and vote (other than as a holder of Common Stock) will terminate, except only the rights of the
holders thereof, upon surrender of their certificate or certificates therefor, to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 25 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
receive certificates for the number of shares of Common Stock into which such Preferred Stock has been converted, and payment of any declared but unpaid dividends thereon. If so required by the
Corporation, certificates surrendered for conversion shall be endorsed or accompanied by written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the registered holder or by his or its attorney duly
authorized in writing. As soon as practicable after the Mandatory Conversion Date and the surrender of the certificate or certificates for Preferred Stock, the Corporation shall cause to be issued and delivered to such holder, or on his or its
written order, a certificate or certificates for the number of full shares of Common Stock issuable on such conversion in accordance with the provisions hereof and cash as provided in Subsection 4(b) in respect of any fraction of a share of Common
Stock otherwise issuable upon such conversion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) All certificates evidencing shares of Preferred Stock which are required to be
surrendered for conversion in accordance with the provisions hereof shall, from and after the Mandatory Conversion Date, be deemed to have been retired and cancelled and the shares of Preferred Stock represented thereby converted into Common Stock
for all purposes, notwithstanding the failure of the holder or holders thereof to surrender such certificates on or prior to such date. Such converted Preferred Stock may not be reissued, and the Corporation may thereafter take such appropriate
action (without the need for stockholder action) as may be necessary to reduce the authorized number of shares of Preferred Stock accordingly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Redemption.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
Unless prohibited by Delaware law governing distributions to stockholders, the Preferred Stock shall, if required as set forth below, be redeemed by the Corporation at a price per share equal to the applicable Redemption Price (as defined below). As
used in this Amended and Restated Certificate of Incorporation, &#147;<U>Redemption Price</U>&#148; means in the case of the Series <FONT STYLE="white-space:nowrap">A-l</FONT> Preferred Stock, $0.4162 per share (subject to appropriate adjustment in
the event of any stock dividend, stock split, combination or other similar recapitalization occurring after the date hereof and affecting the number of issued and outstanding shares of Series <FONT STYLE="white-space:nowrap">A-l</FONT> Preferred
Stock) plus all declared but unpaid dividends, in the case of the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, $0.3397 per share (subject to appropriate adjustment in the event of any stock dividend, stock split, combination
or other similar recapitalization occurring after the date hereof and affecting the number of issued and outstanding shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock) plus all declared but unpaid dividends, in the case of
the Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Stock, $0.6245 per share (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization occurring after the date
hereof and affecting the number of issued and outstanding shares of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Stock) plus all declared but unpaid dividends, in the case of the Series <FONT STYLE="white-space:nowrap">A-4</FONT>
Preferred Stock, $0.30 per share (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization occurring after the date hereof and affecting the number of issued and outstanding
shares of Series <FONT STYLE="white-space:nowrap">A-4</FONT> Preferred Stock) plus all declared but unpaid dividends, in the case of the Series B Preferred Stock, $0.30 per share (subject to appropriate adjustment in the event of any stock dividend,
stock split, combination or other similar recapitalization occurring after the date hereof and affecting the number of issued and outstanding shares of Series B Preferred Stock) plus all declared but unpaid dividends, and in the case of the Series C
Preferred Stock, $0.38811 per share (subject to appropriate adjustment in the event of any stock dividend, stock split, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 26 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
combination or other similar recapitalization occurring after the date hereof and affecting the number of issued and outstanding shares of Series C Preferred Stock) plus all declared but unpaid
dividends. Such redemption shall occur in three annual equal installments commencing sixty (60)&nbsp;days after receipt by the Corporation, at any time on or after the fifth anniversary of the Series C Original Issue Date, of written notice
requesting redemption of all shares of Preferred Stock from the holders of a majority of the then outstanding shares of Preferred Stock, as follows (which must include at least 50% of the then outstanding shares of Series B Preferred Stock and 50%
of the then-outstanding shares of Series C Preferred Stock): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) on the sixtieth (60th) day after receipt by the Corporation of the
written notice described in Section&nbsp;6(a), the Corporation shall redeem <FONT STYLE="white-space:nowrap">one-third</FONT> of the shares of Preferred Stock then outstanding; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the redemption made pursuant to Section&nbsp;6(a)(i) above, the
Corporation shall redeem fifty percent (50%) of the shares of Preferred Stock then outstanding; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) on the <FONT
STYLE="white-space:nowrap">one-year</FONT> anniversary of the redemption made pursuant to Section&nbsp;6(a)(ii) above, the Corporation shall redeem all of the shares of Preferred Stock then outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The date of each redemption pursuant to Section&nbsp;6(a) is referred to as a &#147;<U>Redemption Date</U>&#148;. On each Redemption Date, the Corporation
shall redeem the number of shares of Preferred Stock determined as set forth in this Section&nbsp;6(a) on a pro rata basis in accordance with the number of shares of Preferred Stock owned by each holder of Preferred Stock. Upon receipt of a
redemption request, the Company shall apply all of its assets to any such redemption, and to no other corporate purpose, except to the extent prohibited by Delaware law governing distributions to stockholders. If on any Redemption Date Delaware law
governing distributions to stockholders prevents the Corporation from redeeming all of the Preferred Stock to be redeemed on any Redemption Date, the Corporation shall redeem a pro rata portion of each holder&#146;s shares of Preferred Stock, based
on the respective amounts which would otherwise be payable in respect of the shares to be redeemed if the Corporation were able to redeem all such shares under such law and shall redeem the remaining shares to have been redeemed as soon as it may
lawfully do so under such law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Written notice of the mandatory redemption (the &#147;<U>Redemption Notice</U>&#148;) shall be mailed,
postage prepaid, to each holder of record of Preferred Stock, not less than thirty (30)&nbsp;days prior to each Redemption Date. Each Redemption Notice shall state: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) the number of shares of each class of Preferred Stock held by the holder that the Corporation shall redeem on the Redemption Date
specified in the Redemption Notice; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) the Redemption Date and the Redemption Price; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) the date upon which the holder&#146;s right to convert such shares terminates (as determined in accordance with Section&nbsp;4(a)); and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 27 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) that the holder is to surrender to the Corporation, in the manner and at the place
designated, his certificate or certificates representing the shares of Preferred Stock to be redeemed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Surrender of Certificates;
Payment</U>. On or before the applicable Redemption Date, each holder of shares of Preferred Stock to be redeemed on such Redemption Date, unless such holder has exercised his right to convert such shares as provided in Section&nbsp;4 hereof, shall
surrender the certificate or certificates representing such shares to the Corporation (or, if such holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the
Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate), in the manner and at the place designated in the Redemption Notice, and
thereupon the Redemption Price for such shares shall be payable to the order of the person whose name appears on such certificate or certificates as the owner thereof, and each surrendered certificate shall be canceled and retired. In the event less
than all of the shares of Preferred Stock represented by a certificate are redeemed, a new certificate representing the unredeemed shares of Preferred Stock shall promptly be issued to such holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Rights Subsequent to Redemption</U>. If the Redemption Notice shall have been duly given, and if on the applicable Redemption Date the
Redemption Price payable upon redemption of the shares of Preferred Stock to be redeemed on such Redemption Date is paid or tendered for payment, then whether or not the certificates evidencing any of the shares of Preferred Stock so called for
redemption have been surrendered, dividends with respect to such shares of Preferred Stock shall cease to accrue after such Redemption Date and all rights with respect to such shares shall forthwith after the Redemption Date terminate, except only
the right of the holders to receive the Redemption Price without interest upon surrender of their certificate or certificates (or lost certificate affidavit and agreement) therefor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Any shares of Preferred Stock redeemed pursuant to this Section&nbsp;6 will be cancelled and will not under any circumstances be reissued,
sold or transferred and the Corporation may from time to time take such appropriate action as may be necessary to reduce the authorized shares of Preferred Stock accordingly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Waiver</U>. Except where a different vote is specified in the Certificate of Incorporation or required by the General Corporation Law,
any of the rights, powers, preferences and other terms of a series of Preferred Stock set forth herein may be waived on behalf of all holders of such series of Preferred Stock by the affirmative written consent or vote of the holders of a majority
of the shares of such series of Preferred Stock then outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Notices</U>. Any notice required by the provisions hereof to be
given to a holder of shares of Preferred Stock shall be deemed sent to such holder if deposited in the United States mail, postage prepaid, and addressed to such holder at his, her or its address appearing on the books of the Corporation or given by
electronic communication in compliance with the provisions of General Corporation Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-28- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>FIFTH</U>: The Corporation is to have perpetual existence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>SIXTH</U>: Meetings of shareholders may be held within or without the State of Delaware, as the bylaws provide. The books of the
Corporation may be kept outside the State of Delaware at the main office of the Corporation or such place or places as may be designated from time to time by the Board of Directors or in the bylaws of the Corporation. Elections of directors need not
be by written ballot unless the bylaws of the Corporation so provide. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>SEVENTH</U>: The Board of Directors of the Corporation is
expressly authorized to exercise all powers granted to the directors by law except insofar as such powers are limited or denied herein or in the bylaws of the Corporation. In furtherance of such powers, the Board of Directors is expressly authorized
to adopt, amend or repeal the bylaws of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>EIGHTH</U>: A director of the Corporation shall not be personally liable to
the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (i)&nbsp;for any breach of the director&#146;s duty of loyalty to the corporation or its stockholders, (ii)&nbsp;for acts or
omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)&nbsp;under Section&nbsp;174 of the General Corporation Law, or (iv)&nbsp;for any transaction from which the director derived any improper
personal benefit. If the General Corporation Law is amended after the effective date of this Amended and Restated Certificate of Incorporation to authorize corporate action further eliminating or limiting the personal liability of directors, then
the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the General Corporation Law. No amendment, modification or repeal of this Article shall adversely affect the rights and protection
afforded to a director of the Corporation under this Article for acts or omissions occurring prior to such amendment modification or repeal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>NINTH</U>: The Corporation shall, to the fullest extent permitted by the General Corporation Law, as amended from time to time, indemnify
each person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he is or was, or has
agreed to become, a director or officer of the Corporation, or is or was serving, or has agreed to serve, at the request of the Corporation, as a director, officer or trustee of, or in a similar capacity with, another corporation, partnership, joint
venture, trust or other enterprise, against expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him or on his behalf in connection with such action, suit or proceeding and
any appeal therefrom. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">Indemnification may include payment by the Corporation in defending an action or proceeding in advance of the
final disposition of such action or proceeding upon receipt of any undertaking by the person indemnified to repay such payment if it is ultimately determined that such person is not entitled to indemnification under this Article, which undertaking
may be accepted without reference to the financial ability of such person to make such repayments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 29 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">The Corporation shall not indemnify any such person seeking indemnification in connection
with a proceeding (or part thereof) initiated by such person unless the initiation thereof was approved by the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">The
indemnifications rights provided in this Article (A)&nbsp;shall not be deemed exclusive of any other rights to which those indemnified may be entitled under any law, agreement or vote of stockholders or disinterested directors or otherwise, and
(B)&nbsp;shall inure to the benefit of the heirs, executors and administrators of such persons. The Corporation may, to the extent authorized from time to time by its Board of Directors, grant indemnification rights to other employees or agents of
the Corporation or other persons serving the Corporation and such rights may be equivalent to, or greater or less than, those set forth in this Article. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">Any person seeking indemnification under this Article shall be deemed to have met the standard of conduct required for such indemnification
unless the contrary shall be established. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">Any amendment or repeal of the provisions of this Article shall not adversely affect any right
or protection of a director or officer of this Corporation with respect to any act or omission of such director or officer occurring prior to such amendment or appeal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>TENTH</U>: The Corporation renounces any interest or expectancy of the Corporation in, or in being offered an opportunity to participate
in, any Excluded Opportunity. An &#147;Excluded Opportunity&#148; is any matter, transaction or interest that is presented to, or acquired, created or developed by, or which otherwise comes into the possession of, (i)&nbsp;any director of the
Corporation who is not an employee of the Corporation or any of its subsidiaries, or (ii)&nbsp;any holder of Preferred Stock or any partner, member, director, stockholder, employee or agent of any such holder, other than someone who is an employee
of the Corporation or any of its subsidiaries (collectively, &#147;<U>Covered Persons</U>&#148;), unless such matter, transaction or interest is presented to, or acquired, created or developed by, or otherwise comes into the possession of, a Covered
Person expressly and solely in such Covered Person&#146;s capacity as a director of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>ELEVENTH</U>: The Corporation
reserves the right at any time, and from time to time, to amend, alter, change or repeal any provision contained in this Amended and Restated Certificate of Incorporation, and to add or insert other provisions authorized by the laws of the State of
Delaware at the time in force, in the manner now or hereafter prescribe by law; and all rights, preferences and privileges of whatsoever nature conferred upon stockholders, directors or any other persons whomsoever by and pursuant to this Amended
and Restated Certificate of Incorporation in its present form or as hereafter amended are granted subject to the rights reserved in this Article. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 30 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Corporation has caused this Amended and Restated Certificate of
Incorporation to be signed by its President and Chief Executive Officer on this 10<SUP STYLE="font-size:85%; vertical-align:top">th </SUP>day of January, 2020. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Maria Palasis</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Maria Palasis</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Executive Officer,<BR>Lyra Therapeutics, Inc.</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>3
<FILENAME>filename3.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">BYLAWS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">OF </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARSENAL MEDICAL, INC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE I
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">STOCKHOLDERS </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1.
<U>Place of Meetings</U>. All meetings of stockholders shall be held at the principal office of the corporation or at such other place as may be named in the notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2. <U>Annual Meeting</U>. The annual meeting of stockholders for the election of directors and the transaction of such other business
as may properly come before the meeting shall be held on such date and at such hour and place as the directors or an officer designated by the directors may determine. If the annual meeting is not held on the date designated therefor, the directors
shall cause the meeting to be held as soon thereafter as convenient. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3. <U>Special Meetings</U>. Special meetings of the
stockholders may be called at any time by the President, the Chairman of the Board, if any, or the Board of Directors, or by the Secretary or any other officer upon the written request of one or more stockholders holding of record at least a
majority of the outstanding shares of stock of the corporation entitled to vote at such meeting. Such written request shall state the purpose or purposes of the proposed meeting. Business transacted at any special meeting of stockholders shall be
limited to matters relating to the purpose or purposes stated in the notice of meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4. <U>Notice of Meetings</U>. Except
where some other notice is required by law, written notice of each meeting of stockholders, stating the place, date and hour thereof and the purposes for which the meeting is called, shall be given by or under the direction of the Secretary, not
less than ten nor more than sixty days before the date fixed for such meeting, to each stockholder entitled to vote at such meeting of record at the close of business on the day fixed by the Board of Directors as a record date for the determination
of the stockholders entitled to vote at such meeting or, if no such date has been fixed, of record at the close of business on the day before the day on which notice is given. Notice shall be given personally to each stockholder or left at his or
her residence or usual place of business or mailed postage prepaid and addressed to the stockholder at his or her address as it appears upon the records of the corporation. In case of the death, absence, incapacity or refusal of the Secretary, such
notice may be given by a person designated either by the Secretary or by the person or persons calling the meeting or by the Board of Directors. A waiver of such notice in writing, signed by the person or persons entitled to said notice, whether
before or after the time stated therein, shall be deemed equivalent to such notice. Attendance of a person at a meeting of stockholders shall constitute a waiver of notice of such meeting, except when the stockholder attends a meeting for the
express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of
the stockholders need be specified in any written waiver of notice. Except as required by statute, notice of any adjourned meeting of the stockholders shall not be required. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5. <U>Voting List</U>. The officer who has charge of the stock ledger of the
corporation shall prepare and make, at least ten days before every meeting of stockholders, a complete list of the stockholders, arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the
name of each stockholder. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting, during ordinary business hours, for a period of at least ten days prior to the meeting, either at a place within the
city where the meeting is to be held, which place shall be specified in the notice of the meeting, or if not so specified, at the place where the meeting is to be held. The list shall also be produced and kept at the time and place of the meeting
during the whole time thereof, and may be inspected by any stockholder who is present. The stock ledger shall be the only evidence as to who are the stockholders entitled to examine the stock ledger, the list required by this section or the books of
the corporation, or to vote at any meeting of stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 6. <U>Quorum of Stockholders</U>. At any meeting of the stockholders,
the holders of a majority in interest of all stock issued and outstanding and entitled to vote upon a question to be considered at the meeting, present in person or represented by proxy, shall constitute a quorum for the consideration of such
question, but a smaller group may adjourn any meeting from time to time. When a quorum is present at any meeting, a majority of the stock represented thereat and entitled to vote shall, except where a larger vote is required by law, by the
certificate of incorporation, or by these bylaws, decide any question brought before such meeting. Any election by stockholders shall be determined by a plurality of the vote cast by the stockholders entitled to vote at the election. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7. <U>Proxies and Voting</U>. Unless otherwise provided in the certificate of incorporation, each stockholder shall at every meeting
of the stockholders be entitled to one vote in person or by proxy for each share of the capital stock held of record by such stockholder, but no proxy shall be voted or acted upon after three years from its date, unless said proxy provides for a
longer period. Persons holding stock in a fiduciary capacity shall be entitled to vote the shares so held, and persons whose stock is pledged shall be entitled to vote, unless in the transfer by the pledgor on the books of the corporation the
pledgee shall have been expressly empowered to vote thereon, in which case only the pledgee or the pledgee&#146;s proxy may represent said stock and vote thereon. Shares of the capital stock of the corporation belonging to the corporation or to
another corporation, a majority of whose shares entitled to vote in the election of directors is owned by the corporation, shall neither be entitled to vote nor be counted for quorum purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 8. <U>Conduct of Meeting</U>. Meetings of the stockholders shall be presided over by one of the following officers in the order of
seniority and if present and acting: the Chairman of the Board, if any, the Vice-Chairman of the Board, if any, the President, a Vice-President, or, if none of the foregoing is in office and present and acting, a chairman to be chosen by the
stockholders. The Secretary of the corporation, if present, or an Assistant Secretary, shall act as secretary of every meeting, but if neither the Secretary nor an Assistant Secretary is present the chairman of the meeting shall appoint a secretary
of the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 9. <U>Action Without Meeting</U>. Any action required or permitted to be taken at any annual or special meeting
of stockholders of the corporation may be taken without a meeting, without prior notice and without a vote, if a consent in writing, setting forth the action so taken, is signed by the holders or by proxy for the holders of outstanding stock having
not less </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote on such action were present and voted. Prompt notice of
the taking of corporate action without a meeting by less than unanimous written consent shall be given to those stockholders who have not consented in writing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE II </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">DIRECTORS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1. <U>General Powers</U>. The business and affairs of the corporation shall be managed by or under the direction of a Board of
Directors, who may exercise all of the powers of the corporation which are not by law required to be exercised by the stockholders. In the event of a vacancy in the Board of Directors, the remaining directors, except as otherwise provided by law,
may exercise the powers of the full Board until the vacancy is filled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2. <U>Number; Election; Tenure and Qualification</U>. The
number of initial Directors shall be fixed by the incorporator, and the initial Board of Directors shall be elected by the incorporator. Thereafter, the number of directors which shall constitute the whole Board shall be fixed by resolution of the
Board of Directors, but in no event shall be less than one. Each director shall be elected by the stockholders at the annual meeting and all directors shall hold office until the next annual meeting and until their successors are elected and
qualified, or until their earlier death, resignation or removal. The number of directors may be increased or decreased by action of the Board of Directors. Directors need not be stockholders of the corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3. <U>Enlargement of the Board</U>. The number of the Board of Directors may be increased at any time, such increase to be effective
immediately, by vote of a majority of the directors then in office. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4. <U>Vacancies</U>. Unless and until filled by the
stockholders, any vacancy in the Board of Directors, however occurring, including a vacancy resulting from an enlargement of the Board and an unfilled vacancy resulting from the removal of any director for cause or without cause, may be filled by
vote of a majority of the directors then in office although less than a quorum, or by the sole remaining director. A director elected to fill a vacancy shall hold office until the next annual meeting of stockholders and until his or her successor is
elected and qualified or until his or her earlier death, resignation, or removal. When one or more directors shall resign from the Board, effective at a future date, a majority of the directors then in office, including those who have so resigned,
shall have the power to fill such vacancy or vacancies, the vote thereon to take effect when such resignation or resignations shall become effective. If at any time there are no directors in office, then an election of directors may be held in
accordance with the General Corporation Law of the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5. <U>Resignation</U>. Any director may resign at any time
upon written notice to the corporation. Such resignation shall take effect at the time specified therein, or if no time is specified, at the time of its receipt by the President or Secretary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 6. <U>Removal</U>. Except as may otherwise be provided by the General Corporation
Law, any director or the entire Board of Directors may be removed, with or without cause, at an annual meeting or at a special meeting called for that purpose, by the holders of a majority of the shares then entitled to vote at an election of
directors. The vacancy or vacancies thus created may be filled by the stockholders at the meeting held for the purpose of removal or, if not so filled, by the directors in the manner provided in Section&nbsp;4 of this Article II. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7. <U>Committees</U>. The Board of Directors may designate one or more committees, each committee to consist of one or more directors
of the corporation. The Board of Directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Any such committee may fix its rules of procedure and fix the time and place, whether within or without the State of Delaware, of its meetings
and specify what notice thereof, if any, shall be given, unless the Board of Directors shall otherwise by resolution provide. The Board of Directors shall have the power to change the members of any such committee at any time, to fill vacancies
therein and to discharge any such committee, either with or without cause, at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Any such committee, unless otherwise provided in
the resolution of the Board of Directors, or in these bylaws, shall have and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs of the corporation, and may authorize the seal of the
corporation to be affixed to all papers which may require it; but no such committee shall have the power or authority denied it by Section&nbsp;141 of the General Corporation Law of the State of Delaware. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Each committee shall keep regular minutes of its meetings and make such reports as the Board of Directors may from time to time request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 8. <U>Meetings of the Board of Directors</U>. Regular meetings of the Board of Directors may be held without call or formal notice at
such places either within or without the State of Delaware and at such times as the Board may from time to time determine. A regular meeting of the Board of Directors may be held without call or formal notice immediately after and at the same place
as the annual meeting of the stockholders, or any special meeting of the stockholders at which a Board of Directors is elected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Special
meetings of the Board of Directors may be held at any place either within or without the State of Delaware at any time when called by the Chairman of the Board of Directors, the President, Treasurer, Secretary, or two or more directors. Forty-eight
hours&#146; notice by mail, facsimile, telephone or word of mouth shall be given for a special meeting unless shorter notice or a different method of notice is adequate under the circumstances. A notice or waiver of notice need not specify the
purpose of any special meeting. Notice of a meeting need not be given to any director, if a written waiver of notice, executed by him before or after the meeting, is filed with the records of the meeting, or to any director who attends the meeting
without protesting prior thereto or at its commencement the lack of notice to him. No notice of any adjourned meeting of the Board of Directors shall be required. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Directors or members of any committee designated by the directors may participate in a
meeting of the Board of Directors or such committee by means of conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear each other, and participation by such means shall constitute
presence in person at such meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 9. <U>Quorum and Voting</U>. A majority of the total number of directors shall constitute a
quorum, except that when a vacancy or vacancies exist in the Board, a majority of the directors then in office (but not less than <FONT STYLE="white-space:nowrap">one-third</FONT> of the total number of the directors) shall constitute a quorum. A
majority of the directors present, whether or not a quorum is present, may adjourn any meeting from time to time. The vote of a majority of the directors present at any meeting at which a quorum is present shall be the act of the Board of Directors,
except where a different vote is required or permitted by law, by the certificate of incorporation, or by these bylaws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 10.
<U>Compensation</U>. The Board of Directors may fix fees for their services and for their membership on committees, and expenses of attendance may be allowed for attendance at each meeting. Nothing herein contained shall be construed to preclude any
director from serving the corporation in any other capacity as an officer, agent or otherwise, and receiving compensation therefor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 11. <U>Action Without Meeting</U>. Any action required or permitted to be taken at any meeting of the Board of Directors, or of any
committee thereof, may be taken without a meeting, and without notice, if a written consent thereto is signed by all members of the Board of Directors, or of such committee, as the case may be, and such written consent is filed with the minutes of
proceedings of the Board of Directors or such committee. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE III </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">OFFICERS </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1.
<U>Titles</U>. The officers of the corporation shall consist of a President, a Secretary, a Treasurer, and such other officers with such other titles as the Board of Directors shall determine, including without limitation a Chairman of the Board, a
Vice-Chairman of the Board, and one or more Vice-Presidents, Assistant Treasurers, or Assistant Secretaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2. <U>Election and
Term of Office</U>. The officers of the corporation shall be elected annually by the Board of Directors at its first meeting following the annual meeting of the stockholders. Each officer shall hold office until his or her successor is elected and
qualified, unless a different term is specified in the vote electing such officer, or until his or her earlier death, resignation or removal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3. <U>Qualification</U>. Unless otherwise provided by resolution of the Board of Directors, no officer, other than the Chairman or
Vice-Chairman of the Board, need be a director. No officer need be a stockholder. Any number of offices may be held by the same person, as the directors shall determine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4. <U>Removal</U>. Any officer may be removed, with or without cause, at any time, by resolution adopted by the Board of Directors.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5. <U>Resignation</U>. Any officer may resign by delivering a written resignation to
the corporation at its principal office or to the President or Secretary. Such resignation shall be effective upon receipt or at such later time as may be specified therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 6. <U>Vacancies</U>. The Board of Directors may at any time fill any vacancy occurring in any office for the unexpired portion of the
term and may leave unfilled for such period as it may determine any office other than those of President, Treasurer and Secretary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7. <U>Powers and Duties</U>. The officers of the corporation shall have such powers and perform such duties as are specified herein
and as may be conferred upon or assigned to them by the Board of Directors, and shall have such additional powers and duties as are incident to their office except to the extent that resolutions of the Board of Directors are inconsistent therewith.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 8. <U>President and Vice-Presidents</U>. The President shall be the chief executive officer of the corporation, shall preside at
all meetings of the stockholders and the Board of Directors unless a Chairman or Vice-Chairman of the Board is elected by the Board, empowered to preside, and present at such meeting, shall have general and active management of the business of the
corporation and general supervision of its officers, agents and employees, and shall see that all orders and resolutions of the Board of Directors are carried into effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In the absence of the President or in the event of his or her inability or refusal to act, the Vice-President if any (or in the event there be
more than one Vice-President, the Vice-Presidents in the order designated by the directors, or in the absence of any designation, then in the order of their election) shall perform the duties of the President, and when so acting, shall have all the
powers of and be subject to all the restrictions upon the President. The Board of Directors may assign to any Vice-President the title of Executive Vice-President, Senior Vice-President or any other title selected by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 9. <U>Secretary and Assistant Secretaries</U>. The Secretary shall attend all meetings of the Board of Directors and of the
stockholders and record all the proceedings of such meetings in a book to be kept for that purpose, shall give, or cause to be given, notice of all meetings of the stockholders and special meetings of the Board of Directors, shall maintain a stock
ledger and prepare lists of stockholders and their addresses as required and shall have custody of the corporate seal which the Secretary or any Assistant Secretary shall have authority to affix to any instrument requiring it and attest by any of
their signatures. The Board of Directors may give general authority to any other officer to affix and attest the seal of the corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Assistant Secretary if any (or if there be more than one, the Assistant Secretaries in the order determined by the Board of Director of if
there be no such determination, then in the order of their election) shall, in the absence of the Secretary or in the event of the Secretary&#146;s inability or refusal to act, perform the duties and exercise the powers of the Secretary.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 10. <U>Treasurer and Assistant Treasurers</U>. The Treasurer shall have the custody
of the corporate funds and securities, shall keep full and accurate accounts of receipts and disbursements in books belonging to the corporation and shall deposit all moneys and other valuable effects in the name and to the credit of the corporation
in such depositories as may be designated by the Board of Directors. The Treasurer shall disburse the funds of the corporation as may be ordered by the Board of Directors or the President, taking proper vouchers for such disbursements, and shall
render to the President and the Board of Directors, at its regular meetings, or whenever they may require it, an account of all transactions and of the financial condition of the corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Assistant Treasurer if any (or if there be more than one, the Assistant Treasurers in the order determined by the Board of Directors or if
there be no such determination, then in the order of their election) shall, in the absence of the Treasurer or in the event of his or her inability or refusal to act, perform the duties and exercise the powers of the Treasurer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 11. <U>Bonded Officers</U>. The Board of Directors may require any officer to give the corporation a bond in such sum and with such
surety or sureties as shall be satisfactory to the Board of Directors upon such terms and conditions as the Board of Directors may specify, including without limitation a bond for the faithful performance of the duties of such officer and for the
restoration to the corporation of all property in his or her possession or control belonging to the corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 12.
<U>Salaries</U>. Officers of the corporation shall be entitled to such salaries, compensation or reimbursement as shall be fixed or allowed from time to time by the Board of Directors. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE IV </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">STOCK </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1. <U>Certificates of Stock</U>. One or more certificates of stock, signed by the Chairman or Vice-Chairman of the Board of Directors
or by the President or Vice-President and by the Treasurer or an Assistant Treasurer or the Secretary or an Assistant Secretary, shall be issued to each stockholder certifying, in the aggregate, the number of shares owned by the stockholder in the
corporation. Any or all signatures on any such certificate may be facsimiles. In case any officer, transfer agent or registrar who shall have signed or whose facsimile signature shall have been placed upon a certificate shall have ceased to be such
officer, transfer agent or registrar before such certificate is issued, it may be issued by the corporation with the same effect as if he or she were such officer, transfer agent or registrar at the date of issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Each certificate for shares of stock which are subject to any restriction on transfer pursuant to the certificate of incorporation, the
bylaws, applicable securities laws, or any agreement among any number of shareholders or among such holders and the corporation shall have conspicuously noted on the face or back of the certificate either the full text of the restriction or a
statement of the existence of such restriction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2. <U>Transfers of Shares of Stock</U>. Subject to the restrictions, if any, stated
or noted on the stock certificates, shares of stock may be transferred on the books of the corporation by the surrender to the corporation or its transfer agent of the certificate representing such shares properly endorsed or accompanied by a
written assignment or power of attorney properly executed, and with such proof of authority or the authenticity of signature as the corporation or its transfer agent may reasonably require. The corporation shall be entitled to treat the record
holder of stock as shown on its books as the owner of such stock for all purposes, including the payment of dividends and the right to vote with respect to that stock, regardless of any transfer, pledge or other disposition of that stock, until the
shares have been transferred on the books of the corporation in accordance with the requirements of these bylaws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3. <U>Lost
Certificates</U>. A new certificate of stock may be issued in the place of any certificate theretofore issued by the corporation and alleged to have been lost, stolen, destroyed, or mutilated, upon such terms in conformity with law as the Board of
Directors shall prescribe. The directors may, in their discretion, require the owner of the lost, stolen, destroyed or mutilated certificate, or the owner&#146;s legal representatives, to give the corporation a bond, in such sum as they may direct,
to indemnify the corporation against any claim that may be made against it on account of the alleged loss, theft, destruction or mutilation of any such certificate, or the issuance of any such new certificate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4. <U>Record Date</U>. The Board of Directors may fix in advance a record date for the determination of the stockholders entitled to
notice of or to vote at any meeting of stockholders or to express consent to corporate action in writing without a meeting, or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any
rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action. Such record date shall not be more than 60 nor less than 10 days before the date of such meeting, nor more than 60 days prior to any
other action to which such record date relates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If no record date is fixed, the record date for determining stockholders entitled to
notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting
is held. Unless otherwise fixed by the Board of Directors, the record date for determining stockholders entitled to express consent to corporate action in writing without a meeting, when no prior action by the Board of Directors is necessary, shall
be the day on which the first written consent is expressed. The record date for determining stockholders for any other purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating to such
purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any
adjournment of the meeting; provided, however, that the Board of Directors may fix a new record date for the adjourned meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION
5. <U>Fractional Share Interests</U>. The corporation may, but shall not be required to, issue fractions of a share. If the corporation does not issue fractions of a share, it shall (1)&nbsp;arrange for the disposition of fractional interests by
those entitled thereto, (2)&nbsp;pay in cash the fair value of fractions of a share as of the time when those entitled to receive such fractions are determined, or (3)&nbsp;issue scrip or warrants in registered or bearer form which shall entitle the
holder to receive a certificate for a full share upon the surrender of such scrip or warrants aggregating a full share. A certificate for a fractional share shall, but scrip or warrants shall not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
unless otherwise provided therein, entitle the holder to exercise voting rights, to receive dividends thereon, and to participate in any of the assets of the corporation in the event of
liquidation. The Board of Directors may cause scrip or warrants to be issued subject to the conditions that they shall become void if not exchanged for certificates representing full shares before a specified date, or subject to the conditions that
the shares for which scrip or warrants are exchangeable may be sold by the corporation and the proceeds thereof distributed to the holders of scrip or warrants, or subject to any other conditions which the Board of Directors may impose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 6. <U>Dividends</U>. Subject to the provisions of the certificate of incorporation, the Board of Directors may, out of funds legally
available therefor, at any regular or special meeting, declare dividends upon the common stock of the corporation as and when they deem expedient. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE V </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">INDEMNIFICATION AND
INSURANCE </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1. <U>Indemnification</U>. The corporation shall, to the extent permitted by the certificate of incorporation, as
amended from time to time, indemnify each person whom it may indemnify pursuant thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2. <U>Insurance</U>. The corporation
shall have power to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of
another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity or arising out of such person&#146;s status as such, whether or not the
corporation would have the power to indemnify such person against such liability under the provisions of the General Corporation Law of the State of Delaware. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE VI </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">GENERAL PROVISIONS
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1. <U>Fiscal Year</U>. The fiscal year of the corporation shall be determined from time to time by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2. <U>Corporate Seal</U>. The corporate seal shall be in such form as shall be approved by the Board of Directors. The Secretary shall
be the custodian of the seal. The Board of Directors may authorize a duplicate seal to be kept and used by any other officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3.
<U>Certificate of Incorporation</U>. All references in these bylaws to the certificate of incorporation shall be deemed to refer to the certificate of incorporation of the corporation, as in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4. <U>Execution of Instruments</U>. The Chairman and Vice-Chairman of the Board of Directors, if any, the President, any
Vice-President, and the Treasurer shall have power to execute and deliver on behalf and in the name of the corporation any instrument requiring the signature of an officer of the corporation, including deeds, contracts, mortgages, bonds, notes,
debentures, checks, drafts, and other orders for the payment of money. In addition, the Board of Directors may expressly delegate such powers to any other officer or agent of the corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5. <U>Voting of Securities</U>. Except as the directors may otherwise designate, the
President or Treasurer may waive notice of, and act as, or appoint any person or persons to act as, proxy or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> for this corporation (with or without power
of substitution) at any meeting of stockholders or shareholders of any other corporation or organization the securities of which may be held by this corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 6. <U>Evidence of Authority</U>. A certificate by the Secretary, or an Assistant Secretary, or a temporary secretary, as to any action
taken by the stockholders, directors, a committee or any officer or representative of the corporation shall, as to all persons who rely on the certificate in good faith, be conclusive evidence of that action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7. <U>Transactions with Interested Parties</U>. No contract or transaction between the corporation and one or more of the directors or
officers, or between the corporation and any other corporation, partnership, association, or other organization in which one or more of the directors or officers are directors or officers, or have a financial interest, shall be void or voidable
solely for that reason, or solely because the director or officer is present at or participates in the meeting of the Board of Directors or a committee of the Board of Directors which authorizes the contract or transaction or solely because the vote
of any such director is counted for such purpose, if: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(1) The material facts as to the relationship or interest and as to the contract or
transaction are disclosed or are known to the Board of Directors or the committee, and the Board or committee in good faith authorizes the contract or transaction by the affirmative votes of a majority of the disinterested directors, even though the
disinterested directors be less than a quorum; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(2) The material facts as to the relationship or interest and as to the contract or
transaction are disclosed or are known to the stockholders entitled to vote thereon, and the contract or transaction is specifically approved in good faith by vote of the stockholders; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(3) The contract or transaction is fair as to the corporation as of the time it is authorized, approved or ratified by the Board of Directors,
a committee of the Board of Directors, or the stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Common or interested directors may be counted in determining the presence of
a quorum at a meeting of the Board of Directors or of a committee which authorizes the contract or transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 8. <U>Books and
Records</U>. The books and records of the corporation shall be kept at such places within or without the State of Delaware as the Board of Directors may from time to time determine. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE VII </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AMENDMENTS </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1. <U>By the
Board of Directors</U>. These bylaws may be altered, amended or repealed or new bylaws may be adopted by the affirmative vote of a majority of the directors present at any regular or special meeting of the Board of Directors at which a quorum is
present. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2. <U>By the Stockholders</U>. These bylaws may be altered, amended or repealed or new bylaws may be adopted by the
affirmative vote of the holders of a majority of the shares of the capital stock of the corporation issued and outstanding and entitled to vote at any regular meeting of stockholders, or at any special meeting of stockholders provided notice of such
alteration, amendment, repeal or adoption of new bylaws shall have been stated in the notice of such special meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g805799g11t78.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g805799g11t78.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X7U^:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC
M871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET
M;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/E!R:6YT/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @
M(" @/&1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @
M(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UR97!A:7(B/D9I;&4@
M3F%M93H@(" @(" @(" @(" @("!G,3%T-S@N86DF(WA!.U5S97)N86UE.B @
M(" @(" @(" @(" @<G(R.3,Y.3@F(WA!.TQO8V%L(%1I;64Z(" @(" @(" @
M(" @(#$R+49E8BTR,#(P(#$S.C,X.C$V)B-X03M%4U0@5&EM93H@(" @(" @
M(" @(" @(#$R+49E8BTR,#(P(# T.C X.C$V)B-X03M38W)I<'0@5F5R<VEO
M;CH@(" @(" @(" R+C8F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#$V
M+C N,"8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!!<G1W;W)K)B-X03LF
M(WA!.^* HB S(')A<W1E<B!I;6%G97,@:&%V92!A(')E<V]L=71I;VX@8F5L
M;W<@,C8U+B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P<F5S
M96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!4:6UE<TYE=U)O
M;6%N4%,M0F]L9"8C>$$[(" @(" @(" @(%1I;65S3F5W4F]M86Y04R8C>$$[
M)B-X03M4:&4@9F]L;&]W:6YG(&-O;&]R<R!A<F4@<')E<V5N="!I;B!T:&4@
M9&]C=6UE;G0Z)B-X03L@(" @(" @(" @0TU92R8C>$$[(" @(" @(" @($)L
M86-K)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@:71E;7,@:&%V92!B965N(&9L
M86=G960@9F]R($-3.B8C>$$[)B-X03M%;6)E9&1E9"!I;6%G92!I<R!L;W<@
M<F5S)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TF(WA!.SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!
M;'0^"B @(" @(" @(#PO9&,Z9&5S8W)I<'1I;VX^"B @(" @(#PO<F1F.D1E
M<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB
M(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"\B"B @(" @(" @(" @('AM;&YS.GAM<$=);6<](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]G+VEM9R\B/@H@(" @(" @(" \>&UP.DUE
M=&%D871A1&%T93XR,#(P+3 R+3$R5#$S.C,X.C(Q*S U.C,P/"]X;7 Z365T
M861A=&%$871E/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R,"TP,BTQ
M,E0Q,SHS.#HR,2LP-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX
M;7 Z0W)E871E1&%T93XR,#(P+3 R+3$R5#$S.C,X.C(P*S U.C,P/"]X;7 Z
M0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!)
M;&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @
M(" @(" @(#QX;7 Z5&AU;6)N86EL<SX*(" @(" @(" @(" @/')D9CI!;'0^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIW:61T:#XR-38\+WAM
M<$=);6<Z=VED=&@^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.FAE:6=H
M=#XQ-38\+WAM<$=);6<Z:&5I9VAT/@H@(" @(" @(" @(" @(" @(" \>&UP
M1TEM9SIF;W)M870^2E!%1SPO>&UP1TEM9SIF;W)M870^"B @(" @(" @(" @
M(" @(" @(#QX;7!'26UG.FEM86=E/B\Y:B\T04%14VM:2E)G04)!9T5"3$%%
M<T%!1"\W44%S54=H=F1'.7IA1SEW241-=4U!0311:VQ.02LP04%!04%!0D%"
M3$%!04%!14$F(WA!.T%117-!04%!05%!0B\K-$%$:T9K8C)*;$%'5$%!04%!
M068O8D%)44%"9U%%0D%514)G549"9VM'0E%92D-W9T="9V=,1$%O2T-W;TLF
M(WA!.T1"04U$07=-1$%W441!-%!%03A/1$)-5$9"451%>'=B1WAS8TAX.&9(
M>#AF2'@X9DAW14A"=V-.1$$P645"05E':%521E)O9DAX.&8F(WA!.TAX.&9(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9B\X04%%46=!;D%%04%W15(F(WA!.T%!25)!44U2068O14%A
M24%!04%(05%%0D%114%!04%!04%!04%!449!=TE'05%!2$-!:TM#=T5!06=)
M1$%114)!445!04%!04%!04$F(WA!.T%104-!=U%&0F=C24-1;TQ%04%#05%-
M1$%G44-"9V-$0D%)1T%N34)!9TU20D%!1DE227A15D5'13)%:6-9155-<$=H
M0GA7>%%I4$(F(WA!.U5T2&A->%II.$-2>6=V16Q1>E)4:W%+>5DS4$-.55%N
M:S9/>DYH9%5:2%1$,'5)24IO34I#:&=::$I21E)Q4S!6=$Y62T)R>30O4$4F
M(WA!.S%/5#!:6%=&;&%7,7AD6&PY5UHR:'!A;71S8E<U=EDS4C%D;F0T95AP
M-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\K0VLU4U9L<&59;5HF(WA!.W%B;DHR
M96XU2VIP2U=M<#9I<'%Q=7-R839V;U)!04E#05%)1$)1545"45E%0T%-1&)1
M14%!:$5$0D-%4TU514954DYH26=:>&=:17DF(WA!.V]B2'=&34A2-%-.0T96
M2FEC=D5Z2D121&=H85-5>5=I63=,0T(S4%-.94I%9WAD56MW9TI#:&=:2FI:
M1D=I9&MD1E4S.'%/>G=Y9W F(WA!.S K4'IH2E-K=$U453504FQD65=6<&)8
M1C%E6#%2;%IM9&]A5W!R8D<Q=6(R4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E)
M;4MI-'E.:F\F(WA!.RM$;$I75VPU:5IM<'5C;EHV9FMQ3VMP86%N<4MM<7$V
M>71R<2MV+V%!07=$05%!0T5135)!1#A!.54T<3=&6%EQ-T9867$X2"]W0V,F
M(WA!.W-0.$%J:F58+W=$;4EN+S1G=5=9,FY.>69.=5A/33=&569O34]K5&$Q
M6E)A>DTY='!4>DET.6-2,35P0U0X8DQ22E151' X0G=&27$F(WA!.SDR6#,R
M:F9K.49:=3ER<G0W4&0K;WE24CA(0T928T]%9#)A,5AI<'0Q5713<D)M,E9T
M,45B3$]O9#9M9$HO2U@Y2&AX<DXU.68K<7HF(WA!.W4X5D@Y4#9Y<WER0D5R
M9E90<W1&>DQ-9EDW2#1!8DLQ2'993&MM=#)+=7A6-S4U<2]W1$IA9FPU+W=!
M=TTS-F]C1TQM6%0Y=F-S9G@F(WA!.R]W0C9W=DPS;EA9<3=&5U9Y5U U8WA7
M-F]U;UAD,61-<VQ:;$II:5(T-'=%<6I7-W-W;&PU1F9I,E-N2VI61U984'5D
M;C17:T$K<5(F(WA!.U!Y+S-V52]9;V5:.5 X:C(Y<VIE6'13;G9*+U994U)Z
M<7<O9&(X4TMW>$-U,BLO.&%'2FPQ1%AQ<V5N:D@Y,4EY3CEE-S5":F573T$F
M(WA!.S=&6%EQ.64X."\X04A/.'1F.7,R3"]I2S5G=F]E2#9)*S1-8W0P,#<V
M=4I,:#--9VY26&=J3D=A06=L,E5L4V]954%&5#,V671Q9GDF(WA!.V%F.$%L
M-S9B;5!5-VMY3'DT0FQ)1&)!<#!H3DYZ431Q:#,P+WEC9%%D13%.,7-A4BMK
M-5=2;DQ&<7EC+S-+,$%64T9O<#-+;BM90E8F(WA!.V1$6BM2-49F;F4S34I%
M;$5,16UQ1U9G0U%S1%5P149B<61Z:7$U3$1Y25=)8E5B9TPV<FA303%F4CE/
M<45J,&9T97 X2GA65&MS+THF(WA!.TM)<VDS,7A+4T=:-V-65FQO:6M)2D1$
M>%EM5&M+,$%P=C)O5E9'3W@X<D]B<TYQ1'AL0WDR8D]R.%@T4C U='AJ8V=3
M4VM&5G!52T0F(WA!.U4Q<%962DU69E-/4E,W1EA9<3=&6%EQ.$@O-7EW+S0T
M,VPO+T%*:4HO=T1I0S5::F%C,THX-%%S:7I)>FEQ2W=,0V=/=T\K>#)/5WDF
M(WA!.T=Z:DUO6%AV3$-88W)I>35W4&5P8TER5W-&5F=-:&%714%.4VY"559F
M.6PP<FUR3VQZ;4E(1G9W16963#9Q,E!,=G4O9W%H3G$S;&@F(WA!.W)I.6QI
M=$I)>DY!171W66]84EA%655K>#%52S--8W5A;C(T57)7,D]$3T)%1U%.2&9C
M.2]F,3(R;R\V6E9A6%AV2UIV3&%33%1#<T4F(WA!.U8V6C5166]Y5V=,3V94
M-&QI1%975F5*3D)X<4]P>7-A8E5C0D)N=5E6>E Q54XO=DXY8CAL5WIA=C5-
M=5DW95-B5$I)<FQ3+W)P06\F(WA!.U=':D=6;$%#>4EZ54QP-$=I,')H:F<Q
M35-12F=X,G$K9CA0;#5(=C-+<78Q+W=$3%@V=G@O4G0W-G9D:7<O,S-39U!Q
M,"LS=E5Q9FPF(WA!.S)%4$,Q=D8Y54LO8C=U-WHK2W%..7%0:U4R1C%(66%B
M8U(S8VEC8F%A53AG<F5O5TI0-S%V,D])1S-J,7EE3$9Q=4U'8S0X4%5$,V4F
M(WA!.S=V=%=-6G,Q92ME878O2F%F;#4O>D%Z9G%H=UEU6F10,CEY>"](+V5S
M47,U26]R=4=36F5C4T]R4TI13E919'A1-V(T9%)#57-C;W@F(WA!.TY324YD
M3C-1-%I#37=:8W)41S,Q1%-O=FAA1#%&16]F:S!59DEX;F1L-B]Z1&(R>E@U
M=$QN;G5*8THT4U!Q;#E843AU-VXU,3-/8FHF(WA!.S%'1U!/3BMR*V%/6%5F
M4#='<$PS4GHV>E)W3W)38TM":VI)0E5I=$M5-#E.*W@Y<TU.4'%"=SA59U%,
M-GDV,UAF9C-J=DM*6CA'.5(F(WA!.T\Y9$(K0BMN>5AN571&*W-23W1O4D=J
M5$=18T5025-6.4UC4U-0:')L9C5053A"0FYU94-T>G168U<O4&1L*UIW8U%)
M:G0V=6<V.'8F(WA!.VLV4SDX=GDO1SEO-GEN:CA+04MG;V="1D$V+W16+WHR
M>&AP=%I(651":G9Z-3@O-G V9G%(97-S*VUL=5EM+TQL>3DW8VQZ-5=+55,F
M(WA!.S!N0BM(974K>F9&=GI0564R0T=(6&<W>F@Q*S=B*TAV.#%/6%-6=$=8
M-"M+;&0S3VA.1DET<&)01S=,4D,K.4160T1U-3A'>3-4-&0F(WA!.U=*035*
M9V=(978X04\O;VHK:7=Y-6104C1):T@K>GHY-E8U=%A!979E968K3V0U82]W
M0S)B1B]X1F-W6#!01#E%9F-'2EET<G-64DLF(WA!.UA%06A#=$5#-#),54AJ
M+U1-1U=M>4A*>$-2-&4V>BM/62LY:'=M,5@V,5IC:693,DY+1&=V,#DX>$1O
M.51W06-E.4@K2UA0879K>#0F(WA!.UI6>E5V6'1V5EIU2'=&84MV1F1J.31Z
M2T=(3G=!6#9R,U!%9C%(-6-M5D=L1V0P959M46-63DM#9TAB=T=:3T-%;U%!
M:V)0>EI!8DPF(WA!.TUU4S=&6#!0.6%K.$(K3U)3-S8Q2C1$.&-69#EA:SA"
M*T]+=2MT4V5!+TA&6&97<%!!9FII<GA$+VY+1'HW3C5:="],2T129$PQ:$PF
M(WA!.S@S<DUU<5%Y>D-.;U!10VU,,#5986-V5E!+=&4R14=K14$X,V=V.$%Y
M=3%V*W!).'(O.$%32&1F.6Q72&E+3T%D>5DV3BM:=7,V,4TF(WA!.S!/;2]L
M+S5:=4A495%I>G565E)1:V-N839#:79%,#,S=V-26G=W8U)O0S Y,4AZ8DQP
M559B+WET-51A-$Q54T,R<W)Q44UO1S4U=&0F(WA!.TI49B]!0U1K1&U,;2]W
M06U!0S5%935*;R]W03%F5G56:&HX:RM79FDS3F)/-3)(+T%%:S0K2U=O85-*
M3D)-6B]Z0FE(15(K5&9,4W0F(WA!.U-S:&%Y=4A&5#)&3'!-:4TU8VLY;'AR
M62]9;#$U*UI/<3)S0FY0:UAY=$Q';TIK84]Z=7IW<#$U03-)27 T.4US1U,K
M<FE:9$598W<F(WA!.TM3<B]!2EAA,R]5:V56+RMK3S8O-TMS;'A&>'5!9'IV
M*U8R="]W0E-2-5@O04]K3S8O-TMS94ER=T1U93 O;E@K67,S:R]Y;C5"97<F
M(WA!.S!$4C=U4%4W2U=1,C$U8GEY4E<O1TLR9FIB<6LP6E936FI7<%!164))
M:&AK,"M/9&-546$W,VMN+U%X1W-F.$%5;RM79BMK3S4O-TLF(WA!.V-01V4Y
M<"])-% U:V9K1E-(+VY)2%A*;D-2*U0O3%1-97=S-VHO<W!X3U$Y-T]06C)'
M4F]1:CAG;3%V*V,R=$9!.7@U5SAS<E1D;S$F(WA!.W-R:VUL4#5V<EA8-DUJ
M-'@W,TUH,D9H23E566HT0DYD4"].:64T86MN;%1Y*W4Q9FAT6G9V+W9Z9T]7
M5&5/=V1.+TY(>4@V:WA(-6@F(WA!.U1S2$,K5CE"-41:1TYP3E-P1E)5975-
M9TY22FME=TY.5S!2.&@K<$MT5B]-6'ID85%V4&$K5E!+.3=&1TMU1G-R:$I!
M04YZ=TXP83<F(WA!.RM"2CES<T=5.3=I6D]W.&-D>$-*2'59=DXO>FM&<FM,
M=$A,-4\X='!+:$MU:E=6>4-#3FE#1&,W2$IC6C<S1$]G=T0K0U!Y5V8Y1$4F
M(WA!.V%X+S%+4&QN+W!$=68K>6Y(:E!E:CAJ9R]M4BM1979F;DXK82MP*U8O
M2W9K3%5R5%)T2G4U=&0P.7!R:4\X9VQK:F@T43)Z<6M!4V$F(WA!.TUQ=%HR
M,EET,GE,;$%!8E!+9CA!;UIJ>DXO,4Q(;'HO04M23&XO<W!X=$Y+.70O>FM:
M-79U969O954O3#!G:DA+47):,TY&6'!6:CDF(WA!.UIO3CET.&)41TI02DA1
M9FXS-7!90G!V3&9L>$%33FA:,U V+W)/4C1N26IP:C%43S(O3S=72F9T95A.
M0DAY=' O=T1S;W<R,F9L;V\F(WA!.W%4.#1.85I"-E!L+U%9,C=L-T\T8T@U
M05A+9G)W,F<V560V5&%H*V0S;G5Z1$]02VYL>65&4GE-:V1P8VUG.3$K<SAT
M:'5D<V)A2EDF(WA!.TI"2G8K:&U033,O57-E6% K:U,U+W=#>6Y',G%N9CA!
M47I(;6(O<5=03&XO045I6% O6E1J879S,T-R<U9D:7)S5F1I<C5T+S5Z4B\F
M(WA!.W5V2F8O8GHO04]X5$%R>&HX=CA!.'4W=GI,2TQY-5DR*VEX4V5L3D]P
M<$DW.&580TMO27%+:FM4,'(Y1TQK-F94;DEF2C8Y<61Z;R\F(WA!.VQR4C)T
M=%!H:FAT,%!#1S-J04)-:%5,>6)X66AF:5II4V4U>7529#%$2$=!,D1Z95-'
M835K83=U;4UK<FUT1'5",V]0;&Q91%)L;%HF(WA!.U4O3"ML:W),8W5O0EIY
M<4@R43!0,W1K6DYM:WA74U5X=6)#-%5%<VQ#>"M"83=S468T.4LT:#)*>#=)
M>7E33G0P6#=10G)79S-W5S F(WA!.VE/>D@O3F9K:$I!8FI4,45->7!6-%%0
M9V9I3G5)2%)J,#DO=GDR12LY,65R,% X049$-5!05U5Q84554&AL>G%(,$HO
M>FQ&+WEH=C4F(WA!.UAF.$%B3VXO04]41FQI<G=85#E0:W5P3G1O,3-D=C1$
M05146FIX;5):1'!U;D0Q6%-&96@T<C1N-3555&)T9$QI03-4<6%W161S.&HF
M(WA!.V-H1D=+>4910V%$=T<R1VY*;'1%<'9:4C)+>'=Z5S%W3&Q*559Y,T0P
M*T1%:TUM-6%T04LO5#=:2$IS;D)K-'=Y97=T635983AQ=#<F(WA!.SEA+S5N
M2S-*-%5B1%IK4U-)-$1&,49A:7912&5M*U1"63!L,G,O;'I:96%T4&11571T
M6%-P<S=V<V0V0T]8:4-42#)R,5AQ2S=H<DDF(WA!.T9W=%IP:%!L>F5&-G9P
M3V\V4G%5*VYA:D$Q=&57>F-*;UAP54AR<U)S=TDS5FAS4G5.<W-D1U%184PS
M4"]N2E@O;$%0>6XO-UI5=B\F(WA!.T%&1%=/2TAL9C5F*U$W>GI:<6)X:'I$
M<#EQ1F4K=4)U=U9Q.%519GI0>$Y+-T1C*WA.3311-&I4,%1Z9F]&:&](;'5(
M5#=+3&A%,&DF(WA!.TIY3D]B:V)L,TEP5FIX,RLT8EI6375Y>#1W2T%9,41P
M2G5,4G$W3%1B>')L44QL*T9E>41S6FUJ;&$Q;DA'94DP4'8W:C)/5V=U3T$F
M(WA!.U%A2V97:E)Y9D1U0C-!.3AM1V9#:7AB+T%"8C=5>%-9<UDX>BM4,'54
M3F0R0SAB<%)Y949F<WE$>$%(-U(O2#4T6$%Z-$]O64%25$8F(WA!.W<S-E=9
M54]X5C)+=7A6,DMV05 K8W)D1697.54X9S9A:V]H*W-0<5EE6FA89VEI,EHR
M-#%(26A63D9R=C!X1%!(07IK049#3W<P=7@F(WA!.S!30S!T5BMR,D9J2#9C
M1DM*5VXW5%5)-4UX,UDK2G(Q=U-&:#,K0U!"-E$X*W9P5S%F5TI:+SA!:C%I
M<6M#:F-%3'-4.'IL2D1,3DPF(WA!.V]H=%)I4TM(9W U37@T<6<V:VYA9W=/
M260P.3!B4VU3,6II241&079-;F]3844O:FQ*3'5D3FAO2W<P-DUV5E=*5TIH
M.$)8:5-E3D,F(WA!.U-0:5!J:'1Y-30V0U(V17)E9T9905-29G5P5D<Y1U$X
M8UA8635B:T90<FTR9#=F:TMJ:4]2.7%947IL1VYM4#5G-D(V5'!R1G5G5T,F
M(WA!.V%I5&A25#DT45-(-B]T55!19'9%-6M13G5H,2M$:%!%3W(Q5"]N2GE*
M-69+4#574DE+=2MN>G%O.7I"66=:3C$T1S=Z0WES570T56@F(WA!.U%55E)V
M='54-&XU-5548G,T43124UEA3F%S8FE2:S-A;V]09G!K97)N86%.>%IJ6F%5
M2DE7:F-N:RLU-F134%E:3G5)<$E.0G-M,#4F(WA!.SE8,%<T4FYK=&5.,UEK
M16-20U<T4VPV:U5!0D)Q0C%(:&=)<T]V:F5/9&1'4RM8<#,Y4EEW,B\W2CA+
M*T]653=42$LR5'AO<&8T2T(F(WA!.VA39THV9C=7*T9M46YM:S(V*V]G:C,U
M04=O1DLY36Q&<6U'12]W1$]1=FQ+,W9T1UA7-%DK3V]A66\Y5&IU6'1N86I+
M44)8-$=03F0F(WA!.W=&0F5V55ID9E(Q5W-W6$AI2%):*V8R;5AM<6559GED
M,#9Y:3EA.'9,1#9V8E)60SAP6EEB0D57<D961E=056M$2D(Q5#!445!).7 F
M(WA!.S55.'57,FI7:6AH0TLS33152UIP>4(V:W W+T9487!.0E%6,GEC=DIY
M.$EP-5(K8G5O2V19<V1.6')'1VQK03A7;T9(,T1-95$R8S<F(WA!.T@Y44-R
M-64P8C%B2&U.:5(X5F9N5&)-93-::4M2*V1F2W1Y:7!Q=')T2D%P37%D2V].
M>E1X<&LT>39.1W P-5!Q2$U*5G!D,',X87DF(WA!.TEF:5AQ=FHT:DQ(1VA*
M;%9Q;VYH16EJ;%%$8SEX<V8Q6DE&=7$R9VE%1V\V.2]L:V<P4VDX-B]-1%%X
M83-O=C1&<$1C=%-51&]*9'HF(WA!.U@O6F=6*V1C:UA76CAD1S,S>&58=&Y:
M5W-L,V5Z>#)T<D-/57,X>G)(1V<V5EIM24$K;D9X,$$S;3=Y;W-O:6)7<D%3
M:V=#33--26$F(WA!.W!F,'AT>7(Y=C1F;G1J4E)986TX,RM5-$](<F$Q65)E
M<$8Y66HU,U5+.&]E4E@Q1G$R-F-L235D2VI':71H93-M;GEW<TIM8E8W25$F
M(WA!.W%X4G!$8WAC47EX*W-62C55<4EV:B\Q9"MM3DQ94D]M-G1P5W%7,S%R
M5$QY0RMT=5)4,3=A5DIK-41Q=DI#=W%+-#!O3G9.+WHR:6@F(WA!.T5N;#8V
M66Q:231R-DE%3E%C2D=T;EE%9#DT;%!T9V1H;T%/26YU94QE6B].:W0Q14Y(
M='%I26-1>C$V06(P,DA827IN97IT26IH3CDF(WA!.U5',#8R='%S449/2S=(
M,G!T;&)827%7:5%3-FIF1V1G9E%H,E$W+T4S.6U1:U<S4S1$2U8Y2&]':BM8
M<C8Y:U)B9EE-47%R,#5S4&DF(WA!.W!8<#(W-V92:UEW2F0Y-'--36)K;U!9
M,GEC-6=G1&9%1V9E<%!V-&LY8T9.;5=2<&=N:S(T*W0S;'A)055%<VI4:$]T
M3V)S2V)E1T<F(WA!.U=W961X5#1P5WI&,U1J3$=&<5%P470R3F%D=DAB149Z
M<%)3<E9.2UA54$PK;U=G:D5K:S!,:4)#845U3C1T.75K;%!U>3)"8TQ6674F
M(WA!.TM"1$IF>C-T4DPU8R],1UIG94U';50P8G-'84=Y07(Y1F-S;'ED2'!O
M,TPS4$U&4D9/-FEP<68Q,"]$2VY0:TYK9&\P1&-M:VI&6$PF(WA!.V9#=E%%
M.78Q-&@R5VQG3T9K34IU-'=';%E-<#9+<#-(>DHK4GEW3G,T.7E387)D+U9F
M32MM,U5T<#EE:#E/-FIN=&%L87),15DR2DDF(WA!.T(K>7)C=F\V:G%*4C5U
M<C%W26]Q,FMZ;7HQ6G)0,4)-0DEY2DUU,TI68C=F149Q0G5Q-SE-<6Y(9'DY
M165*;6QL3'EV4D98,E)U<#,F(WA!.S9D9G!Y26,R8V1M5E%&63<K4#!J5TYG
M<7%2=5%+9S$Y<TE98TYH12M98E583G5B931H17-5>79(26MG2$)L8EEQ9EEJ
M63139#)I55$F(WA!.UEL33=V>61$4#5J+T%#=V=V1U-8+T1E:E@Q>%1J>6IK
M;6AJ,"LR46EV47$X=G%)9D92;5)&-6=X;S!N4&U*1T-32TMK1&5V.6-:1GHF
M(WA!.TU%97(U6C@Q6$QA;C5S=4QQ=%8Y9&MJ4"M1;G=R*T%Y<5A*>31F5SE'
M.&XR;V9454Q(6E)Y2C8Q-R]X>D503C-U3T]W5$,O,&IN8D8F(WA!.TID,V(T
M5TAA<$AB0S-C24QW*R]S-61#.'=83FEA:$5B;$-4,U)H540X86903'AU2&YS
M,%!$;5DY3VI.4$PP=V%,<U9)+U5-435-95,F(WA!.W!+>%9P47<T+T51=G5T
M5%$W*S)70G)M16@X>E=I6&UI,VY-,#E/3G!L86TT35DU-V9/;$UM-%=O:F-3
M*WED6C!U1%9D3'5D3FYD;S0F(WA!.TQT1$9+>4)#,T9U;T%K5C$S1S(V;D5/
M<TQX+U=V3'8U5#9&-6AL,$154G%%5G1'66153G,U9V5X4#%M9$Q247!)33E&
M5U1G5C=2<5<F(WA!.TAX04A*9VQQ26E$4VIQ9'8U03 V*T0S1G U:5,O=T))
M.4-Z=%=-.71-67!T4&UT;6AN:5=785-,;EA563EI3T9'8C1!>&%P,U%A5DXF
M(WA!.TMB>50K:V)8>3EA=RM92D)(<61P>',U53 O,&]R<3)12D4W8S9/>4Y"
M<#E3=S5F0T=P4FE29S-32S505E!+4&Q(4V9+=6IR<&5M;58F(WA!.S1G,T]3
M831F,4I:1S1R1T-Z555B2D=Q9TM!04%-:51B6D=.0C5V.$$X-4I86F=T9DQI
M,4Y(*W4W1&%T4%$O<C%Y=5)D;&]/=G=F4#(F(WA!.VYV>G5*6FUO1%AO4$@R
M>6]L,DI+=%!.2F188V1K<')*33-E;3%/<'!896U266U.;#9.;T]J<$9B>'$Q
M5BMR:FEO24A504=P;T)U,E$F(WA!.S5U-C X0D55>6TP.'=V<%1P9$EW9UEQ
M,T8V1%ES2T5I;V(Y;C)Y,DTV1%!0<$)L1DAC5S@W.#4V>6M7;E-,1W<U>6=O
M;FE3,U4K,4(F(WA!.VM/6E1R36Y"07!6-4MT;71.3FYV0VA-;'E64TEF-4MD
M5#AI>'E->C!D8F]S9#=S:'-6;G5*1FIO;V%11&Y3:6II<6A19'1U9S9N9G8F
M(WA!.VAI2$MY56Y5.75S05964'@Y854V0V@V-61Y8V,X:V0K95E72'EP*UAS
M639,65-G2"]69W1136Q*-2]41#%394U3,TY656<W='-V=G8F(WA!.U1P:TA+
M3S5:3#5C=&A2<&5O0E901'15+W)X1'5.4'1';5EX-D1)=6QP<7-K,%II;&QK
M:5-!3E9Y27=P8C16-55(>$1Q82LQ2TA,94<F(WA!.VAB6$Q/2E1-3V]$>F9Z
M<&-3=&0R;VIG2$I:9C-C5$$W.5%19&AS96YT,7=23S=I82M0;RM+36MA13-K
M1C5$2TIR931T-$AJ5F53:$\F(WA!.T-R15DK4$=-3'A:0W$X44)19D0X3DUC
M,TY06D<Y<W(P9C%K2'%Y1EAC+UI0=%AX>DAD=5):96=E6&)C4$8Y66PS2%=L
M3W1A9FA58EHF(WA!.T])84UH<EE*=F9),3(P04%,2TLP2C-O0G1K>G4T=C!G
M<S%U6G)/,D=L0FAY=E)94VDS6'9W0G1X269V-%ID1RM(.&5B>G-H95$K.',F
M(WA!.T,O3516,G-T1W9P:65-:E%S:2M.5T9"*T]2:TXS3W@Q5#5P9'E,<45D
M1UIX=FM*8VUZ1TQM2'18:TLQ-39/-S!0141I1#=M=5DP4G4F(WA!.S<O:311
M13DQ1S(Y2S=4.31S,&,P4WE2;4YG=V\R-')4;W=P=41L,&\P>7=:3TM*,F]G
M=D50>F5S,6@Q83!U5F%R4V\X8D1W.4IG4B\F(WA!.WEC>'@X;E8Y<7AQ550U
M2W9L4UEV63=$<6Q19G S+UAG83A2=4M96&IG059)4$PO87EY2S5%1F91.'1&
M,4)M*W@Y5VQR+W$K;6-S1&DF(WA!.UIJ-E,K>#A857!D<4AL<GDU<4Q33G%'
M;%=D-#!P:F%5,T9V1DM884E-<UIB;7!Q545J0F$Y2VUN6$<P14%R3&IY;C57
M=49:8FI2<D<F(WA!.UI86FYD6DQA1F=89FAY63%5-W0V2U909FEV9TUB2S!&
M4TAY-35E9RMR*VIP9'!&.55)3G!W9VE8,&EP8W%9-DPX1D1+-490-6HT;D<F
M(WA!.S%P34U5=D1V*V-P;C0R,VQF=TEV*W8X03!B-5A.>CE#969W94(R,&YO
M,GI-935,8D1+;EDS=6ET06MI:C%C6%5P<E9#0GDY>4MF:&<F(WA!.U!*;FA)
M-&YP,$8O13A+;4]12WA!2G(T:DMI-U1&;$%,2&9-1W5P0V%.2UHU,$AW>')7
M9U!V=68X*S)%06QY<VUU:D%-5# K>G9D9C$F(WA!.S549'13,VE(3U)H<W%J
M96ER5'5C<TIO4%!:36MS*U-Z>5HK+V]P1W-&;40X3D55065(65I32&)12$-+
M6E8U93!8-G1$>F-6:TI"66,F(WA!.V%C:E198C R.$UY26AQ>5-T16%G,6Q:
M47IA<'%)2FAT;S-L96YX559&3$]D=7 R3U1!,V-83D]O;$I0>CEU5$@U5"],
M6E R-4Y.;6$F(WA!.W9B84-Z0B\T;&AM-E13>3E2.#-J5G9*-G0P;T<O1&]0
M=T=13&XT:&-M65=7<%)796YM0C$O945C:#1623,V66=U,&E$>D-J62M9<&(F
M(WA!.UIJ4'DK1U1K1$=.>'8O=%I0:3)P=$U,-7-:.'DV:V)M83-123!X5FDX
M-&]F:4Q(-%EZ>&]D*SE..%EJ9#%08658;$9K9FPQ<&18=FHF(WA!.TYC>5-8
M1$)15C5-1RMZ,E@Y;FAY8VQ136I-,EA*-T]J=W=V=EIN;VQS,7AE3$1X4$9D
M<4PO1'@Y<W)(3C)"4%8V<&(R349P<$MO5EDF(WA!.WI50E5!.4LW055Y-&I:
M=U1K2FYT>5)D=EIR8E%X=$U3,'II;UAU0CE'241J-4UL,FAV3E!M:7=T=DY8
M:U-21TUK1W5A4G%K5FY,<T8F(WA!.W%5<V)P2&%P2#)K:$MJ,TEY-E!53VE*
M.5AX95EF;6HU9V%6171887)/4U=".78X06)Y2F,X1%HU3W%I6%4T5G%F:%!+
M;GDR+VIL8RLF(WA!.U1K85E835!C+TET.6(R,6LY=$I25S1L-#8W5DY+:78P
M5GEI2$XS95A'6D%5=C%(5C19-U-I9T-6>#9I*TAJ-S=!-5IZ8VU'36=V1W8F
M(WA!.WI5=C%U3"LP:C(O9&\W16HO2TLP+W=#23193VLW6&QV14LS;$8K1VQ2
M4T4P0D1F8T0P+T1!96)69U!P4C=*-CDP<U59,R]A<#<U34DF(WA!.VY*32]-
M5G!(6653.59V2FM*:DYS.%%P,3541#!K4'DU3TUT:4A8-3AM>C9W=T]#-T98
M67$W1EA9<2MF9BMC=#=R,$IV2E-S9F=K1W F(WA!.V=G*TDK<3AC:$E7,S9F
M2G=Y941,8U!)3G9S.6=E;$UP3'-X:U8S=3%C<E$X0V]!1E!B055W>55I-&15
M=30P;UIJ=W!104A';7<V:%,F(WA!.VMU,VY947A$;$I)9'ED>#@R3T5"<&QK
M36EY;E)O,W1O,6=G:DQY4%%L:G95.7EF=7E"1G5D:'%)96@K5V1*:'-L1GIE
M8UI*;49E1$,F(WA!.W1+9SE-=6AJ2%9N4$]3;FIA=W))5E%Q0TLX5U!7<$%.
M5&QL3E)Y4$]0>F4X-F9O+WDO3' X16].-7%)83-"0BM,,%-+5$UA9W%15BLF
M(WA!.T1S9FEQ3VAX<'=T6FYQ1F13:2\K8VPU>D(U5"]!0W-K2%%A9$]#4%EW
M5U=*1G5Q:$MJ8G@O5$PQ5G5'2D]Z1'9L2D1S.$]49$]:9&(F(WA!.S0P;W9X
M:G5"*W)!-TM'86M"4&5L,B]D9D,W.5-A54=36$YQ=45B2U-08G-Z1FEO8S!-
M661E87-W0D%$2U%186IX1T5';E142FU74V4F(WA!.U=B:')6:45A;D9E2U4V
M04@R>41V25,T64%09'9*,7995V1I:S-%1S1A9TQ(8W%&1F-S:$9X<W5C,U-D
M4')6<5-89F)G1'<W,4DR>7<F(WA!.VAG36A99"M9;C5H;E)02F5O6&M5;D15
M<%5&=EI/0U9+>7DQ549303(V3'EC5C(K2$5C;D8Q1U1H1$9F*V-G=%)N,"]Y
M:BM4,2]"5#$F(WA!.S=85'I01GE(2F558T9G=W%/-'%-24QQ=UAN974K85)R
M*W!#.6EQ='-605-.:G5#9#)".38W64,W0T5G43-O-F-R,VQ7=$)12#4O-U<F
M(WA!.U9Y,V-Z5&)3=#9:<$XW0W%X>51V>$9/;S=M;$YZ;$9/.7<U2T,O5TY6
M9T-C;&QQ:V%-6$MN64YS2T@O4'1J5&%C=$,S:C)U,U Q-3<F(WA!.VTU62]A
M3EDO64Q4*T=8>&5:,3 K36MP,W!C-&@P*S)I-F5M9S5,-SE4*T]";D1A265I
M+VQX-5IU3#9/5RMN5#18,U$K=S-Y,D5B8V8F(WA!.TY.:&8U.&5B3%-35S$X
M<C)$2S8R3&5V<4UI:TU"8V-3<7A6039X<7@U55EI<E5.1U4U6DQ95C%D9FML
M6F9:=5%A,UEQ-T9867$W1E@F(WA!.WIB+WIM:B]D95,O*S-N+S)+-$9F4&1N
M<51'24E74'%!54HX4FQC;W56:7EB5551;#!!86M%:G5+,% S-S1+8G5.1E<W
M,T9W9E1283$F(WA!.R]6:%574WE84G1,:6E25VPK16YD:4]P3U!"8FM226IY
M6FQP>%-!:&]!0G=)6FTS3S%.<6Y*:41,>&M2+VEY-5-.:UIW6&I0-W1V154F
M(WA!.W!U34Q)14IF965C63=',6MU-W K3G-U>F-A1GE33FQ12'%X<&E'=DIL
M15$X8CAY95E,=EA.5&4Y=4M+2V5N1$=.*T592DE7=3%E<$HF(WA!.R]H:39V
M2FM-:EIE-"]W1$]56"]+1R]L9"]W0G,V9CA!-4U75TQ7.$5T8FMQ47!/+UDO
M=WE*1&)J;E-/5SEK1S%0>'E00S5!>D9F.$$F(WA!.UA*0G8K3TY)3U,Q5WAF
M,4IV5F9C1%E9:TYM2&,R>5A33&HY-%%/=5)!8S U3FYP;6XK6356.4U%,$Q,
M>'!88EE:84=I53%79GI41%HF(WA!.S)6>&1857%X5S!0.35)+U%,<T)S2VYC
M;6Q",5!42DU$:W T8C4S.#182&U456A*4FMS8F9K=&Y#,S)G<DAD,C-)-4Y1
M5G T06(Y4W4F(WA!.T1L>6-2970O.#5++SAO0BM5+SA!,GEP9BMO87AW3E1W
M=7=V;71N,S-J8C=1+VE-5WI(4&A:5&\R<4MS,TE-0W)5;V9L:T,W4%1:0F(F
M(WA!.TMB8EA54F1Z='155C)Y;V@R<V-G035P8G)F;4YR:$=T-%1S+S)J.#A2
M1F]Z-FYA:V=U5T1M1S-!*T=T5RM1>7=",6-J6G!L9FQ84G(F(WA!.VI73E9T
M-U-)1VIS=G%.,D,T44QB<%1O4%50>D8O3793+W=!='1'5%%D1DU6,35Q;&I7
M<6YI.&1K:$922DMV95)H+V1X;G0X8F9$>$0F(WA!.S-F4S8W2FMS=FPV-G4W
M;3=U6F)Q-FQE935N9'!*<'!#5V0S8S%:;5DQ3$UX3E-4:T-7;"ML6'!39GEN
M1EAE;$HO2V-69#95;CAP>%8F(WA!.S-P4V9Y;D9896Q*+TMC5F5*9CA!3U1N
M-5IE95!/,&9L9V573DXO4T(P-S8Y.6,O9E<X2$0Q+W$O<"\S.&M695AP3CEM
M=E1&6&AG+S4F(WA!.WAO+T\X1V\X=55062]88D0O<V]X5D=7,R]/3V8U,6AG
M2G9,93,X=W9B0VXP+W=#:UI%:'1H:S<P-G-0>4$O3GE%+T9O2$55-FDW<W$F
M(WA!.R]W1$HW14)V1UE*:78U2V9M-G113D)O3V=(,7%Y+S9R65=8:E(W,&9&
M*U0S-7-2,C1184MA=#A4<CEA<RMV.$%Y3WE93$1X67!D9&8F(WA!.VMP*V)I
M25AJ.'9V8U-%-TE,>7A7;%!&;6Y(-%9Y0D1)-FM$:WAB5E K8V9V>C@Q2U98
M=79,,TE*55)O3#)W0W%$=6%$-G@K4%A#-',F(WA!.S5M4C-16"]1<S,U,V8Y
M4S,O=T)0=&@O,E59<TAS;C4X+VQ.*UE(;7)Y>C5#<W1",'(V-6,V3%I4439N
M2#E9=&]V4VME2S%64E=74D$F(WA!.S(X3"]!1U-E;GEX5C0U+S!,4#A!;F0O
M,4QN+U0W668Y;$=+<7-F.$%Z:F8K94,W2'DS6#,K=3)&9BMO:D)425-6=CA!
M;U<O.#9I2T@F(WA!.WDU4W8O3#599CE6.&%:8U-+9R\U># O3T]-0F8X4%5!
M2"],6EDO.$%69DDP5RM'5TE46%,O=T%H4'IC9VM,4V%$>#A+,V1K9C%42$,F
M(WA!.T%Z3V5096TW+VQ&*V)K0T(T+TQZ5'5!,T9&=3=%8C K1W!A9&1V;&LR
M<S5G>%A8=GE/+S5Y03%L9W,O;#=H8DDS2T\R5SES3TE04W(F(WA!.V8V4CA4
M53<O04A5=U<P4VU3:R\O045,4"MD,R]!1DQF+U0W668Y;$=,0C8O*V5(-5(O
M;48U;3AO9FPW<"MH-E8Y8G9.1# Y-V96278F(WA!.W)&=$@V56I15VE"955S
M<4LO=T%53#=O4TYV;&ER>4@O04M&;B]/-R]!2VQV+W Y<U K>6I&5E-(+VY'
M-S@X;U<U4BM884AU4')T:%$F(WA!.R]W1%1X9W!L1U)",E1'4#AG9GIV655K
M.'1L5#=8=&=2+W="4D=$:&-O87,Y5E0O;UAR.#52=5!,,50O>D=74"]!1EAX
M<&EC,75T+RLF(WA!.V-F4'IJ:FM-:W9L,6U*-TQE5T)O4'!U1G<P<V-W1S9B
M3"M79B]/4DYL6F963D4X=$1403,Y-V12,S%G,7EX;U)T2C8T-&5)-$%-1"LF
M(WA!.S%K;VUM=DIM36U)="]W030P9FYE>'%F3&TO.$%Z1S)(+U9F03!T9CE#
M>B]N9"\Q3&8O5#=99CA!6E)I<C=F-78O369V=W$W;2]W1$TF(WA!.V9V>%8S
M3B\U:CDK2W4U=B]!1$@W.%9D>F8K62]F:7)Y8B]N2TQ8=&0P6#AU9$YU.4@Q
M1S8P,C9F5F]9;G5,3V%30U)O>F)83$9#.&(F(WA!.TMX56Q1864R0EAY,R]W
M07)0+TUV+W%B9%HO-VE&,2\Q57A62#9B-3(O3FDO*TM0>E9R4W=!,&%9-FAD
M54AY2'%F161U,S P>4UP04\F(WA!.U)G,# X<#(U9#=)-TQZ3#4K:5AL4#5S
M,75:=W4O3%5B;TQ7=&%G0U1W.&$U56-P8R]W1$E1:'HS5F8X04AF;C4U0V\X
M>#9R461A6'0F(WA!.W@O0CA!:U53>%(W9S%C*V4O4&E13V8X045M<D-G,U Q
M-C5(-"MP:$5I,5-X4C=K0D0U:"]-;35S=EAJ.#1A,T1+-5IK5G11=7EN140F
M(WA!.UEF,VY)5E!F9C599D9R;7EH,F-:>'-&2711."MF;7IP.&]I=2]-*W51
M<W="6&QQ1C%29U%$<V95;V5U5V=G.&Y!>31P67I5:%)1=B\F(WA!.T%#<R\X
M>2\K<'0Q;B]U25A8+U940S%V;TPX-E!.4&UB5"\X06Y(<GE0<75N-G9E,F5Q
M6%HP=C8Q9G=817-6>$PV;6UY>5 V:W%-2&8F(WA!.VTT1$Y5-VYF1EAZ<"]W
M07)3+TTS+W%B=&$O-VE.,R\Q57A3;5=K96-F>FLQ6C976&UB6$AJ0F\X>#%'
M-U=.96QA<UI+5DA+=$)V-UDF(WA!.T-11S-&9VQ0-E%Z2S%N+TU#2T1N965D
M.65M;$)$1EDY475K4VYC1W)S5#@V:DLO161H1',T9GA&9D(U=3@T2DY+4#A!
M14=S36@K14(F(WA!.W14=FI4,T)-,DU:17-C;6UG3U%3;E5F3C-N=%$O<"MA
M9&-3:"M%>#9N96(O05!"4U!T:VA*>#5963E%9G%D=BMB>F\P,F<K8SEA=F@F
M(WA!.U%/8E(Y4W5&:U971E)35#%21SE/+W=";C)'5U4P:D-33$1"3&XX>5!Z
M5W1:,V=U9DY/=7=4>&UK:U5L+V5)-FYW2VU115E';VEL,6HF(WA!.RMA2#5L
M=&4R-G0U=#%P;&%205%D475I0T-W+S1S>%8Y1"\X04]7,VUJ>DYO6"M&4#!*
M<3DW<&8Q:CE)9E=0<59X3&(K<'<K<F-/9G F(WA!.TUV3&IY3DLY2VY&1#4U
M+S579CA!;5@O,4YU=&8Y>$,V+W=#<6U+<'1P6&UV.#(W.5),+VEV5V]B53$O
M9DYQ1C%V5"M69E5Q9C%E*T$F(WA!.VUM-TAG;$PS2FE03T@U9U<W0E0U<S%U
M5G1H>6958G%L86(P55-F<GE";35C9$Y%8SDQ:R\U:&9M14]N;6I6<3%P=&8S
M22\U;5EB5$PF(WA!.T9(=5%6>"M9,S5I9V8X<%1R07(T86AD1#E5;45&;VQJ
M0S503U U;GI7+W%X96)T840P<45/;UA61#E0<5E/3E)P4U)94S(T+TU8.# F
M(WA!.W)E47AZ96%D8FIF=V)53')C5G!59G9.>&LS1VQ%:EEQ4"]+>B]W07DO
M=T1Q8F1:+S=I1C$O=T)635=,-S=W<3=&6%EQ-T9867$X6B\F(WA!.S5Y-2\X
M;&9P9B]B6F@O-FAB<D%R-64X="M86F16;&%744UL;D94;$E"<WHQ2#=S16MF
M<VUP27)4-E)K6E-P>F1&;WIM;"]22%@Y1# F(WA!.T-$4S1G=U=%3$9(=BLV
M4E%&1E15:T%B1#9->%-8<&AJ14DP0E-T9%=3=TEW0DI",S,S+TA%3T9L,U-Q
M,%%63&YQ4U(Y1U1$:%0U;V(F(WA!.U=G,V]L5493>$%51'%35&DQ;#94-6$X
M<U=K96Y1>3-#,6EI:E90:4$K23!!6G0X35EG-VPR.%EM35)%8S!2-74P5%-T
M5#!G,E4Y=7 F(WA!.VEC9V@Q;TA6>#!D5V\Q1"]!3%A43%-A85HV5'A.<%!N
M<E=T2G5.2S%#4WIM0E!%;C S24$U<%5H6$%"4%=N:FMG8F5F>C1*67!C36XF
M(WA!.S!0.$%N=CA!*W-Z+T%*9B]!1#!J+W5L5%E7;#1.-4DX:S-F;5<Y,TIG
M,#9%:C9X8S V;EDK;6QF,FE0*T(V;G-#0V%C=E,V5354+U(F(WA!.T0R:3$X
M=C(Y;F)2,C%V14EB95!:555!04%B;C4W;DUC,CE%3559:FAJ>5%'<W-)=5-,
M46A6<3,T*T="4&AP6$9&8E-A43@X64IU=60F(WA!.T=3:%=I53)O96AR;&]'
M>G)--3E625-X.'9897-88V1R865M,3%-5'=J95=+14U1=T9!6E=693-4<6-K
M031K-55Y>CAS15IP8G%W;6LF(WA!.S4S;'%E13A11%9J1E125TI(54=O24A4
M<#)Y8F1P-#@P2#4K.&=75W91>4]L2616:G$P3C%3;DMN*S8U2V)L9D$Y5C=D
M=U,S-3E)36<F(WA!.S(R:SA-:71,;3 Q94LR=5DR:6YI;5):23)&0T-'1T(P
M:V]K1VDK;'8K8S!0*VU/+S=E6"]!1TLT<UAI;FMR>51C87)X,4<U57!9>'4F
M(WA!.U!25FQ"1355;FM"6#EH4TYZ5&9P-#!4>6-N5#1/23)E5#!'*S!X3%-Z
M16%Q14-R>%9&04%!04%!04<Q0FQ4=$]%35)V1D%,<V5X;V\F(WA!.WE+1$9,
M;5945FTR,G)K;6]P6D]N<51R1VXW5$)64'I.36LT.'1Y>2MX,#1,8G!18D%!
M02]2;%%,<T)':%-J<5=H=U@P0FIC55E636,F(WA!.V=(>$MX+U@W:DIX3DY/
M8D%*:&=&-5IZ5W1X2D)+3TUK6F]W,RLX5C=(=&QR<4I224Y&*VI71FDW1EA9
M<3=&6%EQ.&4O-7EV=')I-B\F(WA!.TQJ4F)A,VIA5S1N,7DS:FAI459:;F4R
M=5%Q9T1U4V-#44PR96)1*U4T9$AS-$Y/=&E:=E-Q<E1C47)333(W3U%#86)N
M659.0G15-6HF(WA!.UI$6F4P,%=N1TM!:6AP8F,R:S=2>6XT841I5'0Q.&9V
M>6MU5D]&:EI#-GI.>'-Y-4%$1&)J.'IK=S9J34M393%C1D9(=%4U34]V2V$F
M(WA!.S)':TQD,V-&5DI53E@W=#A"3&)P-&-5=TAQ;&Y+3$\S=%8Y3EIF4V1(
M145G3%)T5&9I-C=6,C8U2TID<V-014-,<$M(.5=7*SE)+T0F(WA!.T=!5F0Q
M06)J42]%4EAI3U$K67E23SE.=D%/0W=X;CAY4'EY92]W1$MT-7)M:UA#,UHP
M5E!R1GAB;$I)-VA92%E+-T931$=E255S+T8F(WA!.S(T,#DX;$-.934P6&%K
M:$MU24532'A"*TQ)9GIU=#5R:B]N1R]W1$QU,V=1>5144&\P8U5A:7)->F%8
M2T%O2&E38W-D2T)A2#AT950F(WA!.W)4461+9S K1U%0-DHU>7I%0E=L:V(W
M5$U",G)T=51104-U,E94978P9459-&-+9#-.=$E9*U1+14A%;71+-S$R,GE$
M:T-)968V.4TF(WA!.TDW2G!*5C-N;"]:,C)8-%%!8V='=DQ%9T]U,7-9<DLS
M4S-Q=V](;&]W*TII2S V9T$Y=F)-:T1:-3=*36U24U<S4&U(.4I7;SAV<DXF
M(WA!.TYQ2U V<U%G:DQ/;VI)575W<'-V>%4K3#1A13$V;D5&<&QU.4(O3%HW
M3TA83&HP9VIF5VPO9512:VQ8:T(S24933R\S-&<W=7EW638F(WA!.V=*9#9F
M87)!:5-Y06=+=W)8,D%W=61%4$4O>DTP93,O045V639T86]!>E1P1&15-S=J
M,#)/,W1X2BM1>$)D6#)P<#9Q63EX97<O.$$F(WA!.T]7=6QZ-G)Q,VM45&]A
M.#=Q6%5)*U%5=GA"3G!Y8W%/>7)6:C=$2D%/;FI'>E-H;W9L=4-W,"M#,&=1
M:4<Q44I(54Q5,$@R;31H45,F(WA!.W@S2G!U8T5N8G=I26EK<S@P,FI);T9+
M:SES<6LU14)B>F975C1.46)#<')L835.:W),4$I5.49'*S,S9V9H;&=C4U-Z
M4V)66F)Y1W4F(WA!.S5:=5)&3VY%5B]H:%!*:FEJ8W<Y0FIS,U<S5#1.=34V
M.7-R1',K1G(Y1WE&9'A3=30Y.&MW:T=)969.1E Q5T\O44%.0BLW;$AI:D@F
M(WA!.S14=65Z2'-/+W1L:UA787I(+T4K-#AM-CE)9D]8;E!3+TME;C(Y+W%-
M53!S3GIC0S%28F-2;&<U:F57<$5J>&<O1$5D9U-X3D%!4V,F(WA!.TE&<UI3
M<$M,1#@Q=$5V;&Q-3FAF8V]R4C<T4G-T=4=E2EDW959!;C<V:&563#));W9V
M43!B8DAH44IG;VYY="M:5VDK6DY:;C!Q>70F(WA!.W)U0V5#0F)O4&-,17%V
M0S9X4$<T0U-/-FE23&A'6&UQ,49E-G-!;4Y*13=:6F=:34LO3C=213%F5%!,
M345Q33A-1W1*9%-&5%1I66(F(WA!.TLW94UK*TAQ:$%C6$LP56)Y>#DY+THU
M,W)#3$AQ15%&3TY1;DMN:FU*3&TY<FI(<%-,>EA:<$9014YM24E*.38U5DYL
M1&M71V59,E8F(WA!.UE'9U$P;U9&4V1T:4UL1C%/<U$K;E)&9VY*5'5+5C=5
M*V580TQR1U<V1'AA-4)58E)R6#)R4V=Y0D1M-DM.>5IT2T5N<T5D3G!/;TLF
M(WA!.SDY*W4O=&MI-V)'0T-Q*U=T275,+U@W2T-";$-S,TIJ27%U045"3%96
M=&TR2%1*9U=73W1Z4G@T<$5P;BM:36QH<$]K>F%/<T9P3F4F(WA!.S9J4UI,
M:4\R5T-31D]:2D)O1T1!;%-!3U913FE-;&QL561N4V%-4WEY-&IX8TDR;VTW
M,B](4E0X,S9&2DXK53,U8G=43%@Y1GIA5F,F(WA!.U1I=$M.8C9:348O-4LX
M8VQB<G1(:'9-065N-D5S=%E';&-&4E-/<%4P,DDS.3DX<4ES=EA!9U)2,3-:
M>517:$-04FAX03=J8SE$5#4F(WA!.S1K34EZ04QY8GI-:U@V4G1R1UDK;6XQ
M;%!59G=5='8K0D]6>$<V3E8Y2DDW:TQQ,#!S5%A-9%AA1TUS<7-70V=X<V\T
M9D)V5&MI;G0F(WA!.U1B-41-=#5A4G-Q4&MY-C$V86)61S!J;7IF5DAE.59$
M17$O5EEG>&M,*V]'<4%Z0FI112],<FA"1DQW-VAK6&LV9')857)E4DEG9V\F
M(WA!.U%3;T%7<$E)<%0S3UDX3V(P8W-)1T]U-6U'=5A"=50Y67!X2D)$<4]M
M5T9/4&LX,#$U56UH;6AM<5)U=T@K5DA2,"\T6E)L55-B5'(F(WA!.W-);&AL
M-W(K5S<S>C@S3DE7+SA!3VYL0V-L;$YH8F%R36Y(;U=C,F-01G9B:DMX*VI-
M<4%E53!W=6%R6F%42'=Q96@K,$UG96)S*VHF(WA!.T%04$5+<F5T1W5W6&)+
M<'54:4=Z>4QZ36%81$1W,C,R.$)L64<W2$YY4U(U94YM=T9252]%9'%:64A!
M;54U.&M7-S-E;S<P*T)2>"LF(WA!.UHR>&U7,U-I>F(Q:7HP;TYB:&%!03E2
M=&M(649'5R]L,E<V;%=#2D$P:D%L5DY!4&A"63=N,D=306%C:S99;C5R,#8T
M1VEA;&)X:&HF(WA!.T90035A044X6&1!5U%S3VA+<T%2-S5B14],;D9X3#9M
M>51P,VYF;E1Z4#5P<U!-5%)X*U=4<F5I,DES-VDP;6IS-7 U:W9*2G%31TXF
M(WA!.V=72'=7<7EN;6EF0WA5369I;UI!3F-I8C5-9C%D.65S2F)G,EAK+U1,
M;$QE-6Y3>FYJ,$LT2DM&<DMS9U)83&9%=#%.5F@Y=C!J5'4F(WA!.TU+1&9C
M;4=G870U-G0Y67193%AY-UDV6G!L-611=WI88T]M6%5293!55$I'-W)Z:F%&
M;VMT,&HT>7)18VQ0,E-"9TY*1G9636DR2F(F(WA!.S5S=4QE4%-,94-8*SAU
M-793='@O>%ES8VMV.$%X0TIS6$PP4G)+2&MU=39E,$YW2D13;E0U2$U42D=N
M<SE0;#1G>&IZ1U5D66TU8G$F(WA!.U%'4'-2;$IB=6IZ-WI.2U!70SEM6F5H
M.6EF-%I::F1(<G!5:DDW-DAH=VA*04)P>#-O5#AS>5A606TP+SAU<$HV37)S
M2V-Z44U+9'8F(WA!.SEV2TIU,3!(3S)54GI3<$5Q1#1#>$)!-F)F4F=D,7A!
M<WDX9V%Y=6EY5%AL-'A44S4R14TX>'%W5U1I6%0T5D)9;EDY=2M:34]63VXF
M(WA!.S=6=VI-04DO5TYX-VMV.$%Z3S@S,E5U;5!:5T1W+V\V56MW47AO.&)O
M5F9L>F]+3"LY66LY.7%'9V)F235P8E4P841315,T<%AX9FHF(WA!.S=M56%Z
M>6PO3&)Y<7EH5UEP64U&-T@O4D=/,69V=V=B0GAD2$EF;5HO=T-D.3='24=2
M3#%553!!52]#9D@R>$A.,WA(;U5,<35L:6DF(WA!.UI%-4I(>EAK1C,Y=6U1
M3&)'04IT-5 U,4MF<%978U9,0DAB9F9E=F-6>5!6:G%"-E-%2#5O1VU'-'4S
M,"]W0DXW67AX1T=3:F\W1EDF(WA!.S!6,S1.5'$S,F=/4V<W2V5Y-4%'>GE-
M:6)1=6=Y,U(P82]M4U@P-UDS1G-*5E9!07HX2G94*TU$86<U+T-$=C%05$=5
M<41L-E1&>#4F(WA!.T$Y13AV3EI+9U9P1E)G.%1C,T915EEN=T(O;$\O=T1(
M27A$=6,Y,&Y.=W-%:U4T:DY3:$I*.6A816A'37909&1J:FAM16Y73W135#0F
M(WA!.T1C:DE%8G0K5$HK-VQF.$%.4#-0;WHX=TQH0C5K,$<Q2V=T3&$S.&]B
M=4)(3%IQ4CE0<6I-;41Y96M0<5)S1G-G=%%A9G,W57E*1&TF(WA!.T=7-WEN
M>F]O*W4S8E4R5W8T6FIZ-75X>"]3.&(X>7=S=VMD9"M*,U!Y>4E986=E;&ES
M.'IS;U5N875W+W1Y,$(Q535->B],0E$R;WHF(WA!.TQ88W%V6#9C:&MC<E)C
M>3EQ,&TR-4M6<%5D+VYK434X9WDO>79P541A>F)S>3%5<DEP0D<R.&)!:F9,
M66AW3EA+;T9G+VUE>FAS3%,F(WA!.SAK=49!*W)P23!V<T5"2B]6;'-2=3%Z
M;&-B.&YT*T(Q5'-69&ER<U9D:7)Z-S@X=&5':&%0-50Q2C5%:&AJ.'<R.%9Z
M3DE#>7!"4&$F(WA!.UAC37IK1&8T635'27A$6FAN=WI".#!L,7DW='!O;5=O
M2DA2<W@X;3<Q*VXR,UE&-6AN0EIK1S1O37A#2%E#64EE865A2D]%9T)0-UDF
M(WA!.TDO-$4U9&E$;T\P<&-L,FLS1%1S<U-+5V-G;6=Q84)14U0Y04)/6'5Q
M0G,P>F948C-J1W-%42M*9'E$,T%(.%142V%T,U=#6$-M0C$F(WA!.T)8<4$T
M1$EF:%4Y:%AF9C9C43='3U%),SE*>&5K5W%'<'-6-DA,05=%:G5X<GID<49V
M1EE.8TLY5E)3>G)503!(>G!U93)2271P;'$F(WA!.T)J:5I&-EHU>#%T=$@O
M2B\X<7(V;T-'-#!E1U9M4$91:RML5%)->% K4T@U8BM'6E%E5S!U5&=Y06]F
M,6=K<7EO9'A1=5(T6E8Q97<F(WA!.VI-154S<60W16Q99W1'56IC5C1K,38T
M2G1M4'9E5F5B:78V4E5L=71#4'!R+UA+,%HU07A34V8P,W5F45%&=EA#;V$Y
M*TLY0E9G1S,F(WA!.UDP0CDY=#9R:U$U4$HV:4IJ2E9U3DXP5S P:7IU8F57
M8515<'5B6$5:;W-39TU1;D=Q4G-4=V]4='8W6D=98S=S*U93=$=W831Z>&4F
M(WA!.VA%,T9:,4$V:V)G9V=B931'4FE89'EK3V).=$4Q,D]A07!)=U<U44)8
M+VQB;#AS;4,T;D942"]03GIA,E=M.&I1>51Y2D1#<#=T26$F(WA!.TAT,E1K
M,S!:3&AC6%=A:T1'9E!B-79:9GIN,6=A6BM99C5D.#5':F=V5S%/>FQ#9W1Z
M37=T4D5H03='64IK-$AD,$]'5E-$3B]5:48F(WA!.VEO<E0T8T)C,E!.-50U
M,DEA95E)9#-.1#-Y;6)S.%(R95AA,6))3&5313!Q47<K93%C<4-C=DHU<$U7
M16A5:6A5:T5F3&),=S9/6C,F(WA!.UIZ*U=C<UHQ9V\S5FQ&2RM.5&M-<FYA
M13=L-S%P2$5325)3:"LP3S)1:4A0;61M6#)5>5=S:TYY1'1'-$Q5.$LP669D
M;5)!3W1Z96\F(WA!.T5-4B]0<7EB5&9*;7,V,4%Q>C)S.%!P='E92U$Q-#1H
M2DAD<65R>49-<T5T;D-'6# Q,65R-4)X,UEQ-T9867$W1EAJ4"]/6% O:W(F
M(WA!.SE++S=B34@O049#,U="6&QF:R]Z=E!R3VQ+;#%+5W9R4E9J;EIM67,Y
M0E):5UII>$Q-0CA2<C%R;&515S<O439U-%5E65AA:G%033@F(WA!.W%K:DUC
M>&1G37I"4$Y%:E-2;#8Q25E';RLW2C1U8G$K,$1C8E%E;3-2:5=.:69S:T5J
M=FPU1WIR25,S6FA"<41"235!,C5'-$(R,T<F(WA!.U5L,G5027(O04M2-#$V
M1W958C V-49Y4FQA:S%2=T0X6$I4=%AF=&EZ3V)::5AN1%AP2F\P,#E4<TM.
M36998G%V6#94=#1:9$-05C$F(WA!.T=U,48K:V9&-U8K97@O-GAN+TPO04]E
M:V8Y,'%B3$A7<TPX;2MD<&15,$E.9%,X<C8Q4'!Z,2]A2DAW<U%#9G1!9&9'
M=5%)96HP97$F(WA!.S0T-SAW;G1X<3EY,71+3UI864PT;B]-6D5U84UO=&E(
M;4,T.6%9<T]O86]"-UI%:$5S;7E53'(Y=EHO-DIC44=13S9U2D9)0E5B:#$F
M(WA!.W%14U%25"]/=&)-8G!.8695-UAT8G-B;3174%1G5G0T>#9963$K2VA0
M>$%%06EV=F=K5U=N;E%1;')F4GAS0DIS97@Y+TAV:U$U+S4F(WA!.VY:3G)F
M5UDT-2M34V9A<#DT-F1-<T)92$MK6&UR>E$K<V$Q6E<X6B\P5S)L53%$16@U
M0W=$1VY4-&5G*VYX>51P.59M-'I1-4(W<B\F(WA!.T%--6QY4$A*-4UK4FER
M;V126E=";U%2.59)24EX8U9&*U-V>E!4>D(U4G1P;FU$87!A>$-(555R.%%L
M1E9%:&]Q0VMO6&U+0V<S6',F(WA!.V-M9'<U,D-D<&)R*W)&:T16<5-A;DM:
M0C)%2C!W8E8W<U!Y2C=G9VYV5$MM8W!72&TR;TYX=35+9'E4.2M8>#5/;7IF
M554Q.&\V;3DF(WA!.W1R340Q<'E013<O5&=M3FTS4S5+:SDT,'98=UE58TY2
M9TM%2$EX1'-*>EI8<#-M4#%G26U0555(>GI*:31'579#9GIY+TU/-C$S5DDF
M(WA!.R],.79C=2ML-E))-&1#6$-V9&998S!*;W=I031O94\Q6'!S,DUY0G-(
M1&MB3#=.>71I-T9867$W1EA9<3A:+S5Y-2\X;&9P9B]B6F@F(WA!.R]W0V]7
M-G=+*U1T3C%+-S K-E<T=&Y+<TYN5W T=7114W)!159"<&EY:$UX3FAM.7(U
M:'1T5'1Y>69U-6Q&6DE386M#=$%A,$A,-6HF(WA!.TMP4F1R:#%81C<P:S%L
M>$I$26]0=FM98S)'<&QC4VQ6=$Y29F]Y-'5V0E1I=S%):5 P,D]W<%%(9DMZ
M1GEO6D<U3#DQ63<W9&1I8VHF(WA!.W=T+VI)5S<X=U!'<DQ(47EN;V5O6#-Y
M55E.3U165G-%9V0S9#)D>5=D:5-Z13%*2C-*2D]7=4$K;%!Z,R]W1%=:+WDO
M*V5K9CDP<6(F(WA!.T98>E9P=7!85VXS4S-.<S-&,3):5#EL;%!65TAC2$9S
M>#5$03)'9F%4-6UT.5%1.$0V8S%$-FM*3S0X0U U<VI4=#A7<45X-6]F54PF
M(WA!.VUO;S4V:G)K4S-E27AY.5IM54AQ55 T67AD9G%.+V=H,74K3S1/,V-:
M2VY':FMP>EAT97!P.'-(0WDX5E%M,4M8:G=J66HO2S<O4F@F(WA!.T%94WIK
M:6Q$5"\X064K,B\T>7 O>$E:2G!F5&8O3V%(+U1(9CEV3"]!3$9C55!N8E$Y
M8W8Y1W9L=DQ.>7)G1EI%<65,;V5Q<T(Q2#@F(WA!.V0X24Q+37%.=E%R9GIB
M839T8D%X355N54)P24<K,'145'(K,%!C9FAK4TA0>%IG54AQ1G=753!R=C-R
M;&)K8V)#9%-"5S999#AS:38F(WA!.WI..5-Y>6M+6$UB03 T;71C2EDT>G4Y
M23!F5VDQ<4-Z8V5)<5=R44-G,WE!1&XX97E695DO=T%X<FQB96)4=$QK<4I6
M2U1864IQ0E<F(WA!.VA74#90,G9U.&-T0G!W.'57.6=W07-4:U=H*VM/1EA9
M<3=&6%EQ-T98:E O041L>B]W0U-V,'8O04QB35 O54QD649F26U+<C1F5CDF
M(WA!.U9F4W(V;%)W-#%R6'13;3EC56A-5BMV96PK*W!4=GER>G!K1%9U4T]/
M=#!&1GDK:DIU36E)+U9R="M/4DQ:1S%/9C8S>#,K>#,T5B\F(WA!.TAV:$9)
M;'A)5$,Q=7A6.4LO;G8O04]S>B]L+S@Y22\W<%4R2W9M1$9+-E Q3V$K;EAN
M56-E3F$Q-U5P:6]4,D0Y3V96>#9T2V-T=E<F(WA!.W)Z.2\X>FM45&Y9=D9R
M.6)R:7909C=8-UAH:U=5*V%4>B\S:#E0<#-Y66-'6%!:4F)L,W=S5W-65CE0
M+T%.-S=B+VI+;B]%:&ER-F(F(WA!.R]W0V,P4#A!<&IV*S-L+S)+-&]F33)+
M<C1F5CE64%(U97)596YX<GDU5C)P5'9I:TUH='8P+SA!5F@Y631C2VEN<E8Y
M4VYF-U O1S(F(WA!.T%U5FHX5"LQ3&19+W8Q+VTT+T9I1W9.>E%K2%!M3T9+
M.7$O,EE7<4XR<EA(-E4Y23@K9F]F=&-A*VXQ,G)48C<X5U5U3'%G=#A7=#(F
M(WA!.TMV.$$O.6L]/"]X;7!'26UG.FEM86=E/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+WAM
M<#I4:'5M8FYA:6QS/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @
M/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL
M;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @
M(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @("!X;6QN<SIS
M=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U
M<F-E179E;G0C(CX*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI
M9#HP0D%!-4$R-S9%-$1%03$Q.#1&,$%!-#8S,T-%14-&,#PO>&UP34TZ26YS
M=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#HP
M0D%!-4$R-S9%-$1%03$Q.#1&,$%!-#8S,T-%14-&,#PO>&UP34TZ1&]C=6UE
M;G1)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED
M.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X/"]X;7!-33I/<FEG
M:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I296YD:71I;VY#;&%S
M<SYD969A=6QT/"]X;7!-33I296YD:71I;VY#;&%S<SX*(" @(" @(" @/'AM
M<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#HP04%!-4$R-S9%
M-$1%03$Q.#1&,$%!-#8S,T-%14-&,#PO<W12968Z:6YS=&%N8V5)1#X*(" @
M(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#HP04%!-4$R-S9%
M-$1%03$Q.#1&,$%!-#8S,T-%14-&,#PO<W12968Z9&]C=6UE;G1)1#X*(" @
M(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C5$,C X
M.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X/"]S=%)E9CIO<FEG:6YA;$1O
M8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIR96YD:71I;VY#;&%S<SYD
M969A=6QT/"]S=%)E9CIR96YD:71I;VY#;&%S<SX*(" @(" @(" @/"]X;7!-
M33I$97)I=F5D1G)O;3X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @
M(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C$U0T$U,C-%-C4T1$5!,3$X
M-$8P04$T-C,S0T5%0T8P/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#(P+3 R+3$R5#$S.C(P.C V*S U.C,P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V
M=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA
M;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\
M+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A
M;F-E240^>&UP+FEI9#HP0D%!-4$R-S9%-$1%03$Q.#1&,$%!-#8S,T-%14-&
M,#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T
M.G=H96X^,C R,"TP,BTQ,E0Q,SHS.#HR,2LP-3HS,#PO<W1%=G0Z=VAE;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@
M26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N
M=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z
M8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" \
M+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z:6QL=7-T<F%T;W(](FAT=' Z
M+R]N<RYA9&]B92YC;VTO:6QL=7-T<F%T;W(O,2XP+R(^"B @(" @(" @(#QI
M;&QU<W1R871O<CI3=&%R='5P4')O9FEL93Y0<FEN=#PO:6QL=7-T<F%T;W(Z
M4W1A<G1U<%!R;V9I;&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @
M(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X
M;6QN<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]T+W!G
M+R(*(" @(" @(" @(" @>&UL;G,Z<W1$:6T](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS(R(*(" @(" @(" @(" @>&UL
M;G,Z<W1&;G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]&
M;VYT(R(*(" @(" @(" @(" @>&UL;G,Z>&UP1STB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+V<O(CX*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE
M3W9E<G!R:6YT/D9A;'-E/"]X;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#X*
M(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/D9A;'-E
M/"]X;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3X*(" @(" @(" @/'AM
M<%109SI.4&%G97,^,3PO>&UP5%!G.DY086=E<SX*(" @(" @(" @/'AM<%10
M9SI-87A086=E4VEZ92!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(#QS=$1I;3IW/C4Y-2XR.# R-S,\+W-T1&EM.G<^"B @(" @(" @
M(" @(#QS=$1I;3IH/C@T,2XX.#DV-#@\+W-T1&EM.F@^"B @(" @(" @(" @
M(#QS=$1I;3IU;FET/E!O:6YT<SPO<W1$:6TZ=6YI=#X*(" @(" @(" @/"]X
M;7!44&<Z36%X4&%G95-I>F4^"B @(" @(" @(#QX;7!44&<Z1F]N=',^"B @
M(" @(" @(" @(#QR9&8Z0F%G/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T
M1FYT.F9O;G1.86UE/E1I;65S3F5W4F]M86Y04RU";VQD/"]S=$9N=#IF;VYT
M3F%M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86UI;'D^5&EM
M97,@3F5W(%)O;6%N(%!3/"]S=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @(" @
M(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^0F]L9#PO<W1&;G0Z9F]N=$9A8V4^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT5'EP93Y4>7!E(#$\+W-T
M1FYT.F9O;G14>7!E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z=F5R<VEO
M;E-T<FEN9SXP,#$N,# Q/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP
M;W-I=&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1FEL94YA;64^
M351"7U]?7RY01D([($U40E]?7U\N4$9-/"]S=$9N=#IF;VYT1FEL94YA;64^
M"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @/'-T1FYT.F9O;G1.86UE/E1I;65S3F5W4F]M86Y04SPO<W1&;G0Z9F]N
M=$YA;64^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/E1I
M;65S($YE=R!2;VUA;B!04SPO<W1&;G0Z9F]N=$9A;6EL>3X*(" @(" @(" @
M(" @(" @(" @/'-T1FYT.F9O;G1&86-E/E)O;6%N/"]S=$9N=#IF;VYT1F%C
M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/E1Y<&4@,3PO
M<W1&;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV97)S
M:6]N4W1R:6YG/C P,2XP,#$\+W-T1FYT.G9E<G-I;VY3=')I;F<^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O
M;7!O<VET93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&:6QE3F%M
M93Y-5%)?7U]?+E!&0CL@35127U]?7RY01DT\+W-T1FYT.F9O;G1&:6QE3F%M
M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F
M.D)A9SX*(" @(" @(" @/"]X;7!44&<Z1F]N=',^"B @(" @(" @(#QX;7!4
M4&<Z4&QA=&5.86UE<SX*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D^0WEA;CPO<F1F.FQI/@H@(" @(" @(" @(" @(" \
M<F1F.FQI/DUA9V5N=&$\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL
M:3Y996QL;W<\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y";&%C
M:SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO
M>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(#QX;7!44&<Z4W=A=&-H1W)O
M=7!S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(#QX;7!'.F=R;W5P3F%M93Y$969A=6QT(%-W871C:"!'<F]U<#PO>&UP
M1SIG<F]U<$YA;64^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P5'EP
M93XP/"]X;7!'.F=R;W5P5'EP93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z
M0V]L;W)A;G1S/@H@(" @(" @(" @(" @(" @(" @(" \<F1F.E-E<3X*(" @
M(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W
M871C:$YA;64^5VAI=&4\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO
M>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC
M>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P
M,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y";&%C:SPO>&UP
M1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z
M8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT
M83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXQ,# N,# P
M,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @
M(" @(" @(" @(" \+WAM<$<Z0V]L;W)A;G1S/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P3F%M
M93Y'<F%Y<SPO>&UP1SIG<F]U<$YA;64^"B @(" @(" @(" @(" @(" @(#QX
M;7!'.F=R;W5P5'EP93XQ/"]X;7!'.F=R;W5P5'EP93X*(" @(" @(" @(" @
M(" @(" @/'AM<$<Z0V]L;W)A;G1S/@H@(" @(" @(" @(" @(" @(" @(" \
M<F1F.E-E<3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G-W871C:$YA;64^0STP($T],"!9/3 @2STQ,# \+WAM<$<Z
M<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y
M86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^
M,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,3 P+C P,# P
M,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @
M(" @(" @(" @/"]X;7!'.D-O;&]R86YT<SX*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!4
M4&<Z4W=A=&-H1W)O=7!S/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @
M(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @
M>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*(" @
M(" @(" @/'!D9CI0<F]D=6-E<CY!9&]B92!01$8@;&EB<F%R>2 Q,"XP,3PO
M<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R
M9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @( H\
M/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!!P&O P$1  (1 0,1 ?_$ !\
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M5)_^P_\ P7C8J^\&_P#?\[$?\$&2_P">F6Z<]DO\$JO]83_RTX\:_P!F9_\
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M+W)/]D?^^;_3T8,+W)/]D?\ OF_T]&#"]R3_ &1_[YO]/1@PO<D_V1_[YO\
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MHSG_ ,=T8,=VAW$[A23-'_)]K53)&47CJC-[LS.@5!_3WGD?PZR(YF!TN<9
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M8M"+:UFEB*S1@Q,'Z0>J4,I\5[BPWWZ^5[>9ZXLF6]F,RKU(4M!:IUB=:@#
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M^OSL>JI4/E:HU*VDF5;"^YO,;QO&XG'0,JH5!M8@0"4Z=@9$D@;;;_HX[-3
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M!]^T\WGSN8QQ_-,JJ<K?4P^A005*[MPB XB3I7, ^),&!,'W$PE*A5V_5R(
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M7M$ &/@,42NRQFM:JJ"H;0XP2M2$."4I4L$JV(/M$'H=YXQJ3?:W?9H/Z/\
M6E7N=VQQUNWV U]::/'Q/[UJ;MIJFPL]J;1]VRY9I,):9)[6E;]K\Y+62SB)
MGFL8U;ER93I4T%V\0DG_ #B!),>L_ACR_P!K^S3N15BU-MDTKI[Q*TCP-E2U
MH#>J\0$ B8WO)P'WV6,8C^T_^SG ._\ ^O9Z31_<'?O0.Q_N@@[?A].M,4[&
MTY]]-_[XOV??^\KU%_\ +O9[HP8TL=!Z*U%W"U5I_1VD\1>S^I=3YO%Z?P&$
MQM=K=[*Y?+VTHX^A6KHK/+/:M2Q0Q(/!=QO^TLPTI]U#:4DZE $C@DP)Z \G
M81?!N=(L20!M>=HXXO/W8W@_0O\ 9P:2]%':FJV2IXW.]\=:XR"?N3K"%(K
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M[#)W1[:0:GP%!9]<:.Q]G*(T$:QV,E@(V>QE,&76)I)Y($5LKC_=<GWXK=6
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M[8M?8ME;KBUZ97W2A,;@J1/A^Z?S.#5TGC;EZ1<75FM4JBE1:L5Y$19@6,7
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M/?;'059(C.*5R4-LWI0P[J2@K95$ *)B;&\!4#;>8%]YQ)=B,Z><=33AP-L
M!024I40""0 L@J,)@QJ,RD 189;MWD5QY6M,[OC6EAE6-)7F,08@?$J78<2L
MHK0R&)9%"23/Q5P28)YC1!2#S<@\P;7,R)(%O2V.T45:FJMJF;R("B+WW])@
M6DF!<XL-T/,;^&BAR(DMTYWGK[1I&\D;B2*S%NTA0'V@65&16D:7W57Y44C9
M)A,<\&2-A%HYWYCUQ/( [O0+I))4)\@3>T;J,#GF1A\1T8X:@21(&%>S^3YU
M6-_=LQS*Z5V:+V9"X6'B4$@";(-BI4=+) 3I,7(!WZC?XWB,-W6/""!:!MT%
MHF\E((G>VY$'$BZ#P\V00W+D40C6K)6A@7A).BR/QCE, 8$H>2-+Q;\R8RY'
M)ATH%*U3]HD&8_"POO:UM^C)20TW8$*4"5;B;D"Q, F$S$><8(W1F,BBL?#E
MEFF^,BE%?DJLT"*LHF55=D64.2QYR+(8]A"C/L0_IU*=TI7<2=K<QON.IGB\
M2<5VL9\*U  :@)N1M8@@>6W&']ZF^S7;COQV=U/VV[E8F>_H75^!OZ9U6AB3
M\HP0W8XGQV9PYD7^ELMIR]!0S&&D57>MD:%9F"P@A[%WH90D$@-FQL)F #!W
MG:VUKXI&:9"WGE+6Y4ZE)+C"G6%JD%+]Q(4+F D$))TB28)F=%WTC]B-3^FG
M[:OT3=EM7HKYG0_VA7I6Q:9*))HZ>?PY[\=O+6 U'CTG59!C\]A;%+*U0PYH
MEHPR;2Q.JJV*4J&RA(YMZR9G'E3,:"HRNMJ<OJD%+U*ZIM1-M8DE*HV@IB(@
MQO?&QG]] C23N)Z .40F;^0GU%A5WV(WS7:'YA\RC=3L=M_('CH"DI]H R"!
MOOQ$89;&3.D"XX];<_KK(M_=\?L^JEG!9SUQ=RM-"0/D,EHWL)5R5..:L9J/
MN4-:=P*T=B-UEFIV6?2F"N(!\/:&IIH'2S6I2PSU(VFBHU..P77PJ)W#8 B.
M02=02H $?^ZTME=&FI><682$Z-.\"5$1OY28M%N3.R+JK%-%(T,T3;KN7< C
MDW(!CNV_/D0"?KO]2=]^HA\*4R#)@K/69B]^)B3>T^4XZ;EK8#:6&U$I2 K2
M(WD"23<S,;VF2+SBLGU_Z]B[<=@^X.85Q6ELXJ?$XT,.+26;X1&5& #;!78
M^=B1MXWVABU#@*@"F\ Q<V$\[1/KBPA+C* N8L 2(\C8R>0+<3C6)[3UEO/%
M/(><URJCQNS<@)&EJH\C'P246Q(0/K^;)\[CJ!S6$.D\ $#R) (B.9G>-QCI
M/9;]M2(D@Z^[D&PDF;W!B(%N@F).+=^T_;!UP]-J,?OS3X^.S)8F7Y4<Q;<]
MQN=C\_$;;_10#L-X1A[5WA)U7@'I<1Q)FPG\!;H!80TE&E "0 56G<:>22!J
MN1[KV&';F.UM>W%+CK-8B:2N\DON2MSE$C%3ONX+!2%<B-"X'Z*GP.E"LQJ0
M2EQ,%)!O.]IL#!,3:XOAZU2$MEU#85X?9,G6#8@BUH)N 8 ).V*0O4KV)U1V
M+[@6-88JK.=)YFZ&EGAC,<6/OV6W9)O;*\(K4ADFA<*/:<M7/T4M/TE8V\QW
M1/[8#VCO X&TP")$>?ECA7:WLW7=F\W7GU"@_P %5X*'VT"6Z=U_PK*HE4*7
M*TJ-@LA)]H8?';O4];-XZ#BJ1-L4E4_.IE 4;2*HWW(8-^CLWU4$#I0*/G(D
M0 -Q'/ODQ'NBY2NEU"5@F0 3>U]QTV)Z^_!#Z&E_)60_)EN8A;*^_2F4<F5M
M_<,#<=V.RG97.X*>#^CL-^\6"#JW)XOQY"+F/4R9,XGJ9UN2--X!@R=C/GUW
MV(XG!18N(9.!6$(F(C;W)MFWV:$JCL@ *^VL@))&Z^=]MCL]^L3S^'IQY;'Y
MR,2;3'>"7?'&Y/6-X$&<=:[N88UGBX2U(15 0@),(3L)#_;$.IV\C8D;].A<
M \P,0^8L:'0E(A.D6$1OQ-QQY>['VM.O)6FK>VLAEKK.4**"I\>5;8@[CD=O
MTOU_0#I9L'J?:\M_U'3;S.*Y5M%:R5"2DD)4>() B"!TXCKO. W]9/9"#N9V
MYGM4**KK'1E>UF,#,BCW;=01)9RN";B?G%VK&T])/!_*E:%%&]APT@94@;D@
M0/0';TM,=;W._/NUF4?7&%5*6@760I14)!,;S)B3<S YY.*!KD1BE<; ;,5.
MV^VX\^ ?/T_6!TT5$F-OW8Y)!2=)F1O/GM^O+'MZ=:XSA=&#"Z,&%T8,+HP8
M71@PNC!A=&#&=TU_5FI^Y8_S6;HP8TV/MI>U%'4_VUFGN[.>BG?&=I?17VFG
MTZD<#2I8UWGNY'>ZKBGYD"*+\C8F',YJ.7G[L&2K8F95*JQ55*@TV7R8TJT@
M^9'!MUOSM8SCHOT9Y*K-.T;%0ME+M+0?MGPM.I! !(2M)L1:T[$_')=EY:&7
M@CU)GKT-6A1DECBQL\BRM,($V$EAV=(8497,L"EC:=RIFC.P!?45.'I?<5O<
M2=QP2=K\[V'.._Y]5-TKQ12I'=/$.-A $-((T%M %DI"DDA(,"28DV"[UO\
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M!)GWQ@Y,1A(*U6=XE41PQ"599)"9) A!<_I*W%5+.S-]%5F8; CIL+&0((Y
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M)O80\MN%2TEJHH!(58E'C<=(J"3J(/((D]9L9L+;#>V.%]H*$4&;O-)24M+
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M&&N4YX,E5R6!OX_&:CTW)#;->M(+=; :LQ>(R&\/M09G#92*)5C:**.!S"F
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M<<\"K>E^FX^1P-)A8DDS:YB)YB\G! ^E7#N4QCL&^<"9CN=E$@CE &PW!^4
M<F!\[[$C;JC9HX0%PF3,B\;6,B-XV^&/2'T<TW<Y>A0(65$"( @$"2#)L-A/
M)O$7VE_1QJ'$35L+IB^Q2$XP1$1KO(TZNT:<RSQM[3/6(VVEY/R8,%CEV892
MX2M1TD3(WMXE;WM8$[02-N)O/;1FL1EOUBG0%EI+9U*DD))2E0D:B;+DD>R$
MD\F)?UOFX;NM;.-L+!7QV&$TM^W(LD9CK202,D:-(3'-;9$D\(KJ#(DG%GB7
ME9'/:IRA19""=8X(4DP(G>V\7,'??;(,O-/D3=2A3CM55*;^KLI)4E;H4 I2
M@@&6P5B05 ^&# 4<#YWF[DXN#&32UH9:(HU4EB6(5@L"1H&HOP22202331\I
M!8*RQUY02H9U0Y6TTX@D**5@2# B!)%I%S?Y>8Q;>S^6U='J%0X%J=<'>.E*
MRYJ*P%I&Z2B-E).F0#8HC%5/K<[A*.R6N[+1"NT^G<FO!_\ 57ER4#55BC\[
M,3).0G/^U0_0>!'-C54)3<!*D@6F^I-R.I OQ;GF/[:Y@W2=DL[2I M1U\2H
MR2*=TIXWU ;1OS$8U?6F5I*]EP4=BJ2(0>!\*(W'CBP)78D?CO\ JZM9;\%B
M>>!,7B_D>L?/'SI[W74AQ0 ]F0)B0 .FYB3OBXKTV1S0:$TW>8MO[LKUEY <
MEDMV)I/IL6*I[@^FXY?3<[=5T0' W&QF9O$ ><3(Y\HQZ R%S32),D@FVPD$
M'H.D] 8\Q!+Y6U!-''';5)5CC:W9XD<HV2667YV4[L[<U$O(#YN(()\!TS[4
M>=OQM'W";^F']0Z&4ZI*@;P2;3)(Y(@VZ&+^<!O\1F\M.:48]N:RU9%79.$9
ME#, !L"3Y/R@!3NIV/@RK(T203?BW3G?F>>.M\5RKJ$NR%0B9$CSOTB8-HVD
MX,/M_H.69:%5(VDE"1AE*DGZKL21N20?KOX'[6XZ=(*EF(@SX>9\_=S&*=F5
M2E!6G6%1(!)WBW3[O+UQ7S]KWF8]/:5[/=NBXCM93.YS6-F!6V85<)CH,#0G
MD0!7]N2QF,G%$3N&>";8_)MU(!LLMI43_? 2!IB0"0;2)O\ =CDO:JJ#BFDI
M5J@DE,V!^9YD'W8].OICBI871@PNC!A=&#"Z,&%T8,+HP871@QG=-?U9J?N6
M/\UFZ,&-%?[SEJ)!]HMIG3L,2?$P^ESM==F<-QF:&[KON^D/'R#L/@[2[^5!
M(!!+;=0^:ZTI"T@; ;3L2;[>7/3ICLWT:U+2Z"LHE* 6S4KJ4B8)+C3:03U'
M[(IVCSFV-?W"24Z*RSW9(UD5G$9W?W.#E56-&4JR\>/X,-]MGW4;=103#84J
M=4R-H@[3\^+Q$[XZ>]5.+%.T%(+9:"ED Z@YWBTE(4"0 $A,C>?ACJYZU^5_
M8HQ"4*TB,") TI Y!$+-Y\>6*@D_7;?P T6LJ7%H@Q;UVBVP'EAZ4L]R HD(
M@%2I2%!5[:H,#:W6YOC)38YL+#2,MR43/CUN1UV"^YL\J&G-."6>,RQ VJZE
M8W:)TF4,K*2X6HMH@1XA,1/!'EN"/.1QB-RTE56M06"A#B DJ4"8@'F9OTN(
M%CR3';#OK#AUKU[;+)P$=>>8R.I Y\F#<2 =P? ;8GS\Q /42X@NJ4 #(N8G
MD&/0VM^CCJ]+5,BFTEQ-@C8D=03/E(CH =[8,+#>J/!PA";*R")E*0AA.-E0
M^R"1(A)'-G92Q+ [N2  $%40!\4F1U@R#>)VBPYGRP_8SON@6DN)#8TFTR/:
M.^L1N9'/3D17W-]2^5U%CYL?IJ UGE-B&6V\D2MR)95]E?.\8##\YR^4';??
MR,"E0% A!)D"Y)B=S<>0F/=YK5G:Y-'3-Z7Y6"O2#!E13S?K:(B_2Q"35<DM
MB;;(7I<E?]Y);]J>5I6]^7B\D+RM(6>.(R*G%B4 C( 1=]Y=A*T! "4P;&4R
M8^_CRWOCCF?]HG\S?>6NI=45$^#6= ZA*9,;Q(FW(V.<[2=HL;W(U1C\QEJJ
M2:4P62BR3Q3 1P9>[5E815IE(D,E;D6]^$!>:$0#CRX'2NJ'&90T=)5X5D;Z
M=R09 Y%[]=KX:9#D"<S<0I]"G$-*#Z0HV*TJ@!4S*1JDC8V&+9GU!+4PZ!)O
MR?'"CTHN,PBXR,GM-9AA4K^>2)PJE5]J,'\T H5NH+NTK! !N=0/)(CW;D_C
MY][R'+FJ9M!48"40$R"!)3!(M-A:_P"6'-VZT9F.YN2H8?$1VW0SH;-N,O+&
MRS2>9'+,.9BY%>1WY2<5.V^_3NFHGW5:$))3"B;$W&XD"Q\K1SSB<J:II@=X
MM:4A, $$#DQ.\DCXDQUQ:/VW]/U;356IC,XPERZ3\X:6XEIUD4)[2R.I,4DL
MQ)L$.H5G7<(Q"DV6@RQ+"9TK*C)Z"\W TC:+3)&*]6YTAP^TD(2-,C>#,&29
MN8!(]1TQ/$^(CP\]F>U+6>A5C%*^]H IPB6.$6JPVW!1_<8Q2 @%BS@,"1,A
MA<! $ VN)YGKSL.9OBNO5+;JPI,DS:X@V-B!,==_CAG9*W6.*FEIQT+L!3DL
M\8=+%>(@1@S&0E/B2/FXAN))4  ;;-W*-2$]XH^S!(%K$BYDF;7]]NF&+SQ6
MZB2;6"9&F""%2)), F#:"/+%6W\MVM;^VO\ LKNQF)R3VTT[W/S/<74\+<E*
MY'46F=2X'3T%I 0BV:-/"YZU$0) ]3-P2J46P"TC3)'=BT>$JWYG\H(]>DX\
MV_3#F:*C-Z?+&% L4: X4CV@XJ)U$"")"K6ZQL2S/O8V??$?:*^F2E[SQPY7
MT@XZ%D0JHDL0=Y^ZD]969@0=RLJ*!MLS@D\204:U!73KTB2!,6V]_3?%#[*5
MWU/-F0I6E#A@FYO((D"3<A(G83)L,:UV7S[6(%C1Y5'MA6C/#8$%2DJ\!Y="
MNXV XD[[#J#*_ $),E,@B#U\^/?ZS88Z]4.ZG X9"'((5:9 B0D3<#<1(]UR
M-[6"-JV/E(5TF7C()6"D--Q4N74!F)(DV55_3X\A[8/3(:RHZQ XF#)!.VY%
MN.)G><=/R%RG9HFG$N#O%I3"84"=CT /-K=;[8)G/9"6U3I&JU>"_5FACK-4
MD]L+!"RO'(T@# 'PW(;CY54';D=]RHIDIDF;\S(O]PX-SY8Z=D-4R975%*0I
MHH (FZE(.H0E46'PXW&&#JRMD7J4LA%D8);419K$,DC-&&(#22+*TI9R02K,
M8VW;8 <?(=H>,!)4">1XA;<21U@^\>_%C;<802EO3W*KZ^)/LD")N0 1I^ D
MABV-9W+%0452&**FPF>99B[&4%EC*.@&RQ%FD  !#*S$\""=R\-O4'?<<R2-
MY N-C PX6IM*;:$DZBDZI!D<6&W$P 9WF\8:MUS<_)DN*P;2!+$BU+=N.9FE
ML/()^$"O),>>T<4LG&%656(,FS,FX5^$P8\,VGH0;P;'DC?W1CDO;3MDJE;<
MH*=:5J4EQE2T^TV""DWMX@/$F 2#%\111Q-+#9G$Y5:NB?BB*FH(:^K<SG<2
M]O.X]K-4)*8;M3%K'\1!6L1))8>=$2Q$E1Q8=1+T"U%N9]D3$B +S;J.=X^9
M\D9R5N556L!!<?>"TZE*"EDD)!WT"1$A93!FPN00_9J:>1K%K.S+:RN9]ZS>
ML5(HHJ\TDM@--,D4<<"!&D(CK\4'**%#(!-[@6 S*I[Q9*+R>A&QW\0V/OO'
M7'KWZ*<D;H^SZ2MP"JT@J2$F_0RD:>$@3>-X,C%TV)U)BI=#Z>QU:.)LQ>JX
MW'PL2K78*BP+#.%< >VO$,.7+8L023N-T7 5-I@R=(%I%[>@%QSQY8OC3_U1
M2@[X()$F%6'ACPDQ,'@S?DX+WTX>G/4VKLV^2@J1)CZMJ"2S8NCE7HI['N$U
MH0B"2S),P#EFV&VPV_0.E'2+4\HZ;%1(N)))) ,F(Z<WDWQK7]I*%A(:#H4^
MEM)TA#FT DR4  \D@SOL9Q=OVZT/0[?X2TRR(]GX"*PP;B7^(9%WCV50L8E9
M5XJNS+R &QWZMU*RBG;4HD=XI&V\&=I@CH)GD=<<JSW.7,X>:0 H4X>* 28!
M&Q5!A1TWM$'20 >>CFVDU)9I8ZP@:O4YO=YL!R>0EC!\S+R3BWS'RI&PW) V
M9I9<=<&M.EM,G6J"2"9,@&;&PD=?+#RG+-"E:I 54 ); -R4@"?#)\X,2+#K
MB29M4U,3IJ+3NGTJPS&-))7B((@W95?<*FS[;*H8_B2-_&X?!EE0_9J$1I5O
M,W/(XD$\??BBU;*SF#U:^X3W94D)))B9,@7X5-@0.+S <]]_4%5[):X](F'K
MY)$U7WL]<7I%[0X.M/+();5/5_??0TVM9DC(!D6#1>/SU>0KM%#8O4T;<R\2
MZIP&D/%*0H%!02?LE:%#F)(!)M(V!XQS_MOF81ECS*5Z2^%M)2 1WB2DI5<6
M 2DR9-YB^V*POO9/=K478GU5?96]X=(S/7U+VTL]X]<8:1)&B]RYIK6'9;*)
M5E92I-:VM=ZMI.0]RO/*A#!MNE:!X,533A&I-PM,P%(-E@F]BDD;6GTQQ$2"
M%#<$<>_IY?C!BTE][O4WI;N?VTQ?=71]ECIG66FJ.K<'=>?8OALOCER<#62C
M%89JD<AIV(2Q>&Q7DAD"R*R*\S#2RZHH 4E9*TZ8 A03$^_S];XZQV=<0JE9
M7(-DRGUB_$><B+1OC61UOW>?6>I\YES-).+.6N-&KN[$P?%2"%D'( *(5]S<
MG<@@>/KU"Z]YZ^O2;\\G\<6)<J5W@F%#3!N1!,?@+;VQ"^LLK'DX6BA9O<LH
M>/ME6V=N*H"JDL-@$!W(V(\['K1P@I/D";^<"-]^H\K8PB2XV+A2EI3<[$[$
M]>G[KXL'],6,AAR&FZ4Q956L!.4&RGVX:K'W.7D<VC_40N_U\>:;F E:A%N#
MM&XV.]^MS?8S'ICL@%4>6LI"M2E!&J!%O%)._3>/.,6W=O<_D=/6:&5Q]JW6
MD@ECJ5IZ[+QJ2M8,KNRK*K3EO9A5X-E&\WMA3SEW84R@R%>&=1D$$"((/0S:
M;[];0,=ORQ+684"F:M"74+04J0H0#:8)@[*@P+V$&"2"(O:QM9O-9[.S34+T
MERECQ'[D32*?@XYS+[<,Q:2-P\BF?V2\B!DE94ADYQR+E9WOV"2-))D"2)L+
M;;G\X$NZ7+V*"D9IV4J0EAQ3B2%&TF #IM(F 8,BQ&!2[DY&&S?RU6SE&L//
M/7DCJ5RXW%DPF&0P33O)+7K,KS$<XT58]O9<#BR::P@W!()%M6WQ!Y-]N3-\
M6!H-!H%P)*U I3 "2%&0D^<*N3$J$WL,54^M_N3)D,+C]%13K*^4G>Y:\A"]
M.KR:E$RJQ4&Q*T4TL>RA55% !.P>4K96Z'@0)6"4$7\)D@GRX,7DP.<>?/I>
MS1NGRI_+0L!Q[6-:5 R"E0(TS-P8()BUHVQ2)EH9<9D&QTO,;2JT6ZM\T)=?
M:V&_Z)4; C?PI'D=6=M>M!.G;@QZ].-[@S\L>$LR2[2YDW3W4'"DA0D  J.E
M47F8-I/3%T/:FXN![;Z(CF#+,,1"6X@?+))%&[L=R#\L;%/(!'A3N0=Z\40Y
MWDC@P!Q^9W/GTD3W[)U*12)F!:3;:ZNL7(D>6QZ!P9;4TT.,O3LR1SY2T17?
MW &6.5MP%')=@8@96']KNH()\ERV@I),R)&PBW3DF+>IV.V'-:M2T^T!(]T&
MX(B=Q?J-K<S)Z?.W%O5,YRSP2M4K.RU@%+K))RV=@-MBV^^[+X8$D^1U*,RL
M"Q$#<W^$\$^?QWQ3,XK0S"4F3&G4"!<2)(()$\F?,V@XME[/]G7JJMJ:NCVF
M(14,155+ \%"[,2>94*. /(C?8 E9JFIDDMA"N\4L)F+:2JY2;[?>1$@FU!S
M&O6@**P2!(DJ )@[S$1O GY;ZDWVLG>?'=VO5UK>C@+JV],]J1#VMP\]>57K
M7+.FI[AU'D*S1.8_;LZEN96.*9=UL5:M=U)4HQ<9B4DMTX@&G3W:X,A2M2E$
MQ/&H ^F.<5SQ?J'5DRDJL.!82(\CQ%CCUJ^HC#3"Z,&%T8,+HP871@PNC!A=
M&#"Z,&,[IK^K-3]RQ_FLW1@QYZOWJ+5::6^US[?/:V&/R'H\[3TK8+\%)?N5
MWJ>O(Q"LP]BRD+EE!;V_<0?I[,A4M)=;(4"8N(W]/?B>[.YHK*\P#FHA#R>Y
M=!)"=*C90@B%),<[$VL<45OF9KUB)1&ZA.(*[\M@-U8D<B2P;8GBK@_,WE2#
MU7*@K A*1"4]#-B=R($VO\><=THJI*&6PI>K5XTDD&$G9,^HF(DR>-\I3GLR
M6?=@G5OAN+LDD:%Y#N O!''%TW/%]T9'!",""06#:%J45$728$3$>>\_'#I[
M,B6RP%@(5O:5:I L9@ 6FQZ>CLS.LI,KDK&0MN9);<Y>4,\88Q*/E$>W*/8(
M L<*JD:$%5"@! J[WA@$#8S(/ZO[NAF)QI25#24G2XM.DB #%I5)M8GGB#R<
M=19*LTIM03-[DHW*!A[9 7;B_ A24"GZ[$ G<_B$V4*1K( ,D3,D#>-HY-Y\
MHG8S",Y=8A*%I4E8A6HDQIF(A0 L23<W'O+BH7A1#-X9FW!D,D@1?P4*J<@=
MR?)!4\%V7QY"JT*<C4D I)@)$2#N>3\M]\8=SU:4RVM)*@0LQ( $0++$'<&Y
M,QR,95=7%"QC@ABW4* 6'C;R>(^9UV(.[>2Y\@@#88[D@B (F]IC;D>LW'EB
M'=SK6ESOE2J#H U !1L9DJWL#$;';;#6J-D.X^H/R9"/A<32N1?E.Y#LO)XV
M#,D;JO*6Q,0P$<;/Q0CDP;QTZ*DMMR("P"4ZB+[;@1!'G<[W@Q'TP5F#MP0$
MJ!64 BYBP)!!)O>(')F<'UHV6MI'#8['4X@D-94C6)8E!F=5+<I%(94;8MM)
M(2ZL68?/NPA7T%^7E;E02 F0GD3Y["]O43?L&0H;I6$($ %-YB9!!/3J>)$"
M^"0[>Z0U1W&R=+:!:V-:W" &Y+5JQ%E7WK$S,J,\K*RN1QV(5/[4 ;4N7N+=
M2"%:(.T2#T!TG:9F(.XGBSJS1IID%+L&1$J'.Y$$&9$0+ V,7BX3M#H[2_;;
M'5!7R;U+E*Q4CLRUARCLV5*RL5;<2$1HCIQWX^4D]O;PUTH:9MA *1*H(\5[
M'T@VOT]#B KLU54(+;;H)G6 HDBPW5XM^;1$Q-Y,F9GNQ[$TL\;_  UFVU>R
M+*2M,VRR +NK+L&E!W#<%9?F&_M@KT^WV'F1Q;?>>D^X<8B2XZY2N*<6 $E,
ME((/MA)O*A^N#LVLIJR;,5;E"2]"9;DQ>Q:D=O<6E/NIBW))D0LI5F''CR'S
M>!UJ0=,)L;1-XO[_ ';QA#^$!3)*UJ!0G2#)(,DZ4F9 F2#?>YY!$)=RNZ6"
MT+C-0VK.:CQF!TUA;^7U%DIB$IT<=B\=)DK]R1W(]Q8:T$TQB'.20(4A1G*(
M=.Z4I)2H^&8,!,GGX[>=IPVJ,]8HFG:^K6E+#+3CA"20H@H*4[D@WB8@[Q!N
M-=#[+GOCG/43]OEZ5.[F95T75?J#+8:G.S/+B-+8[1>I,5I;#[B5T5L=@:./
MK3^WLLEF.29MVE;DHA(;3I3M$2;GS^/I'2,>2L[S1W.<UK,R=-WW5A( (2EO
M9" "3&E,;$2J3SBQ;[XU9FH^OCTMW:\J135_2=C'0N2/*]Y>ZC #;SY\@[>3
MXZRI(4DC>3$>1&_7\]K8C6W%LN(<;)"TJ! 2?%8@@P!M(]-^8QK,4]1#*XVM
M-'LBRQ@S<6W;W=@7C'DL!$?E'T)'GJ"=8[IQ1*3!-B;B)FW2YGX8Z=19H:RD
M9'> 0B%IU G5L0>0+>'J!/&"<[=ZI]JG5@BE"$QJ"VY+1RQL64(?P;8GB=AO
MN?KU&.A251$P2>>9XZ?>!TQU/*<P0:.E"%B002 02 D6VO(Y!XL-[2?-W#;&
M0K$9)'9BQ,@D,A4NOT(,K%0@7]%D )W)&_0WO%S*3=0V(Y-N?,F!CH-)F$M(
MU.I:\4J)5IF!.VH'8;>1 &&7)W#GMR- [R.)9"AE("HL9?\ U0"/;=@FZE2/
M)VW^O6P&DCK,3Q'KY3/D#[L3]'FS;A[H/A:@=DW!$23*3"@-S<W^3:U7JWX^
M(T<6(JD+S $0A8W.Z+&L;G;W'4>78[E=CY\GI0>+8$>DG5O/ES?]TXB.U7:D
M-TSC--5-I<"84IMU *+D%&XN1>WH0,-Y)C4CAIRNQ"AK;H I53*C,>7+S[D<
M3D<?KP<*?H!TN$$)@@CC8VO;W#?>+G'!,PKW:FI*E.DC42=2]5B23!._SF3O
M P_(<W@;N+^";(V!E\=!93$TZUB&%&LY 4:B6";=+)U[/P<KO--3K5ZDD]"7
M+SID*MN.M*BR7ELI(2"01P)V!G:+P;^OKB RVF5F6;EM2%%.M(20DJ$ZA>_A
ML"28&TW$@XDW0D-9,I5$<L@A;X6&$2;AO9KPS&6;]82697E;ER<LW)F/,#J'
M<22JR2H3P-XD^AX'3X8]<9"__!N70#H," 5 'P@\&#!(.]Y\4[G%HO8"U5U%
MKC3&-D!=(JWN[ ;PQPP2^^2$7Y6E:.%5'XL'/G=@>E4@JB!)])OS;X@[1AGF
M&;$I42JT:K*N1<]3'YWQLG]I+F)TOVUQ3XX0.]VL;M^5RONV+-@O*5<$DHL3
MD*%''B5"@#J<H&0"E1203'$&8ZD$1MYGYXYG59XZK-7BXHI9"%(#BB-$I!39
M1,2>-YXF\OW.]RH\8:E"&6.5[T$4EF0DEXIHXXV,!C&[+L[%#N/# _JZF2V
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M&""03)Y/Z^?G./;GZ3P871@PNC!A=&#"Z,&%T8,+HP871@QG=-?U9J?N6/\
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MJ74**5)V/%C-_*=_+$\8W5$&9@6:.:6.Q%L)8'.Q\ ?-'N 6B)\\B?E)XD;
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M))N[R.Q8NS$L[,78EMR0W)M'EBE*4I1*EJ*E*,E1N2?,[GWR?/'1ZQC&+?\
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M2)._ -S>\;;$@7GK$@::G@:]'^>+1Q.92[>0\FZH@V _1#AN/[I_';;<)@Q
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MS:=FC56ZEZ)+%(G4/VCQF2H& 3UL=7O.\GR-'SWM8Y7++=*-+()\4$3>1 4
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M&_(MNU+#>0SY&1$@@KF#%+W\TG]T+_W 'J'_ /.]V_\ M9=&#"_FD_NA?^X
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M_P#YWNW_ -K+HP87\TG]T+_W 'J'_P#.]V_^UET8,'E]F1W5^[8]S_7/Z?\
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MHPW&XE[M_B-OH?5N1]/VNC&9(V)'OQF8/6%]T980^SZ!_4>S.0D*"+NI+([
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M$I2 -(@0(! @8C/-5T^("5HD*R[@KOR8..:?+NO+< J%.WD_B#NO2C8U+"R
M9-YY@$#8#:W7KN!BMU.I86M8$*3W8FY$)E(GVAL#,BX@VMCMU,'-[@_-<E)C
M(X#Z&/=)&)8,/&RDKR8!PR(=MP7>E14/Y.Q%@(Z1N(Y$\1'.()XD(2C2"2/$
M23)D09,S'D#M;'?OU&4Q-%&7C2/9R -@=@H&SC8%MV4\2 #R^B[<5D)2A#A
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M\:[^?^Z[WMZ,&-F+[Y=_6+>ES]]E!_ _W+Z,&/.5Z,&%T8,9W3FF-0ZNS%'
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M=<=\R[(:7)J5%-1)[HITE;OAU/J*0%%:_$Y,@G39'0!( #2U]BQ &11LS%@
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MZ203@,^]_IZ6PF2U?H7'\;4*O8S6G:D0$=N&)6:?(X>M'M[=J,$O;QD2%+"
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M96K[(YR_EM0"MA7[:AJH(154RB=*T$V.GV56!U"8@@F^;[HK_96LU^]2[O\
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ME1&5+42]N]6O5O0@\6->_2DKW8"?K#.A_'J5L;CI(^7R_=CS+F%(Y05%12/
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M,@20.+8X)V^H7&*VGJUM!DU+3C;J =7[5IT%*E* B5-K3Y0+;$X]*[I/'/\
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M5"^]Q!2" )VM QL(>GO1<U726FY8(B[Q8S',X8'8H:ZJ/!8 J"QWVW.VY((
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M(XTK/)++%(DB-[:JWZ"F8R$@@$,$0A/<*[&0+NP4>X&U,=2J=O8B4E4R#-Y
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M*V\R7%?GR#++;CBEYJS-S'N-$>2\55).3JG$\MQ)ML#Q0DK[B-14(2E) "5
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M=0Y*$T:8DRE[)8O3.-HT&S$\V"PD%*:*3'R4[=YFM.653-2EML**5LME%]B
M1>XN1'I./$7TET*F\WJ:QJ!WLA8) 3X'->]H))(Z[#DX$OO;DZD6"TE5/*C
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M8$[;;[$CZ^!]!^&V_@C?8=1*PDFW11N?>;VN3&\WGUQ%4;Y6L2-0"IF9M(
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MVW2M \*4Z0J^PDJ%QU!).T"T@8Y<SF;<M"M>2)ED:Y^96-PTC!RS@>^N[_(
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M,:-+?B,&3YQ?SO>QM<S)B8Q$=H%LO4+;C*Y0$.$BT!4%02+S<"9CH.1A@93
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M*>"-H7"EJ'BL%BX$-PPRJNRF6V99)P'E;YRXED0))))I*DN]VI14%'=7ATD
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M2"W8$%NHV5E27C%?M58I9:299Q++\TGN6IVFD(1K:I2&PE"CH5[0,C>RI_\
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M((8$LH8G8*%!W!!J#U(E39)0$J02G:(4-P=)!V(-P1.QN<>HV\Z48#9V( $
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MW#*6'"J8I\3@0^Y!=YE&4R:@CAPQU<G_ .<QE_JTM(2%25"5"-AM$]2;FPB
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M(OCZH:QDA?A*59?H3X&X\C8[C8AM_/Z]]]]^E$LJO!4-MY\S]V_W;PM3]I'
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?O)GSO;'QUC&,+HP8+CT)_P!=5VL__&_\'&K^C!C_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g805799g14i04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g805799g14i04.jpg
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M 0$! 0$! 0$! 0$!_\  $0@!"0%M P$1  (1 0,1 ?_$ !X  0 " P # 0$
M           '" 4&"0(#! H!_\0 7Q   00" 0$% P4)"@@*!@L ! (#!08!
M!P ($1(3%!4)5Y<6(7?4V!<Q.$=35(>5QQDB55B2D[2WTM<C,C8W05&VU1@D
M)2<S-4)A=I$T8G-ULK-#15)C9&5G<7*!IO_$ !T! 0 !!0$! 0
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M<-@"SFHS+)KO6(X3]JL]6MV3KTK$GIS8VW0%P.LW*HTQ,CMM:TF(*55B[B%
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MXP<&S]7;TB_0J<FU+=YX0N2"VPL)70FQS:NS-NUMAF!T-]%F-G==6R*S'[I
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M(W?/S,)M/>\;1+7$25>U6[,IKH_3QU.[&?SYZ,HP&!A+%9-<4U\9\:.#-'Q
M3@X<FX)+/"@W:@\>)ZM-#^/J430QS)"8P'-C+@07VOO(FC0N/ .=?FU'1K7S
M3&]M]S\-T4L%;/5=K%U0:.V#:KTQ-U2C,/Z[E*I2(^UPFUXT>G5RK)8HR;:9
M&:WM4-/,R3,B9>*EF#F:_(@G9G+02<NO&_1S<#^+K4DD<8,W@91%(QK;%WA!
MQL6:D^%:[A:QT.A'#H)HG9F-TZ0TWN/$0[7\;9U5KS9F(%]Q3K\)B]U&(M/I
M#SJFVE.NQOJODG'%--*6MG*LMHSGNXO&H!ZEBO;D>]E[Y'.;?IRDB_8I5Y56
MIPB<(G")PBXY^UG_ ! _I4_9QR.3F^7\2V%#]U_ _+5^.N#J4W)T[3^BBM:Z
M[O>T*O/S=D*V52]/Z?SNK<5B@X4JG -1=.@V-F4LFG!LB6:7GY78!=1V'6PS
MH*"J<^FF?*^.GW(UN0 >)MT$FP'GTU^37GU5LM(638EQTYJVV;<I:-<;1LM!
MJDYL"@H*8-Q3K?*0H9D_7%$"F2(RG(B1>(">;'DY1D=UI8[4I)(:2<05%*7"
M)PBK]U6?@W[I^CZP?T17"M?XCOO7?454OK>4F)U)4=AXSCMU+OSI_P!BKSC/
MS^G ;7K,!8>Q7_91\FK',^85VX[!O&^?_1G<89X51)#K^J*2K@TMHYU/(^/C
M_P"(QFG39>&=U?\ 4^S>&XUS[-[8[&8V[F^ AVCP^CK==+-Y!756<W^UYU8B
MN;+J=KL5AJL*[/N355><'GFI&EW2"!!(;P(O ^)J=K\;"ED$#GAGA,@R!+LA
M%D-2P*"(U7FN8;XGL:Q[LF5X!;:2-Q(-]<K7EPL00;@97 M-G:+MJ''<.Q&M
MK</I36FJP]SF5;9\*Q6DAB>W=G)RJKHH*61[V2QS0LBF>Z>G>VIA#X#O%OG>
M3V=O>QV?>[>W'9_Y\C6W3MQV]G;CM_U=OS_^7"+"S%>KEBP#F?@X2=Q%F)D(
MWUB, D\1T@A"VD&@^=8?P(8EIQQM)(_AOI0XM&%X2K.,T('/;Y54$C@2+BQL
M2+C\87@#5JO&%I-C:[ QYR7IDI)8,1'"%I(L<D[,V$A)# [;V'IZ8>>E9EW"
M^_*23KIQRGRG%NY:=7YZ^]"YQ%B21IH2;:"P^8:#H'!:-$:<HT3LZ\;>P&F1
MN-["K$:>9*"0A28@*JQ4C#A"U\I,2S+ ,&ARQ_JC+\H8T4LA?<0PTM;2EA<G
MGT^3F5Q>[*UG -OPN"23<WUL=1T:++JU3JM<8'!KUMK]4, '* 1\.JG5Q48$
M!.#MB300<?F.R*,',",M#2@[+*&9 =IMDM#S;:4X6'0/F";Q][YWWT-\QOIJ
M.?F.HZ%Y/ZLU<5XJBM<T$G+Q!Y3ZGZA77O%*E)"'E9,AW+D>KOD2,I7X"2/=
M7VN&2$'#F$*<(C0G&5AT#YE3._XSNCQCUCIZ"?G*W4080 44$$<8((,=D4(,
M1IH<444=M+(XPH[*4-,#L,H0TRRTA+;3:4H0E*4XQBJM)OJ=2=23SK'GP%>E
MBQSY2$AI(X(21CQ33XT(PL0"7:0Q+ CDD,N/,"2C+3;,B,VM#)K32&R4.H0G
M&*:=7_SZU6Y M<VO?JN/QA:Z;K#64D_(%2.O*)(%3!Y4K*DFU.OE/RLH;"NU
MLV2D'GX]QPX\NNOO0!1A*G2"(5YV*=<6"XMC*PZ!V*N=XTS.&@ \(\ ;@<>
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M1$=(R<Q'D(4B.2IMX"6FYB4"=3G"Q9&7DSF%()/*==6'0/F3._X[O2/0!T]
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MFZ]8VJ=6!X$0)K;7XN 41B 4#4ZNL8#;A #8F&0(EJ.3@=$1%R4C&QB6<(2
M >:&+AH<I]MQ9O0.SS^],[_C.](]1Z>D#Y@M2H_3[JG7\WLV>@JS#J?VK*!&
MV$4J#K&(\&- UW1-7#U""8!@P5 TOY(ZYJPKE:(>- 64,05E/>+=3D ->OS<
M.CS:=BN=+(X-!<[P.&KKWSN=F-SXV9QUT*WAO7&NFA_)M4.E-BJKTG4O*MU>
M"0/FJ33[A4Q6? 2#AO->EB7729.&[OII[[CCQ0SKBU*RL.@6^3G5N=_',Z]P
M;YCQ' \>(YCQ"Q8^GM0"G.RHNK-;#23QK4D_(CTBL,G.R+!8AS![IC<8DA9K
M)P )C12W,OMEA"$(<P\.RM"PZ!\R9WG0O<0/]H^;IZS\ZSD50Z) LE#0=,J4
M,/(1 L :/%5V'CF3H$%4@L*$*:##903$!JEI50L:ZE80ZI.0RTRC)I.7%AT!
M"YQXN<=;ZD\3Q/GT&O'18Z/U9JZ(A)*M16N:#&5R7;$9F("/J%="A)1F/[/(
M-244-'-@&MA=U/E&RF'4C=W'@X1V8XL+<UNQ"]Y(<7.)%[$N-QTV-_G7VLZ^
MU^,6Q(#TBG#GL2<O-#',UJ$:+9F; ,D*>EF"4!)>;DYL-*1)<]M>"I(;"6#7
M7FL81Q8= Z?S^9,S^&9W "USP&H^0<1T+'Q.I]50$>B)@M:Z^A8IB"E*NW&1
M--KD='LUF<,>D)NNH"#CF1FX*8/((.E(A+>(^0,?>)+'>>=6M33JZ.;IX?/V
MH7O.I>XZWU<>(T!X\;<Z_H.JM61C<2S&ZWU_'LP0T$'!- T^N"-PXE6)*,K(
MD2AB.;3'C5TPXTJ"8#PRU$$F%/QZ1W2'5+6'0.Q,[]?#=K>_A'4GC?7GMKTV
M7K#U'J:.&KP4?K'78(=/GS+75! Z76A1JM:)!Q]X^RUYAB-0U"3YKI13IDQ&
MH%D27"7UO$K4\YE2PZ!\P0O?K=SM18W<=1S ZZCJX+[SM?4N3L)EHD8&+/E)
M2.KT9)J/$%.%DFJ?,'SM0(*%,:?94?59:7F3($YI+90+TJ6O#BUH$4*L"?KZ
M_/YDS.  !( )(MS9@ [7H( N.I?>Y3:<]**FG:K679I49)0RY9R#BURBH:9+
M7(2\4H]0N2\QDJ<XLV2!R[Y4XMQ9)33KRLKRL.@*F9UK9C:][7-KC@;<+K#A
M:MU=&Q\1%QVNJ"!%U^37,P$<%4:\+'PDPL-4>N5B!&(]L>-DUQZE@K.";9*4
M&I0V7<L9RCBPZ!^?_P JN=Y).9Q)T/A&Y%[V.NNO-TKT":GUM$P<Y6ZW3*U3
M8NRQBH:<9I4+%U)\^)6@AET)94"("2RA0QAK#) SK)H&#'R(PD(W+93:PUYN
MFVG6JYWD@ESG$&XS$NL>G6_/\_.MXCP8^* "C(L0..BXT0:/C@ 6&1 0 0V4
M#B!!BL);8&%%';;8''90AIEE"&VT)0E.,55IN3<\3K?IZ_G7V=N.WL[<=OW^
MS_3_ .7%_P ^WZE1.\GL[>]CL^]V]N.S_P ^$3MQV]G;CM^_V=OS]G^OA%_>
M$3A%QS]K/^(']*G[..1R<WR_B6PH?NOX'Y:ESVL(]L$N?3%:]3V3J5@-RUZ*
MWB)!-],TSTB4VRE4*>(T\W?2;+=^K9YB$9@8\R.J"1Z=4<OF6>8-!DYEEEBJ
MQT@%&MTWG!M;0ZYK:7^+K>U^JUUTMZ8Y7$YT[:1EOE?<K^L[5]*?(NNQ&H)F
M_6DO,"$DR;NJ*L^35?E5(%I>?GEU4HFKNR:R7:X21"K!>65#Q/GYO?JISX5$
MX15@ZU*O7KKTG=0-3MD0%/5N?UA9HV9AI%K#X4@"^'G#HY#6<X[R%=F,XSC*
M5)5A*T*2I.,X*UQ(:XC0AI(/6 N>/4=[.GI$:Z4K93J/T]:[@'=.4;<MWT@S
M$Q+C"Z'L"QUO$E)S=?7@A3K!T])5R 1(K<4\E]L 5ON=UE"<;+#G-AKZ.2U@
MVIBS?>N> _IXM)7E'=,IJC&.Y]MO0"1[I:K9G%S%8ZNJ:6BGJ:/T:J*-P(L0
M=1JO=H7I:Z4=MW+=G4%*:+UY*W;?%.JD5<[21#X<D+/2-O\ 3_K4ZX0!Z\.X
M:<CK*-).MR>&FFW"$/.]KF/%7E5*NG9"YL>6SF[YCNDEE1-'K\C0/,%78K:*
MLQVFJZYU5))33,V>K:*.XR01XALO@N)$1V&C7354DO$^$\G@I1*]F=T#FZUB
M-/%=*VI7M90%PE]@0],7!.^CQ]SGXJ-@YFQL-X+P]B2DHB&BH\MU3RDNC1P;
M>4=C#?=Q,K>%OK7<<JJ,Q?OGYBT-+KZEH)(!Z@25O;O0YTBO[4F=W.]/NMW-
MKV&KF4J:O*H1/K<C5)"DHUN=!$.>+X&0"J(VFJOMI83ER&[PJE92M>5,K>CZ
M^=6\HFR"/>.R!V8-OH'!V:_I:K0\>S.Z!\:R5IG'2KJ3[ERKRG9:J7Z$[Z/F
M^(@55A-G[GF_']33 +7%87X_A>55E/A=[/>XRMZ.TJ[E51GS[Y^?+ES7URWO
M:_1=;XST.=(H^TJ_NMCI]UNWM6JU>/I5=O"83'K435(JFKUY&P0CGB^ D &D
M.*K S:F%*:B>Z,E6,(1E-<HZ/S_/G5O*)LACWCLA.8MOH23F)\^;7SK1!/9G
M=! &MYS4 ?2MJ0?6EEML+>YVG-P3GI$G<*[&R<1!6 E&2\O*D(N,FI<$-Q+R
M4M#R1J,(["'.]3*WH[2KN55&8/WS\S6EH=?4--B0.HV"W83H6Z00-@ZRVL'T
M]ZV&V)IFLUBFZMMK,+W):D5BEQQ$35(:$<P]X;(L#'%/B1OB-.NL-+QC#F5(
M1E+*--."MY1/E>S>.RO)+VWT<7<2?.M-C/9J=!D-1[YK:+Z6-2@T39\M6)Z_
MU@>!6B,M,O2R90RJGR;?FLN*>@B9N7=C_!<:0SF1+3W<H=4GC(WH[3ZU<:JH
M+FN,SRYEPTWU -KV\]@MF1T"]&;=HT]=4=.6LD6OI_AZU :8G4PF<'ZZAZ;-
M'6.K 5US#_='9@YZ3D)>/R\E]QD\MXCOY<7G/ :T6L.'!6\HGL]N]=:0DO%_
M&)%C?Y L,+[.7H9"A=KUP7IAU2Q![R)B3-M1C<$I(MZ)@K*NX1#LVCS/:O,?
M9UJFATC*'2DWL7E.4I2C#*WH^M7<JJ"6'>ONSQ#?Q;BVGR:+ZU^STZ)75Z=<
M<Z:=6J7T_H8;TRK,%G_F\;&M1%X817_^,=C*&[<658<)(P1CU,D@C.,J><PJ
MN4::<%3E,_A_"O\ A?MFOCZ9=?DT\R\D^SWZ*$%[C.3TUZNP7U!,G#[H?]#5
MW]B,25I&NY[5ASDCL>;)MH0=@<2Q@?'J8HY&.Q3+?=IE;T<?.G*9_ ^%?\'K
M'KXNEM/DT7P%^SBZ%SZ_JRJF]+^J":[I(R:/U3$.P*E!T@NQV!FU3C\,C)/:
ME4G8AV98K!*B$+*;PK"<(SE&61O1T]//Q3E50"\[U]WV#S?QK"PO\BSKG01T
M;/6W;][=Z=-9N7#?L)9ZYN2P+A<JD-APETDPIJUQUA<R_P!TAF>EHT&1D%,H
M8=>+&:>\3"\9SEE!YN*IRB?*QN]=EC(+!?1I (%O,"0M6D_9I=!4S0Z1K&4Z
M5]2'4#6\U9[%1JJ1 K7%5J;NCD2[:Y*.;\UAQ)$\N!ALR.77'4OXC DY3A#"
M$X96]"NY549G.WS\SP&N-]2T7L">@7*W4OH9Z0S]B;(VT9T^ZW)V1M^KV:E;
M,M[L+WI>YU6Y0[-?M4),N9>\)X.=A6&HV12VTTX^,G*,N8RM>5,C>-M>FYY^
M/.K>43!K6;QV5A#FB^@(-P1YBM&)]F=T#F:UB=/$]*NI'M90-QE]@Q%,7!.^
MC@72>B8R"F;&PW@O#V)*2AX:)CBW5/*2Z+'!MY1V#M]UE;T*[E51F+]\_,6A
MI=?4M!) /4"2M\=Z'.D5[:DON]WI^UNO;$]5RZ5,7G,)CUL^JG4A&MC()]S#
MO@9 )H:$U1YM+"<N0W>%4K*5KRIE;T?6K>439!'O'9 [,&WTS9LU_/FU\ZT/
M'LSN@?&LEZ9QTJZDQJYR\HV6NE^A.^CJOC<"NL-V?*/-^/ZFB <<BDK\?PL"
MK4GPN]GO<96]':5=RJHSY]\_/ERYKZY;WM?HNM\8Z'.D4;:5=W8QT_:W:VM4
MJO'4NMWA,)CUJ'JL13G->QD$&YEW+"0 :2XNLC-J86IJ)[HR5=B$937*.A6\
MHFR%F\=D)+BV^A<3F)/63K=:('[,[H'C]<3NH0^E;4@^M+-;(2]3U.;@G,1$
MI;JW'2<3!3Y3>2\O*D(J-FI<(-Q+R4M#R1J,(["'.]3*WH[2KN55&8/WS\[6
MEH=?4-.I ZC8?,MV$Z%ND$'8&L=JA]/>MQMB:8K-7INK+:U"Y1+4BL4H B+J
M<-!NX?\ #8%@(\I\6.\1IUUAM?S.94E"DLHXVZ.GFX*WE$^5S-Z[*\DO%]'%
MQN2?.5IT;[-7H,AZ1?=;Q?2QJ4&B[1EJQ.[ K(\"M$9:9>F%2AM5/DV\%=]3
MT$5-R[T?X+C*&<R)2>[E#JD\9&]'UJXU507-<97ES 0UU]0#Q /78+9$] O1
MFBSZ=NB.G+62;5T_1%9@=+SB83.#M=1%-G#K+5@:XYA_NCLP=@DY"8 RZE]Q
MH\M\COY6O.>,K=-.'#BK>43V>W>.RR7SCXUQ8WZ=/<L0-[.;H:#AML5X7IAU
M2Q";S)BB]MQK<$K U[(A+*JXQ+LVGS/:O(%H5F;'P,H=*3<)7E.4I2G#(WH[
M3ZU4U502PF5]X_$-_%N+:?)HOJ<]GGT2.JT\ISIHU:O/3^EI&F<Y@U?\WB&+
M41>&D5_'F.QI"+<658>Z1@A.9,D@A6,Y><PIE&FG#AQ\Z<IG\/X5_P )]LU\
M;2VOR:+S3[/?HH09N.03TUZNP;U!,2 VZ"/0U>)L4>4M(UVD&;#GS'8\V7;0
M@[ ZEC ^,R8HY&.Q3+?=KE&NG'BG*9_ ^%?\&;LU\4@6N/D-ECC/9P]"TA7M
M6U,WI?U037-)F39^JH=V!4H.D&62?8M,Z_#H\SVI5*6$9B6*P2HA*RF\*PG"
M,J1FF5O1P\Z<JJ+O.]?>0 /-]7 "P!/F)6>=Z">C9ZW;>OKO3IK-RX[\@[16
M]QV%<+E4CL*#NLD%,6N.L+F7^Z^S/2D<"?(990RZ\4,T]XB5XSG+*WHX^=4Y
M3/E8W>NRQV+!S-(%A;S#1:K)^S2Z"IFATK5\ITKZD.U_KF:L]CH]5?@5KBJW
M.7-<4Y:I*.;\UAQ),ZN"ALR*G7'4OXC TY3A+"$X96]'UJ[E51F<[?/S. :X
MWU<&WL#U"Y^=;L7T,](9^Q=C[;-Z?=;D[(V[5[+2MEW!V%[TO<JK<85FNVB$
MF7/&\)X*=@V&HR12VTTX^+A2%+[5N94RMO>VI_'H5;RB;*UF\=E806MY@1P*
MT8GV9W0.9K6)T\3TJZD>UC!W&6V#$4Q<$[Z.!=)V)C8&8L;#>"\/8DI&'AXJ
M.*=4\I+@T>(WE'^ ;SAE;T=I5W*ZG,7[Y^8M#2;ZEH)(!^4E;XYT.=(KNU)3
M=[G3[K=6V)JKE4J5O683'K9U4-HZ-:%P3SGB^!D B@H34WFTL)4N&[1%*RE2
MLY96]':5;RB;((]X[('9@V^F;-FOY\VOG6AX]F=T#IUDYIG'2KJ3&KG;RWLM
MRE^A.>CJOC,"Y6&K/E'F_,>I(@'78I*_'\+ KBD^%WLY5QE;T*[E51GWF^?G
MRY<U]<M[V^=;VQT.=(HNT:UNH?I^UNUM6GU>,I58NZ83'K4+5(:GN:_BH(->
M7<L)  I3BZT*VMA>6HKNCI5V(1E-<HO>WY^;@K=_-D,>\=D<2XMOH23<FW6=
M5HH?LSN@>/UQ/:A"Z5M2#ZUL]KA+S/TYN"<Q$2MNK<?*14#/E-Y+R\J0BHZ:
MEP@W$O)2TQ)&HPCL(<[U,K>CZU=RJHS!^^?G:TM#KZAIU('4;#YE)->Z+^E6
MI['UQMZMZ)U]#;+U#1HW6FL[F!$>#-4RAP\!)5:,K,*_AW*&(X*O2\G#L86V
MX\D(QYKQLXSC.*V&FG#@K#/,YKF&1Q:]V9S>9SB;W/7=6=Y51)PBXY^UG_$#
M^E3]G'(Y.;Y?Q+84/W7\#\M2E[6>S:U:B=;W;8FI^GCJJTMHVQV</<FE-K[#
MZ0*,)";-OT#71-*'VV^=4AP(6N(EMDBQ'DBTZ<AKK8W#:XV_!V^G+F8]N,K=
MMOK8D7Y_"U XC3C\NG'4+ISTR-W-KIST0UL1JAL7EO4.NT6H?5SL8_K@>;34
MXK!P]&(A!(^#(JK#N,M0A$%'Q\&1'H8>A@ HQ8HK16GB?.>/'Y5./"HG"*OW
M59^#?NGZ/K!_1%<*U_B.^]=]17O."&D@3(XUI+X9XI 1;*O\5X8IE;#[2O\
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MJV$*NW*9B\SH,5/2,./).QZI5E@M\!B6%ARYUT91>.\RT:Q!1ATHI"EI=1'
M$D_,R,XI$1?!&[*3&UQ;?+8 EI>&7MQ(+W-;]\X#B5FQ4.*55/RN&GK)Z9D[
MH34,9*^%E3'32UCHS)JULK*2":H()#A!%))XK'$?-/PEDK\B@*SA2<3(K97G
MPI5!#1*6$$E1Q"5I<PI['EC13X\QCL\48T0T$AI!0[[*+HW1/:3%E<T']J!:
M]@X= N06N!YP0;VL5'64E=13B&OBGIIRT^#4![7A@DD@>"#=W@2QS0RLMF9+
M'+$]HD8]HF;8VA=X5N\V&MR-8MUE( >E(46PQD%.9A[1"TR3$J;14&Z0$,LR
M):(%A@8L/P4OXP_"C-")=*!;<Q(*RC?#&\/CC!RNR.>TNC=(#)X5B;.(+G.-
M]/").A*ZG&]C]K:'%ZV@FH,2KGPNJ*6.M@I*ODV(4F%5$6'-DI'/B89:=KXZ
M6*"+*'C/2L$8?)$TQP-KC99*&$!U&U$(;">G1FAHTYWPQ< +E'S6&FD*RAWT
MN.=DG$H3@K,='/&J1D4)UUK(,].";R1@W#'7(&I-@"3S7-NBY XD7T;,#QZ1
MK!'AN(O:(75D;603.RQ[EU0^5C6@V=R>!\Y  D,,#Y<N[B<YN\6/0.QH@D2(
MA8R;NGBY=.9<K5?L9,+Y9-*U[<CY%B0(CV!%9CHZ_0(LZE6&2(C.8YZ22P/*
MQ2GH65L#_">61:6.=[,U][+$&D7O9QB<6\SM;:M*V]=L9CE*^*FI8*O%0\NE
M8Z@HJY]+D&%8+BDT[)GPLC)@@QFCCJP0U],3"Z<,944Y=H4S4-D5\ V5GZ_;
MH>/C)MRMR1DH#*!-1L^DJ8%5#R"B4-Y"D%G5FPB-#$X:<?-K4\,REPB#DVQ)
M624SW-:QT+G.9G:&Y22RS3F;;B V1ATX![3P<+Z6JPS'**&6IK*+$J:&GJS0
M3RU$51$V"L#ZJ/DTV< Q3&6@K8VLD#2^6AK(V9GTE0V/XI^]6JS#5@.8E7'Q
MZ;!8KE>;88&!\C%>H2,HMM:@61UFE/GRI[Y,B<HF1)P\EI\IQA@=MJYD$49D
M+6B\K\[[Z^%8 6!X !K0 + 6&BBK,7Q"OCP^*IJ"]F%T?(:)K&,BW5/OIZ@@
MF)K#+(Z:HE<^>4OF?F#7R%C&-;J^2"%(8;R^]EL;*U#-Y=7E ^7%X6YEA.5=
MUK*UXPM>6\)RI>,*SVYQV\EL-38>%QT&O-KTZ=*U^=Y#&YW98[F,9C9A)N2P
M7LVYU-K7.IU7]042TA#;9#[;;3^"FT(><0ALE.$I20A*582A_"4IQAY.,.8P
ME.,*[,8XL.-A<BQ-N;H\W4JB21H :][0U^\: X@-D%@'@ V#P /"&N@U7@ZZ
MZ\M3KSCCKBNSO..K4XM7=3A*>\M><JSV)QA..W/S)QC&/FQCE0 - +#H&BHY
MSGDN>YSG&UW.)<386%R;DV  '4++JY[&+\-:,^C._?\ R8SG.[4?L6?XQ#]3
MU]%_H6O^]6#_ ,@QG_VTZ_7ASSE?I6G")PB<(G"+CG[6?\0/Z5/V<<CDYOE_
M$MA0_=?P/RUTNV=6Q;95MW0G3?4:B9?[5O71D3U" 7:F&L42]USY5Z9A-\*D
MQ[A#-TF^6 GI2&EJGF:A$32WRHBKU62D<RE<!CXV-;D==^!M;IUMV\>I6;UU
M1*5JZA4W6NMX./K&OZ!686FTJMQ2W5QD!5ZW'L1$'"Q^7WB'O)1<<(.$,EQ]
MU:&6$(RO.4\*B^^?L!$(37QV*S9+"F<FAXA\F 8BWAJZR^A:U3E@5(RT8ZS"
MCY1A!#L:U)G)6M&&X]W&592148K>YMJV!OIV)'O,-,(F-H[5A=B5B&FZ+$;0
MMU3A]PS&NJ?9(>GGZ]L8]DH51!%:D=J.5:1UM. PG;;8RVNJA2JI:"NL-?,#
MU<+GY^;SV4V]8TI*QW3KM%N-K4C8&Y&I30,B^ ="!H@ 7 W,N3)R)>2CW3!!
M\X2EP:);/DEY7C+(;B<*S@HW^*[[T_4=5L'F2OX-(_GPOK/)[GH/9ZUSN1GE
M6^B_V5#^OB2<;#WSG$>_G.;Q4^W'C!]J<_<FH..S/:1C&>W&,9^;.<=F>S/S
M]N.3RGX*FT/VI_1Y>;K7,X*UG?O;#X1O[+8;^U?K_P#;F#_[/UV7KW+I&B[S
MA@(ZZ5Z4&F8 K,I2[W699BO; H$[C"?"G:7:P2$R,+(-K0TMUI*GHR12RV/+
MQ\@)C(^:T]5-2N<Z/5KQEEB>&OAF9>^26,G*]O1P<VY+7-.JIM1L=@6UM+#!
MB@?'54<G*,*Q>@DFHL9P:L \&LPK$8F[^EF:0TN:"^GG#0RIAGBNPU\"WCM?
MIG?$K756PJUZT>+8C:OU2UZ-&"C1L$.)8!C]^5F/<=&H4JIY30J+Y%=ZB2KC
MPZI!-:*R2G.:::"N!?0 QSVS/P][KN-@2YU)(=)6Z$[EQ$S=;;P6*XB+:C'=
M@YH\.[HDK,1V?>]D.']T6BI714T>=P9#3[98?"T]YZHN(8,9IFG!JESF&;D$
MF\"N\%+)D@Q9&.8P?'GC,& G!'1I09@A+:7ABA26"W&2!B&5H=8?96MIUM:5
MMJ4E6,YU9S D%K@02"#8$$:$$$W!!XA>M1/IYXHYX*F&:&:-DL,T1,D4L4C0
MYDD<C 6/C>TAS'M):YI!!(*@C<M9@+)<=#.3]1"EEKV=)QB\R#4<3E^.^Y)M
M.:]/7WWE86+B7B(J6\!WM9P=&!DXQY@=A6,FGD>R.JRES?@6NT-M>40-N+'C
ME<X7T\$D7L;'D-J,*PVNQ38]U73TM478_44[C-"7WIQLUM%5[IV9GA1BJI::
M?)J-]#%);-&TBP'F2OX-(_GPOK/,6YZ#V>M=GD9Y5OHO]E/,E?P:1_/A?6>+
MGH/9ZTR,\JWT7^RGF2OX-(_GPOK/%ST'L]:9&>5;Z+_93S)7\&D?SX7UGBYZ
M#V>M,C/*M]%_LIYDK^#2/Y\+ZSQ<]![/6F1GE6^B_P!E/,E?P:1_/A?6>+GH
M/9ZTR,\JWT7^RGF2OX-(_GPOK/%ST'L]:9&>5;Z+_93S)7\&D?SX7UGBYZ#V
M>M,C/*M]%_LIYDK^#2/Y\+ZSQ<]![/6F1GE6^B_V4\R5_!I'\^%]9XN>@]GK
M3(SRK?1?[*>9*_@TC^?"^L\7/0>SUID9Y5OHO]E0[KJQ;+EKAM4"TFUF1@J;
M<&*O!AP54*@97N&TBB7=DN5E3[_8137!VK<1%N,AQ$>@C(K!^'!\K<!3D3-B
M;'3EC)0^2(R/+I&.;I--%9K1&PB^Z#M7.M<C7BN8P.HQ>IQ/:*'$<0PN:CPO
M%&8?1QTF%5=)4.;+A&#XLV:>HEQ2MCD+!B<E,YC*:#.8FSAS XQ*8O,E?P:1
M_/A?6>8]ST'L]:Z?(SRK?1?[*_%W[4=2E]>74 I;:FE9DJ/VMJRA2D_\U](^
M;.6U*1G_ %_O59^__KYZAL_^P]'YIO\ B9E^5?Z(8 =V/;0 W&_PC47U_P#M
M[".D ]BH#S<KQ=.$3A$X1;S7-@S]7J]UJ$?Y)R'O3$0F326/EX@ Z$>,2%,P
MSZ7&\@RN869L]6((SAYM^MVVQ1ZV>\:V^/#) R22*5UP^'-E(-KAX%VNZ6AS
M62#H?&P\UCMZ'&JS#\/Q7#(=TZEQ=E,)Q*S,^&:D?*(JJE>'-,-0:6JQ##GO
M\(/H,2K8"V\K7LV':>W9/;DCB:LE>KS%@2T&-FQ KL#DZ6$&3.E8&F9&4G9)
MVR$K]:'"58+)B6M2HJNUX!^>?P,<[(QTU,*9N1DCRS4Y#ERAQ#!=H#1D'@DY
M&98\SWD-%P!F[0[2S[23"JKJ&B96AL4?+H36NJY(8GUDF[JIJBKG=72'E4<1
MK:[E&(&GH:*%U8\1RNGE^,ZQ;M&V-^R_(C79I3UTG=C(&+&M^!Q+M;)2ER-O
MF02!+@+)B-64>AP,-(134AB+Q$-/#L"MN$DO/8IPJ(L#!-,T"-L-QNR3%&)1
M&QP,9!+#*YP=:^:W0+=-!W3L5@K7UW>G!)'OQ6KQS=R,Q/)'BN)5&%SXG50O
MCQ2.>)M>S"*.EFIFS<G%,US&1M=)(YV)(ZKKH95RZD;5ZD7'O0U>B@CEDWD:
MPQ3E2%G(ZJE-V6/N84[,B5V)LT[$1%;M1]AJ8L6:/'>A+ AX,6,N&&QMD$@E
MD#@][B,L)8X2%ID&0Q%C7/<UKG2,#9,P+LUW/+L=_=&Q67#Y,-EP_#9(74M%
M3PSF3%F5U.[#65<.'2-KX<4BJZJ*AIJZKI::@Q&:MPZ.GE;!R0PTU)'!\$IU
M/6R7C"HDJGT)(I499HKO,CW!+S ]JUUK76<@ME:KDM.7F8+5E?+#4\AY#<N7
M,/OMD!D!  7-P^-KFN$LMVNC</M=O@YIIQ]SOX\[@=?%#1QN3!4;?XE4T\E-
M)AF#".2"NISE9B8<UE?@F!8#,6DXJ?"92;/44L1<' 5,M4][7Q/BAAQ^X^HV
MT[L&<19:W5H@XBR6.PER%;(N@R"DV&V6JYYBG(25N$S6\#1<O<9=J.E$PV+/
MZ6W'QQL\8RP3DVZEH(Z4@LDD> QC 'B(VRQQQWS-C:_PFQM);FR!UR&@G2':
M?;G$=JXW-KZ'#Z:5]=6ULD]"_%6"05N(XCBG)S2U.*55!NZ>IQ2J;!4"EY?R
M<0P2UDC6/,M>^9RXI.$3A$X1=7/8SK6WUIQBFV5/J^YI?<=Q"FTJ[,LQG;GM
M=6A/S?ZN]V_ZL9YSNU'[%G^,0_EKZ._0L 'NK0 D-'>#&=2"?VM/T E?KC<.
M>9;<==!>;::0IQQQ9 *$-MH3E2UK4HG"4I2G&5*5G.,8QC.<Y[,<\XN?BGL]
M:_2UPC:TN=,QK6@N<XAX#6@7))+;  :DG@%I]/V?2M@HD':)9*[<FXEYL>4<
MJ]EK\ZB.?=60VVP:J-DB4BO+<#+0EM[*%Y6,^G&.\TO"9)(IHK"6&6/,+MWC
M"S,-#<9K7%B-1TCI6LPS&<#QILSL'QK#<4;3N#*AV'U4=6(7N+VM;*8"\1N+
MHI&@.L;QO'%IMN?F2OX-(_GPOK/([GH/9ZUM,C/*M]%_LIYDK^#2/Y\+ZSQ<
M]![/6F1GE6^B_P!E/,E?P:1_/A?6>+GH/9ZTR,\JWT7^RN._M8WGU_<"[X;C
M79]U/L[[HZN]V_<X[>SPW7.SL[,=O>[/OX[.WY^RQ_-I;CT=702LZB &\LX.
M\3@'"WC_ !@./4H!ZU8GV:U6ZP=WM]55MZP)#8UCM=:LUC>Z4-A]9$U2-45&
M3U_4!X9_<U?U"#'T;64\L(',TJ'KI5IG)6L&1%SF 8]4^,DN-;H9B!8-T!XA
MESKS7U/'\2_1'T]UF@4W0^FJKJBR$7'5T!K"CQ>N+:5/N6LFST06MQS=2GW[
M0ZZ\]97)>!P >N?>>>>F<O\ J+KKCA*EJ*,\3S=7#L4P\(G"*OW59^#?NGZ/
MK!_1%<*U_B.^]=]161YD+F5#VO?\XF^__'-2_JEH')Y?M5-_!/\ Z^9<S@O[
M-[8?^;8;_P N8.IAY NF7RF@A289<=)""R$>>,^&< :.T6&:&2TIDD0L5]#C
M!(Q#*UM/L/(6TZTM3;B5)5G&:@D$$$@@@@C0@@W!!YB#J#S%1RQ13Q203QQS
M0S1OBFAE8V2*6*1I:^.2-X+'QO:2U[' M<TD$$%4=-TMM#IE,*M'2LTFW:N>
M)?D+1TJ6"7P'&AX(<40?*:!M$@IQNBRJGE.%+U_+N+H<LX^2F-762E#*SLA4
MPUH#*\[N<"S*]C;N.@#6U;&_;6@"PF:-\W3-O!=>32[+;0;!228AW/&C$MGW
M2/GK^YW6U(B@BSNSS5&QN(3YAA%07%TAP:I<<'J'/D$!H)"R^FW3KQZ6SIC0
MATYL^/H4Q';9ELVRDWX*0K5YU^2QJO959,#OM;('<+JZA)^QP\:H^04F&+R5
MYZ-DS8ME\YN6+"J_+5!E.Z9I@;DEA(DAE&_A>'0R"PD!:QQT\(6LYK7>"M9B
MG=@[GLM5L?-5[008/4P[15)Q'"L8CFH<6P:1FSN.T$L6,4+V.DP\QUE=30&:
M8BED,F]@GEIVNF'1<4H8T8<T(A@L,MAHH0L5UL@8H8AM+K! [[2EM/,/-+0X
MTZVM3;C:DK0I258SG4$$$@@@@V(.A!'$$<Q"]MCDCEC9+$]DD4C&R1R1N#XY
M(W@.8]CVDM>Q[2'-<TD.!!!(*]_**].$3A$X1185=;:QM:-H"*E .5^2KTG9
MF[0JY'MRS<=#/0<<>VNK8I;@N3/69\0<5E-I\%Z.;(D721B4MQ;LXCC,#I=X
M_.U[6;O=MRW=F(.\WM[96$GX.^:S;$>$N>DQ7$F;108,,-HW44]%45XQ XI,
MVI;!2NI()FG#QA3H][RJLB9&WOAD? U\[I(WAM.Z4^0+H4X1.$3A$X11'K?_
M "RZ@/I<AOZA])\GF\2E_BQ_XNK7-X'^R>V7\I*7_E#952YR!=(HYF]/:DLT
MH7.635NN;!-'J:4=,3=(K,M*&J88:&947('QA!9"F1F61VLO/+RVPTTTCL;;
M0G$K9YV-#632L:+V:V1[6BYN; $ 7))/6;K1U>S.S=?425==L_@=;5S93+4U
M>$T%342EC&QL,DTU.^1^6-C6-S..5C6M%F@ 8K[@.B/<IJ3X<4[_ '-R[E53
M_I$_TLGM+'^PW9#_ %5V;_W'AG_2I]P'1'N4U)\.*=_N;CE53_I$_P!+)[2?
M8;LA_JKLW_N/#/\ I4^X#HCW*:D^'%._W-QRJI_TB?Z63VD^PW9#_579O_<>
M&?\ 2I]P'1'N4U)\.*=_N;CE53_I$_TLGM)]ANR'^JNS?^X\,_Z5/N Z(]RF
MI/AQ3O\ <W'*JG_2)_I9/:3[#=D/]5=F_P#<>&?]*GW =$>Y34GPXIW^YN.5
M5/\ I$_TLGM)]ANR'^JNS?\ N/#/^E3[@.B/<IJ3X<4[_<W'*JG_ $B?Z63V
MD^PW9#_579O_ ''AG_2I]P'1'N4U)\.*=_N;CE53_I$_TLGM)]ANR'^JNS?^
MX\,_Z51IL#HBZ2-GC*&N'3YK A2F_"\_!UL6G36&^SL2A,]3O09K"4=N<M)P
M?W6LYSEO"<YSVSPXGB%.?@JRH;_LND,C/0DS,_\ 2M#C7<H[FVT$>3$]B\ >
M;9=]24$>&566U@!689R.JL/VHWUFG46*H!LOV'W379O,$ZWN^R-7G.][P!'B
MH^\UL;M[<I[L?+LQ]B=[N<]F?%MZN\G&,=J5=J\[F#:JOCTFC@J!TV,3S^$R
M[/\ _->,X]^A,V$K\\F!8MCNS\KKY8W20XO0LZ+0U+(:UUN'A8D;BW W)Y[[
M+]A_U+5CS!.N+KK?: +7>\ 1PP^C64GL[<I[L?,L&UUKO8^;/BV_'=5G&/G3
MVKQN8-JZ)]A/#/ 3Q(RS,'RMRO\ FCYEXMCWZ$W;R@SR8'BN![00MOEC=+-A
M%<_HM!5-EHFW_P!K$Q8](U7/?9?1CU5:@\PY?]#;'B01.]DF: @'[-7&,(^?
M.7;-5<S5?0GL[<IRJ2QA2<94GMPG.<;F#%,.J;;FKA<3P8Y^[>;_ .Q)D?V+
MQ;'NY;W1-F<YQG8_'*:*.^>JAHWU]"VW.ZOPXU=&!S@F?47M>Q4O]*'7(5T^
MOA5G8VGM8[OUHV[AIV*ME+JJ[Q L97V.+KMR+A2SGD,8SVHAK&F4 \-I <<]
M!I6LC&)B.$-K09(*B:EG.N9DDABD^_C#@!?X\>4ZW<'Z!=-W.>ZW)L6^+#\<
MV8P#:S 6NRNIL1PK#N^U&V_A&BQ22DDF>&\U+7"HBLT10.I 2]?I>Z;MA=!W
M55!>J:GHVG"Y@89!$Y1IK6])B;S7>]W,+]3@'(QU;XC;BTL^L1#\I!.O9\%B
M3==2M">&K:?%</?EJ7U#6DD,E;-(Z)]OBO!X\^5P:\#BT+[QV%QON/\ =$I.
M4;.83LQ+51QMDJ\(JL"PJFQ>AO8'E%&ZG<7QAQ#>54KZBC<[P65#G @3[,A:
M)T29#V!C6,/6I*:+37XV7UWIHZ5DO-21(83$8090:G(%QV)4HL485DYP9J1=
MPM#/C9'>\/$::JI#F;YSPT9BV:I:QM@";@32-!L 2;7M\H7954.R&R,M+6LP
M"EH)ZJ444%3@FR\U3/O)WQ1,IWRX-AL\L'*))(V1ME,;9W7#<V1V6>&UX=;0
MXG"\)<0E:<.-K:<QA:<*QA;3B4N-KQC/8IMQ*5H5VI4G"L9QS%78-.8!PN 0
M" X%I%Q?5K@"T]((!!T(!42Z8_R>M?TN[F_K0M7)ZCQV?P%/_41KG-E_UEB/
M\I-J/[?Q%2[R!=(G")PBXY^UG_$#^E3]G'(Y.;Y?Q+84/W7\#\M;=U6;_P"K
M[IAV)LZ8T1NSV=54Z=)B](D+I9NM)K=>O;%I._SXL(#81'K12EBTS9]:EY#(
MLW4T24K7;"(;-HHN9-Z$BXDB/C6Z&4\<U^;* ;^K\RNN&@(2.KND=4P\5;0K
M\ )0JRIJ]1D8+"15T65%CF$6R'A %+CH2'L1)#TO$0T:M<9$QI@L?'+6$,PK
M)6J7N$3A%7[JL_!OW3]'U@_HBN%:_P 1WWKOJ*R/,A<RH5ID,JM2]WV5(;-K
ML[3K^4#8FW6HR.BH@'PXR"KL(4+:$3YHAP.8:*"%[ZFT(D#R<F-/,I6V)C(D
M.<1PB%[9(@6<2YQ\)[W QY 0[,XGJ M;G7*X72F@J<6QV?'Z*KPS&9(JUKFT
M\%/30Y8*2BI'LQ 5DL4T/):>*.^5HFF>96N:"V)35S'75)PB<(N GM&_9L[.
MWWU+5G:6N[G3QQ-O%05&/C+>7,@.UN<J]'FY')HBHR&F$&0159I11"F\98.:
MGG/ 2P\*:HL/KL%QR"BH9*>:&0FGSRM=$&'>-DE8,I#G,ROSR<=06"Y((L?C
M7NX]PK']LMO*#:#!,4PQD>TKZ/"9X,3EJH74-7A^$U<YFC-/2U(EHY*#"I'E
MHRS-K#D#'1R[R*_NO8?JOZ5J)3M?KJ=3ZH=7T.M0U8BI.@%_<VW1%0<$ P&.
M@FHW6;DJ3=U AL(%%S&W>J21;;+6,13I&>ZYIIG4%=++-GDH9Y9'2.;*W?4K
MG/<2;21-$L5R;D&&1HOXUE[-@M+W1.YYA&&8*<.P[N@;/X/04M!3U&#R]X]J
MJ>DI(F1,$F&XK5SX5BQBB8(X]QBV'3R-8T"G<\V,Z:WZJ=+;+F\4X.RDTW9*
M,)\WJG9\1(ZXV6*XKM[6VJI:F(\R:;3V?/(5I<W%+QG"FCW$YQGF--0U,+=X
M6"6'B*B!S9X"/X2,N:W[U^5PYVA==@?=#V5QZJ[V15TF%XX -YL[C]-/@>.Q
MF]B&X=B+():IH/W:A-53FX+9G @JQ7,-=LG")PBB(_\ S]57Z(K]_MEK7DX_
M6TG\/#_5SKFIO\L,/_DUC/\ :F!*7>0+I4X1.$3A$X11'K?_ "RZ@/I<AOZA
M])\GF\2E_BQ_XNK7-X'^R>V7\I*7_E#952YR!=(G")PB<(G")PB<(G")PB<(
MG")PB<(G"*$=E=-?3_N'#RMFZ;US<RW\*PN6F*I$N3Z.]CL5D>Q,C,SHBE?Z
M5BR+*\]F.U7S8[,J"MJZ:VXJ9X@/VK)'AGRLOD/RM*Y/'=A-C-I@[O\ [+X'
MBDC[@U%5AU,ZL%^)96MC;5QD\YCG:>!OH%12S>R!Z9L3HEPTY8MM=/\ <HDG
MS\%,Z]O!I;44?CO=TAG%G1,3K6$]Y6,-QUDC/WBLM=_#.<M\VK-HZ\L,52RF
MK(G"SVSPM\(?_P >1M^LL*\BK_T,^P7+(\3V8K=H]C,4II-]1U6"XM+(VGF'
M![1B JJMH&O@P5T&A+;AG@J>TU?J%HT#1JOM?8M,W1"";6U.B/V&W73->[ [
MK=XA<#BV*M .6*JV)Y6>ZVY.1\I57DMM^,3%213SCV,(OI)72/IX9*9QAFO#
MGWT6K'7+)'9)&#_8<).-@YH&O8C#]M,(H\(P_:+&\+VII8]HMG1!C8HI<%QF
MS<5I<D==00FMPZM>=&FLAJ,.=E;FDIIY'.<KO<UJ]841:8_R>M?TN[F_K0M7
M)ZCQV?P%/_41KF]E_P!98C_*3:C^W\14N\@72)PB<(N.?M9_Q _I4_9QR.3F
M^7\2V%#]U_ _+6)ZLZ[JF%ZL;)U4=<NY:WM/4NG-PZYU3TB]+UCJFY":#K_=
M=MIL+,B2(.L==ZCO!74SU!V,@XZS09L2';ON;UB3&PY'"F"@&PL:WC>%AH3Q
M.FHOTDBPZ1S\3U=U=66@J[ZVHMQ.+KYY=IJL'8'S:HN3<K9*Y:/8.\:$5-"@
M3/IJ\/8R*F6 !DT-]B#PA"TO#ME&M]X1.$5?NJS\&_=/T?6#^B*X5K_$=]Z[
MZBL%?*@+?J=8:::>;%"V*.=CGI*.8B29 %#JD*\T"U.1LQ$^<9RC"QG38PQM
MA["'TLY=;0I.9%(8I&2 !Q8X'*[,&FW,<CFNL><!PN-."X?&,,CQG"ZW"Y9I
M::.M@= Z>!E-)/"'$'>0MK(*JFWK;7C=+3RM8^SPW,T$58QT=C_<<B]8_=#F
M$2<?9A+>NPM1$.VER4;IX=-(C6G$C8L[,&D$;+P#GRI59F&T"015C-J@J8!6
M=WQ/*75&Z;8QF+(7./@F4RYCKD+[FSO@]V;EP8V0EZ\]'<R9]C%/@'?NJ%1#
MB$>)FN;34K;U#<,CPM\#2(^7MI!"TNA/?$U[ (Z22OEPZ,49M;2*J-1Z?6:<
M&83(BUB#C8,<\P:*#+-:C16Q4%%"P<=$0[)+^&_%?1&Q@ >'5*RP*RC.$8P)
M'F61\A !D>YY +B 7$FP+W.<0+Z9G./225Z)A.'1X3AE!A<4LDT>'TD%(R:6
M.GBEE;!&V,221TD%-2MD>&YGB"GABS$Y(VC1;1RQ;!.$40[+_P K] _2])_U
M'[GY/%]KJOX!O_$TZYO'?V2V._E)4?\ *>U"E[D"Z11WLC4FL=P0F:[M"AU>
M]0Z<J6.+9(<21<CWU8QCS<28ZWDZ'/3W4Y;D(LD,UE24J:(0K&,XFAJ)Z=^>
M"62)W ECBW,/BN T<WI:X%IYPM)CFS> ;34O(MH,'P_%Z8',R.NI8IS"_P K
M3R.;O::86&6:G?'*WBUX5=O^#QN+5?\ A^F_?,RS"C_.QJ#J!Q)[9U_X2/WK
M,=!75TX;;5-%9;SE#';9;='#=UO"8%QM&&\9?+*>?2LI6EY_SBDRT\WG?%8T
MTI)X_!Q.-S=_.N)^PG:;9[P]AML*IM*P>!LSMGRC:/!LHT;#1XJZ9FTF%L:W
M1GZOQ*".PM1N: T?W'5=-ZW[!.J'3-PTZRSGN.[,JV"-MZ0?QC/AX,(N-5C4
MV.G#D.8RI*;_ $RMCBMYQXTDZA*GLN0,F-Z&ICJ+\()+4]5TV$4AW<A \C+(
M3S-'!/\ M%J\"^#[H&R^)[,-;H['L.#]I-DW@:"5^)X= *["V/=<@8SA5#'&
M",U0X>&K35&Z5"_P0EGHMIKUQKAZ>\%.U>9CYV(*QV)5G#,A&$$BK6C"D^(C
M#O?;SGNK2E7S<P9(Y(G%DK'QO'%CVECAYVN *]"PW%,,QFDCK\(Q"BQ2AF%X
MJS#ZJ&LII- 2&S4[Y(R1<7&:XO8@%:0?_GZJOT17[_;+6O)!^MI/X>'^KG6I
MF_RPP_\ DUC/]J8$I=Y NE3A$X1.$3A%5/16[-07S:/4+5J5LVC6JQL[* F%
M0L!9HF4D7(@#46HZT?*##!E.N&1P%@BI&%.-$P\,')BN!DN-/]U"LZJI:F&&
MDDE@EC88"P/?&YK<QJ:EX:20+.+'!P!L2TW LO.]D=J]F<8V@VTP_"L?PC$:
MYF.PU)I:.OIJB<TT.S>S=!-4,CBD<Z2&&MIIZ666/,R*>-T3W-?8&UG,%>B)
MPB<(G")PB<(G")PB<(G")PB<(G")PB<(G"*(MR?]3TOZ7=3?[=PO)X/&D_@)
MOZMRYK:C];85_*79S^UJ92[R!=*H4T5)QLG7;BJ-D 9!(^X=RM$9"+'+PPZK
M9=F>2T]EAQS#3BF7&W4H7W59:<0YC'=6G.<BI:6OCS B]/3D7!%QN6:B_-HN
M5V2J(*BBQ,P3PS9-IMIVOW4C),CCCM>\-?D<<KBUS7 &Q+7 \""IKYCKJDX1
M.$7'/VL_X@?TJ?LXY')S?+^);"A^Z_@?EJW?4%TX](='ZB]?]6/4/U2G:IF:
MDO8;W3_3-L[=U#4-*ZWVC?8,&(O^UM:U?8-<'7/;-*B\)(S\JY^ZUNO%RILM
M#U2*,/P1B-;H%Q%@+\+V%R0-;7XVTYK<%>[1XE4"T]K-BC7U>U:C\BJ\_7]H
MNRE>G"-EQQ<<P6SL$J<J,?$U6;,NF7U64V8KD9'P<H5)O'Q88P1#+22M4I\(
MG"*OW59^#?NGZ/K!_1%<*U_B.^]=]161YD+F4X1.$3A%\94C'A/1XQAP8A$N
M8N/B1RBF!WI.0; -E7 8]IU:%FF-Q<9)22QADNO) CS3%(P.(^XW4 D$@$AH
MNX@$AHN&W/0,SFMN=+D#B0HI)X8G0LEFBC?4RF"G9)(QCJB9L,M0886N(,LH
MIX)YS&P.>(8992,D;W",[U2A[S9Z@IC9=EJ4S0CE7$."K&: 0Z0[)1-BJ+,M
M+A6JGVB2\B['2]ABQ5B.@!.OJ>7CQ#0FW&)HI#$R2\+)&RC=ETF^%LKF296F
M.2-MP6L<;@FUN8ZZ+%L*9BU?AI9CM?AM5@\IQ.*DH.\SW/=/35N&MJ*F+$<,
MQ"?<N@J:VGC,;H8G/+CX4L37,DP61CSEFMA'!F.1ABH^20*4P0N//0..6L$U
M+*UJ$,2*6*2H9_#;R1R1WLHPV\VI4)!%K@C,+BX(N+D7'2+@BXTN".9;V.>&
M8RMAFBE=!*8)Q'(QYAF#&2&&4-),<HCDC>8WV>&2,=;*YI*.D8^7 !E8DX.4
MBY,,:0C9*.)9- D #&4$!G F#+='+#*'<;?&)8<<9?9<0ZTM2%)5D06DM<"'
M-):X$6((-B"#J""+$'4'0I#-#4PQ5%/+%44]1%'-!/#(R6&:&5@?%+%*PN9)
M%(QS7QR,<YCV.#FD@@K[.44J_F<8SC.,XQG&<9QG&<=N,XS\V<9QGYLXSC[^
M.$56;=T?:AF9TNZT1NQ:)V.8KQ";]HZ9509.3>PI3G>L]?$8(H]U;<=SA9"+
MA5IM;V,93AUO*LJYG1XA4-:(Y<E5"-!%5-WS6\WP;B1+%IPW4C%Y[B7<RV:J
MJN7%<'%=LACDOA28SLE5=YYZAW&^(44;),)Q4.=8O&)X?5N=:P<WBOSHSU[]
MH[#=?+%>:M.V+)M"(ON:S7PI(.2CJ%9-?LSH@S<C(5J $$IPVNK!$B 3EDD(
MV,&CV.U<TMX:8":*'[-D.".P;.64[(G0[QY#FF=D^0DM:]Y,AF8XEK&N<3:S
M;%IL?B&LQ?NY4O=D91-Q#:.NQ^FQ@T%%%413PX-78(VKC8V>:@HHHL+CP2MI
MHH:ROFIX(X6'-5%T=5$U[/T*>!U^$?\ UGT?1';_ /D>Z+%W?_\ 0U?Q.S_]
MF^W_ +N<=?"A^UQ!WX=,SS_M'V[5]J9.[&__ #CN9TW#_--J:ZW3_GN'YNKQ
M?D7]^2776?\ ^E;OZ:8'&?O^B]/^P97*/_XYF-[M87G'_K)3C/\ JQRN\PH?
MYK7/^^K(6_\ MHBG>WNNS?;-K-@Z,?\ ZFQF-5)'FY5M>P&W-<#K7\^Y-UBD
M?.7U@4T/M^^F"Z8(0;N_Z^XN;VC8?_ZRM"OO8[<9^?E.48</_P =*?OJYQ_]
MM.Q/L<[IS_MG=,PN._-1[ 4L=O,:O:&M^2X/F*?<+ZG2/_3>N"Z,)S_C)@M&
M:)C_ )O].$*EJI8EH_[L]Y2L?Z<Y^?M<JHAPPR+\*JJS_P"V5B?8CM\_[;W6
M,58#>XI-DMD(?1-3AM:1;SD]:PUDZ4-JVFNST)+];/48\N9A96+[0XO1\&!W
MY$%\3&2V(/4@$@L/&7L9(9 E8TQ;/?0+(!O*02W>ROIXWL<W"Z+P7-=JZL<?
M!-^+ZIPOT9FN'2'#18E=W.=HL0HJRDJ>ZOMP\U5+44_P5/LE1PWFA?'\(RDV
M:BF,?A>&V&H@E+;B.:)]GCC!TC>SQZN^GWJ'D=NQ41KZW/=/MBD(@JKA[#?@
M"-F/3U&!)?AJU)OU\@:/4]4[T#+,.VUF'CW)%#,26L?M*,"Z?$L:PZMHA3.,
MT7*V->)'0AXI\DQ <]H>"[X2%S3NBYP;=PN;-/RWW->XGW2MB]MIMI:>FP7$
MG;&5L]-)A\6-/HGX\ZLPB)[Z6AJ'T3XX"_#L7BJ&.Q%M-"Z<-II7,^$EB_0#
MJ#J*UYN(F3KT:N7I^R:VVA5QU%?H_-9V35%*RG&'SJ^2XO$G#/94C(5HKI,S
M69%#C2@Y=U2LH3Q]1234X:]V62%YM'41'/!)U!X\5PYXWADC?VS OLS9G;?!
M=IWU%% :G#,=H6@XGLUC,!H,=PZ^@?-12.._I7$C=5]%)54$P<TQ5+B;">.8
MJZ].$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%^?\ ]JIU^[<TIN:H:8U.NM1H
M=:C*?LN?F)"-$GI$^RMSQ<E"PSC!#K@\;&1S4/'G$->"U)2"I#YWF D,Y*Z_
M9_!Z:KII:JHWCB]TD#&M<6-:S( Y]P+N<2X@:EHR\";V^,_T1'=EVEV4VIPS
M9;9PT,$5!3X9CU94SP1UD\U>*R6:DIBQ[G,@IX&TT,KVY&SS&;QF1!ADMA9;
M=UD]7O1M#2VIZSJ^AO;@T:LV=DY.WVV*NK]C,=E Y."H<,U ^CPT3:HV/&=@
M[%8;JYY<"SI;?:3@'U9[71QX;AV).;4OGF%-5V8&Q1NBW;<I:^5Q?F<^-Q(>
MQD0\*.XXY5Z/7XEW4.Z7W+Z6IV<H-G\'=M-LB9:NHJ,3Q*FQ5]=*ZHBGH\'I
M6T?):6FQ&"&,TE=6XJ<D->&O:!%REU*?8]=+_4KJ?<>Q;W?:_,4'6Z*S/426
MB94\3.+5>(JS!#-M#Q AI*7ODH]&3K3L^XA+3+I3D;&$%-2,EEC:;25]#4T\
M$4#VS3;QLH>T$;N%T;M"X@?;,S#DZLS@"&W\I_0R=S_;S9S:?&\7QBBJL&P,
M8?68144U1-%_]1Q:GKXHVM931RR9N]SH*QKJP@!KI'00/D;//E_1-SC5]MIP
MB<(N.?M9_P 0/Z5/V<<CDYOE_$MA0_=?P/RU]/M38VP[?V#JMZNZ5ZT/5M.R
M6[=?-SVI>A'I0ZL86X1-JA.G*Y$V:-<ZEY>6AJ[4%F(%KL-,0T/'3]BM59OL
M42T-&U)M^8C6[;8<2->MPMJ?B@]'FL>DKK7TC1YT3TM=.\7)Q]GB9&/TSKD,
MZ,NU"J^J[C'ECU6+:("M>LJ1G-+U[8AG4J9FJ54<_)BL2*"(:!_Y+#%X5IXG
MSGK[58CA43A%7[JL_!OW3]'U@_HBN%:_Q'?>N^HK(\R%S*<(G")PBK1NGIQ#
MW%;Z5:G[A+UW%9<R/(1X$97S&9.-3'69+7=7)11>73LR,T,*\S-XFZ\JK$6J
M*9@&)6Q(GXW-IJPT\<L8C:_/J"2\979F7\5PTRM)\'*_.(W9\K"QW";5;#Q;
M3XEA6(/Q.IHA0$LG@AIZ*5M1!N*\- ,]/(72[^JC8YM7RNB.'OQ&F;1LJ*X5
MD #IP#!WT?NW%QEW<%NID455497L1S4JY 3U:)['41*5I$3'S"#13FD-VWU-
M4JP=9SJ[*.0+=#6.-**7=MTTWF9^;+G9(-,UB;M((-X\N4MC:]N<H=AXH=L)
MMJ^^=2[>N$PP\T]$(6U#J.LH'^$*8'="&I$L<K0,2Y0:ADV(2T-0:)NG4GH_
MBJE$;(A7=AV<X>^C5Z*'-:B*8/)5^+KGI! A,8IVM%!!3*RP'$-)C0@:S$!C
MP:J_68F4BLR14LN(.D="[<Q@PE[B,TI#R^]P[X0$LL=<Q=(XE^>1S791J\*[
MF=/AM-CM*[&\0F9C$=%3LE;387'/14]#R=\3Z<NH)(HJHR0N#1!%%04T3*3D
M5!33T^_DF31&I$Z5UW&4G,\]8RF/+%R,FX ''L9D?2(N.*'C&!VU&HA!UQV&
MX)B<D9Z:CXC 427.R3<>.[C&JJCE,SI<N0&X:VY)RYG$9B3;-8^%D:QA==P8
MTDKI]D-FQLK@E/A7+'5TC,DD]0Z&*!AGY-3P2,@8P&44C#!EI&5<]95PTPBI
MY:RH$+'*9.8ZZA.$3A%$1_\ GZJOT17[_;+6O)Q^MI/X>'^KG7-3?Y88?_)K
M&?[4P)2[R!=*G")PB<(G"*(];_Y9=0'TN0W]0^D^3S>)2_Q8_P#%U:YO _V3
MVR_E)2_\H;*KX]P:!UMNT:,<MT88!::XXLFE[&J<B15]D4605A78=4KC&9:E
M(W/?5WR(YU94+)=U+4M%GL=K6;J>JFIB[=N!8_[;#(T/AE'1)$[P7::!VCF_
MM7 ZJ+:78[ MJV4[L2IY8<0H7&3"\<PV=^'X[A$QO\+AN*4^6H@UU? XR4D]
M@VIIYF>"H'^Z5O?IK_XKO6-.WAIT7M2QOW7M<5\O:B CY\/;EU9!M.KD0@V>
M^HV^:U%)&2P-DN8IT3XKA/,K<TM;K2D4M2?\TE?\#(>BFJ'GP23PAG(-S9DK
M^ Y#O[M?L)\'M=!-M9LQ'HS;+!:(]^<-A'[;:C9VD:YT\4;;F7&,!C?&&1[R
MJPNFS.D%NJ=<ZEL*N1=PHUDA;=5IH?!45/UZ1%E8LYG.<I5E@P-QUK+C2\*:
M(94I+PSZ'&"&VWFUH3KY(Y(7NCE8Z.1ALYCVEKFGK!L>L'@18BX*])PS%,-Q
MJAI\3PBNI<2P^K8)*>LHIXZBGF8>=DL3G-):;M>TD.8\%CPUP(&S<L6>OD/
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MJ)=VEI[Z'*C;J_9$*1V=O>2J&D#<93V?/VXSV=G.:D@FA-I898CT21O8?_4
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MBWT+QK')NI98L[=<DCVWLXK5IKI]TY8'*6N3H, ZW0&1@JN,V&AH0")!CI<
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M!(PY)+8IT)J*5KPSS#2_)RTY''OM$B"$"/D4H4*W!; HU,OD:*8#'7:IUVW
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8B<(G")PB<(G")PB<(G")PB<(G")PB__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g805799g19c30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g805799g19c30.jpg
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M2D_$_9_PGUZ+V126M&U6XG:7;AED'J0V@%7T#_7S,#DB^>..W''';@=@./8
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MCG+G[=I' 5'NHL&Q:=3[I6Z_%5-3SR>5,RVE]^Q]>:S.KZBRH*3<J5 B' '
M1C!"I\AGG'J9P.J^P/V2ZLVM+G9"TL'524OZ0_=Z8XVK,% M;A+) .0VXRXS
M(22V=J8V%>%C[6C>/8>[BSZ'*LIVVE*D-JE3,(M)DG%9_24DG(L"MC,J[>.%
M?C\X67'!2U#Y(5K(C6+:\(3JMFVL*$*N&$!#\YVJ"@1 !B4C!$QFN6W?^S_V
MP[$+<U3V/=O=2M'4*[Y>A:VZV6KS:,-J>2P=,N)'ZMMN^TQ"8,JNT+AU/L2\
M!?VYNVN^$>AQ7Q!O8YB5Q;K:A4N[&-./(V]NI;A:98C9/ E/29>#V3SBB'9+
M[[U('BHS!CS0;;<IW>C)[K[5IMP+RWV%:P(#C6T$J21C<4"-P W=8CC,=C?;
MU=6^L#L=[6M&_L=VD2H--:AL6SHUXM2@A'>=ZX[]E#L[T7S3]QI;H*E?:+<)
M"5>@9A]F4RU)CNMOL/MH>9>9<0ZTZTXD+;<;<05(<;6A25H6A12M)"DDI(.L
M!7ID$* 4DA25 %*@0001(((P01D$8(K[:5&FE*:4II2FE*\\G_: L$@4&W?A
MK\3]33P4Y9M3OE0T5C>LP8XM'\;LX5GDU= FSPA,EZMA9!C"/@HCSRHS$J[F
M+;;0N6^I?.O:);)%C8:FEM)797J$NK@!SN7D+ &Z)*0Z$XS!5(&3.]=AGG'+
MR\TX+4!=6BG&T22CO65)W*">-Y:4K/)"2*MJ+)8FQ8TR*L.QI<=F5&=2>4NL
M2&TO,N)/H4K;6E23Z<$<=M:V)@2(,"1T!C('PXK/D02/(D?0U:%KFS%%9+AW
M-780X*E(3%N6V_BX3Q4A!4'4M +86AQ2T>4"\ZI*0YT)"T)504_L40I, <F>
MD X^O6)XYJ=+94F0I$G]G=X^8XCY_#-7/76M;;,_$5DZ--:[<J8=2LIY] X@
M'K;)_56E)_+55"TN^Z01,?A/Y_G4JTE'/,3@_GRJV[A3F0VJL886I%=$;9E9
M(^TH@N-/?/$ID+!!0N8GA^84\%,,AOK2ITIU2<&]2DG&SD\R# C'J#UZ]*A_
MPPOKF1Y?/^G];Q0A"$(0A*4(;0A#:4I"4H0VE*&TH [)2A"4I0!^%*0!Z#58
M %(QB/S_ *U"K7R##:3(4$R8R8\P=VK*(E#4UI0X*/TG20ZD$$]+R7.DGJ:+
M;@2L4U,I5).%$SN'^N/+GB?/$0I8,A1CR_)JW(-O=XA(:K,K>5/IG7/*KLF"
M3^A) \N-;CCJ:*N"$2%EPI61YC[C9)CR)46U!N"1,;CR2>, =?S)FJA 6-R<
M$>^G/ACKUDJYZ=?*I,2I*TA22"E0"DD=P01R"".Q!!Y!'(/L=7-4JY:4II2F
ME*:A(\QZ?PI3ZCV/?CVY/')X].3QW/J?WG4<?P_I2FE*:4II2FE*:4II2FE*
M:4J!=V/_ "WVH_\ >LJ_^1K-9G3_ /HKM!_DTG_TJYKGG:?_ ,.O9K_D[<?_
M )9H]33(CPG8\63-BMRONTIL8Q5$,QZ-)9BO-"1#9;:>?,L,/OM-?#-JD*#R
MVF@I3G2<,F8 !B0 <Q(Q@^GQQ70C')$QD8F#YCU^&:TH;?;#[G7WV16Y6TXV
MQRJOWC>J=^HM-A^2XO9XUE[\>]WGNLWC0*V%D,*NFN)R.HB4\^$PP/*LY+=<
MP"J6TAMO9GKIA/:!FX[Y!MMUJ5.(6E;8VVR&B5%!4/ HJ!G*1N/%81IAU6DN
MM=TL/0_"%(*5D%TK@!0!.X $1[QCTK+'<LV^Y'ADW/.+X7N,[-:\%&Y6WL:B
MM=MLZH,HMLXS3"HT*MQ:HQ6\Q^OR*TM(TVE,.P$*L?BQI-A#9,E2Q*$>P8VL
MWK&]QF/TDPZ5I>:6VEIMTDN*<2LH2DA4B5 P"8B)NW"7+9W:VX?]R<;VEM:5
MEQ2(" A20HD$08$ F">8Q-\.&WV[F'9[AUYO+MMN)-=<^SEP+:'9S)<4VZRZ
M%2X6W1XU73]Q-I=W\<:K+:_@;IC+(;"\;N;65!Q^[JH;D2GIXMY,,?5_>.V[
MC3J;=YD?\L.W%PAQULJ<W+(9N+=9*4ECNR=Z "M*C*E%,&K2W;>0X@O-NJ/Z
M.0TRM+2PE&U(+C3R0"H.[P-I,)4D8&ZHK\+FT&]&+J\/TRYVJW/MF<9\#.[N
MW.8G--NLLPN;LI?SYUQ8T^-X>V*2A7N3:Y]8*BPIU$_6Y?;TD9$>U@6E?'>>
MC2:]_<6Z_M82^PG?JEN\WW;S;HN4 !*EN>)7<I9&0J4)69!23!%*U:?3W!+3
MI";%YI>]I:"RHE12E'A27"LP"DA92,R,U.VU?A6.\_@[\)^RNXM!N+M=N5@F
MS&8W&(YG(PK+Z#(MEMX:',,&G8E>&RF5<"/46R?@K BHFV$"3D%&+-NN<2LL
M3XUH_??9M1O[EE3+[+MRA+C8<;6BYMUMNA:8"B5)R/$ 0A43U!KM6O?V=JRX
MEQIU#*U(66UI4R\E:%(424@ X."1N$QG(GG%Z'??<WPWM[&[Z8E(KMT=U[S=
M'$]X+*A&3T&(2L4HI%A1V>15F;4V*Y!5T2=U(T>DG4U?-A14V=%D=\Q7LQ'*
MXMQK5Q=JQ>?:K5P*882PXPE10MP.+ 6E"FRM*E&WE0403M4A&Z0J#<)2^[;=
MP^B'75.H>(WI1L3*2H+"5 =["=H,;DJ5$1BQMMF]W\B^SCWKVMW3VYSIS?+:
M?9??CP[5DB1@.7?>>Y\.'B5OC."Y'M[\;2(M<JJ<XK(V+,N3:YN2Y/MZYR=8
MH92J.O59[[.C6+5]AYK[*_<VMXH!UN&"7$K=0]M5M0IHE>%1"3 G-4V^^5IK
M[3K;G?M,/VX);7+HV%+:FY3*PL; 2)DB3TJP]Z-M<ZG>!KP 45+MWN <]P[,
M/!&YG5?3[;91;9EA]9M;1LMY-+R.@CT$JUB1L+G/6;BH]I!$?XA]],9I_P",
M(=J6SS0U/5E*=9[IUK4PT5/(2TXI]1V!"]X2>]  E)F(S@53>;<-CIZ4MN=X
MA=EO :65H#:(45)VR @DX4(Y\ZV7;%3WW\6?J["/E,V_QU5%2YCG658)D&WL
MG<K,(6)T#%MET"FR6GI+";7NQ&JNO%NQ#55_&0I='7/NM42E:PUT!O"AW:4+
MW*;:;=0\&6]ZMK94A2@#.Y6TG=!"R/'62MR2D@A94G:%N+0MOO5A"05A*PDD
M0$B8B92"=LU-NK:KBFE*YH]?W?Q&E*]&NNT5R>FE*U1_:7?: .^%_'JW:7:,
M-77B+W+B)9QYAEENQ&"U%BZN!&RF57E+K<^ZG3 Y#Q.FD-EB5,9?LIZ'8$ 0
M;/.:)H[NJ/ ['%,(4$J#8\;BC'ZM!, 8RM<PA.:X'[:_:XYV'MK;LWV8;&H=
MNM?#;6G6K;8N#IK-RZ;=N_=9/@7<..A35@PZ>[+H-S<(7;LEFXU5^';PV5^'
M27=U-V;%6=[X9%,=O;:_NY3MW]Q6EBKXB4(<^2X^[8Y"XXXX;+)7'5.J<4N-
M4?#PPZ].Z]:60LD)2VAL>&(;'@2!@!LJ *4;(GPA1425%0YT_P!F7LAM^SKC
MG:;M>X]KG;C4%K?N[V]=4_\ HU;XEYIH.%7>7Q<*VW[U3KI6A;J$2%=XK+MY
MB/(!:5PE25$)=[\ D<<*[]A\W=0ZD\@$\)]+T%2<C,@RG'4YXG!SCF*[JM06
M1. GB8)QX0<XG$CB:PB\2'V>GAA\54><_GV#Q*G-7FO+;W#PY$?'LW8=0GH:
M<D6+4=<.^2@\($?)8%S':;4OR6FE=+B+#4=,L-21MOK9+LI"4/CP/($E4(=2
M-X3DG;)03RDU<L75PQ):<(@R6U92?B#Q/!B#ZBM OB(^PDWSP6/87FPN74^\
M=7$==6,7L&6,2SEN*.HI;8^(E/8[=OMI2GJ6W84[KY7_ %>N))0G1[_L,ZE)
M<TZ[2]U#-RE+"C($!+P_5*),C]8&0(]X]<PSK+:B$W*.[4=P"D2I,C_"<B!&
M 5=9\ZTGYOMUG.VV0SL4SW$\@Q#)*Q9;GTF154RHLHR@5#J5$FM-.J96!U-/
MH2IEYM27&7%H4E1TF[LKNQ=4S=,.,N))$+20%02"I"LI6F086@E)&0:RJ%MN
MH"VEI6GJI*@<D2!&"/IQGTJS5!23P>Q''[N0#JV,C!Z5,04X]/QQ^'YQ4I;6
M;M9=M9=M6&.S#\,\\T+"HDK><J[5H* #$V*EUI/*>>IB4T42HRP%LNI'6E=S
M:7EQ8N][;N%)X4G]A8ZI4(R"/">L8K2.W?L][,^T72%Z3VALDJ<2A?Z/U5A*
M$:II3RQ'>V5P6UD)48[^V<2NWN4C8\A0B/;9]BU]KO!7&Q?9#=G)G9&UUU*C
M8_B%WD$Q#MIM#E,DLMQ,3NY[CB0]@EFXM+=5-4DM4+[[+@4S2JGII\]>VS.J
MVAU2R;VW"23>L(R"<RXE.2%=8!A2>/% KSMV![7]HO8YVL9]E'M&N%7.@7BD
M#LAVG5N^R-L.K[NV;<<<6LVVGNN;;9;#CSITF]4AK>+!UI;?KO!"@"/0@$?L
M/<:U>O7]?NE*:4II2FE*UF_;";=,[D_9U^(^$6 [,Q3&ZC<2N<Z>I<5W!,FI
MLAL'V^Q*5&BAV\92AW\F0Z/0G6L]LK?[3V9U= 3N4W;&X2/6V6E\_P#BMJ'P
M-;#V4N/L_:#3%[MH6_W"C, "X0MG/H"L'Y>=:>O"OD[N8^'79Z^?=+[[F$U5
M5)>)*E/2\;2O')CJE'U4Y*JGE*/NKDD D@<QL7N\M;9625-A)),DE"8*OF0>
M<CK6_P!XV6KEQ!())+@B<)6HE(,QX@")Q'EBI[=88D-K9D--OLN)*7&G4)<0
MM)]E(6"E0_Y5 I/H003J[4D*!!$@U;R1D<CC\BHYLMM*U<CX_'9LK&; 'J0Y
M"4M4;K'8$L!QM:!P2.EEUML#G]&204T%6R)E(@Q'/.9R/C_#XFJEY8$$R#S@
M3!P0"9C%4>N>S3##*1.HT9'"ERWI\NSJ7"J<Y(>Z?->?;7RZYTMMI2E!AH0E
M" @2N$_+*"MB927)F2F)QYR>L_+/PJ.UM8\'ACG=DF9.(^\GGH>E7K3YMCUT
MH,L31$F<]*H%BGX24E?'/0$ND-NJ'O\ #N/#\]3IN$'F1_,=/ZU(MMQL E,R
M8PH>N<$XQSQQUQ5V\@^A!_8=5@00".M25\766I;:X[K3<AMY):6RM*7$NH5^
M)"FU ]0(/<<'V/8D:D4J. /.=R4\_'X\^N*#>9[M*E* X2"3F/+XU3JO#,OJ
M9++-)17MOCLAX(3#$:4[)HR\I(2N$\^CB14A79V(I?G1 H.LNN-I6WJ@JY:;
M("E\B<*"H$Y,C'Q'O9'I5XS8WC\$,JSU((^LCX9$Q(X$5*$?;?,Y'3_N<LA7
MJ7Y<)DI_[R%R L'N.W2?<D\#G4BM1LT_\<*!ZA*A'QD#/PJ[;T/4W)VV_$3*
MT]9C()'3S\JKC&T&3N\>;)J8WU"Y$EY0_P#Z>(XCL>W9P_MX/(MSJ]OG8'%G
M/"1Q/.=N.(SUSQ5TCLY>GWU--8Y45'/[N$\\GJ,?,U9C9:<HI$B^C-GOREB"
M[()'N4EQ^+Z=^W')/Y:D7K!@A*)/ "X"?F02>.L1ZBJH[.*.';QH)&' A4[3
MR,%.X3(]?ATJ*MI*""@NVF2/,MI'*G%"%7MC\RN2M](!_,CN0?0<:I?I=\@P
MRUN _P 1'3//6<$'X=*N&^R[)/\ ?W"R/$$-PO<"<!,)DX(])Y@G%NS(VPM)
MS]];H8U#*!RX+//<2K^ /U@XME2??^UZ=^3[43JMWYMHZ0DXSU.XS(XY%9=G
ML6IU,IT_5+C@[D65PL#R!*$P/.#DSTQ5HSMU/!S3'BQWAVR4I 5RG_:-72U\
M#@\^7 M5+(].DH;/)Y'<^M#]*78B7F<S^TD$CX3]X'PZUE;?V;ZBZ5;>S.KJ
MB"0NR? &<1@"2>03T]*MUWQ-^!J 3U[J86[PKO\ #2\EL^> DD@PFI?//H.2
MD\\G@>\GZ4N/VKJ1T"8CT]8XB3FLDW[*]?W2.RM\01C>A#( ,Q)?=;3\IG&.
ML4ISQ@^!)I:A_M&Q\DG@]&-Y])XX[=UHQ]Y)Y]1RI0/L3T]J9OWB9%XJ)XB"
M(]0D\_ZBK@>RGM"!GLM<9!$%VUGGK#Z@3\"0*^:/&-X$7BE!W%I4=2N@%6*;
MA11U>G*EC&VOD[^O)!'< GT"_N 0?M9Q\I_\7Y?Q$U$^R;M"04CLO<21@EZU
M\XQ+P^\@1DF*N.JWV\%66/(C5&[V!QI+R@AM$[))V.KZE'I"0WDOP*.LJ[!(
M21[I_$-5AJMR3 N4+,QXR ?E$<_P&,5B;SV8:S;@N779O4FDH!&YAI-RF>9F
MU<= (Y&X@D1CBI79VVQ?(X*;3"\NB6D)WNU*CS*^\KW>W4$MV56XVR/E4._0
M\KI(44\'O?MZJXG<5-IR!!;'7K,DB/A('0UJ5WV7+*UH2;FU?C#5RVMMT$\!
M;2D[VX/50 )P(S4?WV%9%CO4N="4Y$3_ /K\17Q,7CL.7%I2E;/J/FD-,I//
MR<CTR%O?V]R=J5A*\RDX&X>\)XF3Z&?G6NW.EWUJ3WC2EH \3J"% F?(9SS,
M5:FKWBL<#(G(^(@_2H%W8_\ +?:C_P!ZRK_Y&LUF=/\ ^BNT'^32?_2KFN>]
MI_\ PZ]FO^3MQ_\ EFCU.S/_  FO_9H_^$:PHX'P'X5T.OIJ-*M"-F$"3EUO
MAR6GD6%17TMDX\L(,>0S=KMFV4,E*RX'(YJ7"^7$(1P^SY2EGS BZ<LW6K.U
MO2I!:NW+MM" %;TFS5;APKD!,*^TI"8*IVJ)C ."M-?MKSM#K?9UME]-UH=C
MH=_</K[ON'F]>5K MT,[5ES>S^AGR_WC:$_K6N[*_'M@'QC;W[B^'K:%_<[;
M?#*;<"PH["3,OL5M7K"&_,Q"BQK(<ORN=3SX#I\BTJ<>QFSGQV9,.6Q+\HM$
M-+"2NKIULS=W 8><4T% !#B8(#BUH;;"DD92I:T@P4D<UDKQ]RW9[UM"7"DR
MI)F=B4J6LI(/*4I)SS4:3?&5(OO$7X6]K-M:S';O;3Q%87G65IW"G+GO6,)[
M$]N<?W-AUU94QI4..ZW-QW+\4=D3)$EQ##MI(C(;7)K9+1JC3@FSOGWE+2_:
M.M-]T-NTAQU;)4I4$X6VX !$P#P15/[857%LTT$EJX;6OO#,@I;2X  "!E*T
M3/$D<B*ABF\>FZ5UM5LCGJ,4P")9;N^-U/A&?AJB9%)@T5>_?970,YPT!D,:
M18367,65,=HEO0V'T3TQD6D=40R9-RK2V$7-RR7'2+?3#J ,H!4I*&UEKW"
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M6Q>LMZ?>]J-*N=+U2UNG#I]^FRNF'M/O4['@ZY;K2E",*2^A:E (6WN"@0J
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M2U*5R25$DDGD\\ZIPA,DP.94?4]?O'RS%;:7DIB&QM2G:D!( "> G$#;$CK
M@3P*E2FVB+BDAN(5+/'8('//8<CL>??]^F])P"#\OGQ@'ZXZ^EF[=MLS"4-"
M) $#),F8^)&?G'%2Y4; V3Z4K17\)5Z*Z>.W?T' ]>?7\^/3UJI;<<'@08XD
M P#P(D >69Q6/5KMJW(4XDF/,^ISU^?\L214^'&:Z 5H98! )*PV> ..YY].
MZ?0^_P!1JNBS>\6]8&<3'7X>4SU@ 8Z5BKGM/;-%L);42K=^TKI'Q,^+YXQ@
MU>37AV0RGE4N(%@@<*4TE)([C]Q^H[^I'KJ#EHH#PO)*@3,?"/( P1'G5 =J
M)S]G<0D<*(5!5Y=>@Z^417"1LPS6I*W'HB^D?-Y:VE?F!WY/T!Y]CSZ>ELXR
MXV@K4M)"8D1YJ GRG-7;.M-/E  =#BP3$0D$ DYB> ?BK'6N@G"JED]+C940
M>X*$#COW'X>?[]4=RB)"@,G]D?/\P.*O?M"U9!('0&9\O0^?E7;3C%0DCB."
M ..X3]./3C_,]]1W+ZJ!'PBH=^Y$3]:[2:.K21_56R.W(*0?[O8?3T]M2;?4
M_7\_=%4]RO,F?7\_GFOL*>K2.!$0!_W4Z;0>?Q/\ZAN7^]]Q_P#:K]^Z:S_[
M*C_"G3:/,CX$TE7[WX_SKJ.8_5N<?H D]^>!^1'N>#^\<'40(,R<1Z\?&>OE
M%3!:A&3C\Y\ZH<W"H+Z%>7P#T_A4E/?]_P##42I?F#@Q($Y]8C[O0^=5 \O&
M?*>@Y_AS/^M1S?;>)*%D,\I/5Z)2>/H2!W[_ )?M''KJ*%&3O5 ]3SGI XB.
M(^DQ>-W !(+@!\QC Y_'SCUJ!LHV[!0L!H=BON$I'H ?7@<=_K[^X' U/N2?
M"2"?0'Y=,_AZ15\W<J.-^(P8$^A!B0KR4"")]:L/ <XW/\.^8MYQME=OU,\*
M;;M*IT./4.2U[:UJ<JL@JNM+$Z(L%9:6/*FPW5F57RX<PB2)@I2"5-D9Y3^R
MOT4! 'H1D=(F#9:SH>E]I+3[)JC8=P>ZNTI_WRV61'>LNI <44R)0HJ2I/A*
M2@D5M!IO$KM_XO,BV;B(B2,2W&HAE_\ 2S''FR\J*IRIK#'L*6R*4MW&/RI4
M:0IEIU35E""5M3(S!4S,E[IH-T6=$U]X2M7>::E;/O*2&WG7)!(@I,G:00>0
M1@5X,]L7L_NM#]IGLO9>/VBQN6_:!]BU%*?$HIT?2U-A]L%7<K"M@<$!("MR
M2!(3EA?8K;XPXAJP8YC* 3%GM<JBR4< I*%J/4VX4E)4P\$/))XZ5I <558N
MVGQ*5 &,HZI]#/7R'Q]*PE[875B5%]'ZJ)2ZF5)(G))$\]///EBW]5PH$D#D
M<_GFK*L?8/\ ^D!EO_[IX)_\YEVL_<_^#^C_ /SO6_\ SFEUS;1/_?1]H/\
M]'/9S_YSMY4>>-Y[?"+LZF5X=<LGXINO#MK2VQ\0X%9;LY0C%<"S3.9.%3*J
MW@SXDE.5_P!%6::,\TB+.BS)3"X\^,TJ4EZSTP6QN(NVPXP4I2N2I.SO'6F@
MZ%)(([OO-Q$P0#(XC?;[O^YFW64.@J*8 .[:VM>P@X\6T"<$=#S.*F.^+/-]
M[_$?X!;;"<EM\<V+\1&WV]MI?X0S&@M??E_MWMKCF1R)#]XY7HOF$XSFV0V6
M'O1ZR?#ARI^%39*G)]=9A!OEV#=M9ZJEU"5W-H];)0[*O AUY:("9V^-M"7
M2#"7 (!%6J+M;]S8E"E)8N&WBI$ ;E-MI43,;H2M11@P2@Y(-5WP%[K;N[RP
M$WVXN<;B.HQ+<[>")(O;9.#LX+N!25N9Y3MUC&!QX]?!1:Q+7%I+]!=RYRF:
M2QGSV:.,T]>1;.S#<NJL6]LK8RTS^L8MR$I[SO65%MMY;I).TAP!:0/$D K,
M(*4U&P>=>&YU;G@<=\1V!MP!:FTMP!,I)223!)"8W2:DW$_%?<2?'!/V2OYM
M O:[<S;B<_L9-KY45Z>YG^T609!"W1J+H-=3R+#(ZJ4UDM"DO/0'L/QNGL89
M:FV]BR*#EBD:8+E 7W[+P%T"#M[FX0A3"D=(01L7@$.+4DX2DU51=DWQ844E
MIUL]P01/>,J4'4J]5#Q)Y!0E)'O&K7PNRW=E>-C/?#_/WTW GXG@?AZV>W&B
M29$7#TR[7+I>=3(>42[-#&-,I-;E=;5*K)M5%7'8K8LU]VD77SFV)C=1T,#3
M6KL6K*7';RX9(&^$MAI)0!*^6U*D*Y40-TC%2H+QO7+<ON%#=NRX#X)*RLA1
M/AX4!!'2<0:X>&7<W<O<';7?FPR[/LDLK3#_ !\9'L]CUCYL"'+K-MZ#>?!,
M3A8JD0Z^.P\RYC]W;5TRRE,/7LGXWXM5H+"'72H:]89:?M4MM("7-*1<+$$A
M3RK5UPN9)(\:4J !VB(C:2#"V=<<:?*G%$HORRDR 0T'FT!.!!\*E DRHS,R
M 1PV[W]W0I?$U7[1[\P\^Q5[-]T-T'MG-P: 4N4>'_>[;YBLR^TPO TS(L)4
MS;;/\-QYJ!.DPUO-6.2V6+7+MW8SDV=5'2>M&%61N+4M+#;+ N&5[D7=J\2V
MEQT@F'F75R <A <3M2F%5!NX=3=!I_O$[W7.Z<3"K=]N%E" 0F6W$)B1,J*#
MN)FMFFL+64II2N:/7]W\1I2O1KKM%<GKR!_;\[AQ:7Q38H;J0Y'H\,V4Q#E8
M"G W+O\ -LL<<=2V/13BEU[*BGU#:>>2 -=A]E#;2M4L.]*4I_2#ZRM1 "2F
MQ*6R200(4HQ(,$R!)BO&/M7*M1_VC?9]8[%/#2]%LM1;85*FU.V[W:+4CN0F
M"4K79VP= 4E10A.TI(W5HRK-]L#GK :NH:>.3Q)\R-R$]^_FI0"2!Z GN.W/
M!(]6_J74>%]"N)@A,2/\0 ZQ](SSUD*>8.6SCPA2DJD@<%1P)(YP,GZ7.C>'
M;WE(>R2B:/8A"[.(V #P1V=="E<GUZ KMZ\=SJV=2AH^)YE(,1O>0DD_-0GK
M\\15VV^I21^H=61&[8VM0!Z< Q\^O%<I.[NWC;?4[DM*4*0ZZ S/CO..!MM;
MJPTVR75K5T-N*2A*5+6H!#:5+4E)I.[&T]XI]KNR(W)<00 .5849@#D=!\Z%
M:E& R]/'B0I.< %6Y C.)/I\[/E[]X%'D(CP77K.2ZZ(S+<4=9?D.K6U$8C@
M<.ONSGVUQ*]++2Q/E-NL15.KCR SKE[VIT&P4.]OD&2@$-RLJ4XHAL(V\EP@
MA'[^0D*@U=-V=\[.RT<P2DR0 -@!7)) &T&5?NRG=$U6:'/)65M1)-;4.Q:F
M;7TUO%M7H@7%<J,AR=>$U=JPOXEDS(DG,VGL:08:'UO63<F2R%TE=9W,75KG
MVGZ"V#]G9NGBIUIEI000V3<H>=94I0$A(;8>6L),!("@=HW5=?H;425@I924
M(6=LF0M);.U7B_=6H\CA,Y@&VMUMS*G;:14U4VJGSK:W9>^*FM65<J+3R*N]
MR+&\HB2JB/ ?L_/QF?C<F:IR:[6Q[V@D0;VC5+JYD>8[HFI>VRZ:<+>F:-;O
M$VKCK9?=?4ZVY#\.%I ;"DH"$RDK21))6!67'9QHIW./N;D*]T%L[B/"D>[C
MO5$)!!("H!]=:^^%Q9Y=CD>ZOW;4O4UNN% 9++*Z^/8Y$7KJT@ONDH=0F+4,
MT:JE]I+B7XBC%D@28KCAX?>W^JZQ>W.KZLZ]<7-XIH%QP;$)#;*5!+;2E+<:
M;*7$]TA2C*05A2MTUM&EMLVI-LR $K27CMF2E,-;SSXE+"MR8 D$B$E,8IZM
MJR]-*5M?^RKSJ7A^]=-;1'2R_C.X&T>9QE!Q8\N10Y<EPN\I((ZD):Z^DI/R
M'@=P-;+H*E.,:K;'+;EJI?&4K2AP I/&4R((G]V(KR9_M.[=+USV0=J&1MO-
M+[4.(#DP"AJZTK44-K,;BCO+,I@*'@== $J21_503^$?L'^FM:KUG^?SQ7[I
M2FE*H.4Y1CV$XU?9AEMQ Q_&,7J+&_R"\M'T1:ZIIZJ*[-L;";(<(0U&B167
M7G5D]D(/ )X&I''$-(6ZXI*&VTJ6M:C"4I2)4HGH  2:F0A;JT-MI4MQ:@A"
M$B5*4HPE( Y))@5X[WMS+[[2#QK9-XK,@A3H>Q.S$L8AL/CMBCRVW5U3OQ=;
M/E13RDV;DF6YFUZX%*=AVD_'Z=+\N%3MI3Q&]U!7:35GM06A?V"T4&-.2J D
MI0"5N*3D[W5*[PP1 #:22$ 5UZTL4Z#I3-@E3:KZ\2;F]6B5+0#X$MI4"  D
M$(@@@^-4 KFMC.-XM9Y/*^'@-I1';*1*FO$(C14J/ ZE$CS73_8CM=3JOQ=(
M0%*$+JZ:M$PX25$#:!U)'[4#=\8@@U4L;"XOW EJ$($A2E(41X>B8(&8QY1Q
MD51-\/$SLMX0J<P9:QF6Y\^('H&'5DEA-[,0]P&I=Q,+<J/BM I8"TNO-/29
M2$K^[H%FZR\6]9NKY3A)68"L!")DC&,E6W $DD\XGBNS=B?9WJ>M.$:>ANWL
MDJ N]9N4*[I*]Q_5I3X2\X@> !HI""G:M04).C[>?Q$[W>)RV4[G=^Y!Q9$A
M#]5M_CWGU^)UG0?T3CL4/./W,]')4JRNG9LE#A6(?P<8I8&-4I;A&[PID'8D
M&/\ M9SZGZ""0/3W9_LAHG95$Z:RA^]4@=YJESM<N'%&.\2@*2$--J(@)2B4
MI)E94=U4;&-OT_HP6>4@IY/0.3R2 .P/)]Q[^O[- E(X_,?=(^ZMC+RR %*"
MH*R) P"0=HB(2F! ''7%9#8OMZE?EI#'*OEZOE'8=NY]!Z)_/\_7G4BEJ"1'
M,YZXSQ'\2.*QKKQ(Y3SQ/H?SZ9J<JG!X,1MLNI3U'@=*4]_4>X]2/;_+5,E1
M!! $YZ$GKSQGUX^=8YVX7X@# !F?03\OY<D361F$XC5QHJ7%0FE+"0H*6GJ/
MKSP#SV]>1_'61LFTE(*T=9DC.3/^D9ZUI.L:DZ' D.$;H2-N0,"3U]>9@\5?
M-C.CU<;D(2@ >B.P Y'MP?V=_KJ^>6+=!*=H',' \CP1/$?AG-8JT9=NG3*E
ME,28ZD#(\L@<_(5']GF"B.EI3A41W'4!QT\CV!'([D=C['6->O2N V,2J3[H
M,QP)S!!CH/G6Q6^CMHAP( 4<P<^D2K,3D]3]QLB5;39*^LONI]_E<4GO^X^G
MOW!(//[-6F]P\N*D\P8'P \OY5FF;=ID>%"<\D@*_$?GB:BW/L\O,5^Z6JC#
M[C,IMN[8CRHE@Q!CQF*R#\?)=E39*'VT/+9"TP(JT-F<XAQ"'65-A+LLJ4H!
M1)!/GY"9DGS&!)GCU-[;6Z7E25(0V@PHJ &3(24CDRJ!B<$SGGI8#NOC&X)E
M1(7QM3D-<GJM<8NHXAW$%/H9"$)6['GP O\ 1?&P'WVD$H^*3%6ZA"F)(!)@
MB9'F!Q!CY@D<_"JMQ9N6_BD+;,;5(!R./Y$]!/7I*R(4E:.L,/*3[*2GD$=O
M0CGZ^AX/Y:C"CP"?@DJ^X?,_*K(N-C!4"?10QQ@B)ZU\C'?2"2VH >IX_/C2
M9IN2>%)/S%?/H7^JK_"?Y:A(\Q]:C(\Q]17YTJ_543].._\ GJ-)'[P^M?81
M9"OPM+5_W1S_ *?3WTJ!6D<J \\B:^R8$M?X([O[T\>OII"CPE1\X2?XU27<
MM)B"#\QCXG%?<45FX./@'E@\@CHY!![>OY_]?E#:XOW$D1SN3B/K^%4S?6R,
MK=2B/4'ZD*Q\_EQ5OVNU]G:M+5&K'NL(ZN $GGJ[]@I7K]>>_P"?L*Z;5\0K
M9^SB08&[U)GIY@??51K6K(*.ZZ:*1(\(5/W*(/'7US-8QYQML_#6ZU*C=#@Z
MN$*"21W6 #P#W^HY]NVHPM!V+$*3A0 .#$CGT_$>>,[97S3^TMJ"D_LJ (!B
M00=V?/&(K#/.\?M\8NZ2TH9LZFN8]@F;56E;)?@6,&97NQY#4F)+BK9?8<;*
M@I#C:TJ3R1W2H@[+I)*=![1%!@[]/S/&7>.L1$1BN/>T<-7'M6]B;-TTV_;.
M-^TUMRW>3+:T*T#1UKE.%%1VD A708!S6T78#[3"9408.#>)RC<O*X1V8:-R
MZ2O;D25,(;2A"\PQEEI*9BT*)2[;4"3)6D-E5$_(#TMW!(?+3@45E)5RI$%)
M _>2!((SD$S/NC%5^TWLE3<!R[[-=W"P'W=.N5!4I/B/V1U0$  P&WB2"<+C
M V/XNC9C>2M3?;2;@4EQ'>;#RVZ2PCV@B]7"@U84SSL:ZIGN#P8TY$9UCI5U
MQ00$G*L:N\@)0N;A!,A8C<.IW&>/2)^!Y\_ZOV(N;!Y:+JSO-,?R BY84TT>
ML)<\3;D<G8J/6L<V-L<@3XC,Z@PG84Y<+%-O2XM+RHX6F5(S5;(0E]L +2&%
MEP%S@ IZ2L\G6XW6I6Z>S6B.*W JU'6FRF<B4:6YY=%2F>"!QQ7"=%T.]5[5
M?:*RP$O.,]F_9NM<'!2MSMZ$J$$@#!)Y'/7B6;G9&\NIV/V-E12GYF*VSEU1
MJAY&N"F-9.UEA3N27XU?<Q(]FVNKL[&'\-9LS8ODRW_T'4LJ&%;U:U&Y(=V=
MXG8L*0%>&0OWH,92#@#('BKHKF@ZE 4;92E-^-,+VB<IYF.#!W2,D0>*B:5X
M2<*CY#MQE:=J5P+S9^MO:C;.91OW->QAE;D\5,+(XM) H;-BL8;O8B&V+1:X
MCBYK;;/Q*UAIHINOTNC:ZW]L)3<J0IU*D!7>J09;4M2TJ5"28&0 2>A,V2M%
MNTEM9LMJF$J#>U4]VE6%!(0H"3P1!)]:L7&_"QLYM\U!K<<PV[QN%69';YA
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M0E2T(VE"%K2D+6E)2@A*E$>!&/ F(I8:200G*5*4F5*(2I4[E)224I4=RI(
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M]I9FX[/:E[./:79-%;W9K7V[2YB8<;WIU2T:=*2DAE:[&\MU'< 3=AOES/\
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M=4[M(0]N6/+E/ $05#KR8!CU@U"4:JWHVWXC8GF5PFMC@(:I[MMN_KV6D_\
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ME(!!WYC',\^OG_/SJ([G".CJ4AHI4.Z5-CA22#RE8X]"D]QSZ$=N/74I0#R
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M(QU/5/8MV:MK@+LW?:,;&^M[6^M5/>TSVK?J[>[LN\VEQ/:XO;FW5>[LW%Q
M!2)J2-F/"OC57N-DEZO.KR>Q%M%5\6+<1F[GR(U;$:99C)GNRV9)Z9;]A,+3
MJE--JG*\I2DDE60U\-W-EHC:W6K<-:8S>+#+-O;-.7-^XKO+@,VC3+'>I94F
MV+B4;U-MA*RH<Z/[)-*T_0M=]JNL65O>W]\]VWN^S"'=8[1:WK][9Z1V2LM.
M8L]+8U+M!=ZAJ#EL[J>J:YJ;=J[>J88>N77FT-H?;*L^+#9^/.K'3"OH3P0R
M74LNP'V%$("E*2"%NA/"4JZ2KI2I7RI) "CJ+NAI6@EFZ2L<G<%*43U5('H
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M"!&WUP3@_+/IQ66U5N'FG=OB=:!6OJM?)) ZP1)@>7PN]CMO1D?'_P"P,/\
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MMV0YY;3:6T%3CBE)0E"2I1Z 5)S#5RJZ?;MY4XZXL(:025+WK(2E*4?M*68
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M' ^?G\NHJ \GH1TND([GD'L3Q^8'MSV[^OKVU720.2)(GD23/ESQP!ZUD65
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M?R/8^P_/U.H('C 5TW0?,00!QT,?7B*O&')6$X@ YR)A.#GGC(\XZ5BSFU6
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MKHKMC6G4IYB)/Y^4">PYY_">3QTCM^W5""2=Y!'.!!_'TQ/T'%%7C38W).9
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MA(,(')$]5<C<K!)D0('05[4[+=FK/LKI(MF2W<:B]#NHW03M=<?' :68/V5
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MDH2ZF!&<'SHK89Z')LI!_K#R2$D\Q&]=EM;>Q[ :$J]N"BXUBY:2$(,!9N5
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M!2#'3X])Y^<X^5=QO:9OT6\![\J=2/H./;W^NH[8&=V?@(Y]/Q^GG25VG42
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MDY@)22(S!$5,M9]F5NTM*'+S?G&:U? +J*?$+6V2.?7H<G75+U\#D?,VV/\
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MUCRU_&S!(39QK.RX'VRL=4;UE^YU5&Y%PHIL[ALJ4PIA!5L:05SW2VD%"5H
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M*4\D%:TCE6KANVL4$EI*%*(X)*Q$C$*) ^4&L<YJ&I.Q-PM'6&PEH'!DPVD
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MEQJ^'+GS'VXT2%&?ERI+I"6H\:,TMY]]Q1[);::0IQ9/8)23J!( ).  22<
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M.P;:<6!^C6M!2%=N1U\IY]1P"E)'(]>1J@<**>8ZC(/'!^?XULSMBZV"?>$
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MD()G: <81G:*\H>TKL)<:!=%I 4Y;.I6]I5VE$]\@G<Y;O$ ;G604HSEPD+
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MK;+%RZ^5M(Q+K)22H*E.02,;8CWDY*1D0K@8$B:]"]G.V6@]J0+9!5INJEL
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MI!XW)(4GQ1(!,X)JSI,F1,D/2I3SDB2^LN//NK*W'%GU4I2B2?H!Z) "4@)
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MD:$ZGT('4W+6GDCIY('/H"2-SB1/GG'7'X*^_P",Y2P)4S<-&(4VZ>,X0HI
M_"!GZS4L9RR5U@4!SPA?IZCL3W[< 'GM_#WII$&.!N,$\SU//$3/Q'PJPMSM
M6I(/A\(/G, $#IB((/!QS6N7=V/R))Z2%#S%#L .4DJX';UY/('H!^8YU<<
M>6"3T'&3QZP>GTC9+5(40G]Y)2<=%)*8!\X//P%>B3(K$W^&[3Y0HJ*\BP"B
MLU*5P2HS:JLLN>H<<][$GD@<DGMP-;5HZRI%P#T<!$"/"O<H$SG.8/\ *3X
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g805799g20m10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g805799g20m10.jpg
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M 0             " 0,$!08'"0C_Q !<$0 " 0," @,("0\)!@8" @,! @,
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MBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4K[QO\
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M'<N#V'<,' ).#G!P 3R]H$T%E>-))"+2Y,L6WI8A!*9(M[*J=(@3<F]G15W
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MNB"V14Z1/<C%%*FW*-@1(A ,)#%97<ALMR!!'-<8R<#EBISSP2!]LB$M<22
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M%JVDVJF\33-6X5N[1KNUUB5&N'NP8GM;[2[WH)6@AU4V,+2(MR#5-Q[.0.<
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M>)EDVP6#RX^48*2A)"NE6!0E1EU8\NB2MZ&T"<L,GW,=#7PJ$[%@-.M2&R[
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MEM^'M,X6A::^NKL)HNCS74^G6H6YDD4M;2WMTRS$&5EF,;NT:1)'7';S//\
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M0KE+F&*<^"=)DCET^RA:16:"*VEACD4PE'=EQ(SJS*V<)=EO9=U;TZ:-<6Y
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M'>PBY@UC_P#]_P#'_P#K/4?]>[_\UP],4IBE,4IBE,4KREM7^)['_P >,?\
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MY/\ 5JL7FF:=>1->Z-X]<,Y?UL@"LD00HH"='J=ZZ!AP&5E73Y*.")SS%7K
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M,@'H& >Y:UC)==KS(\JN.0+*H6)F#%<MD*!GG5,\Z]E1K?0KDHG61-O,UWL
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MXQ&T4C)'$RAG26:1^8?.#TS%=P.'9VP"QJ<C_ ,VQX)AO$0C>XSUCK]\MO0
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MT8M-D;<U(>=O-9CPPEJ94[\%.CQXQ@BQ(T+'[C26>9<;9'&T*HP>P(VY!_\
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MC<FR$[T,G,2&R(BVD#\X@9F'Q<R&3D$B1.8[)4^2G+D4Z63=NWMNVA,DYZ@
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M>ZG#G71T,Z"Z!4?'[FOD$Y0R#L^A(;BCCHF\'ZB LL?4\T]9J*1D$Z(*KA6
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M(21K\8Z6F3"AE@5)B-DR4N5.FI?E2'G5NED(93(^UL%EWMAB!@%AG!P.0SG
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MQX4*(RY(E2Y;S<>+&CLIVMU^1(>4AIEEI"5+<=<6E"$ZVI2M:UO>9W;V5,D
M9)  [2>0'_.NQBJTQ2F*5U]RXB9:("I,?4YV.[+;A[>;U+<B,.,LOR41]J]^
M7'9>D1VG7DHVVVX^RA:M*=1I3_7^O\#3(SC//MQ[>/=KL8I3%*8I777+BHE,
MPER8Z)LEF1)CQ%O-IE/QXBX[<I]F/M6G768SDN(B0ZA"D,KDQTN*3MYO2G^O
M]?X&J9&0,C)S@>V<=N!][(S^&NN@N*=)OA&R8]PS%B,$)0A$V,LG&@27'&8T
MU^ EW<MF)(>9=:8DN-)9=<:<0VM2D*UJN#C.#@\@<<B1VC-,C.W(R!DC(R >
MPX[<??K(92JTQ2F*4Q2F*4Q2F*4Q2F*4Q2F*53M)_2QVW_,<[^R69,OVO:_@
MF_:5S.E?=%Q5_:T3Y.:KBS&KIJISF?\ CGR'_>V _P# O%<R9_L-G^(D_P"J
MN*YG0OYVXT_**S_[1X7JX\QJZ:F*5C%F@S:UMN%AC;C:E(6A<^*E:%IWM*D+
M2IW2DJ2K6]*3O6MZWK>MZUO62V/[UOS3ZJL&ZM02#<P @D$&:,$$<B""V00>
M1![*_/QZ$_;(K^(Q/OL;']ZWYI]54[[M/*;?TT?SJ?'H3]LBOXC$^^QL?WK?
MFGU4[[M/*;?TT?SJ?'H3]LBOXC$^^QL?WK?FGU4[[M/*;?TT?SJ?'H3]LBOX
MC$^^QL?WK?FGU4[[M/*;?TT?SJ?'H3]LBOXC$^^QL?WK?FGU4[[M/*;?TT?S
MJ?'H3]LBOXC$^^QL?WK?FGU4[[M/*;?TT?SJ?'H3]LBOXC$^^QL?WK?FGU4[
M[M/*;?TT?SJ?'H3]LBOXC$^^QL?WK?FGU4[[M/*;?TT?SJ?'H3]LBOXC$^^Q
ML?WK?FGU4[[M/*;?TT?SJ?'H3]LBOXC$^^QL?WK?FGU4[[M/*;?TT?SJ?'H3
M]LBOXC$^^QL?WK?FGU4[[M/*;?TT?SJBUT$T'H-;GU*V389  3<'.SX42SS0
MCDGXK)PR\5ER>"*C"7P54V!&U.A)EIB%(?OXPFQ+&3)<1^2B1&#*K C."4SV
M@CL(([#R..1YCF :B]Q92*5>YMRIP2!.@["".:N#VCF,X(R#D$@R5DQ7H[33
M#!0,PPPVAEEEF;!;:9:;3I#;33:'4H;;;0G2$(0G24)UI*=:UK6LCL?WK?FG
MU5+ONT'9<V_IHOG56MIYUR.YV>'<3ZT.GXHAJO27QE[L=?@GZZQ,F3X]<N02
MO6,6#O5=CRR1-Z.!N8T\)8V5+):AH04()DS4RJ"H4X)SS0$@^ZI*DH>0YJ03
M@<^0JVTUB[!VN(-P&TD7*J&7).UPL@5U!)PKA@,G YG-G?'H3]LBOXC$^^R&
MQ_>M^:?55SONT\IM_31_.I\>A/VR*_B,3[[&Q_>M^:?53ONT\IM_31_.I\>A
M/VR*_B,3[[&Q_>M^:?53ONT\IM_31_.I\>A/VR*_B,3[[&Q_>M^:?53ONT\I
MM_31_.I\>A/VR*_B,3[[&Q_>M^:?53ONT\IM_31_.I\>A/VR*_B,3[[&Q_>M
M^:?53ONT\IM_31_.I\>A/VR*_B,3[[&Q_>M^:?53ONT\IM_31_.I\>A/VR*_
MB,3[[&Q_>M^:?53ONT\IM_31_.I\>A/VR*_B,3[[&Q_>M^:?53ONT\IM_31_
M.I\>A/VR*_B,3[[&Q_>M^:?53ONT\IM_31_.I\>A/VR*_B,3[[&Q_>M^:?53
MONT\IM_31_.I\>A/VR*_B,3[[&Q_>M^:?53ONT\IM_31_.I\>A/VR*_B,3[[
M&Q_>M^:?53ONT\IM_31_.I\>A/VR*_B,3[[&Q_>M^:?53ONT\IM_31_.I\>A
M/VR*_B,3[[&Q_>M^:?53ONT\IM_31_.K^Z.!5;TE)@6I2MZTE.B$3>][WOVM
M:UK3WM[WO?\ NUK7^_>\;']ZWYI]5!=VI.!<VY)Y ":/)/N>RK*9&LBF*5YW
M>R8_H(J?[VP/V.ON;71_MF3\0W[2*O%N[K]R.G?E'9_)FKUM=X[?J_<*_<YS
M'[$A,PKO[;NO[Q-^T:O0N"?N,X1_)C0/DJTJX\QZZ>J4\E!,H]X[=X!0!$VP
M$#?'.EAQP,:+E&R)@B3IIF"/&P1,&/+ED)<V8^Q'CQ8\9YUUUQ*4HW__ %<B
M.)8R2 !(A))   8$DDX Q[M6;@%H)@ 6)BD 4 L22A   !))/8 *\\8-K\PJ
M7%J WF ;HTH56 7+JE6>6G>0PQ%"E(F^'70R;L<_9I7/AMJ$00_?@'/Q),MN
MZC(==(%) (^XF!.:AQ<K; Y8N4!)9C()"6)[X0<E#D?8BQ VG(&1SYU@!KM
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MEW 7HF=IM;/'N3SP=$;C3+<G8FZ$PP>H<ZM%0H!E-_%/0 H0I42YV^U L26
MF5[JA>-82\"O6G2+=$%*X9@'!;LYJ"6=6<;#DD, K 9R@P";\<EQT=P760LB
MLT1"#+<G*JD;)&W2#"J48NI.TK*P8A=5K#USS=F5>_R:U([A$+U.@>7-BI6H
M_CWI]V[VZG@^&V[QOK1'5JX& DSH]GEV#I%.T@76*84L$* 4@R$#;@#T2@7@
MEON4$1X9H%;,OL0S2+*1ME(& $;)9@,@^Q.#CM+>%)"IFW*ETR?^']FRK"\"
MD- N=VYTY*I;!!PZY%S\U)=3NOF+3K=T*J]*$2*?7O./G+B)_+2@GFH6HD>U
M<'(<#( .B;ID6,:?Z1R"G1;:6:FW8U\"N.K37G!]=)B-U^';<(L!5"AR;=^4
M@+EA'*)04W'&V1L#"C*X;)!S5V,RO=H\BR*46\C(,9$80S0F K(8QNZ2)-YZ
MY"N74@,,"D^BD>_\PG>1EXYM6^T&>C%>N=X*T$\GA#5O4^!!\CXU) U,<3B\
MDL-D53[T>J40**BP6A]>MSW/H,=/00UB$!85NF@C<1*[1A D88=)MYF23+$&
M10&4')SDKO)V%2=MAS/&;AXUF+F6<HW0;^J(H2J@B,OM=EP% "OT?LU8+OM(
MW;O*4[U:./G?*W&YF$\DZ-.@V2FT*6)@S.5R3?:P\BL6*IG>3QK6I @FUS=-
MALHFQ=#IYNKPZYT1TMSM)0\#9B%A"9'1ES"X(9\D/MC(((DV\P7P"%(?<A#8
M!JZSW)EP>EZ,3H0R)@='F4;&1H@_(]'N8-(A4+)F/+*/4+,.ME3%*8I3%*8I
M3%*8I3%*8I3%*IVD_I8[;_F.=_9+,F7[7M?P3?M*YG2ONBXJ_M:)\G-5Q9C5
MTU4YS/\ QSY#_O; ?^!>*YDS_8;/\1)_U5Q7,Z%_.W&GY16?_:/"]7'F-734
MQ2JZE\?Y)/E29T[EW.ILV;(>ES)DNDUF3*ERI+BGI$F3(>&+>?D/O+6Z\\ZM
M;CKBU+6I2E;WNZ+B<  32@   "1P !R  #8  [!6DDX:X<FDDFFX?T2665WD
MEEDTJP>221V+/)([0%G=V)9W8EF8DDDDFNO\BG&O5)S+^0JK_I65[XN/AYO2
MO\ZH>*O#'FYH/Q/I_P!'I\BG&O5)S+^0JK_I6.^+CX>;TK_.IXJ\,>;F@_$^
MG_1Z?(IQKU2<R_D*J_Z5COBX^'F]*_SJ>*O#'FYH/Q/I_P!'I\BG&O5)S+^0
MJK_I6.^+CX>;TK_.IXJ\,>;F@_$^G_1Z?(IQKU2<R_D*J_Z5COBX^'F]*_SJ
M>*O#'FYH/Q/I_P!'I\BG&O5)S+^0JK_I6.^+CX>;TK_.IXJ\,>;F@_$^G_1Z
M?(IQKU2<R_D*J_Z5COBX^'F]*_SJ>*O#'FYH/Q/I_P!'I\BG&O5)S+^0JK_I
M6.^+CX>;TK_.IXJ\,>;F@_$^G_1Z?(IQKU2<R_D*J_Z5COBX^'F]*_SJ>*O#
M'FYH/Q/I_P!'I\BG&O5)S+^0JK_I6.^+CX>;TK_.IXJ\,>;F@_$^G_1Z?(IQ
MKU2<R_D*J_Z5COBX^'F]*_SJ>*O#'FYH/Q/I_P!'I\BG&O5)S+^0JK_I6.^+
MCX>;TK_.IXJ\,>;F@_$^G_1Z?(IQKU2<R_D*J_Z5COBX^'F]*_SJ>*O#'FYH
M/Q/I_P!'I\BG&O5)S+^0JK_I6.^+CX>;TK_.IXJ\,>;F@_$^G_1Z?(IQKU2<
MR_D*J_Z5COBX^'F]*_SJ>*O#'FYH/Q/I_P!'I\BG&O5)S+^0JK_I6.^+CX>;
MTK_.IXJ\,>;F@_$^G_1Z?(IQKU2<R_D*J_Z5COBX^'F]*_SJ>*O#'FYH/Q/I
M_P!'I\BG&O5)S+^0JK_I6.^+CX>;TK_.IXJ\,>;F@_$^G_1Z?(IQKU2<R_D*
MJ_Z5COBX^'F]*_SJ>*O#'FYH/Q/I_P!'I\BG&O5)S+^0JK_I6.^+CX>;TK_.
MIXJ\,>;F@_$^G_1Z?(IQKU2<R_D*J_Z5COBX^'F]*_SJ>*O#'FYH/Q/I_P!'
MI\BG&O5)S+^0JK_I6.^+CX>;TK_.IXJ\,>;F@_$^G_1Z?(IQKU2<R_D*J_Z5
MCOBX^'F]*_SJ>*O#'FYH/Q/I_P!'I\BG&O5)S+^0JK_I6.^+CX>;TK_.IXJ\
M,>;F@_$^G_1Z?(IQKU2<R_D*J_Z5COBX^'F]*_SJ>*O#'FYH/Q/I_P!'I\BG
M&O5)S+^0JK_I6.^+CX>;TK_.IXJ\,>;F@_$^G_1Z?(IQKU2<R_D*J_Z5COBX
M^'F]*_SJ>*O#'FYH/Q/I_P!'I\BG&O5)S+^0JK_I6.^+CX>;TK_.IXJ\,>;F
M@_$^G_1Z?(IQKU2<R_D*J_Z5COBX^'F]*_SJ>*O#'FYH/Q/I_P!'KD:XSQ]A
MUM]CE/-F7F7$.LO-46KMNM.MJTMMQMQ O2T.(7K2D+3O2DJUI2=ZWK6\=\7!
M[9YO2O\ .JJ\+\-(RNG#NA*RD,K+I&GJRLIR&4BW!!! (((((R*LG+-;VF*5
MYW>R8_H(J?[VP/V.ON;71_MF3\0W[2*O%N[K]R.G?E'9_)FKUM=X[?J_<*_<
MYS'[$A,PKO[;NO[Q-^T:O0N"?N,X1_)C0/DJTJX\QZZ>L:9,B:Z()GSQ*$'"
M!H,HF6+$I+4,>-'065R)DV;+?4AF/&C,-K=>>=6E#;:%*5O6M94 D@ 9)(
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M:P3]0U.@QI@$!*''5[0IN&#$EK,!BEC$U<<:*^,X\@A*C1O?'D52*20$HC,
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MQ(&21S5^C8$$9&'ZISC!Y&L#5_*:KDYQABW+I]"B #WD.*)Z,7A]\T\+X%?
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M3<8);@TM,>PP!<.=(T7$"YTXY7; ,&1:%T4LV!@@8SS.20"/:894^Q)(Y$@
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MMP.HV<#-],I(^VLU ]+DB4OF;,.E+FBY-?BUFHGQL.Q2RJ8RQSUXRC1[2 <
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MG%TPH$I$EA+"[MR2H%HK,K4I,*.P\#B^]5]D6*&5%Q( %PF  .:\\!'C'/\
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M%W;F29;B.26!HD$FZ19HHI9(2@(DCCD="RHQ$^DCR!TB9(! W+DA@2I SS!
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M(+*S"56VH )"X&QR W5((YCGCM!)+&J=ZS;TZJ%%:!U#2,QB5"W21@E#N!#
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MA*217)W6 WG\[Q3HQB9%)6TG!&TDCRF!*O,Z.GW#U9@EC!5-G7 4,("@AC!
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5:WD:ON@L(G.$E<;2Q4[LD$@$?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g805799g23k01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g805799g23k01.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2J:4&AO=&]S:&]P(#,N,  X0DE-! 0
M     #P< 5H  QLE1QP!6@ #&R5'' (   (E\!P"4  @4&%T=&EY86=E(%-O
M;F%L:2!397=W86YD:2!!<FEY87(X0DE-!"4      !#U@A_]^E9@I)%RH&QY
MSVWH.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #P     $  @/      0 ".$))300F       .
M             #^    X0DE- _(       H  /_______P  .$))300-
M   $    >#A"24T$&0      !    !XX0DE- _,       D           $
M.$))32<0       *  $          CA"24T#]0      2  O9F8  0!L9F8
M!@       0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U
M     0 M    !@       3A"24T#^       <   ____________________
M_________P/H     /____________________________\#Z     #_____
M________________________ ^@     ____________________________
M_P/H   X0DE-! @      !     !   "0    D      .$))300>       $
M     #A"24T$&@     #-0    8              EP   -4          $
M                         0             #5    EP
M         0                         0     0       &YU;&P    "
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   EP     4F=H=&QO
M;F<   -4    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90
M !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O
M<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC
M     0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N
M9P          0G1O;6QO;F<   )<     %)G:'1L;VYG   #5     -U<FQ4
M15A4     0       &YU;&Q415A4     0       $US9V5415A4     0
M    !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0
M  AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI
M8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53
M;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0
M !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M        "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_
M\        #A"24T$$0       0$ .$))3004       $    "#A"24T$#
M   ?_@    $   "@    <0   >   -/@   ?X@ 8  '_V/_B#%A)0T-?4%)/
M1DE,10 ! 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C
M<W!-4T94     $E%0R!S4D="               !  #VU@ !     -,M2% @
M(
M    $6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0   'P    %&)K<'0
M  ($    %')865H   (8    %&=865H   (L    %&)865H   )     %&1M
M;F0   )4    <&1M9&0   +$    B'9U960   -,    AG9I97<   /4
M)&QU;6D   /X    %&UE87,   0,    )'1E8V@   0P    #')44D,   0\
M   (#&=44D,   0\   (#&)44D,   0\   (#'1E>'0     0V]P>7)I9VAT
M("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY  !D97-C
M !)S4D="($E%0S8Q.38V+3(N,0              $G-21T(@245#-C$Y-C8M
M,BXQ
M          !865H@        \U$  0    $6S%A96B
M    6%E:(        &^B   X]0   Y!865H@        8ID  +>%   8VEA9
M6B         DH   #X0  +;/9&5S8P         6245#(&AT=' Z+R]W=W<N
M:65C+F-H               6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                                     &1E<V,
M        +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E
M("T@<U)'0@              +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@
M8V]L;W5R('-P86-E("T@<U)'0@                            !D97-C
M         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y
M-C8M,BXQ               L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N
M(&EN($E%0S8Q.38V+3(N,0                                  =FEE
M=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:(       3 E6
M %    !7'^=M96%S          $                        "CP    )S
M:6<@     $-25"!C=7)V        !      %  H #P 4 !D '@ C "@ +0 R
M #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0": )\
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M>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^ 7YB?L)_(W^$?^6
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M 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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M $W]O_!_I?3K>E(IRGY62T95C&5O:&-:VO0.8U\>^MSOI*7IY7_<RW_-J_\
M22C4]IR\V#Q8P'XBMB-N;X_E26DFT?IY7_<RW_-J_P#227IY7_<RW_-J_P#2
M2)N'BEN;XI*LH_3RO^YEO^;5_P"DDO3RO^YEO^;5_P"DD3<WQ2W-\4E64?IY
M7_<RW_-J_P#227IY7_<RW_-J_P#22)N;X_E2W-\4E64?IY7_ ',M_P VK_TD
MEZ>3_P!S+?\ -J_])(FYOBEN;XI*LH_3RO\ N9;_ )M7_I)+T\K_ +F6_P";
M5_Z21-S?'\J6YOC^5)5E'Z>5_P!S+?\ -J_])*GD=0LHN92ZW-<;'FL.9CL+
M9 G=N]'](S_BEH2#W6%U/.^NM6?CU],Z5B7X3[7-OM?DNW>D"T5VO;Z='V7>
MS>[V5]3_ /2R0>([&O--D=8OQWV&QV7]GK:TF[94T[WC<*C5=15M=M_X5]N_
M]'Z/Z;']4F'U0Y>5]D9DY++@S>X.91#8.U['0S?['M<SU/3]'?\ X1+[5]8V
M/:78=.QT2VJSU/3^CN;ZKSBNR-^[Z7HT^ELN_G/T7JQ=E=:J#&LZ=6+'BQUA
MK,MT(<WAU?NW7V/V/?\ K5OJ^GZ'J^M6EW1T?3RO^YEO^;5_Z23XS\AN;Z-E
MSKF.JW^\,!!#MFGI,K6?3G=9=DU4VX(:TOBZP$D-8?</?.S=55^=^D]5_P"B
M^GZOH7ZO^4Q_X7/_ %:2A=O_T/54Q:UW(![Z^6JBVVIUCJFO:;& %[ 07 'Z
M.YOYNY!SZ,J^EK<6WT'BQCG.\6@^YO\ W[9_A?YK_")*0U_TO,_KL_\ /;5/
MU&;_ $]P]0#=LD;MLQNV_NH58?\ :\SW#^<9^;V]-D?G+!OZ;]9#]:KLVKK
MQ^F#'#QB.8Y[&PQM3K'5OV8G\\RR[^D>HDM.[TLI&1RN2ZA;];:^I]*RZ^HL
M_9+[VU9-;:/2?:W])D.>R@_:[-EM-/HU_I:+'_X.G_#+I<5I%3BQS=K[;'-(
M;((+S[F^[\Y%&C8248?^\/\ -_\ ,DH?^\/\W_S)!3)*2HP_]X?YO_F24/\
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M11<K W_!@_ZM]"K&YV-72/*RRL?]&UBR&_5_H3/K-]NPNHWXV><;8US+F6L
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M82T;*KGN>6?S3MMGLNJ?9^L=48]_Z6O]%TS_ $?Z$[NG?7.<BUO4:#:]CVT
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M &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '
M( !# %, -@    $ .$))300B      %B34T *@    @ " $2  ,    !  $
M  $:  4    !    ;@$;  4    !    =@$H  ,    !  (   $Q  (    >
M    ?@$R  (    4    G $[  (    E    L(=I  0    !    V    00
M(E40   G$  B51   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD
M,C Q.3HQ,3HP-2 Q,SHR,3HT.0!0871T:7EA9V4@4V]N86QI(%-E=W=A;F1I
M($%R:7EA<F%T;F4       .@ 0 #     ?__  "@ @ $     0   U2@ P $
M     0   EP         !@$#  ,    !  8   $:  4    !   !4@$;  4
M   !   !6@$H  ,    !  (   (!  0    !   !8@("  0    !
M      !(     0   $@    !.$))30/]       (          #_X0%D34T
M*@    @ " $2  ,    !      $:  4    !    ;@$;  4    !    =@$H
M  ,    !  (   $Q  (    >    ?@$R  (    4    G $[  (    E
ML(=I  0    !    V    00   /      0   \     !061O8F4@4&AO=&]S
M:&]P($-3-B H5VEN9&]W<RD ,C Q.3HQ,3HP-2 Q,SHR,3HT.0!0871T:7EA
M9V4@4V]N86QI(%-E=W=A;F1I($%R:7EA<F%T;F4       .@ 0 #     ?__
M  "@ @ $     0   U2@ P $     0   EP         !@$#  ,    !  8
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@! @%L P$1  (1 0,1 ?_$ !\
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M$IR"4Q ] C$J1VU='(D@W(<CLS4QYRITQ2F*4Q2L#7U7K!S</\0W.N*&XO\
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MV9L6+1%)LU:H)IHH()D23(4A0 +G=I&9W8L[$LS,<DD]I)K.JA0%48 [ /\
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MP\CR.?3S_O@US\5RF*5XF.0G0)S%( ^@!,8"]/\ ].D0Q7"0.T@?F<5^@("
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M/BV8NG:RSIP+=JF*[A55=7K*J',,RS-M#,2$4(H))VHOU57/8H[E& .X5$
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MN1B1^9102.L%R%(#-G,2E I2E*'04H 4 Z1'H  Z #I'I$?1_J(]/_G%;0
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M3D*X2.4IQ .L4IQ;$$Y2FZ0 PD()@#IZI>GH#/7THE.!F*$' R &(![P#D9
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M"Z2?3\R:/:(M#2LV]0;,T'<M("D+N1<HM&J2[M595-NB0P)EX3DD\ADDX
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MDJDF&V%3S',S=D*]^N.Y>-&21EWCINT1(43'6<KI()$*'WS&45,0A2A_J(B
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M&ANJ[;'3V*)$S*ZM_B)$\DS2?KKI/4FQZVJW9&&( $^LX65&43<$,@BCZ%K
MK1LS@G?E0.8ZN1^6<L,@]G(8[\_@7^)'EOJ=EK=MI^C7D,4.G".Y>6%8+AC?
MD2HT<C.LBKP89-C08!S*QD!.P+L\T_?=B;$X^T78!H*"+L*R56/D_"IM](5Z
MOO72CCL0D%GD?$S[Z-92T<GXTS(VBG_5!VW;E $3"N3(RQK*RLS<,,0650S
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M!,ZRZZZA$D44DRB=155502D333( F.<Y@*4H"8P@ ".9J^J9@H+,0JJ"S,Q
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MIQ=0&ZC[EVH<[<<RBEN7=AB1CGMQC<V-Q^DLIWEM8I+NRZ/<,&XL/%)X9#L
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MU$-/6%3%&^V.?@EV!D7!W&0OL?)Y)D#.:Y$)JU2'V9-[!&T33Q&69D0) .'
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MQKQL_8NF^DUVSMFNFY;.$5J?,JI*HK(F.FHFHF<BA#%,(&(8I@'H$!S/*""
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M%Y]FR/LN*<)_P^VGS4\3:_@O/LV1]EQ3A/\ A]M/FIXFU_!>?9LC[+BG"?\
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MIBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4K -$?+GR8_(TQ_"<YE<G=^O\
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M=XE[!<K%(ZR:M%=0R1O)&3;16@MI4PL9DFC7FK=WUG6_DUM46K1Q-$W6)\J
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M\*TNMKE,=IGAHU"$E#H*3CK:$UKEFSA';.U).'-5=MYI1'NF2)HU)DEBL)S
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M[#[GVOI;_P"#O;?^E]U_R?\ I_'_ ,OIRSB+V]'AQX_2_P#W:^=_8-YOX?\
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%E,4K_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g805799g24g58.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g805799g24g58.jpg
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M 1$  A$! Q$!_\0 'P !  $$ P$! 0            <%!@@) P0* @$+_\0
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M'>O;Z#ZIHM8H-7<ZU;/.Z!:.I1-!?N0[9-ST2[H$S"@=XHBT*KR&Y2&<K(H
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MX]>,J5X-*;0[5%4./OBERL[^OJLY"><P)&!&<4>1!TFLVC),RYU#%Z(4C)I
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M&];$8'8/P$=2Q7F2/[#>MB,#L'X".I8KS)']AO6Q&!V#\!'4L5YDC^PWK8C
M[!^ CJ6*\R1_8;UL1@=@_ 33KQ ))H;DOR21 (F29(4A"\O(4.X&8\@<O*/]
MN),[6P:[*)P,8\3A9,[:.2;#)275;I"(CBN&Z0-FL4Z[U(%!6).=4 %VJ_E^
MG=G0Z-?G+@^ET38EPX1<>XTI1%EFJ2BIV4H)SFYW*;DGY8H<O(8 \A0 /_3$
MC [!^$GU%%)ND5%$A4TB<O-(7\!><83#R<O*/E,(B/\ WCB3-'GNY?P0Z/\
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M5,/%F\JYAB"$@K)K0)X5XNU-*1UC923Z+EJRJUGX8\DV>LDG%;4]E0TV8#!
M+#) Y ]6 <C."I (;(."#+4J=)3%15;XPR%. 3S(Z\[<'&0P)!7!&<C,>->*
MBI(P->L=IJ]LIT9)ZCW9MZ=<2Y(9TG5H70<U582[LG)HF6?&F3NU+025J\M
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MEUI%9MRL0,!'IA1R 2H'#@9R<GI'()S@GL&)!H+L903EGIU2Q.2:E(TS3)P
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M'1@AOZ-6+"IAMBJ4  (S>J]<BJ=6J[48% S6#JT%$5R&;'4,L=O%0<>WC(Y
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MA%TB1P@?GI*<X2&YIB\O-,)!]Z<"F#D,40\H!^#_ (8F0.><T>^[E_!#H_\
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MD."B8DYY!(8#% 2CR,C&<C'7G(Q@]1SU<Y(HU35-$4JAK!F0T0C&J'7(9#3
MW[E((9<9&#D<C.Z:NV KYK&&@I@LD]Y19QYHQZ#YV!><(BU:"@"[CD A^7HD
MS\G--R_[(\D;TP6WKM'6=PP/O.<"6FRO!5IVYM+D5ZO]51-"KTM3K_JZ>S>_
M4?DJ>H]AAM7I]X191I!S#I-NLJW<';1CU<B#A'D%9!8R2!BI+) 8HJI'$IT^
M4.<4.4,%T'(NH)Y@%@,@]1Z_GA+*\JAFIVES45&9'*4*KA'7&Y&*H0K+D;E.
M",C($I)R'3.=-0ADU$S&(HF<HD.0Y!$IB'*8 ,4Q3 (&*( (" @( (9EU]4U
MR"I*L"&!((((((.""#S!!Y$'F#)VX:_A:8?^2=O_ /P_>\U;W]G;^TH?[BE.
MNX%_>2C_ -JXE_\ &=7D#YM3D(Q$^B$.H<B:9#***&*1-,A1.<YSB!2D(4H"
M8QC&$ *4 $1$0  $1QU=<D L0J@EB0  "223@  <R2>0 YDRJJU^>0Y.FA)=
M'G+';EZ6->)\YPFD9=1 .>B'*LF@0ZQT@]^5(AE#% A1,&(=#U,IY9Y,.K.,
M]?5D@?>9L-9W:8WVMRN6*#=0JKEU4NR#*C+! 6*]84%B, F4M--191-%%,ZJ
MJIR)I))D,=110Y@*1-,A0$QSG,(%(0H"8QA   1$ S+JZYKJK,RJJEF8A550
M2S,3@*H&2220  ,D\A.=)B]7>DCD6;I:04< S38)-UE'JCL5.B!J1J0@KF<"
MK_1 @5,514]X!>=Y,@D ;B0!C.21C';GJQ_&9K2JO5%!:51JS/T8HJC&J:F=
MO1BF 7+[OB[ -V>6,SZ/'2";4SY1B\39$=F8'>':KE:E?D3%4S(S@Q 1*[*D
M J&;"<%@3 3B0"ARXR"< C.,XR,X[<=G\>J2:-9:9K-1JBD*AHFJ:;BF*P7<
M:1<C:*@4%C3SN"\\8G3R95&(D[\.G_7ZQ_J(XHO_ *T[:S5O/ZE/[U8_[VWG
M7<$_^LWO^$>Z!_X'Q)((S:G(RI-(68D$R+,(F3?)*+F;)JM&#IRF=R1(5SMR
M'12.4RY$ %8R0"*A4@%02@0!',2R@X+*"!D@D XZL\SU9Y2^E:W-8!J-O7JJ
M6*!J5*I4!<+O* JI!8("Q4<PHW$8YSJ+MG+;H^Z6Z[?IDQ51Z=)1+I4@441%
M1/I"EYZ8*I*I"<O*4%$E"<O.(8 R!!ZB#]TJ>FZ;=Z.FY=R[U*[EW,NY<@97
M<K+D9&Y6'6#/PS9R5NF[,W7*U55402<F24!NHLD4AU44UA+T9U4R*)F43*83
MD*H0Q@ #%$8R,XR,CF1GF >HX@TW""H4<4V9E6H5(1F4 LH;&TLH92P!R 02
M.8G,TCI!^=-)BQ>/5%ER-44VC99R=5RJ4YTVZ9$2',==0B:AR(E 5#E3.8I1
M AA 64=9 P,G) P.WG\W\9G3HUJS*M&C5JL[BFJTZ;NS5&!*HH4$EV"DA1EB
M 2!R,^4&+UTY[C;,W3AYSQ3[E0;K*N>>4W,,3H$R&5YY3B!!+S.4#>]$.7R8
M) &20!VD@#\9"4JKU.B2E4>KDKT:(S5-P."-@!;(/(C&<\NN=\*Y81?H100,
MR,HY3,LVC0BWW=[A(@*"=5!GT'="J9025$QTTS%*"2@B( 0W)&],%MZ[1R)W
M# /83G EW>-[TR6_>=UWQ44M3H=[U>F=0&)9*6S>R@*Q)52 %;/49U48J3<(
MJN$(U^NW;N$VBZZ+-PHBB[6*H9%JJJ1,Q$W"I45C)HG,50Y4E!*40(;DDLHZ
MV R,C)'4.L_<,CG_ !E:V]PZLZ4*SHCK2=UI.RK48,5ILP4A78*Q5"0Q"L0#
M@XZ&3*8Q$8B,1&(F;?"SQ:(</M:FXN5@7=F=P.R=>[FU4W!P1&-BKW7U7=/N
M["9*/(JI7KWJJS3T9,MDP5(]DZ_54G2)FA%S%\R_T\W;JRN$#4:UM7.,EJ3@
M5*17_P"=*X1&4]85JF"#B?5>Y_W1EX-L+JWN+.I?U+/7=&XHX>4.%HVVL635
M=,U6C=?]366K\/7]W;W5-=PJW%EIRNO1AR+JKVU^#;K.:7M6LI^5KB&^8,(:
M ?(*NI0>&6/G*PY;0L))LIF.+ WQHRA;*K84B.64593WV3Z5XN\9LG#'![?4
M=JBG717[T?<XP%-\R5 6=64[Z19J>PD%DZ(<L$@^A9<1=S'I[M]0T&\N;%>+
M[3O6SK(U2X\ Z-W8U*=K:5Z5U1%GK%*E:WQO5%2E;7YUBONJ/4I4GI?5WV_P
MWV+A[L.JX]&2B[? 7W8=PUS)15302I[OKZH<,]3<+R$-(%6=P4]?AU/=YUW)
M02D5'5.3DD&4; HPMA%C48I6]ZEVM<E6IO2HTZRM4/2#94O:@ 8<F6CT])0&
MW&HH)+EES4G5>).![W@R]X?HK7M]3L]8UK4]$KV^FHNFU>^]-X$TYWK6U8-4
ML[O6#P[JMY5KVAMZ&G7%=:5"S6UO32TV(KWMK5$[PMZMU'4ZM:X"\U#9EFMM
MF=24Q"RL!+I3]$I$)(R[)1E6(2327EK!7W*[.)DWLPO7HUN#+KF5:.8YO";%
M*WN$OJ]Q4J4WI5*"4T"JRNI6K495(+NI"HP!90H=CG8I!+<WJ_$?#UWW/^'^
M&M.T_4;/5M-UZ_U*^J5[FUN+.Y6\TC2K2O<TFI6%I75[F\LW>G;7%6Y>RH(*
M7?5S3J4$M,5<WY\]C$2<^%_^LMP\?KSU+_/U?S5OOV*\_NMQ_HO.MX _?O@K
M_%O#G_,64@]3_>*?^,W_ +AS97J'W#\IR;=9^\_G/C)D1B(Q$8B,1&(C$1B)
M.W#!_6(TO^L:K?YHAFK??L=S_8U/_J9UO 7[Z<+_ />]/_W"2"<VIR4RVX9N
M)4-$0NRXQZP?2HRA]?[%UIW(MT9:OOK4=R83NN[>YYZA0-#H0TC<X.R,D (Y
MF(F9&/*N@/1KH^??61NFHLK!=HK4:^1_66EQ3*UJ8_\ EN6DZ$\E9<SZ-P)Q
MUX(VNNV]6C5N.^#HVMZ%T;;1I_%_#>J4;O1=3<%@#;):UM4L[ZDF'N;:ZZ$.
MN%99/G-V<*%JLF[[#)ZNETHV<OT/*:MJCXAGI(G74R?8DGL*KQDM'OXYQ7)U
M.\7&)M]5?](9N1C!I0<D\6C&SN!M%*6U_32U1:RY2DRUW7ENJKT*T:C*P8.G
M14FINN,Y<L.9#T_?N^*NYWJ%[Q9>W'#]T*%WK%M<</Z?5!JBWT2Z;6KC6=/H
M7%"M0>QO!JVIVVIZ=6#%%HVBVE>H]NE6RU"Y[=NGA/E]8[HUG!1TO (2]\<6
M_43V)IZ!(1J[C:1,0<+)6ZN22K]%)_+1[\E2D3U]2//7IAQW[L.O5XC_ *05
M4[74%KVU=V5R*0IW :H=W.J'<4W4#XJD=(H8-O4=$13##9OZEQ3W.[G0>*=!
MLZ%S9I<ZP^I\-U;?35%K3J6^DW5I:U]2L:[5D6M<T:PTVL;-J!LKEQJU'OM[
M;_\ =CB@;OUO5=&Z\HETMFP]ALXK;?A%F=0-F+2'A*N[BX&X0E3EZC<[&:X0
MK4L8[L3VRV>MI:[,QO,G,,6DRZ*WK .)>^K:UGNJU6E3HT2UOT*W!)9G#/3>
MHM2DG1N=P38C].#2525&7POAZ-Q5H6G\):+I&JZCK6M4K?B3^>[KAJG22UM=
M/J6]GJ=IIUSINJ7QU.TI]!4O:M_?V*Z(:.K5[JC3NJFS3]]S<2V[]13>Y.*C
M9<8,A#);!W]5-ITM_/%;A-KZZ;[N>W>ZP!$VR:2:4S*]U56R-X5(QS@UJ[F-
M!_(.FZ:K_#O6X6UL:!PQI6E2WJ!"=HK&U%*D_/K5<5$+'YZ@; '5O/Q7PW=\
M3]T+7;<UK5=9XQT_B'2ZUX$[[?1$XKJZKJEF%IJH6YN.DTZ_2U4DBGI[T.FK
M5$#5;CV'Q,ZIM-CXLU8I\[CDN(AE=&5#G&L58A0UNE);JJ6RU#RY)5Y(335;
M;%?A9."V2A5B2;")?F8H0R,E6WCF,B\:-E<4TL P#=YFD:JEDS7*V[T?B[0%
M/>[,KT#4(+ $OBH QW-:X[X>U"^[HS6]6K07C6EJE+2+NG;WNS0UN.*=.UYC
M<BXJUKJF_$=G:U[/7%T\5Z5O5-)+9;BQJU+>W^;;Q>4Z:9\2*-?DK9!/+IHK
MA\US0)3H7#20L&QM3VC2,Q=-GS98]XLE7I>[%U7(R0ODUW<JZ?N8(LNL+@9%
M\T)I]139[Q384[J[K55Y$)1KI<K2H+D#>M+IPN" H&_:,8!:CW2=,NJ7'*65
M?4;2IJO"7!FB:/<%7IUKS6^'-0X4N=4U^Z%&JZV5SJPX?KU^E5ZEP]6I:"Y<
MN:U6GB-O:=JL[-4(:V9LZ?PVGM85VZRK,Z:K26ND-66S625172_HG2D5'A$U
MI\]2$Z+Z2@GKQ%P]173>N=^U2HBU=_(-<5WI*>16DSDKD?-N.YP/F#@$ \A\
MXXNN]/N[K1^\2E2M:\,Z!9:K<4B&IW.JVMA3IUV5U)6H;>B+>QJU5RM6O:5:
MJ/55Q6J=GAK^%IA_Y)V__P##][Q>_L[?VE#_ '%*6<"_O)1_[5Q+_P",ZO('
MS:G(1B)^E,8ABG(82F*(&*8HB4Q3%'E Q1#D$! 0 0$! 0$.4,0"0002"#D$
M<B".H@_,1-D.V.-2F;0UA<:Z_ITT6]VUOK'8*ME.\0(W;[\9T5SIS=MG123$
M3)P.S=>%C+ =H!1=I[#9%F7+E5HDW8)^-;Z;4H5Z;BHO1(:]'9C)-H:O?-LA
M/SO1K$ID\NA)4 $YGW'B/NI:7K^@:G95=-NQJ^HT] UEKXU5")QC2TBIPQQ5
M?JJDE;/7M%Z"]-,#I!K5(7-1VI*E!>29V[P5M)>WR5$UVI$G;6RH2.N',C7)
M#NEK2S2VP)5['2AVLZ<S.^T16P4%DA/,#%86^+H21IQW.O59D+R6WU(K3%6M
MNS3J+6"N,&IMI*&7*C-*KLK-L/.F:WQ0F%Z*;KB3N64[G4J^D:*UL:>HZ;6T
M.I7L:V^GI1N=9N:M"XZ*[8T]8TAKW1Z27E$BEJ=OHZF[J7=5KH:O96R]IZ.L
MO%K$[@UY>-CZVHTU:+-;[7,Q<(5KL:NRTK:[9+3 0TG7G< YEPN31^V482"[
MUI(51C8%ZP[-,,ZLWD)VRC0NDT]K>M2HUJJI3ITU9R:+JJ4U7<KA@O1D$,H!
M%0IT@"FH57R]=X@X3O\ NCVW$NBZMKFA:3=ZA?ZEJ-U;VO1ZW8W-QJ.HW%UW
MK7LJEG4N?YSIUJ;4:SU:=;3Z5Z]A4:YIZ>E>[O;>G%AKS96C;]0A<2EEV!:-
MFV*\)WDE-C:.L^6LNWKE?9^*<PS20FF2&MWK*7A[%7HQQ*2-ZKU[7G(U:<>4
ML[5J2NUL*U&ZHU<*E&G02GT72-5 V6].BK!B%)K JR.P44GI!3M%7)/J<6]T
M31==X2UC1R]Q?:SJ&OWVK#5ETRCI35VO^)-3UB\MZEK3KW5)-#JTKFVO;.@]
M>OJ]GJ[75!KNII1ITQK8SV9\-C$2=^'3_K]8_P!1'%%_]:=M9JWG]2G]ZL?]
M[;SKN"?_ %F]_P (]T#_ ,#XDD$9M3D9F=PO<5G_ "?:W<8UY#O)]\PN.MMQ
MZB(1ST+&O;@H,V:'7>2?*;GA 6+6EIN<7/MD2+A,.H^MQSUNHQZ95OYM]8=]
MO38,$!IUK>X.,E[:JNX!?_FE=*3(21M!<J0V)]0X [H?@99:G0JVU6\K4=3T
M+B?AL+4"4K+B71KLVS5;C_J[RO="U#5+>\IH&[YJ4;&C50T=[)>[/;G!TZFK
MX\F]73KNK#NZ!5I=5>HG7?(<.*,\I(R%<@9.-EHX*M>2K"_EGHIND(N54LT@
M@Y?ONKT6SRHVVHA:06NHJ=[-TE13A3>;=JNRLIWTL;5&064(/BC.1ZM/B3N9
M5+K5ZMUP_=U-//%=FVEZ=53?53@A+QJ]>QLZ]"YH#3]7#&M<5<5%MKAK^LM2
MM6Z!*=7OW/<7#).Z-V#JV+;2D1.-;Y;;AJV1B*BW2JJBSFE:5JJ;^;@)#NA6
M*FKPUH=L%^^@EXQM4YN62?QL2M'O"M8>*=O?)=4J[%74TJ=.NK5#TF!4NG(1
MUP&6D:U/"N&-15(+@C+7:IQ-P'=\):SP_;I7MKRGK&I:EH%>VTQ%T]FJ:7PK
MIXK75G6W-;76K4]'U'IJMHU!-.NKE:U"V:A5%.VK.C^*?0>N-24FG+T:Q)VB
M"F]I/K,SL+F(LFOKT2_:)GM</6]B3B*Q"6^+@;',2C:-D$XB6D;16:ZBLI!S
M+AT9KW#%S8W=:XJU.E0TV6@$*!DK4^BNDK#9N=Z;,BKN&Y5INY 90,D[/"G=
M!X/T3AO2M,?2;U=0M+OB"M?T[VI;7VBZLNL<(WNAU4O5MK"UU.WM+ZYN:="L
M+:XKW]A8H[6ET]0TNBHD'OC4:NUMQ[10<3,<><XT-.;RB7]A1CPN$AI.OWK9
MMDNM?$D6#=@XGW$Y.ZQG7%<CC]#(.*^F^2$K>MJ.B2UK<"A;4"%8+IUQ:LJ%
MC3%R]*BE-_C9(0(M= ['D'(ZW .I:<7<.-Q#Q/KZ/=46N^ZCPSQ9;UKQ:/\
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M0'R_@-3I 1#D_!Y1*7_O#D\GX1Y>LX2_:KO^[K_J#US^-OY9G[I<'_XCN?\
MC*T\HF=Y/SPC$1B(Q$8B,1&(C$1B(Q$8B,1/Z*7#, %X;^'XH!R 72.J  /^
M !0X$ #R^7\'_'/D%[^V7?\ >:_^J\_:W@0 <$<&@=0X4X> ^X:19R;LUIU<
..8B,1&(C$1B(Q$8B?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g805799g25m49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g805799g25m49.jpg
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M $@%,4IA$1 H#I[O9T#33X;,0"A3JH&;36V_TC',F(4OW2_.NVS>NHC(/9Y
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M"(>?,/AIM4&FSVT&O2@ZN]:VC4$/=F+.+T/+H\;;6\DV68[L.$Q"I<)1U*<
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M'RRZI@ 1(J=34 T#Z6HCTYZ^[EU#9LN9D !J2I1!#,'2-'U^N[N<\TIS>XD
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M)"@'/A'0=# .NOQZ?$!YZCY[=V-0YW]?DMRVM&Q5))5R\*F8#F0)ZZNGT03
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M2[BU3Y[7T'-C=DIDJHSMR&G,Q"FS0;V/=@!N]43.80(<PF-KJ(=-?=IJ&OR
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M.OMY[+BT*&S=9PX;-T$S++.%DDD$DPXCJJJFT3(0H:CJ8P@ !IS$0Y"(@&P
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M5E-.VM.?)V+6CFC[4C=ZR/0=\ZX,&=<G)"*R-*1\K2%BLW!_2A)1JT*\AX\
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MD_X'AO9?!3A_$.6C!S?9O#8O#JFKE2\).X#BI6 Q/$,2DGPOU?\ ARY<I<_
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M[Q7,0Z6<5 W^_KE#GS$PTK[%-SW)$Q*GW<3&DY#J30H++%'HF4P@8QN?$8=
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MI6+AFL[6560?(@JW$ZIS&%4X:&U, _1'3BU NF@\MF&:N[Y32H'.@I\P//6
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MWVWVB35?S='YYM-1HE+?.6;R4=$7<',FY:N6+9FF#QRJ54A.$JB:")B(*D4
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MD'@]X"73B#; M"I1*9CO_P 5-.?SAZ",KG?4#Z7?Y:M>,T2-BG E=GX#+&4
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MEK;%U 1\,[AD8)HN^10//'=IH]XX/&D17*W:"LY%03E'5(%!U3^.IXE[6?Q
MG\2X',X3A^"<'P6,G(Q$_%HQ'ZJ;+E$_I?",P)3XBEI"U!*,H2QS$.#BFY\2
MB9),I24T]Y0(!8A1&4O0TK\HVZT]H1B>?/7R/(Z?FXHRZ!9^'2(6+<F8G*8C
ME/QPN"D(=(Q@5*#=57ON[*43D$1VYN#_ (6<9D)Q/A8G!2,0$+5AIY49R1,!
M=),LH;W@&]X#+F) >^1/#5(<I4UBR?=L.1>^A:M8C)OSUK C%*AVC#UV6LJ]
MGC0<242I-,Y@L2V%LV=(@EHD1W'=RLNHV.U>&,NJ)?TGZ5,YS>O_ (<8[VHF
MHXKP_P!H.&(P2,%.2F1B$X4X8X@B8M"CF)R3LR4)6)DOW0XT( V803TYD3;"
MH.[UUKN_VL*YS::CP_1U'37V:\OV;?2SRM&V/FQ! V((&Q! V((&Q!#_ $-^
M\\5_-K'^JI;$$--(C^N.O_>7(C\UCC_=\MB"-GHM5E+58(V/C6:[Q=Q(,&;9
ML@03K/)!ZX*G'L4"=#*.7!2E,!M"%1!0YA*' (W0@J--&?I%5*";^O[Z1/[.
M&3SQ+29P-$6()V"GJ[6&&56KR#AC%ALQ1#9,LJ^@9=%F5QX1I+E,W7=HJ)G<
MI@Z:B $+PETS)GB2PD%R  = &T&G($G9FA EY"9AHH?-.C\_G=S%Q?8WM:RW
M[%7MV6>0E;&SK*$-AI"S*55G&O;*@U20M9' 1+27>QT8L]!4H$*5X]00 HF,
M)A$H%/C-*1H!S *W /G6-$Q3VFK/?A[0;L)=WG'F)WF*, [B>7, 8BQ4C:[8
MVO.3;D*UBQ+5Y>WWNP1]?K$(T<R$9CBMF;5N B 81CPTLX])/D7K)G$$3#$]
ML?B2WY7[<;>^IM%@W=DO5[S=0JA2(%JV(NM(2\UC/'[ AD3&53*DL5=5%)L9
M4ITS**C]$Q U9+2Y)I[H>O>_8'Y"Y:%E8!RUS:4WH/7>T*>SOS47=CR_3-\N
MO'Q('YE,GU3".*6>2;E0Z2:WUIB^C+!O;V^JR-G?Q[65L4;C2=CL902ZH+>C
M4,_I6%BNG)U<IDR8H*4XLPZQ67+*')+%R=&]-1M/JN_=&6ZDPW7^T 1WFL$R
M1"8&W[JB&\MB6Z4]V*,*O8K<T0'+3*"F&)TBKIR\C/,<AD.R$K0L!E*(9H'.
M5-0 7#7'R?M$C:M__"09(_\ Z@C'_P#[%"V(F-[_ '-4X=6W=X[< UI5GK&@
M]W&H:N.Q2E$D9IU#1F,<_P!?9PD5+R[659L%F4"T9P\*H\8/X^*0;L2&8+LF
MQ6I@!R!O2(-CT,>.SRRAN8L^V?W <3X[</T<$Q<-"+J&R-8X:>F93>U@<;9L
M@ZX\O#V)9Q4*_L\;F"T.F>-GC:)C52HS%6.P9-6#IBW(PEDE)HH%M79Z]H6E
M#%_Z=J,[7ISYQ '>:@\O(?ND:V$:>F%,D.^U4K3^DG*#D)+P#G>'@W6-Q:ZA
MWH,VU3-72LS!^@)%)(J%'PG"85Q?, 6KY>C'3MC=SBIU^Z^<K#C$T2=^CNEO
MVV5E(44!:'RJAC>FDF 7,U_5S2R%;_)1K.@4173FT)!&0TDTWI0(M%<F.*E6
M-VGL/]_G..X,]FMYH^]YE"7PWOT%R(DQK5EW3*;!*W2M/D(C%E9-926@'K3(
M;\RE]4NS#T?7KO4+P:N TKUA9P4@.6B"6#PD[%[>1I6/<FX'[/O/3DDMA+M$
M-V7,N$+W$O)#BC&E[F<JY<''D9WRIG!$I)]&S-OQTU%LD+A:>O5?544($24"
M64,M']Y)_=K-SKSBH]XDCX2/G;T10\X>KL9<;--UO>@[3?<4A;1&W-CNL;D^
M\E&7>X08B:%N>9[9D&!2N,XP*I^M,QKU(JN+L62D4L84F5FQS8GK8B8RS@RM
M(O'"7L00[F*H5NM-LWLR<[2&0$KZ9>@7FQA454_%N=.$1'B)J1+0!,<QN$I1
MX]!/7KU]H6HC,!F()%/3P=<Y\EN8(1;$PN8VKKRAJN[69-V\HX@'#L5C-9-1
M!,@K.&Z12N"I^N"!A<E2'A.0NQ%@0 Q->N\,[L1:!L00YV/(/QDHW4>\+=EP
M.G3MVL75-K%-"<<@\'70#<"*2H)$'_&G  +KKL0M3Y@ 2'&G>#+K(!/M6)&J
M+(6\0#@L<];L2LW3Z+<+ H0KXI5%.)9F85#%*;](4BIBF,8"%#8B[M<BD-;L
M1,??V>_W=-B"):[O=*:/7X*2Y3,VQDCO9=^KZB;&+*F(I)@;705G*P "0'U#
M42@(:".UTH4JS><*60+DVMI\O.T8K+\0K,)J+,EDG U4QV9. #<;Z*.X.H5T
M)0T QD.( , !Q  ZCJ4HCM/AJY;W]7TWBDLY2HFQ):V]>?XB,ZIRB42\P-YA
MIIY]!_'L\]=EQHA-S\@$?@&NGQV((E/@FAI(-5LD6AFF,/$..XKS-\BH*,S.
M 81XB%T$JJ,:4@K'X@%(ZW=$];A4#;1*LYT?4"K^>_.E(3-+I* ?>+:&W4=M
M1>\3FN]A@%<0,)!!EW,THLW(^!,4RJ-TSBL8.BQS%2< 9%),BA$S\C")=!#1
MBG4E0W31@?S7:CW!A*1)84.8 "Q^,7O_ ,7-MXK+R-7/03\7Z!3#%RIS.&QQ
M ?T9SCQ';B(:EU3-KUZAI[!VS%)#O\K7'[\MH;+?,+MSO8W^0WWAIQZCITU'
M:D/AP\6TYU=KU5X!'Q!4I&5;%=+-2\:S=BW4!P_< '("]RT164XCF*4!* B.
M@\[!)-8JI02'-A%UT)5*&^I4Q(U^:0B6M;8/3E0FW'?2#I:/;'$RI@2,8 !1
M4H!J3Z1PX #4.6E*I@84:@+%J<GO9F<UVTRJ&&4E3*#G8U<VIRT;?44BH7-<
M1+H6=_8'HF=,9]XH\9OP4,L4_$ AX81U-W0H\B)IGX!X!+H'794UV?<[OO:'
MRB@#*DDD,]#MS_?9X9?[MDPV/O\ 8'7Y?7^S]G,@BW3<@Q8WK=.1R7;I]Y%*
M6%X[95:O"B4$7*).! 90'('U1$YS+)@H=-(>'0P 8I@-MLD>XE04?BL!73U:
M[&.?BUI^ 'WBPY7!OLP:'NWJJ;:W.'EF+*061CK#XU^S$CD3GDS11T7*T88Y
M#&4.7A$!%$XE*H8>( -ZVEE$*H"7OK6]30WH;]-(SH0J443%-E*F#%S4<O[=
MQ%%#U(R"YT5"B15(3)J$-J!B'(80,!@'S 0$!#ISY;8U!BWKO'627 /KM"4@
MB!@$HZ&UT#Y\N?QVK%H>7#&,K'F&_P '1H-+5:1?%+(R AJVAHE(Y!D95X8H
M 4C9FW,941$2@H8"I@8#' =F2DE:@WJA^T*FS$H22KEIN>_32/U1>QID*A+=
MEW"X\QVI)R$5B!?)>+FJ\RNBZ?O)*'<FM23Y<4 !, >FLC9V@0@:($5*D'K)
MFVN% 3D#_2MCW(%_K2*2RX)T.MM#?F:4!VAE\D;R.#ZM'3,GD7)R+/T?+.&A
MXP1; ^5>,>-F\%NV$FK5-)PB8R9T4B*E*05C:F4 3^SERUO+7[H'AI%QH&J"
M?5ZB,6I >_SW#5+%]/G:$-)[3S<^N63(O#%'M@*S5A.NP0.\14D7_=L$ 6=#
M'F69,RM'BA%#@V*D@H M0=+I*+.4!:&UI1)7,RC%)$YBM,O,U@X27Y^42QN0
M::Y0U]=-3J-W+AI\Q2TK<8,M7J+):*@W/#XNV 1F#YRF@0BRB;! Z)@37?K*
M%[EPZ!4Z9>,113X--I"D(5XDX9IE0!=P:7%-:;$6J\0S=6=NKBQ%6%WKV$,Y
MOQ1%EB<*K!5+7,M5RR3)HYB408)/WXD*<&CM1Z5BR3.=%R4C/B5#N>%^)>\X
M3\87P9$S$9C*R%BS"Y8TI8 @$6$2-;4;5A<W(H:5=NSQ!+<6[5MY1F<[BG>%
MID@F,99GK"*O$>AX]-RQ*N9NF5<R*@]VHD)3<)EC&2.85"(D23!-5QAQ6"7B
MYB_?4A>8@)/PABP+OYW^Y:DA(>MWMU?;<T:.A.DW#%V4H"*L=8L<)8(^5;*
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M_>T-0=:4-@.GU:%Z6O3EJP!)+!ZG76(U;SL+!W%LPC7QO2"1HKQ!&CMB3O5
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M'(-E)7ETWUW#1I(<-O$VJ5O][V6 L'Y%P1B'(-<K.%L]MSQF:J.YPS@^UI9
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M<10 +4%VRL!5P:O^U><-/"/U4%B$#0XIF[U,IN93D  *N@<-!U351X@,'(=
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M)"BH7-_72-(YC\N7V\N0?M^O:L6]>4;S4'J8+*QJ_")3E*X;=\8>$IB< KH
M(\BE7(81$.1="*:_3$=I =0&YBJR$ %M4DTK6L.[2\>3$#,IVM&$4=E*Z;)5
M%FH*(@[FY0QRL2G*J"J9@BU0.90%B$2XBMU#& IRFV:04#,FFCW^OU8C:%^*
MA;I%7TM3KI&,W@;>A*3D71X=RDX@<?LQBU%FZ@&0EK2N/B+3.FTT(<SF5.NW
M:J@'^1-4.$>'0 6I14SD4V#<_6FT60+T(?>K[-VB/F@Z<NGG\?Q]7[1K#(VF
ML+'%T* $,N;N5@(WU$P+I*$X%FYB !C"51,3#H4!T #FTY#K(J1JYBI8 E@
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M/R\^<1$LDQ)6F<D[!)&*=[*O'#U<"Z 0AUU#*=RD4  "HHE$$T2::$2*0@=
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M]V&LVNY5R2S1!'D6L6@<)PM;G6Q54VW=*^&"3!JHJ*PM%@+^@05(=9,PD$_
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M3$*XAVM9:Q"[]W.NDET>_:E(D8B:;A!0YFA5R%(0CKA(=/A6("G-P^.5-/\
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MA&<LS=(N4S,W_")#)O#+BIZBK83G;<*6S/%*O>!^*M0]]*U@"4T=VIJW?FP
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M;H/+D.@^0Z:".>.K0@&X]?V\Q *W XD*0-3G-PD#UA$1'H %#41$VO+ES-H
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M <M7"*AA$3$.@LGQ".@@;4I@*8IB[*C:#8.*-KJU /1Z;:L5,5# 0@ZF-H
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M75WJ]/Z:&YIIO%.=OK,A4K#+5R2()'<8\51$PE$A54.+C;N"<7,4UVXIJIF
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M5&IUV-/.X^1CSF%G3/%6U E1-;4/,^A:.,_>5P5)X*R?*55=(R\$_3)/TZ4
MY#DDZK*G57BES=R<2).D$]&SYL;15!R0Q3$X3 8>2M!06(J/B:WY^VT>FP\W
MQ$U(+BWH?+F7B/(MRE$>6HAJ.@AKH.NN@AYZ[4C5'Z'_ &&E_K_:@]B5FK<"
MR#)I.;SAR"G\+LU)$2.'4?6I])2WX&NB:2@F$4Z?9&JT4R'A$4"TEJ FT4*
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MQGWBYJ7?:O:/4.=MP!].7S/(Z0041*(@ Z"(::Z!S 0 .7U /+3V>6T@D6B
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M<>1+VI$J=S7():=EIE5YAZHVJ632)4><,74R;!])+@6LSQB@<@&)#3Z[15V
MCW@Q"LJW0.11V.VC#J.<)>AOT\ON#]L>.EYY+$ LZ@!N'>S7#\B=M;WVVX7=
M\J0DCC#-]%MU(3JTA%SBE@>UJ40D8Z-],IH&=)D>-DE#LI!@1TW*Z:IK-UB*
M$4 PB!1+J7+2MR146(/RVY&GG'"1.F2?@)'_  WO07VN(Z0]YJ;J>ZMC[%-S
M)EN#W5-SC N&X^,J,)Z),IG.XHS$2QA)5O1<8AZ)D&EFG&3A2J1ECFW4"SBY
MB7>S)'9S+%>!E4A 9DOW+MNY+5I;]H[2"J8E"%%U3$^[2H4[YB.CEN>I:..O
M>:[7YZM/7V-W"L5EW4XB]'<L+?GE_(H6/>^R+"F*#<(B0RJ@F5#%5.71(D)*
M!B%" 9MCE/X^PSHKJJ"N8I2FS!F#"H--A&R3*1*3D2*ABLN2ZMZZ[]H@#NDY
M@;U'-*/YP9!R^J63!6K5ZD9$_I)T5:7< I'6E91\MJZD8B<,A(+.G2ICN&IW
MZ*QS%=*B+,.6F#F&/?D]?(?G+Q"6M>&FE*CF =-J-?3;34VJT6C95P:GDJG6
MK"QE47-PJT@LO17P.5),%Y9N=QZ,;L78(EX(F<9@>'*B)2&77,P?@!_T92:I
MLOQ*LZC0.3=]JC<VMI=^#A9YP\Q"B3X9<*%&VU;5K$=:1;/V,^ZJU[/'=9O'
M:&9UJCB/WA<LGG\8;M]7FF*:=AQ]58Y=S&77(2D1)"T<LY)^LF[2;G]1<L/'
M()D%)M8%#[9!)(4R[#M?JWE?[^@_4)R)6DL%J9[L17GL[[12CVSO:<VO?GRG
M#4&$[V'PSA]$*Y5H@RY7#J64C3*(IR,^X3$$)"33 3J/%BE,BK*KO%D3J($9
MJ!28 E@-K-KK7L.>A:L,DI*CFF$J)JDFGNZ4 &I,4EMUU4'*#A)0Z:R*I545
M"&$IDU$3<9#%$--!*( )1 >0@&F@AJ%![BO=HQI&I207!%*B+S=WK-9K%4ZU
MD]D_.VMD8Z"H9((3A436,9B)$Y19F1RB=8LXAW;Y,R@J(*/!ETSI!W! 'HX1
M6=\QS&NN]Z#ZMK'EL?@E"< @$"I#$M1U==/[7&TX([-4-X'M *+$N63F&W;)
MM.1SADFS&;*M6$!CZD*MI?(M?:JF(1$DH]<*HPT(T(83\5ACA(7A04$N7$(
MFD"@)Y[U+DZ^GCJ\.Q(_2$3*S)5*FI L:-LU='.D6W=K;VCU5KF[G.UNF8_&
MAWQ[:FM9Q=(]VWCY:N52#AUH&JU>/8MQ3.QB,=U(Q)UP1$"H%N$Q7RF PQJ2
MZS5I3)1F02DK2 6J2*9KTY4V[1GEJ7Q":*G+)7F)W%P"UF()9](O=['[?-'M
M2.S,K+Z8E(2;WEL&MVM OB,V=)91/)%+C^.A7>0*=-9RBWR'7TH][(3*:7&G
M*NK0DP,#F-,4BL'B)F%GB:"Z<S$4K++.FW5C4UO'96A*PQ&E+T+7HVH=HXZN
MTCW^MX^4WOKQBM&U7:AKU6S-F4_"-)LC5_7;)'HD]-L@70102:$BSD68%(**
M"BYA.]7-XEP<1]1,XHDKDIPPR2E))4 0HO\ $"ZW8TJWYA PQ%3[P&FX\@37
MGV=FK)J>6:'D/(UER3<[E,URZEG&LPH_M,@E9(>Q/UG1&[]SZ/=MR+'=D:D[
MPR+@ZI1,<@MSMSI$.7$C&(FSYDR:3H "6!H0X 84U#4NU"UBD);* *5:XM0O
MO;J=;P]^'+U=9'+,I8Z/7&;?&R<RM,&2828/2@F\*,7(.F#63-+.HN0FV:(&
MD(\[U)/]"@#U#O4DE"_-?XH<2X9-]G\5P/&I!G<1FR<3@%.K^3,PU/$4$D$)
M6H!\Q)OE#O&7%94RZJ(4H-L3ML[#3735K6ZKVM6\+A7"L]NZ?FEQRI0+,UL]
M=C+BLK8DYQD2UO919=Q-M6LF$:K)>"DC-F[AJ#-$JB2)U4U.#@/YG@/M3*P/
ML_@^%\/EH.*X5ASESYOYH6D#$%(6I1F)6HG,%,R:)3H*H6<@+NZ4O31J@4&@
MM\Z&-P[+3/N[ANV6/)T[F:I)L;:YK[F5QYDY/Q,H4%%E4F[ZKH,%?4B9QZU4
M S619BF5Y'>.:.%D>[[U?TOL)QOAO%<?,PT_#2I'$%)F3_$2E(<2@%$)=5'4
M2S!BVA, K:C%F84!WI6NE-SO$W+1VMKZP2 (T^)8Q]>16,BW;.5F9W+IL7]&
M4SHO?J%(<Y=3Z% P]"F44 1U^U2)>&$Q4U2C.6P2'4Z4BH("<R4U/_"]( .5
M&>KIZ[DGUH&=ZB9RQYO3H2D??JM"2Q6+%JJY;R$>T>-54C*"D)OTR+@HIE,;
M@.*8>IJ)!$!$2AH_385: A4F6N7XGB)"TYR%O50*G52M'9V #!H!<BVU1M=]
MJ.;Z=Y*0%8IM9BZQ3\>T1G5JNU%F]1;P\2VC(]L59R5P\,R(T(1MWRPD IU0
M#B4#4@G,4NFSZ(3[@;W22P  Z>N3 T!5R_<N&35@:VUI?O9Z;_FC'&+(0+/D
MZV05.K<:9JV[^9==P+M5VX1;)))F ARC^L*)AP$[K10Q.,>$P"?G3T%0<$A1
M-WY&FMRV]HJ4]S1VV["G?RH\;5;;5Q-%W+)5@U;K,4Y),J:Q0,Y9@FD0IC*J
MG03*BNGW) !),#")^(1#C.(VPN'7X@)435K!M+4YW</SBUR?V=[.X%& TU:*
M) W1(&6[0QOO:P#RR4J-;RC&9G:JNFQ4C)!6,:-TEI(SM&0\*T;R0-UG<BFJ
MJJEJX>+ ;O3G3/H/#Y2<0N>)RD35@!8!+62U#8AOK=XL"Z<KNV[&K=_=.MC3
M=XL^CZ+N*9CN\O.1K^L66V2,F5>62B[4N[3=2#0P&48.VB:_A5>$P]P4G>JH
M\!2F2 1,)MDK.*&8E'NBZJEJWL [UMJUHH7;1M3\M":6TYM#^WU%LI KLVQD
M8IE&D I%7 '1BV#"/2$443]]P$2:MFB9@463X023()N]$ ':,/-*5'-8@TH+
M$.[6Y.=+:1 9^X &AZVM0\XIOWAQS!O14J0Q?NW7ZG3SA[)+PUB?1<V+B,%D
MW*L4\<T>QZ,B5H(%T*\50!5=?F0A2F6[P.C-3XLK-*HGE<D:N7L&VIMJP/LV
M_;9KC^P)M%6.#K+ ;O62T]U963_*W(LA:)9&;!)&26J5;FF#7_"+=!T[X7CI
M9PFRX#L4SDU<IHJ')Q$.57G87'848M&!ES4S\8MLTM1#(-R'<FE7>H'6@0[F
MP#CJ]'Z!A6H;4:3MSQ:<>QKJG1I;!%*W1@H,,M6F("HY:JS -=5%G@D2BF;M
M)5-!'P3EZ@Y!)33N%!XC;?"OX_)PO'I/#,'@>*X.?Q7AN,7)Q7"9"WR&:E*0
M:9@2%!+E3%())RB.;,09B2E) 4XV=ARJ[@T#:[QDT.S7WJLMS$%DV%?5/'<-
M77"Y9N(N2;UY-/X^.($@ @E&-'QHLRSEJ9("E<E6,5;OE4DTQ+Q\C^'W\+<5
M@>&XP\?,K"8G$9?T>'$XJF)<$F9,2@A"D*"DI2E:5, :N89(PTQ"5!1#\@PM
M0>J:[/%C>\L.1]UJB0>5L-Y7QGD6V1F1&%;<M<;O3V_\B#"U>+/'UG.D(MXU
M45D!CTTW[=- !XU#\9C%('N?9WV!'LOC/\47BAB)JIZO E)8% F%)+Y0*,!<
M$ \A5\J3EG,JY235V.PKE\JTH.4EGO:1;Q^Z]N7HY]S/(,;->,IS8P>(HJ8D
MFZRZCARP[Y6P24;&),6IHV,11[U-K'H($.7PB2JA%%AU^FSYTN3A!.GH/BJ4
M,E6*5'X:6+:_<N(T905E+<B7T_+4'84!BWOLI,MW+>*W2,>YER[)F/<;BC,-
M)4K$R[2,DXJ)FI2+CIJ7CE5C,BN7)$ .*3<B+8Z3(%!;D1<]^IEG**DX>8?B
M6 Y&H(^6KM#"D T'-GH;V!Y; UO4.:+/W1!OF2KK*F/]RPF13.,/H-:K<<J&
MB6S0RQ'3UZHM&(&59F7!=&)@CH20-S&53([<]\*8B1!,G*XW-G83 3S@I29V
M+F8:<9<M1("YJ$O+=[#.6)<;EJ$,0DJ2MKM[I.];[Z?F("XGN<!G>MR<'39B
M1&OXGK\+ G,T6(*<ZX,P4;M_"N^'Q1D4FT>*KC]6;"*CD")&."*A=OR'QW!8
MOV;Q.&G\0D21BN.8C$XD I][#)\4*5G .0**IF5.52Z)]YBH&/.*X<<)/7/6
M KQ9F<DUR.7)M2_-OI-).^X^K>/&COQ]=AH-E$@B\*_<LF;=J5LCW2R+]-0Z
M114)P%*L1<O>*G$#@4QE>(>K@</BL;.EIPLV=FSH (4LE!<,6&9@*,30U-J1
ML025(*=P015]00X+L&Y7I01R@9.?04C?+B_K3<C:OO;18'<&BFEW":,6XEG*
MS(B:( 0$T_#')P)\  D7A(4I0#0/T)ATS$87"HFG--3)0F8HW*PE(43S)OSC
MO)?*E[M6T:!LV+0-B"!L00-B"'^AOWGBOYM8_P!52V((;M<?UEUU 1>.O_\
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M+F(RJ()>G?;UWO#'9ZSS>\N2Y&ME9HPC**6>)IPT>W%B!7Q1!(R[],QN]4=
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MD,(F.)#J*E  V\M[%^Q?!O8S#8W!<.DS#+QN.5CU+G3C.6F8I.3PDJ6!EDI
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ME!5LU%NZ*5XD8P/BAP+Z /&8XF ?S9[;>Q_M-C,0,3.P&)F8J=.4QPDN;,E
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M?TVL94K,G$9%? LECK6HU85&P%=88%0ID5E6Z@&(JDH=,Y#%,4Q3$,)1 2F
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M" =KOYPG$2_'Q*$;.?E6H[/6X%XKGGIU[/2TC+R*QUGD@Y7<+**")C"<YQ$
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M514= ,8ZAS',;0!#F(F$=/+IR#;-'22 $AMA"-)91!9)9(P$415*H0W30Q#
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M;PJ:M>5PJS!J.]>O2_=KVMU6RIQ31%HR7:E:M"#HD ]V=,>NG%T<%4 -0U(
M\M-!UYNGR?$((T"A3<^OO%)2BI\ROA9G9JO]#K0@:M8V_;T.+<:-6)[U:XZ
M9O"J(=XY(9T<7I/6,S(T;@HX,N<.(X"5'@T#7BYEUR*EI0<I )%2_,/J7U%-
M1%Z.P*C:HVYW=K6$,G&[RF$;ZHZ?U4Y;,+=07"2J<-(<;=X!N$C:/*O'=XU[
M](A#JK<"12F7.!U0)TE*BXYM\MG<-RO76\"RR5"WNGG^UB>=+FA@J>_+;(!X
MMRUCFC-L4QA129I =PF7EW:SE1RX I3$ P'."0$ 3',*A#'#B'1+NK3W3]1"
M)8!74/0TCGLWOL<YP>9U0;K8KL$I-V^6<I0KIG$>DFDJDD\!-J1!5L986BP
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MGT%CR>["&%*I HOXBS'DPI:U-:LT1W[0#<MIF[,O"/,;'MDG753N8J:DK,1
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M&M.1H[,&%-+\B]<V\#O:;Y&[P,5 V(CJ0%= Z?IYU&Q\DR,Y:*<#T"/VB0/
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M$> QN$NH[:%3Y4J65K4$I'Q&M/ET!;]HLE))  <G0&C'J^VC>4-W@//>.^T
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M4_P?4DUTB2,#2>(Q 7(SE['XF4;L&D,<HH2&#*KO7["VO[11?$(J>B8SU/\
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M8N&3Y>'Q4E$U?O90E1()=S2K/<4%30\XXTC-U04,FIQ)G+R. @)3$$HB!BF
MW,#!]$Y>I1U*/37;DQ[7.&?Y>G]/"59N :Z#[0'4!\OGY_@=B)2K,2&9F^>W
M3\0ZV[_A:_[PN7Z-AG&<.K.7"]3*<5%M$P$"H$316>24F[4X@*WCX>,;.Y20
M<G$I&[)FNJ8=";60G,H)LY \_7/I"YTQ,M"B2S!^WJD?H^/(RG;L&ZCNV8-Q
M#DZ;<A@S')$[; RBBZJ4V](B1X^GI%.0*4S$7DLYDS,V0:IIL3-TFJ9B()E'
ML2I)1D<NV5B+T8TKS'5R\>)XA/DS9H,J9EEN3-!?XW&95+5%=:#6.%/M3(?*
M;K>WOE_R8C-".2E4+'5W<NW<(ZP?A6S9-BU Z9$BH1X)D3("8AQI*(.# *C@
M=L.-"C.<J"@;7.X;;3F:B/1<'F8;]*KP%A2@0)E&S%GS&EFH'T$5KKM^'40#
MET,'RYB'GH//K[]L<=A*LSQX1.HD7D(::"/0==  1'H(<M $?;IRZ[$441F+
M@G2]J;1W-]A3^9[<&W9&&\%:[G5'V9,T1[B4&E^ ?.+-"5STT$:Q:$=()J-V
M[J2:LF\F*#P$DA0,T[LZBCKNQZTD2AAO#6@DJ)*E Z$::]'Z:QYO'XR9*Q:%
M2G4Q3+'NDL7 !)V%7=FTL8Z,<-=H+@_>.G[I@+.T/ U=XC&,'46_N[Z*B8*\
ML9)\2,;)QK>1<D<,+,V>.&IT4V@G4'B!ZS604:'33SJ0O#K3-PBEH4D@AW<5
MLX:C4(+7C9A>+(6KP<6GPU$*RK+95'1/6W5C5PT5B]IAV5N0*Q&3&6]WZ"D\
MS4=!%65EL?LT4YJ^5J/1*L]7=1$=P=[<XI!N!D4&\01Q9B=XW*6+D$RO9(OH
ML-[0(Q$H2,:D"8E@E:0 ""6+AW>@'R$;5R,ASH#I5MNV]G\_H_,A3KQ 6N\K
MPF/JPFS<KE",FE).-7C@:+$66#NEHUH#5^D[9K)+(NDY!1J#90BR9O7*4@[9
M,V2I?_1SF)J5"STN Q</VVL86L&6G.H*+4(+$ORZMY:B-WR'6,]2L'(52K3;
M&H>',4@6&':O#K+J.RG\.?OQ"1;L44S.T$DU%G[1YWH@4G=J:;:IAGJ0I*24
MJ*2$JJ6)>K&[4N=C>@D934AW9ZAF;ENV@?I$Z^R@H^2JS,N\7RS%&-O$A.2+
MN5R.Y<1DL]FZ\W39(+LXQD+91[%O6#Q5TX>*.F;7OQ>- [QR5,JAIDYY<H^,
MK,I"25*:BF:HN0^G(=8D^\:$ ,>=-@YN-=;1TZ0$'#Q1V<>HH^L#ADB4LE+2
MZW&9RHHR%RFMP' &X W#@26;-DB)('< 82B=(-.;,6%'.DT4]C:NK@[;#O%T
MAGK<O0'RH6U8OOSCU!*O7DVX5;(H-1%186;I,3]ZHR(8PB*Z)M")]X70Z!2<
M)P3(83F4[PO=Y<2QEO\ ?K^XMV:+,;@"XKY,+VK=GWUB14<B9-HDD*PZJ(@(
MJ' 3B)^7$).H!J(#H&O(!YAMCB4Z _U.--+[AJ5I7M7*"BFD3C4$HB!0U$Q2
MB8WQ$.?]VQZ]>42I+5"@;  B_P FWYZ",.A-,'+Y1EQ$ Z28F.4#:E -=.(V
MHZ\QT  ]H!L0)4D#WAK_ $LVG7SUC)':-7:)R(B00/R$0/Q"/4>9/+Y?W[2Y
M.K[/6+%(54*8'=[:49MC_>&_MZ\'!1#J3EI!M'-&<<Z5,X>.?"))IHZG4.!Q
M,4W$F0AUBD >+0O(!$=!URBN?[J9:G.[:,3RMR;M"EL$U^3,?>%#3SI'$5O\
M9<S9OZ;T#.O8 JEVR;3\53<A UU6 BI5W7G30JX(R<P^?]TX;-?2IB'!1TN5
MLD+!LU!131,I=MIES/Y:5(*,I-35PP<>;'K4-HL,!=K^?D*C3Z1'/M;8_(N&
M=W[ V"[PLY<3TG.O;O*,RNP=>AQ1K[&$91IU6P)HK+)D+HHLHD*IU4#GX@U-
MK3BI6C"RT@$B8IG%K4!HXT%OG#I'Q9J-:S/6I>UZM%B?[GLW5\E.817>8OC6
M'C*-^2DO0: S4>.RS-F<)2C)20G%FB3H6Z<7$E:+1!#/$%3.WBSD[=!'P0JJ
MIP9G292"HURV#EDL&U9VZ4%GA<TA2RVIJ]6;<-:NA[Z1T@7?'M:EX)\R3:.4
M7#XBL>E(,$P2<(F>IG;G\&Y*4''Z,R@&U3,4 #330 Y="1B2N:$S" &-35J4
M\[4A:Y9 /O-9RQ H7%*;,V[QQ7PO9,9&F\^[P>$;H>R5BVP31[9,8Y*12<%;
MS1)&6(JS;V86K=QZ7CY=DJ_9O'#=P4[9TU*LJ!"*&(?G_P"'^,N>2H44,J@#
MNIP:VL#>@?G#A. 2 U@Q#T) T#4ISU:.I'=OW=B[L^YUBO=_D'3&4R!5(F6)
M+ F496"E'-D?^,F(I5TS;)G]"N1?)#'JN2H%*5LBJHL4XF/MT\,M2%A*!E2D
M)2YL6I;6OXA94%*>H# ]#9_G70\XJ_SG0]ZND9%A\PTVV&"EQRK:#R1B1 %Q
MC%54U">B;+7(E<X%*JJD#9%=(%'!P?I@FV.X*Z* ;I\N8N<A97F04I"@Q<43
MS:@Y5U9X@D)23U+<G^FNU><2EMV]_DV0I!(F?&'5D$'+,2&CYIZVE)F%;115
MSMU$Y ADHUBP2*X355'OC"^[U,J!E0'5B,+)*@0AP"_PBC=/V\H1XPI15&U#
MZWKV#:.*O%6R?8\;T^^QGI_DO=]:A6(>[3T?-6'(=DL<@W@:=XGQ 3H3,NW1
M=/IH0%PBZ:0S%J>4?D,95-FFP.+HG XJ9&$FJFF<DS%?Y<M!(4 G_4X:H(I9
MP0-HT2E>)0@I%*GWN^^U?G'9KC:@8&[.G"U8')-J6RIEF"J#5BZM3YDU<W:V
M/VS!%"0-58 %%C5V%=.DP*=07)B))F2))RC@_=$-YJ?BL3CR'5_+#Y4@AN9-
M>5?E=HF=-D8)!F3 I9 LER>0'*E- 6J[&.'W]T3;P^^GF/*F,IG+,S.U[=8O
M5;3M."L811W+&EL7#, ;R+V>*7N6]LN14W#5UZ9D#NB-&ST[>#:QS8BB!\T[
M#JE 9JDC0$,S/<5W\S".'\1EX]*RA11E)9*G<AV#,38T.@M>.;A!(YPT HZ@
M&NHZ<]>8AUY]=.8?/H&V>.BW,'S^X$/_ !#7_!49ZW_J]E_5D_=L1$3U@X2H
M[P^[QD]I&F@VUML%4)9X>">H&(_1O./>(\HC#/SO%E#N9Y1H_2:L1*!E3V-9
M,&A$NX63T@E<I:E.Z;-0:7\SU'01Q):YV$Q_Z=24L2<I8NH,37WFIJ; EQ6]
M+*@"0QR@',IA#F//4-0Y^8#_ *0#Y\ATTVS1Z))< F,A Q#BPSD5!L_\JE))
ME'(!ZVA5G;A-$AC"!3CP$$_$80)R( C_  =K)&90!U,"BR5'9)(ZBOKT(MPR
M?DXF :%B2K19F:!)]TVBU19-D&ZIL=0#56,<KNTBD*L=[*2$D9V94VH"YCE"
MD$Y/6VVS%>%D0EFI\5RW3H!SC@2Y"L4F?.7\946(L[TNY":,=6AH-[*AISV.
MH*XLBBZF\=(,&$Z^*<#!+4ZRB#RORR1$R^JE'N'*+=4IE3'*,BHH<$1 Y!IB
M$ CQ 2="*;^8O;9HV8%9ED2%_$0X M2^I]4&T5L<AUYZZZ]! =>6@AJ'4/8'
MGIY]-L<=2-HI<&XLUDA*VT,)59=^W:%..O"DD<^JKA3A*(@FW1 ZZ@@&I2)F
M-RTVO+3F4$G5QW ?UZ$)G+")<Q>J$OSZ:.]O[Q9SO'71#$.(\=5*G2@,9ZR+
MQTJB:/441<Q%4IKI(8DHN"&1.DI)S2*2YUDBE%4D<H?O# <-MF)64>&A+ (2
M -Z "M6TK1GCA<.E*G3IT^8D'Q"H<@5$N0*FF[F-TS@BCO(;IJ5W9%<N)BI]
MS>8X[@C0BB HLO"9#AR*'<*OW"0<*;QJY$%"O/0(E,*#CO$0J5&=*455(:HI
MUN^S7%'O#I _28LRI=432HD*(=P"S$->G?K%-1B:$ !UY"<H@/4 +RYZ@&@]
M0YE#33D #RVQ:D;?O^([@J 8W_&%25NUWK=;(544)"01*]41YJI1C<17D7!
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M8B96<LNS.'+;BREPCL4!J! GK4R;&(<%B6%LHP-!N>$2@<OY,F[M9!0/T9Y
M0T]4"[.GSE"8P   + !@07!<.7Y;-K>.=@Y*E2YJYI*C,!!S5NQI6C'K;M&G
M;TL!)66"K64T$A6AB%"O-7Q"@":T*OWLG".#E3XTVZAB.3@JVU R)URD,&H"
M853$IRH6,Q*R7U&[ ,-][0S!@2 J2G,4I)5[UZG< #Y/3I$&3%]8"@;B^ :!
MIJ(CUZ:?5H'7RV1'127#Q:]N@8<&L4DF2I!!,;ED$5(.B(\_%1$ D;AE)L2C
MHH162,)$D3D*;@8)Z\0IR EVVX>2D,LE0U-:5KSM?O'#XCBV*I<HA1264[GD
M10AN?9JO"+?2RVI46T7A6F2RB:[,S.<N[ABH9!0'R)TG,?&G61. F.FJ O')
M3<(F,+<I@$Y3ZS/G)!R()NY+U?8/:VFD3@<-XG\R:EK@ #<,]7L*<K 6:Y#"
M&7(7>BW1,39O2(FYM>(U28,WG()DFNN]G*K(-4_0ERF&B+95(\>_C$2L7#AT
M\,I(/H\C8B*2@"MLU&1<L *42H,H*()# .U&J;[]J\S$X94K%KEU2@J2J6I-
M%$5=R00XI_3WVYR]]'=PE-VW.EAJ H$&H31AM=!DFZA'#*0J\PIXQBFV<)G4
M26+'E5%H)R*J&52!LX,8"KE$^"8D(40-&NT>FD3<TM)-2S.]V]=MH8>G5B8N
M4_#5>!:B]E9N0:QS-N37UE'"H)\9AT'@12*)E5E!#1-$ASB&A1VJD.I(-BH
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MD!%=51JR4)HZ$ Z*YQDRP4M0L'["@<?1CS$<7"2_U$Y0%4.ZB7=Z.'M7H_\
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MW<WK$HFD5#-6R/"B*IT$U"D,HD!DS"<5-1,8Y0$QBB?4HCS$Q0'4P=<X65J
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M>+F57UV:.T$%C4EL8"/5THT3)I*L8-V[,\<JK.>Z7554CM2F;E#N0X<2U*F
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M5FB1>_(5VR!,BQQ 0!9(FIM5 V3.E3%#Q!+4'H7T:E!;2-W#O:/@Y0)7^)2
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MT,2!76UQZ]"/&OO'ER$ UUY^>O733X>SXVB[#;5^^\#KUTYZ_7R -1ZZ\_:
MZCL7O$N=X+, \6NO,   ]W+GI[-?=IL<M-H-&TVTCR;F ^W0>8\]B""!#78@
M!:"5   Y>PWW#]O/8AB22[G_ $W]?WUA*/,-!Z==/> ZA^W8AD >?7V</R]G
MP]VPT#Z:06< T#D'7V>X=AO7KJ8(+Z^?3\:?C[>>TVTN/1]?2D'/YQY  TY
M ?+V^W[]DJ)"B =J L.WVI$N;PGZ#Y!IH4- T$ Z:!_V1U$O+EH/+J.C&%V#
MP.69RUSMW_?[QZT\_,>0CM,0_P"8+[I/77@+K\-/9_=\]H8"PB<RMSY^O76$
MRGTQ]PAI[M!X@T]FAN8>P>?792B<QKM](:D^Z._U,)%3G*?4IS (EYB!A 1U
M$VNH@//7SVJ\6V&@MRZ0F$I1Z@ ZCJ.H .HCY_'W]=B)<[GSCZ'(=0Y#[0Z_
M7L1$>%""?GQ" ZZB/41\^?,//GL18*(Y]X^E*)0YCQ#_ *0]?=YB/+X['H^?
MJ\!427MW,$/>B0^8\8B/F/(G4?/8BR->WWA!L0R/8**%#0JARA[ ,8 ^H!TV
M'@CYQFUXN(VO(==1UY<PYZZ\AYAL01][Q302\9^$==0XAT'7KJ&N@Z^>Q PN
MU=X\;$$&=ZKIIWBFGLXS:?5KL.=XESN8^=X?IQGT]G$/]OO'8B(?^&54"'B0
M YM C6/G_P!U2V((MI/U^7]NWNTW!YGZ==^7>/YFR['_ )O_ /6,:/4?B/V[
M-C2+#H/I!)^H?R0_'E]7EL2M32YOT%7ZMJ\;97P]]FVT^G*$H]1^(_;LI?Q*
MUJ*[TAR3R=M!OI];ASV@LP:%Z:] U^KV_/IK^W3:D/1\0-[V-+'FT8];Z?R#
M9J?AYV^I^\;$6[G[0D6Z!\_ATT^_Z]-I.G4;OO\ :O)X>BW3YTWU]%X) !\A
M'3R]_/30=/V#Y==0VH2-@^HMH[CGOO9C#!<-R:M_6_-](2'^F/LT_;R^K[_?
MIRR3M>WUC3_3S>OK7[<M4R_\#^E]VV>+R]>WWC&+?3^0;2;#I]S&^3\'<P4/
MT3?#[AY_+V?V;1#A<=1]80F^D/MY?8'X]WV22_UJ3V\A_>T/^OKUR^B)7K\Q
MY[-)-&K3SML==](>+#H(2GUU^KS\M/CIM(MZW[18V [WZ\VWTA*/4?B/V[)-
MSU,;A8=!]((/](?E]@;,34#E^=^U6_,/1\([_4P0?K\OO';'B?B3T/U)<[7M
M#I>O;[PE6^@'EZWU_2#[OV^>S)?P)Z1J3\([_4PC4^@;X;7BXN.HC'J= ^/]
MNT#3=K>5=:VU,:9=^WX]7/FY*-;I\@^W:%_">WU$;)?PG_=]/6V];PB4\OG]
MVR8:B_;[B$ZO^+-\O]H-L\/3\0[_ $A'L0[GK"=7F<H?]D/M'X#[^O[=B(&O
M7["$RO0/>.H#[M/;J/3\==B&(OV^XC&*?2Y>P.NQ&I%N_P!A!8_1-[=!^K0=
M?Q_=L0^7KV^\)]B&1]'J/Q'[=B-"/Z?^7[1X/T^8;4F6[_8QH@@W0?A]VRH;
M*OW3]8(V(UP4IU+U^[\>WY;47^?M^8@BH]-?T=Z0F7^@'\H/L':J+]ON(8B_
M;[B$NS8;'P_T $.6@\_(1UU\_A]^U?ZB-Q346]/NXM#$;5K;8,_W^H@HP 'G
M\AZ^7N_&G7RV$DG3N+:\_3VUBX/*FA\^?SU>T)C?2-Y<Q^7V;+(K>E-;[;MW
MYD;1=%#V^X]-<V@D_7Y?C]NUT,W)R^NWVO3Y1*W?FP;3?[VK\X*-T$ Y<M?B
M'XTV0K_,)-?>;H7!_-HNFP]:^ND$[6BT >@[$ N(3[$:(^#_  ?>/4?/3^S3
MZ] TY[$.2[#I?S^E/M'D  -=0Z:!J.GP]NGN]OMYB.Q%H   ?V>?E[].N@].
M7NV((+-U'\?>/V\MB"/(]!^ _9L001L004KT^0[$71M>H/V<>8A)L0V!L01X
M/T^?W#L005L00-E*/O'L;:T@A*'7[?CKR]W[=>G79L$>MB"!L00B4^F;X[)7
M\1[?00Y'PCO]3")?Z8?R0^T=JQ:"=B"!L00-B"!L00E>" @D'/EQ]0_D_P!F
MQ#$:]OO"'8AD#8@@;$$#8@@;$$#8@@;$$/\ 0W[SQ7\VL?ZJEL01;<;Z7]$?
ML-M[M-T]5?01_,Q%CU^PC&#U'XC]NS8UBP]?6OG!)^OR^\=K2?@/4_0=>_DP
M:NR7\/<_;^VKWUA*/4?B/V[(F?&KK#1\Z-Z]=XE?&[EF9C0L1/7M]BO"#.QL
M&LK6X_/&8,=XIML[%ODRJ1DPPQ[:+ VR$2O2R2B:T5:GU695:1;J Z;3*C4B
MJY<QGRP2$YYI%%&7+6M(L_O@97%B'<69X]5*]F.)^'*G8M6 X6F<A,R0CBO$
ML'@,3.EK#RYB,'/G)QG@S 09>(7(3AUI.832ES#39?W><MX51@Y:]5MH-3M0
MN"5+(=/LU6R-C"VJLBD.^:UC)>/IFS46;DHXBJ1I:'8SZLQ"BLDG+L&*QRI[
M.D3D3,P2KWDWEJ!0M+ZE"P%@%J%F-2'O%,;P?B'#$REXJ2GP)Y5^GQF&GR,;
M@<04@9TR,=@YL_"S5RW'B2T3C,E.!,0@D0T\-6YRT+/FD#'JR+B,A)NQODDE
M$4Q;PM=CEY::?F%=1(IDV,<U7<JD()EE")B1%-102D')Q3B_#>#2L+/XGBD8
M25C.)<.X3AES$S%";Q#BN*EX'A^%'AH60O$XN?*DH4H"6E2PI:DI!4$8:3-G
ME:)*"M4N5-Q"P"!EE2)9F35DDBB$)*B Y(% 32%-.H5YR))F@\?TRV7F:(W4
M=FAZ?7)>S2B;-'3OG1H^%9O7?ADM2]ZL*7=)@(<9@VV+6E#E:D(H7*E  DCG
M0'Z]X=AL+B<9,\+"X>?B9GQ>'AY,R<O*#511+2HY=RS->,HZPQF%M:HND.<4
M9*;W2<9ED(6HKT6THVB78&*8Q7L97U(HLK(,S$3.8KEHU61$I#B!]"F$,DU:
M"DJ"TE(8%0*2'=F)!9W(V-A&X\.X@F:C#*P.,&(FISRY!PLX3IB/]<N64>(I
M/-*2.<8I#%&4I.U2=%C<:W^1NT"D\7G*<QIUB=VJ%18=T+Y:5KS>.4EXY)F"
MJ0NU'C1$C<%$^]$G&75&9(&8J 3_ *G#5M6T3)P6-7/FX9&$Q2L3*!,S#IP\
MU4^6$_$5R@@S$!+C-F2&</&G6.HVNKV-Q4K+6+#7;4T7;M'59G862B+ V=NB
MIG;-7$-(-F\BBX<$61.@BHV*HL55(R93 H41EP4@@@AK@@BYC4F1.DJ,B=)F
MRIZ5,J3,EKES05,P,M0"P2X8,Y<;B-CN&&LP8];'=W[%.2:.U*F4QW-OHUHK
M3<I%3-4TS&6F8MDF!5%'S(A#"8 .=VU*41,X1 ]4K0KX5)5T(5]XUS<#C<,R
ML3@\5APX+S\/-E"I2U9B$BN9+?[AN(QLQB#+4%6$;S-XNR+#TEPA&N6]PE:3
M98ZK+MIGB"(<(V!W&(Q*J$J)#^C52.Q3?"4WA3*\([3G25%(4EZND*!+B_/?
MI#UX+&2Y(Q$S"8I$@A)$Y<B:F20M\A$Q20@A?])!956>,%9,;Y$J<'7[3:J%
M=*U6+8592JV.P5:<AH*RIHD(JL>OR\BQ;1\R1)-5-10T<X<@F11,YA IRB+2
MI*BP4DE-2 02#1J/K45AB\+B9,J5-FX>?*E31_*FS)4Q$N:P<^&M20E;"OND
MQG$<!YU=KU=NUPMEIRXO,:$S2F[?'-P67N,.+)*0"5JR2<.8]@C?1ZZ#X'L2
M5VV%HJDY[WN#D.()DMC[Z/=+*]Y-"]C6[N.9!C0GA^//A!."QA,]!7) PTXF
M=+RYL\GW/YB E25 H<$%W9C&E7/'U^QV_;QF0*1<*+)/&WC6<=<:U,UA\Z9&
M.=,';9I-,F+A=J90AR X23,EQE,3C$2B&R\R5$E*@0Y#@A5;M3T'ATW#S\,4
MHQ$B;(6I(4$SI:Y2BF@S!,Q(-PSBA(W=L(VK-D?S<-7&%>G'M@LBT,WK\"TB
MG[F9GU["+<L A#1:+<[V46G#.VA8=-B@N>3,Y;@R!<5DP-9PQ+CW0JK@,S]Z
M?%6W)B[9<N8HRY:9:S,F%(EH"5%:S,/\L(2!F45N,F4',XRNXAR)7=KWC(>.
M<S4O@'-<7#LF,C)O):1Q7>F,8TCH?49>0<OG,"DU;L8H $9%TJJ1!B #XE1+
M3;).6@J2RTDMHH&I+M1S;?G>-Z>'X]"5+7@<8E 25%2L-.2D)0^9144 !*?Z
MB[)U:,<MNZ;P7IB'K08*S(-CL$:M.P,!^;&[>FIN$0#B7F(B*"$\=)12)3%%
M619H+-$P, G6* [,EK3D!S)I0EPP.QV/*-"<!CG1+_1XK.M)6A'Z>=G6@&JT
MIR.I-1[P!%;QK[_"&:8^R0])?XAR@RN=E:@\KM1=T"V-K//M!U$'4+ +1))6
M5;#P&T78M%TAX3:&Y#I?.AB0I) 9R"" ^Y>D3^DQ:9LN2K#8A,V8Q1+,F8)B
MQNA!3F4.8!$:?(T"^1MN"@25)MS"^>D$HH:0]K<RTMWI5;0J,9^3:[).9](*
MF,4I&?@O$',8"D3$1#8"@V9QENY(;8\@._6&HDSDS3)5*F)FT2)*D*3,SEO=
M\,C,"3_2Q+O&P7' &>*+#R=BN^%,MTZ A5F3:8G;5C>Y5Z'B7,BLFA'-Y*3E
MX9FR8+/EU4D62+I9)1TJJFF@50QR -5+000%I)V"@3Y QO\ TF*E2U+FX;$2
MD)(S*F29B G,P3F*DAG- ]S05AEE/+Y_=LN*HOV^XA.K_BS?+_:#;/#T?$._
MT,(]B'00K](/+ESZ<P$1Y<_9Y^[8@W]:""DVSATN@T:(+.G+I=)NV;MTS++N
M%UC@DB@@BD!U%5EE#%3233*8ZAQ I2B80#8ADL.IA4F@&I<BT3-6W LL5TK9
MOF3(V[QNZ6EXV1<(8YSGFFLU3*33Q "+1O:\<1 62WXV=NBAWB;7*,32EB("
MD[<$0:.&RZU,X-@I0W2"1V-CV?SCL(X?.0&GS,/AEFOA3YR4S0X#9Y2<RY1-
MVFA!:I8$&&1S=NS9BP G7)'(5=8*TZ[HO5Z#DZD6>LY'Q-?DH\K<TD6FY.H<
MM8:5/2$0#QF$_!M)H9^MJNVS6Q1<4Z6(@-@H%V-1<$$$;."Q#Z4KI O#3L.Q
MF)&1?^7-0M,V5,;XLDV65(40XS)?,EP% &&B@Z?9;+&6N9@XI:0C*/"(6.U.
MTCMB)PT(YFXFN(/W!5EDCJIJ34Y%, (U(X6!5XF<4P2*JHG@QG%>'\/Q'#,)
MC,2B1B.,XQ> X9*4F83B\9+P>*X@N0@H0I*5)P>"Q4\F84(RR5 **RE*DNU#
MRU)->E6=@Y;701DZ-C+).49%Y$XSQ]>,B2L>T-(/XRBU.>MTBR8%.!#/G;*
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MTVKO[G9CHJ-DPB:Q'/8V.>RR_B%D1400>R\:W,FW!9R8[H@D1,0JAB8,=Q3
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M;?)R->1LI"L8YRZK 6:INW!:[;)=HK66J8K"IQ"D,N1+\5,W,"9B4^],EJ
M.5: 7!)964BH$=R=A>&8?VHQOL]A<6)V XWQ9?"\1PU."7AY'#Y\Y9D<.Q>'
M6M:T&=@,5-EJ3,E)EE4GQI"CX,^8DU=;O:2C:U9*07(*:R&!<^HJIF^D15+&
M5B(H0V@]2F*(#STU =!V\!_%NO!O9-C?^)_\,6/_ /6?"6.T>0X&")^/!H1P
MGC (U<</G@^J_F?O8,,W;GM-,,*MVCMTBUJ&<5'AVR*BA6Z*V$[\T2,NHFFH
M5 JKM=!LBHJ $.Y<()% ZBB9#?0.)$?HUV'O2]?_ )Q!WV^AM6/5_P +TJ5[
M9\.*4J4$X?B944@D 'AN+2'(=G44@$T*B '):+(\0P;MQ%]@JDP83N.&-&WD
M[U"1N!\ID/8,]%;2V0'5AL^6AMH1U46>8@<K1+9A#Q*.,Z6QK1G#1!:4N28(
MR[/GS2,W$'RK)EI)F(82W"0$H9U-,K4YU9B]$VCW& E$R_X8A")N#3AN+XJ6
MGA>.'B\39>*7-G8[Q\D@JP!* F6@8/#IE%21GGAEIC-G1O$RVYGVJE QLP6-
MO#(=J#9;EF^N,&BWY=S>[*ULTPE3'YHQ%,)>5HM?RFY4DI+N$'+*$D7[:5EC
M-D)&,5-"'\7#*5_E_I@$'^GQ" ];!1334D#JW*QX0O@'MMA,(A1XJ/;*?B.)
M24)/ZF9P@3U_IUE 'B+PLK&$K4P*9:U"8MDK28F/NUS6"8"P=E53,S/:E$;\
M%5W)-YB+ICB[*QK25IEXL4M$.]S""OJ\X)4(:PLZ0M=#XSA["+:2AGLG$&9M
MD'LO7!55,"R,2I+F29TLEJND#^<4M<%39F<%C5@8]/P:9P^6KV-D8]4I'M#)
M]G^*RY!Q&43,/B)BT'@4O$^)1$P88SSA)<TI6A2I92$JF2GH+W865]Q#O,4!
M7>XK]_JN IG>5Q,AO.LLKQ,PP@+ \KN16MA=FNS"U(IGL4G".$Y>5L)447\Z
M2M.;2FX 8V7DR.MDQE2SX125B6KPRDBCI8%)2[ Z:.!J WSOA*<3@N+8;_&9
M6)D\.F<5P0XLG&HF(ES52L4)I_4)G &:N6<ZYH94P2C.S>XM;VY8=1?5CMAN
MT5RGO,D<?]$R3H>\[(96M=CXEL;W3=VNQ$/S'0D--..*!LZ=IAC8];8PAX9R
M]>2JL>T1K""ZL>8J.9;'"R$2O\QY02!0IFI_S"H7&56;,2*7,>ZP(7*]M/:7
M&<5!/!U8?BJ\9.FC_HL_AD]OT")<PO+F^-+_ $PPJ$%2EY1X0)26C=ARX8YR
MAV=MYW0MZ1^^IT5AK%U%WZMWB6G4'<:^DTH+)-BIN7\;U-T\134<.LG5:>C8
MRC,&2I(LUKGWUE>CX>/<.".F)4G$)FRF)6M<B8!9RET*4!_I+DDZ!J/&' 3L
M-BO9N=P?BI5)1@L)A^/<.5,"DJ4$8J;)QF&DDL2<5)F)3(2DY#-F*FGX28GY
M$JW6W[\G[GLN5@AI(LK.[L[2>G#(0[QHR9/7S.Y3,BD1OW0IQS1F@_;G3:B)
M4V,<HU+H1N*(CG]U,CB"01_F "KO4-U^L>C0J?.XY_#R=,0K/,X8)DPB60D%
M2)TQ0 ;W0 0PLE!&C13EO%YCE-YZ3QYN!5?%]BJ%*W=,\[SV2;GD.PO'^1<@
MLH6Q7.Q7;+%F0AX6H0*E1H-%J4?+3WY%QK&P24T\CFKM63>RB[1F;2A'AYIY
M4"I:):0GX4N$@)#DER20'+,]@';RW$<8KB2Y' 9.%F2I'#\=Q/$SL0LJQ&(2
MB9.F3\5-"$2I?A8>3+3,7X*4S%+*0?$,QDEY]^> B\Y;E>YYVBV[FVA("R[L
MTNSW1LPK8G86^/AJ0MB]VC9MV^Z1CFSUBISYS1%7>QD#/7*0AD4EK4\K\.@]
M748D#:L@Y)LZ1,<B8#-05,2<U)@(!(^(.!M6EQTN+I3CN#<(]H.'B7+7P]2>
M%8K]*F>$23ACXG#IR#-ERE^[**43)JD!YJI: HY1&C[[3BZ5'LINQ7DXCT_!
M/%JEVA=<?O6R#QHH>'R)E6OP[Z)<JBD7]5M]1E95H#=33TK$.W1D051,8X)4
MQQ.)U]Z0=/Z4;<E,^QB.*&;*]FO9)2<Z"97'994 1[L_%)24DM:;)4H-_4@E
MG$6Z8V@; AVS/8;.',-,(H1W928S;2*R\<]328N&6[KO1,WR#U11$"-EFCU^
MQ:NTEQ(=!T^:(+%(LY1*=3C]'BJWQ!;_ -:5^#Y1ZW#RY@]I_9 E"P$^SF&"
MB4J9)&"QX4#2A!*07L2 ;B&(QC7G:U#[")M'Q=BQ:QH/:$2T(QP%EY,]CSW+
MEF\KC:K9FN$M?HJF'_,>T6B$H,(%EBZK,8"8?-O2=AN2R2,NDQ1KC'.8F2#G
M31(9+!!%??K4E1)V%HSX>6?"]D0E,S#IE<:6D8/%#/C%9L0J8O%)FY91_2#+
ME"$X>6E"E#,N:0%Q41O-;NF;I/M)-[/)X8UN<?1:MO\ ]Q>.+/*UF?CXF7<7
M7>F?1=4B:Y(+QH-)N:G49!6=CF#-<5'=<B)F80,H@R$%-$N8GP):7#^ F@(-
MI3DFM &;JV\<#%X+%GCG$I_@34R9?%II$Q4M:4K,['E,M,LE++4M\Z4@N4)4
MH4 B7?;FT"UR&]MOE3V*\:YAKR<=8EY?>HR-,)/E<36?%ZE*W2#8318RZ=3A
MHJ.1+D^*D(R-K[B8LTNZMZR#U"60C9(\9%IPQ'@RPI230>&D?$%9IF:CDGW:
MDL VE([?M+*F''\25(DXA $S-C9RG\!<GPN'_I\JO#2D?SDE"49IBLY)"@%,
MGFM4\OG]VVB/)HOV^XA.K_BS?+_:#;/#T?$._P!#"/8AT)U?I=?X/(/?J/,?
MNUZCL0>O7SB=>Z5(!AW$^\OO<Q;=$^1L0-\6XHP?*K(H+%HF7<^O;LLURE'$
M716 +51,:XJR<O0WR94'-:O4C6[LP>(2M7CB+T54I1H7*N82U.Y4'Y.-7'3P
M!\&5BL:/\V1X,G#EG\.=B"LB:/\ B1*DSO#/],PIF YD!W#W"<18.WFH'-T)
MF\Z,7*8+?US?+NU],X?FMUTW;\9'EHW>7Q,PD!.MXJY6].S4.;H2ZX$71GHZ
M?,NHZ])%(A"R4Y<NON :!1^%70,7:MFC=PV3)Q*)XGT,A2<8N87*YF'EN,3+
M!U6O-+,M_P"H*_U>[J.Y==RY@S7>-U65@X^+PUOJ2MDK3'&L8*J]<QGF*40G
M'V[Y>Z G+&?+Q$YCF]N86K!*$<)RLYC"9N-'E)0(ZRO5R"PP"JDHJ]R1_4"U
MW%>18M1HO@5^--FX4A*9.-*DB6'*94TYC(6@$N#+7E2[NJ45H)91(8;=Z_\
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MW#,9.2E2U883)DC%87%A"/>F)P?$,+@L3-EI"ES)$N;+ECQ%AIXWK+V\W@K
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M<.%5%EU]TO(2RRRIC'5555R%BPZBJAS")CJ*',8QS&$3&,(B(B([?.?XA_\
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MI'*6'&XITI$,=C7K6%UBW=-ZG'\:9>V8)W@J3#A8F50.M8L89&K<:%LF._\
M1U7,I)0;)J%BE?#N?!0@CZ2?=POW#97NE.$<;C?32!CL=M=82Y!P#O78RB)B
M;RAA3>%Q]78=PQCYV7ON-\D5.%BW4RF0T8REI"PPS!BR7E4EDQ8-GBJ2CY-4
M@MR*E.&JE?$>WTAJ?A'?ZQH% I.;,P6(E/Q)4<IY1M(LEWI*OCF!MMVGQ8-"
MB=T[+"5EI)R(M&R8<3A<&W<HDYJ'*7GM6+,]H(E\'9KK]LKE!GL/Y2A+U<"M
M3U&ER^/[9&VRTD?*F09&KE<>Q",Q-E>+$.BU-&,W0.%2F31$YRB $$92^[N6
M\+BJ--,Y0P/F;&\.68+7C2M]Q?=Z?&EGSI X)!F?6&#CFH3!D!!8L8*OC3)"
M"@("0>+8@@R5W;-XJ!FZ369S >:H:R9+;(/,<5^5Q9>8Z;O[-R0%6SNDQ3R"
M1?VILX3,"B"\$W?I*D$#IF,40'8@:,/3L&YKR)^48X^P]E*]!3G2#*W?D=CZ
MV6?\EGKIPJT;-+'Z$B'WH1TX=(+MD&\GX559PBJBF0RB9R@01HUWIEPH,VI6
MKU5++2[&T335=U^VP4I7)MJDZ236;*N(J8:LWZ*;A$Q54#J(%*JD8JB8F*(#
ML0R7KV^\:=L0R!L00-B"!L00-B"!L00-B"'^AOWGBOYM8_U5+8@BVXWTOZ(_
M?M[M&G4];5TZ:^<?S,EV[GZ",8/4?B/V[-C7!!^H? /Q[MK2?A+?ZC]NQZV>
M-DKX=+Z=!T]5@CR4]^G^U^/P&R)GQJZPX:=QUY>CTARZ%G#-6)V[MMBS+^4<
M:-I$RII!O0,@6RFHOC+I$06,\2KLO'$=&50(1!45BJ"HB4J9]2%  4J5+F?&
MA"V_U("OJ"WRCKX'BO%.'NG <2Q^!2O-G3@\9B,,E;I8YA)F("G  +W  -(;
M:R6&?M4T]G[1.3%DG9$Y%9":GI-[,2S]4J94BJ/)*17</'2A4R$3*==8Y@(0
MI 'A*  ^6 $@   .P   '00*G3L0I<V?-F3IJU.N;-6J9,66%5+62I1YDDP\
M6[K_ .<F1?/_ /<#GK_Y86'R^>GU[?+?XMG_ .)_93_TH?PR_P"V?":1V^!?
MYV-_^I^,=O\ XOG<G_M:-ZW'[WDW$F;!S1B6-F)"WX<IEJR,U-%Q\@_1;I5M
MB5ZL6<+'(JBG 2"1#Q<SXCA:N(]ZX:+"*:YBF^CXE"%R_#F$!,Q02'(#N6HY
M=P6*=:1M]F<5C,!Q/_$<"B8N?P_#SL6/#0M8 DI"E";D!:4M+HF9J%*BG41T
M2X7+AZ1WXM\N?W6UW%BI6\]N!9@WJK;&0[!5W^0EARUC2LR%8Q=)>$(9-A9F
MEFLN2K*ZAV:2*)FUUK4&5)9_5U2-^+-S_IY0G!ERIZ)()-5!"B"KHP2E_P#A
M)/Q1]AX=_AZO:/V@F\%)FX?C7LOC^-SDRT$_IIN.PDA<C!*RN$SA-G8R>J6D
M -B9,L#-)+0T1Q])3'8Z;FD:YPSFB^V\^8-[D,:)8XB)UT]K&1YB&L#7'ECF
M:_%5&;G)IBK84T48$8N5JRL?/D9SPR,FTB'<,]D%L9..9*1EE/F( *?=S $D
M :NX(TH[QPY6$6OV X A7#^(XJ><?QS]&,)+FJ5)Q<R7.3A)TR4B1,F3$&;2
M7D7)*9H3-S+$M4M16ZW&Q$]#XCW7-]7$&3JI<6^\?F*P[O>_7@60,I/8'SVM
MDS\F\E-\N,A;?DC)UZ'OV-V%HG;&_.LE#4]JS?MR,(EHZL$5,PD%<R4M)3X:
M1,DKLM&4E.34$I40!J7%30Z.!H1,DX+@_'L%BY6(3Q;B$WAOM#PU3S.'<2.,
M\+%C&I*?!5+1BL(F;,FJ?)(2E0RH29J$XTF*A.RQW%X.5J=\R;&,NT7R<PJD
MYCN6+5FLNF>57C8&UHGDZ!>QE("Q@S.M$-FR48JZXA*C*'.F<@0%$XF<04I_
MDH)"@[4#BBDL1K>&> B7['^STM<G$8M"?:?%)DS,*OP0L>(I$N=[^&Q&>5-9
MT !!4X 6X,08[<U@_9=J?O8*/63MH20GZ"^8'=-EFY7K$^):$@F\:&6(0'+0
MRS==$CA$3HF4153 XF3.!78,_P#1I?13_P#K*:.+[?)4GVMXN5)4 J9AE))!
M 4G]%A@Z7N'!#BC@C2*CE.OS'G[.8![O;YCIMO4+7W?2F]1ZM'EA8=!"8PZ"
M.G00T_N^//EIRYZ#KS':18?>_P!_5(N#3K3O6G5C0BE:BYA(/TO/_D//3^WV
MZB/GLLW.M^6M2&Y"^]8V#X=/[BC_ (V8#2"#<S#YC_=SV@6%6[\SH-CJ3TTC
M0CX1W^L)S]?E]X[9<0/>2.74W\O+E8PZ7KV^\)5OH!_*_P#S?;UV;+^!/2-2
M/A'?ZF$:GT#?#:QM^S_*+BX_O"!7I[^+RZ=.6GXYASV@-9F]?O\ ,:N!HE?$
MJ@%--WKZ^E0$:W^Z'X_M]_(-A?PGM]1&Q'PGK^&]=X0J>7S^[9,.1?M]Q"=7
M_%F^7^T&V>'H^(=_H81[$.@A7F;37R >N@\A'H&GVC]@;$$)5>@!T !^?GK[
MNNQ%T7[?<0^V-M[W>OPG!*U+#6\WO!8GJJP..\K.-LR9$I%?,9VH95TH$-6K
M%&QQ5G"ISG57(V*J<YSF,<1.<35*$JJI*2>8!^HCI8?%XJ2C+)Q.(E)<^[+G
M3$)ZY4J UV^<,E:[;:KS/REKN]FL%QM,TMXF9LMJF9&PS\LY*F1('$E,2[EW
M(OEP2332!5TX54!-,A.+@*!0LS4%!$A2YA6M:E+6IG4M14HEF<DDJ.E7Z6B0
M^[USQ/OE>_ 5>_;G[#?P^[;YG[=?^$_\)O\ SXQ__8;VNB%4;D/HI/K7O%G/
M[G5AI.5W]K@=G"S$RU;;I^\D@_)$-EU50&2I!F3)KXE)F^2:.I-R<K*.%9LO
MWSU1--)LY4T1/]$Q/^7_ ,P^\>DX "<62 2!A9SL";I#6!O8;F'O[-'$N0Z]
MVJ_9XV*#P]FC$V[G)7JSCB2F9:C9C\H4+-5]UFD1V\59$7#FI4].9C27IQ!)
MV*\,:S7*Q-S3Y$\5%L5RR<>PRDT-=/J[:F_6'</ES$\2P)$J=*D%2O"3-!?,
MG#($]7PI?W\N982E*B: 5 J]R5N*;T^0,X95E6F&LAP4-9=["2Q'!REFH]PB
MD)>W7V?R19&I8=)2".O+QM>J5&L]MN$C')N&];K[!)_)&1+(1Y7+@I(8.'RO
M38 7.^T*_2SS/FJ\):4JQ.1)4E0!*E3%4I4!*5*40X2D.;A[(]Z7$]&WQ.RC
MQSF7 ,/!RUP[,7)<WN[WH*;4;O%.9;=8R+8I"R8SM]X;6NG5IV[N],M+MR.0
MQB(]U$$D[/?;G(/44'2B#: <LP@TSA^BAH*FC6?I'2G(3/P29DL!2L&HRE94
MJ#R5ET*6Z1[R5/G891F6HTMN6_9)XXR9B/>QWG5J#EKL_>T2P-><)Q&\#48>
M2?NMV?>TN#/*E=B(*XX7=RJ2+F OT'*54F8JXUK8D8ITNOR\I&K6YE(V.X1U
M"X8.%)+Y=T[ MRIUO8"+8@H7+G3LB\-BI:I?B@%Y,]6=(S2W9E I\0,&"06<
M$F(_[] 7*C]C]V%,X1G:Z^BC!=HW 6%ZT;/HMP%:R;F.#C7L.X>*H$3;(7NA
MR<XV:).!*G-0;QXJW*X9BJ<"75:^@;J&(^CQ$X+3@^'EE)]S%))J*+F"A/\
MQ)>FH>XB>^7$I"W=O=N/;Q&[FHFGN/Q= W;;%BS)]?UC\)8\W4:!CDD=F6NS
M%H$R=4HL154$LDP=ZJ\_(1CF%DIE2(GV2$A,)(.@4E*!^)R&-R7C6OWN(29D
MND@)E%*V:6F4E/O@GX4@>\"Y#$L;U:_=8R=@6SW;?%W39$@8Z[.GM,=X+?\
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M00-B"%A9!^5B>,*^>%C57!7:D>5RL#%1T0G=D<G: ?PYW!4_4*L9,5"D]4#
M7EL01ZCY23B%Q=14B^C'1DE$#.8]VX9+B@J  JB*S91)04E   43$W < #B
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M.%)\&6E4Q>=*D*FRTA )6J2599F4$)4#4I8F.O;39 QO>L][OS6LV.NW7+%
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MZNX>O?E\XT(^$>M83GZA\/[=LF(=TU=TO6NI:O\ :'2]>WWA*M]$/;Q#]_\
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MAN8B/^4/O/G_ .SMJFY&U/(-Z^<-1+-6(#!M?QR@@^++"(@/C(;H'_6'OO\
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MW_#MC..?R_,&0\OG^(3FQ%9#&$0>P>@C_&7_ /PW9:BY)AB0P A&MB*R<?\
MET'R*'_67_M$?_9FT1,$_FALO\>@_P#67_\ PS8@@?FALO\ 'H/_ %E__P ,
MV(('YH;+_'H/_67_ /PS8@@?FALO\>@_]9?_ /#-B"$;O$-E_1_KT'_#_P"L
MO_\ L_\ AFQ#)>O;[PC_ #0V7^/0?^LO_P#AFQ#('YH;+_'H/_67_P#PS8@@
M?FALO\>@_P#67_\ PS8@@?FALO\ 'H/_ %E__P ,V(('YH;+_'H/_67_ /PS
M8@@?FALO\>@_]9?_ /#-B"!^:&R_QZ#_ -9?_P##-B"'YA\3V((B+#QL+RCF
-(?Y2^\FR7_AVQ!'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g805799g25x88.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g805799g25x88.jpg
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MX=.W3A11=PX74.LNL<ZJIS',8P_9BXN+9BXIEF*B !$/@ 'SP  /&@  &I
M5 # M2T(H50V)H71&(B*)49?Q#^B]P'S]^^N#<IZ^?/GMRH1MZ]>O6X1IMX\
M>-M--O'C;1:;:)::)))4O>#?P[^872_HMH_J+(^?(S5<3O[WI+T^@.@^LRBG
M!VY'4T\&_AW\PNE_1;1_46,^1FJXG?WO230'0?6913@[<CJ:>#?P[^872_HM
MH_J+&?(S5<3O[WI)H#H/K,HIP=N1U-/!OX=_,+I?T6T?U%C/D9JN)W][TDT!
MT'UF44X.W(ZFG@W\._F%TOZ+:/ZBQGR,U7$[^]Z2: Z#ZS**<';D=33P;^'?
MS"Z7]%M']18SY&:KB=_>])- =!]9E%.#MR.IIX-_#OYA=+^BVC^HL9\C-5Q.
M_O>DF@.@^LRBG!VY'4T\&_AW\PNE_1;1_46,^1FJXG?WO230'0?6913@[<CJ
M:>#?P[^872_HMH_J+&?(S5<3O[WI)H#H/K,HIP=N1U-/!OX=_,+I?T6T?U%C
M/D9JN)W][TDT!T'UF44X.W(ZFG@W\._F%TOZ+:/ZBQGR,U7$[^]Z2: Z#ZS*
M*<';D=33P;^'?S"Z7]%M']18SY&:KB=_>])- =!]9E%.#MR.IIX-_#OYA=+^
MBVC^HL9\C-5Q._O>DF@.@^LRBG!VY'4T\&_AW\PNE_1;1_46,^1FJXG?WO23
M0'0?6913@[<CJ:>#?P[^872_HMH_J+&?(S5<3O[WI)H#H/K,HIP=N1U-/!OX
M=_,+I?T6T?U%C/D9JN)W][TDT!T'UF44X.W(ZFG@W\._F%TOZ+:/ZBQGR,U7
M$[^]Z2: Z#ZS**<';D=33P;^'?S"Z7]%M']18SY&:KB=_>])- =!]9E%.#MR
M.IIX-_#OYA=+^BVC^HL9\C-5Q._O>DF@.@^LRBG!VY'4T\&_AW\PNE_1;1_4
M6,^1FJXG?WO230'0?6913@[<CJ:>#?P[^872_HMH_J+&?(S5<3O[WI)H#H/K
M,HIP=N1U-/!OX=_,+I?T6T?U%C/D9JN)W][TDT!T'UF44X.W(ZFG@W\._F%T
MOZ+:/ZBQGR,U7$[^]Z2: Z#ZS**<';D=33P;^'?S"Z7]%M']18SY&:KB=_>]
M)- =!]9E%.#MR.IIX-_#OYA=+^BVC^HL9\C-5Q._O>DF@.@^LRBG!VY'4T\&
M_AW\PNE_1;1_46,^1FJXG?WO230'0?6913@[<CJ:>#?P[^872_HMH_J+&?(S
M5<3O[WI)H#H/K,HIP=N1U-/!OX=_,+I?T6T?U%C/D9JN)W][TDT!T'UF44X.
MW(ZFG@W\._F%TOZ+:/ZBQGR,U7$[^]Z2: Z#ZS**<';D=33P;^'?S"Z7]%M'
M]18SY&:KB=_>])- =!]9E%.#MR.IIX-_#OYA=+^BVC^HL9\C-5Q._O>DF@.@
M^LRBG!VY'4T\&_AW\PNE_1;1_46,^1FJXG?WO230'0?6913@[<CJ:>#?P[^8
M72_HMH_J+&?(S5<3O[WI)H#H/K,HIP=N1U-/!OX=_,+I?T6T?U%C/D9JN)W]
M[TDT!T'UF44X.W(ZFG@W\._F%TOZ+:/ZBQGR,U7$[^]Z2: Z#ZS**<';D=33
MP;^'?S"Z7]%M']18SY&:KB=_>])- =!]9E%.#MR.IIX-_#OYA=+^BVC^HL9\
MC-5Q._O>DF@.@^LRBG!VY'4T\&_AW\PNE_1;1_46,^1FJXG?WO230'0?6913
M@[<CJ:>#?P[^872_HMH_J+&?(S5<3O[WI)H#H/K,HIP=N1U-/!OX=_,+I?T6
MT?U%C/D9JN)W][TDT!T'UF44X.W(ZFG@W\._F%TOZ+:/ZBQGR,U7$[^]Z2:
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M1_ &4+51J:P'$J@"8K&$6\R^4#9]PONNUKC;(R60LL+7]:; N$G5'<4R;QT
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M=*F62%J],(M&N$*.CWFMIQ1VQ:.5"WB1(51PW16.! @:V8" 90AA H&,80*
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M,4Y3 )3%, \A 0$!#Q#EK>D:\%KD*^S1WN_<;Y3@O.':V$[CAO),;\1;?5Y
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M]E8*MN&\BH)_#M7[IYGPO6@Z:))++)?0[;MIMN89:!=Y]+\7H:>1,0R]D60
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M3(2-VEV-CD41=5ELN]K>2'M<(&&TVUS QF=IV%C%U0_>AJ,+3;MY$/6B[9
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M+?N;L#^W5W]7E\C/\+.T>5;=[&/N%V/YL%]B)5WLP+::81,(F$3"+'?V6/\
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M;?\ J6A9FY,6ATPBM;P@K*(;%GS)-'#PPTI\44VYFI3E 9ROCTQ%VY:I]$!
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MLG=M7)\7B?*.E2G)"U>F$6DW!S[F<][^I+Y@K.17^G'@CE*W=V->X47\K/\
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MZHOR:P^)M_J\2%@R!)FTY2G=47Y-8?$V_P!7B0L&0),VG*5_!BXHH"8T='@
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M&2EK;.0@.B,E9E6"2%)5V2-;FN:%3.P:\)W968>0*C.$[1E7+U]"K/L^O/\
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3>(>9GFF9O+R_E?WC=[.]:E__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g805799g27k30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g805799g27k30.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1=X4&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@     !%0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4    &0!!
M %H ,  Q #4 ,0 M %@ 10!2 $\ 6  M #$ ,P @ %0 : !E "  0@!E ',
M=       #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M    #@             _@   .$))300-       $    'CA"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #-0
M  8              -P   +N          $
M 0             "[@   -P                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   -P     4F=H=&QO;F<   +N    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $    !#A"24T$#      ,T@    $   "@    +P
M >   %@@   ,M@ 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ +P"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
MZS%ZYU&SZS.Q'V XKKK*!3M$ 5A^U[7QZF_=7[O<NI7#X7_BO_\ 0N_\ER[A
M$L'+2,A.R34SNI5^H69-6#D68C=^0RMSJF1,N ]OM_.5A)!F(L$;/)]$^MEA
MM%/5+ ZJS^;RH#=I_=N#(9Z?_"?X/_"_OKJ^=0N<^L'U9.0YV;T]H%[M;J-
M+/\ A*_S6W?O?Z7_ (Q9'2?K#F]+G&>PW8[#M-#Y:^LC\QA=]#_B;/\ P-.J
M]FM'++$>#+9'Z,WNTE@#ZZ=+VR:KP[]W:W\OJ;5C]5^M&9GM./CM.-19[2UI
MW6OG\S<SZ.[_ $=7O_X1"BR2YG%$6#Q'L&]UWZU/KM.-TQ[0*Y];)(#A(_,J
MW>SV_P"$L5N_KN7A= QLO)8#GY #6,(VB=7>K8SZ3?T3?4>S]_\ 1JIT#ZKE
MI9F=19!;#J<4\-CZ+[_Y?[E7^#_K_P V_P!=_P#M#\;?R,1TNF+BRB$\LCPV
M*C#]V_TG'/UBZXXD_:WZ_NL9'_GM-_SAZY_W+L_S&?\ I):_2_K3@873\?$L
MIN<^E@:XL:S:2.=LV-5K_GITW_09'^:S_P!*I?1C ! )Y@CP]7_?//?\X.N?
M]R[/\QO_ *22_P"</7/^Y=G^8S_TDNEJ^N/1WF'^M4/%]9(_\"-BU,/J&%FM
MWXE[+@.0TZC^NSZ;/[25^"^.+B^7F"?K_P"AN)]6_K%?F7?8LXAUI:74W 1N
MC5S'M;[=^WW-V+HUQ/0<>^[ZR&ST30*++K;:X(%8=O975_X)[/Y"[*^^K'I?
M?<X,JJ:7/<>P"!W9>6G(XR9'Y219[!S?K%U@],Q VDC[7?+:01.T#^<N</\
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M '-H_P"W&_WI?MSHW_<VC_MQO]ZYK_F9U3_38_WO_P#()?\ ,SJO^FQ_O?\
M^02H=T^[S'^:>KQL_!RRX8N17>6:N%;@XB?':@Y_1NF]0.[*I#K (%K26O\
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M    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\
M8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300B
M  %^34T *@    @ # $   ,    !!,T   $!  ,    ! ;(   $"  ,    #
M    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !  ,   $:  4
M   !    I $;  4    !    K $H  ,    !  (   $Q  (    >    M $R
M  (    4    TH=I  0    !    Z    2  "  (  @ +<;    G$  MQL
M "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.3HQ,#HR-2 P
M-SHU,SHT.      $D   !P    0P,C(QH $  P    '__P  H ( !     $
M  +NH , !     $   #<          8! P #     0 &   !&@ %     0
M 6X!&P %     0   78!*  #     0 "   " 0 $     0   7X" @ $
M 0              2     $   !(     3A"24T#_0      "      !
M_^$!@$U- "H    (  P!   #     03-   ! 0 #     0&R   ! @ #
M P   )X!!@ #     0 "   !$@ #     0     !%0 #     0 #   !&@ %
M     0   *0!&P %     0   *P!*  #     0 "   !,0 "    '@   +0!
M,@ "    %    -*':0 $     0   .@   $@  @ "  (   #P     $   /
M     4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,3 Z,C4@
M,#<Z-3,Z-#@     !)    <    $,#(R,: !  ,    !__\  * "  0    !
M   "[J #  0    !    W          & 0,  P    $ !@   1H !0    $
M  %N 1L !0    $   %V 2@  P    $  @   @$ !     $   %^ @( !
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M 0$! 0$! 0'_P  1" !& / # 1$  A$! Q$!_\0 'P   04  P$! 0
M    "  &!PD* P0% 0(+_\0 5!   00" 0($ @0'!PP3     P$"! 4&!P@
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M:.2!+DW(IA37.IU).*[-G^%QJG5DZ('->;6M]>,M/.ZIA;#HJ6AL)@V.\JO
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M%-BUJ,$N6_LWND:@EWLGW3\7V1W:ZBS&!R UXVZL/)O:WT@3PZMNZ>WSW/\
ML:VMR>-ZBB6GSVF2Y;XO+K6*@%]YJ*<*\AY!*62JD/XO&P+X!LG9FDLP9DF
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M5C\P8D6Y=;:_K].!;:VX7T_5[_Y 5N0--K2P\0'D';;1TUD>]Z/%]&Z^M8.
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MG'$:UBM:<[WD1O9Y%[JO4</&=' M(7^GGYEC?(CP^-I<E=A3,SN;DNU<?O\
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$7'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g805799g30r61.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g805799g30r61.jpg
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M(C-7DI.4QM'3U.$()&)"14=2<G."HK+$(T-4E9:DU?_:  P# 0 "$0,1 #\
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MSIJ*-YI$XDK^E/HXSUNR.WM^S@V489,!@,"Q2/VS7OVLG_3SX%]P& P& P&
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MX,IR/VS7OVLG_3SX%]P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M# 8%BD?MFO?M9/\ IY\"^X# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M4[)E4P, 9*. >@OV0#VSI]!=(=>\2>$CU4^G>?73?G(Q.7ZQ'AR-C "Q@((
MDHX1Z _9"('(F( Z0$045>'CTR=.\^NH_348D+]8[PAVQ0%8IB  DE'*"4"/
MV1Q.#<2 1T@83@[.NDU$H H(F!RJV<IMQ#KWQVZY$^T9)0"A0DG&J=UW<@Q/
MWY43H=AVW-WQ'""SIN9+LJ#WA5VS=PX1,3J"J""RQ!,FD<Q0H$K&"0% D6 I
MCT$#@\;]@>K,9$.AN\[(]8\HO@Z#[68"Z#\P GP*GE(Q,%3'D6)"H@H98QW;
M<H)%1:I/EC*B*@ F"3)9%XH)N@$:JI.#=$E"G$*GDHY,5"J/V29DBKF5 [I
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MJ"N=:I]';UNR.WM]X;/<,F P&!8I'[9KW[63_IY\"^X# 8# 8# 8# 8# 8#
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M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@6Z8^R93]W/?Y97
MQQ@:8^3]^](SKKD[O4G$3@/M/8]<EMR:AM\UR!I/(OBM03[,J,-HO3<98-/G
MJO(2A7F=A*S'O8V:;)3-4/"E;V*2FY>-5\1<RIW)N(IF(UJB-T[IBKCK._=W
M:?;#;)Q4VGN?<6H6-TW]H=YQHV>K8+-$S6F9&[06QY"J,X>5690B[R\U9%M6
MK&K8X=-E9R.H-L@R9MYA&*$JKJ/<N%C,Z1.Z=8YZ:>U)#"& P&!8I'[9KW[6
M3_IY\"^X# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8%NF/LF4_=SW^65P,<8'YPO2L07%/6G**WWFW^D%YMM-R[9&DBTX$\->
M0>PZ[L]U,Q=#K-7CG])U]K"L7YO&/K57*Q'2S5AL:NU!E:)=X\D$]E,H_P!2
MC4CDIUT^C3I_K54QIZ9G3WTW-Y/ /6<=JKB[08")D>34BPEG%@N2 \R'PRG)
M>/&WS3R;6AMK2)G#A1U-1#ATK'QY%3]\P@$(B+5%8[$7*YBJ=9GA_P .Z/0F
M9A# 8$7=!<HJ[ON6<QL5 /(--[K6F[FISMR_3?!9M8; M^RJE5IAR@5FS/"3
MBQM;+S$G F-(H1\;9:\1*9?/AEFD668T]GAI^]("671;RU>476203[Z2#MK*
M$3)U&/4Z!VCB4O4?T!UZCA%S\5B_>3#SC?XF \5B_>3#SC?XF \5B_>3#SC?
MXF \5B_>3#SC?XF \5B_>3#SC?XF \5B_>3#SC?XF!UFT]$.>_[#]H3N'*K8
MW>.6Q>T=$0 QR=%A[29NO]@WLZ_J# [/BL7[R8><;_$P'BL7[R8><;_$P'BL
M7[R8><;_ !,!XK%^\F'G&_Q,!XK%^\F'G&_Q,#K.YZ(9H'<*/VAR$,D42I.6
MQU![U4B0"!16+U IC@8X]?80##[>G00[/BL7[R8><;_$P'BL7[R8><;_ !,!
MXK%^\F'G&_Q,!XK%^\F'G&_Q,!XK%^\F'G&_Q,!XK%^\F'G&_P 3 ZP3T0+L
M[/U]KWA&R;H5/66W<B1155(" ?ONHJ 9(QC%[/0"B4>T/7H =GQ6+]Y,/.-_
MB8#Q6+]Y,/.-_B8#Q6+]Y,/.-_B8#Q6+]Y,/.-_B8#Q6+]Y,/.-_B8#Q6+]Y
M,/.-_B8'69ST0]:H.TW[1,CA(BI"+.6Q%2E.'4"J$!8P%.'T&#M#T'].!V?%
M8OWDP\XW^)@/%8OWDP\XW^)@/%8OWDP\XW^)@/%8OWDP\XW^)@/%8OWDP\XW
M^)@=9>>B6YVB9G[4PNW'JR8IN6QBD.#=PY[:P]Z'83[#<Y.T &_.'3+TZ&$0
M#L^*Q?O)AYQO\3 >*Q?O)AYQO\3 >*Q?O)AYQO\ $P'BL7[R8><;_$P'BL7[
MR8><;_$P'BL7[R8><;_$P+,_G8IS'SZ";YJ!V:#IH?M.6X JHI%HO"F0Z*F%
M1/L/$TQ-T*/?$5(!1 @&,'C\#'7S.^/I=Q;(W^TJ$Q"[DVT:OEONP:KL#8E*
ML4\RJU4KU,@(AR]IMJ@###1L)6(PJ$:(&; ]%V^$@N7:QQ+K.FG9#--%H<'K
MN)>0L YLCMF^FY2?66M=LLMWF!?3"Q7#PI['<)2;L3MJ14.RQ;/Y5VG%M 1B
MXT&L4S8L6I'M,!@,##6L=#:XU%*34Q2XMRS>2\'"5)+UEX=RW@J16;#=K56J
M37V_832CZW 3^QKH]C&YBKO44)E*)._5A82NQT0-=??WY,K.E8L[AK'O5&!W
M;HKA=DQ=';F<.2,P2!TLU;*B*BQ6H.$0<*)$," +I=X)>])V@KX9&^[V/E&_
MP\!X9&^[V/E&_P / >&1ON]CY1O\/ >&1ON]CY1O\/ >&1ON]CY1O\/ >&1O
MN]CY1O\ #P.HR3KTDD=>.)#/T4G#EHHLR*Q=))NV:QVSQJ=1 %"$<-7":B#E
M$P@H@LF=)4I3E,4 [?AD;[O8^4;_  \!X9&^[V/E&_P\!X9&^[V/E&_P\!X9
M&^[V/E&_P\!X9&^[V/E&_P / ^2[.&:H+.7+2,;MFZ2B[APN@U20002(*BJR
MRJA2II)))E,=10YBD(0HF,(  C@?7PR-]WL?*-_AX#PR-]WL?*-_AX#PR-]W
ML?*-_AX#PR-]WL?*-_AX#PR-]WL?*-_AX#PR-]WL?*-_AX'P.U@TW"#11O%$
M=.2+*-FQTFA7#A-MW?K"B")B@HJ1#OD>^,F4Q4N]3[8E[9>H??PR-]WL?*-_
MAX#PR-]WL?*-_AX#PR-]WL?*-_AX#PR-]WL?*-_AX#PR-]WL?*-_AX'$\?%)
M$.HHQCTTTRF.HH=LV(0A" )C'.8Q *4I2@)C&,(   (B( &!\&:$#(M&[^/1
MB'[%XB1PT>LTV3IHZ;JE R2[=P@!T5T5"B!B*I',0Y1 2F$!P.SX9&^[V/E&
M_P / >&1ON]CY1O\/ >&1ON]CY1O\/ >&1ON]CY1O\/ >&1ON]CY1O\ #P.F
MY)76:+QR\)"M6\<B9S(+N2L4$6+<J9EC+O%50*1JB5(IE3*KF(0$RF.)NR C
M@=LL;%F #%8,#%, &*8K5N(& 0Z@(""?00$/: A[!# KX9&^[V/E&_P\!X9&
M^[V/E&_P\!X9&^[V/E&_P\!X9&^[V/E&_P / XGCXI,AE%&,>1,A3'.<[9L4
MA"% 3&,8QB 4I2E 1,81   !$1Z8'4 M<,\2C@"$&079GD46( P%XM'D531.
M^2:A^?49D6612.Z(04"JJIIB<#'* A>.[3_\LG^TO_ZP.> P& P& P( [<T;
MMVS\ED+U6TA-7)*1X?/(RX>+138NOHS1>R=[6_<<,>,7D$)L3;/IE[C*(U<P
M$;)^,DM<FQLAXV$KZ3E4L::>/IUB-/"8U3^PA@,!@,#Y+]006Z)*+CW2G1%$
MY$UEA[ _FDE%%4"$44^HF<ZZ)"F$!,JF "< B7Q.HOR1;;9FSZ G..CO8E]C
MK8[H[]74)(-,(VC5:A1?R>9:;V!?8(#(U^F0PV"5E3P\M*3KAXF@T4@X^'%$
ML^?7Q^U+G"& P& P(6<^=2[HWAQJVGK33)ZD[E+5K3:$.[K%F6?1RUOE)2A3
MD93(6-G&\C&L(@R=J>,)0RLPY:Q2[^/B23#Y.NEG(^4+$Z3'GC^O8F0P]>]1
M9^)BT&2]4;^("P!8&(ONY)ZV+,' F< T%QWGJX+F%8$>P"HB?M#A';P& P&
MP(-:^UKR"KO+'9]^E9%=[KB[VN;.\<2PT9]#GUI&:MU5&ZMKM+5;HFV=6YFL
M;%:;,>2E>?N2Z^D!LMXN MALEFB%2EW:??KQGT3]W).7"& P& P,,<C*A,[
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M[DVSMBX!VQ0(F)\'?V?NT_?#+^ P& P& P& P& P& P& P& P& P& P& P&
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ME/'?W3&Z.7)MVPR8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8'_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g805799g50p93.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g805799g50p93.jpg
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M 0$! 0$! 0$! ?_  !$( 7("  ,!$0 "$0$#$0'_Q  >  $  @,  P$!
M        !@<$!0@" PD!"O_$ %<0  $# P(!!PD""0<)" (" P4#! 8! @<
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M '%*R.J>Z6WPR,BD^2?)89M^H:][?Y*5(FN:N4E7"HD'E^(S(%9S?&7*V0Q
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MUKKO_-E=_AI?])Z;R,?TK\G_ /FFU?[AH\H3_IO[IO\ C5./\66TM'\V4/\
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MQ%^=HJ[*D-LR6(L,9&Q]%\ZA7\R+,<J+3.-O) 8EPQ_,TY@&!.R3!22GK1B
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M!M#4SUUPM,<M!M"V2B2U7JTU])0Q5\5?<IX;S1/H&I)$M=)"]/D1KZ _-PT
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M!5(UK,Z(T T T T T T T T T T T T T T T T T T T T T T T T T T
MT!V7Y03_ $NLL_\ LQ__ /5\*UKK3_-]/Y)/_-(>G\LO]).T?DLW_H+4<::V
M)Y@- - - - - - - ?9+:[EF!82V783R9.',G7KC#RBQ?*36+0UF%('3[<5@
MZ*,1B+Y$O(P%P2,&3+)V$<2M-,PFU7;O6" @BZNO21^<K8)JFY54,21IS]H;
M LDBO:UN]4O5RM5K'[SVM5'<WXN<M57(G'].; ;16?97DNV6OUVDN#_ /+94
M[01V^UQTLU76,IMDK=# V9M36T:TE!5544E(^XHVI2-S)H64T\BJUM+9+WKQ
M/(^'89'V3698VGXP',\=3T)%(CCTG )SCB5YB=Y?9VVR@H]:S8&Z!F7OG#N+
MM!B@N1EAPTI9((ZO8K=7LP6V2&HD>JQS0JZ*:)TDDR3131TZ4Z_R:(L;D>UN
M$D5V\QJJW<>A\M?>52W7O9FUT44=SL=XIZ6Z62\4MNMMFJ+/=K'<=II-I8T2
MX5$L=UI)*2JDWY*".!U/75,,-0E;1/1V98?WWX]D.[_<OG]X/R?=!<U8@R9C
MZ*QM=J#=&HV9R#C(!CVQ\^8J2ZT,DP'VA45EUQQ!5X]9,Q[7S5*MEOF^#;5*
MRWT5(BP<[35$,LCT5R->V&9TJHCN;5V7;W]9N$557*].RK.5VRUO*7MUME+#
M?UM&U.S5]LUOH7QTDE50U5YL-'94EEA6Y)2MAA2E:Y[X)W22Q10Q\VW";FVM
M\HU#!PY4T/QJ3(3 Z&V. ST:)HB&L'#([/)4A)W;F.DT2#\D\MGUP,*.;#7<
M<%61L>5/ME'QKH6JCW%+-(KD:Z=$C8ZYO8]JN65RW&/<3?141$6+><Y51[M]
M4:N&Y7'83ENMD$#JJ"QSS7*KI>2>DJZ"=M-'::5G)G<&5\DE%.V>:>5+NM+2
MP1P245.E#!45C%FJMV-98)N%WBXQFF-)+%</URJ,D\BWDY7W26EIB!B8UDQ$
MY8BJ8,G"5?1,RD]Q7S*Y5\->J/6'HR2AE5O2#%HF1<"4.:DM\\<S'U',*QEN
MIZ+=C=(JJZGD5S9?&CCW<Z.1$7>8Y$PJ[J.74[:<IE@NEBK[?LS_ /(:>OK>
M4[:+E 2HN=';H(HJ?:*WI2U%J=\GNE>M1S2NE@E=+#S%?2N=ST,:3OIF< /<
MA3DD.?"B4M/DF!)@/$O$2)-T_N5#BGR91@$M7=J+.$ B!1!H3]#(*I"U20X4
M_7:*.Q0U9KM4AB1R.2-B*U7.14:B>,Y-U783";RMRW>5-["JB+ARY\:EO-VG
MAEIY[C63PS0PTTC9YY)E=2T\K:B&D1\CG/92,J&13_)6.;3NG@IYGQNDIX'1
MP[7(:T: : : : : : : [&\GM_IO[6?^-4'_ ,61UKKO_-E=_AI?])Z;R,?T
MK\G_ /FFU?[AI_:E+)GC9E)3;0GB:,ER#<DY2>%'0L"JX?N+%*T4<K*. ZR]
MZBM?QKKE55+ZUK^-?6OVZ\L2:5J(C99$1-$1'N1$\B(N$/Z\RV6SSR/FFM-M
MFED<KY)9:"EDDD>Y<JY[WQ*YSE757.555>*D<]?\2TNI97"T0I?=;==;9Z)C
M7.NMLK;2^ZEOH/EK;;6^REU:4Y+:WVTKR5NIRWGY_II?6/[SC\ 6+[%M/LZC
M_1,.N4,*TOJG7$L$HI:XHTNLJRB=+Z.[JUI:UK;Z'YU'%U;;J41K3I*UI7DM
M^RNG/S_32^L?WCP!8OL6T^SJ/]$S;I_B:RVZ^_"T1MLMMK===<(C5MMMMM.6
MZZZZH.E*6TI2M:UK7DI3[:Z<_/\ 32^L?WCP!8OL6T^SJ/\ 1/WU]Q/^I2)=
MCQOP/3GY_II?6/[QX L7V+:?9U'^B>AMD?#SQ/IFF'86Z2YU;.E;#8NNGS[>
M3G6\](+=;SK>6G+;R\M.6G+3[=.?G^FE]8_O'@"Q?8MI]G4?Z)[_ %]Q/^I2
M)=CQOP/3GY_II?6/[QX L7V+:?9U'^B/7W$_ZE(EV/&_ ].?G^FE]8_O'@"Q
M?8MI]G4?Z(]?<3_J4B78\;\#TY^?Z:7UC^\> +%]BVGV=1_HF$ZR=A=C6RU[
MB."L[E*5JG:Z8Q1O6^EM:4NK914-96ZE*UI2M;>6E*UIR_ETY^?Z:7UC^\>
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M,)II*V*(VI\Y%12U&W0C.#_[B_BAMLE95E>V/;3'\O8<2QY8?Q=E+!4I\HA
M\2QD*;$O/6V)X[CF<;X:V%,U$0LXCS!.-S"YJP0L<JQA=T5+LO/B[,DB(B(J
MX7*91=U5\ZIGL7I[=>L_,I[K]RT4W&P_;R'-P"*R4I@.-;A0=^774<AXB<OI
M!N#O#2S#I M48HHZ?8XP^SN MDX*R:3$M-C3"7D4JQYBL(>"HB;N=5U5-$X:
M91?3QUX9*EQYOEW*F]U83'9B;QEWCPOY1?=KLY] )0D&U+-X1BW"H6?0B272
M%*_I5I,)D!.Q!;D8(#B3.UPW(LW2KALJP=?Q\=1=U,=2HQ'9SIG*)[\^G!16
M*-[FYS'FQ[;EFY_/C&5&TDF6Z^0[F78UICT_F+&HT1G S'X[+0F.7HIFI+,;
M1(W(F;S(T.%JAY6($'H@SAYF,Q-G>U1!6HKU:B]2)T(NG#/0J]"ZY7RY/Z5:
M5Y:4K3EY*TI7[:5I7[?_ #I6E*TK_P"=*TI6GY*TY=#C/W0#0#0#0#0#0#0#
M0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0$TR'_ #P+_P#Q_P#A;+0$+T T
M T T T T T T T T!\H-VS=BU\I[Y)5[2^J3TD_WMM7/.>+TL=(C=MZM1UE6
MEZWFU:M%BS^C=2Q"BEEY%S;2_E<WTOB\4\^?1\?'#)/V7_\ +GT]YR]M5W"Y
MPNWJOW$^C\9FI'/6[[>+M]D;<F .V9/V\0#;C#04IQ6*BYZ^3.(ZTQ44"KL"
M1\6A# 5\AD<W9S562G7QH:PNIDJ-W<IT-:OE55POGS[DQCI/Z -#C&@&@&@&
M@&@&@&@&@&@)GCO^?,4_WVQ_YM- 3V;8V.%95(GJ3@#YL^)O%;$W)=HDI5):
M^OXBR"E>6RZMM>2].^G_ )TKH"JU=M@=82@ 6BN+U035S>\;!548TH);NU*7
M44=(#KVE6:+E2E]]+UTT;5;J7W<ZZO.KR@8]VV".7]+SX7B>_IW#=VOSF45N
MZ9TSL53:.5>5E7I'#5-=>QNM?RJ(6+*VI76VJ7TJ!(5\&N'15D==,H0Y-C4E
M4!QA=Z'6*L$%Z7VKHLB"B=SMJDM:HI15-!9.Q2E]]+Z5I==R@:&NV0!<S,CK
MH=BJX?([4[)"QJTB]69ZU)>KI*TRUJRZ I:FYK5PG1]8O2Q>M5K:44K6[0&W
M88$H*9.!PP3 1P]V]5).V#!<&S9.B*[FCQ8@X:MT4T%GJSNVUTJZ4LN74<TH
MO>I56E+M ?K_  -4H5$'28N!$3D?JZN F7[@([*A+GJ=$7MP@BX14=C:NT;;
M4G562R-7"=*6*\^VE*: P4]N0Y$62!I1K&B04RMYP8#IV1RP66<<Y._IR0^U
MK1H^6YZ25W2ND5;^<FG=SN6RVM /V[;H/OMC5E\<QK?9#+[%(?9=;';K8FHF
MC8WLOC5M6U: K[&Z::%EPNC6MJ*=B5*TLMMMH![CVWMM*:M[I."QW(ZLZ*4:
M5/7 "]6M%>;56C>I!NXJA12MEE5*)<WG\VWG<O-IR >0S;^B%&.PH8+CT2&?
MWK*/A(Q0"P&/5'*";5Q>[8-4$FKF]PV11;K7+)7W*H))I7UN3LMMH![2>!JF
MGX8J8%P(L4CCE5Y'B1-P$?OP3Q>RU)=T&>.D57 MRLE98FJNQ4054LMMLONK
M;;2E -8EMK#(/4B2,4Q>B1;D53"#])",IO42ZUZ:BQ1)U8THNF15411O5?6*
M6N5+TD[KU:ULMK0#]<;;1+NK2KJ+8P<U8&%Y"QJX1C2U64@=.4GCHXTJHTN\
MV,.7B"#M<FCS'JSE%)=1>Y5.RZ@$MX5R3VN.]NLOO: <*Y)[7'>W67WM .%<
MD]KCO;K+[V@'"N2>UQWMUE][0#A7)/:X[VZR^]H!PKDGM<=[=9?>T X5R3VN
M.]NLOO: <*Y)[7'>W67WM .%<D]KCO;K+[V@'"N2>UQWMUE][0#A7)/:X[VZ
MR^]H!PKDGM<=[=9?>T X5R3VN.]NLOO: <*Y)[7'>W67WM .%<D]KCO;K+[V
M@'"N2>UQWMUE][0#A7)/:X[VZR^]H!PKDGM<=[=9?>T X5R3VN.]NLOO: <*
MY)[7'>W67WM .%<D]KCO;K+[V@'"N2>UQWMUE][0#A7)/:X[VZR^]H!PKDGM
M<=[=9?>T X5R3VN.]NLOO: <*Y)[7'>W67WM 2B9XY/$I*2>MW0.U%;S/F6K
MF&B*M.C8-4KN<G?7G6\MR=:V\O\ G6UMNI]E:: B_"N2>UQWMUE][0#A7)/:
MX[VZR^]H!PKDGM<=[=9?>T X5R3VN.]NLOO: <*Y)[7'>W67WM .%<D]KCO;
MK+[V@'"N2>UQWMUE][0#A7)/:X[VZR^]H!PKDGM<=[=9?>T X5R3VN.]NLOO
M: CQ#;Z@6*,S94)CPF:']%5@7(7@7A1CT"E5D?,W[E!1VVZ%6M54NA5LZ-2M
M;[.2ZM:Z ]Z&!JMCKV4-A<#;R4BT18$)$@Y")'7[!OT70,GI9-&U^Z:(="CT
M+9=Q>BGT27,LMZ.WD W7"N2>UQWMUE][0#A7)/:X[VZR^]H!PKDGM<=[=9?>
MT X5R3VN.]NLOO: <*Y)[7'>W67WM .%<D]KCO;K+[V@'"N2>UQWMUE][0#A
M7)/:X[VZR^]H!PKDGM<=[=9?>T X5R3VN.]NLOO: D\+QP>&RR/OW#H'<@S*
M-%U;4##19:ZQ-2EUU$DK*\Y2^M/\VRW[:UT!9$A_/A7^NK_WJZ ^8>!MY^5-
MW$3S-F#;5C""&<0XYG4\QKB_U\FID!)]PTAQW2C,X?$/A,;,A\7PH@?NO#1$
M@9934N>HS</S0>'(*)6T&2MQA%XKA?(B_CIY#IQINEPA;.QV)C&008W*;@P'
MAS^+53*J-F.2"\&6R.WQFI([1]T:MR&XA31Y*V,#4,VS![&T*&6X55@HDO>)
MA>..WS9QGR9TSUZ%,(^4SV-.&RCMMGP.Y0MC,_ER-S:(Y%<7D0>*"5PO)Z@5
M%&'WK'B6/%;%'TU !4WY^, 4E9,9&,XXDH5M#=7JZNSCP]/1UDDG?E!MG&-/
M1UTTSG'1*1;$<7SX-<H!Y<99N\*3(JU"1W*B3T%'B;3U$>%'S5HXDERUHP7<
MM10LX8HVWJ6ANJO1TX\_5Y>PE W>GM=+B9X9'Y@CZ[3&LWAF.)<C5C(4"S:;
M9)L#*XU !@+@.D=ESG)*,A"+XZ7B(XZRGC<DU<1-R80OJI0,+IIQ153R)Q]&
M-32R/?IM(B86#GSN9PS8;DA/)]835J"F)5^=>851>KY9"(AQ$<?&&LHQ[:-(
M)RJ)$&+23"73%VR<B;7:"J%H;J]7#'OX>G.G7T'24%G$2R;"HGD6 GQ\J@\Z
MC@:6Q&2B5:K#3T<D ]N4#%F2EUME]6[Y@Z0<)T5335LM4YBR::MM]EHAREM<
MWK0?=?,-T\ A3!U')3MKRFV@*K60I+WJ2:*2.'BY'CS+K-C2@]=2#9$5OD+F
M(K(N*4-QT,V--7E&I=FMH545$1>A4RGIQCS=)SIL3\H+DS>E&('+F$#Q "]*
M33(X;)$!%9'.EY[ (1!9-)8*QG]B*T8:L2+:1S 2+;L0Y2V/+*B71Q^,?%58
MV[:K"N;NKC.=$7TX7'FS\9.SLA;BFL7S9&]O\1BA*?Y*(XDG>>3X$0^$,7PK
M&<')"8RQ0&5/D0@4A-,D3HZ/B$%%F9!&8_9:QEDDD$F&,8PFP-B8TST9QYS=
MXZW*8DR5(/4=@=?1+)Z;1=ZYQ%DP$7QOE))HSMY7Q%C"Y>T%%)* 9W<ME\OA
M]DBAKGDHJ/D+ULHDNH&%^-?P*HR!NN,0?>WMZVC78[9NA&=L<Y>R"CDJZ676
MNA/"=@(6> [(=8 NM5](N3X[HRZTE3HFDB\2H)ONJDXH&-%7J5$]*+W$.WD[
MOYIMJRMM'QM%XA")&ENCR3)L:*'II)2T880-['XHXEB9]XL.%E[20IT@V59N
MT;K!RHZMMKVUP]LON;)"HB*CM<83/#CJB=:=97VW;RJV ,I;:8+N!S*Z9[>W
M,K9STH]BQ4@7F[%G%L=9$9XQ.Y0'2,%%VBSC#:LE+@&S?)AX!&8XV<&D&1!P
MV5045N!6X7":\.C"ZIG&.OLZ].)O,\^4?QQC5YN[@\-:I/\ )&TW%N+L@R<I
MD,9D**X:3?Y:6D2D<#'\C@8)*D0S5$*%8&J&_,E0YJV0-6 4@NL&EB\>!&KH
MO0JXZUTQG"=/'ATG4?\ E1X,;S1IC,CD,&GD1=-L@M'!J)TPC9(7$!=Y1LA[
M<TV"6C7,T<X['OIT+A%ZK:;E88W]9FL9J+4M7T,<=_Y?CH4FAY2_944@L_R'
M%\SM)F QQA(KN).V16*S4D1(8>"%R$<*36+,U(\U]:1 V3"WT;,NPBKQO'#3
M=5I)5@U$5U$A=U<XQKG&NFO5J2/&N\F*3V8[>HT]CQB+LMU>&C^6<+/3C$N'
M)/"4":QA]D?'<A!'10H@R,B@TN$RJ)'VR:X6<QMK)WXZUHR "R4K#''L7"_'
MF_#K.S-"#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0&YD'YW=_[&W_
M $J&@--H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H#<Q[\^"OZZ
MA_>IH!(?SX5_KJ_]ZN@/F-M7V99.V6 <DX=P9D."/,#S')\QR?CQO.8J==3C
M"-T\<(D#\+8V"3C4'DN,LBB2[Z*N2B\++"*$5FQM>5V-D[UADYV]A5XXPO;U
M+WE;E?)C5(9W7GEN3+:8W=;^8;Y11<)>,=4FM,KPS#A'%[;'5A>QU45ZAD3K
MIM-ES%6M";4>@O!$@BR#FV3H"[^G#7=5N?/G.,=6GO.>HIY'S),:C.+8_?F^
M#O+L;XN\H9CJYU;##R%"RV^UZ7))EZ(U.K59IXR=$44KV-5'-TM;HJ5M>1U1
M2WHQ=_CIQ5G3_93'5T^[M/=./(_9#E\&:0U/-\,8U;>2JQSY-.K^^&'''.7@
MD_CLP4S#1O:>2Y$23(%<.3@W2\]HY<VN[I6X21JV4#?Z<?\ Y-_CY=.';Q]Q
M8)+R5$I-Y#RAE(EEJ/V2.0[CM@NY_'XED +V!@\SV.P</!J126N5"-7)F-Y-
M&L"%]23!JQ>PYX1:O:#9/431J^$W]$TZ'HNO]K*^;&>W/8:U/R2TF&E\-2<1
MF"/U.PC(GE#<O3M A&BR@H_-=^T"D4(6%1:B)6BP&,XM;F62J2CQ,@]F=XQ=
MQ>WBZI2^QF"OT<F.*-:FO]G&JZ:JN/-VG<F&-MV1<'[&L:;58Q/0#B<8]Q"!
MQ$GDBH\V*8*LQ;-,$]DHL<Q(*%A!Q8%19<-S2;E,(?4:O%+RK1C<U>C%5RY5
MQQ55QGK[<?D4_%]@Y;$.^(?NUP3+AL2B1W;^SP?F'$$G,3Z9\1KHVXJ[Q[)F
M,PD1HL[BK^!ILPT:&6^C#;52(LG(IDQ"WOW"MXN]XNZJ=.47JZTX<%T]!"]D
M/D_\N[-H#"\?B,B8<+.1F0Y4?F^31V.9(.GLJQW+<EKY1)8W:)K2M<4TMM+J
MW!FA\S=(/1H(@=H($#2A=0@D#G;RYQC1$]"8^/-U%WS[ 4O;[[P^Y("_D+*.
M9*V@2C:9)9'$D!#Z3XJE [)-,GXSR"P&'Q,A".ASFIZ=#7A I'SHD+(V$*K(
M 1.-DS"PP,^+CMS^2]O5IY2_\=;:L28VD-)RR"/Y?E"]HNR<9=R:=+Y(RC>T
M>V\C\>/F4N=E"47 /KN6]2(0VL<AK?EHDPCS-NFDBF)E?C3\"F\F[6Y?.]\.
MVO=BRED;'1W &/,P0!S"G0\FN:E5F8&P)!Z70-)+)L0MT<O -5&H]0<4H8M5
M<)JOQ5;DU$@SXJICBJ+G/5GHQV]9H=X.S@QN@S!LZR'8=AK.-;7<L&<H&XC+
M #J0)Y&M,QZZ-7QRE:7VL B#5LHJ_M(NV1^B[OH$:C$$T+EEQ47".TXICR:H
MOY%+>49\GADS>X@E&8=F*"XPQU7 F1,5.8N5QN1+/O6:3'H@:CTA;'XO*XD]
M6 "THHB.K#CU#L/'NKD)4A%2<J'1TG'0:[=7AG5%]&<IP7CGL(5FCR7>0<GL
M=\S$;FR&B4M\&WW;'B22>?8]-N5(/*-O(DH ND811O-$[2 &1,"[MY:%?HT(
M-'E&[:I>Y%%1PY!'8W=/V7*O'CG"_D6-C'R>!W'.XO+&771W#<ZB&3Y##\OC
M0\VQD1-9&Q5G*.8A:8E*DL:SU:1>CQ,=D;%BBXJ37BJTD"!71:,#+;:%%#2(
M;WBHG#&4SGBBKG"IY>WS'+N+O(QS"$P%/'AK/,;?#KO)DYK\G>N6%P4HB\\Y
MRQEX[E1IEE)@[DEZ%405"30&XA=[RBA#H71%*4LNF28I#)7Y7./ZZ/X]71PZ
M3KF.;5\BKYX\GHYDSUB_";!\)92'2&<BPQ". I[D'(^-HMA>(Q^*!BA4P0<,
MP\'8R^1S(LH_68-BZL49,*7.B)8=&ACG1W_$O#LSGN[CZ>Z&(T T T T T T
M T T T T T T T T T T T T T T!N9!^=W?^QM_TJ&@--H!H!H!H!H!H!H!
MH!H!H!H!H!H!H!H!H!H!H!H!H!H!H#<Q[\^"OZZA_>IH"O)GDDP,E<@'HBX\
MJDS*.FZ:CD<JJO?:FI6E+E5*.[*7WUI_G74MMY:_ZJ: C/%<Y[GB_92W?= .
M*YSW/%^REN^Z T*FX%HB;MC2KO'*4CN03<V@%+VEANYLK=;8DXM%7%J/JH*7
MW6VIJT0Z.^ZZVVVZM:TIH#?<5SGN>+]E+=]T XKG/<\7[*6[[H!Q7.>YXOV4
MMWW0&N(9N7$^8T*I0894F0;"1M"#>QEZ0*/*W4:#6/G))/SL@ZK9?1LS0Z1P
MO6VZB2=W-KR 9#S,A <T=$"#*',&#)NL[>O7C&K5HT:MT[E5W+IRN0L1;MT$
MK;E%EE;[$TT[;K[[K;:5KH#"'YVH776:BKH"3<MV(LHX;C[$'JZ TW8X5"D5
MD6Q-51)B739NU!;N^VUN0L:N+VBBMJ"M;0-MQ7.>YXOV4MWW0#BN<]SQ?LI;
MON@->,S<N;:W/0R4'+LK73YC<[&-['[6U\,>+CB3.YPU)*I4=#R#5RQ?-ZW]
M,T>-UVKBQ-=)2RT#8<5SGN>+]E+=]T XKG/<\7[*6[[H!Q7.>YXOV4MWW0&N
M)9N7#)M52Z4&%)/B+ 0R5)-[&*;PL5<ILA8MK>Z))6N"))XJDT8,DJWN7CE1
M-!NDHK?;94#8\5SGN>+]E+=]T!KWN;EQJXUJ12@[!T9>7#P[9ZWL:KE2%K9P
M]N8C45R2:CYY:S:.G=S9K:JM1LV<+ULZ)%2^T#8<5SGN>+]E+=]T!@-LV.7C
MTB-:(PAT1#W-;"P]LVL7>B[GS>CIE:1:I$;EV5SQK6CEK1RFE5PWK19*EZ=>
M=H XS8Y:OQXMTC"&Q,M:\O%#G#:Q%^3M'IIK/[A[-0C:X>6L4EDE7E6R:E&R
M:J=ZU;+;[:U S^*YSW/%^REN^Z <5SGN>+]E+=]T!@$LVN K6CXPC"!+*KH>
MPH\)-K&+6KXL0;"13.CAT222JZ)E'K,:/;\_IGI!VV9MK%'"Z2=X&?Q7.>YX
MOV4MWW0#BN<]SQ?LI;ON@, IFQR#'/"YI&$!Q(]"]T_*%&U@\<Q;)TY5'#QZ
M[(HMFR%E/MO565L3MI_G74T!G\5SGN>+]E+=]T XKG/<\7[*6[[H!Q7.>YXO
MV4MWW0#BN<]SQ?LI;ON@-8\SE>.=L1Y"V",'Y2U[>-9/$4FKLC8-;U>$;F+9
M<G8L[M8-*5=/;F]BE&K>E5UZII4YV@,>_/J"<=]<%'&/+(E0/215E-_FUL=I
M'[F="-IWTW<5H,]#W#ZT?4)^=>959UHYHOT-:7Z W?%@Y[GB_92O?= .*YSW
M/%^REN^Z <5SGN>+]E+=]T XKG/<\7[*6[[H!Q7.>YXOV4MWW0#BN<]SQ?LI
M;ON@)/,<DF!DD(L41<>530\SYJC@:HHM=TC!JK7GWVN[*5Y+E*VV\EM.2REM
M/MY.6H$8XKG/<\7[*6[[H!Q7.>YXOV4MWW0#BN<]SQ?LI;ON@'%<Y[GB_92W
M?= .*YSW/%^REN^Z <5SGN>+]E+=]T XKG/<\7[*6[[H!Q7.>YXOV4MWW0#B
MN<]SQ?LI;ON@'%<Y[GB_92W?= .*YSW/%^REN^Z <5SGN>+]E+=]T XKG/<\
M7[*6[[H!Q7.>YXOV4MWW0#BN<]SQ?LI;ON@'%<Y[GB_92W?= .*YSW/%^REN
M^Z <5SGN>+]E+=]T XKG/<\7[*6[[H!Q7.>YXOV4MWW0#BN<]SQ?LI;ON@'%
M<Y[GB_92W?= 2:&9),$Y7'QZPN/))/"C5NHHV'*I+V6J*4I6Y)2KN^EE]*?Y
MMU;;N2O^JN@*\R)_/F5_[[??\VN@(9H#3R*XW;'SMT:L:J2.T.3N )OZ\UBH
M;HR7J*L>7<M.:UN?=!:XKRTY$:WUY:?ET!\>X#/8W%/)QX5E9.*Q2;Y>:Y-V
MW ,ZQW)+=;UY;;KIAG7',(R3)I/5LY:2(;DN#Y/D+W( RKI.KIT%CPUF-N8Q
M]Z.*,QFO[2]6N%ZTPN/2FG8;Z8;OLON8KN9FD2ROB".'\+1/>FS,86,*M#F1
M8F;P0K*5<2S.V$IQ<:9""386,!STH(S&826&RD;D*-O8>X#7/0PTH&[^SHNN
M[Y->.%UUZ.&F-=3;R'=IDO'DOD$$F>3(E='W^5,#1]QELRE&H -Q8#S5@G),
M];MWQFZ.32,"A3_)< CL)A9J9QB0W5NR(S"F2A$E<+-6"(F>'4NB955QCR="
MYZM/,>RS<)G9@]ESB4[A\2M8_B'9LSW'2B50C&RTWALP<C)-G:.DI*VI1V+D
MY2%/ L%CDF>H0U!DJ5(M[TX653!$V]"#XSZ1C3AJJXQGR=GF_(A#S.!/*Q85
M&Y;*H_*G.)/*(;50,.)U>0-U);8Y-,08^GMU#B\ 64B2I#UIE$R&-UXY5=DD
MR8^@+BT@=A7QI^*G3_<7\<'0&]G+Z[!],<#$I2,QO'9=M!W#Y)8R4PWCREL[
ME<43 Q]OC\9?*VSH0NV$BI&[D,K#CDDI61:O@+D(8!LQ9I5Z,43IQG"I[\]W
M'O*:QYG')0X%(@.,5X-)"03!OD^EX:,9O8/$I3)6D_$9 LED5!3J3-B47*3(
MF&B2_#=K/;T8S4X^4#).1*AJA"@N.&>G.=.&.C37R^4\_P#+/RK(X)DF60<D
M43D>(\8[>9["8!-H2!C\DW!J9(D9H%+!QH*C1XN/?DSP=SBJ)VXT-(# V1V*
MI=0C-8\9"AJAC7SKT]7=QUQGL)*KN4R\$+%#<IRN"9P(OO@/[2EGR,/C T9B
M:-ME"ID%,RTA?+$$E)&;>B1N)AUTB24CZ9V?1@HY$NWC-1J9#&G#^KGWX[E\
MGI.>L3[AC\"A;_$,&S5A_'3XWE7RC,KB>6LF&HP @TMR%$]YLY]$1E\FA&#0
M%ZSN 2AI,I3"HHM#Y6>C)UF6@YZ/#Q3M1854UU15\5G#^XGH\N%QTYZ>EN-6
MY8F]W$F8_.HJ=4QKN)CF%XKB1L.A\%*GF<AQMMUR@]'QR>SYNY'MLD-VLMR#
M'(.)GXT6$D)(DQ''UQ1-,<L/$PFG1E,YU7@J]71IYO27<3W#VI;2<>9EMFA:
M..YD6PY'/6*70@$+DZI&;Y2BL$+!G,;=&6<%C,P,^D24=$GR9IYC:.21VPE3
MR^10]E5J3$QKC"KQTZ=$7LZ.G3T'&C'=QG:9Q4'Z"S%#0Y)MB#RFYXZ8#QR&
MRI=U*-F.XJ$X]Q:0O<*T2")TDD(/ID9>DU!,AYL>^<EH\/C?GX9Z#&2M1.O^
MI_W-55_=^9K<K;DE,TCQ"<TF$9@3G&&[_P F:Z%8[5I'$;IA&<B2O;3E%SE!
M!\=M<2!(0O)9O+XJ#>1THB.;#L7'FQBKUX^+V#0W<8QKH_*^3*>["+Y_(=0;
MX=STBP.K>C#I\  'P.*C645(J:&QY)J<;B,A0,%8X-'I*\HNZ!.![Z0@J1J"
MC:2M4J29%GLCC8QD@J]$:F5QA?*G1Q^/,41-<XH9>S7@=X4R%&XZ3QOY1B<8
MF$8Y6I%+W(H +VW9Q80R=N%W=EDI=O,B)$PTS".T"B,4*Q>:1L,U#N"*"9QX
M&,(O:U%_[DX>1=/,OD(*VW8[FU\#HY.KFB,W'2'DW)'O0HU2QS$:,6D]QFT8
M+*QMFE5917U*FRQ1)M+DGBKTVW<,E_4TW$?.;6[07">;?W>W'NU3X0O><;A<
MFC,@Y281"3PJ.*7[B-BD!9O?4\(2?4BV>T(N/D;$JZN=M'1T@D@;<+ B3Y?I
MF;5NDV8I(-Z7W5$PF$\CO=E4-5'MR&4%BF-VQR9XX)F@TL\H] 7<QF$9#CT7
M5VVJ52,! Y2=> 4DUXTVJ##"G624(<R&H%K$G3UJR8-;FHQ$7":XZFJB=JIK
M[UT-4"SYE*79/VU@YMD'(&)2K+<I-L?9(B9[@ZN!*$EMHZ^1H:#93R* UXMD
MR)2-\0]9(<\$718ZX'2MN-/1H7-8P&)#'43&B].B*B^=$_C[EP5\=W@9QBNU
MV-Y>+9]BCS(4^VX[A<Y1*,68_@\>"U+8)#@T+&-9 7)N&A",*&CX9&31$8T(
MY,E!HZR2A3^*QL3)WX9^/QT#'C8XIE$X]?Y]Q-9/GB6LS&Z*0M\LC9,V%[BM
M@X^&P>4-8')8L)QMEPKM=3-D(L/M$-2-&J9C(LG=1R5JD"=C(Z@V(V+.33!-
MZD&-$Z-':]?'X\A92>YS,)8G'C @DP;/#&Z;<IMOG&)'H,4JOC.(XM YE*P;
M*Z;VU) ]Z4<A,<X]R(;H?)/8<<B^6&[$&W8*JQDD]#")GIT:J>?&4\V5\Z<.
M))-E^><L9-.0P=DJ:AIA3(6R7:[N63281L/'+XY+,GW3<7,1PNT3?<J\CCRX
M %?HVE;GKMB8N+5:/4!+]@$#@J)T?VE3'Y_'9YZ>S7NBRK'XSNO%FEQJ+N'8
M\S[,\:$%0F/\A82FL6QAEN/P>K2QU:DTDD<R!!K3(^#Y6Q_DU@09E)83<'X$
M3(@Q;Q@/!&HJIVX]*IP[<]!D2/<C*\59;W+!CN9+6H)WO9QCB5N1G)V$  &#
ML:3?9=BG)P62HDE("=L !)%F%U;BL,<E8:01E0W+6]'Z2TE5)GEA<)AO]W*X
MU55WE3''JUZ-#HV4YXF^,=G(G,<MF&/Y@=9',?@IEE:"-W3S'8Z#R?-L=QQ*
MLT,TW39D@^&0/'!DADHP[0:)1%VYCY!\QMI#5$5:"8RN,*G'"=.<91/3Y\$&
MOSK,7D\C>*1>X>(/HQ+8'N0R!$=Q0N.0^\,0,8T-XVMBF-"9&^I+'<G<Q.-3
M63GLB$8DRCKT^/AZR0>V)O(S-E-!CIQPPBIYN/IX%# ]W^XT\*%Y"D1@#CNY
MA;Y,$K*,.N(B-YX];>-D2.8_RQ%3)@PY6DHZ@)I(GIJ-7?\ =YH47%,$B][I
M@D6$O1=U,JG']O"_W4RB^?XQQ,2F<E<MYEVVY!+SV-@9FPR!OWQ^MBU^TBOG
MN,GN.X_/HE&QY1DXL;2U4RN"C0P[)V1\@Z$R!Z90* &08!>.;+"8PB_W6KZ<
M>;K^,E=+;B<DML*9JR(MDL,V>M/(W[7=Q<-Q44C>.UL6N)T=BVYM_/; L!5
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MDP?NTT6KQNJH!,] - - - - - - - - - - - - - - - - - - - - - -
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M23Q48\CTE7=+&TBS\F+H&=$3_AQ_W9_#0^I.AB- - - - - - - - - - -
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MRO=[N$GVSC-,L?N\?0R2R[R63S>#"#<!"RYB3@1XMCZ4KGP5'I*;NU";VQ5
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M\GG3B79&Y1&9D'0D,0D0*5 '+DDS;&XV68'!#AV&)O IAJ@2&.'3-5R*,CB
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MHF.]Z <54^J(KM$QWO0#BJGU1%=HF.]Z <54^J(KM$QWO0#BJGU1%=HF.]Z
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M\&2< P9L1LB79FBD?,F$'AV+/%8T3$UH(J84O30@T T T T T T T T T T
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MQ^_SIPZ:^C.]_*)#&\&RZ\FV!GL+S&EMQ$+,PIL@7E6WB69=RL"@4[<S\=<
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M7-5!*(!1M<RA%4+P39U:];A;T:H='<);O++':(VZVK-)U9:XL1M5MI?0,]Y
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MK>NI:V9M%46R%JBRJBU]$D[:7*J7J7<M]]U:@;#A5*OZ0!\Q".]: <*I5_2
M/F(1WK0#A5*OZ0!\Q".]: <*I5_2 /F(1WK0#A5*OZ0!\Q".]: <*I5_2 /F
M(1WK0$HF>.)&2DI)ZVO"T16\SYE%S@Q!7^38-4KN<DJXMOL_'3NY.=2G.MY+
MJ<MM:5T!%^%4J_I 'S$([UH!PJE7]( ^8A'>M .%4J_I 'S$([UH!PJE7](
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MG)5ZA>E03"]1O7>?\,#Y,0B!'(\9&G!@N8F7*9-Y<.'7L,=6C[\B7LCSU-
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M+(DDQN<-PN4.0T<>G(D9)1IR^$.24>"%&E%%A10<B_'.+KQ5T]WO3)T!H0:
M: : : : : : : : W,>_/@K^NH?WJ: 2'\^%?ZZO_>KH#3: : : Q7MSRQFZ
MO'(M7#^UNM<R0>N56;-9U1.ZJ"3IV@U?+-F]ZO-M6729.E$DZW7V-UKJ4LN
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M;=$U>JP=+BR# DBW=6)+*L'S-Y99<W<HJ7@9_%@Q[ABOP!#Q;0#BP8]PQ7X
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M%M .+!CW#%?@"'BV@'%@Q[ABOP!#Q;0#BP8]PQ7X AXMH!Q8,>X8K\ 0\6T
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M!-X4:M[UFS)[8X3M44I;6]&^\DK9:I3\MM;D[Z4K^6VN@*ZR)_/F5_[[??\
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M:/PTI+AI<BJSB8BUZ)%"=/#JT^.LY2AVYK,.0YS"\8",MQP/>6W49XPH5/M
M^/Y;+[(5&=O1;+\.?.%!?-A-DK#%4?1BS\:!<QU[:/YB[4VFW>.28JICM\5%
M[,JOQVG-65]V,ASYM#G G)4RB<")UV+[<<\U;VLHZS9Y?D^3#,J;9$>!49)Y
M^LWC40(0H,,8-8D_;&8Y(I7TALD\;>@&CD5$PJ+KC>5/1C'QA.'H^I>X&>SL
M3D/:M"<?SH?$AF;\DSV%R(LF""R,DH&&;?,LY*%%(TH8O7&H/V)J$BEFRZ[
MH/7HYL\_8OV/2,'@Q3I[-?>B:^DX("[V\YQC'<%R'+I9%9BC/=H9K,YQ-M%6
M8(+CTG <UX6Q1*<@-JA_31AQ&6<3R=(LBS5D2N--63B&*U H"!%[D3:+CBG_
M !*B+UZ+I[O>7 /W'2YY*X)BJ69VQ"3@^62.X=S',Z0Y_$I8&5'8^B&)S$3Q
M =D!**@,8')L6MR'.I*3=@HRS:$8%C504W;-I%62%F 8T7LQE%XZYUQU(B)G
MM4YTVV;AWN.]O> V2$TA\?!"?)N^3<5$R)** #<B'R7)$]5PJ4!*&7A88R44
M<$D6X*/7S H/@D F)-U()G;4$UD"=PR<FKEZ=]W2G!,K\>CB6DPWG975@@:4
MK'QTD!13)NZ>&90,8U<8XDF0@$=Q9N%9XYQGD$I!'Z#!A/(,QB*[5/+*N+K@
MLN\^DD6E,-C+D62]$VC'&./9QTX\?/T)G3CDVF-\MSM*9XP#%LI-YT2DGE)]
MTN&SK";"8.7.PZ)Q?&6[0SCSU=N%B C^)NDV.-8TR;N*IW+E8V_?CF2[<<6=
MVNWQ^/\  *G'3@UJZ?\ *F5]/9J1"&[R<OCX7"I7D/+\5JUR?M??Y/M(I8_
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MQPF<=B+E>'C(U=<="97'FR?2'%\H0G&-,=S5L16+MI?!8E*&Y9R'6CK@FA(
M \LD17C[FM7 )9ZF[M<JAW%:K#+U;F2M:J(7:&).M - - - - - 33(?\\"_
M_P ?_A;+0$+T T T T T T T T T T T T T T T T T T T T T T!,\=_S
MYBG^^V/_ #:: L&9XW-$Y7(""!  FB\*.ET['!2B2]EBBE;J6JI]!=S+Z4_S
MK>6O)7_7H",<*C_O.-=KT[OH#P5Q*:72416?Q=9%9.])5)4K8HDJDI;6Q1-1
M.]M6V].^VM;;[+J5MNMK6E:5I6M- :-/;\U285%)#<=IBZNK7U1J=!MC"KZV
MVRVUY5G:/HWJZMM3LMM<='TU+;+*4OY+:<@'XKM]:+IFTEQF.EDI*JDM(TU;
M1JB9]9"VRQ!4W9>.K:551L33L24?47O3M3LMLK2EMM* 5A;LL"TS(WS3>3"+
M%Q^.P.-@L566B5\-CPJ-'R\B$%@+7U2H>%2!L\-OF]CMM(;62;"Y-L@.1JG1
M2HN=,=N2SE=OC-=PL[7%XY6=.':;]=RK8,4<+/TJJ52>K+7CJJ*.TJJJU3<W
MW7+6544K;?3GW<HA[DL")H/UBB++'Z)-PX</'!%*X>F_7=NVB#!VZ6>6,*.%
M7#IBV;,G"]ZERJ[1N@W4NN123LM 5P(G5<*YJRQ_5S&TE$(ZXK</JN!050L;
M*HA5:L.D%I*-DTVZB;&Y"R]!.Q*ZE4[;;: 0*?;37,X IQEC,[,=AGARA*7M
ML=D8D(4R $<#"@DU"I4Z+0XZZ2CTB;%*W%"$76C<U;N&3%<'+@RB:URX$Q>[
M>$R,@C<H>TB+@S#VY1O&7-Y-.E M#+6Q@268V6M;:)KN1]E1_25K=T+)9TW;
MT2L=NNF SB&!Z%[U%"K6 D[U;6MJMY!1B]O4M97.;V5JESE@I6^UI<]>7-:7
M5K1O<[<U2YE5U:W@8CC;P/=M%F#H1C9RQ<D$BSADX2%K-%RJ-_2(DUFZ@VY%
M4@E?2EZ3R^RYRG?3G6J4K]N@,M? ]KIP1=N6D!<.B[%086<KJ,%7!0:LE8@J
M/(K*,+E'K%5!)-%1HYN50O23L3N3K99;2@&+?MY8*L%12@C&Z@Q=PP=KCKTQ
M=[!9V*;LF@MTJSN&U;J.!K4</;,%KTZJ,V[!DBWN33:H6V 92^![72I-=TT@
M+E8TSN'F5EU&"RI9A>E:A>Q)J*,+KW[.Y&RQ&YLZJJC<E9:G6RMEM*4 R*X1
M<5$U 5MA-051_HJH6KIK43475OYI4;4=YEYGZ/\ -?\ LWF?0^;^;_R/1]'^
M+H#5TV[CJ5LK0/C6E4[^D3K1(52J:E6+09S[/^[?Q;_1H]@/YUO)7S%DT:<O
M0-D4[ /Q3;J-6L')K!<:*IA[7M@E-1$5?8+L)5Y2-@ZRX;6UC:_K]KVUM1*C
MJOVKT4T!LW^#UBJK5<HG!R2S&JES)9^X:/%6=RU+*+7-5'#)2]O56B:=%*HU
MLK?2RREW+S;>0#":[?FK%1%9D-QTS5;MEF;=5K:-;J(-'-RU[AJC>D.LN2;+
MWN'%RR%E;4E;EUKK[;JJWUN _+=O;.T6-!VB\<VA0SIN^$![;!E!8IZT6O<-
M7@T?0=YHQ=-EU%%V[AJBDJBLI>HG?;?===4#UJ;=AJR*K98-C55NN,2"KH*(
MBKT5@R%J-B(E5*X;6Q08C8W0L287VU:IVH(VV)4HG92T#ROV],5%F;E03C=1
MP.(JF![B],7<LQ+N+[55RC-6X=6]L164LL45?(W6.5+[;;[U;KK:5H![W. T
MGBU'#QCCYVXH\O(47<W#UUJ/U$6S=1]155A=?YY>@S9H7N>=TUR+1LG6^MB"
M5MH&%=MQ$7HW-[P6,;F][)P-O0N;"+D;QSNJMSMA<E496RYDZN77N<-:VU07
MJLK51.ZJE_*!EIX ;HK(.41^/$G#5TJ_:KI^CK%FSY>Q!-9X@K:/I>BZ63:M
MDU7"=UJREC="V^^MJ*=+0/84P-8;<,W9II "[H=:ZL'N2E[!^X8V/K+$WMC-
M9VP54;6O$TTTW5J%UE'%EEEJM+[;;:4 PGFW081L=)D N,WUCY]83>V/$!+F
MQX22N4O2(.K5AM]'#Y.]9:^QVM2]>RY52ZU2E5+JU V2V#+W!5 ZNC!5S;9D
MJ-;&5EV:A5N.7NK>NP0(WL;G:3):^ZZ]5JFM:@I==6Z].M:UKH##NV]LKQ=0
MEXK'-X6KM)_41=8,N%U?(*I+H/:L*CJM*NT5T45DG'1=,FJDDI9?2].VM /?
M7 ME5 RU6< JK':K5CZM;V'2 JN4?-W%0U_F'.&5<(?R"U654.E1_D[^=9^+
MH#"7VYBW(^\2Y"8S<"E'MI*\8N@)5'WD;+>980O9*#+FUSVVS\2UU5.J]MOX
MM%*4^S0$GIBD_3[*$HU2E/LI2A>GV?\ ^OH!PJ/^\XUVO3N^@'"H_P"\XUVO
M3N^@'"H_[SC7:].[Z <*C_O.-=KT[OH!PJ/^\XUVO3N^@'"H_P"\XUVO3N^@
M)/,L<&B4D)/4" !-)?S/FV."E$EJ=&P:I5YZ?0W<WEN3K6W[:\MM;;O]>@(Q
MPJ/^\XUVO3N^@'"H_P"\XUVO3N^@'"H_[SC7:].[Z <*C_O.-=KT[OH!PJ/^
M\XUVO3N^@'"H_P"\XUVO3N^@'"H_[SC7:].[Z <*C_O.-=KT[OH!PJ/^\XUV
MO3N^@'"H_P"\XUVO3N^@'"H_[SC7:].[Z <*C_O.-=KT[OH!PJ/^\XUVO3N^
M@'"H_P"\XUVO3N^@'"H_[SC7:].[Z <*C_O.-=KT[OH!PJ/^\XUVO3N^@'"H
M_P"\XUVO3N^@'"H_[SC7:].[Z <*C_O.-=KT[OH!PJ/^\XUVO3N^@'"H_P"\
MXUVO3N^@)/#,;FADKCY!<@ 419E&JZEC<I15>^Q-2EU;4D^@MY]]:?YMO+3E
MK_KT!8LA_/A7^NK_ -ZN@--H!H!H#7%["Z@M_8!<#FAJYJM06Y+LW) 6B]YE
M?-[W[)D_&.W+6BG)19-N_:K5LK6MBM+J4I4#YW8'WR'LZX> FU8D'Q;GB/SC
M!,4S1B"4T?': @V;Y#&1L4G\+(,28-8Y YO&I*E,8!);['#5W<P,0PRDRD\?
MD"0P541.G*:X7]W1KQ3JUZ4.FQFZ[;^85-HC<AMW*@%H$?K<@"6)6F&4ER _
MQ3'7<-47 IISYN<R0.7A8E6#7R&Q_(%AS!K554N)\]#"_'I^/W'D^W58'%NP
MS I-UQCTV0CHM-J1A\Y8KAGTOR>]PM$TIDF[C*-T!LD^5AI&!1YQ.*1YL:D;
M%XQ&JN;FRUU@F%/5M]RY),I6YRME;0 POQ7N R'B<6N#0?LV[Z.Q)E'7PXF4
ML)$B5;2RJ9I6T@JW6;L;JHV7H-&]O.I4#G"8[YQ#6>9$&QF50X5BV-[6!>?0
MN5)5C;+!,+8Y,Y 7B0L]S!-12D_Q<3&IIEF!^!)JM72%]2#>1+#>C4O%QV=.
M...'%-3K8EG_ !$'+RH.4EZ8]6$,I$_E95T&D2,5")Q(4$-R5L\FMXBD/]*!
M1<C#NWX5(XH81L=7V>8U5:/4VXF/CI]'$TC?=!A)V@3N:2HJZ*!IB4@!2(-H
M%D1QD5G, L0&9 * U<9(Q2_(?G+2#FPDMO5LC%S2Z/&@Q5-Q>S*CU7 N%^/+
MC\2&EM\>U<*@U>N\LL7 IW#<=9'M/AXS-I#&&V.LKERP""Y")R@!&B4>#P0J
M<!E!+Z8E2;*-QLBUJTE!,,NJA8J&%^.S^)$,K;V\?QR!VR''53TF.W[A\7[;
M2PY_BS*WI""S/(<A@J2[N60>^-A)E<FQ@LZ%SJ+L+41:6161*-HQ8RLTD+,G
M:")^&?C\"?Q#<I"V+<'$LHSJ*JY0O4F@4BY@\3R(U@$FEF.F!(W,XY B)L62
M;E9@ CPHD4D&,QLEDTUCRX.6C%D2-\1-NVP8^%^.';P([!M\V \GY"Q9C['!
M"<2Y7+T1E4XB4I:8KR>,AKJ.185BHVJ23D1R'C![M@1%YE@[QL78K. ;.U\J
MU+E!Q*C=BY#"HF>W''R]RG86A!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!
MH!H!H!H!H!H#<R#\[N_]C;_I4- :;0#0#0#0#0#0#0#0#0#0$*R OD!&,NK,
M7CXN]FCI9LU%K39X1:1,38JK2KTR;L#)*FB2+!G8M>T"BJ-G!@G<Q'+E0(]P
M]/BP*NVPY7F^8<7N)'D>)!XA-([D;+6+Y A%R;TQ#3Q+$N2I1C=W+H6_*,V!
M>^,29Q&52@]H6:6$!5ZS@0X<$:L+2CT5<9T7*?&GF^.HZ&T(- - - - - -
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MU= .*LA]WQOL9+ZN@'%60^[XWV,E]70#BK(?=\;[&2^KH!Q5D/N^-]C)?5T
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MG;HN$]*)P_M>0\<49LOCV9,NQ4#F=!7'>5]\LN82O<&P<8Q(5&51V-;?#^.
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MP;0#A.6ZPQ3XTIX-H!PG+=88I\:4\&T X3ENL,4^-*>#: <)RW6&*?&E/!M
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ME+_QU+N;SKJ\VWDMIR6TI30$7XJ2K] #\NA^Z: <5)5^@!^70_=- .*DJ_0
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M!] .%#CK5'/W#G@^@'"AQUJCG[ASP?0#A0XZU1S]PYX/H!PH<=:HY^X<\'T
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C,4[K;TV32R^VM+K;[&R-MUM:?DK;=;92M*T_U5I7ET!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g805799g66u56.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g805799g66u56.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2]@4&AO=&]S:&]P(#,N,  X0DE-! 0
M    +T2^$A #A"24T$!       %QP!6@ #&R5'' %:  ,;)4<< @   @   #
MA"24T$)0      $,==%^5TM6[UV[XYE,#I>5PX0DE-!#T     ' P"    (&
MYI5P    !8 $4 4@!/ %@ ( !" "8 5P
M                                   00#!MP  !M3_X ! 0 ! .H*;P
MAD  $ #P!8 @$  0!8 @,  0!, &4 = !T &4 <@
M
M         !          0    "     0
M  4%))5N(0
M                                                           !
M@      ! G$"<0)P  $"<          ,@ O ,
M         #         $07$ !<2P, :$,$             0 !
M            "$QT6$!0   /\  0#_    !
M
M
M
M
M
M
M
M
M
M
M                                               0
M                                                  R    %--5$
MH     $ "X
M
M
M
M                !$%P  ,4Y26 $    ,%P
M                               %XM/,H(  $ CP@0     0 '(-$5%
M4     35-#1@    !R"        "P          P$!  $    Y,   4@
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M9+9_:\?P "_____P  )[5#3TTU @!F "  < !R &D ;@!T '4 :0 N &0 ;
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MRM&0 $  $
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M  (1 0,1 ?_$ !X  0 " @,! 0$            &!P4( P0) @$*_\0 21
M  <  0$&! (&!P0'"0    $" P0%!@<1"!(3%575%"&1E18Q(B,U-G6T"1<R
M05%TM3=287<80F.!EJ&V)"<T1&*QM_#Q_\0 &P$!  (# 0$
M  (# 00%!@?_Q !+$0 " @(! @,$!@0*!@D%     0(#!!$%$B$&,4$347&!
M%"(R89'P!U)RH146(S-"<Y*QLN%B=8*BM,$E-#9#@[.UT?$U4V-TE/_:  P#
M 0 "$0,1 #\ _OX    !1;L?E(^=F'VBN"XW*C:\9\YE%^$OA"K+)#\$JWXL
MM-^.E:I57-38G7JHRR;3L1$]N>IZ,Z!Y]]G'E3MU7?;&Y1P?*,)"<+5PM':N
MT5[6P:;-TM,NV7%Q-EBKBNK%VEQ'F^"4-I_XFT:F0U3I%LM-G';<;W[H8JQX
M3K?UVXK:;;;UN2FGVCKS\EWUKLSXGX0Y?](=_CWEN.\0565\1"K,R/8W8]-6
M-30KY5\?=QM\:XV9$)2C[%R5ET9P=D[W[>"UZF>-NO3\G]XN/8QH'VP>-NO3
M\G]XN/8P \;=>GY/[Q<>Q@!XVZ]/R?WBX]C #QMUZ?D_O%Q[& 'C;KT_)_>+
MCV, /&W7I^3^\7'L8 >-NO3\G]XN/8P \;=>GY/[Q<>Q@!XVZ]/R?WBX]C #
MQMUZ?D_O%Q[& 'C;KT_)_>+CV, /&W7I^3^\7'L8 >-NO3\G]XN/8P \;=>G
MY/[Q<>Q@!XVZ]/R?WBX]C #QMUZ?D_O%Q[& 'C;KT_)_>+CV, /&W7I^3^\7
M'L8 >-NO3\G]XN/8P \;=>GY/[Q<>Q@!XVZ]/R?WBX]C #QMUZ?D_O%Q[& '
MC;KT_)_>+CV, /&W7I^3^\7'L8 >-NO3\G]XN/8P \;=>GY/[Q<>Q@!XVZ]/
MR?WBX]C #QMUZ?D_O%Q[& 'C;KT_)_>+CV, /&W7I^3^\7'L8 >-NO3\G]XN
M/8P \;=>GY/[Q<>Q@!XVZ]/R?WBX]C #QMUZ?D_O%Q[& 'C;KT_)_>+CV, /
M&W7I^3^\7'L8 >-NO3\G]XN/8P \;=>GY/[Q<>Q@!XVZ]/R?WBX]C #QMUZ?
MD_O%Q[& 'C;KT_)_>+CV, /&W7I^3^\7'L8 >-NO3\G]XN/8P!G*F8NQJZVP
M=;0R[.KX<QQEM9NH:7)CMO+;0XI#:G$-J6:4K4V@UD1*-"3/ND!D      !K
M#JU)S7/F!VI-]&+ZVM>'KIXC,D-1M9CX.QSTJ3\NA^%I./XM+#-1EW9&H6VG
MJI\B%L/K5VQ_54;%_LOIDO[,^I_=$\WRFL3G/#_(:U')GF\%D2]%#-H^GXLI
M_#+XR&/6_2>8TE]<V>%1Z0
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M 8+0
M             #"YO]W:#^"U7\BP ,T    ",_C/)_BO\#?B*H_&!U?G19KX
MYCS@ZHG/#.;\%W_&\'O?/KW>]W/UO=\/], ?E2E*KW7I4DE)5+JDJ2HB-*DG
M2Q"-*B/J1D9&9&1ET,OD8!I---;3[-/R:]S*O[.AE6<<_@!;AKD<1Z;3<5]Q
M9F;C5+DK-QO#&[WNIDY+XZEY"Q,C-1$4TB)2DD2CMN[SZO2R,9^GG)?6\M_T
MU+X'F_"K]EQ7\&N6Y\'F9G#:;^M''PKFN.ZM]TY\7/!MU[K%IM:;O<5'I
M
M       #"YO]W:#^"U7\BP ,T    "I*?BENGY!1M4ZC06E?#HY]12YO0V-M
MHT44BXL%65Y:5UU>6UA:*E6SI1HCB9JY::RHKX-)0'45"),*6'Y_/Y^!+Z%A
M#%]LNXIY7C65:^OQI,B3T6[30S4EKXAUWP&2Z?JXS/AQVBZDTT@C,C IK\0T
MW%W,_*:[QYRNS>SP6<Y7=F-Q9TXD6V1>1Q[MYJHE?&ER38AT']6#DMUEA2(S
M!2)DHVV&W7DW:<ZJ]=Y1G*O79=I?7BMM^;EU^?W)'E/I5'#\]S#R&ZL3/XW%
MYJ5BA99J_!DN+Y&QPJA.;C7C?P.YRC%J$5.R;4%*2V%KYT>SA1;"*4@HTQE$
MA@I<*9722;<+O)\>#8,19T5SI_:8E1V7D'\EMI/Y"IK3UV[>YIK\5M/Y,]17
M9&VN%D.M1G%2CUUV53T_+JKMC"R$O?&<(R3[-)G<&"8
M                                                   87-_N[0?P
M6J_D6 !F@     !&:C]OZW_.5/\ HL0 :T=L'Q:'&U/(#'1#-.QM<)H73Z=3
MS7+&,MLI%C]?S(E\C)XX?5TZ?HQ3Z_+Y'L8_>3A[^B2^-<T]_P!CK_$\-XZW
MC<?3R<>T:(<AQN4^VWB<UQ]^%"._<^57%2:WK4&_-(V]&N>Y
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MC!<
M         !A<W^[M!_!:K^18 'D3_28%E6.3.(Y_(&*[.O)^4C8C6/L8_E][
MF"'HZ*9#NZEVVW+%EPEQ!R5>UW',.L=CUNQ>VTJ!@52'ZYR6TU+C*??$6O\
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M^5>J_P#5V-%B_FI?UD?\,SC3_P"T.-_J;-_X[ +4%9V0
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MH0A"2)*$(21)2E)$E*2(B(B(#)]@  (S4?M_6_YRI_T6( ),
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MIN$E8I]"C6[;8%9V@                            PN;_=V@_@M5_(L
M#-     A/]8N._'O]67FY_C;R+\2^4>6VW@^4>/\/XI7'P/D9R^]^L.J*R\V
M*+TFG"^#,GP!D*C]OZW_ #E3_HL0 28
M                                           !A<W^[M!_!:K^18 &
M:    !3M#P1QQF-]_6/0U+M;?^73:[N,R.]$[EC(>DS724\VY9$B0[(>=75E
M9>0?%N':)J$VY%8$!-J&-'C7VR^'898\>RK9+W@M(:\:0[30S=?=[B4^(\Z9
M$;CJ^JUF1&I1] !+
M                             &%S?[NT'\%JOY%@ 9H      1FH_;^M
M_P Y4_Z+$ $F
M                         87-_N[0?P6J_D6 !F@     !&:C]OZW_.5/
M^BQ !)@
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M+KZ57NH >;2?0+KZ57NH >;2?0+KZ57NH >;2?0+KZ57NH >;2?0+KZ57NH
M>;2?0+KZ57NH >;2?0+KZ57NH >;2?0+KZ57NH >;2?0+KZ57NH >;2?0+KZ
M57NH >;2?0+KZ57NH >;2?0+KZ57NH >;2?0+KZ57NH >;2?0+KZ57NH >;2
M?0+KZ57NH >;2?0+KZ57NH >;2?0+KZ57NH >;2?0+KZ57NH >;2?0+KZ57N
MH >;2?0+KZ57NH >;2?0+KZ57NH >;2?0+KZ57NH >;2?0+KZ57NH >;2?0+
MKZ57NH >;2?0+KZ57NH >;2?0+KZ57NH >;2?0+KZ57NH >;2?0+KZ57NH >
M;2?0+KZ57NH >;2?0+KZ57NH >;2?0+KZ57NH >;2?0+KZ57NH >;2?0+KZ5
M7NH >;2?0+KZ57NH >;2?0+KZ57NH >;2?0+KZ57NH >;2?0+KZ57NH >;2?
M0+KZ57NH >;2?0+KZ57NH >;2?0+KZ57NH >;2?0+KZ57NH Y:)AZ+24\60V
M;,B-55[#[2C0I33S,1EMULU-J6VHT+2I)FA:D&9=4J470S RH      H3 7G
M*$[E;D.LT[%LG'PTRCJD3L\Q6TM6ZS=.1LTWD] W71'M6WH<L17FJ.1877X>
MOB;JV7JU+JJQH8^7S_/Y9?8&0      *:YCO^4*./ARXTR\R_*=R)B(VUEP&
MZ*7+JL0[K**-I"CP+NYJ"-R?4RIJ'[6.F>=)61K&>J/'>*+80P+E
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M],5EHXSTJYK3I[&QKHNALX]-82*Q>4PKT,Y52W#6VW(QV>?4UW''(3G?*9*
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M;6];6_=ZF:0M#B4K0I*T+2E:%H42DK0HB-*DJ(S)25$9&E1&9&1D9'T R?0
MZBY\!N4F$Y-B(F*;-U,1<EE,I324K4;J8YK)TVR2VM1K)'=)*%F9]$F9 ?,>
MRKI9L%$GPI1RHZY<8H\IAXY$5MQ#3DE@FW%&]'0ZXAM;S?>;2XM"%*)2B(P.
MZ9D1&9F1$1=3,_D1$7YF9_W$0 X8\AB6PU)BOLR8SZ$NL2([B'F'FUEU0XTZ
MVI3;B%$9&E:%&E1?,C,@!^MO,NK>;:>:<7'<)J0AMQ"UL.J:;>2V\E)F;3BF
M76G20LDJ-IQMPB[JTF8'*
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MO%Q\VSHIU15UT*5 :S#L:$Q . VD2_/P^/XKU^!Z(@9
M                                                        #@1%
MBMR'Y;<9AN7*;8:DRD,MID2&HIO'&;?>2DG'6XYR'S80XI263>>\,D^(OO <
MX    .NS#B1W9<B/%CL/SW42)SS+#33LQ]J.S$;>EN(2E<AUN+'8C(<>4M:(
B[#+*5$VVA*0.P                             #_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g805799g88b20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g805799g88b20.jpg
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M 0$! 0$! 0$! ?_  !$( ,D!I@,!$0 "$0$#$0'_Q  >  $  04! 0$!
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M#*SS\B%(Z-'$"'E!Y$F.,@J[8B!"AQ*Z'%KX$8,.%"CABQ(L<;1 C1HXVB"
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MD( *-$-C4Y')(\LCRR-NDD=G=CU9W8LQ^))/LZ#D*Z=A% 2-=D2*L<2#HD:
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M0<$'D0""*J<S5XZ8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I6F^H>"^QX+Y:
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MVJF$1%&$1%Y*$4 *% P % &,5G2*CD[HJ*GYT7NG^M,5Y\8ZUB.R?[^<<?\
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M N&B#(UKQD9QWJ3V/8]$<U['-JU:YKFJCFN:JHJ*BHJHN=#\_O?U9<_?Y/\
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M^$GV5:1Q)<IZ'DO0*]_(?<;2%']43T!%:X,9.RK]L@C2B-7^,<#^18J\E5Y
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M>Z>T1=@&88# ,0K>P'D1GGT_]LUU_3=$M])MHK:PO=7M(UC3?:SS6M_;"1D
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M@_CJY=P(9<Y4@\AG'OJUMIY T>://^$GN>KW'C@\8<Q>S?MV%:\KXY3$5/\
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M]0,9F9\>)D DS\=]=2T60/9Z:^>0C@7)QTC/8-\!LP?=65Q9 YD6-+"OD*4
M,@3OSC.-I6+_ %M<BYK:SD8)'@2/JKWQ5*8I1$55[(G=5^B)[KEK.J#<[*BC
MJ6(4?62!5Z1R2$+&CR,>05%9B?<%!-:LW3FWBCCVQ2FVW=ZFNO58PJZ_$'87
MVPC$1.XBGH==A6UO%$;W]$LF&$9NRJ-SD15S4W&N6,!VAGF/0]D%*@_=NR*?
M>NX?AQ.M#\FO&'$$/G-AI4HMLX$]P1;Q,0>866;9$67Z2F0,O>!42>>.=M>Y
M&@56EZJ>6S6"W$.=L%K:Q)-(^]L:M66M#JM?7V*1[)OC, &_LVV,.!(*VNK
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M#4%78M]96MXJ8F&P74$<X7%Q!;3C:'QB>VMYACYV")]T:WJ298\:1(: \EP
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MW?MVT[BGB:YADNG"=J&>?A&V;,3((<;" T4C*S+*#4WOB^<__H#B?^U^X?\
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MJR*68))=M50(O9_K>"ZK6K.SO-/EB62_)4I*4B@@+R"([]BAKE 22 5!;FP
MK;:+J/'MG?QR-IW!8WK) ))=<UQ$A,R]GVK,G#TC!0"58A3A68]U07KMZY4N
M**'L576\33JV>1(\90[7N;92SO7=$)5GB'T84B%:19K"P9U=.'&E5\T)XLX4
M<P#,9S8KH2YS<:N"#M(\SM,[LXVX\^R"#R(/,'KC%3S?Y3=VWY)X&R!NS]D&
MOD;<9# CAH@J1@J1D,"",YJY0=BYIG%)%37N+HLT+/4+!F[3N4:4T2N1J&8U
MVD*R0#R5&_$12' CU1CB(_[.4 T$\O.-7!\#9V8/^W<Q[1D9Y=:-)Y3%&[Y*
MX%*]-R\0:^1GP_\ XSD'V$"JB=8\Z "POR+BEJ-DQ&.1FW;:[R8>4*.YKD?I
M")X]B]U5JH].W=ODJ>+JE=#_ %1JW4?_  =GWD#]751)_*63@:5P-G!P?L@U
M_E@$Y'_1GKRKE1R@'D#C/J+Y!K-DJ=4K'<FRX^\T,E+:Y37['X^-&'<,J[$E
M"(LF1#NVS 6(3Q(YP&*$I&NCRHLB1SN]M>&H+B6-[G7E9'92!I^GD8SE2"=3
M!*D'(..F.^OMS@/7O+/KG!ND2Z?HODIG73X?,IQ+QAQ:EU&49C%V\*<$2+'F
M+9L*R,IVLN=R.J;TX29J$W>XXNH(LNFXZ6HMWDF\=3)EC>+=I'9\G$44ZA[,
MKR.4ZO+'&8GQC8+#,;!?+*/-ID?!1N?[_NM:,/9OCM;2WA3?M]'+VMW=2Y^U
M BVEL;F"YSZ]=N_+^+/^\=$\G<,O:QY;2-?UO4[S&]<@6^L</:)9B+;N[:0W
MAE51B*)W8%8V\\S3,TP]-3L/(L-AL TU-&,@VS)9YTEL2O"1@G$&DDY3QV/:
M)SVH5SD&KD[=XJXC,[]B6,0D;LR_)NSW':6 R <8R!W\A7==':6."*XU'LTE
M@LUFOFBR84DCB#W)3=@]FI#E2<':,\N==M]0UJ+IFIZMI\)4=#U/7*+68KFM
M\4?'H*N+4A>C?N\QQ&N[?K[K[^^=%TR+L;"V3O,8D/CF4F3GUZ;L?#%?GSQ3
MJ+ZMQ#K&HOZUW?W,IP<\VD8GGW\\UD6>ZM!3%*8I3%*8I5!,GLAGK([F*YUI
M.=!$J.1J#>R!.L%>[OW[IZ<%[$:GNKWM^[OE"<%1]L<#]ZS?B4U<J[@Y^T7<
M?K _GJORM6UY&,&,$LB048  &\IC%>T8A"&U7/(1[E1K&,:BN<YRHB(BJJX)
MQS/(#F2>ZJ@$D #)/05C, 1KV:&\FB(&OBJYU! ,U6$<KV*-UW-$Y$<R083G
MCKH[T\HD0CSE1)4I1Q<8RY#$8 ]0'K]T1XXY*.X$YYGED8[%,8]8^NP_\ ([
MA]+Q/L%97F2L58+L5);\F;7H_ VM3959:<J3)[-ENX*JV7JW%FOA#+Y"OXY4
M83X6QF0),/4->E.:B1]CVBKE(]J17*GMT^R;4+R&U&0KDM*PZI"F#(V>>"1B
M-200'=<C%8[BZ2PM)[]P&[ !84/22ZDR(%/,953F5P.9CC?%=C]:UNBT[7J/
M4]8JXE+KFMU4"CHZB"-!0ZVJK(PX<&''&G?Q%'CB&-O=7.=X^3W.>KG+UB.-
M(8TBC4)'&JHBCD%51@ >X"N7RRR3R232N9)97:21V]9G<EF8^TDD^'A5[R^L
M=,4IBE,4KF1SE3EH>H?>%]FPMUU#0]TC^WCZMM$'<Z/>(W[GNC5VJZHXSD_)
M2;'1?RD[\[XHA[/4A+W3P1M[V3=&WU*B?7[*GW#\O::6B=]O<31'G]%PDR>[
M+/+\5)[ZP;(W6ZK".2=!I>4="VSCW86(M5ME++J3&\$>2!(*WU*ZVBHO9&S:
M:R'$M83_ .9*AA=]V:[5+475G(H&9(P9(CW[E!RH^[7*X\2#W"I1P=Q!<<,\
M1:9JUN^TV]S'VBYPLD18!XY#@_-NI*2<N<;..\UQ U+D0&C0Y>A<@+\NV_2[
M2SUF]BN(U4%84\LL.2@WO\/5 X@E)%.WN.1&>(XU49&JO.F4ACRY>S_T[O"O
MT'5$U.*WU&Q826M[!%<PMR&8YD#KD#HP!PZGFK JP!!K--+A774WOT3B_2C2
M:[4(S 6O)6W1D3RIM9]7P?#B2%1X$O;U[75U)&<A'>LI[$H"P:R9XY[6VDN9
MDB1<N[84=,?MFZX51DM[ 3TJ.\5\067!&B7&L7Q1[O:\>G6I.3-<[>3%003%
M#D-*01G*1*RR31UV8K]/U^LUJ+H\"F@Q-/KJ=E! I&"&:M2B9!6M6GF0Y#2,
MF12Q"%%)22AOC$(XTA[I+W$7H$>G6Z60LF7=&1EVZ,TG(F0'')L@;>N% 7F!
MBOA.[XFU6ZUV3B)KN4:D]R;D3;FWJYD[0$,I&T[L$[-N&RR!<#&/Z!QEQSQ%
M$LZW1Z(&N1;F8RQL7EGVUB:6<3'BC"?:7L^PDI$@B>0=?6#DLB0&F.Z/'8Z4
M9[[+'2[>P9WCW.[C;O?;E5Y95=H ](@%C[ !@9S[^*.-N(.,#;-K-UVXM$V1
M(B)&@\6,<:HI9CS9RI=\ NS;5Q0WW$/%^Z;Q3<A7>I0+?:=>!''77A9%@D?U
MH$ATBI))JQ2V4=Y)ISD/(K9=K7V!*TRB6,1CQ"0.*?1;2>Y\Y8R LVYXU*A&
M;O.<%AN^G@C/,C!)->K2_*'Q1HVA3\/V5\8K"XWADVJ9%210CJDA!DC5E 1E
MC=%=1MD5UR#X\R\/TO,^@6>BW<AT1SFBL=:OT'\19:WMD%".JM@CO<YKG>@]
MY(L^*-POF%5,L8#RB9(:YE=4TY;NW B4++ OS0 Y,@'.+PP1ZG@V!R!:J\"<
M:WG"&OPZDK-+;SOV>HP,Q[.XAD8=KOZ\R/2W$-MD5)=K-&HKDG&WB3I-A;:%
MRH%=?WK3YCJFYCO[N!,]-B/B6L [T'\566L1P9]=-:U&2X<@)T1KG.8WG[HR
MG&/$8Z$8R.>?;@'ER-?=-I);:Q9VVJ:5(MQ97L2S1,,93/KQR %@LD39CD3)
MVNK#)P":75X$3J2YKT'BJM[SM/CS/PNY <SR42Z?KQ0R;*+*<-4<(=[+?7ZP
M-[7(\9KL9&JG@JIFMH'FF2-1Z4CK&N1T+$#)Y= ,DG/( ]U:SBS65X0X6U;6
M96[.Z$+6UCT#&[F1Q&R9Y%X4$ER%.0W8E<>E7=)C&#8P8F,$(;&C&(;6L&(;
M&HT8QL:B-8,;$1C&-1&L:B-:B(B)G2X8D@BCAC&$C4*OPZD^TG))[R2:_/6Z
MN9;NXFN9F+RSR-([$DG+'.,G)P!@#GT KZJHU%<Y41K45555[(B(G=55?N1$
M]U7,M8*G_P!-$1\7@'B0I1J*1<:13;1,&K5:YL[;P?A3/1S5]T>LRX.KT7LO
MDJ]T1?;.L:5'V6FV*$8/FT3$?MG4.WX6-<XU>3M-4OVSD"YEC4_M8F,2XQW;
M4&/9WGK6\LV%:ZF*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*5$3F#I+U_
M=[BQWSCF[7C#DBQ(.7<2XU<.VTC>)<=K4 7>M.<:&*79(T8Q)M=!.HMK:,8&
M2[2SAQ 5Z:'4] M=0+3)_>UT<DRHH*2-W&:/EN.?IJ5?Q+  5O\ 3-?N;%5@
MF7SJT')8V<I+"#U[";!*C'Z6ZO%UPJDEJA#-K+VOVP^C\ET/X+<C:F*/<A;5
MV1IM)>TDPQ(@=GT^W<"&^WUVP-&+ L(5C BV51,:M?<5X7O@RIG/[ZPGL9^Q
MN4VNOI1NI)21"<;D;EN4XP58 @C#*#4VM;R&Y@[>TD[2&3T'1P!)%(!DQRID
M[7 .5925<892>8%V/%ERY#&G?''7A."0T8D>^1))'<TP4,]Z-& 8I+&%5@FE
M>91C12C9Z@R>,@D]< 8/M..?7N&?K\<<JS J!RSN(QDXP,]<=^?#ICGU[L#Y
M:X>T3FO5GZIO=6^7&&99M1:P2I"O]<M$&HQVU!9H,KH<QC%\"#(*1 FA[QK&
M'+C*HEU^H:;#?+D_-S*,)*!GEW*XR-RYYCF".X]09=P=QOK7!>H"\TR;,3^C
M<VDF6M[B/()22/(!!QU!#*<,C(X5Q "PZ,.HW7SD@:/RMQ[L- )RI7R-T!L5
M#>-CJO=@IH:>EV: 4P6J@W2 2PLD*WU4BQO) CBDF@WZ,0L(<9]:.2/:?;AF
M5AGNROU=*^EK+R\<%W,*2:EIVI6EV5':QVRQSQ;@!DJ\DD! /4+Z97U=[XW5
M?>.^BOE9>2-%W/F/?='M*/1=AA;5'UW4@W\X]G;4[OC:09YUO640(D2-<A@3
MY7:)-=*!$?#08_B%.++;:#>F1>UC[*/<-S-(A8+D9P$9CG'3/>,9'6M5Q1Y<
M^&Y]#U/3M!M-0\[O[66U6>Y1(DC28;)?11Y-Q>)GC!#J$W=H"S+L/3')N
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M#YM8]K8L(1H\Z^F>!&O0,8L*L9XF%(N@3 _!$5<H0 ,YY=RKZQQX]RCWY/>
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M3%*8I3%*HK*MKKFOG5%O AVE5:0Y-?95MA&#-@6$"8%\>7"FQ)#"1Y464 A
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..A^X/_B6K'Z?'^8U__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g805799g99l17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g805799g99l17.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ P 'L P$1  (1 0,1 ?_$ !\
M 0 " @,! 0$!           &!P4( P0) @H+ ?_$ $$0  (" @,   () @0$
M @D%  0% P8"!P !" D6$1(3%!495Y77E]87&%66(5C4U2(C"B0V-V%U=[2V
M)3%1AL'_Q  = 0$  04! 0$              0(#! 4&!P@)_\0 4Q$  00!
M 00$!@X&!P4( P   0 " P01!082(3$'$T%1%!8B87&1%1A25%:!E):AP=/4
MU? 7,I.5L=$C)$)55Y+Q"#-TL^$T-39B<G:RM25#HO_:  P# 0 "$0,1 #\
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M*M8J#NO4\NM,Z.SV;6:BU7LY<;53=QO$=WE75BV,ATVL8=B-"\P=BF+EV$)
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M499DIRT9H;4[7R/CJ222U)>INUV.B=8K1]:S,R^9*[],?7X\E^F4/MA%U^*
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MKV\?2'9FEEMVJ!ATNMM35T^L:-XNN249^B^';IYOU)*#X[+FFVZ!D%6U7+K
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MCFV)V6BEC9+%+LMH<<D4C6OCDC?I-5KV/8X%KV.:2US7 M<"0005*"M>4 Y
MFJAM&IYE7KN8F=?K9592D($68 DX .:9/*%FN69!@E%!"]A#P=CB$D#1?4AF
MDPRLBS8;(^9MB9LLN\)91+()) YP<X/>';S]YP#G;Q.7 $\0%LY= T*>C3TN
M;1=)ETW3S$ZAITFG4WT:+H(GP0FI4=":]8PPRR0Q&&-ACBD?&W#'N:>$+6FN
M5LP9*Z@4D A=.I)7SA55$+,"2A3RUY&0'+ !A(-.F033(U4T.6$BY1-*M#RA
M"DSA[EUJTX$.LSN#@\.#II"'"1XDD!!<<A\@$CP>#G@.=EPRJ8=G=GZ[X9(-
M"T>"2N^K)!)%IE*-\,E*HZA2DB>R .C?4HO?2JO80Z"H]U>(LA<6'&!Z:U O
M6YI@-5:W"420OAY%0E&K R[,>U1#P6>#,&%7@-E!8X Q(7T7<7<;>$4:)AB1
MA!%CA6Z]=<_K'7+3G@QD/=8E+\PDF([Q?G,1<XQ\?());@DK&BV1V3KUS4@V
M8V>AJ.9>C=6BT738Z[H]3;&S4HS"RL(RS4&0Q,O,+=VVR*-LXD:QH&8[UWK_
M +89-NZ-3NVF9F+'-EW64OW_ #881JH<#LC/N7WC(S"%$DBQ)RD[FQC3*L.L
M^L5P?4-'A-G=W/")]S=W=WK9-W=\OR=W>QN_TDG#&/+?[IV<H[/Z"9S:.BZ2
M;1F%@V3IU/KS.&U6"8S=3UAE#*-)HD+M\-IU6YQ7A#)CRPMNG")PB<(G")PB
M<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"
M)PB<(G")PB<(G")PB<(G")PB<(G")PBK'=:5U9=.;6K=<62NK!8]<7:OI%4)
M*\+-@V=UMDL7B_?&I8"X7"4HJ+J2<PP>"*/Z^>>?_AZZ[(O,M=XUW94KAH01
M:"M>:O\ .OJLQ]H1<.T3PMM6^;+GKW9#AZHL(9[98&?/1KY?ZGIZF5A"6^S"
MU1IBOM@VGW^QM@<BJR.//)!SD]O?]?'M.. XK[K7G7V"2!J?&[/MD?2"N\GH
M=[JDV]&@T-^V'KESLJ+T/N6NLE=[3&+J3L=&XJN<-:QR1.K+W F_%=?5P^E@
M2SDX<>[RL</4.'+ZN6>*@B/SQ[;J:BE191;FM%=ZU]HQ3NBH1>D%Q]YNA]4Z
M]2U*ZQT2S;"O5@1);1$'??/%T-9%-*TOO"?6A2EC88+4"KRD)D<CCMX@8'9C
ME@]_9ZUP;&\L^OJ_0_2-6U.LV,SN&U'>-CINS^O1GT6<*Q ?#MUUHRG/GS V
MT4.!A857HJA-GEGMTM;PR%D:4Z\U>EM&04,VLW?YTR"1GACF,</UB<#GV>;O
M'IO1EJGV!/M9Q98<+*VTTUVXCMMLUZ]OBI7LEU0"#=DA-M=U.R5S8V-*95-.
MPL.O]A+H'JO6-I"KM--TRXM>U*V6HF4DX8Y\?1RY<^?G[^>>"K]1YM]J*+!5
M&\MXV6V>UP#RTN3V,_=;5M7E<%?OOH_/;V5GI[*_P*KV<LT_>=/T^T.W* ]I
MLNR54RQP9%ML.WLS\_G\_P#6/YGCCT8Y<N7T]RW#\7T/;=+H;6;= FQU5[=?
M*N%H5WS;B#;*F:WUVJKZ]:K3KDM  -BDH]R. A=APNLUUH>,I&5AM-0K%@8L
MLFY"03PQCS?7Y_H[N"W*X4)PB<(G"+\:77Q0O;]-ZZJ%<W(.!7JKU\MH@>];
MZK+["3(__P!+5B=EFTH@PGL8$6"'L@LB<F;O#[2>:67+//+VP[*Z#,3-)2+I
M)299'>%6QO/D.^\X;.&C+B3@  <@ %^0X_VD^F;20-*T_:YD%#3!['TH/%_9
MJ7J:E+^K5HNMFT>2:3JX8V,ZR61\C]W>>]SB7%^;-[X_6\;^E^HO[$Y'BAL]
M[P/RN[]X4^VCZ<OAFSYN;*_@B?FS>^/UO&_I?J+^Q./%#9[W@?E=W[PGMH^G
M+X9L^;FROX(GYLWOC];QOZ7ZB_L3CQ0V>]X'Y7=^\)[:/IR^&;/FYLK^")^;
M-[X_6\;^E^HO[$X\4-GO>!^5W?O">VCZ<OAFSYN;*_@B?FS>^/UO&_I?J+^Q
M./%#9[W@?E=W[PGMH^G+X9L^;FROX(GYLWOC];QOZ7ZB_L3CQ0V>]X'Y7=^\
M)[:/IR^&;/FYLK^")^;-[X_6\;^E^HO[$X\4-GO>!^5W?O">VCZ<OAFSYN;*
M_@B?FS>^/UO&_I?J+^Q./%#9[W@?E=W[PGMH^G+X9L^;FROX(GYLWOC];QOZ
M7ZB_L3CQ0V>]X'Y7=^\)[:/IR^&;/FYLK^")^;-[X_6\;^E^HO[$X\4-GO>!
M^5W?O">VCZ<OAFSYN;*_@B?FS>^/UO&_I?J+^Q./%#9[W@?E=W[PGMH^G+X9
ML^;FROX(GYLWOC];QOZ7ZB_L3CQ0V>]X'Y7=^\)[:/IR^&;/FYLK^")^;-[X
M_6\;^E^HO[$X\4-GO>!^5W?O">VCZ<OAFSYN;*_@B?FS>^/UO&_I?J+^Q./%
M#9[W@?E=W[PGMH^G+X9L^;FROX(GYLWOC];QOZ7ZB_L3CQ0V>]X'Y7=^\)[:
M/IR^&;/FYLK^")^;-[X_6\;^E^HO[$X\4-GO>!^5W?O">VCZ<OAFSYN;*_@B
M?FS>^/UO&_I?J+^Q./%#9[W@?E=W[PGMH^G+X9L^;FROX(GYLWOC];QOZ7ZB
M_L3CQ0V>]X'Y7=^\)[:/IR^&;/FYLK^")^;-[X_6\;^E^HO[$X\4-GO>!^5W
M?O">VCZ<OAFSYN;*_@B?FS>^/UO&_I?J+^Q./%#9[W@?E=W[PGMH^G+X9L^;
MFROX(GYLWOC];QOZ7ZB_L3CQ0V>]X'Y7=^\)[:/IR^&;/FYLK^")^;-[X_6\
M;^E^HO[$X\4-GO>!^5W?O">VCZ<OAFSYN;*_@B?FS>^/UO&_I?J+^Q./%#9[
MW@?E=W[PGMI.G+X9L^;FROX(OT(?#_\ B 5+U_4<:]8<EU8WK5UT<ELJD<GV
M =C#A^SASN-.CFDREG53RY1_BJKZ\QE<-FP'(RG7D+F)OG.T.SLVC3&2/>EH
M2N/4S8RZ(GB(9L< X?V'\!(!D8<'-'WIT$].NE=+&E"A?-?3=MM-KM=JFEM=
MN1:A"S=8=6TEKW%SZKW%OA5;>?-I\SQ'(7P25[$WH[SFE]!IPB<(G")PB<(G
M")PB<(G")PB<(G"+3OU=Z7>^=VFF 5*B@L(-K6#8]>(8[!N#*DIDA5%TU?MN
M@]YMER"S2Y]6#*ARU;'#!204&2Y%9"B-I!.TQQ2!G/\ KV@?6JQTI\02K73%
M]UN>F6K1+;*:JD5FIOZ=L!NY"C9^--9>OK;2KHU4U0FOK-KTJO6?8 AE"',Z
ML#1?KEH8H4FD83#XE);W$$=_QXSZ#PX^=;!*_6V@G+ )0#=B,G!3:[IITY%4
MN ;5*5K>W)Z->R;*O+0P%5I-5K/8$P+>P/(P4(XK&!S^)9(_M&6!1@_DCS_R
M/\.:SFN_0>O=VU^]LM'N1+XWI'<($ZEB/8::/,];54"VU84@][7<284E@6-U
M<N%D6*G00G4K 7N$ARE:J!B$$<^"C6H]H[DV#3=H8N]?T=+L?76T7>M%TRRX
MO&>K+W$H#J[&>X5^QD5,&PPKE.=A:5&RIY4)!:K8=&MU:B.+A$A9Y$/U>A5S
MI3U<]M]2DNVUJ]5*BI:[N]$Z I2>CGW.^W*V7[SSNO<^JV@JFJA4V-DUQLE:
MTC;-FQ#J8S"*Y7U[?!MU,$G)=Y$(QY^ /+O /UX_U4D0>Y_,UOL53JE2O[!P
MSOD]/75-OUKC:D%$*=[$IY=XH*5ML*:DQTJO-;6C"*Q5*WKU<Q)>#$5' 7YP
MBS1=$P?5_/'KR1PY]O)5QIWWE2+7KS5ESV83'6GVQM%>1=DS42FT+;=U<JK=
MZE27]FA4 E)*@T$L-=;L*(Y15<Q3C.8(TKKH.T_AQC*O"F$P?I(SZ,>KT\E<
MU4]C^<+NZU?7JQL>!FWW$ F/H8G5=MHO9N5@I+78R94[D-0C1TZPFTQ(S=?+
MEPS1/!>H15YP S5LF!8$P?5_/'\5LYPH3A$X15)OV].]7Z+W-LRM0JB;!KK5
M>P+XE%>"EF)BV=0JC:PAB-!0&"DV8$J==@.3B(R"(ZBDRRBGPSZZX1:WT/US
MF/5J;9]GXF,(MC0R+ZL+6].7C61@MNK>AK!Z%N*4H':%P*,=J":,A,SJ%L6Q
M!(3FZUFE-*CF^YE3E./H\X]'/TK/UWW#JVV./P2O5/9[ LRU5:@UR;)%70 ;
M=?KEI>C>B$5+KQK2VA#Y.YM+WJ"_EYMLU*E<IK=LA/9CLE8X)Y,'CGL_GC^/
M#_IQ48L'Q$=&J*J!:EJC83\=]0;U=*L)%7P415A::ZUWLC95LH(L-H<I2H;2
MC2ZFO2UV=*+\FH[2EEJ;6U"V.4=7,3';D<_X<,^CB//YE:VOO5-*O]RKVO1J
MY= ;4U7P]._LU@+VNTRU9:]K&T):9:7U>9L\%3'NG6Q4Q =EB05!F7EG7A;%
MW;/J5_(F/S]'Y]"V=X4)PB<(G")PB<(G"+^>G9__ &EL/_SQM_\ ?D<^C8_]
MW'_Z&_\ Q"_!/4?^\+W_ !EK_GO6#Y6L-.$3A$X1.$3A$X1.$3A$X1.$3A$X
M1.$3A$X1.$3A$X1.$3A$X1.$7I/\-?R3N3?FY4&PJ4_?ZPI&L'X3-_M=3UU
MP@/'ZPG^5*CV3%*$UL#4*7N!E 7 :E5I39)["(= : D=\SM/K%+3J4E>>..U
M/;C<R.F_BTM/#KIL$.9$QPRTM+9'R- B<TM=)']$?[._17M=MSM=1U_1[U[9
MO1=FKT-B]M15PR=D[ '^Q>E=8UT-F]:A?N662LFIUJ<SGWXIF304[G[(>O\
MAUUU]/??T=?_ +]_1]/?_P >_HZZZ^GO_P"'777_ /'77/%5^N'T_GS)PB<(
MG")PB<(G")PB<(G")PB<(G"*IKWIZO[ OVF=BMG%C!<:-M%EMU2 4SIXE#%M
M:J)9-<L^K%">D8GEBX5FV.X1(5K%1E$63&7G++(/!U@3O\_\P?J5([*\2ZWV
M@UNSAQ=]L(S+SL*P[0.EJ5BKJ(E-<+'Y2>>-RF-:9X5&=RI[!T_8#LU673*>
M<&X1B6/$C/(?H/(IR1ZL?3G^*B<?P[M'$B+EMH;W:[)U>R2]K@*;"-K$,9;;
MV)J4QM+72JGK2L-:4L>1J2TMC541C6 [+4+)8:)8(V5() KRXF\?HQ\7G^/C
MYCQ'(*]M=:&SUKJ9AJ5;N3=+Z#.OYU2MWNU/ZFTV!1:Z,H_!*X!6&4%)!1$F
M5,+ZN:NRVZMVFVN38XC[N_MI<4<V!"<G*DFFM59Z=J&-0[V)?=DP0F?; -M@
MXT2%FL Q"#$A2 "ZZHVO:[&NAD%G8Y$2H9G9S)FQ*:-S^Y!L!2CXL>OZR55*
MCQ_KU%5*;6UMIV% QUWZ&VMZ=HMU[857*V5G:&[+)MVP[+E$Q[I_RN<@L<6^
M-LUV1(ZK#2(.NV^<4"88Y6B8JRG)^@ CO QCEZ!ZE4^J_#:FA;*N91!O0VGE
M[31#_4].5O!V)<EHT[3&BB"W;!A:408W*P"VQAA;UG:NXLU39T$&U=K(Y(I@
M2B9X8_..'\E*:GX*U33(]>1)KCM'O#6-.\P42M=%M*7/]:M>1R]C&ZF#8]XT
M.+LJ;[?:-H[LY<?8Y+G'M=C%*!T)E]L3//EV_3S4ATIXUI.@7JEIKS8^X1$@
MM;KZ.PT0ZQ5<BF7MI4E9-?JUTM0@U+#=16Q/690:U+G5'E7KUB55^M=V^O6)
MB@6'CD)S^?SZ<>K"V]X4)PB<(HE?:37]ET>X:[MD!1=5O=9>4^S!A'F*BC:_
M8UI*AT#"S73#,%^9JTLD7[X 2,:-U+W*(1 1A'+@15C>/->K-ATW6]&LH=ER
M3:F(Q(HQ*BZVNO/E?TZ]M&J2X"+"B;+V[,5EK^Z66N,QV1949L++LZ;KMJ*$
M>,4Y/Y].5%$OC;1-;2Y)$22RKXX;]KS:2=GW>K>P?5K8.K-7U/2M,M%>=-W#
M!@ 8+JJDUVC.0\IYU-M00M0[:O=XV6S=N"9/Y\YS_'BHP1X"\OD,!C<J;8HA
MA_M),T0NR=C"5TXLS5U_TTX9M$X]HC%:-K%K[9EM4V-F?U.:[-8R/SYYGQ![
M(PF3R_B >7'''LX<E8VN?+NI]4W4^^TK"]@.&RU"(Y /VGLE[573:N4Y+KU=
M='%/=V@^LL;_ -T6N5^IFW0I7(_.2I5HY1LF8V$O"C/Y_/\ !;#\(G")PB<(
MG")PB<(O%JA?!Z\FWRBTN\O&6W<'5SJ=<M;?$&XI!PL6EB3AMV&(<$E1GDA%
MQ+,FZ'BSGFSCAZPPREDRQ[S[[BQMIJ]>Q/ QE(L@FEA870R%Q;$]S&EQ$P!=
MAHR0 ">0')?'NA?[)G1;KFB:-K5VQM4+FKZ5I^J6Q!J]-D(LZA4AMSB%CM*>
MYD0EE>(V.>\M9@%SB,F6?DG^.O\ 5-S_ .]D/]F<L^/.M>XH_L)?MUM?:<]$
MGOG:_P#?-+\(3\D_QU_JFY_][(?[,X\>=:]Q1_82_;I[3GHD]\[7_OFE^$)^
M2?XZ_P!4W/\ [V0_V9QX\ZU[BC^PE^W3VG/1)[YVO_?-+\(3\D_QU_JFY_\
M>R'^S./'G6O<4?V$OVZ>TYZ)/?.U_P"^:7X0GY)_CK_5-S_[V0_V9QX\ZU[B
MC^PE^W3VG/1)[YVO_?-+\(3\D_QU_JFY_P#>R'^S./'G6O<4?V$OVZ>TYZ)/
M?.U_[YI?A"?DG^.O]4W/_O9#_9G'CSK7N*/["7[=/:<]$GOG:_\ ?-+\(3\D
M_P =?ZIN?_>R'^S./'G6O<4?V$OVZ>TYZ)/?.U_[YI?A"?DG^.O]4W/_ +V0
M_P!F<>/.M>XH_L)?MT]IST2>^=K_ -\TOPA/R3_'7^J;G_WLA_LSCQYUKW%'
M]A+]NGM.>B3WSM?^^:7X0GY)_CK_ %3<_P#O9#_9G'CSK7N*/["7[=/:<]$G
MOG:_]\TOPA/R3_'7^J;G_P![(?[,X\>=:]Q1_82_;I[3GHD]\[7_ +YI?A"?
MDG^.O]4W/_O9#_9G'CSK7N*/["7[=/:<]$GOG:_]\TOPA/R3_'7^J;G_ -[(
M?[,X\>=:]Q1_82_;I[3GHD]\[7_OFE^$)^2?XZ_U3<_^]D/]F<>/.M>XH_L)
M?MT]IST2>^=K_P!\TOPA/R3_ !U_JFY_][(?[,X\>=:]Q1_82_;I[3GHD]\[
M7_OFE^$)^2?XZ_U3<_\ O9#_ &9QX\ZU[BC^PE^W3VG/1)[YVO\ WS2_"$_)
M/\=?ZIN?_>R'^S./'G6O<4?V$OVZ>TYZ)/?.U_[YI?A"?DG^.O\ 5-S_ .]D
M/]F<>/.M>XH_L)?MT]IST2>^=K_WS2_"$_)/\=?ZIN?_ 'LA_LSCQYUKW%']
MA+]NGM.>B3WSM?\ OFE^$)^2?XZ_U3<_^]D/]F<>/.M>XH_L)?MT]IST2>^=
MK_WS2_"$_)/\=?ZIN?\ WLA_LSCQYUKW%']A+]NGM.>B3WSM?^^:7X0GY)_C
MG_4]S]__ -V1?_Y3./'G6O<4?V$OVZ>TYZ)/?&U_[YI?A"]0-;:VI&H:17M=
M:ZKP-7I]7!P 4* ,.^HXX^N^Y)B29I.\R#F)Q&<IC)D9+.<Q.GG,,GF(FDDR
MY6U:GNSR6;,CI9I7;SWN[>P  <&M:,-8QH#6M :T  !?2>SNSNC;*:-0V?V?
MH0:9I.F0""I4@!#6M!+GR2/<3)/8GD+IK-F9SY[$[Y)IGOD>YQG/,=;I.$3A
M$X1.$3A$X1.$3A$X1.$3A$X1.$7A=>*HZ.']GPZBI]J&]1-/>]+;>=+95ZC8
MES)6O@J'F.-W96EV#6#JA-#0D+]H#[/P>N,:-:@\+I4LQ7=J=BI6)5#'#/+!
MS]('Q\L=WH4T@]*>DKWM 5!$RVTBUTKVYYT<G.TNC6U==95ZU[8]8T'8M">"
M'TBSQ+:ZC)UGHOLL 1U8;2/'9Y3[)<(U=J)J-:(0,>?S'/N?^OF[ELGX[WUL
M'=M?V[WN %OG7EU:UC94AUSU6YUE.4DOFL!V5W3.*VX6XK5N2"V@6-8UI7X]
M?6U$)^_TZQWZYEJNG)!" ,8/'CR.<8Y>OG_)>;'C-YN_S9H.OW:Q4B\ 75KX
MF^'DM352JT.\=UES5Z[U7DGJ':=X2X)KDWF]EZA^>=@S[/KTU3/LM@I6O=>M
MA*I?S,;+5*B[_P _0JG$$D9'ZSN79W8)X;I[.WF.XG:%]ZU]356Q:S65M6\W
M,8<I;%L$XFB+Q24MY7.=>>QK-JTT.QL*[&;TW?6G6&A*99[).LU?4%#%^2V7
MU4Y=LQ8!K)^2J< Y[/C![L^?OQSSW]\6U/MS9L6V+U953.^**9ONV:EFO.^&
MFCF2+&BLQ/)+1DM695IW3PU0L<NUZ\/2&\ST%FRKY^"[53HZ"^6BO/8R$#U
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M:W;NE[0HVPV5P54YW^-ET-\;5[5E"N:P!K+$L9-%#--TQ,!'7FL5C%.>.Q$
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M>K:KRMWHIZ]C1J\,\,C3P='+$]S'M/-KB.U1E9YNK2O4;/1D5VV*1K(NA/\
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M %/N_P#WSE7L;IWO"E\E@^S5C](.WOPWVO\ G+K/WU/\QGH3]=]R_P!3[O\
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MJQ-%[1] [/L(U481.2>ZZN?2[Z(J5%589&1:_K%14BD$6G&;[$,F3P\Q)]8
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MZ'97977=M-=H;.;.4)=1U749>KAACX,C8.,MFS*?(K5*S,RV+$I;'%&TDG.
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M6JR540MJT-F7(W;)>NS%@+EPR)GGY_\ 51I%Y5T'6<Z_)7]?P)\ZH=6&59S
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M( X\L,>^B9/?Y_C[U.N$3A$X1.$3A$X1.$56Z-_]RFGO_I;K[_\ $U',N_\
M]NN_\79_YSUS.Q7_ (-V2_\ ;.@__55%:7,1=,G")PB<(G")PB<(G")PB<(G
M")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB
9<(G")PB<(G")PB<(G")PB<(G")PB<(O_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
